6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 114_CD Shareholder_NN information_NN Registered_NNP office_NN address_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Registered_NNP in_IN England_NNP No._NN ._.
05492592_CD Investor_NNP relations_NNS Europe_NNP and_CC Rest_VB of_IN the_DT World_NNP :_: Cla_NNP Rosenfeld_NNP Tel_NNP 44_CD 0_CD 1256 894160_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Email_NNP investorrelations@uk_NNP ._.
com_NN North_NNP America_NNP :_: Brian_NNP Piper_NNP Tel_NNP 1_CD 484 595 8800_CD Fax_NN 1_CD 484 595 8151_CD Email_NNP bpiper@us_NNS ._.
com_NN Registrars_NNPS and_CC transfer_VB office_NN All_DT administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN shareholders_NNS name_NN and_CC address_NN ._.
Lloyds_NNP TSB_NNP Registrars_NNPS Customer_NN Services_NNP ,_, The_DT Causeway_NNP Worthing_NNP ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP United_NNP Kingdom_NNP Tel_NNP 44 870 600 3970_CD 114_CD Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD Shire_NNP plc_NN 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 115_CD This_DT page_NN has_VBZ been_VBN intentionally_RB left_VBN blank_JJ 6420_CD Annual_JJ Report_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:44_CD Page_NNP 116_CD Designed_VBN and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP ,_, London_NNP The_DT paper_NN used_VBN in_IN this_DT publication_NN is_VBZ made_VBN from_IN 100_CD %_NN recycled_JJ fibers_NNS sourced_VBD entirely_RB from_IN post_NN consumer_NN waste_NN ,_, is_VBZ Elemental_JJ Chlorine_NNP Free_NNP ECF_NNP and_CC is_VBZ accredited_VBN to_TO ISO_NNP 14001_CD ._.
Shire_NNP plc_NN Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD 6420_CD Cover_NNP 2005_CD ._.
qxd_NN 28_CD 4_CD 06_CD 17:21_CD Page_NNP fc1_CD Shire_NNP plc_NN Annual_JJ report_NN and_CC accounts_NNS for_IN the_DT y_JJ Hampshire_NNP International_NNP Business_NNP Park_NNP Shire_NNP plc_NN Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Fax_NNP 44_CD 0_CD 1256 894708_CD www_NN ._.
com_NN tog_NN Shire_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 6361_CD Cover_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP fc1_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN together_RB 6361_CD Cover_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP fc2_CD Contents_NNP 01_CD Introduction_NNP 06_CD Financial_NNP highlights_VBZ 07_CD Chairmans_NNPS statement_NN 08_CD Chief_NNP Executives_NNS review_VBP 12_CD Product_NNP portfolio_NN 14_CD Product_NNP pipeline_NN 16_CD Operating_NN review_NN 36_CD Corporate_JJ Responsibility_NN 40_CD Board_NNP of_IN Directors_NNS 42_CD Executive_NNP Committee_NNP 44_CD Financial_NNP review_NN 56_CD Nomination_NNP Committee_NNP report_NN 56_CD Directors_NNS remuneration_JJ report_NN 68_CD Audit_NNP Committee_NNP report_NN 70_CD Corporate_JJ governance_NN statements_NNS 77_CD Report_NNP of_IN independent_JJ registered_JJ public_JJ accounting_NN firm_NN 78_CD Consolidated_NNP balance_NN sheets_NNS 79_CD Consolidated_NNP statements_NNS of_IN operations_NNS 80_CD Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS equity_NN 81_CD Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN 82_CD Consolidated_NNP statements_NNS of_IN cash_NN flows_VBZ 84_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS 128_CD Five-year_JJ review_NN 129_CD Statement_NN of_IN Directors_NNS responsibilities_NNS 130_CD Summary_JJ financial_JJ statement_NN 140_CD Shire_NNP head_NN office_NN and_CC main_JJ operating_NN locations_NNS 141_CD Shareholder_NN information_NN 142_CD Shire_NNP Trade_NNP Marks_NNP 142_CD Cautionary_JJ statements_NNS 143_CD Glossary_NNP of_IN terms_NNS Cover_NNP :_: Barbara_NNP Deptula_NNP Executive_NNP Vice_NNP President_NNP Business_NNP Development_NNP Page_NNP 2_CD :_: Jeff_NNP Poulton_NNP Vice_NNP President_NNP Therapeutic_NNP Area_NNP Finance_NNP Page_NNP 5_CD :_: Stephanie_NNP Read_NNP Global_NNP Medical_NNP Affairs_NNP Senior_NNP Manager_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 01_CD Its_PRP$ all_DT coming_VBG together_RB for_IN Shire_NNP ._.
Weve_NNP reorganized_VBD the_DT business_NN to_TO create_VB a_DT leaner_JJR ,_, more_RBR resilient_JJ Company_NN ,_, and_CC what_WP we_PRP have_VBP now_RB is_VBZ the_DT right_JJ structure_NN and_CC the_DT right_JJ team_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 01_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 02_CD plus_CC 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 03_CD Were_VBD seeing_VBG the_DT benets_NNS from_IN clever_JJ acquisitions_NNS and_CC shrewd_JJ partnerships_NNS ,_, and_CC were_VBD developing_VBG whats_NNS acknowledged_VBD to_TO be_VB one_CD of_IN the_DT richest_JJS pipelines_NNS in_IN the_DT specialty_NN pharmaceutical_JJ sector_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 03_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 04_CD Add_VB to_TO that_IN the_DT professionalism_NN of_IN our_PRP$ people_NNS ,_, a_DT high-performing_JJ portfolio_NN of_IN profitable_JJ drugs_NNS ,_, and_CC an_DT unrivaled_JJ understanding_NN of_IN the_DT needs_NNS of_IN specialist_NN physicians_NNS and_CC their_PRP$ patients_NNS ,_, and_CC it_PRP all_DT adds_VBZ up_RP to_TO a_DT business_NN thats_VBZ a_DT lot_NN more_JJR than_IN the_DT sum_NN of_IN its_PRP$ parts_NNS ._.
04_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 05_CD add_VBP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 06_CD Financial_NNP highlights_VBZ Revenue_NN growth_NN up_IN Revenue_NN $_$ million_CD Revenue_NN growth_NN over_IN the_DT last_JJ five_CD years_NNS $_$ million_CD 2005_CD 1,599.3_CD 2005_CD 1,599.3_CD 2004_CD 1,363.2_CD 2004_CD 1,363.2_CD 2003_CD 1,211.6_CD 17_CD %_NN 2002_CD 1,023.3_CD 2001_CD 845.1_CD Sources_NNS of_IN revenue_NN $_$ million_CD Sources_NNS of_IN revenue_NN %_NN Revenue_NN by_IN location_NN $_$ million_CD 1_CD ADDERALL_NNP XR_NNP 730.8_CD 1_CD ADDERALL_NNP XR_NNP 46_CD 2_CD CARBATROL_NNP 72.1_CD 2_CD CARBATROL_NNP 4_CD 1_CD North_NNP America_NNP 1,233.5_CD 9_CD 9_CD 8_CD 3_CD PENTASA_NNP 136.1_CD 8_CD 3_CD PENTASA_NN 8_CD 2_CD Rest_VBP of_IN the_DT world_NN 365.8_CD 2_CD 4_CD AGRYLIN_NNP XAGRID_NNP 92.8_CD 4_CD AGRYLIN_NNP XAGRID_NNP 6_CD Total_JJ 1,599.3_CD 5_CD FOSRENOL_NNP 53.5_CD 5_CD FOSRENOL_NNP 3_CD 6_CD REPLAGAL_NNP 41.3_CD 6_CD REPLAGAL_NNP 3_CD 7_CD 7_CD 1_CD 1_CD 7_CD Other_JJ 201.1_CD 7_CD Other_JJ 13_CD 8_CD Royalty_NN income_NN 242.9_CD 8_CD Royalty_NN income_NN 15_CD 6_CD 6_CD 9_CD Licensing_NN and_CC 9_CD Licensing_NN and_CC 5_CD 5_CD 1_CD Development_NNP Development_NNP 4_CD 4_CD and_CC other_JJ 28.7_CD and_CC other_JJ 2_CD 3_CD 2_CD 3_CD 2_CD Total_JJ 1,599.3_CD Total_JJ 100_CD This_DT represents_VBZ REPLAGAL_NNP sales_NNS for_IN the_DT five-month_JJ period_NN since_IN the_DT acquisition_NN of_IN TKT_NNP ._.
06_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 07_CD Chairmans_NNPS statement_NN Its_PRP$ all_DT adding_VBG up_RP for_IN Shire_NNP ._.
Increasing_VBG competition_NN from_IN generic_JJ drugs_NNS 2004_CD :_: $_$ 1,363.2_CD million_CD ._.
Although_IN there_EX were_VBD and_CC patent_NN expirations_NNS present_JJ another_DT major_JJ diluted_JJ losses_NNS per_IN ordinary_JJ share_NN for_IN the_DT year_NN challenge_NN to_TO the_DT pharmaceutical_JJ industry_NN ._.
of_IN 82.1_CD 2004_CD :_: diluted_JJ earnings_NNS per_IN share_NN We_PRP are_VBP responding_VBG by_IN focusing_VBG R&D_NNP in_IN the_DT of_IN 53.3_CD ,_, these_DT included_VBD the_DT write-off_NN specialty_NN area_NN with_IN products_NNS for_IN smaller_JJR of_IN $_$ 673_CD million_CD of_IN in-process_JJ R&D_NNP following_VBG populations_NNS and_CC biologics_NNS as_RB well_RB as_IN inthe_JJ acquisition_NN of_IN TKT_NNP ._.
Excluding_VBG this_DT write-off_NN ,_, licensing_NN or_CC developing_VBG drugs_NNS with_IN strong_JJ earnings_NNS per_IN ordinary_JJ share_NN would_MD have_VB been_VBN intellectual_JJ property_NN ._.
Our_PRP$ success_NN has_VBZ been_VBN 51.8_CD in_IN 2005_CD ._.
built_VBN on_IN innovative_JJ products_NNS that_WDT focus_VBP on_IN areas_NNS of_IN unmet_JJ medical_JJ need_NN and_CC we_PRP will_MD On_IN November_NNP 25_CD ,_, 2005_CD ,_, Shire_NNP plc_NN ,_, a_DT Company_NN continue_VBP to_TO pursue_VB this_DT proven_JJ formula_NN ._.
incorporated_VBN in_IN England_NNP and_CC Wales_NNP Shire_NNP ,_, became_VBD the_DT holding_VBG Company_NN of_IN Shire_NNP Dr_NNP James_NNP Cavanaugh_NNP In_IN todays_NNS market_NN ,_, pharmaceutical_JJ companies_NNS Pharmaceuticals_NNP Group_NNP plc_NN SPG_NNP pursuant_JJ to_TO Chairman_NNP need_VBP to_TO look_VB to_TO additional_JJ partnering_NN ,_, licensing_NN ,_, a_DT scheme_NN of_IN arrangement_NN under_IN Section_NN 425_CD mergers_NNS and_CC acquisitions_NNS as_IN ways_NNS to_TO fill_VB their_PRP$ of_IN the_DT United_NNP Kingdom_NNP Companies_NNP Act_NNP 1985_CD product_NN pipelines_NNS as_RB well_RB as_IN to_TO minimize_VB the_DT Scheme_NN ._.
As_IN a_DT result_NN of_IN the_DT Scheme_NNP ,_, SPG_NNP Shire_NNP made_VBD considerable_JJ progress_NN in_IN challenges_NNS created_VBN by_IN the_DT industrys_NNS recent_JJ is_VBZ now_RB a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ._.
2005_CD in_IN positioning_NN itself_PRP for_IN success_NN in_IN a_DT low_JJ productivity_NN ._.
Almost_RB 75_CD %_NN of_IN New_NNP Chemical_NNP global_JJ pharmaceutical_JJ industry_NN that_WDT faces_VBZ Entities_NNS NCEs_NNS entering_VBG the_DT market_NN are_VBP New_NNP Board_NNP member_NN unprecedented_JJ challenges_NNS and_CC opportunities_NNS specialty_NN products_NNS and_CC or_CC biologics_NNS ,_, showing_VBG We_PRP are_VBP continuing_VBG to_TO strengthen_VB our_PRP$ Board_NNP in_IN the_DT coming_VBG years_NNS ._.
The_DT challenges_NNS are_VBP multithat_JJ the_DT smaller_JJR ,_, more_RBR nimble_JJ biotech_JJ model_NN of_IN Directors_NNS with_IN the_DT appointment_NN during_IN faceted_VBN ,_, and_CC therefore_RB require_VB a_DT disciplined_JJ has_VBZ proved_VBN particularly_RB effective_JJ to_TO date_NN in_IN 2005_CD of_IN Patrick_NNP Langlois_NNP as_IN a_DT Non-executive_JJ and_CC co-ordinated_JJ response_NN on_IN several_JJ fronts_NNS ._.
Director_NNP and_CC member_NN of_IN our_PRP$ Audit_NNP Committee_NNP ._.
Mr_NNP Langlois_NNP ,_, who_WP held_VBD senior_JJ positions_NNS at_IN One_CD challenge_NN faced_VBN by_IN Shire_NNP during_IN 2005_CD Our_PRP$ acquisition_NN in_IN 2005_CD of_IN Transkaryotic_NNP Aventis_NNP S._NNP A._NN and_CC the_DT Rhone-Poulenc_NNP Group_NNP ,_, was_VBD the_DT Canadian_JJ government_NN decision_NN to_TO Therapies_NNPS Inc._NNP ._.
TKT_NNP ,_, a_DT US-based_JJ brings_VBZ additional_JJ expertise_NN to_TO our_PRP$ Board_NNP ,_, withdraw_VBP ADDERALL_NNP XR_NNP ,_, our_PRP$ medicine_NN for_IN biopharmaceutical_JJ company_NN specializing_VBG including_VBG a_DT wealth_NN of_IN experience_NN in_IN financial_JJ treating_VBG Attention_NN Deficit_NN and_CC Hyperactivity_NNP in_IN therapies_NNS for_IN the_DT treatment_NN of_IN rare_JJ genetic_JJ and_CC operational_JJ management_NN within_IN the_DT global_JJ Disorder_NN ADHD_NNP ,_, from_IN the_DT Canadian_JJ market_NN ._.
diseases_NNS caused_VBN by_IN protein_NN deficiencies_NNS ,_, pharmaceutical_JJ industry_NN ._.
Shires_NNP team_NN demonstrated_VBD incredible_JJ fits_NNS this_DT profile_NN ._.
The_DT acquisition_NN significantly_RB success_NN by_IN reinstating_VBG ADDERALL_NNP XR_NNP in_IN builds_VBZ our_PRP$ pipeline_NN while_IN bringing_VBG us_PRP a_DT new_JJ ,_, Positioned_VBN for_IN growth_NN Canada_NNP during_IN 2005_CD ,_, following_VBG a_DT review_NN by_IN sustainable_JJ area_NN of_IN specialty_NN pharmaceutical_JJ Our_PRP$ industry_NN offers_VBZ significant_JJ growth_NN independent_JJ experts_NNS ._.
expertise_NN in_IN a_DT market_NN where_WRB there_EX are_VBP only_RB opportunities_NNS for_IN medium-sized_JJ specialty_NN a_DT small_JJ number_NN of_IN players_NNS ._.
We_PRP continue_VBP to_TO pharmaceutical_JJ companies_NNS like_IN Shire_NNP ._.
The_DT The_DT traditional_JJ investment_NN and_CC actively_RB look_VB at_IN other_JJ acquisition_NN opportunities_NNS global_JJ pharmaceuticals_NNS market_NN is_VBZ forecast_VBN commercialization_NN model_NN of_IN the_DT pharmaceutical_JJ involving_VBG companies_NNS with_IN good_JJ products_NNS to_TO fill_VB to_TO reach_VB an_DT annual_JJ growth_NN rate_NN of_IN 8.2_CD %_NN from_IN industry_NN that_IN hinges_VBZ on_IN blockbuster_NN brands_NNS our_PRP$ pipeline_NN and_CC pursue_VB our_PRP$ growth_NN strategy_NN ._.
2004_CD 2011_CD and_CC achieve_VB $_$ 967_CD billion_CD in_IN sales_NNS could_MD face_VB considerable_JJ challenges_NNS in_IN the_DT in_IN 2011_CD ._.
Such_JJ expansion_NN is_VBZ expected_VBN ,_, however_RB ,_, coming_VBG years_NNS ._.
This_DT reaffirms_VBZ the_DT value_NN of_IN We_PRP have_VBP strengthened_VBN our_PRP$ European_JJ focus_NN to_TO be_VB based_VBN on_IN the_DT ability_NN of_IN pharmaceutical_JJ Shires_NNP strategy_NN of_IN diversifying_VBG our_PRP$ product_NN and_CC we_PRP also_RB have_VBP established_VBN a_DT presence_NN in_IN companies_NNS to_TO adapt_VB to_TO changes_NNS in_IN patient_JJ portfolio_NN with_IN a_DT focus_NN on_IN the_DT development_NN emerging_VBG markets_NNS through_IN relationships_NNS with_IN population_NN ,_, and_CC target_NN diseases_NNS of_IN unmet_JJ and_CC marketing_NN of_IN smaller_JJR ,_, specialty_NN products_NNS ._.
We_PRP are_VBP well_RB positioned_VBN to_TO serve_VB medical_JJ need_NN to_TO maximize_VB revenue_NN potential_NN ._.
With_IN our_PRP$ operating_NN model_NN of_IN cross-functional_JJ ,_, the_DT growing_VBG needs_NNS of_IN these_DT markets_NNS ._.
I_PRP am_VBP confident_JJ that_IN we_PRP have_VBP the_DT right_JJ strategy_NN global_JJ teams_NNS responsible_JJ for_IN each_DT of_IN our_PRP$ and_CC the_DT right_JJ people_NNS to_TO be_VB able_JJ to_TO benefit_VB from_IN main_JJ therapeutic_JJ areas_NNS ,_, nimble_JJ sales_NNS forces_NNS We_PRP are_VBP adapting_VBG our_PRP$ development_NN and_CC sales_NNS this_DT future_JJ growth_NN ._.
dedicated_VBN to_TO building_VBG relationships_NNS with_IN processes_NNS to_TO support_VB a_DT diverse_JJ product_NN portfolio_NN specialist_NN physicians_NNS and_CC their_PRP$ patients_NNS ,_, and_CC global_JJ markets_NNS ,_, to_TO realize_VB financial_JJ gains_NNS and_CC a_DT deep_JJ pipeline_NN of_IN innovative_JJ products_NNS and_CC continued_VBN growth_NN ._.
with_IN strong_JJ patent_NN protection_NN ,_, we_PRP are_VBP best_RBS positioned_VBN to_TO respond_VB to_TO changing_VBG 2005_CD results_NNS under_IN USGAAP_NNP marketplace_NN dynamics_NNS ._.
Shires_NNP highly-focused_JJ growth_NN strategy_NN continued_VBD to_TO produce_VB superior_JJ results_NNS in_IN 2005_CD ._.
Dr_NNP James_NNP Cavanaugh_NNP Revenues_NNS were_VBD up_RB 17_CD %_NN to_TO $_$ 1,599.3_CD million_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 07_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 08_CD prep_NN arati_NNS on_IN 08_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 09_CD Chief_NNP Executives_NNS review_NN Today_NN Shire_NNP has_VBZ one_CD of_IN the_DT richest_JJS product_NN pipelines_NNS Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP Officer_NNP in_IN the_DT specialty_NN pharmaceutical_JJ industry_NN ._.
The_DT year_NN 2005_CD was_VBD pivotal_JJ for_IN Shire_NNP ._.
With_IN a_DT breakthrough_NN acquisition_NN ,_, a_DT key_JJ collaboration_NN agreement_NN ,_, several_JJ product_NN launches_NNS and_CC continuing_VBG advancement_NN of_IN our_PRP$ pipeline_NN ,_, we_PRP have_VBP made_VBN excellent_JJ progress_NN in_IN setting_VBG the_DT stage_NN for_IN continued_JJ growth_NN ._.
We_PRP are_VBP seeing_VBG the_DT results_NNS of_IN our_PRP$ focused_JJ business_NN strategy_NN through_IN a_DT significant_JJ increase_NN in_IN the_DT number_NN of_IN late-stage_JJ product_NN candidates_NNS ._.
Today_NN Shire_NNP has_VBZ one_CD of_IN the_DT richest_JJS product_NN pipelines_NNS in_IN the_DT specialty_NN pharmaceutical_JJ industry_NN ._.
Simultaneously_RB ,_, we_PRP have_VBP put_VBN in_IN place_NN a_DT strengthened_JJ organization_NN to_TO deliver_VB on_IN the_DT opportunities_NNS in_IN key_JJ markets_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 09_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 10_CD Chief_NNP Executives_NNS review_NN Our_PRP$ strong_JJ competitive_JJ position_NN is_VBZ the_DT result_NN Pipeline_NNP successes_NNS as_IN Shires_NNP authorized_VBD generic_JJ ._.
Shire_NNP will_MD of_IN the_DT hard_JJ work_NN of_IN all_DT 2,400_CD Shire_NNP employees_NNS ._.
The_DT year_NN saw_VBD a_DT number_NN of_IN other_JJ exciting_JJ receive_VBP royalties_NNS from_IN Impax_NNP on_IN these_DT sales_NNS ._.
We_PRP have_VBP made_VBN good_JJ on_IN our_PRP$ strategic_JJ advances_NNS in_IN our_PRP$ pipeline_NN :_: This_DT latest_JJS development_NN is_VBZ excellent_JJ news_NN for_IN commitment_NN to_TO grow_VB our_PRP$ underlying_VBG business_NN Shire_NNP as_IN it_PRP removes_VBZ some_DT of_IN the_DT uncertainty_NN while_IN expanding_VBG our_PRP$ portfolio_NN of_IN new_JJ submission_NN of_IN a_DT NDA_NNP with_IN the_DT FDA_NNP that_WDT surrounded_VBD ADDERALL_NNP XR_NNP ._.
We_PRP have_VBP continued_VBN to_TO evolve_VB our_PRP$ for_IN MESAVANCE_NNP ,_, the_DT first_JJ once-daily_JJ continues_VBZ to_TO vigorously_RB defend_VB its_PRP$ intellectual_JJ manufacturing_NN capabilities_NNS both_DT in_IN small_JJ mesalamine_NN treatment_NN for_IN mild_JJ to_TO moderate_JJ property_NN rights_NNS relating_VBG to_TO ADDERALL_NNP XR_NNP molecules_NNS and_CC proteins_NNS to_TO mitigate_VB supply_NN ulcerative_JJ colitis_NN UC_NNP ._.
In_IN addition_NN ,_, we_PRP filed_VBD in_IN the_DT ongoing_JJ patent_NN litigations_NNS with_IN Barr_NNP chain_NN risk_NN ._.
this_DT product_NN with_IN Health_NNP Canada_NNP and_CC Laboratories_NNP Inc._NNP and_CC Teva_NNP Pharmaceuticals_NNP the_DT European_JJ authorities_NNS during_IN the_DT first_JJ USA_NNP Inc._NNP ._.
The_DT acquisition_NN of_IN TKT_NNP in_IN July_NNP is_VBZ an_DT excellent_JJ quarter_NN of_IN 2006_CD :_: strategic_JJ fit_NN and_CC will_MD bring_VB significant_JJ value_NN Product_NNP launches_NNS in_IN 2005_CD to_TO the_DT Company_NN over_IN time_NN ._.
It_PRP broadens_VBZ our_PRP$ submission_NN of_IN an_DT amended_VBN NDA_NNP FOSRENOL_NNP ,_, for_IN the_DT treatment_NN of_IN revenue_NN base_NN while_IN building_VBG our_PRP$ pipeline_NN with_IN the_DT FDA_NNP for_IN DAYTRANA_NNP ,_, the_DT first_JJ hyperphosphatemia_NN in_IN end-stage_JJ renal_JJ in_IN the_DT relatively_RB low-risk_JJ area_NN of_IN Enzyme_NNP transdermal_JJ patch_NN for_IN the_DT treatment_NN disease_NN ,_, and_CC Shires_NNP first_JJ global_JJ product_NN ,_, Replacement_NNP Therapy_NNP ERT_NNP ._.
Historically_NNP ,_, of_IN ADHD_NNP an_DT approval_NN letter_NN was_VBD received_VBN was_VBD successfully_RB launched_VBN in_IN the_DT US_NNP in_IN enzyme_NN replacement_NN drugs_NNS have_VBP had_VBN a_DT high_JJ in_IN April_NNP 2006_CD :_: 2005_CD and_CC performed_VBN in_IN line_NN with_IN its_PRP$ major_JJ success_NN rate_NN in_IN reaching_VBG the_DT market_NN ._.
Now_RB competitor_NN when_WRB launch_NN periods_NNS are_VBP called_VBN Shire_NNP Human_NNP Genetic_NNP Therapies_NNPS submission_NN of_IN a_DT NDA_NNP with_IN the_DT FDA_NNP compared_VBN ._.
We_PRP also_RB launched_VBD FOSRENOL_NNP Shire_NNP HGT_NNP ,_, this_DT dedicated_JJ team_NN is_VBZ working_VBG for_IN ELAPRASE_NNP ,_, as_RB well_RB as_IN submission_NN into_IN the_DT first_JJ four_CD countries_NNS in_IN Europe_NNP and_CC it_PRP on_IN disease_NN areas_NNS where_WRB there_EX is_VBZ high_JJ unmet_JJ of_IN a_DT MAA_NNP in_IN Europe_NNP :_: and_CC will_MD be_VB rolled_VBN out_RP to_TO more_JJR European_JJ countries_NNS medical_JJ need_NN ._.
In_IN addition_NN to_TO near-term_JJ in_IN 2006_CD ._.
In_IN addition_NN ,_, we_PRP launched_VBD higher_JJR products_NNS ,_, it_PRP provides_VBZ Shire_NNP with_IN important_JJ obtained_VBN the_DT reinstatement_NN of_IN dose_NN formulations_NNS in_IN the_DT US_NNP ._.
XAGRID_NNP ,_, our_PRP$ intellectual_JJ property_NN and_CC discovery_NN ADDERALL_NNP XR_NNP in_IN Canada_NNP ._.
treatment_NN for_IN a_DT rare_JJ platelet_NN disorder_NN known_VBN capabilities_NNS that_WDT will_MD provide_VB value_NN over_IN the_DT as_IN Essential_NNP Thrombocythemia_NNP ET_NNP ,_, was_VBD very_RB long_JJ term_NN ._.
Shire_NNP HGT_NNP already_RB has_VBZ one_CD ADDERALL_NNP XR_NNP successfully_RB launched_VBD in_IN Europe_NNP ,_, achieving_VBG approved_VBN product_NN in_IN Europe_NNP REPLAGAL_NNP for_IN ADDERALL_NNP XR_NNP ,_, our_PRP$ once-daily_JJ treatment_NN sales_NNS of_IN $_$ 46.8_CD million_CD in_IN 2005_CD ._.
EQUETRO_NNP ,_, the_DT treatment_NN of_IN Fabry_NNP Disease_NNP ,_, a_DT lipid_JJ storage_NN for_IN ADHD_NNP ,_, continued_VBD to_TO perform_VB extremely_RB the_DT first_JJ ever_RB carbamazepine_JJ treatment_NN disorder_NN ._.
At_IN the_DT end_NN of_IN 2005_CD ,_, we_PRP submitted_VBD well_RB during_IN the_DT year_NN ,_, reaching_VBG an_DT all-time_JJ approved_VBN for_IN manic_JJ phase_NN of_IN Bipolar_NNP Disorder_NNP ,_, a_DT New_NNP Drug_NNP Application_NNP NDA_NNP to_TO the_DT Food_NNP high_JJ market_NN share_NN of_IN 26_CD %_NN in_IN the_DT US_NNP ._.
In_IN the_DT was_VBD launched_VBN in_IN the_DT US_NNP ._.
and_CC Drug_NNP Administration_NNP FDA_NNP for_IN idursulfase_NN ,_, interest_NN of_IN patient_JJ safety_NN ,_, during_IN 2005_CD we_PRP filed_VBD the_DT first_JJ human_JJ ERT_NNP treatment_NN for_IN Hunter_NNP a_DT Citizen_NNP Petition_NNP with_IN the_DT FDA_NNP requesting_VBG Five_CD launches_NNS in_IN 2006_CD and_CC the_DT first_JJ half_DT Syndrome_NN ,_, under_IN the_DT trade_NN name_NN ELAPRASE_NNP ,_, that_IN they_PRP ask_VBP companies_NNS seeking_VBG approval_NN of_IN 2007_CD as_RB well_RB as_IN submitting_VBG Marketing_NNP Authorization_NNP for_IN generic_JJ ADDERALL_NNP XR_NNP or_CC any_DT follow-on_JJ In_IN 2006_CD and_CC during_IN the_DT first_JJ half_NN of_IN 2007_CD ,_, Application_NNP MAA_NNP in_IN Europe_NNP for_IN this_DT product_NN ._.
of_IN ADDERALL_NNP XR_NNP to_TO undertake_VB more_JJR rigorous_JJ we_PRP are_VBP planning_VBG no_DT fewer_JJR than_IN five_CD new_JJ Our_PRP$ GA-GCB_JJ compound_NN for_IN Gaucher_NNP Disease_NNP bioequivalence_NN testing_NN or_CC additional_JJ clinical_JJ product_NN launches_NNS ,_, this_DT is_VBZ a_DT record_NN breaking_NN will_MD enter_VB Phase_NN 3_CD trials_NNS this_DT year_NN and_CC there_EX trials_NNS ._.
This_DT petition_NN is_VBZ currently_RB under_IN review_NN achievement_NN in_IN this_DT industry_NN ._.
These_DT will_MD are_VBP several_JJ other_JJ very_RB promising_JJ compounds_NNS and_CC to_TO date_NN ,_, no_DT approvals_NNS for_IN follow-on_JJ require_VBP additional_JJ spending_NN on_IN advertising_NN in_IN the_DT pipeline_NN ._.
generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP have_VBP been_VBN and_CC promotion_NN ,_, and_CC in_IN some_DT cases_NNS additional_JJ granted_VBN ._.
On_IN January_NNP 19_CD ,_, 2006_CD we_PRP announced_VBD sales_NNS representatives_NNS ._.
As_IN a_DT result_NN ,_, our_PRP$ Selling_NNP ,_, Another_DT major_JJ milestone_NN in_IN 2005_CD was_VBD our_PRP$ that_IN we_PRP settled_VBD all_DT pending_VBG litigations_NNS relating_VBG General_NNP and_CC Administration_NNP SG&A_NNP costs_VBZ collaboration_NN with_IN New_NNP River_NNP Pharmaceuticals_NNP to_TO ADDERALL_NNP XR_NNP with_IN Impax_NNP Laboratories_NNPS are_VBP expected_VBN to_TO rise_VB in_IN order_NN to_TO support_VB the_DT New_NNP River_NNP to_TO develop_VB and_CC commercialize_VB Inc._NNP ._.
Impax_NNP ._.
Impax_NNP confirmed_VBD that_IN all_DT Shire_NNP success_NN of_IN these_DT launches_NNS ._.
NRP104_CD is_VBZ a_DT very_RB promising_JJ patents_NNS covering_VBG ADDERALL_NNP XR_NNP are_VBP valid_JJ and_CC investigational_JJ compound_NN for_IN the_DT treatment_NN enforceable_JJ and_CC that_IN their_PRP$ proposed_VBN version_NN of_IN of_IN ADHD_NNP ,_, an_DT area_NN of_IN leadership_NN for_IN us_PRP ._.
ADDERALL_NNP XR_NNP did_VBD infringe_VB those_DT patents_NNS ._.
The_DT New_NNP River_NNP made_VBD excellent_JJ progress_NN during_IN agreement_NN states_NNS that_WDT Impax_NNP will_MD be_VB permitted_VBN the_DT year_NN ,_, filing_VBG a_DT NDA_NNP for_IN NRP104_NNP with_IN the_DT FDA_NNP to_TO market_VB their_PRP$ generic_JJ version_NN of_IN ADDERALL_NNP in_IN early_JJ December_NNP and_CC we_PRP are_VBP looking_VBG forward_RB XR_NNP no_RB later_RB than_IN January_NNP 1_CD ,_, 2010_CD ._.
In_IN certain_JJ to_TO launching_VBG this_DT product_NN in_IN early_JJ 2007_CD ._.
situations_NNS ,_, such_JJ as_IN the_DT entry_NN of_IN another_DT generic_JJ before_IN 2010_CD ,_, Impax_NNP may_MD be_VB permitted_VBN to_TO market_VB Shires_NNP ADDERALL_NNP XR_NNP in_IN the_DT US_NNP 10_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 11_CD We_PRP made_VBD good_JJ on_IN our_PRP$ strategic_JJ commitment_NN to_TO grow_VB our_PRP$ underlying_VBG business_NN while_IN expanding_VBG our_PRP$ portfolio_NN of_IN new_JJ products_NNS ._.
What_WP the_DT analysts_NNS say_VBP In_IN February_NNP 2006_CD ,_, we_PRP submitted_VBD a_DT MAA_NNP welcome_JJ to_TO them_PRP ,_, as_RB well_RB as_IN to_TO thank_VB all_DT for_IN MESAVANCE_NNP to_TO both_DT European_JJ and_CC members_NNS of_IN our_PRP$ team_NN around_IN the_DT world_NN for_IN We_PRP believe_VBP the_DT Company_NN has_VBZ Canadian_JJ Regulatory_NNP Agencies_NNPS ._.
During_IN 2006_CD their_PRP$ exceptional_JJ efforts_NNS and_CC dedication_NN one_CD of_IN the_DT best_JJS ,_, if_IN not_RB the_DT best_JJS and_CC the_DT first_JJ half_NN of_IN 2007_CD we_PRP also_RB expect_VBP to_TO :_: in_IN helping_VBG us_PRP achieve_VB our_PRP$ business_NN goals_NNS ._.
pipelines_NNS ,_, in_IN the_DT entire_JJ sector_NN as_IN we_PRP project_VBP it_PRP will_MD launch_VB at_IN launch_NN MESAVANCE_NNP in_IN the_DT US_NNP :_: Shires_NNS transformation_NN least_JJS seven_CD new_JJ products_NNS over_IN A_DT few_JJ years_NNS ago_RB ,_, we_PRP imagined_VBD a_DT new_JJ the_DT next_JJ three_CD years_NNS ._.
launch_NN DYNEPO_NNP for_IN anemia_NN in_IN Europe_NNP :_: Shire_NNP ._.
Since_IN then_RB weve_JJ transformed_VBN Shire_NNP Deutsche_NNP Bank_NNP to_TO deepen_VB our_PRP$ product_NN pipeline_NN ,_, enhance_VB November_NNP 3_CD ,_, 2005_CD launch_NN DAYTRANA_NNP in_IN the_DT US_NNP :_: our_PRP$ responsiveness_NN ,_, and_CC capitalize_VB on_IN opportunities_NNS in_IN the_DT global_JJ specialty_NN The_DT closure_NN of_IN the_DT acquisition_NN launch_NN NRP104_NNP in_IN the_DT US_NNP :_: pharmaceutical_JJ market_NN ._.
We_PRP are_VBP driven_VBN of_IN TKT_NNP on_IN July_NNP 27_CD ,_, marks_VBZ the_DT by_IN a_DT common_JJ objective_NN :_: to_TO make_VB the_DT most_RBS completion_NN of_IN the_DT major_JJ strategic_JJ launch_NN ELAPRASE_NNP in_IN the_DT US_NNP and_CC Europe_NNP :_: out_IN of_IN science_NN and_CC technology_NN to_TO increase_VB changes_NNS undertaken_VBN by_IN Shire_NNP since_IN the_DT number_NN of_IN projects_NNS we_PRP are_VBP undertaking_VBG the_DT appointment_NN of_IN Matt_NNP Emmens_NNP file_NN a_DT NDA_NNP with_IN the_DT FDA_NNP for_IN SPD465_NNP ,_, a_DT so_RB that_IN we_PRP can_MD help_VB many_JJ more_JJR people_NNS as_IN CEO_NNP in_IN 2003_CD ._.
longer-acting_JJ formulation_NN of_IN ADDERALL_NNP XR_NNP lead_NN healthier_RBR ,_, less_JJR impaired_JJ lives_NNS ._.
We_PRP are_VBP HSBC_NNP for_IN ADHD_NNP :_: delivering_VBG on_IN that_DT goal_NN ,_, and_CC can_MD all_DT be_VB proud_JJ September_NNP 21_CD ,_, 2005_CD of_IN our_PRP$ achievements_NNS ._.
file_NN a_DT NDA_NNP with_IN the_DT FDA_NNP for_IN SPD503_NNP ,_, We_PRP believe_VBP that_IN the_DT operational_JJ a_DT non-stimulant_JJ treatment_NN for_IN ADHD_NNP :_: Just_RB imagine_VB what_WP we_PRP can_MD achieve_VB in_IN performance_NN of_IN the_DT Company_NN over_IN the_DT future_NN ._.
the_DT next_JJ 12_CD months_NNS will_MD be_VB critical_JJ continue_VBP the_DT rollout_NN of_IN FOSRENOL_NNP for_IN the_DT long-term_JJ potential_NN of_IN Shire_NNP ._.
in_IN Europe_NNP :_: and_CC Morgan_NNP Stanley_NNP March_NNP 29_CD ,_, 2006_CD continue_VBP the_DT launch_NN of_IN FOSRENOL_NNP higher_JJR strengths_NNS in_IN the_DT US_NNP ._.
Strengthened_VBN management_NN team_NN Matthew_NNP Emmens_NNP Shire_NNP continued_VBD to_TO build_VB its_PRP$ senior_JJ management_NN team_NN in_IN 2005_CD and_CC we_PRP added_VBD proven_VBN talent_NN across_IN all_DT areas_NNS of_IN the_DT organization_NN and_CC to_TO our_PRP$ leadership_NN team_NN ._.
I_PRP am_VBP particularly_RB pleased_VBN to_TO welcome_VB David_NNP Pendergast_NNP ,_, former_JJ CEO_NNP of_IN TKT_NNP ,_, as_IN Executive_NNP Vice_NNP President_NNP Shire_NNP HGT_NNP ,_, and_CC Michael_NNP Cola_NNP ,_, formerly_RB President_NNP of_IN the_DT Life_NNP Sciences_NNPS division_NN of_IN Safeguard_NNP Scientifics_NNP Inc._NNP as_IN Executive_NNP Vice_NNP President_NNP for_IN Global_NNP Therapeutic_NNP Areas_NNS ._.
Both_DT bring_VBP a_DT wealth_NN of_IN experience_NN in_IN the_DT pharmaceutical_JJ industry_NN and_CC are_VBP welcome_JJ additions_NNS to_TO our_PRP$ Executive_NNP Committee_NNP ._.
With_IN the_DT acquisition_NN of_IN TKT_NNP and_CC the_DT strengthening_NN of_IN our_PRP$ organization_NN on_IN both_DT sides_NNS of_IN the_DT Atlantic_NNP ,_, we_PRP increased_VBD our_PRP$ staff_NN numbers_NNS by_IN 570_CD ,_, bringing_VBG our_PRP$ total_JJ All_DT products_NNS in_IN development_NN and_CC registration_NN are_VBP staff_NN numbers_NNS to_TO over_IN 2,400_CD highly-skilled_JJ subject_NN to_TO regulatory_JJ approvals_NNS ._.
I_PRP would_MD like_VB to_TO take_VB this_DT opportunity_NN to_TO extend_VB a_DT warm_JJ Source_NN :_: IMS_NNP Data_NNP 2005_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 11_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 12_CD prod_VBP ucts_VBZ 12_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 13_CD Product_NNP portfolio_NN Proven_NNP drugs_NNS ,_, profitable_JJ position_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 13_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 14_CD Product_NNP pipeline_NN Rich_NNP ,_, deep_JJ and_CC coming_VBG on_IN stream_NN ._.
Pipeline_NNP On_IN the_DT market_NN Central_NNP Nervous_NNP System_NNP CNS_NNP ADDERALL_NNP XR_NNP US_NNP CALCICHEW_NNP UK_NNP Ireland_NNP DAYTRANA_NNP approved_VBN by_IN FDA_NNP Mixed_NNP salts_NNS of_IN a_DT single-entity_JJ amphetamine_NN Calcium_NN carbonate_NN adjunct_NN in_IN Osteoporosis_NNP Methylphenidate_NNP transdermal_NN system_NN ADHD_NNP ADHD_NNP PROAMATINE_NNP AMATINE_NNP US_NNP ADDERALL_NNP US_NNP Midodrine_NNP hydrochloride_NN NRP104_NNP in_IN Registration_NNP US_NNP Mixed_NNP salts_NNS of_IN a_DT single-entity_JJ amphetamine_NN Postural_NNP Hypotension_NNP Amphetamine_NNP ADHD_NNP ADHD_NNP Royalties_NNPS SPD503_NNP Phase_NN 3_CD US_NNP CARBATROL_NNP US_NNP 3TC_NNP EPIVIR_NNP Worldwide_NNP Guanfacine_NNP ADHD_NNP Carbamazepine_NNP extended_VBD release_NN trademark_NN of_IN GlaxoSmithKline_NNP GSK_NNP capsules_NNS Epilepsy_NNP lamivudine_NN HIV_NNP SPD465_NNP Phase_NN 3_CD US_NNP Mixed_NNP salts_NNS of_IN a_DT single-entity_JJ amphetamine_NN EQUETRO_NNP US_NNP COMBIVIR_NNP Worldwide_NNP ADHD_NNP Carbamazepine_NNP extended_VBD release_NN trademark_NN of_IN GSK_NNP capsules_NNS Bipolar_NNP 1_CD Disorder_NN lamivudine_NN HIV_NNP Gastro-Intestinal_NNP GI_NNP MESAVANCE_NNP in_IN Registration_NNP EU_NNP US_NNP REMINYL_NNP REMINYL_NNP XL_NNP UK_NNP Ireland_NNP TRIZIVIR_NNP Worldwide_NNP 5-ASA_NNP mesalamine_NN UC_NNP Galantamine_NNP hydrobromide_NN trademark_NN of_IN GSK_NNP Alzheimers_NNP Disease_NNP lamivudine_NN HIV_NNP Shire_NNP HGT_NNP 1_CD I2S_CD ELAPRASE_NNP in_IN Registration_NNP EU_NNP US_NNP PENTASA_NNP US_NNP ZEFFIX_NNP EPIVIR_NNP HBV_NNP HEPTOVIR_NNP Worldwide_NNP Idursulfase_NNP Hunter_NNP Syndrome_NNP 5-ASA_NNP mesalamine_NN UC_NNP trademark_NN of_IN GSK_NNP lamivudine_NN Hepatitis_NNP B_NNP infection_NN GA-GCB_NNP Phase_NN 3_CD COLAZIDE_NNP UK_NNP EU_NNP US_NNP Gene-activated_VBD Gaucher_NNP Disease_NNP Balsalazide_NNP UC_NNP REMINYL_NNP REMINYL_NNP XL_NNP RAZADYNE_NNP RAZADYNE_NNP ER_NNP Worldwide_NNP General_NNP Products_NNPS REPLAGAL_NNP EU_NNP trademark_NN of_IN Johnson_NNP &_CC Johnson_NNP DYNEPO_NNP Manufacturing_NNP Registration_NNP Agalsidase_NNP alfa_NNP Fabry_NNP Disease_NNP excluding_VBG UK_NNP and_CC Republic_NNP of_IN Ireland_NNP Erythropoietin_NNP EPO_NNP Anemia_NNP in_IN chronic_JJ Galantamine_NNP hydrobromide_NN renal_JJ failure_NN FOSRENOL_NNP EU_NNP US_NNP Alzheimers_NNP Disease_NNP Lanthanum_NNP carbonate_NN Hyperphosphatemia_NNP All_NNP products_NNS in_IN development_NN and_CC registration_NN are_VBP subject_JJ to_TO regulatory_JJ approvals_NNS ._.
XAGRID_NNP AGRYLIN_NNP EU_NNP US_NNP 1_CD Anagrelide_NNP hydrochloride_NN This_DT is_VBZ not_RB a_DT comprehensive_JJ list_NN of_IN Thrombocythemia_NNP trademarks_NNS for_IN this_DT product_NN as_IN various_JJ others_NNS are_VBP used_VBN in_IN smaller_JJR markets_NNS ._.
14_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 15_CD pipe_NN line_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 15_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 16_CD Operating_NN review_NN peo_NN ple_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 17_CD Shire_NNP has_VBZ a_DT can_MD do_VB culture_NN based_VBN on_IN an_DT exceptional_JJ level_NN of_IN competence_NN ,_, experience_NN ,_, creativity_NN and_CC above_IN all_DT ,_, energy_NN ._.
This_DT is_VBZ what_WP makes_VBZ us_PRP unique_JJ and_CC destined_VBD for_IN success_NN ._.
Dr_NNP Eliseo_NNP Salinas_NNP Chief_NNP Scientific_NNP Officer_NNP and_CC Executive_NNP Vice_NNP President_NNP ,_, Global_NNP R&D_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 18_CD Operating_NN review_NN 01_CD 02_CD 03_CD Shires_NNP winning_VBG formula_NN Ms_NNP Deptula_NNP heads_VBZ a_DT team_NN which_WDT is_VBZ based_VBN both_DT Over_IN the_DT past_JJ 24_CD months_NNS ,_, Dr_NNP Salinas_NNP says_VBZ ,_, Highly-skilled_JJ and_CC dedicated_JJ people_NNS ,_, working_VBG in_IN the_DT UK_NNP and_CC US_NNP and_CC is_VBZ composed_VBN of_IN highly_RB Shire_NNP has_VBZ delivered_VBN on_IN its_PRP$ promises_NNS while_IN together_RB across_IN functions_NNS and_CC on_IN a_DT global_JJ experienced_JJ and_CC dedicated_JJ professionals_NNS with_IN drastically_RB transforming_VBG the_DT way_NN it_PRP operates_VBZ basis_NN ,_, to_TO develop_VB and_CC market_VB specialty_NN both_DT scientific_JJ and_CC business_NN backgrounds_NNS ._.
Management_NN has_VBZ done_VBN exactly_RB pharmaceuticals_NNS that_WDT fill_VBP unmet_JJ medical_JJ needs_NNS ._.
Business_NN development_NN efforts_NNS are_VBP coordinated_VBN what_WP it_PRP said_VBD it_PRP would_MD do_VB :_: divest_VB non-core_JJ throughout_IN the_DT Company_NN ,_, with_IN ideas_NNS and_CC businesses_NNS to_TO reinvest_VB freed-up_JJ resources_NNS in_IN These_DT ,_, in_IN a_DT nutshell_NN ,_, are_VBP the_DT qualities_NNS that_WDT make_VBP contacts_NNS gained_VBD from_IN individuals_NNS across_IN the_DT the_DT core_NN ones_NNS ._.
In_IN R&D_NNP ,_, this_DT has_VBZ translated_VBN into_IN Shire_NNP one_CD of_IN the_DT fastest_JJS growing_VBG specialty_NN organization_NN ._.
Shires_NNP interdisciplinary_JJ structure_NN applying_VBG additional_JJ resources_NNS ,_, defining_VBG new_JJ companies_NNS in_IN todays_NNS pharmaceutical_JJ industry_NN ._.
allows_VBZ integrating_VBG the_DT specific_JJ technical_JJ and_CC processes_VBZ to_TO increase_VB efficiency_NN and_CC reliability_NN ,_, scientific_JJ input_NN brought_VBN by_IN each_DT function_NN into_IN and_CC increasing_VBG the_DT ownership_NN and_CC control_NN of_IN Shire_NNP is_VBZ a_DT very_RB dynamic_JJ organization_NN ,_, says_VBZ a_DT coherent_JJ plan_NN that_WDT helps_VBZ meet_VB long-term_JJ our_PRP$ data_NNS while_IN still_RB relying_VBG on_IN outside_JJ vendors_NNS ._.
Barbara_NNP Deptula_NNP ,_, Shires_NNP Executive_NNP Vice_NNP corporate_JJ objectives_NNS ,_, she_PRP notes_VBZ ._.
Its_PRP$ like_IN Dr_NNP Salinas_NNP notes_VBZ that_IN Shire_NNP has_VBZ decided_VBN to_TO a_DT small_JJ start-up_JJ entrepreneurial_JJ company_NN Replenishing_NNP Shires_NNP pipeline_NN concentrate_NN on_IN the_DT core_NN areas_NNS of_IN CNS_NNP ,_, GI_NNP and_CC but_CC has_VBZ all_PDT the_DT infrastructure_NN ,_, support_NN and_CC Shires_NNP Business_NNP Development_NNP team_NN is_VBZ firmly_RB General_NNP Products_NNPS GP_NNP such_JJ as_IN renal_JJ therapies_NNS ,_, people_NNS of_IN a_DT large_JJ company_NN ._.
In_IN this_DT kind_NN committed_VBN to_TO expanding_VBG and_CC constantly_RB each_DT led_VBN by_IN dedicated_JJ Strategic_NNP Therapeutic_NNP of_IN environment_NN ,_, everyone_NN can_MD contribute_VB replenishing_VBG Shires_NNP product_NN pipeline_NN ._.
In_IN addition_NN ,_, with_IN the_DT to_TO the_DT success_NN of_IN the_DT organization_NN ,_, which_WDT Accordingly_RB ,_, it_PRP is_VBZ on_IN the_DT lookout_NN for_IN in-licensing_JJ acquisition_NN of_IN TKT_NNP ,_, Shire_NNP has_VBZ a_DT new_JJ biologics_NNS is_VBZ very_RB appealing_JJ to_TO me_PRP ._.
opportunities_NNS for_IN new_JJ products_NNS essentially_RB in_IN business_NN bringing_VBG exciting_JJ new_JJ products_NNS to_TO its_PRP$ Phase_NN 2_CD or_CC 3_CD with_IN robust_JJ intellectual_JJ property_NN portfolio_NN ._.
The_DT Shire_NNP HGT_NNP business_NN is_VBZ managed_VBN Shires_NNP adoption_NN of_IN a_DT global_JJ operating_NN structure_NN ,_, that_WDT offer_VBP a_DT strategic_JJ fit_NN with_IN Shires_NNP current_JJ by_IN Dr_NNP David_NNP Pendergast_NNP ._.
Shire_NNP has_VBZ very_RB with_IN cross-functional_JJ teams_NNS dedicated_VBN to_TO business_NN and_CC allow_VB for_IN use_NN of_IN the_DT Companys_NNP interesting_JJ compounds_NNS under_IN development_NN developing_VBG and_CC marketing_VBG products_NNS in_IN core_NN expanding_VBG specialty_NN sales_NNS force_NN ._.
We_PRP seek_VBP in_IN these_DT areas_NNS and_CC managing_VBG the_DT lifecycle_NN therapeutic_JJ areas_NNS ,_, gives_VBZ it_PRP a_DT competitive_JJ edge_NN product-oriented_JJ deals_NNS that_WDT would_MD add_VB value_NN of_IN its_PRP$ current_JJ portfolio_NN will_MD be_VB important_JJ ._.
in_IN todays_NNS complex_JJ pharmaceutical_JJ market_NN ,_, to_TO a_DT targeted_JJ audience_NN of_IN specialist_NN physicians_NNS At_IN the_DT same_JJ time_NN ,_, we_PRP are_VBP actively_RB supporting_VBG adds_VBZ Dr_NNP Eliseo_NNP Salinas_NNP ,_, Chief_NNP Scientific_NNP Officer_NNP and_CC their_PRP$ patients_NNS ._.
There_EX are_VBP literally_RB thousands_NNS the_DT search_NN for_IN new_JJ molecules_NNS ,_, including_VBG and_CC Executive_NNP Vice_NNP President_NNP ,_, Global_NNP R&D_NNP ._.
of_IN opportunities_NNS in_IN the_DT market_NN and_CC its_PRP$ some_DT outside_IN these_DT areas_NNS on_IN an_DT opportunistic_JJ While_IN drug_NN development_NN is_VBZ a_DT global_JJ task_NN ,_, important_JJ that_IN we_PRP maintain_VBP a_DT focus_NN and_CC basis_NN as_RB long_RB as_IN they_PRP meet_VBP our_PRP$ risk_NN criteria_NNS ._.
customers_NNS in_IN regional_JJ markets_NNS can_MD be_VB very_RB prioritize_VB them_PRP ,_, says_VBZ Ms_NNP Deptula_NNP ._.
Her_PRP$ teams_NNS different_JJ ,_, he_PRP notes_VBZ ._.
Our_PRP$ structure_NN ensures_VBZ we_PRP biggest_JJS transaction_NN to_TO date_NN is_VBZ the_DT acquisition_NN Both_DT Ms_NNPS Deptula_NNP and_CC Dr_NNP Salinas_NNP say_VBP Shires_NNP stay_VB close_RB to_TO our_PRP$ customers_NNS and_CC understand_VB of_IN US_NNP biopharmaceutical_JJ company_NN TKT_NNP ._.
biggest_JJS trump_NN card_NN is_VBZ the_DT quality_NN and_CC talent_NN of_IN regional_JJ specificities_NNS ,_, with_IN their_PRP$ commercial_JJ It_PRP was_VBD a_DT very_RB exciting_JJ process_NN and_CC a_DT great_JJ its_PRP$ people_NNS ,_, who_WP share_VBP a_DT strong_JJ entrepreneurial_JJ and_CC economic_JJ realities_NNS ,_, allowing_VBG for_IN a_DT good_JJ opportunity_NN for_IN Shire_NNP ._.
It_PRP allows_VBZ us_PRP to_TO move_VB spirit_NN and_CC are_VBP highly_RB motivated_VBN ._.
Shire_NNP has_VBZ integration_NN of_IN basic_JJ science_NN and_CC medical_JJ needs_NNS ._.
into_IN a_DT new_JJ direction_NN while_IN still_RB ticking_VBG all_DT our_PRP$ a_DT can_MD do_VB culture_NN based_VBN on_IN an_DT exceptional_JJ strategic_JJ boxes_NNS ._.
level_NN of_IN competence_NN ,_, experience_NN ,_, creativity_NN Ms_NNP Deptula_NNP ,_, a_DT pharmacist_NN and_CC MBA_NNP in_IN finance_NN ,_, and_CC above_IN all_DT ,_, energy_NN ._.
This_DT is_VBZ what_WP makes_VBZ has_VBZ 20_CD years_NNS of_IN pharmaceutical_JJ experience_NN in_IN Dr_NNP Salinas_NNP ,_, a_DT Psychiatrist_NN with_IN a_DT Masters_NNP us_PRP unique_JJ and_CC destined_VBD for_IN success_NN ._.
Since_IN Degree_NN in_IN Pharmacology_NNP and_CC 15_CD years_NNS joining_VBG Shire_NNP in_IN September_NNP 2004_CD ,_, she_PRP has_VBZ been_VBN of_IN industry_NN experience_NN ,_, says_VBZ Shires_NNP model_NN of_IN developing_VBG a_DT Company-wide_JJ ,_, streamlined_JJ searching_VBG and_CC developing_VBG lower-risk_JJ products_NNS business_NN development_NN process_NN ._.
We_PRP are_VBP now_RB is_VBZ what_WP attracted_VBD him_PRP to_TO join_VB the_DT Company_NN able_JJ more_RBR effectively_RB to_TO identify_VB ,_, evaluate_VB in_IN 2004_CD ._.
We_PRP are_VBP focusing_VBG on_IN searching_VBG and_CC act_NN on_IN product_NN ideas_NNS and_CC opportunities_NNS ,_, and_CC developing_VBG molecules_NNS intended_VBN for_IN the_DT including_VBG partnerships_NNS ,_, which_WDT will_MD contribute_VB specialist_NN ,_, where_WRB the_DT added_VBN medical_JJ value_NN to_TO our_PRP$ growth_NN ._.
We_PRP can_MD react_VB expeditiously_RB of_IN the_DT compound_NN is_VBZ more_RBR important_JJ than_IN and_CC with_IN an_DT entrepreneurial_JJ spirit_NN ._.
This_DT approach_NN is_VBZ good_JJ for_IN our_PRP$ business_NN and_CC for_IN society_NN as_IN a_DT whole_NN ._.
18_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 19_CD 04_CD 05_CD 01_CD Supporting_VBG a_DT global_JJ vision_NN FOSRENOL_NNP ,_, ELAPRASE_NNP and_CC MESAVANCE_NNP ,_, Shire_NNP is_VBZ increasingly_RB attractive_JJ to_TO In_IN todays_NNS pharmaceutical_JJ industry_NN ,_, bringing_VBG and_CC becoming_VBG the_DT best_JJS specialty_NN prospective_JJ partners_NNS small_JJ enough_RB the_DT right_JJ products_NNS to_TO market_NN in_IN a_DT timely_JJ pharmaceutical_JJ Company_NN in_IN the_DT world_NN with_IN to_TO care_VB ,_, large_JJ enough_JJ to_TO deliver_VB ._.
manner_NN is_VBZ a_DT critical_JJ challenge_NN ,_, requiring_VBG expert_NN the_DT most_RBS dedicated_JJ employees_NNS to_TO achieve_VB David_NNP Colpman_NNP knowledge_NN of_IN complex_JJ regulatory_JJ requirements_NNS this_DT goal_NN ._.
Companies_NNS always_RB like_VBP to_TO talk_VB Vice_NNP President_NNP ,_, Business_NNP and_CC a_DT highly_RB focused_VBN commercialization_NN about_IN the_DT future_NN being_VBG bright_JJ ._.
Here_RB ,_, we_PRP can_MD Development_NNP strategy_NN ._.
For_IN a_DT global_JJ Company_NN such_JJ as_IN Shire_NNP ,_, use_VBP that_IN phrase_NN with_IN absolute_JJ conviction_NN ._.
this_DT challenge_NN is_VBZ heightened_VBN by_IN the_DT need_NN 02_CD to_TO gain_VB new_JJ product_NN approvals_NNS from_IN dozens_NNS Our_PRP$ regulatory_JJ experts_NNS on_IN both_DT sides_NNS of_IN The_DT TKT_NNP acquisition_NN was_VBD a_DT perfect_JJ of_IN regulatory_JJ bodies_NNS worldwide_NN while_IN managing_VBG the_DT Atlantic_NNP work_NN closely_RB with_IN all_PDT the_DT STATs_NNS ,_, fit_VBP with_IN Shires_NNP strategy_NN ._.
Looking_VBG hundreds_NNS of_IN existing_VBG product_NN licences_NNS and_CC our_PRP$ R&D_NNP and_CC manufacturing_VBG colleagues_NNS forward_RB ,_, we_PRP will_MD continue_VB to_TO expand_VB ensuring_VBG all_DT products_NNS efficiently_RB reach_VBP their_PRP$ and_CC worldwide_JJ regulatory_JJ agencies_NNS within_IN the_DT specialty_NN arena_NN ._.
to_TO ensure_VB the_DT successful_JJ registration_NN and_CC Suzanne_NNP Hare_NNP commercialization_NN of_IN Shires_NNP new_JJ and_CC existing_VBG Senior_JJ Corporate_JJ Evaluations_NNS At_IN Shire_NNP ,_, these_DT vital_JJ tasks_NNS are_VBP overseen_VBN by_IN products_NNS ,_, explains_VBZ Doug_NNP Hay_NNP ,_, Shires_NNP Senior_NNP Director_NNP STATs_NNP responsible_JJ for_IN the_DT Companys_NNPS core_NN Vice_NNP President_NNP ,_, Global_NNP Regulatory_NNP Affairs_NNPS ._.
businesses_NNS :_: CNS_NNP ,_, GI_NNP and_CC GP_NNP and_CC a_DT Global_JJ Their_PRP$ role_NN is_VBZ proactively_RB to_TO identify_VB and_CC address_VB 03_CD Regulatory_NNP Affairs_NNP Group_NNP ._.
regulatory_JJ challenges_NNS to_TO minimize_VB potential_JJ This_DT is_VBZ a_DT time_NN where_WRB the_DT delays_NNS in_IN product_NN approvals_NNS and_CC optimize_VB Company_NN is_VBZ set-up_JJ for_IN future_JJ Mike_NNP Cola_NNP ,_, Executive_NNP Vice_NNP President_NNP ,_, Global_NNP approved_VBD labeling_VBG ._.
Therapeutic_JJ Area_NN ,_, says_VBZ his_PRP$ job_NN is_VBZ to_TO build_VB on_IN Arnaud_NNP Partiot_NNP this_DT work_NN by_IN leveraging_VBG the_DT Companys_NNPS global_JJ Building_NN relationships_NNS and_CC trust_NN Senior_JJ Vice_NNP President_NNP ,_, Global_JJ resources_NNS and_CC developing_VBG strategies_NNS to_TO ensure_VB Regulatory_NNP approvals_NNS have_VBP been_VBN complicated_VBN Clinical_NNP Research_NNP and_CC Development_NNP approved_VBD products_NNS get_VB to_TO the_DT patients_NNS who_WP in_IN recent_JJ years_NNS by_IN increasing_VBG agency_NN scrutiny_NN need_VBP them_PRP ._.
The_DT essence_NN of_IN a_DT great_JJ company_NN on_IN drug_NN safety_NN and_CC effectiveness_NN relative_JJ 04_CD is_VBZ a_DT culture_NN of_IN commitment_NN ,_, excellence_NN to_TO standards_NNS of_IN care_NN ._.
With_IN regard_NN to_TO safety_NN ,_, Our_PRP$ regulatory_JJ experts_NNS on_IN both_DT and_CC discipline_NN ._.
The_DT aim_NN is_VBZ to_TO focus_VB on_IN your_PRP$ regulatory_JJ agencies_NNS worldwide_NN are_VBP seeking_VBG sides_NNS of_IN the_DT Atlantic_NNP work_NN closely_RB customers_NNS and_CC provide_VB them_PRP with_IN the_DT greater_JJR assurance_NN that_IN a_DT drug_NN is_VBZ not_RB associated_VBN with_IN all_PDT the_DT STATs_NNS ,_, our_PRP$ R&D_NNP and_CC best_JJS products_NNS and_CC services_NNS in_IN the_DT industry_NN ._.
with_IN adverse_JJ events_NNS that_WDT may_MD not_RB be_VB detected_VBN manufacturing_VBG colleagues_NNS and_CC Physicians_NNP tell_VBP us_PRP what_WP they_PRP need_VBP and_CC our_PRP$ in_IN clinical_JJ trials_NNS ._.
In_IN addition_NN ,_, many_JJ agencies_NNS worldwide_JJ regulatory_JJ agencies_NNS to_TO role_NN is_VBZ to_TO come_VB up_RP with_IN the_DT answers_NNS ,_, he_PRP says_VBZ ._.
are_VBP requiring_VBG more_JJR definitive_JJ data_NN concerning_VBG ensure_VB the_DT successful_JJ registration_NN To_TO provide_VB this_DT level_NN of_IN service_NN the_DT key_NN a_DT drugs_NNS effectiveness_NN in_IN comparison_NN and_CC commercialization_NN of_IN Shires_NNP is_VBZ to_TO build_VB an_DT effective_JJ link_NN between_IN product_NN to_TO approved_VBN therapies_NNS ._.
We_PRP work_VBP closely_RB new_JJ and_CC existing_JJ products_NNS ._.
development_NN and_CC marketing_NN to_TO ensure_VB with_IN our_PRP$ R&D_NNP colleagues_NNS ,_, strategic_JJ and_CC Doug_NNP Hay_NNP successful_JJ delivery_NN ._.
In_IN order_NN to_TO do_VB that_IN you_PRP commercial_JJ teams_NNS ,_, as_RB well_RB as_IN manufacturing_NN ,_, Senior_JJ Vice_NNP President_NNP ,_, Global_NNP need_VBP to_TO further_JJ strengthen_VB the_DT connection_NN to_TO optimize_VB development_NN programs_NNS and_CC their_PRP$ Regulatory_NNP Affairs_NNPS between_IN the_DT Companys_NNP STATs_NNP and_CC functional_JJ documentation_NN for_IN each_DT registration_NN dossier_NN ,_, units_NNS ,_, building_VBG a_DT matrix_NN that_WDT enables_VBZ Shire_NNP says_VBZ Dr_NNP Hay_NNP ._.
Externally_RB ,_, this_DT requires_VBZ more_RBR 05_CD people_NNS to_TO work_VB together_RB toward_IN well-defined_JJ frequent_JJ communication_NN and_CC meetings_NNS We_PRP are_VBP building_VBG a_DT truly_RB multiand_JJ measurable_JJ goals_NNS ._.
with_IN regulatory_JJ agencies_NNS and_CC the_DT building_NN product_NN ,_, multi-therapeutic_JJ and_CC of_IN stronger_JJR professional_JJ relationships_NNS ,_, global_JJ organization_NN ,_, to_TO become_VB Aligning_VBG the_DT global_JJ effort_NN broader_JJR respect_NN and_CC trust_NN ._.
the_DT best_JJS specialty_NN pharmaceutical_JJ Mr_NNP Cola_NN who_WP joined_VBD Shire_NNP in_IN mid-2005_NN with_IN company_NN ,_, in_IN the_DT world_NN ._.
a_DT wealth_NN of_IN pharmaceutical_JJ industry_NN and_CC Shire_NNP boasts_VBZ a_DT dedicated_JJ ,_, experienced_JJ and_CC Mike_NNP Cola_NNP business_NN experience_NN gained_VBD at_IN companies_NNS talented_VBD team_NN of_IN regulatory_JJ professionals_NNS Executive_NNP Vice_NNP President_NNP ,_, Global_NNP such_JJ as_IN AstraMerck_NNP ,_, AstraZeneca_NNP and_CC who_WP are_VBP highly_RB knowledgeable_JJ about_IN regional_JJ Therapeutic_NNP Area_NNP Safeguard_NNP Scientifics_NNP ,_, says_VBZ hes_NNS also_RB very_RB regulatory_JJ requirements_NNS and_CC accountable_JJ excited_VBN about_IN the_DT caliber_NN of_IN Shires_NNP people_NNS ._.
We_PRP have_VBP a_DT regulatory_JJ group_NN with_IN the_DT competence_NN ,_, expertise_NN and_CC Shire_NNP has_VBZ already_RB taken_VBN many_JJ of_IN the_DT capabilities_NNS that_WDT are_VBP far_RB beyond_IN those_DT normally_RB steps_NNS necessary_JJ to_TO establish_VB itself_PRP as_IN a_DT truly_RB expected_VBN of_IN a_DT company_NN our_PRP$ size_NN ,_, says_VBZ Dr_NNP Hay_NNP ._.
multi-product_NN ,_, multi-therapeutic_JJ ,_, global_JJ organization_NN ,_, he_PRP notes_VBZ ._.
It_PRP now_RB is_VBZ moving_VBG to_TO the_DT next_JJ tier_NN ,_, perfecting_VBG its_PRP$ business_NN model_NN ,_, introducing_VBG truly_RB global_JJ products_NNS such_JJ as_IN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 19_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 20_CD Operating_NN review_NN General_NNP Products_NNPS Our_PRP$ exible_JJ organizational_JJ structure_NN and_CC ability_NN to_TO focus_VB around_IN key_JJ business_NN goals_NNS allows_VBZ us_PRP to_TO seize_VB new_JJ opportunities_NNS faster_RBR than_IN anyone_NN else_RB ._.
David_NNP Milton_NNP Senior_NNP Vice_NNP President_NNP and_CC head_NN of_IN Shires_NNP GP_NNP STAT_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 21_CD 01_CD 02_CD 03_CD 01_CD General_NNP Products_NNPS GP_NNP Working_NNP closely_RB with_IN Shires_NNP Business_NNP Launching_NNP XAGRID_NNP in_IN Europe_NNP has_VBZ While_IN most_JJS of_IN the_DT pharmaceutical_JJ industry_NN Development_NNP team_NN ,_, members_NNS of_IN the_DT GP_NNP STAT_NNP been_VBN great_JJ and_CC the_DT future_NN for_IN the_DT is_VBZ struggling_VBG to_TO find_VB and_CC develop_VB new_JJ help_NN to_TO review_VB thousands_NNS of_IN disease_NN states_NNS and_CC renal_JJ portfolio_NN is_VBZ really_RB exciting_JJ ._.
products_NNS to_TO launch_VB ,_, Shire_NNP is_VBZ preparing_VBG to_TO assess_VB their_PRP$ suitability_NN to_TO Shire_NNP and_CC importance_NN Sally_NNP Gosden_NNP introduce_VB a_DT large_JJ number_NN of_IN new_JJ and_CC exciting_JJ to_TO specialist_NN physicians_NNS ._.
For_IN example_NN ,_, it_PRP played_VBD Hospital_NNP Business_NNP new_JJ medicines_NNS over_IN a_DT relatively_RB short_JJ period_NN a_DT key_JJ role_NN in_IN identifying_VBG TKT_NNP ,_, a_DT US-based_JJ of_IN time_NN ._.
According_VBG to_TO David_NNP Milton_NNP ,_, Senior_NNP biopharmaceutical_JJ company_NN specializing_VBG in_IN 02_CD Vice_NNP President_NNP and_CC head_NN of_IN Shires_NNP GP_NNP STAT_NNP ,_, therapeutics_NNS for_IN the_DT treatment_NN of_IN rare_JJ genetic_JJ At_IN Shire_NNP we_PRP can_MD make_VB a_DT difference_NN ._.
this_DT is_VBZ the_DT direct_JJ result_NN of_IN the_DT Companys_NNP diseases_NNS caused_VBN by_IN protein_NN deficiencies_NNS ,_, as_IN a_DT A_DT difference_NN to_TO patients_NNS ,_, to_TO doctors_NNS successful_JJ strategy_NN of_IN identifying_VBG and_CC strategic_JJ acquisition_NN in_IN 2005_CD ._.
This_DT was_VBD our_PRP$ first_JJ with_IN medicines_NNS that_WDT are_VBP needed_VBN ,_, focusing_VBG on_IN a_DT number_NN of_IN new_JJ ,_, late_JJ stage_NN major_JJ acquisition_NN since_IN the_DT introduction_NN of_IN the_DT I_PRP really_RB have_VBP the_DT scope_NN to_TO make_VB pipeline_NN products_NNS ._.
STAT_NNP operating_VBG model_NN and_CC represents_VBZ a_DT perfect_JJ things_NNS happen_VB ._.
strategic_JJ fit_NN for_IN Shire_NNP ,_, says_VBZ Mr_NNP Milton_NNP ._.
TKTs_NNS Sheila_NNP Stranks_NNP Shires_NNP strategy_NN of_IN focusing_VBG on_IN the_DT key_JJ differentiated_JJ products_NNS with_IN long_JJ product_NN life_NN General_NNP Manager_NNP ,_, GP_NNP STAT_NNP pharmaceutical_JJ markets_NNS of_IN North_NNP America_NNP cycles_NNS ,_, specialist_NN prescribers_NNS and_CC clear_JJ unmet_JJ and_CC top_JJ five_CD European_JJ countries_NNS ,_, on_IN diseases_NNS medical_JJ needs_NNS are_VBP highly_RB complementary_JJ to_TO 03_CD treated_VBN by_IN specialist_NN physicians_NNS ,_, and_CC on_IN a_DT Shires_NNP business_NN and_CC commercial_JJ capabilities_NNS ._.
Our_PRP$ team_NN is_VBZ incredibly_RB motivated_JJ pipeline_NN of_IN late_JJ stage_NN products_NNS ,_, has_VBZ enabled_VBN by_IN the_DT future_NN of_IN our_PRP$ UK_NNP business_NN ._.
us_PRP to_TO build_VB a_DT rapidly_RB growing_VBG business_NN with_IN Two_CD global_JJ product_NN launches_NNS We_PRP are_VBP now_RB looking_VBG forward_RB an_DT impressive_JJ portfolio_NN of_IN innovative_JJ products_NNS ,_, 2005_CD also_RB saw_VBD the_DT launch_NN of_IN Shires_NNP first_RB two_CD to_TO the_DT successful_JJ launches_NNS he_PRP says_VBZ ._.
truly_RB global_JJ products_NNS :_: FOSRENOL_NNP Shires_NNPS new_JJ of_IN FOSRENOL_NNP ,_, MESAVANCE_NNP phosphate_NN binder_NN that_WDT reduces_VBZ elevated_JJ blood_NN and_CC DYNEPO_NNP ._.
One_CD of_IN the_DT important_JJ roles_NNS of_IN the_DT GP_NNP STAT_NNP levels_NNS of_IN phosphate_NN in_IN patients_NNS with_IN End-Stage_NNP John_NNP Freeman_NNP is_VBZ to_TO help_VB identify_VB ,_, search_NN and_CC support_VB the_DT Renal_NNP Disease_NNP ESRD_NNP ,_, in_IN the_DT US_NNP ,_, and_CC XAGRID_NNP Managing_VBG Director_NNP ,_, Commercial_NNP acquisition_NN of_IN new_JJ products_NNS through_IN ina_NN treatment_NN for_IN chronic_JJ disorder_NN of_IN bone_NN licensing_NN or_CC merger_NN &_CC acquisition_NN in_IN new_JJ marrow_NN associated_VBN with_IN the_DT increased_VBN therapy_NN areas_NNS that_WDT meet_VBP Shires_NNP strategy_NN of_IN production_NN of_IN blood_NN platelets_NNS ,_, in_IN Europe_NNP ._.
targeting_VBG specialist_JJ diseases_NNS with_IN significant_JJ unmet_JJ medical_JJ needs_NNS and_CC growth_NN potential_NN ._.
Both_DT these_DT launches_NNS have_VBP been_VBN successful_JJ ,_, It_PRP also_RB works_VBZ closely_RB with_IN the_DT Companys_NNP says_VBZ Mr_NNP Milton_NNP ._.
XAGRID_NNP is_VBZ enjoying_VBG good_JJ Regulatory_NNP Affairs_NNPS team_NN to_TO obtain_VB global_JJ market_NN acceptance_NN across_IN Europe_NNP ,_, it_PRP has_VBZ registration_NN for_IN new_JJ products_NNS ,_, manages_VBZ some_DT been_VBN designated_VBN an_DT orphan_JJ medicinal_JJ 80_CD products_NNS in_IN the_DT GP_NNP portfolio_NN and_CC oversees_VBZ product_NN ,_, providing_VBG it_PRP with_IN up_RB to_TO ten_VB years_NNS relationships_NNS with_IN partner_NN organizations_NNS such_JJ market_NN exclusivity_NN in_IN Europe_NNP ._.
GSK_NNP markets_NNS Shires_NNP patented_VBD 3TC_NNP that_IN over_IN 40,000_CD patients_NNS suffer_VBP from_IN Essential_JJ lamivudine_NN ,_, which_WDT is_VBZ a_DT key_JJ component_NN in_IN Thrombocythemia_NNP across_IN the_DT EU_NNP ,_, where_WRB it_PRP is_VBZ FOSRENOL_NNP demonstrates_VBZ reliable_JJ most_RBS HIV_JJ combination_NN treatment_NN regimes_VBZ and_CC currently_RB the_DT only_JJ approved_JJ platelet-reducing_JJ efficacy_NN and_CC safety_NN in_IN many_JJ wellis_NNS also_RB used_VBD to_TO treat_VB Chronic_NNP Hepatitis_NNP B._NNP treatment_NN across_IN Europe_NNP ._.
By_IN the_DT end_NN of_IN 2005_CD ,_, designed_VBN clinical_JJ trials_NNS ,_, with_IN the_DT GSK_NNP pays_VBZ a_DT royalty_NN on_IN sales_NNS of_IN 3TC_CD to_TO Shire_NNP ._.
FOSRENOL_NNP had_VBD captured_VBN over_IN 8_CD %_NN of_IN new_JJ added_VBN benefit_NN of_IN a_DT lower_JJR pill_NN burden_NN ._.
US_NNP phosphate_NN binder_NN scrips_NNS and_CC had_VBD been_VBN I_PRP believe_VBP that_IN FOSRENOL_NNP leads_VBZ us_PRP The_DT work_NN of_IN the_DT GP_NNP STAT_NNP is_VBZ a_DT major_JJ approved_VBN in_IN Europe_NNP ,_, where_WRB it_PRP will_MD be_VB rolled_VBN closer_RBR to_TO the_DT ideal_JJ phosphate_NN binder_NN ._.
contributor_NN to_TO Shires_NNP future_NN ,_, says_VBZ Mr_NNP Milton_NNP ,_, out_RB in_IN 2006_CD ._.
Dr_NNP Alastair_NNP Hutchison_NNP a_DT biochemist_NN and_CC MBA_NNP with_IN almost_RB 25_CD years_NNS Manchester_NNP Institute_NNP of_IN Nephrology_NNP of_IN pharmaceutical_JJ industry_NN experience_NN FOSRENOL_NNP ,_, the_DT subject_NN of_IN nine_CD years_NNS &_CC Transplantation_NN ,_, UK_NNP in_IN strategic_JJ commercial_JJ planning_NN ,_, portfolio_NN of_IN research_NN and_CC development_NN ,_, clinical_JJ studies_NNS prioritization_NN ,_, resource_NN allocation_NN ,_, and_CC business_NN and_CC regulatory_JJ reviews_NNS ,_, received_VBD FDA_NNP development_NN ._.
Our_PRP$ portfolio_NN of_IN marketed_VBN approval_NN in_IN October_NNP 2004_CD ,_, six_CD months_NNS after_IN products_NNS around_IN the_DT world_NN makes_VBZ a_DT critical_JJ it_PRP received_VBD its_PRP$ first_JJ European_JJ regulatory_JJ contribution_NN to_TO the_DT bottom_JJ line_NN and_CC enables_VBZ approval_NN from_IN Sweden_NNP ._.
FOSRENOL_NNP is_VBZ the_DT us_PRP to_TO fund_VB our_PRP$ ongoing_JJ R&D_NNP ,_, infrastructure_NN first_JJ Shire_NNP compound_NN taken_VBN from_IN the_DT test_NN tube_NN and_CC business_NN development_NN activities_NNS ._.
to_TO approval_NN and_CC is_VBZ strategically_RB very_RB important_JJ for_IN us_PRP ,_, says_VBZ Mr_NNP Milton_NNP ,_, noting_VBG that_IN the_DT drug_NN has_VBZ been_VBN studied_VBN more_RBR extensively_RB than_IN any_DT other_JJ phosphate_NN binder_NN prior_RB to_TO launch_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 21_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 22_CD Operating_NN review_NN General_NNP Products_NNPS 04_CD 05_CD 06_CD 04_CD In_IN March_NNP 2005_CD ,_, regulatory_JJ authorities_NNS in_IN the_DT He_PRP notes_VBZ that_IN in_IN order_NN for_IN Shire_NNP therapeutic_JJ Interactions_NNS with_IN enthusiastic_JJ and_CC EU_NNP granted_VBD marketing_NN authorization_NN for_IN teams_NNS to_TO work_VB together_RB ,_, it_PRP is_VBZ important_JJ that_IN experienced_JJ people_NNS at_IN Shire_NNP make_VBP FOSRENOL_NNP in_IN 16_CD member_NN states_NNS ,_, completing_VBG they_PRP share_VBP a_DT clear_JJ and_CC common_JJ vision_NN ._.
From_IN it_PRP a_DT stimulating_VBG place_NN to_TO work_VB ._.
the_DT first_JJ step_NN in_IN securing_VBG marketing_NN approval_NN this_DT foundation_NN a_DT comprehensive_JJ plan_NN of_IN action_NN Prerak_NNP Mehta_NNP throughout_IN the_DT remainder_NN of_IN the_DT EU_NNP ._.
can_MD be_VB developed_VBN ,_, with_IN individuals_NNS and_CC teams_NNS Medical_NNP Information_NNP Associate_NNP assigned_VBN to_TO critical_JJ activities_NNS ,_, pulling_VBG together_RB Two_CD additional_JJ studies_NNS released_VBN in_IN 2005_CD further_RB the_DT best_JJS talent_NN within_IN the_DT organization_NN ._.
05_CD confirmed_VBD the_DT safety_NN and_CC efficacy_NN profile_NN of_IN In_IN this_DT way_NN ,_, it_PRP is_VBZ possible_JJ to_TO maximize_VB fully_RB These_DT are_VBP very_RB exciting_JJ times_NNS for_IN FOSRENOL_NNP ._.
Data_NNP presented_VBD at_IN the_DT National_NNP the_DT talent_NN within_IN our_PRP$ organization_NN ,_, irrespective_RB Shire_NNP as_IN we_PRP expand_VBP the_DT portfolio_NN Kidney_NNP Foundation_NNP 2005_CD clinical_JJ meeting_NN in_IN of_IN function_NN ,_, department_NN or_CC location_NN ._.
Once_RB with_IN true_JJ global_JJ brands_NNS ._.
Washington_NNP ,_, DC_NNP in_IN May_NNP showed_VBD that_IN in_IN vitro_NN their_PRP$ goals_NNS have_VBP been_VBN accomplished_VBN ,_, these_DT Shirley_NNP Wakelin_NNP FOSRENOL_NNP binds_VBZ phosphate_NN across_IN a_DT broad_JJ teams_NNS can_MD be_VB disbanded_VBN and_CC new_JJ teams_NNS Director_NNP ,_, Renal_NNP Products_NNPS ,_, GP_NNP STAT_NNP pH_NNP range_NN with_IN higher_JJR affinity_NN than_IN a_DT competitor_NN ,_, formed_VBN as_RB necessary_JJ ._.
Additional_JJ clinical_JJ 06_CD data_NNS presented_VBN at_IN the_DT American_NNP Society_NNP Shires_NNP decision_NN to_TO consolidate_VB its_PRP$ business_NN Teamwork_NNP and_CC effective_JJ regulatory_JJ of_IN Nephrology_NNP in_IN November_NNP showed_VBD that_IN to_TO fewer_JJR sites_NNS ,_, divest_VB non-core_JJ businesses_NNS ,_, dialogue_NN allows_VBZ us_PRP to_TO reach_VB our_PRP$ non-calcium_JJ FOSRENOL_NNP effectively_RB maintains_VBZ such_JJ as_IN vaccines_NNS ,_, and_CC focus_VB its_PRP$ resources_NNS goals_NNS and_CC achieve_VB our_PRP$ ambitions_NNS ._.
reductions_NNS in_IN mean_JJ serum_NN phosphorus_NN levels_NNS on_IN the_DT most_RBS important_JJ products_NNS in_IN Venetta_NNP Lunn_NNP while_IN demonstrating_VBG safety_NN and_CC tolerability_NN development_NN also_RB gives_VBZ it_PRP a_DT competitive_JJ Senior_JJ Director_NNP ,_, Regulatory_NNP Affairs_NNP in_IN ESRD_NNP patients_NNS for_IN up_RB to_TO six_CD years_NNS ._.
advantage_NN in_IN todays_NNS market_NN ,_, Mr_NNP Milton_NNP notes_NNS ._.
Most_JJS pharmaceutical_JJ companies_NNS The_DT GP_NNP STAT_NNP has_VBZ also_RB contributed_VBN in_IN recent_JJ have_VBP traditionally_RB attempted_VBN to_TO do_VB everything_NN years_NNS to_TO the_DT launch_NN of_IN several_JJ other_JJ new_JJ in-house_NN ,_, from_IN basic_JJ research_NN through_IN products_NNS ,_, including_VBG SOLARAZE_NNP ,_, a_DT leading_VBG development_NN ,_, manufacturing_NN ,_, sales_NNS and_CC topical_JJ treatment_NN for_IN actinic_JJ keratosis_NN ,_, and_CC marketing_NN ,_, Shires_NNP strategy_NN is_VBZ to_TO focus_VB VANIQA_NNP ,_, a_DT new_JJ product_NN designed_VBN to_TO slow_VB only_RB on_IN those_DT areas_NNS of_IN critical_JJ importance_NN ._.
unwanted_JJ facial_JJ hair_NN growth_NN in_IN women_NNS ._.
In_IN late_JJ By_IN out-sourcing_VBG less_JJR critical_JJ items_NNS ,_, it_PRP can_MD 2006_CD and_CC in_IN the_DT first_JJ half_NN of_IN 2007_CD ,_, it_PRP also_RB intends_VBZ concentrate_NN on_IN critical_JJ business_NN issues_NNS to_TO support_VB the_DT European_JJ launch_NN of_IN DYNEPO_NNP ,_, without_IN distraction_NN and_CC have_VBP the_DT ability_NN used_VBN for_IN the_DT treatment_NN of_IN kidney_NN diseaseto_NN change_NN direction_NN very_RB rapidly_RB ._.
related_JJ anemia_NN ,_, a_DT product_NN acquired_VBN from_IN Well_NNP for_IN me_PRP ,_, I_PRP take_VBP fewer_JJR tablets_NNS TKTs_NNS portfolio_NN ._.
This_DT strategy_NN has_VBZ clearly_RB delivered_VBN results_NNS over_IN the_DT past_JJ couple_NN of_IN years_NNS ._.
We_PRP have_VBP developed_VBN and_CC the_DT slightly_RB sweet_JJ taste_NN and_CC less_JJR chalky_JJ texture_NN makes_VBZ it_PRP a_DT lot_NN Remarkable_JJ track_NN record_NN and_CC launched_VBD several_JJ new_JJ products_NNS and_CC Mr_NNP Milton_NNP says_VBZ Shires_NNP remarkable_JJ track_NN record_NN achieved_VBD impressive_JJ sales_NNS growth_NN while_IN less_JJR troublesome_JJ to_TO chew_VB and_CC swallow_VB ._.
Three_CD months_NNS later_RB ,_, in_IN bringing_VBG new_JJ products_NNS to_TO market_NN has_VBZ been_VBN also_RB building_VBG a_DT development_NN pipeline_NN that_WDT enabled_VBD by_IN its_PRP$ nimble_JJ organization_NN structure_NN ,_, will_MD continue_VB to_TO fuel_VB Shires_NNP growth_NN in_IN the_DT my_PRP$ phosphorus_NN levels_NNS are_VBP three_CD points_NNS lower_JJR ._.
based_VBN around_IN the_DT principle_NN of_IN forming_VBG flexible_JJ ,_, next_JJ decade_NN ._.
multi-functional_JJ teams_NNS to_TO achieve_VB clear_JJ Wayne_NNP Jones_NNP FOSRENOL_NNP patient_NN business_NN goals_NNS ,_, and_CC by_IN a_DT corporate_JJ culture_NN Playing_VBG an_DT important_JJ role_NN in_IN the_DT search_NN and_CC that_IN champions_NNS creativity_NN and_CC innovation_NN ._.
evaluation_NN of_IN new_JJ business_NN opportunities_NNS that_WDT could_MD contribute_VB to_TO Shires_NNP future_JJ portfolio_NN Our_PRP$ flexible_JJ organizational_JJ structure_NN and_CC ability_NN of_IN products_NNS gives_VBZ Mr_NNP Milton_NNP the_DT greatest_JJS to_TO focus_VB around_IN key_JJ business_NN goals_NNS allows_VBZ job_NN satisfaction_NN ._.
As_IN a_DT manager_NN of_IN a_DT rapidly_RB us_PRP to_TO seize_VB new_JJ opportunities_NNS faster_RBR than_IN growing_VBG business_NN ,_, my_PRP$ biggest_JJS challenge_NN anyone_NN else_RB ,_, he_PRP says_VBZ ._.
We_PRP are_VBP also_RB blessed_VBN on_IN a_DT daily_JJ basis_NN is_VBZ balancing_VBG the_DT demands_NNS with_IN talented_JJ ,_, experienced_JJ and_CC hardworking_VBG for_IN investment_NN in_IN the_DT future_NN with_IN the_DT need_NN employees_NNS who_WP have_VBP a_DT drive_NN and_CC passion_NN for_IN to_TO maintain_VB a_DT healthy_JJ P&L_NN this_DT however_RB business_NN success_NN ._.
is_VBZ a_DT problem_NN many_JJ other_JJ industry_NN executives_NNS would_MD like_VB to_TO have_VB ._.
Data_NNP presented_VBD May_NNP 5_CD ,_, 2005_CD at_IN the_DT National_NNP Study_NNP published_VBD October_NNP 24_CD ,_, 2005_CD in_IN Nephron_NNP Kidney_NNP Foundation_NNP NKF_NNP 2005_CD clinical_JJ meeting_NN Clinical_NNP Practice_NNP ._.
Data_NNP presented_VBD November_NNP 12_CD ,_, 2005_CD at_IN the_DT annual_JJ meeting_NN of_IN the_DT American_NNP Society_NNP of_IN Nephrology_NNP ._.
22_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 23_CD Working_VBG with_IN the_DT FOSRENOL_NNP matrix_NN teams_NNS delivering_VBG Shires_NNP first_JJ global_JJ launch_NN is_VBZ an_DT exciting_JJ challenge_NN ._.
Diana_NNP Stokes_NNP General_NNP Manager_NNP ,_, Renal_NNP Products_NNPS 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 24_CD Operating_NN review_NN Gastro-Intestinal_JJ MESAVANCE_NNP could_MD be_VB the_DT most_RBS important_JJ product_NN for_IN mild_JJ to_TO moderately_RB active_JJ ulcerative_JJ colitis_NN launched_VBN in_IN more_JJR than_IN five_CD years_NNS ._.
Mike_NNP Yasick_NNP Senior_NNP Vice_NNP President_NNP ,_, GI_NNP Therapy_NNP Area_NNP Team_NNP Leader_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:53_CD Page_NNP 25_CD 01_CD 02_CD 01_CD Gastro-Intestinal_JJ GI_NNP accountability_NN for_IN performance_NN is_VBZ shared_VBN In_IN the_DT history_NN of_IN Shire_NNP ,_, excellence_NN Mike_NNP Yasick_NNP is_VBZ unequivocal_JJ about_IN his_PRP$ role_NN by_IN the_DT markets_NNS ,_, functions_NNS and_CC the_DT business_NN ._.
I_PRP lead_VBP a_DT diverse_JJ This_DT creates_VBZ an_DT environment_NN where_WRB ideas_NNS and_CC Excellence_NN is_VBZ what_WP we_PRP are_VBP all_DT about_RB ._.
group_NN of_IN Shire_NNP team_NN members_NNS whose_WP$ objective_JJ initiatives_NNS can_MD be_VB challenged_VBN and_CC tested_VBN by_IN Jeff_NNP Kirby_NNP is_VBZ to_TO build_VB our_PRP$ GI_NNP portfolio_NN and_CC successfully_RB many_JJ experts_NNS ._.
The_DT result_NN is_VBZ a_DT development_NN National_NNP Sales_NNP Director_NNP ,_, Specialty_NNP commercialize_VBP the_DT GI_NNP products_NNS we_PRP have_VBP and_CC and_CC commercialization_NN process_NN that_WDT optimizes_VBZ Products_NNPS optimize_VBP our_PRP$ marketed_VBN products_NNS ._.
We_PRP are_VBP the_DT value_NN of_IN our_PRP$ brands_NNS for_IN the_DT Company_NN helping_VBG to_TO develop_VB not_RB only_RB global_JJ products_NNS and_CC the_DT help_NN that_IN we_PRP provide_VBP to_TO patients_NNS ._.
02_CD and_CC strategy_NN in_IN this_DT promising_JJ therapeutic_JJ area_NN ,_, The_DT GI_NNP STAT_NNP has_VBZ great_JJ opportunities_NNS but_CC also_RB ensuring_VBG that_IN we_PRP have_VBP the_DT optimal_JJ The_DT power_NN of_IN teamwork_NN ahead_RB we_PRP are_VBP all_DT part_NN of_IN growing_VBG financial_JJ and_CC human_JJ resources_NNS available_JJ In_IN Mr_NNP Yasicks_NNPS opinion_NN ,_, strong_JJ teamwork_NN global_JJ organization_NN and_CC I_PRP look_VBP to_TO implement_VB our_PRP$ strategy_NN ._.
will_MD be_VB a_DT key_JJ success_NN driver_NN for_IN Shire_NNP moving_VBG forward_RB to_TO the_DT successful_JJ European_JJ forward_RB ._.
You_PRP get_VBP the_DT most_RBS robust_JJ analysis_NN launch_NN of_IN what_WP will_MD be_VB an_DT important_JJ Mr_NNP Yasick_NNP is_VBZ particularly_RB well_RB qualified_VBN for_IN and_CC solutions_NNS when_WRB people_NNS with_IN different_JJ global_JJ brand_NN ._.
the_DT challenge_NN ,_, with_IN 20_CD years_NNS of_IN experience_NN perspectives_NNS work_VBP together_RB ._.
The_DT role_NN of_IN STAT_NNP Richard_NNP Jones_NNP in_IN the_DT pharmaceuticals_NNS industry_NN in_IN sales_NNS ,_, is_VBZ to_TO define_VB the_DT objectives_NNS ,_, set_VBN metrics_NNS to_TO track_VB International_NNP Marketing_NNP Manager_NNP marketing_NN ,_, new_JJ product_NN development_NN and_CC and_CC evaluate_VB performance_NN and_CC to_TO allow_VB our_PRP$ commercialization_NN ._.
He_PRP says_VBZ he_PRP was_VBD attracted_VBN talented_JJ teams_NNS to_TO produce_VB the_DT outcomes_NNS 03_CD to_TO Shire_NNP because_IN it_PRP offered_VBD the_DT perfect_JJ mix_NN we_PRP need_VBP to_TO achieve_VB our_PRP$ goals_NNS ._.
People_NNS want_VBP Its_PRP$ exciting_JJ to_TO be_VB a_DT part_NN of_IN Shires_NNP between_IN a_DT solid_JJ ,_, well-resourced_JJ business_NN to_TO work_VB together_RB when_WRB they_PRP can_MD see_VB the_DT high-performing_JJ regulatory_JJ team_NN ._.
typical_JJ of_IN a_DT big_JJ pharmaceutical_JJ company_NN and_CC benefit_NN of_IN their_PRP$ collaboration_NN and_CC when_WRB they_PRP Tracy_NNP Rockney_NNP the_DT entrepreneurial_JJ environment_NN of_IN a_DT start-up_NN ,_, feel_VBP their_PRP$ efforts_NNS are_VBP valued_VBN by_IN the_DT teams_NNS ,_, Senior_JJ Director_NNP ,_, Regulatory_NNP Affairs_NNPS with_IN a_DT clear_JJ mission_NN to_TO be_VB a_DT leading_VBG specialist_NN he_PRP adds_VBZ ._.
The_DT real_JJ motivation_NN for_IN teamwork_NN 04_CD pharma_NN company_NN ._.
The_DT Companys_NNP employees_NNS comes_VBZ from_IN a_DT shared_VBN vision_NN of_IN the_DT future_JJ Shire_NNP has_VBZ one_CD of_IN the_DT richest_JJS portfolio_NN are_VBP accomplished_VBN ,_, energetic_JJ and_CC enthusiastic_JJ ._.
and_CC from_IN creating_VBG an_DT environment_NN of_IN of_IN products_NNS in_IN the_DT specialty_NN arena_NN It_PRP is_VBZ led_VBN by_IN a_DT new_JJ management_NN team_NN empowerment_NN ._.
We_PRP have_VBP to_TO both_DT trust_NN and_CC I_PRP am_VBP looking_VBG forward_RB to_TO being_VBG composed_VBN both_DT of_IN people_NNS who_WP have_VBP built_VBN Shire_NNP each_DT other_JJ and_CC be_VB willing_JJ to_TO challenge_VB part_NN of_IN making_VBG it_PRP a_DT success_NN ._.
into_IN a_DT billion_CD dollar_NN Company_NN as_RB well_RB as_IN people_NNS each_DT other_JJ to_TO achieve_VB the_DT best_JJS results_NNS ._.
Ronald_NNP Diebold_NNP with_IN fresh_JJ ideas_NNS and_CC best_JJS practices_NNS from_IN every_DT North_NNP America_NNP ,_, Commercial_NNP model_NN of_IN the_DT pharmaceutical_JJ industry_NN ._.
The_DT GI_NNP STAT_NNP is_VBZ composed_VBN of_IN a_DT small_JJ ,_, Development_NNP Manager_NNP dedicated_VBD group_NN of_IN employees_NNS with_IN an_DT Since_IN taking_VBG on_RP his_PRP$ new_JJ position_NN in_IN 2004_CD ,_, average_NN of_IN more_JJR than_IN 20_CD years_NNS of_IN experience_NN Mr_NNP Yasick_NNP has_VBZ been_VBN focusing_VBG on_IN implementing_VBG in_IN the_DT pharmaceutical_JJ industry_NN ._.
For_IN example_NN ,_, Shires_NNP new_JJ global_JJ operating_NN model_NN in_IN the_DT GI_NNP the_DT general_JJ manager_NN of_IN MESAVANCE_NNP ,_, Roger_NNP therapy_NN area_NN ._.
The_DT biggest_JJS challenge_NN has_VBZ been_VBN Adsett_NNP ,_, was_VBD the_DT US_NNP commercial_JJ lead_NN for_IN to_TO put_VB together_RB complete_JJ commercialization_NN the_DT launch_NN of_IN one_CD of_IN the_DT largest_JJS GI_NNP brands_NNS in_IN plans_NNS that_WDT ensure_VBP we_PRP have_VBP all_PDT the_DT bases_NNS the_DT world_NN :_: and_CC the_DT GI_NNP STATs_NNP Scientific_NNP Lead_JJ ,_, covered_JJ ._.
When_WRB you_PRP consider_VBP the_DT sweeping_JJ Robyn_NNP Karlstadt_NNP ,_, is_VBZ a_DT certified_JJ GI_NNP physician_NN changes_NNS in_IN roles_NNS and_CC structure_NN we_PRP have_VBP seen_VBN who_WP has_VBZ authored_VBN dozens_NNS of_IN papers_NNS and_CC was_VBD at_IN Shire_NNP in_IN the_DT past_JJ year_NN ,_, combined_VBN with_IN the_DT a_DT writer_NN and_CC editor_NN of_IN a_DT GI_NNP section_NN in_IN a_DT text_NN challenges_NNS of_IN meeting_NN launch_NN objectives_NNS and_CC book_NN ._.
Dr_NNP Karlstadt_NNP was_VBD also_RB a_DT key_JJ member_NN submitting_VBG a_DT NDA_NNP for_IN our_PRP$ newest_JJS product_NN ,_, of_IN the_DT launch_NN team_NN for_IN a_DT multi-billion_JJ dollar_NN Shires_NNP commitment_NN to_TO treating_VBG IBD_NNP MESAVANCE_NNP ,_, you_PRP feel_VBP truly_RB rewarded_VBN with_IN GI_NNP brand_NN ._.
Our_PRP$ team_NN knows_VBZ what_WP makes_VBZ has_VBZ already_RB improved_VBN many_JJ patients_NNS these_DT achievements_NNS !_.
successful_JJ brands_NNS and_CC has_VBZ hands-on_JJ lives_NNS ._.
I_PRP have_VBP prescribed_VBN PENTASA_NNP for_IN experience_NN in_IN executing_VBG those_DT plans_NNS ,_, says_VBZ many_JJ years_NNS and_CC look_VB forward_RB to_TO the_DT Mr_NNP Yasick_NNP says_VBZ Shires_NNP GI_NNP team_NN has_VBZ a_DT wellMr_NNP Yasick_NNP ._.
Our_PRP$ collective_JJ past_JJ success_NN approval_NN of_IN MESAVANCE_NNP ,_, a_DT product_NN deserved_VBD reputation_NN within_IN the_DT Company_NN is_VBZ the_DT best_JJS reason_NN to_TO be_VB confident_JJ in_IN our_PRP$ that_WDT will_MD in_IN my_PRP$ mind_NN ,_, set_VBD the_DT standard_NN as_IN being_VBG highly_RB collaborative_JJ and_CC effective_JJ ._.
ability_NN to_TO deliver_VB in_IN the_DT future_NN ._.
for_IN current_JJ and_CC future_JJ approved_VBN The_DT business_NN model_NN relies_VBZ on_IN people_NNS in_IN the_DT medications_NNS for_IN the_DT treatment_NN functions_NNS and_CC markets_NNS working_VBG together_RB in_IN of_IN patients_NNS with_IN IBD_NNP ._.
product_NN strategy_NN teams_NNS led_VBN by_IN product_NN general_JJ Dr_NNP Gary_NNP Lichtenstein_NNP ,_, MD_NNP managers_NNS and_CC our_PRP$ team_NN has_VBZ embraced_VBN this_DT Director_NNP IBD_NNP Program_NNP Division_NNP style_NN of_IN work_NN ._.
Shire_NNP is_VBZ unique_JJ in_IN that_DT of_IN Gastroenterology_NNP ,_, University_NNP of_IN Pennsylvania_NNP ,_, Philadelphia_NNP Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 25_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 26_CD Operating_NN review_NN Gastro-Intestinal_NNP 03_CD 04_CD Strong_JJ track_NN record_NN We_PRP are_VBP very_RB excited_VBN about_IN the_DT market_NN mesalamine_NN products_NNS ,_, only_RB MESAVANCE_NNP The_DT GI_NNP STAT_NNP will_MD be_VB building_VBG on_IN Shires_NNP already_RB potential_NN of_IN this_DT new_JJ product_NN and_CC by_IN delivering_VBG has_VBZ been_VBN clinically_RB proven_VBN to_TO do_VB that_DT ._.
strong_JJ track_NN record_NN in_IN the_DT GI_NNP therapeutic_JJ area_NN ,_, on_IN our_PRP$ promise_NN to_TO achieve_VB these_DT submissions_NNS ,_, With_IN PENTASA_NNP and_CC MESAVANCE_NNP ,_, Shire_NNP leveraging_VBG its_PRP$ extensive_JJ capabilities_NNS ,_, resources_NNS says_VBZ Mr_NNP Yasick_NNP ._.
There_EX are_VBP approximately_RB a_DT will_MD have_VB the_DT only_JJ two_CD products_NNS in_IN their_PRP$ class_NN and_CC expertise_NN to_TO bring_VB specialist_JJ projects_NNS million_CD patients_NNS worldwide_JJ with_IN UC_NNP and_CC more_JJR to_TO demonstrate_VB in_IN clinical_JJ studies_NNS the_DT ability_NN through_IN the_DT development_NN and_CC registration_NN than_IN 70_CD %_NN of_IN them_PRP are_VBP being_VBG treated_VBN with_IN to_TO control_VB symptoms_NNS and_CC induce_VB remission_NN phases_NNS in_IN the_DT most_RBS effective_JJ manner_NN ._.
MESAVANCE_NNP will_MD be_VB further_JJ our_PRP$ sales_NNS and_CC marketing_NN network_NN targeting_VBG has_VBZ a_DT chance_NN to_TO be_VB one_CD of_IN the_DT most_RBS important_JJ differentiated_VBN from_IN other_JJ products_NNS in_IN the_DT class_NN GI_NNP physicians_NNS ,_, we_PRP have_VBP had_VBN considerable_JJ product_NN launches_NNS in_IN mild_JJ to_TO moderately_RB because_IN Shire_NNP decided_VBD to_TO use_VB the_DT innovative_JJ success_NN in_IN the_DT commercialization_NN phase_NN ,_, severe_JJ UC_NN in_IN more_JJR than_IN five_CD years_NNS ._.
The_DT entire_JJ Phase_NN 3_CD study_NN design_NN ._.
Global_JJ experts_NNS were_VBD notes_NNS Mr_NNP Yasick_NNP ._.
Company_NN is_VBZ behind_IN MESAVANCE_NNP and_CC we_PRP surprised_VBD that_IN we_PRP would_MD be_VB willing_JJ to_TO include_VB will_MD launch_VB it_PRP with_IN passion_NN and_CC enthusiasm_NN ._.
the_DT market_NN leader_NN as_IN a_DT reference_NN arm_NN ,_, and_CC they_PRP Shire_VBP has_VBZ established_VBN itself_PRP among_IN the_DT market_NN were_VBD impressed_VBN with_IN the_DT results_NNS of_IN the_DT studies_NNS ._.
leaders_NNS in_IN drug_NN therapies_NNS for_IN UC_NNP ._.
UC_NNP is_VBZ a_DT MESAVANCE_NNP utilizes_VBZ a_DT novel_NN multimatrix_NN chronic_NN ,_, relapsing_VBG type_NN of_IN Inflammatory_NNP Bowel_NNP delivery_NN system_NN to_TO provide_VB the_DT highest_JJS strength_NN Seizing_VBG opportunities_NNS Disease_NNP IBD_NNP in_IN which_WDT part_NN ,_, or_CC all_DT ,_, of_IN the_DT large_JJ of_IN 5-ASA_JJ per_IN tablet_NN of_IN any_DT product_NN available_JJ ._.
Shires_NNP GI_NNP STAT_NNP is_VBZ actively_RB evaluating_VBG a_DT variety_NN intestine_JJ becomes_VBZ inflamed_VBN and_CC often_RB With_IN this_DT technology_NN ,_, UC_NNP patients_NNS are_VBP able_JJ to_TO of_IN GI_NNP licensing_NN and_CC acquisition_NN opportunities_NNS ulcerated_VBD ._.
Patients_NNS experience_VBP intermittent_JJ treat_VB their_PRP$ disease_NN for_IN the_DT first_JJ time_NN with_IN a_DT once_RB to_TO expand_VB its_PRP$ GI_NNP portfolio_NN for_IN the_DT treatment_NN attacks_NNS separated_VBN by_IN periods_NNS of_IN remission_NN ,_, and_CC daily_JJ dose_NN of_IN medicine_NN ._.
The_DT unique_JJ technology_NN of_IN IBD_NNP and_CC other_JJ conditions_NNS and_CC contribute_VBP can_MD suffer_VB diarrhoea_NN ,_, bleeding_VBG and_CC abdominal_JJ ensures_VBZ continued_VBN and_CC prolonged_VBN exposure_NN to_TO future_JJ growth_NN ._.
IBD_NNP is_VBZ treated_VBN with_IN several_JJ pain_NN ._.
The_DT most_RBS frequently_RB used_VBN treatments_NNS of_IN the_DT colonic_JJ mucosa_NN to_TO the_DT active_JJ ingredient_NN ,_, classes_NNS of_IN drugs_NNS ,_, explains_VBZ Mr_NNP Yasick_NNP ._.
The_DT MMX_NNP MultiThese_NNP include_VBP anti-TNF_JJ and_CC other_JJ agents_NNS Matrix_NNP System_NNP which_WDT enables_VBZ this_DT was_VBD that_IN target_NN pro-inflammatory_JJ cytokines_NNS ,_, Shire_NNP has_VBZ two_CD marketed_VBN products_NNS containing_VBG developed_VBN by_IN Cosmo_NNP S._NNP p._NNP A_NNP and_CC is_VBZ a_DT patented_JJ immunosuppressives_NNS and_CC glucoticosteroids_NNS the_DT mainstay_NN treatment_NN for_IN IBD_NNP ,_, mesalamine_NN technology_NN licensed_VBD from_IN Giuliani_NNP S._NNP p._NNP A._NN that_WDT are_VBP used_VBN stepwise_NN and_CC in_IN combination_NN 5-ASA_NN :_: PENTASA_NNP and_CC COLAZIDE_NNP ._.
Shire_NNP has_VBZ commercial_JJ and_CC to_TO treat_VB IBD_NNP ._.
Given_VBN our_PRP$ position_NN with_IN PENTASA_NNP ,_, delivers_VBZ mesalamine_NN throughout_IN the_DT small_JJ development_NN rights_NNS to_TO this_DT technology_NN in_IN the_DT COLAZIDE_NNP and_CC MESAVANCE_NNP ,_, these_DT would_MD and_CC large_JJ bowel_NN and_CC is_VBZ marketed_VBN in_IN the_DT US_NNP US_NNP ,_, Canada_NNP ,_, the_DT Pacific_NNP Rim_NNP and_CC Europe_NNP be_VB great_JJ additions_NNS to_TO the_DT Shire_NNP portfolio_NN ._.
in_IN 250mg_CD and_CC 500mg_CD capsules_NNS and_CC with_IN the_DT exception_NN of_IN Italy_NNP where_WRB Giuliani_NNP In_IN addition_NN ,_, we_PRP are_VBP looking_VBG at_IN other_JJ products_NNS COLAZIDE_NNP is_VBZ an_DT oral_JJ mesalamine_NN formulation_NN retains_VBZ all_DT rights_NNS ._.
Our_PRP$ Phase_NN 3_CD program_NN was_VBD which_WDT GI_NNP physicians_NNS could_MD use_VB to_TO treat_VB hepatic_JJ for_IN the_DT treatment_NN of_IN UC_NNP in_IN the_DT UK_NNP ._.
We_PRP worked_VBD with_IN the_DT FDA_NNP ,_, and_CC disorders_NNS ,_, non-acid_JJ esophageal_NN disorders_NNS ,_, and_CC COLAZIDE_NNP offer_VBP us_PRP a_DT powerful_JJ jumpstart_NN a_DT panel_NN of_IN global_JJ GI_NNP experts_NNS to_TO create_VB very_RB strict_JJ pancreatic_JJ insufficiency_NN and_CC the_DT like_JJ ._.
for_IN our_PRP$ efforts_NNS to_TO expand_VB our_PRP$ relationship_NN endpoints_NNS ._.
Also_RB ,_, in_IN one_CD of_IN our_PRP$ Phase_NN 3_CD studies_NNS ,_, with_IN GI_NNP specialists_NNS and_CC serve_VB the_DT growing_VBG we_PRP utilized_VBD a_DT reference_NN arm_NN containing_VBG By_IN extending_VBG and_CC optimizing_VBG new_JJ uses_NNS for_IN needs_NNS of_IN their_PRP$ patients_NNS ,_, affirms_VBZ Mr_NNP Yasick_NNP ._.
Asacol_NNP ,_, the_DT market_NN leader_NN ,_, at_IN its_PRP$ indicated_JJ Shires_NNP products_NNS through_IN the_DT GI_NNP STAT_NNP ,_, both_DT in_IN dose_NN ,_, notes_VBZ Mr_NNP Yasick_NNP ._.
Both_DT products_NNS existing_VBG and_CC in_IN new_JJ territories_NNS ,_, Shire_NNP intends_VBZ to_TO MESAVANCE_NNP milestone_NN showed_VBD improvement_NN in_IN symptoms_NNS compared_VBN build_VB a_DT truly_RB global_JJ franchise_NN in_IN this_DT promising_JJ The_DT GI_NNP STAT_NNP achieved_VBD a_DT major_JJ milestone_NN to_TO a_DT placebo_NN ._.
However_RB ,_, MESAVANCE_NNP showed_VBD market_NN segment_NN ._.
We_PRP have_VBP a_DT team_NN of_IN talented_VBN in_IN 2005_CD with_IN the_DT filing_NN of_IN a_DT NDA_NNP to_TO the_DT FDA_NNP significantly_RB higher_JJR rates_NNS of_IN disease_NN remission_NN people_NNS with_IN a_DT track_NN record_NN of_IN success_NN in_IN GI_NNP and_CC for_IN MESAVANCE_NNP ,_, which_WDT would_MD be_VB the_DT first_JJ versus_IN a_DT placebo_NN while_IN Asacol_NNP did_VBD not_RB ._.
in_IN launching_VBG products_NNS to_TO GI_NNP specialists_NNS ,_, says_VBZ available_JJ once-daily_RB mesalamine_JJ treatment_NN Mr_NNP Yasick_NNP ._.
We_PRP intend_VBP to_TO make_VB the_DT most_JJS of_IN this_DT for_IN active_JJ ,_, mild-to-moderate_JJ UC_NNP ._.
MAAs_NNS IBD_NNP is_VBZ a_DT life-long_JJ disease_NN that_WDT requires_VBZ opportunity_NN we_PRP have_VBP to_TO create_VB a_DT new_JJ standard_NN for_IN MESAVANCE_NNP were_VBD submitted_VBN during_IN the_DT constant_JJ treatment_NN ._.
Failing_VBG to_TO adequately_RB treat_VB for_IN the_DT pharmaceuticals_NNS industry_NN ._.
Through_IN first_JJ quarter_NN of_IN 2006_CD to_TO the_DT EMEA_NNP and_CC the_DT IBD_NNP can_MD lead_VB to_TO greater_JJR numbers_NNS of_IN flare-ups_NNS ,_, excellent_JJ execution_NN ,_, we_PRP intend_VBP to_TO prove_VB the_DT Canadian_JJ Regulatory_NNP Authorities_NNP ._.
This_DT is_VBZ the_DT more_RBR resource_NN utilization_NN greater_JJR cost_NN ,_, poor_JJ value_NN of_IN the_DT specialist_NN pharmaceuticals_NNS model_NN ._.
first_RB simultaneous_JJ global_JJ regulatory_JJ filing_NN for_IN quality_NN of_IN life_NN ,_, and_CC greater_JJR risk_NN of_IN colorectal_JJ Shire_NNP and_CC it_PRP represents_VBZ a_DT terrific_JJ effort_NN by_IN the_DT cancer_NN ._.
MESAVANCE_NNP meets_VBZ a_DT need_NN in_IN the_DT R&D_NNP team_NN and_CC the_DT Product_NNP Strategy_NNP Team_NNP market_NN to_TO improve_VB compliance_NN and_CC reduce_VB pill_NN 5-aminosalicylic_JJ acid_NN or_CC known_VBN as_IN mesalamine_NN or_CC mesalazine_NN ._.
It_PRP also_RB raises_VBZ the_DT level_NN of_IN performance_NN of_IN this_DT class_NN of_IN drugs_NNS ._.
Going_VBG Asacol_NNP is_VBZ a_DT trade_NN mark_NN of_IN Proctor_NNP &_CC Gamble_NNP ._.
beyond_IN simple_JJ symptom_NN relief_NN to_TO inducing_VBG disease_NN remission_NN is_VBZ a_DT significant_JJ advance_NN Study_NNP presented_VBD November_NNP 1_CD ,_, 2005_CD at_IN the_DT 70th_JJ Annual_JJ in_IN treating_VBG UC_NNP ._.
Among_IN the_DT pH_NNP dependent_JJ American_JJ College_NNP of_IN Gastroenterology_NNP in_IN Honolulu_NNP ,_, Hawaii_NNP ._.
26_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 27_CD I_PRP help_VBP underserved_VBD patients_NNS in_IN markets_NNS that_WDT represent_VBP new_JJ areas_NNS of_IN growth_NN for_IN Shire_NNP ._.
Lynda_NNP Berne_NNP Executive_NNP Director_NNP ,_, Gastroenterology_NNP Nephrology_NNP ,_, US_NNP Marketing_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 28_CD Operating_NN review_NN We_PRP have_VBP congured_VBN Central_NNP Nervous_NNP System_NNP ourselves_PRP along_IN product_NN lines_NNS with_IN the_DT some_DT of_IN the_DT best_JJS people_NNS in_IN the_DT industry_NN working_VBG together_RB to_TO drive_VB our_PRP$ growth_NN strategy_NN ._.
Tom_NNP Anderson_NNP Vice_NNP President_NNP and_CC Commercial_NNP Leader_NNP ,_, CNS_NNP STAT_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 29_CD 01_CD 02_CD 03_CD 01_CD Central_NNP Nervous_NNP System_NNP CNS_NNP Shires_VBZ CNS_NNP STAT_NNP has_VBZ a_DT solid_JJ record_NN of_IN I_PRP enjoy_VBP working_VBG for_IN a_DT Company_NN Ask_NNP Tom_NNP Anderson_NNP and_CC Gerardo_NNP Torres_NNP why_WRB achievement_NN to_TO build_VB on_IN ,_, including_VBG several_JJ that_IN consistently_RB puts_VBZ its_PRP$ faith_NN they_PRP believe_VBP Shire_NNP has_VBZ one_CD of_IN the_DT strongest_JJS milestones_NNS in_IN 2005_CD :_: and_CC trust_NN in_IN its_PRP$ people_NNS ._.
franchises_NNS in_IN the_DT high_JJ potential_JJ CNS_NNP segment_NN David_NNP Chapman_NNP of_IN the_DT global_JJ pharmaceutical_JJ market_NN and_CC ADDERALL_NNP XR_NNP ,_, Shires_NNP patented_VBD novel_JJ General_NNP Manager_NNP ,_, Transdermal_NNP ,_, theyll_NN give_VBP three_CD simple_JJ reasons_NNS :_: the_DT right_JJ formulation_NN of_IN ADDERALL_NNP that_WDT provides_VBZ CNS_NNP STAT_NNP people_NNS ,_, a_DT great_JJ portfolio_NN of_IN products_NNS ,_, and_CC all-day_JJ treatment_NN for_IN ADHD_NNP with_IN one_CD daily_RB a_DT clear_JJ strategy_NN for_IN future_JJ growth_NN ._.
dose_NN ,_, continued_VBD to_TO be_VB the_DT most_RBS prescribed_JJ 02_CD ADHD_NNP treatment_NN in_IN the_DT US_NNP ,_, with_IN over_IN 26_CD %_NN Shire_NNP has_VBZ a_DT wealth_NN of_IN opportunities_NNS ._.
We_PRP have_VBP configured_VBN ourselves_PRP along_IN product_NN share_NN of_IN the_DT prescription_NN ADHD_NNP market_NN :_: My_PRP$ teams_NNS information_NN helps_VBZ lines_NNS with_IN the_DT some_DT of_IN the_DT best_JJS people_NNS in_IN the_DT us_PRP choose_VB the_DT best_JJS ones_NNS ._.
industry_NN working_VBG together_RB to_TO drive_VB our_PRP$ growth_NN the_DT FDA_NNP approved_VBD ADDERALL_NNP XR_NNP Matt_NNP Handel_NNP strategy_NN ,_, says_VBZ Mr_NNP Anderson_NNP ,_, Vice_NNP President_NNP as_IN a_DT treatment_NN for_IN adolescents_NNS aged_VBN Senior_JJ Director_NNP of_IN Business_NNP and_CC Commercial_NNP leader_NN of_IN Shires_NNP CNS_NNP STAT_NNP ._.
1317_CD with_IN ADHD_NNP ,_, offering_VBG continuity_NN Analysis_NNP And_CC we_PRP have_VBP a_DT proven_JJ strategy_NN for_IN acquiring_VBG in_IN the_DT management_NN of_IN ADHD_NNP symptoms_NNS and_CC developing_VBG unique_JJ products_NNS that_WDT will_MD as_RB children_NNS become_VBP older_JJR :_: 03_CD serve_VBP unmet_JJ needs_NNS going_VBG forward_RB ._.
Shires_NNS can_MD do_VB attitude_NN is_VBZ a_DT study_NN presented_VBN at_IN the_DT US_NNP Psychiatric_NNP invigorating_VBG and_CC sets_VBZ us_PRP up_RP Shires_NNP CNS_NNP STAT_NNP is_VBZ responsible_JJ for_IN driving_VBG and_CC Mental_NNP Health_NNP Congress_NNP in_IN Las_NNP Vegas_NNP for_IN long-term_JJ success_NN ._.
CNS-related_JJ product_NN and_CC project_NN strategies_NNS ._.
demonstrated_VBD that_IN adults_NNS with_IN ADHD_NNP David_NNP Baker_NNP Its_PRP$ priorities_NNS include_VBP continuing_VBG to_TO build_VB and_CC experienced_VBD significant_JJ long-term_JJ ADHD_NNP Vice_NNP President_NNP ,_, ADHD_NNP Marketing_NNP strengthen_VB Shires_NNP position_NN as_IN the_DT leading_VBG symptom_NN control_NN when_WRB treated_VBN with_IN onceADHD_NNP pharmaceutical_JJ Company_NN in_IN the_DT US_NNP ,_, daily_JJ ADDERALL_NNP XR_NNP :_: while_IN building_VBG a_DT value-added_JJ pipeline_NN in_IN CNS_NNP therapeutic_JJ areas_NNS that_WDT are_VBP traditionally_RB poorly_RB Health_NNP Canada_NNP reinstated_VBD marketing_NN served_VBD ,_, through_IN in-licensing_NN and_CC other_JJ means_NNS ._.
authorization_NN of_IN ADDERALL_NNP XR_NNP following_VBG a_DT six-month_JJ suspension_NN after_IN accepting_VBG Today_NN ,_, Shire_NNP has_VBZ one_CD of_IN the_DT best_JJS portfolio_NN recommendations_NNS made_VBN by_IN a_DT New_NNP of_IN marketed_VBN and_CC development_NN drugs_NNS in_IN the_DT Drug_NNP Committee_NNP :_: ADHD_NNP business_NN ,_, notes_VBZ Mr_NNP Anderson_NNP ,_, who_WP has_VBZ 20_CD years_NNS of_IN industry_NN experience_NN and_CC the_DT FDA_NNP issued_VBD an_DT approvable_JJ letter_NN for_IN a_DT strong_JJ commercial_JJ background_NN ._.
We_PRP intend_VBP DAYTRANA_NNP ,_, the_DT first_JJ non-oral_JJ medication_NN to_TO continue_VB to_TO be_VB the_DT No._NN ._.
1_CD ADHD_NNP Company_NNP ,_, for_IN ADHD_NNP designed_VBN for_IN once-daily_JJ use_NN to_TO building_VBG on_IN the_DT success_NN of_IN ADDERALL_NNP XR_NNP treat_VB ADHD_NNP in_IN children_NNS aged_VBN 612_CD ._.
Shire_NNP while_IN introducing_VBG multiple_JJ new_JJ products_NNS with_IN since_IN received_VBN FDA_NNP approval_NN in_IN April_NNP 2006_CD unique_JJ benefits_NNS to_TO patients_NNS ._.
At_IN the_DT same_JJ time_NN ,_, for_IN this_DT product_NN and_CC is_VBZ targeting_VBG a_DT launch_NN we_PRP will_MD make_VB sure_JJ our_PRP$ other_JJ CNS_NNP products_NNS in_IN the_DT US_NNP by_IN mid-2006_NN :_: are_VBP successful_JJ and_CC look_VB at_IN adding_VBG drugs_NNS for_IN other_JJ diseases_NNS in_IN CNS_NNP where_WRB we_PRP a_DT NDA_NNP was_VBD filed_VBN with_IN the_DT FDA_NNP for_IN the_DT can_MD succeed_VB with_IN the_DT specialist_NN model_NN ._.
investigational_JJ compound_NN NRP104_NNP for_IN the_DT treatment_NN of_IN ADHD_NNP in_IN children_NNS aged_VBN 612_CD ._.
Wealth_NN of_IN experience_NN This_DT cleared_VBD the_DT way_NN for_IN Shire_NNP and_CC partner_NN These_DT efforts_NNS are_VBP being_VBG supported_VBN by_IN what_WP New_NNP River_NNP to_TO work_VB toward_IN an_DT approval_NN and_CC Dr_NNP Torres_NNP describes_VBZ as_IN a_DT unique_JJ team_NN with_IN subsequent_JJ launch_NN in_IN late_JJ 2006_CD early_JJ 2007_CD :_: a_DT wealth_NN of_IN industry_NN experience_NN covering_VBG all_DT and_CC domains_NNS ._.
Dr_NNP Torres_NNP is_VBZ the_DT Vice_NNP President_NNP and_CC Scientific_NNP Leader_NNP for_IN the_DT CNS_NNP STAT_NNP ._.
He_PRP says_VBZ Shire_NNP progressed_VBN with_IN plans_NNS to_TO file_VB NDAs_NNS the_DT degree_NN of_IN energy_NN at_IN Shire_NNP is_VBZ incredible_JJ ._.
with_IN the_DT FDA_NNP for_IN SPD465_NNP ,_, a_DT longer-acting_JJ One_CD of_IN my_PRP$ favorite_JJ aspects_NNS of_IN this_DT job_NN formulation_NN of_IN ADDERALL_NNP XR_NNP ,_, and_CC SPD503_NNP ,_, is_VBZ brainstorming_VBG with_IN groups_NNS of_IN such_JJ bright_JJ a_DT non-stimulant_JJ treatment_NN for_IN ADHD_NNP ._.
people_NNS ,_, with_IN their_PRP$ wide-ranging_JJ expertise_NN and_CC innovative_JJ ideas_NNS ._.
Study_NNP presented_VBD November_NNP 8_CD ,_, 2005_CD at_IN the_DT US_NNP Psychiatric_NNP and_CC Mental_NNP Health_NNP Congress_NNP in_IN Las_NNP Vegas_NNP ,_, NV_NNP ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 29_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 30_CD Operating_NN review_NN Central_NNP Nervous_NNP System_NNP 04_CD 05_CD 06_CD 04_CD The_DT ADHD_NNP market_NN has_VBZ become_VBN increasingly_RB Cilag_NNP under_IN the_DT trade_NN name_NN REMINYL_NNP XR_NNP ,_, Shire_NNP has_VBZ a_DT tremendous_JJ team_NN competitive_JJ ,_, notes_NNS Mr_NNP Anderson_NNP ._.
Strong_JJ with_IN the_DT exception_NN of_IN the_DT US_NNP where_WRB in_IN place_NN and_CC we_PRP can_MD now_RB see_VB that_DT market_NN growth_NN over_IN the_DT last_JJ few_JJ years_NNS has_VBZ it_PRP is_VBZ marketed_VBN under_IN the_DT trade_NN name_NN the_DT results_NNS of_IN years_NNS of_IN hard_JJ work_NN made_VBD this_DT a_DT very_RB attractive_JJ area_NN for_IN drug_NN RAZADYNE_NNP :_: and_CC are_VBP paying_VBG off_RP ._.
companies_NNS ,_, and_CC we_PRP now_RB have_VBP multiple_JJ Simon_NNP Tulloch_NNP companies_NNS competing_VBG with_IN their_PRP$ products_NNS EQUETRO_NNP for_IN the_DT treatment_NN of_IN Bipolar_NNP 1_CD Senior_JJ Vice_NNP President_NNP ,_, CNS_NNP STAT_NNP for_IN the_DT same_JJ patients_NNS ._.
In_IN this_DT environment_NN ,_, Disorder_NN ,_, was_VBD launched_VBN in_IN the_DT US_NNP in_IN April_NNP ._.
new_JJ products_NNS have_VBP to_TO be_VB clearly_RB different_JJ An_DT efficacy_NN study_NN presented_VBN by_IN University_NNP of_IN 05_CD from_IN what_WP is_VBZ out_IN there_RB ,_, and_CC this_DT means_VBZ they_PRP North_NNP Carolina_NNP researchers_NNS presented_VBN at_IN the_DT The_NNP General_NNP Manager_NNP position_NN at_IN must_MD have_VB important_JJ efficacy_NN and_CC safety_NN US_NNP Psychiatric_NNP and_CC Mental_NNP Health_NNP Congress_NNP Shire_NNP is_VBZ a_DT great_JJ opportunity_NN to_TO lead_VB benefits_NNS that_IN other_JJ products_NNS do_VBP not_RB ._.
in_IN Las_NNP Vegas_NNP in_IN November_NNP demonstrated_VBD the_DT functional_JJ teams_NNS to_TO drive_VB better_JJR that_IN EQUETRO_NNP significantly_RB reduced_VBD manic_JJ decision-making_NN and_CC results_NNS ._.
Future_JJ growth_NN and_CC mixed_JJ symptoms_NNS for_IN patients_NNS and_CC Mark_NNP Charles_NNP Shires_NNP portfolio_NN of_IN marketed_VBN and_CC development_NN was_VBD generally_RB well_RB tolerated_JJ ._.
We_PRP believe_VBP CNS_NNP STAT_NNP ,_, General_NNP Manager_NNP drugs_NNS make_VBP it_PRP very_RB well_RB positioned_VBN in_IN ADHD_NNP EQUETRO_NNP brings_VBZ unique_JJ benefits_NNS to_TO SPD503_CD Dr_NNP Torres_NNP adds_VBZ ._.
Our_PRP$ vision_NN is_VBZ to_TO have_VB several_JJ patients_NNS and_CC their_PRP$ families_NNS while_IN offering_VBG unique_JJ products_NNS serving_VBG most_RBS if_IN not_RB all_DT types_NNS physicians_NNS a_DT useful_JJ option_NN in_IN the_DT treatment_NN 06_CD of_IN ADHD_NNP patient_NN ._.
Our_PRP$ development_NN products_NNS of_IN manic_JJ and_CC mixed_JJ episodes_NNS in_IN bipolar_NN Focused_VBN ,_, cross-functional_JJ product_NN are_VBP all_DT different_JJ and_CC serve_VB different_JJ patient_NN disorders_NNS says_VBZ Dr_NNP Torres_NNP ._.
teams_NNS with_IN visionary_JJ leadership_NN needs_VBZ on_IN a_DT more_RBR individual_JJ basis_NN ._.
DAYTRANA_NNP ,_, will_MD drive_VB Shires_NNP future_JJ success_NN ._.
for_IN example_NN ,_, will_MD offer_VB patients_NNS an_DT alternative_JJ Mr_NNP Anderson_NNP says_VBZ the_DT CNS_NNP STAT_NNP is_VBZ refining_VBG Michael_NNP Skoien_NNP route_NN of_IN delivery_NN for_IN methylphenidate_NN no_DT plans_NNS to_TO make_VB sure_JJ Shire_NNP has_VBZ the_DT right_JJ Vice_NNP President_NNP and_CC General_NNP pill_NN swallowing_VBG but_CC a_DT transdermal_JJ patch_NN ._.
marketing_NN support_NN ,_, geographic_JJ spread_NN and_CC Manager_NNP ,_, ADDERALL_NNP CNS_NNP STAT_NNP NRP104_NNP could_MD be_VB better_JJR than_IN current_JJ product_NN life_NN cycle_NN management_NN ._.
It_PRP is_VBZ striving_VBG amphetamine_NN and_CC other_JJ products_NNS in_IN that_DT it_PRP to_TO build_VB a_DT value-added_JJ pipeline_NN for_IN the_DT CNS_NNP may_MD offer_VB lower_JJR diversion_NN and_CC abuse_NN potential_NN ._.
area_NN by_IN looking_VBG for_IN opportunities_NNS to_TO in-license_JJ Moreover_RB ,_, we_PRP are_VBP always_RB on_IN the_DT lookout_NN for_IN drugs_NNS already_RB under_IN development_NN ._.
With_IN new_JJ opportunities_NNS and_CC are_VBP clearly_RB interested_JJ our_PRP$ new_JJ product_NN focus_NN and_CC cross-functional_JJ in_IN new_JJ ADHD_NNP treatments_NNS ._.
organization_NN ,_, it_PRP will_MD now_RB be_VB easier_JJR to_TO set_VB parameters_NNS for_IN the_DT types_NNS of_IN products_NNS we_PRP Shires_VBZ other_JJ drugs_NNS in_IN its_PRP$ CNS_NNP portfolio_NN also_RB want_VBP to_TO develop_VB ._.
We_PRP will_MD also_RB be_VB taking_VBG performed_VBN well_RB in_IN 2005_CD ._.
a_DT fresh_JJ look_NN at_IN other_JJ disease_NN states_NNS within_IN CNS_NNP where_WRB a_DT specialist_NN company_NN such_JJ as_IN CARBATROL_NNP ,_, Shires_NNP extended-release_NN ours_PRP can_MD succeed_VB with_IN a_DT limited_JJ sales_NNS force_NN ._.
formulation_NN of_IN carbamazepine_NN for_IN the_DT Shire_NNP has_VBZ a_DT longstanding_JJ treatment_NN of_IN epilepsy_NN ,_, continued_VBD to_TO hold_VB Dr_NNP Torres_NNP adds_VBZ that_IN Shires_NNP new_JJ business_NN commitment_NN to_TO understanding_NN and_CC a_DT significant_JJ share_NN of_IN the_DT US_NNP prescription_NN model_NN is_VBZ ensuring_VBG that_IN it_PRP operates_VBZ more_RBR addressing_VBG the_DT treatment_NN needs_VBZ market_NN in_IN its_PRP$ category_NN ._.
CARBATROL_NNP consistently_RB and_CC makes_VBZ the_DT best_JJS use_NN of_IN its_PRP$ of_IN children_NNS ,_, adolescents_NNS ,_, and_CC continues_VBZ to_TO be_VB an_DT important_JJ product_NN resources_NNS ._.
It_PRP is_VBZ allowing_VBG for_IN better_JJR alignment_NN adults_NNS with_IN ADHD_NNP ._.
Their_PRP$ portfolio_NN of_IN for_IN us_PRP notes_VBZ Dr_NNP Torres_NNP :_: between_IN our_PRP$ commercial_JJ and_CC R&D_NNP functions_NNS ._.
currently_RB available_JJ and_CC medicationsIt_NNP is_VBZ critically_RB important_JJ that_IN our_PRP$ marketing_NN in-development_NN clearly_RB signal_VB their_PRP$ REMINYL_NNP XR_NNP ,_, a_DT once-daily_JJ treatment_NN plans_NNS are_VBP congruent_JJ with_IN our_PRP$ plans_NNS for_IN intention_NN to_TO continue_VB being_VBG a_DT leader_NN designed_VBN to_TO slow_VB the_DT progression_NN of_IN the_DT developing_VBG new_JJ products_NNS and_CC this_DT approach_NN in_IN this_DT field_NN ._.
symptoms_NNS of_IN Alzheimers_NNP Disease_NNP ,_, was_VBD will_MD help_VB us_PRP get_VB the_DT right_JJ products_NNS to_TO market_NN Dr_NNP Timothy_NNP E._NNP Wilens_NNP launched_VBN by_IN Shire_NNP in_IN the_DT United_NNP Kingdom_NNP in_IN a_DT reasonable_JJ time_NN frame_NN ._.
Our_PRP$ ultimate_JJ goal_NN Associate_NNP Professor_NNP of_IN Psychiatry_NNP and_CC Ireland_NNP in_IN June_NNP ._.
REMINYL_NNP is_VBZ one_CD of_IN the_DT is_VBZ to_TO have_VB a_DT strong_JJ portfolio_NN of_IN global_JJ products_NNS at_IN Harvard_NNP Medical_NNP School_NNP ,_, Boston_NNP ,_, main_JJ products_NNS for_IN treating_VBG mild-to-moderate_JJ and_CC we_PRP are_VBP well_RB on_IN our_PRP$ way_NN ._.
Massachusetts_NNP dementia_NN of_IN the_DT Alzheimer_NNP type_NN ,_, and_CC is_VBZ Data_NNP presented_VBN May_NNP 24_CD ,_, 2005_CD at_IN the_DT American_JJ licensed_JJ for_IN use_NN in_IN more_JJR than_IN 70_CD countries_NNS ._.
Psychiatric_NNP Association_NNP in_IN Atlanta_NNP ,_, GA_NNP and_CC study_NN Outside_IN the_DT UK_NNP and_CC Ireland_NNP ,_, this_DT product_NN is_VBZ presented_VBN November_NNP 8_CD ,_, 2005_CD at_IN the_DT US_NNP Psychiatric_NNP marketed_VBN by_IN Johnson_NNP &_CC Johnson_NNP Janssen_NNP and_CC Mental_NNP Health_NNP Congress_NNP in_IN Las_NNP Vegas_NNP ,_, NV_NNP ._.
30_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 31_CD Shire_NNP has_VBZ one_CD of_IN the_DT best_JJS portfolios_NNS of_IN marketed_VBN and_CC development_NN drugs_NNS in_IN the_DT ADHD_NNP business_NN ._.
Gerardo_NNP Torres_NNP Vice_NNP President_NNP and_CC Scientific_NNP Leader_NNP ,_, CNS_NNP STAT_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 32_CD Operating_NN review_NN We_PRP have_VBP advanced_VBN Human_NNP Genetic_NNP Therapies_NNPS technologies_NNS and_CC a_DT clear_JJ mission_NN ._.
David_NNP Pendergast_NNP Executive_NNP Vice_NNP President_NNP and_CC General_NNP Manager_NNP ,_, Shire_NNP HGT_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 33_CD 01_CD 02_CD 01_CD Human_NNP Genetics_NNP Therapies_NNPS Shire_NNP HGT_NNP High-potential_JJ market_NN We_PRP have_VBP unparalleled_JJ technology_NN Shires_VBZ new_JJ HGT_NNP team_NN ,_, the_DT former_JJ TKT_NNP ,_, Dr_NNP Pendergast_NNP notes_VBZ that_IN the_DT evolution_NN of_IN the_DT to_TO develop_VB treatment_NN for_IN genetic_JJ specializes_VBZ in_IN discovering_VBG ,_, developing_VBG biotechnology_NN sciences_NNS has_VBZ allowed_VBN for_IN the_DT diseases_NNS and_CC I_PRP am_VBP very_RB proud_JJ to_TO and_CC commercializing_VBG protein_NN therapeutics_NNS engineering_NN of_IN proteins_NNS and_CC producing_VBG them_PRP be_VB part_NN of_IN the_DT team_NN that_WDT is_VBZ making_VBG primarily_RB for_IN the_DT treatment_NN of_IN genetic_JJ diseases_NNS ._.
Combined_VBN with_IN the_DT these_DT therapies_NNS possible_JJ !_.
This_DT business_NN extends_VBZ Shires_NNP reach_NN by_IN discovery_NN of_IN inherent_JJ and_CC engineered_VBN means_NNS David_NNP Whiteman_NNP strengthening_VBG its_PRP$ portfolio_NN and_CC pipeline_NN with_IN of_IN delivering_VBG proteins_NNS to_TO cells_NNS throughout_IN the_DT Principal_NN Medical_NNP Director_NNP ,_, a_DT range_NN of_IN new_JJ therapeutic_JJ possibilities_NNS body_NN ,_, this_DT provides_VBZ great_JJ potential_JJ to_TO address_VB Shire_NNP HGT_NNP for_IN patients_NNS suffering_VBG with_IN genetic_JJ diseases_NNS ._.
a_DT number_NN of_IN serious_JJ diseases_NNS previously_RB not_RB approachable_JJ with_IN drug_NN therapies_NNS ._.
The_DT number_NN 02_CD By_IN adding_VBG the_DT proprietary_JJ protein_NN technologies_NNS of_IN these_DT diseases_NNS is_VBZ large_JJ since_IN there_EX is_VBZ the_DT Im_NNP very_RB excited_JJ about_IN our_PRP$ of_IN TKT_NNP to_TO the_DT proven_VBN commercialization_NN knowpotential_NN for_IN a_DT single_JJ gene_NN mutation_NN to_TO occur_VB ability_NN to_TO truly_RB make_VB a_DT difference_NN how_WRB of_IN Shire_NNP ,_, weve_JJ generated_VBD an_DT entity_NN worth_NN with_IN any_DT birth_NN and_CC we_PRP have_VBP had_VBN centuries_NNS in_IN patients_NNS lives_NNS ._.
far_RB more_JJR than_IN the_DT sum_NN of_IN its_PRP$ parts_NNS ,_, says_VBZ David_NNP of_IN evolution_NN for_IN these_DT problems_NNS to_TO develop_VB ._.
Andrew_NNP Komjathy_NNP Pendergast_NNP ,_, Shire_NNP HGTs_NNP Executive_NNP Vice_NNP At_IN this_DT time_NN protein_NN replacement_NN therapy_NN Vice_NNP President_NNP ,_, Commercial_NNP President_NNP and_CC General_NNP Manager_NNP ._.
Together_RB ,_, is_VBZ often_RB the_DT only_JJ treatment_NN for_IN these_DT patients_NNS ._.
Operations_NNP weve_NN signalled_VBD our_PRP$ intention_NN to_TO continue_VB growing_VBG as_IN market_NN leaders_NNS in_IN serving_VBG specialist_NN Shire_NNP HGT_NNP employs_VBZ slightly_RB more_JJR than_IN 500_CD 03_CD physicians_NNS and_CC their_PRP$ patients_NNS ._.
individuals_NNS worldwide_JJ and_CC has_VBZ a_DT presence_NN Breakthrough_NN products_NNS and_CC in_IN those_DT countries_NNS which_WDT reimburse_VBP protein_NN exceptional_JJ staff_NN make_VBP Shire_NNP TKT_NNP ,_, acquired_VBN in_IN 2005_CD ,_, is_VBZ an_DT excellent_JJ therapies_NNS for_IN genetic_JJ diseases_NNS and_CC where_WRB a_DT great_JJ place_NN to_TO work_VB !_.
strategic_JJ fit_NN for_IN Shire_NNP ,_, adds_VBZ Dr_NNP Pendergast_NNP ,_, patient_JJ populations_NNS warrant_VBP a_DT presence_NN ._.
Jerry_NNP Justin_NNP former_JJ executive_NN vice_NN president_NN and_CC chief_NN Based_VBN in_IN Cambridge_NNP ,_, Massachusetts_NNP the_DT team_NN Senior_JJ Director_NNP Manufacturing_NNP operating_VBG officer_NN of_IN TKT_NNP who_WP has_VBZ 33_CD years_NNS is_VBZ at_IN work_NN on_IN a_DT number_NN of_IN exciting_JJ scientific_JJ Operations_NNP ,_, Shire_NNP HGT_NNP of_IN pharmaceutical_JJ industry_NN experience_NN ._.
Both_DT Shire_NNP and_CC TKT_NNP leverage_NN relationships_NNS 04_CD with_IN highly_RB specialized_VBN physicians_NNS and_CC focus_VB We_PRP use_VB several_JJ technologies_NNS including_VBG gene_NN We_PRP are_VBP committed_VBN to_TO accelerating_VBG on_IN the_DT development_NN of_IN products_NNS that_WDT offer_VBP activation_NN ,_, fusion_NN proteins_NNS ,_, and_CC standard_JJ the_DT development_NN of_IN protein_NN a_DT strong_JJ benefit-to-risk_NN ratio_NN ._.
Both_DT also_RB care_VB transfections_NNS ,_, explains_VBZ Dr_NNP Pendergast_NNP ._.
enormously_RB for_IN the_DT patients_NNS and_CC families_NNS that_WDT Our_PRP$ approach_NN for_IN glycoproteins_NNS is_VBZ to_TO use_VB Yas_NNP Saotome_NNP are_VBP ultimately_RB served_VBN by_IN our_PRP$ product_NN lines_NNS ._.
human_JJ cells_NNS either_CC employing_VBG gene_NN activation_NN Senior_JJ Director_NNP ,_, Cell_NNP culture_NN or_CC standard_JJ methods_NNS ._.
This_DT approach_NN yields_NNS Process_NNP Development_NNP Shire_NNP HGT_NNP provides_VBZ specific_JJ disease_NN area_NN a_DT truly_RB human_JJ molecule_NN in_IN both_DT the_DT amino_JJ acid_NN expertise_NN ,_, a_DT high-quality_JJ product_NN portfolio_NN sequence_NN and_CC the_DT carbohydrate_NN structure_NN and_CC a_DT low-risk_JJ ,_, well-balanced_JJ development_NN thereby_RB making_VBG the_DT therapy_NN highly_RB active_JJ and_CC pipeline_NN with_IN one_CD marketed_VBN product_NN and_CC less_JJR immunogenic_JJ ._.
two_CD attractive_JJ late-stage_NN products_NNS directed_VBD at_IN genetic_JJ diseases_NNS ._.
In_IN addition_NN ,_, protein_NN Dr_NNP Pendergast_NNP notes_VBZ that_IN genetic_JJ disease_NN replacement_NN therapy_NN provides_VBZ a_DT good_JJ platform_NN research_NN is_VBZ less_RBR risky_JJ than_IN traditional_JJ for_IN further_JJ expansion_NN through_IN research_NN and_CC pharmaceutical_JJ research_NN ._.
The_DT diseases_NNS and_CC product_NN in-licensing_NN ._.
Shire_NNP HGTs_NNP approach_VBP their_PRP$ causes_NNS are_VBP well_RB known_VBN ,_, the_DT treatment_NN to_TO product_NN development_NN is_VBZ to_TO use_VB protein_NN path_NN clear_JJ ,_, and_CC if_IN we_PRP get_VBP good_JJ animal_NN model_NN therapies_NNS to_TO replace_VB lost_VBN biological_JJ function_NN data_NNS ,_, the_DT likelihood_NN of_IN a_DT late_JJ stage_NN project_NN resulting_VBG from_IN a_DT malfunctioning_NN or_CC missing_VBG failure_NN is_VBZ low_JJ ._.
Hunter_NNP patients_NNS who_WP will_MD receive_VB gene_NN in_IN affected_JJ patients_NNS ._.
It_PRP does_VBZ not_RB conduct_VB ELAPRASE_NNP are_VBP set_VBN to_TO have_VB high-risk_JJ discovery_NN research_NN and_CC protein_NN a_DT brighter_NN future_NN and_CC I_PRP am_VBP glad_JJ replacement_NN therapies_NNS generally_RB benefit_VBP from_IN that_IN I_PRP took_VBD part_NN in_IN the_DT development_NN fast_RB development_NN timelines_NNS ._.
These_DT drugs_NNS have_VBP of_IN this_DT new_JJ treatment_NN ._.
a_DT high_JJ success_NN rate_NN in_IN reaching_VBG the_DT market_NN Adam_NNP Cohen_NNP and_CC normally_RB benefit_NN from_IN long_JJ lifecycles_NNS Hunter_NNP Syndrome_NNP patient_NN and_CC once_RB marketed_VBN due_JJ to_TO orphan_JJ drug_NN status_NN Elaprase_NNP clinical_JJ trial_NN participant_NN ._.
exclusivity_NN seven_CD years_NNS in_IN the_DT US_NNP and_CC ten_CD years_NNS in_IN the_DT EU_NNP and_CC robust_JJ patent_NN protection_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 33_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 34_CD Operating_NN review_NN Human_NNP Genetic_NNP Therapies_NNPS 03_CD 04_CD Shire_NNP HGT_NNP works_VBZ on_IN genetic_JJ diseases_NNS ELAPRASE_NNP :_: An_DT enzyme_NN replacement_NN A_DT focused_VBN team_NN with_IN serious_JJ mortality_NN and_CC morbidity_NN effects_NNS therapy_NN in_IN registration_NN since_IN December_NNP Since_IN the_DT acquisition_NN of_IN TKT_NNP by_IN Shire_NNP on_IN patients_NNS that_WDT are_VBP amenable_JJ to_TO protein_NN 2005_CD for_IN the_DT treatment_NN of_IN Hunter_NNP Syndrome_NNP ._.
Dr_NNP Pendergast_NNP has_VBZ overseen_VBN a_DT complex_JJ replacement_NN therapy_NN ._.
One_CD large_JJ category_NN is_VBZ The_DT product_NN has_VBZ gained_VBN fast_JJ track_NN status_NN transition_NN and_CC built_VBD a_DT business_NN and_CC Lysosomal_NNP Storage_NNP Diseases_NNPS LSDs_NNP resulting_VBG in_IN the_DT US_NNP and_CC Shire_NNP hopes_VBZ it_PRP will_MD be_VB management_NN team_NN that_WDT is_VBZ focused_VBN on_IN from_IN the_DT bodys_NNS inability_NN to_TO produce_VB a_DT specific_JJ launched_VBN in_IN mid-2006_NN ._.
Shire_NNP also_RB submitted_VBD protein_NN therapies_NNS for_IN genetic_JJ diseases_NNS and_CC enzyme_NN designed_VBN to_TO metabolize_VB different_JJ a_DT MAA_NNP to_TO the_DT EMEA_NNP for_IN idursulfase_NN and_CC the_DT is_VBZ organized_VBN around_IN four_CD critical_JJ business_NN waste_NN products_NNS ._.
These_DT products_NNS build_VBP up_RP subsequent_JJ review_NN is_VBZ expected_VBN to_TO take_VB processes_NNS :_: discovery_NN ,_, development_NN ,_, in_IN the_DT lysosomes_NNS of_IN cells_NNS over_IN time_NN resulting_VBG in_IN 12_CD months_NNS ._.
Hunter_NNP Syndrome_NNP ,_, also_RB known_VBN supply_NN and_CC sales_NNS ._.
We_PRP are_VBP well_RB positioned_VBN the_DT engorgement_NN of_IN cell_NN lysosomes_NNS ,_, cell_NN stress_NN as_IN II_NNP MPS_NNP II_NNP for_IN success_NN because_IN we_PRP have_VBP a_DT culture_NN that_WDT and_CC death_NN followed_VBN by_IN tissue_NN distress_NN and_CC is_VBZ a_DT rare_JJ ,_, life_NN threatening_JJ genetic_JJ disorder_NN is_VBZ very_RB committed_JJ ,_, focused_VBD ,_, team_NN oriented_VBN ,_, organ_NN failure_NN ._.
LSDs_NNS can_MD interfere_VB with_IN the_DT caused_VBN by_IN a_DT lack_NN of_IN the_DT enzyme_NN iduronateopen_NN ,_, science_NN based_VBN and_CC data_NNS driven_VBN ._.
central_JJ nervous_JJ system_NN in_IN ways_NNS that_WDT can_MD often_RB 2-sulfatase_JJ ._.
Symptoms_NNS include_VBP hernias_NNS ,_, His_PRP$ favorite_JJ parts_NNS of_IN the_DT job_NN are_VBP developing_VBG have_VBP a_DT distressing_JJ physical_JJ effect_NN ._.
Often_RB named_VBN frequent_JJ ear_NN infections_NNS ,_, enlarged_JJ livers_NNS and_CC therapies_NNS that_WDT help_VBP patients_NNS and_CC working_VBG with_IN for_IN the_DT physician_NN that_WDT first_RB described_VBD them_PRP spleens_VBZ ,_, reduced_VBN respiratory_JJ capability_NN ,_, joint_JJ bright_JJ people_NNS to_TO solve_VB problems_NNS ._.
Our_PRP$ team_NN clinically_RB ,_, these_DT conditions_NNS are_VBP today_NN known_VBN malformations_NNS ,_, short_JJ stature_NN and_CC cardiac_JJ has_VBZ a_DT broad_JJ range_NN of_IN experiences_NNS and_CC as_IN Fabry_NNP Disease_NNP ,_, Hunter_NNP Syndrome_NNP ,_, problems_NNS ._.
A_DT number_NN of_IN patients_NNS will_MD also_RB expertise_NN from_IN very_RB large_JJ pharma_NN to_TO folks_NNS and_CC Gaucher_NNP Disease_NNP ,_, among_IN others_NNS ._.
Shire_NNP suffer_VBP significant_JJ CNS_NNP damage_NN ._.
The_DT market_NN that_WDT started_VBD with_IN TKT_NNP over_IN 15_CD years_NNS ago_RB ._.
HGT_NNP also_RB has_VBZ early_JJ research_NN programs_NNS is_VBZ estimated_VBN at_IN $_$ 300_CD million_CD worldwide_NN :_: and_CC They_PRP all_DT have_VBP proven_VBN track_NN records_NNS and_CC the_DT in_IN a_DT number_NN of_IN non-LSD_JJ genetic_JJ diseases_NNS ._.
We_PRP have_VBP good_JJ GA-GCB_NN :_: A_DT gene_NN activated_VBD technologies_NNS and_CC a_DT clear_JJ mission_NN ._.
A_DT strong_JJ pipeline_NN glucocerebrosidase_NN which_WDT recently_RB Shire_NNP HGT_NNP has_VBZ one_CD approved_JJ product_NN and_CC two_CD completed_VBN Phase_NN 2_CD studies_NNS for_IN the_DT Dr_NNP Pendergast_NNP says_VBZ that_IN Shire_NNP will_MD help_VB Shire_NNP late-stage_JJ clinical_JJ development_NN candidates_NNS treatment_NN of_IN Gaucher_NNP Disease_NNP ,_, a_DT genetic_JJ HGT_NNP make_VBP the_DT most_RBS out_IN of_IN its_PRP$ science_NN and_CC with_IN rapid_JJ development_NN time_NN lines_NNS :_: disorder_NN caused_VBN by_IN deficiency_NN of_IN the_DT technology_NN allowing_VBG an_DT increase_NN in_IN the_DT number_NN enzyme_NN ,_, This_DT deficiency_NN causes_VBZ a_DT fatty_NN of_IN projects_NNS it_PRP can_MD now_RB undertake_VB and_CC allowing_VBG REPLAGAL_NNP :_: an_DT enzyme_NN replacement_NN substance_NN to_TO accumulate_VB in_IN certain_JJ body_NN all_DT of_IN the_DT fruits_NNS of_IN that_DT research_NN to_TO be_VB marketed_VBN therapy_NN currently_RB approved_VBN and_CC marketed_VBN tissues_NNS such_JJ as_IN the_DT spleen_NN ,_, liver_NN ,_, and_CC bone_NN internally_RB ._.
Shires_NNP corporate_JJ infrastructure_NN ,_, to_TO treat_VB patients_NNS with_IN Fabry_NNP Disease_NNP LSD_NNP marrow_NN ._.
An_DT individual_JJ affected_VBN by_IN Gaucher_NNP financial_JJ support_NN ,_, business_NN development_NN that_WDT affects_VBZ 810,000_CD patients_NNS in_IN countries_NNS Disease_NNP might_MD exhibit_VB one_CD or_CC several_JJ of_IN expertise_NN and_CC ability_NN to_TO market_NN products_NNS likely_JJ to_TO reimburse_VB for_IN the_DT treatment_NN ._.
these_DT symptoms_NNS :_: enlarged_JJ liver_NN and_CC or_CC targeted_VBN at_IN larger_JJR patient_NN populations_NNS will_MD Symptoms_NNPS usually_RB begin_VBP during_IN childhood_NN spleen_NN ,_, anemia_NN ,_, fatigue_NN ,_, easy_JJ bruising_VBG ,_, ensure_VB that_IN Shire_NNP HGTs_NNP innovative_JJ protein_NN or_CC adolescence_NN and_CC include_VBP burning_VBG impaired_VBN blood_NN clotting_NN ,_, bone_NN pain_NN ,_, and_CC platform_NN reaches_VBZ the_DT greatest_JJS number_NN sensations_NNS in_IN the_DT hands_NNS that_WDT get_VBP worse_JJR fractures_NNS ._.
The_DT total_JJ worldwide_JJ estimated_VBN of_IN patients_NNS in_IN the_DT least_JJS amount_NN of_IN time_NN and_CC with_IN exercise_NN and_CC hot_JJ weather_NN and_CC small_JJ ,_, market_NN is_VBZ more_JJR than_IN $_$ 840_CD million_CD ._.
make_VB a_DT real_JJ difference_NN in_IN peoples_NNS lives_NNS ._.
raised_VBN reddish-purple_JJ blemishes_NNS on_IN the_DT skin_NN ._.
Lipid_JJ storage_NN may_MD lead_VB to_TO impaired_VBN Shire_NNP HGTs_NNP key_JJ products_NNS REPLAGAL_NNP ,_, arterial_JJ circulation_NN and_CC increased_VBD risk_NN ELAPRASE_NNP and_CC GA-GCB_NNP are_VBP manufactured_VBN of_IN heart_NN attack_NN or_CC stroke_NN ._.
The_DT heart_NN may_MD through_IN a_DT proprietary_JJ process_NN derived_VBN from_IN also_RB become_VBN enlarged_JJ and_CC the_DT kidneys_NNS human_JJ cell_NN lines_NNS ,_, an_DT advanced_JJ technology_NN often_RB become_VBP progressively_RB involved_VBN compared_VBN to_TO conventional_JJ method_NN of_IN using_VBG resulting_VBG in_IN ESRD_NNP ._.
REPLAGAL_NNP is_VBZ approved_VBN Chinese_JJ hamster_NN ovary_JJ lines_NNS ._.
Currently_RB relying_VBG in_IN 34_CD countries_NNS outside_IN of_IN the_DT US_NNP where_WRB on_IN a_DT combination_NN of_IN internal_JJ manufacturing_NN ease_NN of_IN administration_NN one_CD fifth_NN the_DT and_CC external_JJ manufacturing_NN filling_VBG partners_NNS volume_NN infusion_NN of_IN the_DT competing_VBG to_TO produce_VB its_PRP$ products_NNS ,_, the_DT unit_NN is_VBZ in_IN the_DT product_NN and_CC a_DT broader_JJR label_NN have_VBP helped_VBN early_RB stages_NNS of_IN planning_VBG for_IN expanded_VBN to_TO establish_VB REPLAGALs_NNS competitive_JJ manufacturing_NN capability_NN ._.
It_PRP is_VBZ estimated_VBN the_DT current_JJ market_NN is_VBZ $_$ 190_CD million_CD in_IN Western_NNP Europe_NNP :_: 34_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 35_CD We_PRP nd_VBP that_IN nature_NN is_VBZ always_RB surprising_JJ us_PRP and_CC these_DT surprises_NNS are_VBP the_DT essence_NN of_IN discovery_NN ._.
Michael_NNP W._NNP Heartlein_NNP Vice_NNP President_NNP ,_, Research_NNP ,_, Shire_NNP HGT_NNP 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 36_CD resp_NN onsi_NN ble_NN 36_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 37_CD Corporate_JJ Responsibility_NN Our_PRP$ business_NN touches_NNS many_JJ peoples_NNS lives_NNS ._.
Responsibility_NN in_IN pharmaceuticals_NNS Managing_VBG our_PRP$ products_NNS The_DT supply_NN chain_NN There_EX are_VBP few_JJ sectors_NNS that_WDT can_MD have_VB so_RB positive_JJ This_DT section_NN will_MD explore_VB how_WRB we_PRP address_VBP We_PRP made_VBN particular_JJ progress_NN in_IN this_DT area_NN an_DT impact_NN on_IN society_NN as_IN pharmaceuticals_NNS ._.
Our_PRP$ any_DT specific_JJ issues_NNS that_WDT occur_VBP in_IN relation_NN in_IN 2005_CD ._.
Our_PRP$ new_JJ global_JJ procurement_NN ability_NN to_TO treat_VB ,_, prevent_VB and_CC cure_VB disease_NN gives_VBZ to_TO our_PRP$ drugs_NNS ._.
Two_CD examples_NNS from_IN 2005_CD are_VBP services_NNS group_NN is_VBZ now_RB implementing_VBG us_PRP enormous_JJ power_NN for_IN good_JJ ,_, but_CC this_DT brings_VBZ the_DT withdrawal_NN of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP ,_, a_DT Company-wide_JJ procurement_NN process_NN with_IN it_PRP an_DT enormous_JJ responsibility_NN ._.
So_RB much_RB so_RB ,_, where_WRB we_PRP successfully_RB addressed_VBD questions_NNS across_IN all_DT suppliers_NNS ._.
This_DT will_MD allow_VB us_PRP to_TO in_IN fact_NN ,_, that_IN the_DT whole_JJ concept_NN of_IN responsibility_NN raised_VBN by_IN Health_NNP Canada_NNP ,_, and_CC REMINYL_NNP manage_VBP our_PRP$ relationships_NNS more_RBR effectively_RB is_VBZ inextricable_JJ linked_VBN to_TO the_DT day-to-day_JJ running_NN in_IN the_DT UK_NNP ,_, where_WRB a_DT multi-faceted_JJ campaign_NN as_RB well_RB as_IN to_TO introduce_VB social_JJ and_CC of_IN a_DT pharmaceuticals_NNS business_NN like_IN Shire_NNP ._.
from_IN the_DT medical_JJ community_NN ,_, patients_NNS ,_, environmental_JJ criteria_NNS for_IN suppliers_NNS ,_, politicians_NNS and_CC members_NNS of_IN the_DT public_NN may_MD and_CC conduct_VB compliance_NN audits_NN ._.
This_DT is_VBZ one_CD of_IN the_DT reasons_NNS why_WRB we_PRP have_VBP now_RB help_VB to_TO retain_VB National_NNP Health_NNP Service_NNP NHS_NNP decided_VBD to_TO move_VB away_RB from_IN using_VBG the_DT phrase_NN funding_NN for_IN treatment_NN for_IN Alzheimers_NNP Disease_NNP ._.
Engaging_VBG with_IN our_PRP$ people_NNS corporate_JJ social_JJ responsibility_NN ,_, in_IN favor_NN of_IN the_DT Our_PRP$ business_NN relies_VBZ on_IN the_DT enthusiasm_NN ,_, much_RB broader_JJR term_NN corporate_JJ responsibility_NN Running_VBG Shire_NNP in_IN a_DT responsible_JJ way_NN commitment_NN and_CC motivation_NN of_IN its_PRP$ people_NNS CR_NNP ._.
Talking_VBG only_RB about_IN corporate_JJ social_JJ CR_NN also_RB extends_VBZ to_TO the_DT way_NN Shire_NNP operates_VBZ and_CC the_DT feedback_NN we_PRP received_VBD from_IN responsibility_NN can_MD suggest_VB that_IN the_DT external_JJ as_IN an_DT organization_NN ._.
Our_PRP$ CR_NNP Report_NNP will_MD review_VB :_: employees_NNS during_IN 2005_CD was_VBD particularly_RB impact_NN of_IN the_DT business_NN is_VBZ limited_VBN to_TO social_JJ encouraging_JJ ._.
Acquiring_VBG TKT_NNP was_VBD a_DT major_JJ issues_NNS ,_, to_TO the_DT exclusion_NN of_IN wider_JJR environmental_JJ our_PRP$ environmental_JJ performance_NN :_: event_NN for_IN Shire_NNP in_IN 2005_CD and_CC like_IN any_DT acquisition_NN and_CC ethical_JJ concerns_NNS :_: and_CC it_PRP can_MD also_RB imply_VB it_PRP had_VBD to_TO be_VB managed_VBN in_IN human_JJ as_RB well_RB that_IN this_DT area_NN is_VBZ the_DT preserve_VB of_IN specialists_NNS ,_, health_NN and_CC safety_NN :_: as_IN commercial_JJ terms_NNS ._.
We_PRP quickly_RB renamed_VBD rather_RB than_IN being_VBG the_DT responsibility_NN of_IN everyone_NN the_DT business_NN Shire_NNP HGT_NNP but_CC made_VBD few_JJ other_JJ who_WP works_VBZ for_IN Shire_NNP ._.
We_PRP wanted_VBD our_PRP$ new_JJ colleagues_NNS to_TO feel_VB part_NN of_IN Shire_NNP as_RB quickly_RB as_IN possible_JJ ,_, This_DT will_MD be_VB reflected_VBN in_IN Shires_NNP dedicated_VBD the_DT way_NN we_PRP engage_VBP with_IN our_PRP$ people_NNS :_: and_CC and_CC this_DT involved_VBD an_DT intensive_JJ program_NN 2005_CD CR_NNP report_NN ,_, which_WDT will_MD concentrate_VB of_IN communication_NN and_CC integration_NN ,_, including_VBG on_IN the_DT key_JJ issues_NNS that_IN we_PRP face_VBP as_IN a_DT specialist_NN our_PRP$ role_NN in_IN the_DT community_NN ._.
a_DT number_NN of_IN high-profile_JJ activities_NNS in_IN the_DT area_NN pharmaceuticals_NNS business_NN ._.
of_IN Cambridge_NNP ,_, Massachusetts_NNP where_WRB the_DT Environmental_NNP performance_NN main_JJ office_NN and_CC manufacturing_NN site_NN is_VBZ located_VBN ._.
The_DT areas_NNS of_IN focus_NN in_IN the_DT 2005_CD CR_NNP report_NN are_VBP :_: We_PRP established_VBD a_DT new_JJ environmental_JJ As_IN a_DT result_NN ,_, retention_NN of_IN these_DT employees_NNS management_NN system_NN in_IN 2005_CD ,_, which_WDT was_VBD has_VBZ been_VBN very_RB high_JJ over_IN 90_CD %_NN ._.
Drug_NN safety_NN developed_VBN with_IN input_NN from_IN both_DT Deloitte_NNP and_CC This_DT will_MD cover_VB our_PRP$ policies_NNS and_CC practices_NNS the_DT International_NNP Safety_NNP Council_NNP ._.
We_PRP have_VBP new_JJ Our_PRP$ role_NN in_IN the_DT community_NN in_IN relation_NN to_TO clinical_JJ trials_NNS ,_, drug_NN testing_NN and_CC environmental_JJ performance_NN targets_NNS for_IN 2006_CD ,_, We_PRP have_VBP an_DT extensive_JJ community_NN program_NN ,_, quality_NN procedures_NNS ,_, and_CC our_PRP$ commitment_NN covering_VBG matters_NNS such_JJ as_IN management_NN of_IN ranging_VBG from_IN our_PRP$ support_NN of_IN employee_NN to_TO publish_VB research_NN data_NNS ._.
It_PRP also_RB includes_VBZ waste_NN ,_, reduction_NN of_IN CO_NNP emissions_NNS ,_, disposal_NN volunteers_NNS to_TO making_VBG corporate_JJ donations_NNS 2_CD the_DT ongoing_JJ monitoring_NN of_IN our_PRP$ products_NNS ._.
of_IN hazardous_JJ materials_NNS ,_, water_NN and_CC energy_NN to_TO organizations_NNS working_VBG in_IN our_PRP$ own_JJ conservation_NN and_CC reduction_NN of_IN use_NN of_IN volatile_JJ therapeutic_JJ areas_NNS ._.
We_PRP were_VBD particularly_RB proud_JJ Responsible_JJ marketing_NN organic_JJ chemicals_NNS or_CC VOCs_NNS ._.
of_IN the_DT efforts_NNS our_PRP$ people_NNS made_VBN to_TO support_VB This_DT will_MD address_VB our_PRP$ approach_NN to_TO marketing_VBG the_DT victims_NNS of_IN the_DT tsunami_NN in_IN South-East_NNP Asia_NNP pharmaceutical_JJ products_NNS ,_, how_WRB we_PRP train_VBP and_CC Health_NNP and_CC safety_NN and_CC Hurricane_NNP Katrina_NNP in_IN 2005_CD $_$ 166,103_CD manage_VB our_PRP$ sales-force_NN to_TO ensure_VB that_IN we_PRP We_PRP carried_VBD out_RP a_DT global_JJ Environment_NNP ,_, Health_NNP was_VBD raised_VBN around_IN the_DT world_NN ,_, which_WDT was_VBD comply_VB with_IN local_JJ regulations_NNS ,_, the_DT highest_JJS and_CC Safety_NNP assessment_NN in_IN 2004_CD ,_, and_CC will_MD matched_VBN by_IN the_DT Company_NN ._.
ethical_JJ standards_NNS and_CC codes_NNS of_IN practice_NN ._.
be_VB repeating_VBG this_DT exercise_NN in_IN 2006_CD ._.
We_PRP have_VBP It_PRP also_RB explains_VBZ our_PRP$ Medical_JJ Legal_NNP Review_NNP a_DT comprehensive_JJ system_NN for_IN identifying_VBG and_CC process_NN ,_, which_WDT strives_VBZ to_TO ensure_VB effective_JJ addressing_VBG possible_JJ workplace_NN risks_NNS ,_, with_IN the_DT and_CC accurate_JJ communication_NN as_IN part_NN aim_NN of_IN reducing_VBG reportable_JJ incidents_NNS by_IN 50_CD %_NN ._.
of_IN the_DT production_NN of_IN our_PRP$ educational_JJ and_CC promotional_JJ materials_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 37_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 38_CD Corporate_JJ Responsibility_NN Principles_NNS ,_, policies_NNS and_CC practices_NNS enterprise-wide_JJ risk_NN assessment_NN process_NN of_IN which_WDT this_DT CR_NN assessment_NN is_VBZ a_DT part_NN ._.
Identified_VBN Accountability_NN risks_NNS are_VBP reviewed_VBN twice-yearly_JJ by_IN the_DT The_DT Company_NN attaches_VBZ great_JJ importance_NN to_TO Executive_NNP Committee_NNP ,_, the_DT Audit_NNP Committee_NNP social_JJ and_CC environmental_JJ issues_NNS and_CC to_TO ethical_JJ and_CC the_DT Board_NNP ._.
Accordingly_RB ,_, ultimate_JJ responsibility_NN for_IN them_PRP is_VBZ taken_VBN at_IN the_DT highest_JJS Training_NN and_CC assessment_NN levels_NNS ._.
The_DT Board_NNP reviews_VBZ the_DT Companys_NNPS In_IN keeping_VBG with_IN our_PRP$ belief_NN that_IN CR_NNP is_VBZ an_DT general_JJ approach_NN to_TO CR_NNP ._.
Shires_NNP CR_NNP strategy_NN integral_JJ part_NN of_IN our_PRP$ business_NN ,_, we_PRP seek_VBP to_TO New_NNP targets_NNS in_IN 2006_CD for_IN water_NN and_CC is_VBZ implemented_VBN by_IN our_PRP$ CR_NNP Committee_NNP ._.
raise_NN awareness_NN of_IN CR-related_JJ issues_NNS in_IN our_PRP$ energy_NN conservation_NN ._.
This_DT Committee_NNP is_VBZ chaired_VBN by_IN our_PRP$ Chief_NNP business-related_JJ training_NN ._.
Specific_JJ training_NN Financial_NNP Officer_NNP ,_, who_WP also_RB takes_VBZ responsibility_NN is_VBZ given_VBN on_IN Shires_NNP code_NN of_IN conduct_NN and_CC at_IN Board_NNP level_NN for_IN CR_NNP ._.
We_PRP made_VBD a_DT number_NN for_IN those_DT working_VBG in_IN areas_NNS such_JJ as_IN sales_NNS of_IN changes_NNS to_TO enchance_VB the_DT composition_NN and_CC marketing_NN ,_, environmental_JJ legislation_NN ,_, of_IN the_DT Committee_NNP this_DT year_NN ,_, and_CC now_RB have_VBP a_DT and_CC corporate_JJ governance_NN ._.
good_JJ balance_NN of_IN senior_JJ managers_NNS and_CC function_NN heads_NNS whose_WP$ roles_NNS have_VBP particular_JJ relevance_NN CR_NN issues_NNS are_VBP included_VBN in_IN performance_NN to_TO CR_NNP ._.
Members_NNS of_IN the_DT CR_NNP Committee_NNP include_VBP appraisals_NNS for_IN all_DT senior_JJ managers_NNS ,_, as_RB well_RB as_IN Caroline_NNP West_NNP ,_, our_PRP$ new_JJ Chief_NNP Compliance_NNP line_NN managers_NNS with_IN functional_JJ responsibilities_NNS ,_, Officer_NNP ,_, Eliseo_NNP Salinas_NNP ,_, Chief_NNP Scientific_NNP Officer_NNP ,_, and_CC those_DT where_WRB CR_NNP issues_NNS have_VBP a_DT direct_JJ and_CC David_NNP Pendergast_NNP ,_, who_WP is_VBZ the_DT General_NNP impact_NN on_IN their_PRP$ role_NN ._.
Manager_NN of_IN our_PRP$ new_JJ Shire_NNP HGT_NNP business_NN ._.
Feedback_NN from_IN employees_NNS in_IN 2005_CD Stakeholder_NNP engagement_NN was_VBD particularly_RB encouraging_JJ ._.
Objectives_NNS We_PRP put_VBP considerable_JJ emphasis_NN on_IN Shire_NNP sets_VBZ corporate_JJ objectives_NNS annually_RB ._.
maintaining_VBG productive_JJ relationships_NNS with_IN Achieving_VBG our_PRP$ CR_NN objectives_NNS is_VBZ key_JJ to_TO our_PRP$ all_PDT our_PRP$ key_JJ stakeholders_NNS ,_, and_CC the_DT feedback_NN overall_JJ performance_NN targets_NNS ._.
Functional_NNP we_PRP receive_VBP from_IN them_PRP is_VBZ taken_VBN into_IN account_NN and_CC individual_JJ objectives_NNS are_VBP aligned_VBN with_IN in_IN developing_VBG our_PRP$ CR_NN policy_NN ,_, CR_NNP strategy_NN ,_, overall_JJ corporate_JJ objectives_NNS ._.
In_IN this_DT way_NN our_PRP$ and_CC CR_NNP performance_NN targets_NNS ._.
Stakeholder_NNP CR_NNP objectives_NNS permeate_VBP right_RB through_IN the_DT dialogue_NN ranges_VBZ from_IN meetings_NNS with_IN business_NN ,_, from_IN the_DT Board_NNP to_TO every_DT member_NN institutional_JJ shareholders_NNS conducted_VBN by_IN our_PRP$ of_IN staff_NN ._.
Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP ,_, to_TO regular_JJ interaction_NN with_IN regulators_NNS Our_PRP$ CR_NN objectives_NNS are_VBP formulated_VBN and_CC agreed_VBN and_CC health_NN providers_NNS such_JJ as_IN the_DT FDA_NNP ,_, by_IN the_DT CR_NNP Committee_NNP ,_, and_CC monitored_VBD at_IN Board_NNP the_DT Medicines_NNP and_CC Healthcare_NNP Products_NNPS level_NN ._.
They_PRP cover_VBP all_PDT the_DT commercial_JJ aspects_NNS Regulatory_NNP Agency_NNP and_CC National_NNP Institute_NNP for_IN of_IN our_PRP$ business_NN ,_, as_RB well_RB as_IN the_DT way_NN in_IN which_WDT Clinical_NNP Excellence_NNP NICE_NNP ,_, to_TO the_DT relationships_NNS we_PRP operate_VBP as_IN an_DT organization_NN ,_, and_CC include_VBP ,_, we_PRP have_VBP with_IN specialist_NN physicians_NNS and_CC for_IN example_NN ,_, objectives_NNS relating_VBG to_TO clinical_JJ patient_NN groups_NNS ,_, such_JJ as_IN Children_NNP and_CC Adults_NNS trials_NNS ,_, product_NN safety_NN ,_, patient_JJ education_NN ,_, with_IN Attention_NN Deficit_NN Disorder_NN CHADD_NNP ,_, ethical_JJ selling_NN ,_, procurement_NN ,_, and_CC environmental_JJ the_DT Mucopolysaccharide_NNP MPS_NNP Society_NNP ,_, performance_NN ,_, as_RB well_RB as_IN people-related_JJ issues_NNS the_DT Alzheimers_NNP Society_NNP and_CC the_DT National_NNP such_JJ as_IN diversity_NN and_CC work-life_NN balance_NN ._.
These_DT objectives_NNS can_MD be_VB viewed_VBN in_IN our_PRP$ CR_NN report_NN or_CC on_IN our_PRP$ website_NN ._.
We_PRP also_RB welcome_JJ feedback_NN from_IN anyone_NN else_RB with_IN an_DT interest_NN in_IN our_PRP$ business_NN ,_, and_CC if_IN you_PRP Risk_NNP management_NN have_VBP views_NNS or_CC comments_NNS you_PRP can_MD send_VB them_PRP We_PRP undertook_VBD a_DT full_JJ CR_NN risk_NN assessment_NN to_TO cr@shire_VB ._.
com_NN Main_NNP picture_NN right_NN :_: in_IN 2004_CD ,_, and_CC this_DT was_VBD reviewed_VBN in_IN depth_NN and_CC We_PRP were_VBD joint_JJ sponsors_NNS of_IN the_DT re-affirmed_JJ during_IN 2005_CD ._.
Our_PRP$ CR_NNP Committee_NNP MPS_NNP Awareness_NNP Day_NNP and_CC took_VBD members_NNS are_VBP responsible_JJ for_IN ensuring_VBG the_DT CR_NNP part_NN in_IN a_DT ceremony_NN to_TO ring_VB the_DT bell_NN risks_NNS are_VBP assessed_VBN and_CC revised_VBN as_RB necessary_JJ at_IN NASDAQ_NNP ._.
Shire_NNP engages_VBZ in_IN an_DT 38_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 39_CD 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 40_CD Board_NNP of_IN Directors_NNS 01_CD 01_CD Dr_NNP James_NNP Cavanaugh_NNP Dr_NNP James_NNP Cavanaugh_NNP 68_CD Chairman_NNP Dr_NNP James_NNP Cavanaugh_NNP has_VBZ been_VBN a_DT member_NN of_IN Shires_NNP Board_NNP since_IN March_NNP 24_CD ,_, 1997_CD and_CC 02_CD Chairman_NNP since_IN May_NNP 11_CD ,_, 1999_CD ._.
He_PRP is_VBZ a_DT General_NNP Matthew_NNP Emmens_NNP Partner_NNP of_IN HealthCare_NNP Partners_NNPS ,_, the_DT General_NNP 01_CD 02_CD Chief_NNP Executive_NNP Officer_NNP Partner_NNP of_IN Healthcare_NNP Ventures_NNP ,_, a_DT venture_NN capital_NN fund_NN devoted_VBN to_TO healthcare_NN ,_, Non_NNP -_: 03_CD executive_NN Chairman_NN of_IN Diversa_NNP Corporation_NNP Angus_NNP Russell_NNP and_CC a_DT Non-executive_JJ Director_NNP of_IN MedImmune_NNP Chief_NNP Financial_NNP Officer_NNP Inc._NNP and_CC Advancis_NNP Pharmaceutical_NNP Corporation_NNP ._.
He_PRP is_VBZ a_DT former_JJ President_NNP of_IN SmithKline_NNP &_CC 04_CD French_JJ Laboratories_NNPS ,_, SmithKline_NNP Beecham_NNP Robin_NNP Buchanan_NNP Corporations_NNS clinical_JJ laboratory_NN business_NN ,_, and_CC Non-executive_JJ Director_NNP Allergan_NNP International_NNP ,_, and_CC served_VBD as_IN Deputy_NNP 03_CD 04_CD Assistant_NNP to_TO the_DT US_NNP President_NNP on_IN the_DT White_NNP 05_CD House_NNP Staff_NNP ._.
Dr_NNP Cavanaugh_NNP is_VBZ also_RB Chairman_NNP The_NNP Hon_NNP James_NNP Grant_NNP of_IN Shires_NNP Nomination_NNP Committee_NNP ._.
Non-executive_JJ Director_NNP 02_CD 06_CD Matthew_NNP Emmens_NNP 54_CD David_NNP Kappler_NNP Matthew_NNP Emmens_NNP has_VBZ been_VBN Shires_NNP Chief_NNP Non-executive_JJ Director_NNP Executive_NNP Officer_NNP and_CC a_DT member_NN of_IN the_DT Board_NNP since_IN March_NNP 12_CD ,_, 2003_CD ._.
He_PRP began_VBD his_PRP$ career_NN 05_CD 06_CD 07_CD in_IN international_JJ pharmaceuticals_NNS with_IN Merck_NNP Patrick_NNP Langlois_NNP &_CC Co_NNP ,_, Inc._NNP in_IN 1974_CD ,_, where_WRB he_PRP held_VBD a_DT wide_JJ Non-executive_JJ Director_NNP range_NN of_IN sales_NNS ,_, marketing_NN and_CC administrative_JJ positions_NNS ._.
In_IN 1992_CD ,_, he_PRP helped_VBD to_TO establish_VB 08_CD Astra_NNP Merck_NNP ,_, a_DT joint_JJ venture_NN between_IN Merck_NNP Ronald_NNP Nordmann_NNP and_CC Astra_NNP AB_NNP of_IN Sweden_NNP ,_, becoming_VBG President_NNP Non-executive_JJ Director_NNP and_CC Chief_NNP Executive_NNP Officer_NNP ._.
In_IN 1999_CD ,_, he_PRP joined_VBD Merck_NNP KGaA_NNP and_CC established_VBN EMD_NNP 09_CD Pharmaceuticals_NNP ,_, the_DT Companys_NNPS US_NNP 07_CD 08_CD Barry_NNP Price_NNP prescription_NN pharmaceutical_JJ business_NN ._.
Non-executive_JJ Director_NNP He_PRP was_VBD later_RB promoted_VBN to_TO President_NNP of_IN Merck_NNP KGaAs_NNP global_JJ prescription_NN business_NN ,_, based_VBN in_IN Germany_NNP ._.
Mr_NNP Emmens_NNP holds_VBZ a_DT degree_NN in_IN Business_NNP Management_NNP from_IN Fairleigh_NNP Dickinson_NNP University_NNP ._.
He_PRP is_VBZ also_RB Chairman_NNP of_IN Shires_NNP Executive_NNP and_CC Portfolio_NNP Review_NNP Committees_NNS ._.
09_CD 40_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 41_CD 03_CD 06_CD 08_CD Angus_NNP Russell_NNP 50_CD David_NNP Kappler_NNP 58_CD Ronald_NNP Nordmann_NNP 64_CD Angus_NNP Russell_NNP has_VBZ been_VBN Shires_NNP Chief_NNP David_NNP Kappler_NNP has_VBZ been_VBN a_DT member_NN of_IN Shires_NNP Ronald_NNP Nordmann_NNP has_VBZ been_VBN a_DT member_NN Financial_NNP Officer_NNP and_CC a_DT member_NN of_IN the_DT Board_NNP Board_NNP since_IN April_NNP 5_CD ,_, 2004_CD ._.
He_PRP is_VBZ currently_RB of_IN Shires_NNP Board_NNP since_IN December_NNP 23_CD ,_, since_IN December_NNP 13_CD ,_, 1999_CD ._.
He_PRP also_RB serves_VBZ as_IN also_RB serving_VBG as_IN Non-executive_JJ Chairman_NNP 1999_CD and_CC previously_RB served_VBD as_IN a_DT Nona_NNP non-executive_JJ Director_NNP of_IN the_DT City_NNP of_IN London_NNP of_IN Premier_NNP Foods_NNP plc_NN and_CC as_IN a_DT Non-executive_JJ executive_NN Director_NNP of_IN Roberts_NNP Pharmaceutical_NNP Investment_NNP Trust_NNP plc._NN ._.
Between_IN 1980_CD and_CC Director_NNP of_IN Intercontinental_NNP Hotels_NNPS Group_NNP plc_NN Corporation_NNP ._.
He_PRP is_VBZ also_RB a_DT Director_NNP of_IN 1999_CD ,_, Mr_NNP Russell_NNP held_VBD a_DT number_NN of_IN positions_NNS and_CC HMV_NNP Group_NNP plc._NN ._.
In_IN addition_NN ,_, he_PRP was_VBD Neurochem_NNP Inc._NNP and_CC Par_NNP Pharmaceutical_NNP of_IN increasing_VBG responsibility_NN at_IN ICI_NNP ,_, Zeneca_NNP and_CC a_DT director_NN of_IN Camelot_NNP Group_NNP plc_NN from_IN 1996_CD -_: Companies_NNS ,_, Inc._NNP ._.
Mr_NNP Nordmann_NNP is_VBZ CoAstraZeneca_NNP plc_NN ,_, including_VBG Vice_NNP President_NNP -_: 2002_CD ._.
Mr_NNP Kappler_NNP retired_VBD from_IN Cadbury_NNP President_NNP of_IN Global_NNP Health_NNP Associates_NNPS ._.
Corporate_JJ Finance_NNP at_IN AstraZeneca_NNP and_CC Group_NNP Schweppes_NNP plc_NN in_IN April_NNP 2004_CD after_IN serving_VBG He_PRP has_VBZ been_VBN a_DT financial_JJ analyst_NN in_IN healthcare_NN Treasurer_NNP at_IN Zeneca_NNP ._.
Mr_NNP Russell_NNP is_VBZ a_DT chartered_VBN as_IN Chief_NNP Financial_NNP Officer_NNP since_IN 1995_CD ._.
equities_NNS since_IN 1971_CD ,_, holding_VBG senior_JJ positions_NNS accountant_NN ,_, having_VBG qualified_VBN with_IN Coopers_NNP &_CC He_PRP worked_VBD for_IN the_DT Cadbury_NNP Schweppes_NNP group_NN with_IN Deerfield_NNP Management_NNP ,_, PaineWebber_NNP ,_, Lybrand_NNP ,_, and_CC a_DT fellow_NN of_IN the_DT Association_NNP of_IN between_IN 1965_CD and_CC 1984_CD and_CC rejoined_VBD the_DT Oppenheimer_NNP &_CC Co._NNP ._.
F_NN Eberstadt_NNP &_CC Co._NNP ._.
Corporate_JJ Treasurers_NNPS ._.
He_PRP is_VBZ also_RB a_DT member_NN of_IN Company_NN in_IN 1989_CD following_VBG its_PRP$ acquisition_NN and_CC Warner-Chilcott_NNP Laboratories_NNPS ._.
He_PRP holds_VBZ Shires_NNP Executive_NNP Committee_NNP and_CC is_VBZ Chairman_NNP of_IN Trebor_NNP Group_NNP ,_, where_WRB he_PRP was_VBD Financial_NNP a_DT bachelors_NNS degree_NN from_IN Johns_NNP Hopkins_NNP of_IN the_DT Corporate_JJ Responsibility_NNP Committee_NNP ._.
Mr_NNP Kappler_NNP is_VBZ a_DT fellow_NN of_IN the_DT University_NNP and_CC an_DT MBA_NNP from_IN Fairleigh_NNP Chartered_NNP Institute_NNP of_IN Management_NNP Dickinson_NNP University_NNP ._.
Mr_NNP Nordmann_NNP is_VBZ also_RB 04_CD Accountants_NNS ._.
He_PRP is_VBZ also_RB Chairman_NNP a_DT member_NN of_IN Shires_NNP Audit_NNP ,_, Nomination_NNP Robin_NNP Buchanan_NNP 53_CD of_IN Shires_NNP Audit_NNP Committee_NNP ._.
Robin_NNP Buchanan_NNP has_VBZ been_VBN a_DT member_NN of_IN Shires_NNP Board_NNP since_IN July_NNP 30_CD ,_, 2003_CD ._.
He_PRP also_RB 07_CD 09_CD serves_VBZ as_IN a_DT non-executive_JJ director_NN of_IN Liberty_NNP Patrick_NNP Langlois_NNP 60_CD Dr_NNP Barry_NNP Price_NNP 62_CD International_NNP plc._NN ._.
Mr_NNP Buchanan_NNP is_VBZ Senior_JJ Patrick_NNP Langlois_NNP has_VBZ been_VBN a_DT member_NN of_IN Dr_NNP Barry_NNP Price_NNP has_VBZ been_VBN a_DT member_NN Partner_NNP of_IN the_DT UK_NNP operations_NNS and_CC director_NN Shires_NNP Board_NNP since_IN November_NNP 14_CD ,_, 2005_CD ._.
of_IN Shires_NNP Board_NNP since_IN January_NNP 16_CD ,_, 1996_CD of_IN the_DT global_JJ business_NN consultants_NNS Bain_NNP &_CC He_PRP is_VBZ also_RB a_DT Non-executive_JJ Director_NNP of_IN Coley_NNP and_CC is_VBZ the_DT Companys_NNP senior_JJ Non-executive_JJ Company_NNP Inc._NNP and_CC is_VBZ a_DT member_NN of_IN that_DT firms_NNS Pharmaceuticals_NNP Group_NNP ,_, Inc._NNP and_CC was_VBD a_DT NonDirector_NNP ._.
He_PRP also_RB serves_VBZ as_IN Chairman_NNP of_IN worldwide_JJ management_NN committee_NN ._.
He_PRP executive_JJ Director_NNP of_IN Rhodia_NNP SA_NNP between_IN Antisoma_NNP plc_NN and_CC Biowisdom_NNP Ltd._NNP ._.
Dr_NNP Price_NNP previously_RB worked_VBD for_IN American_NNP Express_NNP December_NNP 2002_CD and_CC April_NNP 2005_CD ._.
Mr_NNP Langlois_NNP worked_VBD for_IN Glaxo_NNP for_IN 28_CD years_NNS ,_, where_WRB he_PRP International_NNP Banking_NNP Corporation_NNP in_IN New_NNP previously_RB served_VBD as_IN Vice_NNP Chairman_NNP of_IN the_DT held_VBN positions_NNS of_IN increasing_VBG responsibility_NN York_NNP ,_, McKinsey_NNP &_CC Company_NNP ,_, and_CC Deloitte_NNP Management_NNP Board_NNP of_IN Aventis_NNP S._NNP A._NNP Strasbourg_NNP ,_, with_IN the_DT Companys_NNP research_NN group_NN ._.
Dr_NNP Price_NNP &_CC Touche_NNP ,_, where_WRB he_PRP qualified_VBD as_IN a_DT chartered_JJ having_VBG been_VBN Group_NNP Executive_NNP Vice_NNP President_NNP is_VBZ also_RB Chairman_NNP of_IN Shires_NNP Remuneration_NNP accountant_NN FCA_NNP ._.
Mr_NNP Buchanan_NNP holds_VBZ an_DT and_CC Chief_NNP Financial_NNP Officer_NNP for_IN several_JJ years_NNS ._.
Committee_NNP and_CC a_DT member_NN of_IN the_DT Audit_NNP and_CC MBA_NNP with_IN Distinction_NNP Baker_NNP Scholar_NNP from_IN He_PRP also_RB spent_VBD many_JJ years_NNS in_IN senior_JJ financial_JJ Nomination_NNP Committees_NNS ._.
He_PRP is_VBZ also_RB a_DT roles_NNS with_IN the_DT Rhone-Poulenc_NNP Group_NNP ,_, including_VBG member_NN of_IN Shires_NNP Remuneration_NNP Committee_NNP ._.
three_CD years_NNS as_IN a_DT member_NN of_IN the_DT Executive_NNP Committee_NNP and_CC Chief_NNP Financial_NNP Officer_NNP ._.
D._NNP in_IN Economics_NNP The_NNP Hon_NNP James_NNP Grant_NNP P._NNP C_NNP ,_, C._NNP M_NNP ,_, Q._NNP C_NNP 68_CD and_CC a_DT diploma_NN in_IN banking_NN studies_NNS ._.
He_PRP is_VBZ The_DT Hon_NNP James_NNP Grant_NNP has_VBZ been_VBN a_DT member_NN also_RB a_DT member_NN of_IN Shires_NNP Audit_NNP Committee_NNP ._.
of_IN Shires_NNP Board_NNP since_IN May_NNP 11_CD ,_, 2001_CD and_CC previously_RB served_VBD as_IN a_DT Director_NNP of_IN BioChem_NNP Pharma_NNP Inc._NNP since_IN 1986_CD ._.
He_PRP also_RB sits_VBZ on_IN the_DT boards_NNS of_IN two_CD Canadian_JJ public_JJ corporations_NNS and_CC the_DT boards_NNS of_IN a_DT number_NN of_IN other_JJ private_JJ corporations_NNS and_CC not-for-profit_JJ foundations_NNS and_CC councils_NNS ._.
He_PRP is_VBZ a_DT partner_NN and_CC Chair_NNP Emeritus_NNP with_IN the_DT law_NN firm_NN Stikeman_NNP Elliott_NNP in_IN Montreal_NNP ._.
Mr_NNP Grant_NNP holds_VBZ degrees_NNS in_IN Arts_NNS and_CC Law_NN from_IN McGill_NNP University_NNP ._.
He_PRP is_VBZ also_RB a_DT member_NN of_IN Shires_NNP Nomination_NNP Committee_NNP ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 41_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 42_CD Executive_NNP Committee_NNP 01_CD 08_CD Matthew_NNP Emmens_NNP Tatjana_NNP May_NNP Chief_NNP Executive_NNP Officer_NNP General_NNP Counsel_NNP ,_, Company_NNP and_CC Chairman_NNP of_IN the_DT Secretary_NNP and_CC Executive_NNP Executive_NNP Committee_NNP Vice_NNP President_NNP Global_NNP Legal_NNP Affairs_NNP 01_CD 02_CD 03_CD 02_CD Angus_NNP Russell_NNP 09_CD Chief_NNP Financial_NNP Officer_NNP David_NNP Pendergast_NNP and_CC Executive_NNP Vice_NNP Executive_NNP Vice_NNP President_NNP President_NNP Global_NNP Finance_NNP and_CC General_NNP Manager_NNP ,_, Shire_NNP HGT_NNP 03_CD Mike_NNP Cola_NNP 10_CD Executive_NNP Vice_NNP President_NNP ,_, Dr_NNP Eliseo_NNP Salinas_NNP 04_CD 05_CD 06_CD Global_JJ Therapeutic_NNP Areas_NNS Chief_NNP Scientific_NNP Officer_NNP and_CC Executive_NNP Vice_NNP President_NNP ,_, 04_CD Global_JJ R&D_NNP Barbara_NNP Deptula_NNP Executive_NNP Vice_NNP President_NNP ,_, 11_CD Business_NNP Development_NNP Joseph_NNP Rus_NNP Executive_NNP Vice_NNP President_NNP 05_CD and_CC General_NNP Manager_NNP ,_, Greg_NNP Flexter_NNP International_NNP 07_CD 08_CD 09_CD Executive_NNP Vice_NNP President_NNP and_CC General_NNP Manager_NNP ,_, North_NNP America_NNP 06_CD Anita_NNP Graham_NNP Executive_NNP Vice_NNP President_NNP ,_, Global_NNP Human_NNP Resources_NNPS 10_CD 11_CD 07_CD John_NNP Lee_NNP Executive_NNP Vice_NNP President_NNP ,_, Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP 42_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 43_CD 01_CD 06_CD 10_CD Matthew_NNP Emmens_NNP Anita_NNP Graham_NNP Dr_NNP Eliseo_NNP Salinas_NNP See_VB page_NN 40_CD ._.
Anita_NNP Graham_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN Dr_NNP Eliseo_NNP Salinas_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN January_NNP 2004_CD ._.
She_PRP was_VBD previously_RB Vice_NNP June_NNP 2004_CD ._.
He_PRP was_VBD previously_RB Head_NNP of_IN Global_NNP 02_CD President_NNP of_IN Human_NNP Resources_NNP at_IN Cytyc_NNP Central_NNP Nervous_NNP Systems_NNPS and_CC Vice_NNP President_NNP Angus_NNP Russell_NNP Corporation_NNP ._.
She_PRP also_RB held_VBD senior_JJ HR_NNP for_IN Regional_NNP Clinical_NNP Research_NNP &_CC Development_NNP See_VB page_NN 41_CD ._.
positions_NNS at_IN Serono_NNP ,_, Inc._NNP and_CC Scudder_NNP at_IN Wyeth_NNP Research_NNP ,_, one_CD of_IN the_DT worlds_NNS leading_VBG Kemper_NNP Investments_NNP ,_, Inc._NNP now_RB part_NN pharmaceutical_JJ companies_NNS ._.
03_CD of_IN Deutsche_NNP Bank_NNP and_CC has_VBZ extensive_JJ Mike_NNP Cola_NNP experience_NN in_IN all_DT aspects_NNS of_IN HR_NNP ,_, both_DT 11_CD Mike_NNP Cola_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN July_NNP in_IN Europe_NNP and_CC the_DT US_NNP ._.
He_PRP was_VBD previously_RB President_NNP of_IN the_DT Joseph_NNP Rus_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN 1999_CD ._.
life_NN sciences_NNS division_NN of_IN Safeguard_NNP Scientifics_NNP 07_CD Following_VBG the_DT merger_NN of_IN Shire_NNP Pharmaceuticals_NNP Inc._NNP ._.
Mr_NNP Cola_NNP also_RB worked_VBD for_IN AstraMerck_NNP John_NNP Lee_NNP and_CC BioChem_NNP Pharma_NNP in_IN May_NNP 2001_CD ,_, he_PRP was_VBD AstraZeneca_NNP and_CC was_VBD responsible_JJ for_IN John_NNP Lee_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN April_NNP appointed_VBN President_NNP and_CC Chief_NNP Executive_NNP developing_VBG AstraMercks_NNP product_NN 2000_CD ._.
He_PRP was_VBD previously_RB Vice_NNP President_NNP ,_, Officer_NNP of_IN Shire_NNP BioChem_NNP Inc._NNP ._.
He_PRP has_VBZ more_JJR development_NN ,_, medical_JJ affairs_NNS ,_, business_NN Operations_NNP at_IN Schwarz_NNP Pharma_NNP ,_, and_CC also_RB than_IN 25_CD years_NNS of_IN experience_NN in_IN the_DT international_JJ research_NN ,_, licensing_NN and_CC pharmaceutical_JJ worked_VBN at_IN Central_NNP Pharmaceuticals_NNP ,_, The_DT pharmaceutical_JJ industry_NN including_VBG European_JJ business_NN ._.
Vitarine_NNP Company_NNP now_RB Eon_NNP ,_, and_CC Glenwood_NNP country_NN management_NN ._.
He_PRP has_VBZ over_IN 31_CD years_NNS of_IN 04_CD experience_NN in_IN the_DT pharmaceutical_JJ industry_NN ._.
Barbara_NNP Deptula_NNP Barbara_NNP Deptula_NNP has_VBZ been_VBN with_IN Shire_NNP 08_CD since_IN September_NNP 2004_CD ._.
She_PRP was_VBD previously_RB Tatjana_NNP May_NNP President_NNP of_IN the_DT biotechnology_NN division_NN Tatjana_NNP May_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN May_NNP of_IN Sicor_NNP Inc._NNP and_CC Senior_NNP Vice_NNP President_NNP for_IN 2001_CD ._.
She_PRP was_VBD previously_RB Assistant_NNP General_NNP commercial_JJ and_CC product_NN development_NN at_IN Counsel_NNP at_IN the_DT corporate_JJ headquarters_NN Coley_NNP Pharmaceutical_NNP Group_NNP ._.
She_PRP also_RB held_VBD of_IN AstraZeneca_NNP plc_NN and_CC prior_RB to_TO that_IN she_PRP senior_JJ management_NN positions_NNS focused_VBD worked_VBN at_IN the_DT law_NN firm_NN Slaughter_NNP and_CC May_NNP ._.
on_IN licensing_NN and_CC business_NN development_NN at_IN US_NNP Bioscience_NNP ,_, Schering-Plough_NNP ,_, 09_CD American_NNP Cyanamid_NNP ,_, and_CC Genetics_NNP Institute_NNP ._.
Dr_NNP David_NNP Pendergast_NNP Dr_NNP David_NNP Pendergast_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN 05_CD July_NNP 2005_CD and_CC was_VBD previously_RB Chief_NNP Executive_NNP Greg_NNP Flexter_NNP Officer_NNP of_IN Transkaryotic_NNP Therapies_NNPS Inc._NNP until_IN Greg_NNP Flexter_NNP has_VBZ been_VBN with_IN Shire_NNP since_IN its_PRP$ acquisition_NN by_IN Shire_NNP ._.
He_PRP was_VBD previously_RB Vice_NNP President_NNP as_IN Vice_NNP President_NNP of_IN Product_NNP Development_NNP and_CC head_NN of_IN the_DT neuroscience_NN business_NN and_CC Quality_NNP at_IN Biogen_NNP ,_, Inc_NNP ,_, and_CC held_VBD senior_JJ of_IN Novartis_NNP Pharmaceuticals_NNP ,_, responsible_JJ for_IN positions_NNS at_IN Fisons_NNP Ltd._NNP s_VBZ Pharmaceutical_NNP US_NNP Marketing_NNP ,_, Sales_NNS and_CC Medical_NNP Research_NNP ._.
Division_NNP and_CC The_DT Upjohn_NNP Company_NN ._.
He_PRP has_VBZ Mr_NNP Flexter_NNP has_VBZ more_JJR than_IN 22_CD years_NNS of_IN over_IN 30_CD years_NNS of_IN pharmaceutical_JJ and_CC experience_NN in_IN global_JJ and_CC domestic_JJ marketing_NN ,_, biotechnology_NN experience_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 43_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 44_CD perf_NN orm_NN ance_NN 44_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 45_CD Financial_NNP review_NN For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, total_JJ revenues_NNS increased_VBN by_IN 17_CD %_NN to_TO $_$ 1,599.3_CD million_CD compared_VBN to_TO $_$ 1,363.2_CD million_CD in_IN 2004_CD ._.
Angus_NNP Russell_NNP Chief_NNP Financial_NNP Officer_NNP The_NNP following_VBG discussion_NN should_MD be_VB read_VBN in_IN conjunction_NN with_IN the_DT Companys_NNPS US_NNP GAAP_NNP consolidated_JJ financial_JJ statements_NNS contained_VBN on_IN pages_NNS 78127_CD of_IN this_DT annual_JJ review_NN ._.
Results_NNS of_IN operations_NNS For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, the_DT Companys_NNP total_NN revenues_NNS increased_VBN by_IN 17_CD %_NN to_TO $_$ 1,599.3_CD million_CD ,_, compared_VBN to_TO $_$ 1,363.2_CD million_CD in_IN 2004_CD ._.
Net_JJ loss_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD was_VBD $_$ 410.8_CD million_CD compared_VBN to_TO net_JJ income_NN of_IN $_$ 269_CD million_CD in_IN 2004_CD ._.
The_DT Companys_NNPS net_JJ loss_NN for_IN 2005_CD was_VBD primarily_RB attributable_JJ to_TO the_DT in-process_JJ R&D_NNP write-off_NN of_IN $_$ 673_CD million_CD following_VBG the_DT acquisition_NN of_IN TKT_NNP ._.
Total_JJ revenues_NNS The_DT following_JJ table_NN provides_VBZ an_DT analysis_NN of_IN the_DT Companys_NNPS total_VBP revenues_NNS by_IN source_NN :_: 2005_CD 2004_CD Change_NNP Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD $_$ million_CD %_NN Product_NN sales_NNS 1,327.7_CD 1,112.5_CD 19_CD Royalties_NNS 242.9_CD 230.4_CD 5_CD Licensing_NN and_CC development_NN 15.0_CD 13.4_CD 11_CD Other_JJ revenues_NNS 13.7_CD 6.9_CD Total_JJ 1,599.3_CD 1,363.2_CD 17_CD All_DT product_NN sales_NNS are_VBP reported_VBN in_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ,_, all_DT royalties_NNS are_VBP reported_VBN in_IN the_DT Royalty_NN segment_NN ._.
Product_NN sales_NNS Product_NNP sales_NNS US_NNP prescription_NN 2005_CD 2004_CD growth_NN growth_NN Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD $_$ million_CD %_NN %_NN CNS_NNP ADDERALL_NNP XR_NNP 730.8_CD 606.7_CD 20_CD 12_CD ADDERALL_NNP 43.1_CD 34.5_CD 25_CD CARBATROL_NNP 72.1_CD 54.3_CD 33_CD 8_CD GI_NNP PENTASA_NNP 136.1_CD 115.0_CD 18_CD 6_CD COLAZIDE_NNP 8.6_CD 8.2_CD 5_CD GP_NNP AGRYLIN_NNP and_CC XAGRID_NNP North_NNP America_NNP US_NNP and_CC Canada_NNP 46.0_CD 119.1_CD 61_CD 48_CD Rest_VBP of_IN the_DT world_NN 46.8_CD 33.4_CD 40_CD FOSRENOL_NNP 53.5_CD CALCICHEW_NNP 38.7_CD 38.3_CD 1_CD SOLARAZE_NNP 12.5_CD 9.5_CD 32_CD REMINYL_NNP REMINYL_NNP XL_NNP 13.5_CD 10.8_CD 25_CD LODINE_NNP 12.6_CD 7.6_CD 66_CD Shire_NNP HGT_NNP i_FW REPLAGAL_NNP 41.3_CD Other_JJ 72.1_CD 75.1_CD 4_CD Total_JJ 1,327.7_CD 1,112.5_CD 19_CD i_FW This_DT represents_VBZ REPLAGAL_NNP sales_NNS for_IN the_DT five-month_JJ period_NN since_IN the_DT acquisition_NN of_IN TKT_NNP ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 45_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 46_CD Financial_NNP review_NN The_DT following_VBG discussion_NN includes_VBZ references_NNS to_TO prescription_NN and_CC market_NN On_IN February_NNP 9_CD ,_, 2006_CD ,_, a_DT FDA_NNP Advisory_NNP Committee_NNP recommended_VBD to_TO the_DT share_NN data_NNS for_IN key_JJ products_NNS ._.
The_DT source_NN of_IN this_DT data_NN is_VBZ IMS_NNP Health_NNP ,_, FDA_NNP that_IN risk_NN information_NN about_IN cardiovascular_JJ events_NNS be_VB included_VBN December_NNP 2005_CD ._.
in_IN a_DT black_JJ box_NN warning_VBG for_IN all_DT stimulant_NN medicines_NNS used_VBN to_TO treat_VB ADHD_NNP ._.
In_IN making_VBG its_PRP$ recommendation_NN ,_, the_DT Advisory_NNP Committee_NNP recognized_VBD During_IN 2005_CD ,_, the_DT Company_NN concluded_VBD new_JJ fee_NN for_IN service_NN agreements_NNS that_IN the_DT reported_VBN incidence_NN rates_NNS of_IN the_DT rare_JJ serious_JJ cardiovascular_JJ with_IN two_CD of_IN its_PRP$ three_CD significant_JJ wholesale_JJ customers_NNS ._.
These_DT adverse_JJ events_NNS that_WDT were_VBD discussed_VBN by_IN the_DT Committee_NNP are_VBP generally_RB agreements_NNS ,_, which_WDT are_VBP commonplace_JJ in_IN the_DT pharmaceutical_JJ industry_NN ,_, within_IN the_DT rates_NNS that_WDT would_MD be_VB expected_VBN from_IN the_DT untreated_JJ general_JJ change_NN the_DT way_NN wholesalers_NNS are_VBP compensated_VBN ._.
ADDERALL_NNP XR_NNP and_CC ADDERALL_NNP already_RB include_VBP a_DT black_JJ the_DT wholesalers_NNS receive_VBP a_DT distribution_NN fee_NN from_IN pharmaceutical_JJ box_NN warning_NN in_IN their_PRP$ labels_NNS for_IN safety_NN concerns_NNS related_VBN to_TO amphetamine_VB suppliers_NNS ._.
These_DT fee_NN for_IN service_NN agreements_NNS eliminate_VB wholesalers_NNS abuse_NN or_CC misuse_NN and_CC also_RB warn_VB of_IN the_DT risk_NN of_IN sudden_JJ death_NN in_IN patients_NNS incentives_NNS to_TO acquire_VB and_CC hold_VB excess_JJ inventories_NNS ._.
The_DT Company_NN with_IN structural_JJ cardiac_JJ abnormalities_NNS ._.
Shire_NNP stands_VBZ behind_IN the_DT current_JJ believes_VBZ this_DT will_MD reduce_VB the_DT significant_JJ impact_NN of_IN wholesaler_NN stocking_VBG labeling_VBG and_CC believes_VBZ that_IN further_JJ action_NN is_VBZ unwarranted_JJ ._.
and_CC fide-stocking_JJ on_IN its_PRP$ product_NN sales_NNS ._.
Further_RB ,_, the_DT wholesalers_NNS will_MD provide_VB data_NNS regarding_VBG their_PRP$ inventories_NNS of_IN the_DT Companys_NNPS products_NNS it_PRP In_IN January_NNP 2006_CD ,_, Shire_NNP settled_VBD its_PRP$ ADDERALL_NNP XR_NNP patent_NN infringement_NN has_VBZ on_IN hand_NN ._.
The_DT Company_NN is_VBZ negotiating_VBG a_DT fees_NNS for_IN service_NN agreement_NN lawsuits_NNS with_IN Impax_NNP ._.
The_DT litigations_NNS involved_VBN Shire_NNP US_NNP patents_NNS ,_, Nos._NNP ._.
with_IN its_PRP$ remaining_VBG significant_JJ wholesale_JJ customer_NN ._.
Fees_NNS for_IN service_NN 6,322,819_CD the_DT 819_CD Patent_NN ,_, 6,605,300_CD the_DT 300_CD Patent_NN and_CC 6,913,768_CD are_VBP treated_VBN as_IN a_DT sales_NNS deduction_NN ,_, thus_RB affecting_VBG revenues_NNS rather_RB than_IN the_DT 768_CD Patent_NN ._.
As_IN part_NN of_IN the_DT settlement_NN ,_, Impax_NNP has_VBZ confirmed_VBN that_IN its_PRP$ cost_NN of_IN sales_NNS ._.
proposed_VBN generic_JJ ADDERALL_NNP XR_NNP product_NN infringes_VBZ Shires_NNP 819_CD ,_, 300_CD and_CC 768_CD Patents_NNP and_CC that_IN the_DT three_CD patents_NNS are_VBP valid_JJ and_CC enforceable_JJ ._.
ADDERALL_NNP XR_NNP Under_IN the_DT terms_NNS of_IN the_DT settlement_NN ,_, Impax_NNP will_MD be_VB permitted_VBN to_TO market_NN US_NNP prescriptions_NNS for_IN ADDERALL_NNP XR_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP in_IN the_DT US_NNP no_RB later_RB than_IN January_NNP 1_CD ,_, were_VBD up_RB 12_CD %_NN ._.
ADDERALL_NNP XR_NNP further_JJ strengthened_VBD its_PRP$ position_NN as_IN the_DT 2010_CD ,_, and_CC will_MD pay_VB Shire_NNP a_DT royalty_NN from_IN those_DT sales_NNS ._.
In_IN certain_JJ situations_NNS ,_, leading_VBG brand_NN in_IN the_DT US_NNP ADHD_NNP market_NN with_IN a_DT 1_CD %_NN increase_NN in_IN market_NN such_JJ as_IN the_DT launch_NN of_IN another_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ,_, Impax_NNP share_NN to_TO an_DT all_DT time_NN high_JJ of_IN 26_CD %_NN in_IN December_NNP 2005_CD December_NNP 2004_CD :_: may_MD be_VB permitted_VBN to_TO enter_VB the_DT market_NN as_IN Shires_NNP authorized_VBD generic_JJ ._.
In_IN addition_NN ,_, the_DT US_NNP ADHD_NNP market_NN grew_VBD 5_CD %_NN overall_JJ compared_VBN to_TO the_DT same_JJ period_NN in_IN 2004_CD ._.
Shires_NNP ADDERALL_NNP XR_NNP patent_NN infringement_NN lawsuits_NNS with_IN Barr_NNP continue_VBP ._.
Shire_NNP is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ Abbreviated_NNP New_NNP Drug_NNP Application_NNP Product_NNP sales_NNS growth_NN was_VBD higher_JJR than_IN prescription_NN growth_NN for_IN the_DT ANDA_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN year_NN due_JJ mainly_RB to_TO the_DT impact_NN of_IN price_NN increases_NNS in_IN December_NNP 2004_CD ADDERALL_NNP XR_NNP infringes_VBZ the_DT 819_CD ,_, 300_CD and_CC 768_CD Patents_NNP ._.
Barrs_NNS and_CC August_NNP 2005_CD ,_, partially_RB offset_VBN by_IN a_DT decrease_NN in_IN pipeline_NN inventory_NN 30-month_JJ stay_NN under_IN the_DT Hatch-Waxman_NNP Act_NNP expired_VBD on_IN February_NNP 18_CD ,_, and_CC higher_JJR sales_NNS deductions_NNS ._.
Following_VBG the_DT expiry_NN of_IN the_DT 30-month_JJ stay_NN ,_, the_DT FDA_NNP may_MD approve_VB Barrs_NNP ANDA_NNP ._.
A_DT final_JJ pre-trial_JJ conference_NN in_IN the_DT 819_CD and_CC 300_CD Patent_NN FDA_NNP approval_NN of_IN the_DT adolescent_JJ indication_NN for_IN ADDERALL_NNP XR_NNP was_VBD cases_NNS took_VBD place_NN on_IN March_NNP 10_CD ,_, 2006_CD where_WRB the_DT trial_NN date_NN was_VBD set_VBN received_VBN on_IN July_NNP 22_CD ,_, 2005_CD ._.
for_IN October_NNP 30_CD ,_, 2006_CD ._.
Shire_NNP is_VBZ continuing_VBG its_PRP$ discussions_NNS with_IN Barr_NNP in_IN connection_NN with_IN these_DT lawsuits_NNS and_CC the_DT discussions_NNS are_VBP progressing_VBG ._.
On_IN February_NNP 12_CD ,_, 2005_CD ,_, Shire_NNP announced_VBD that_IN it_PRP had_VBD suspended_VBN For_IN further_JJ information_NN see_VBP Note_NN 21_CD d_SYM to_TO the_DT Companys_NNP consolidated_JJ sales_NNS of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP at_IN the_DT request_NN of_IN Health_NNP Canada_NNP ._.
If_IN the_DT Company_NN does_VBZ not_RB prevail_VB On_IN August_NNP 24_CD ,_, 2005_CD ,_, Shire_NNP announced_VBD that_IN Health_NNP Canada_NNP would_MD in_IN the_DT lawsuits_NNS ,_, the_DT Companys_NNP sales_NNS of_IN ADDERALL_NNP XR_NNP will_MD decrease_VB ._.
reinstate_VB the_DT marketing_NN authorization_NN of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP Any_DT decrease_NN in_IN the_DT sales_NNS of_IN ADDERALL_NNP XR_NNP would_MD significantly_RB effective_JJ August_NNP 26_CD ,_, 2005_CD ._.
This_DT reinstatement_NN follows_VBZ the_DT acceptance_NN reduce_VB revenues_NNS and_CC earnings_NNS ._.
by_IN Health_NNP Canada_NNP of_IN the_DT recommendations_NNS from_IN the_DT New_NNP Drug_NNP Committee_NNP ,_, which_WDT was_VBD appointed_VBN by_IN Health_NNP Canada_NNP at_IN Shires_NNP request_NN CARBATROL_NNP to_TO review_VB the_DT suspension_NN of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP ._.
US_NNP prescriptions_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, were_VBD down_RB 8_CD %_NN compared_VBN to_TO the_DT previous_JJ year_NN ._.
This_DT was_VBD due_JJ primarily_RB to_TO supply_VB During_IN October_NNP 2005_CD ,_, Shire_NNP filed_VBD a_DT Citizen_NNP Petition_NNP with_IN the_DT FDA_NNP requesting_VBG constraints_NNS ,_, a_DT 4_CD %_NN decrease_NN in_IN Shires_NNP market_NN share_NN of_IN the_DT total_NN that_IN the_DT FDA_NNP require_VB more_JJR rigorous_JJ bioequivalence_NN testing_NN or_CC additional_JJ US_NNP extended_VBD release_NN carbamazepine_NN prescription_NN market_NN to_TO 42_CD %_NN clinical_JJ testing_NN for_IN generic_JJ or_CC follow-on_JJ drug_NN products_NNS that_WDT reference_NN in_IN December_NNP 2005_CD December_NNP 2004_CD :_: 46_CD %_NN and_CC a_DT 5_CD %_NN decrease_NN in_IN that_DT ADDERALL_NNP XR_NNP before_IN they_PRP can_MD be_VB approved_VBN ._.
Shire_NNP believes_VBZ that_IN these_DT market_NN as_IN a_DT whole_NN ._.
The_DT supply_NN constraints_NNS have_VBP now_RB been_VBN resolved_VBN ._.
requested_VBN criteria_NNS will_MD ensure_VB that_IN generic_JJ formulations_NNS of_IN ADDERALL_NNP XR_NNP or_CC follow-on_JJ drug_NN products_NNS will_MD be_VB clinically_RB effective_JJ and_CC safe_JJ ._.
In_IN January_NNP Product_NNP sales_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD up_RB 33_CD %_NN 2006_CD ,_, Shire_NNP chose_VBD to_TO file_VB a_DT supplemental_JJ amendment_NN to_TO its_PRP$ original_JJ Citizen_NNP compared_VBN to_TO the_DT previous_JJ year_NN ._.
The_DT difference_NN between_IN sales_NNS growth_NN Petition_NNP ,_, which_WDT included_VBD additional_JJ clinical_JJ data_NNS in_IN support_NN of_IN the_DT original_JJ and_CC the_DT lower_JJR level_NN of_IN prescriptions_NNS is_VBZ due_JJ to_TO price_NN increases_NNS in_IN August_NNP filing_NN ._.
The_DT FDA_NNP has_VBZ six_CD months_NNS to_TO respond_VB to_TO Shires_NNP petition_NN and_CC while_IN this_DT 2004_CD and_CC October_NNP 2005_CD and_CC to_TO lower_VB sales_NNS deductions_NNS than_IN in_IN 2004_CD ._.
petition_NN is_VBZ under_IN review_NN it_PRP will_MD not_RB grant_VB final_JJ approval_NN of_IN generic_JJ or_CC follow-on_JJ drug_NN products_NNS referencing_VBG ADDERALL_NNP XR_NNP ._.
Patent_NN litigation_NN proceedings_NNS with_IN Nostrum_NNP and_CC Corepharma_NNP relating_VBG to_TO CARBATROL_NNP are_VBP in_IN progress_NN ._.
For_IN details_NNS ,_, please_VB see_VB the_DT litigation_NN update_VB on_IN page_NN 111_CD ._.
46_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 47_CD PENTASA_NNP US_NNP prescriptions_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD up_RB 6_CD %_NN compared_VBN to_TO the_DT previous_JJ year_NN ._.
The_DT increase_NN was_VBD due_JJ to_TO the_DT success_NN of_IN the_DT co-promotional_JJ agreement_NN with_IN Solvay_NNP Pharmaceuticals_NNP Inc._NNP the_DT impact_NN of_IN the_DT 500mg_JJ dosage_NN form_NN launched_VBN in_IN the_DT third_JJ quarter_NN of_IN 2004_CD and_CC a_DT 2_CD %_NN increase_NN in_IN the_DT total_JJ US_NNP oral_JJ mesalamine_NN prescription_NN market_NN ._.
Product_NN sales_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD up_RB 18_CD %_NN ,_, compared_VBN to_TO the_DT previous_JJ year_NN ._.
The_DT difference_NN between_IN sales_NNS growth_NN and_CC prescription_NN growth_NN is_VBZ due_JJ to_TO the_DT impact_NN of_IN the_DT September_NNP 2004_CD price_NN increase_NN and_CC a_DT normalization_NN of_IN pipeline_NN inventories_NNS compared_VBN to_TO lower_JJR levels_NNS in_IN 2004_CD ._.
PENTASA_NNP had_VBD an_DT 18_CD %_NN share_NN of_IN the_DT total_JJ US_NNP oral_JJ mesalamine_NN prescription_NN market_NN in_IN December_NNP 2005_CD December_NNP 2004_CD :_: 18_CD %_NN ._.
AGRYLIN_NNP XAGRID_NNP AGRYLIN_NNP XAGRID_NNP sales_NNS worldwide_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD $_$ 92.8_CD million_CD ,_, down_RB 39_CD %_NN compared_VBN to_TO the_DT previous_JJ year_NN 2004_CD :_: $_$ 152.5_CD million_CD ._.
North_JJ American_JJ sales_NNS were_VBD $_$ 46_CD million_CD ,_, down_RB 61_CD %_NN compared_VBN to_TO the_DT previous_JJ year_NN 2004_CD :_: $_$ 119.1_CD million_CD ._.
This_DT reduction_NN was_VBD expected_VBN following_VBG the_DT approval_NN of_IN generic_JJ versions_NNS of_IN AGRYLIN_NNP in_IN the_DT US_NNP market_NN in_IN April_NNP 2005_CD ._.
Rest_VB of_IN the_DT World_NNP sales_NNS all_DT sales_NNS outside_IN North_NNP America_NNP were_VBD $_$ 46.8_CD million_CD ,_, up_RB 40_CD %_NN ,_, compared_VBN to_TO the_DT previous_JJ year_NN 2004_CD :_: $_$ 33.4_CD million_CD ._.
This_DT was_VBD primarily_RB due_JJ to_TO the_DT successful_JJ launch_NN of_IN XAGRID_NNP in_IN the_DT UK_NNP ,_, Germany_NNP and_CC France_NNP in_IN the_DT first_JJ quarter_NN of_IN 2005_CD and_CC Spain_NNP in_IN the_DT third_JJ quarter_NN of_IN 2005_CD ._.
In_IN accordance_NN with_IN current_JJ orphan_JJ drug_NN legislation_NN in_IN the_DT EU_NNP ,_, XAGRID_NNP will_MD have_VB up_RP to_TO ten_VB years_NNS of_IN marketing_NN exclusivity_NN in_IN the_DT EU_NNP ._.
FOSRENOL_NNP FOSRENOL_NNP was_VBD launched_VBN in_IN the_DT US_NNP in_IN January_NNP 2005_CD ._.
Product_NN sales_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD were_VBD $_$ 53.5_CD million_CD ,_, with_IN US_NNP prescriptions_NNS for_IN the_DT year_NN totalling_VBG 137,000_CD ._.
FOSRENOL_NNP had_VBD an_DT 8_CD %_NN share_NN of_IN the_DT total_JJ US_NNP phosphate_NN binding_JJ market_NN in_IN December_NNP 2005_CD ._.
On_IN November_NNP 28_CD ,_, 2005_CD the_DT FDA_NNP approved_VBD new_JJ ,_, higher-dose_JJ formulations_NNS of_IN FOSRENOL_NNP ._.
New_NNP ,_, higher-dose_JJ strengths_NNS of_IN 750mg_NNS and_CC 1,000_CD mg_NN were_VBD shipped_VBN to_TO wholesalers_NNS in_IN the_DT US_NNP in_IN December_NNP 2005_CD ._.
Higher-dose_JJ strengths_NNS should_MD help_VB to_TO reduce_VB the_DT number_NN of_IN pills_NNS that_WDT end-stage_VBP renal_JJ disease_NN patients_NNS need_VBP to_TO take_VB to_TO achieve_VB target_NN phosphorus_NN levels_NNS ._.
Product_NN sales_NNS in_IN Q4_NNP 2005_CD were_VBD $_$ 29_CD million_CD compared_VBN with_IN $_$ 9.7_CD million_CD in_IN Q3_CD 2005_CD ._.
The_DT variance_NN relates_VBZ primarily_RB to_TO increased_VBN pipeline_NN inventory_NN sales_NNS to_TO wholesalers_NNS of_IN the_DT new_JJ higher-dose_JJ formulation_NN during_IN December_NNP ._.
FOSRENOL_NNP was_VBD launched_VBN in_IN Austria_NNP in_IN December_NNP 2005_CD ._.
Shire_NNP continues_VBZ its_PRP$ discussions_NNS relating_VBG to_TO FOSRENOL_NNP with_IN regulatory_JJ authorities_NNS and_CC reimbursement_NN agencies_NNS across_IN Europe_NNP and_CC other_JJ regions_NNS and_CC further_JJ launches_NNS are_VBP expected_VBN in_IN European_JJ markets_NNS over_IN the_DT next_JJ few_JJ months_NNS ,_, subject_JJ to_TO obtaining_VBG national_JJ approvals_NNS and_CC concluding_VBG pricing_NN and_CC reimbursement_NN negotiations_NNS ._.
REPLAGAL_NNP REPLAGAL_NNP was_VBD acquired_VBN by_IN Shire_NNP as_IN part_NN of_IN the_DT TKT_NNP acquisition_NN ,_, which_WDT completed_VBD on_IN July_NNP 27_CD ,_, 2005_CD ._.
Product_NN sales_NNS for_IN the_DT period_NN since_IN acquisition_NN were_VBD $_$ 41.3_CD million_CD ._.
The_DT majority_NN of_IN REPLAGAL_NNP sales_NNS are_VBP in_IN Europe_NNP ._.
Total_JJ sales_NNS for_IN the_DT full_JJ year_NN ,_, including_VBG pre-acquisition_JJ sales_NNS ,_, were_VBD $_$ 94.6_CD million_CD 2004_CD :_: $_$ 77.4_CD million_CD ._.
The_DT increase_NN in_IN sales_NNS including_VBG pre-acquisition_JJ sales_NNS is_VBZ primarily_RB due_JJ to_TO greater_JJR European_JJ coverage_NN by_IN an_DT increased_VBN number_NN of_IN sales_NNS representatives_NNS ._.
Foreign_JJ exchange_NN effect_NN As_IN many_JJ of_IN the_DT Companys_NNPS sales_NNS revenues_NNS are_VBP earned_VBN in_IN currencies_NNS other_JJ than_IN US_PRP Dollars_NNPS primarily_RB Canadian_JJ Dollars_NNPS ,_, Pounds_NNPS Sterling_NNP ,_, Swedish_NNP Krona_NNP and_CC Euros_NNP ,_, revenue_NN growth_NN reported_VBD in_IN US_NNP Dollars_NNPS includes_VBZ the_DT impact_NN of_IN translating_VBG the_DT sales_NNS made_VBN in_IN a_DT local_JJ currency_NN into_IN US_NNP Dollars_NNPS ._.
With_IN the_DT US_NNP Dollar_NNP strengthening_VBG against_IN these_DT currencies_NNS over_IN the_DT last_JJ 12_CD months_NNS ,_, the_DT translation_NN of_IN sales_NNS made_VBN in_IN these_DT currencies_NNS into_IN US_NNP Dollars_NNPS has_VBZ impacted_VBN on_IN the_DT reported_VBN growth_NN rates_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT effect_NN of_IN foreign_JJ exchange_NN translations_NNS on_IN the_DT revenue_NN growth_NN of_IN the_DT key_JJ affected_JJ products_NNS as_RB well_RB as_IN the_DT underlying_VBG performance_NN of_IN key_JJ products_NNS in_IN their_PRP$ local_JJ currency_NN :_: 2005_CD sales_NNS Impact_NN of_IN 2005_CD sales_NNS in_IN growth_NN in_IN translation_NN 2005_CD sales_NNS US_NNP Dollars_NNPS local_JJ to_TO US_NNP growth_NN in_IN Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD currency_NN Dollars_NNPS US_NNP Dollars_NNPS AGRYLIN_NNP sales_NNS in_IN Canadian_JJ Dollars_NNP 5.3_CD 49_CD %_NN 4_CD %_NN 45_CD %_NN AGRYLIN_NNP XAGRID_NNP sales_NNS in_IN Euros_NNP 28.3_CD 41_CD %_NN 41_CD %_NN AGRYLIN_NNP XAGRID_NNP sales_NNS in_IN Pounds_NNP Sterling_NNP 18.9_CD 11_CD %_NN 1_CD %_NN 10_CD %_NN CALCICHEW_NNP sales_NNS in_IN Pounds_NNP Sterling_NNP 35.0_CD 1_CD %_NN 1_CD %_NN REMINYL_NNP and_CC REMINYL_NNP XL_NNP sales_NNS in_IN Pounds_NNP Sterling_NNP 11.8_CD 27_CD %_NN 1_CD %_NN 26_CD %_NN Revenue_NN growth_NN analysis_NN does_VBZ not_RB include_VB sales_NNS of_IN :_: ADDERALL_NNP XR_NNP in_IN Canadian_NNP Dollars_NNPS due_JJ to_TO the_DT fact_NN that_IN sales_NNS of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP were_VBD suspended_VBN for_IN most_JJS of_IN 2005_CD :_: and_CC REPLAGAL_NNP sales_NNS of_IN $_$ 41.3_CD million_CD in_IN Euros_NNP and_CC Swedish_NNP Krona_NNP ._.
There_EX is_VBZ no_DT comparative_JJ data_NNS for_IN REPLAGAL_NNP as_IN it_PRP was_VBD acquired_VBN with_IN TKT_NNP in_IN July_NNP 2005_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 47_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 48_CD Financial_NNP review_NN Royalties_NNP Royalty_NNP revenue_NN increased_VBD 5_CD %_NN to_TO $_$ 242.9_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD :_: $_$ 230.4_CD million_CD primarily_RB as_IN a_DT result_NN of_IN strong_JJ sales_NNS growth_NN ._.
This_DT was_VBD due_JJ to_TO the_DT continued_JJ growth_NN in_IN the_DT nucleoside_NN analog_NN market_NN for_IN HIV_NNP and_CC a_DT small_JJ positive_JJ impact_NN of_IN foreign_JJ exchange_NN movements_NNS ._.
Shire_NNP receives_VBZ royalties_NNS from_IN GSK_NNP on_IN worldwide_JJ 3TC_NNP sales_NNS ._.
GSKs_NNS worldwide_JJ sales_NNS of_IN 3TC_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, were_VBD $_$ 1,211_CD million_CD ,_, an_DT increase_NN of_IN 2_CD %_NN compared_VBN to_TO prior_JJ year_NN 2004_CD :_: $_$ 1,184_CD million_CD ._.
ZEFFIX_NNP Royalties_NNPS from_IN sales_NNS of_IN ZEFFIX_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, were_VBD $_$ 30.5_CD million_CD ,_, an_DT increase_NN of_IN 11_CD %_NN compared_VBN to_TO 2004_CD $_$ 27.4_CD million_CD ,_, due_JJ to_TO strong_JJ growth_NN in_IN the_DT Japanese_JJ market_NN and_CC a_DT small_JJ positive_JJ impact_NN of_IN foreign_JJ exchange_NN movements_NNS ._.
Shire_NNP receives_VBZ royalties_NNS from_IN GSK_NNP on_IN worldwide_JJ ZEFFIX_NNP sales_NNS ._.
GSKs_NNS worldwide_JJ sales_NNS of_IN ZEFFIX_NNP for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, were_VBD $_$ 266_CD million_CD ,_, an_DT increase_NN of_IN 11_CD %_NN compared_VBN to_TO prior_JJ year_NN 2004_CD :_: $_$ 240_CD million_CD ._.
Other_JJ Other_JJ royalties_NNS are_VBP primarily_RB in_IN respect_NN of_IN REMINYL_NNP and_CC REMINYL_NNP XL_NNP now_RB marketed_VBD as_IN RAZADYNE_NNP and_CC RAZADYNE_NNP ER_NNP in_IN the_DT US_NNP ,_, a_DT product_NN marketed_VBN worldwide_NN by_IN Janssen_NNP Pharmaceutical_NNP N._NNP V._NNP Janssen_NNP ,_, an_DT affiliate_NN of_IN Johnson_NNP &_CC Johnson_NNP ,_, with_IN the_DT exception_NN of_IN the_DT UK_NNP and_CC the_DT Republic_NNP of_IN Ireland_NNP where_WRB Shire_NNP acquired_VBD the_DT exclusive_JJ marketing_NN rights_NNS from_IN May_NNP 2004_CD ._.
Sales_NNS of_IN the_DT REMINYL_NNP RAZADYNE_NNP range_NN ,_, for_IN the_DT symptomatic_JJ treatment_NN of_IN mild_JJ to_TO moderately_RB severe_JJ dementia_NN of_IN the_DT Alzheimers_NNP type_NN ,_, are_VBP growing_VBG well_RB in_IN the_DT Alzheimers_NNPS market_NN ._.
On_IN April_NNP 11_CD ,_, 2005_CD ,_, Ortho-McNeil_NNP Neurologics_NNP Inc._NNP ._.
Janssens_NNP US_NNP affiliate_NN company_NN announced_VBD that_IN REMINYL_NNP would_MD be_VB marketed_VBN in_IN the_DT US_NNP under_IN the_DT new_JJ product_NN name_NN of_IN RAZADYNE_NNP ._.
Subsequently_RB ,_, in_IN the_DT US_NNP ,_, REMINYL_NNP XL_NNP was_VBD launched_VBN as_IN RAZADYNE_NNP ER_NNP ._.
Ortho-McNeil_NNP Neurologics_NNP Inc._NNP worked_VBD closely_RB with_IN the_DT FDA_NNP on_IN a_DT name_NN change_NN following_VBG dispensing_JJ errors_NNS in_IN the_DT US_NNP between_IN REMINYL_NNP and_CC the_DT Type_NN 2_CD diabetes_NN mellitus_NN drug_NN known_VBN as_IN AMARYL_NNP ._.
Shire_NNP is_VBZ only_RB aware_JJ of_IN one_CD similar_JJ dispensing_NN error_NN outside_IN the_DT US_NNP ._.
On_IN March_NNP 1_CD ,_, 2005_CD ,_, NICE_NNP in_IN England_NNP and_CC Wales_NNP issued_VBD an_DT Appraisal_NNP Consultation_NNP Document_NNP ACD_NNP ._.
This_DT document_NN included_VBD a_DT recommendation_NN that_IN all_DT existing_VBG approved_VBN products_NNS for_IN the_DT symptomatic_JJ treatment_NN of_IN mild-to-moderate_JJ Alzheimers_NNP Disease_NNP in_IN England_NNP and_CC Wales_NNP should_MD no_RB longer_RB be_VB reimbursed_VBN by_IN the_DT National_NNP Health_NNP Service_NNP NHS_NNP when_WRB used_VBN in_IN the_DT treatment_NN of_IN new_JJ patients_NNS ._.
The_DT recommendation_NN potentially_RB affected_VBD sales_NNS of_IN REMINYL_NNP and_CC of_IN REMINYL_NNP XL_NNP in_IN England_NNP and_CC Wales_NNP ._.
An_DT amended_VBN ACD_NNP was_VBD issued_VBN by_IN NICE_NNP on_IN January_NNP 23_CD ,_, 2006_CD ._.
The_DT new_JJ ACD_NNP recommends_VBZ that_IN REMINYL_NNP and_CC REMINYL_NNP XL_NNP ,_, together_RB with_IN other_JJ drugs_NNS in_IN the_DT same_JJ class_NN ,_, be_VB reimbursed_VBN by_IN the_DT NHS_NNP when_WRB used_VBN for_IN the_DT treatment_NN of_IN either_DT i_FW patients_NNS with_IN existing_VBG Alzheimers_NNP Disease_NNP already_RB being_VBG treated_VBN with_IN one_CD of_IN these_DT drugs_NNS :_: or_CC ii_FW newly_RB diagnosed_VBN patients_NNS once_RB their_PRP$ disease_NN has_VBZ progressed_VBN to_TO a_DT moderate_JJ stage_NN ._.
Therefore_RB the_DT current_JJ recommendation_NN excludes_VBZ the_DT reimbursement_NN of_IN treatment_NN for_IN patients_NNS presenting_VBG with_IN mild_JJ symptoms_NNS of_IN Alzheimers_NNP Disease_NNP for_IN which_WDT REMINYL_NNP and_CC REMINYL_NNP XL_NNP are_VBP approved_VBN ._.
A_DT final_JJ appraisal_NN document_NN is_VBZ expected_VBN from_IN NICE_NNP in_IN July_NNP 2006_CD ._.
Cost_NN of_IN product_NN sales_NNS For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, the_DT cost_NN of_IN product_NN sales_NNS amounted_VBD to_TO 16_CD %_NN of_IN product_NN sales_NNS 2004_CD :_: 13_CD %_NN ._.
The_DT decrease_NN in_IN gross_JJ margin_NN is_VBZ primarily_RB due_JJ to_TO the_DT addition_NN of_IN REPLAGAL_NNP to_TO Shires_NNP product_NN portfolio_NN following_VBG the_DT acquisition_NN of_IN TKT_NNP ._.
REPLAGALs_NNS cost_NN of_IN product_NN sales_NNS relates_VBZ entirely_RB to_TO the_DT acquired_VBN inventories_NNS ,_, which_WDT in_IN accordance_NN with_IN US_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNPS GAAP_NNP ,_, have_VBP been_VBN accounted_VBN for_IN at_IN fair_JJ value_NN ,_, estimated_VBN to_TO be_VB 97_CD %_NN of_IN the_DT expected_VBN sales_NNS price_NN of_IN REPLAGAL_NNP ._.
Accordingly_RB ,_, little_JJ or_CC no_DT margin_NN will_MD be_VB reflected_VBN for_IN REPLAGAL_NNP sales_NNS until_IN all_DT acquired_VBN finished_VBN goods_NNS have_VBP been_VBN sold_VBN anticipated_VBN Q3_NNP 2006_CD ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT cost_NN of_IN product_NN sales_NNS for_IN REPLAGAL_NNP includes_VBZ a_DT $_$ 41.9_CD million_CD adjustment_NN in_IN respect_NN of_IN the_DT acquired_VBN inventory_NN of_IN which_WDT $_$ 39.8_CD million_CD related_VBN to_TO sales_NNS of_IN acquired_VBN finished_VBN goods_NNS and_CC $_$ 2.1_CD million_CD was_VBD a_DT write-off_NN of_IN damaged_JJ work-in-process_NN ._.
In_IN 2005_CD ,_, this_DT fair_JJ value_NN adjustment_NN increased_VBD Shires_NNP cost_NN of_IN product_NN sales_NNS by_IN 3_CD %_NN ._.
48_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 49_CD R&D_NNP R&D_NNP expenditure_NN increased_VBD from_IN $_$ 196.3_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD to_TO $_$ 336.2_CD million_CD in_IN 2005_CD ._.
Expressed_VBN as_IN a_DT percentage_NN of_IN total_JJ revenues_NNS ,_, R&D_NNP expenditure_NN was_VBD 21_CD %_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: 14_CD %_NN ._.
The_DT increase_NN was_VBD primarily_RB due_JJ to_TO :_: the_DT initial_JJ payment_NN to_TO New_NNP River_NNP of_IN $_$ 50_CD million_CD for_IN in-licensing_JJ NRP104_NNP ,_, which_WDT has_VBZ been_VBN expensed_VBN in_IN accordance_NN with_IN the_DT Companys_NNP accounting_NN policy_NN :_: and_CC the_DT addition_NN of_IN two_CD significant_JJ R&D_NNP projects_NNS following_VBG the_DT acquisition_NN of_IN TKT_NNP ELAPRASE_NNP and_CC GA-GCB_NNP ._.
The_DT New_NNP River_NNP payment_NN and_CC the_DT R&D_NNP expenditure_NN on_IN ELAPRASE_NNP and_CC GA-GCB_NNP represented_VBD 5_CD %_NN of_IN R&D_NNP expenditure_NN as_IN a_DT percentage_NN of_IN revenues_NNS ._.
Shires_NNP pipeline_NN is_VBZ now_RB well_RB advanced_VBN with_IN seven_CD projects_NNS in_IN late-stage_JJ development_NN or_CC registration_NN ._.
Selling_VBG ,_, general_JJ and_CC administrative_JJ SG&A_NNP expenses_NNS Total_JJ SG&A_NN costs_NNS increased_VBD from_IN $_$ 516.6_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, to_TO $_$ 705.6_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, an_DT increase_NN of_IN 37_CD %_NN ._.
As_IN a_DT percentage_NN of_IN product_NN sales_NNS ,_, SG&A_NNP expenses_NNS were_VBD 53_CD %_NN 2004_CD :_: 46_CD %_NN ._.
2005_CD 2004_CD Change_NNP Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD $_$ million_CD %_NN Sales_NNS costs_VBZ 181.8_CD 141.5_CD 28_CD Marketing_NNP costs_NNS 252.2_CD 175.9_CD 43_CD Other_JJ SG&A_NNP costs_NNS 197.2_CD 140.7_CD 40_CD 631.2_CD 458.1_CD 38_CD i_FW Depreciation_NN and_CC amortization_NN 74.4_CD 58.5_CD 27_CD Total_JJ SG&A_NN costs_NNS 705.6_CD 516.6_CD 37_CD i_FW Excludes_NNS depreciation_NN from_IN manufacturing_VBG plants_NNS of_IN $_$ 3.5_CD million_CD 2004_CD :_: $_$ 2.7_CD million_CD which_WDT is_VBZ included_VBN in_IN cost_NN of_IN product_NN sales_NNS ._.
SG&A_NNP expenses_NNS increased_VBD from_IN $_$ 458.1_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, to_TO $_$ 631.2_CD million_CD in_IN 2005_CD ,_, an_DT increase_NN of_IN 38_CD %_NN ._.
As_IN a_DT percentage_NN of_IN product_NN sales_NNS ,_, these_DT expenses_NNS were_VBD 48_CD %_NN 2004_CD :_: 41_CD %_NN ._.
This_DT increase_NN was_VBD expected_VBN ,_, with_IN additional_JJ costs_NNS attributable_JJ to_TO four_CD product_NN launches_NNS during_IN 2005_CD ,_, together_RB with_IN incremental_JJ costs_NNS in_IN 2005_CD associated_VBN with_IN the_DT new_JJ FOSRENOL_NNP and_CC EQUETRO_NNP sales_NNS forces_NNS ,_, patent_NN litigation_NN and_CC infrastructure_NN ,_, $_$ 24.5_CD million_CD of_IN SG&A_NNP costs_NNS related_VBN to_TO the_DT acquired_VBN TKT_NNP business_NN and_CC $_$ 4.5_CD million_CD related_VBN to_TO the_DT set_VBN up_IN of_IN the_DT new_JJ listed_VBN holding_VBG company_NN for_IN the_DT Shire_NNP Group_NNP ._.
The_DT depreciation_NN charge_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, was_VBD $_$ 29.2_CD million_CD 2004_CD :_: $_$ 19.8_CD million_CD ,_, which_WDT in_IN 2005_CD included_VBD property_NN ,_, plant_NN and_CC equipment_NN write-downs_NNS of_IN $_$ 6.5_CD million_CD 2004_CD :_: $_$ 1.6_CD million_CD ._.
Amortization_NN charges_NNS ,_, including_VBG the_DT amortization_NN on_IN acquired_VBN products_NNS ,_, were_VBD $_$ 45.2_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 38.7_CD million_CD ._.
Intangible_JJ asset_NN impairments_VBZ The_DT charge_NN for_IN intangible_JJ asset_NN impairments_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD was_VBD $_$ 5.6_CD million_CD 2004_CD :_: $_$ 13.5_CD million_CD ._.
The_DT approval_NN of_IN generic_JJ versions_NNS of_IN AGRYLIN_NNP in_IN April_NNP 2005_CD and_CC the_DT decision_NN not_RB to_TO support_VB and_CC promote_VB certain_JJ non-core_JJ products_NNS going_VBG forward_RB resulted_VBD in_IN changes_NNS to_TO the_DT estimate_NN of_IN the_DT Companys_NNPS future_JJ cash_NN flows_NNS and_CC ,_, as_IN a_DT result_NN ,_, impairments_NNS were_VBD required_VBN in_IN both_DT 2005_CD and_CC 2004_CD ._.
Reorganization_NN costs_NNS 2005_CD 2004_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD $_$ million_CD Employee_NN severance_NN 1.6_CD 20.0_CD Relocation_NNP costs_VBZ 13.8_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD Consultancy_NNP costs_NNS 0.5_CD 2.9_CD Duplicate_NNP facilities_NNS 7.2_CD 5.1_CD Information_NN technology_NN costs_VBZ 2.1_CD Other_JJ costs_NNS 3.4_CD 9.3_CD 48.5_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 49_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 50_CD Financial_NNP review_NN As_IN previously_RB disclosed_VBN ,_, the_DT Company_NN began_VBD a_DT consolidation_NN of_IN its_PRP$ North_JJ American_JJ sites_NNS in_IN 2004_CD ,_, with_IN the_DT aim_NN of_IN decreasing_VBG the_DT number_NN of_IN sites_NNS from_IN 16_CD to_TO four_CD ,_, including_VBG the_DT opening_NN of_IN a_DT new_JJ US_NNP headquarters_NN office_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
The_DT Company_NN recorded_VBN costs_NNS of_IN $_$ 9.3_CD million_CD in_IN 2005_CD and_CC $_$ 48.5_CD million_CD in_IN 2004_CD primarily_RB associated_VBN with_IN :_: severance_NN costs_NNS relating_VBG to_TO 137_CD employees_NNS :_: retention_NN payments_NNS to_TO key_JJ employees_NNS :_: relocation_NN costs_NNS relating_VBG to_TO 85_CD employees_NNS who_WP relocated_VBD to_TO Wayne_NNP ,_, Pennsylvania_NNP :_: costs_NNS of_IN duplicate_VBP facilities_NNS including_VBG lease_NN exit_NN costs_NNS :_: and_CC other_JJ incremental_JJ costs_NNS associated_VBN with_IN the_DT site_NN closures_NNS ,_, such_JJ as_IN legal_JJ ,_, consultancy_NN ,_, the_DT write-down_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN and_CC information_NN technology_NN costs_NNS ._.
Following_VBG the_DT closure_NN of_IN the_DT Newport_NNP site_NN in_IN July_NNP 2005_CD ,_, the_DT site_NN consolidation_NN is_VBZ now_RB complete_JJ and_CC no_DT further_JJ reorganization_NN costs_NNS are_VBP expected_VBN ._.
Integration_NN costs_NNS For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN incurred_VBN $_$ 9.7_CD million_CD of_IN costs_NNS associated_VBN with_IN the_DT integration_NN of_IN the_DT TKT_NNP business_NN into_IN the_DT Shire_NNP Group_NNP 2004_CD :_: $_$ nil_JJ ._.
This_DT included_VBD retention_NN payments_NNS for_IN key_JJ staff_NN of_IN $_$ 7_CD million_CD ,_, information_NN technology_NN costs_NNS of_IN $_$ 1_CD million_CD and_CC other_JJ costs_NNS of_IN $_$ 1.7_CD million_CD ._.
In-process_JJ R&D_NNP write-off_NN During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, as_IN required_VBN by_IN Financial_NNP Accounting_NNP Standards_NNP Board_NNP Interpretation_NNP No._NN ._.
4_CD ,_, Applicability_NN of_IN FASB_NNP Statement_NNP No._NN ._.
2_CD to_TO Business_NNP Combinations_NNPS Accounted_NNP for_IN by_IN the_DT Purchase_NNP Method_NNP FIN_NNP 4_CD ,_, the_DT Company_NN wrote-off_NN the_DT portion_NN of_IN the_DT TKT_NNP purchase_NN price_NN allocated_VBN to_TO in-process_JJ research_NN and_CC development_NN of_IN $_$ 673_CD million_CD ._.
This_DT amount_NN represents_VBZ the_DT value_NN of_IN those_DT intangible_JJ assets_NNS acquired_VBN as_IN part_NN of_IN the_DT TKT_NNP acquisition_NN ,_, which_WDT at_IN the_DT time_NN of_IN acquisition_NN had_VBD not_RB been_VBN approved_VBN by_IN the_DT FDA_NNP or_CC other_JJ regulatory_JJ authorities_NNS ,_, including_VBG ELAPRASE_NNP and_CC GA-GCB_NNP ._.
For_IN the_DT determination_NN of_IN the_DT fair_JJ value_NN of_IN in-process_JJ research_NN and_CC development_NN see_VBP Note_NN 4_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 95_CD ._.
Interest_NN income_NN For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN received_VBD interest_NN income_NN of_IN $_$ 35.3_CD million_CD 2004_CD :_: $_$ 21.9_CD million_CD ._.
The_DT increase_NN compared_VBN to_TO 2004_CD is_VBZ due_JJ to_TO higher_JJR interest_NN rates_NNS on_IN the_DT Companys_NNPS US_NNP cash_NN deposits_NNS which_WDT were_VBD partially_RB offset_VBN by_IN the_DT interest_NN foregone_JJ by_IN the_DT Company_NN on_IN the_DT net_JJ payments_NNS of_IN $_$ 1.1_CD billion_CD made_VBN to_TO date_NN in_IN respect_NN of_IN the_DT acquisition_NN of_IN TKT_NNP ._.
Interest_NN expense_NN For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN incurred_VBN interest_NN expense_NN of_IN $_$ 12_CD million_CD 2004_CD :_: $_$ 12.3_CD million_CD ._.
In_IN 2005_CD ,_, this_DT expense_NN included_VBD a_DT $_$ 7.7_CD million_CD provision_NN for_IN interest_NN ,_, which_WDT may_MD be_VB awarded_VBN by_IN the_DT court_NN in_IN respect_NN of_IN amounts_NNS due_JJ to_TO former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN who_WP have_VBP submitted_VBN written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS see_VBP Note_NN 27_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 120_CD ._.
In_IN addition_NN ,_, interest_NN expense_NN includes_VBZ $_$ 1.2_CD million_CD ,_, relating_VBG to_TO the_DT costs_NNS of_IN a_DT bridging_VBG loan_NN to_TO finance_VB the_DT TKT_NNP acquisition_NN and_CC other_JJ interest_NN related_VBN expenses_NNS of_IN $_$ 3.1_CD million_CD ._.
In_IN 2004_CD ,_, interest_NN expense_NN included_VBD the_DT write-off_NN of_IN $_$ 7.4_CD million_CD of_IN deferred_JJ debt_NN acquisition_NN costs_NNS arising_VBG on_IN the_DT issue_NN of_IN convertible_JJ loan_NN notes_NNS in_IN August_NNP 2001_CD ._.
The_DT write-off_NN was_VBD required_VBN as_IN a_DT significant_JJ portion_NN of_IN the_DT convertible_JJ loan_NN notes_NNS were_VBD redeemed_VBN ._.
The_DT $_$ 7.4_CD million_CD represented_VBD the_DT balance_NN of_IN these_DT fees_NNS at_IN the_DT date_NN of_IN redemption_NN in_IN August_NNP 2004_CD ._.
In_IN addition_NN ,_, interest_NN expense_NN included_VBD a_DT $_$ 4.2_CD million_CD interest_NN charge_NN incurred_VBN prior_RB to_TO the_DT redemption_NN and_CC $_$ 0.1_CD million_CD of_IN other_JJ interest-related_JJ expenses_NNS ._.
Other_JJ income_NN expense_NN ,_, net_JJ 2005_CD 2004_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ million_CD $_$ million_CD Investment_NN income_NN 8.3_CD 18.9_CD Write-down_NN of_IN non-current_JJ asset_NN investments_NNS 2.0_CD 15.4_CD Gain_NN on_IN sale_NN of_IN drug_NN formulation_NN business_NN 3.6_CD Foreign_NNP exchange_NN and_CC other_JJ 0.3_CD Total_JJ 9.9_CD 3.8_CD 50_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 51_CD An_DT important_JJ part_NN of_IN Shires_NNP business_NN strategy_NN is_VBZ to_TO protect_VB its_PRP$ products_NNS For_IN further_JJ details_NNS see_VBP Note_NN 26_CD and_CC Note_VB 6_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN pages_NNS 120_CD and_CC 97_CD ._.
and_CC technologies_NNS through_IN the_DT use_NN of_IN patents_NNS ,_, proprietary_JJ technologies_NNS and_CC trademarks_NNS ,_, to_TO the_DT extent_NN available_JJ ._.
The_DT Company_NN intends_VBZ The_DT write-down_NN in_IN investments_NNS in_IN 2005_CD and_CC 2004_CD resulted_VBD from_IN events_NNS to_TO defend_VB its_PRP$ intellectual_JJ property_NN and_CC as_IN a_DT result_NN may_MD need_VB cash_NN for_IN funding_VBG litigation_NN expenses_NNS incurred_VBN ._.
and_CC circumstances_NNS that_WDT indicated_VBD there_EX was_VBD an_DT other-than-temporary_JJ impairment_NN of_IN investments_NNS and_CC ,_, accordingly_RB ,_, management_NN recorded_VBD The_DT Company_NN ordinarily_RB finances_VBZ its_PRP$ activities_NNS through_IN cash_NN generated_VBD an_DT impairment_NN based_VBN on_IN its_PRP$ assessment_NN of_IN fair_JJ value_NN ._.
Further_JJ details_NNS are_VBP disclosed_VBN in_IN Note_NN 11_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ from_IN operating_VBG activities_NNS ,_, private_JJ and_CC public_JJ offerings_NNS of_IN equity_NN and_CC debt_NN securities_NNS and_CC the_DT proceeds_NNS of_IN asset_NN or_CC investment_NN disposals_NNS ._.
Multicurrency_NNP Revolving_NNP Facilities_NNP Agreement_NNP Investment_NNP income_NN for_IN 2005_CD included_VBD a_DT $_$ 3.9_CD million_CD realized_VBD gain_NN on_IN the_DT sale_NN of_IN a_DT portfolio_NN investment_NN 2004_CD :_: $_$ 14.8_CD million_CD ._.
In_IN connection_NN with_IN the_DT acquisition_NN of_IN TKT_NNP ,_, Shire_NNP and_CC certain_JJ members_NNS of_IN the_DT Shire_NNP Group_NNP entered_VBD into_IN a_DT Multicurrency_NNP Revolving_NNP Facilities_NNP Income_NNP taxes_NNS Agreement_NNP the_DT Facilities_NNP Agreement_NN with_IN ABN_NNP AMRO_NNP Bank_NNP N._NNP V._NNP Barclays_NNP Capital_NNP ,_, Citigroup_NNP Global_NNP Markets_NNP Limited_NNP ,_, HSBC_NNP Bank_NNP plc_NN The_DT Companys_NNPS effective_JJ tax_NN rate_NN for_IN 2005_CD was_VBD negative_JJ 29_CD %_NN a_DT tax_NN charge_NN of_IN $_$ 92.1_CD million_CD on_IN losses_NNS from_IN continuing_VBG operations_NNS and_CC The_DT Royal_NNP Bank_NNP of_IN Scotland_NNP plc_VBP the_DT Lenders_NNP on_IN June_NNP 15_CD ,_, 2005_CD ._.
The_DT Facilities_NNP Agreement_NNP comprises_VBZ two_CD credit_NN facilities_NNS :_: i_FW a_DT committed_VBN before_IN income_NN taxes_NNS and_CC equity_NN method_NN investees_NNS of_IN $_$ 320.9_CD million_CD ._.
The_DT significant_JJ difference_NN from_IN the_DT prior-year_JJ effective_JJ tax_NN rate_NN multicurrency_NN three-year_JJ revolving_JJ loan_NN facility_NN in_IN an_DT aggregate_JJ amount_NN of_IN $_$ 500_CD million_CD Facility_NN A_DT and_CC ii_FW a_DT committed_JJ 364_CD day_NN revolving_JJ loan_NN of_IN 28_CD %_NN is_VBZ due_JJ to_TO the_DT in-process_JJ research_NN and_CC development_NN write-off_NN of_IN $_$ 673_CD million_CD ,_, which_WDT is_VBZ not_RB tax_NN deductible_JJ ._.
facility_NN in_IN an_DT aggregate_JJ amount_NN of_IN $_$ 300_CD million_CD Facility_NN B_NN and_CC together_RB with_IN Facility_NN A_DT ,_, the_DT Facilities_NNPS ._.
Shire_NNP has_VBZ agreed_VBN to_TO act_VB as_IN guarantor_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD deferred_VBN tax_NN assets_NNS for_IN any_DT of_IN its_PRP$ subsidiaries_NNS that_WDT borrow_VBP under_IN the_DT Facilities_NNP Agreement_NNP ._.
net_NN of_IN valuation_NN allowances_NNS of_IN $_$ 116.2_CD million_CD 2004_CD :_: $_$ 78.1_CD million_CD ._.
The_DT increase_NN in_IN deferred_JJ tax_NN is_VBZ primarily_RB attributable_JJ to_TO the_DT acquisition_NN Facility_NN A_DT may_MD be_VB used_VBN for_IN general_JJ corporate_JJ purposes_NNS ,_, including_VBG financing_VBG the_DT purchase_NN price_NN and_CC other_JJ costs_NNS with_IN respect_NN to_TO the_DT of_IN TKT_NNP that_WDT resulted_VBD in_IN a_DT net_JJ deferred_VBN tax_NN asset_NN of_IN $_$ 60.4_CD million_CD being_VBG recorded_VBN in_IN the_DT opening_NN day_NN balance_NN sheet_NN ,_, although_IN part_NN of_IN the_DT asset_NN acquisition_NN of_IN TKT_NNP including_VBG refinancing_NN TKTs_NNS existing_VBG indebtedness_NN ._.
Facility_NN B_NN may_MD be_VB used_VBN only_RB for_IN financing_VBG certain_JJ milestone_NN payments_NNS was_VBD subsequently_RB realized_VBN in_IN the_DT post_NN acquisition_NN period_NN ._.
Realization_NN of_IN deferred_JJ tax_NN assets_NNS is_VBZ dependent_JJ upon_IN generating_VBG sufficient_JJ taxable_JJ due_JJ under_IN the_DT agreement_NN between_IN Shire_NNP ,_, and_CC inter_VB alia_NN ,_, New_NNP River_NNP Pharmaceuticals_NNP Inc._NNP ._.
New_NNP River_NNP ,_, dated_VBN January_NNP 31_CD ,_, 2005_CD ._.
income_NN to_TO utilize_VB such_JJ assets_NNS ._.
Although_IN realization_NN of_IN these_DT assets_NNS is_VBZ not_RB assured_VBN ,_, it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT amount_NN recognized_VBN Facility_NN A_DT terminates_NNS on_IN June_NNP 15_CD ,_, 2008_CD ,_, and_CC Facility_NNP B_NNP terminates_VBZ on_RP will_MD be_VB realized_VBN ._.
See_VB Note_VB 29_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 121_CD for_IN expiry_NN dates_NNS of_IN these_DT tax_NN losses_NNS ._.
At_IN Shires_NNP request_NN ,_, the_DT Lenders_NNP may_MD agree_VB to_TO successive_JJ annual_JJ extensions_NNS of_IN Facility_NN B_NNP ,_, but_CC not_RB beyond_IN the_DT maturity_NN date_NN of_IN Equity_NN in_IN earnings_NNS losses_NNS of_IN equity_NN method_NN investees_VBZ Facility_NNP A._NNP Alternatively_RB ,_, Shire_NNP has_VBZ the_DT right_NN to_TO draw_VB Facility_NN B_NN or_CC convert_VB existing_VBG loans_NNS under_IN Facility_NN B_NNP into_IN a_DT term_NN loan_NN with_IN the_DT same_JJ maturity_NN Net_JJ losses_NNS of_IN $_$ 1_CD million_CD were_VBD recorded_VBN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: net_JJ earnings_NNS of_IN $_$ 2.5_CD million_CD ._.
This_DT comprised_VBN earnings_NNS date_NN as_IN Facility_NNP A._NNP The_NNP availability_NN of_IN loans_NNS under_IN each_DT of_IN the_DT Facilities_NNPS is_VBZ subject_JJ to_TO customary_JJ conditions_NNS ,_, including_VBG the_DT absence_NN of_IN of_IN $_$ 5.3_CD million_CD from_IN the_DT 50_CD %_NN share_NN of_IN the_DT antiviral_JJ commercialization_NN partnership_NN with_IN GSK_NNP in_IN Canada_NNP 2004_CD :_: $_$ 4.4_CD million_CD ,_, offset_VBN by_IN the_DT any_DT defaults_NNS thereunder_RB and_CC the_DT accuracy_NN in_IN all_DT material_NN respects_VBZ of_IN Shires_NNP representations_NNS and_CC warranties_NNS contained_VBD therein_RB ._.
Companys_NNS share_NN of_IN losses_NNS in_IN the_DT GeneChem_NNP and_CC EGS_NNP Healthcare_NNP Funds_NNPS of_IN $_$ 6.3_CD million_CD 2004_CD :_: $_$ 1.9_CD million_CD ._.
The_DT Facilities_NNP include_VBP representations_NNS and_CC warranties_NNS ,_, covenants_NNS and_CC Discontinued_VBN operations_NNS events_NNS of_IN default_NN ,_, including_VBG requirements_NNS that_WDT Shires_VBZ ratio_NN of_IN Net_JJ Debt_NN to_TO EBITDA_NNP as_IN defined_VBN in_IN the_DT Facilities_NNP Agreement_NNP not_RB exceed_VB 3.0_CD to_TO 1_CD During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD gains_NNS on_IN disposition_NN of_IN the_DT discontinued_VBN operations_NNS totaled_VBD $_$ 3.1_CD million_CD ._.
This_DT resulted_VBD from_IN the_DT and_CC that_IN the_DT ratio_NN of_IN EBITDA_NNP to_TO Net_JJ Interest_NN be_VB not_RB less_JJR than_IN 4.0_CD to_TO 1_CD ,_, both_DT in_IN respect_NN of_IN the_DT most_RBS recently_RB ended_VBN fiscal_JJ year_NN ,_, and_CC limitations_NNS finalization_NN of_IN the_DT working_VBG capital_NN agreement_NN with_IN ID_NNP Biomedical_NNP Inc._NNP ._.
IDB_NNP ,_, which_WDT was_VBD part_NN of_IN the_DT sale_NN of_IN Shires_NNP vaccines_NNS business_NN to_TO on_IN the_DT creation_NN of_IN liens_NNS ,_, disposal_NN of_IN assets_NNS ,_, incurrence_NN of_IN indebtedness_NN ,_, making_VBG of_IN loans_NNS and_CC giving_VBG of_IN guarantees_NNS ._.
As_IN a_DT result_NN ,_, a_DT disputed_VBN amount_NN ,_, which_WDT had_VBD previously_RB been_VBN provided_VBN for_IN ,_, was_VBD received_VBN and_CC the_DT corresponding_JJ provision_NN Interest_NN on_IN loans_NNS under_IN the_DT Facilities_NNPS will_MD be_VB payable_JJ on_IN the_DT last_JJ day_NN was_VBD released_VBN ._.
of_IN each_DT interest_NN period_NN ,_, which_WDT period_NN may_MD be_VB one_CD ,_, two_CD ,_, three_CD or_CC six_CD months_NNS at_IN the_DT election_NN of_IN Shire_NNP or_CC as_IN otherwise_RB agreed_VBN with_IN the_DT Liquidity_NN and_CC capital_NN resources_NNS General_NNP Lenders_NNP ._.
The_DT interest_NN rate_NN on_IN each_DT loan_NN for_IN each_DT interest_NN period_NN is_VBZ the_DT percentage_NN rate_NN per_IN annum_NN ,_, which_WDT is_VBZ the_DT aggregate_NN of_IN the_DT applicable_JJ The_DT Companys_NNPS funding_NN requirements_NNS depend_VBP on_IN a_DT number_NN of_IN factors_NNS ,_, including_VBG its_PRP$ development_NN programs_NNS :_: corporate_JJ ,_, business_NN and_CC product_NN margin_NN ranging_VBG from_IN 0.35_CD to_TO 0.65_CD %_NN per_IN annum_NN ,_, depending_VBG on_IN the_DT ratio_NN of_IN Net_JJ Debt_NN to_TO EBITDA_NNP ,_, LIBOR_NNP ,_, and_CC mandatory_JJ cost_NN ,_, if_IN any_DT acquisitions_NNS :_: the_DT level_NN of_IN resources_NNS required_VBN for_IN the_DT expansion_NN of_IN manufacturing_NN and_CC marketing_NN capabilities_NNS as_IN the_DT product_NN base_NN expands_VBZ :_: as_IN calculated_VBN in_IN accordance_NN with_IN Schedule_NN 5_CD of_IN the_DT Facilities_NNP Agreement_NNP ._.
Shire_NN shall_MD also_RB pay_VB fees_NNS equal_JJ to_TO 35_CD %_NN per_IN annum_NN of_IN the_DT increases_NNS in_IN accounts_NNS receivable_JJ and_CC inventory_NN which_WDT may_MD arise_VB as_IN sales_NNS levels_NNS increase_NN :_: competitive_JJ and_CC technological_JJ developments_NNS :_: applicable_JJ margin_NN on_IN available_JJ commitments_NNS under_IN Facility_NN A_DT for_IN the_DT availability_NN period_NN applicable_JJ to_TO Facility_NN A_DT and_CC 20_CD per_IN cent_NN per_IN annum_NN the_DT timing_NN and_CC cost_NN of_IN obtaining_VBG required_JJ regulatory_JJ approvals_NNS for_IN new_JJ products_NNS :_: the_DT timing_NN and_CC quantum_NN of_IN milestone_NN payments_NNS of_IN the_DT applicable_JJ margin_NN on_IN available_JJ commitments_NNS under_IN Facility_NN B_NN for_IN the_DT availability_NN period_NN applicable_JJ to_TO Facility_NN B_NN in_IN respect_NN of_IN the_DT on_IN collaborative_JJ projects_NNS :_: the_DT timing_NN of_IN and_CC quantum_NN of_IN tax_NN and_CC dividend_NN payments_NNS :_: the_DT timing_NN and_CC quantum_NN of_IN purchases_NNS of_IN Shire_NNP period_NN prior_RB to_TO January_NNP 1_CD ,_, 2007_CD ,_, and_CC 30_CD %_NN per_IN annum_NN of_IN the_DT applicable_JJ margin_NN thereafter_RB ._.
Interest_NN on_IN overdue_JJ amounts_NNS under_IN the_DT Facilities_NNP shares_NNS in_IN the_DT market_NN to_TO satisfy_VB option_NN exercises_NNS and_CC the_DT continuing_VBG cash_NN generated_VBD from_IN sales_NNS of_IN Shires_NNP key_JJ products_NNS ._.
will_MD accrue_VB at_IN a_DT rate_NN ,_, which_WDT is_VBZ one_CD percent_NN higher_JJR than_IN the_DT rates_NNS otherwise_RB applicable_JJ to_TO the_DT loans_NNS under_IN the_DT Facilities_NNPS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 51_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 52_CD Financial_NNP review_NN Upon_IN a_DT change_NN of_IN control_NN of_IN Shire_NNP or_CC upon_IN the_DT occurrence_NN of_IN an_DT event_NN of_IN default_NN and_CC the_DT expiration_NN of_IN any_DT applicable_JJ cure_NN period_NN ,_, the_DT total_JJ commitments_NNS under_IN the_DT Facilities_NNPS may_MD be_VB canceled_VBN ,_, all_DT or_CC part_NN of_IN the_DT loans_NNS ,_, together_RB with_IN accrued_VBN interest_NN and_CC all_DT other_JJ amounts_NNS accrued_VBN or_CC outstanding_JJ may_MD be_VB immediately_RB due_JJ and_CC payable_JJ and_CC all_DT or_CC part_NN of_IN the_DT loans_NNS may_MD become_VB payable_JJ on_IN demand_NN ._.
Events_NNS of_IN default_NN under_IN the_DT Facilities_NNP include_VBP :_: i_FW non-payment_NN of_IN any_DT amounts_NNS due_JJ under_IN the_DT Facilities_NNP ,_, ii_FW failure_NN to_TO satisfy_VB any_DT financial_JJ covenants_NNS ,_, iii_FW material_NN misrepresentation_NN in_IN any_DT of_IN the_DT finance_NN documents_NNS ,_, iv_NN failure_NN to_TO pay_VB ,_, or_CC certain_JJ other_JJ defaults_NNS under_IN other_JJ financial_JJ indebtedness_NN ,_, v_FW certain_JJ insolvency_NN events_NNS or_CC proceedings_NNS ,_, vi_FW material_NN adverse_JJ changes_NNS in_IN the_DT business_NN ,_, operations_NNS ,_, assets_NNS or_CC financial_JJ condition_NN of_IN the_DT Group_NNP ,_, vii_FW certain_JJ ERISA_NNP breaches_NNS which_WDT would_MD have_VB a_DT material_NN adverse_JJ effect_NN ,_, viii_FW change_NN of_IN control_NN of_IN a_DT subsidiary_NN of_IN Shire_NNP that_WDT is_VBZ a_DT party_NN to_TO the_DT Facilities_NNP Agreement_NNP ,_, or_CC ix_VB if_IN it_PRP becomes_VBZ illegal_JJ for_IN Shire_NNP or_CC any_DT of_IN its_PRP$ subsidiaries_NNS that_WDT are_VBP parties_NNS to_TO the_DT Facility_NN Agreement_NN to_TO perform_VB their_PRP$ obligations_NNS or_CC they_PRP repudiate_VBP the_DT Facilities_NNP Agreement_NNP or_CC any_DT Finance_NNP Document_NNP as_IN defined_VBN in_IN the_DT Facilities_NNP Agreement_NNP ._.
The_DT Facilities_NNP Agreement_NNP is_VBZ governed_VBN by_IN English_NNP law_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD not_RB drawn-down_JJ on_IN these_DT facilities_NNS ._.
Shire_NNP anticipates_VBZ that_IN its_PRP$ operating_NN cash_NN flow_NN together_RB with_IN available_JJ cash_NN ,_, cash_NN equivalents_NNS and_CC short-term_JJ investments_NNS and_CC the_DT above_JJ mentioned_VBN debt_NN facility_NN will_MD be_VB sufficient_JJ to_TO meet_VB its_PRP$ anticipated_JJ future_NN operating_NN expenses_NNS ,_, outstanding_JJ costs_NNS related_VBN to_TO the_DT acquisition_NN of_IN TKT_NNP ,_, capital_NN expenditures_NNS ,_, dividends_NNS ,_, share_NN repurchases_NNS and_CC debt_NN service_NN and_CC lease_NN obligations_NNS as_IN they_PRP become_VBP due_JJ over_IN the_DT next_JJ 12_CD months_NNS ._.
If_IN the_DT Company_NN decides_VBZ to_TO acquire_VB other_JJ businesses_NNS ,_, it_PRP expects_VBZ to_TO fund_VB these_DT acquisitions_NNS from_IN existing_VBG cash_NN resources_NNS ,_, the_DT debt_NN facility_NN discussed_VBN above_IN and_CC possibly_RB through_IN new_JJ borrowings_NNS and_CC or_CC the_DT issue_NN of_IN new_JJ equity_NN if_IN necessary_JJ ._.
Sources_NNS and_CC uses_NNS of_IN cash_NN The_DT following_VBG table_NN provides_VBZ an_DT analysis_NN of_IN the_DT Companys_NNP gross_JJ and_CC net_JJ cash_NN funds_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD :_: 2005_CD 2004_CD Change_NNP December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD %_NN Cash_NN and_CC cash_NN equivalents_NNS 656,456_CD 1,111,477_CD 41_CD %_NN Short-term_JJ investments_NNS 6,947_CD 324,411_CD 98_CD %_NN Gross_NNP cash_NN funds_NNS 663,403_CD 1,435,888_CD 54_CD %_NN Total_JJ debt_NN 116_CD 116_CD Net_JJ cash_NN funds_NNS 663,287_CD 1,435,772_CD 54_CD %_NN Cash_NN flow_NN activity_NN Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD was_VBD $_$ 381.1_CD million_CD ,_, a_DT decrease_NN of_IN $_$ 107.6_CD million_CD compared_VBN to_TO the_DT previous_JJ year_NN ._.
The_DT reduction_NN in_IN cash_NN generation_NN is_VBZ primarily_RB due_JJ to_TO the_DT operating_NN losses_NNS of_IN the_DT acquired_VBN TKT_NNP business_NN ,_, the_DT $_$ 50_CD million_CD payment_NN to_TO New_NNP River_NNP and_CC the_DT timing_NN of_IN working_VBG capital_NN payments_NNS ._.
Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS was_VBD $_$ 836.4_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
Decreases_NNS in_IN short-term_JJ investments_NNS of_IN $_$ 366.7_CD million_CD along_IN with_IN proceeds_NNS of_IN $_$ 60_CD million_CD from_IN the_DT redemption_NN by_IN IDB_NNP of_IN its_PRP$ subscription_NN receipts_NNS and_CC the_DT receipt_NN from_IN IDB_NNP of_IN additional_JJ proceeds_NNS from_IN the_DT sale_NN of_IN the_DT vaccines_NNS business_NN of_IN $_$ 32.2_CD million_CD ,_, offset_VBN cash_NN paid_VBN on_IN the_DT purchase_NN of_IN TKT_NNP net_NN of_IN cash_NN and_CC cash_NN equivalents_NNS acquired_VBN of_IN $_$ 1,151.5_CD million_CD ,_, loans_NNS made_VBN to_TO IDB_NNP of_IN $_$ 43.2_CD million_CD see_VBP Note_NN 6_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 97_CD ,_, capital_NN expenditure_NN on_IN property_NN ,_, plant_NN and_CC equipment_NN of_IN $_$ 86.2_CD million_CD and_CC intangible_JJ assets_NNS of_IN $_$ 20.5_CD million_CD ._.
Capital_NNP expenditure_NN on_IN property_NN ,_, plant_NN and_CC equipment_NN included_VBD $_$ 23.3_CD million_CD leasehold_NN building_NN improvements_NNS ,_, $_$ 16.3_CD million_CD on_IN computer_NN equipment_NN and_CC $_$ 3.1_CD million_CD on_IN furniture_NN and_CC fittings_NNS for_IN the_DT new_JJ Shire_NNP US_NNP headquarters_NN at_IN Wayne_NNP ,_, Pennsylvania_NNP ,_, $_$ 10.6_CD million_CD on_IN IT_PRP projects_NNS ,_, $_$ 5.4_CD million_CD on_IN the_DT expansion_NN and_CC refurbishment_NN at_IN the_DT Basingstoke_NNP Head_NNP Office_NNP ,_, $_$ 3.2_CD million_CD of_IN plant_NN equipment_NN and_CC $_$ 15.9_CD million_CD on_IN the_DT expansion_NN and_CC modification_NN at_IN Shire_NNP US_NNP Manufacturing_NNP Inc._NNP in_IN the_DT US_NNP ._.
Capital_NNP expenditure_NN on_IN intangible_JJ assets_NNS included_VBD the_DT final_JJ payment_NN for_IN the_DT acquisition_NN of_IN the_DT exclusive_JJ commercialization_NN rights_NNS to_TO REMINYL_NNP in_IN the_DT UK_NNP and_CC Republic_NNP of_IN Ireland_NNP ._.
Net_JJ cash_NN provided_VBN by_IN financing_VBG activities_NNS was_VBD $_$ 9.6_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
This_DT was_VBD primarily_RB due_JJ to_TO inflows_NNS of_IN $_$ 37.1_CD million_CD from_IN the_DT exercise_NN of_IN employee_NN stock_NN options_NNS being_VBG offset_VBN by_IN the_DT dividend_NN payments_NNS of_IN $_$ 28.5_CD million_CD in_IN respect_NN of_IN the_DT six_CD months_NNS to_TO December_NNP 31_CD ,_, 2004_CD and_CC the_DT six_CD months_NNS to_TO June_NNP 30_CD ,_, 2005_CD ._.
The_DT total_JJ cash_NN consideration_NN for_IN the_DT acquisition_NN of_IN TKT_NNP is_VBZ expected_VBN to_TO be_VB approximately_RB $_$ 1.6_CD billion_CD ,_, subject_JJ to_TO change_VB as_RB may_MD be_VB required_VBN by_IN the_DT appraisal_NN rights_NNS process_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, shareholders_NNS owning_VBG approximately_RB 24.8_CD million_CD TKT_NNP shares_NNS had_VBD accepted_VBN the_DT offer_NN and_CC $_$ 916.9_CD million_CD had_VBD been_VBN paid_VBN to_TO them_PRP ,_, $_$ 83.9_CD million_CD was_VBD paid_VBN in_IN connection_NN with_IN TKT_NNP stock_NN options_NNS and_CC $_$ 170.1_CD million_CD in_IN connection_NN with_IN convertible_JJ notes_NNS ,_, outstanding_JJ at_IN the_DT date_NN of_IN acquisition_NN ._.
Following_VBG the_DT exercise_NN of_IN appraisal_NN rights_NNS by_IN former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN ,_, the_DT remaining_VBG $_$ 419.9_CD million_CD ,_, together_RB with_IN any_DT interest_NN that_IN the_DT Court_NNP may_MD award_NN ,_, will_MD be_VB paid_VBN to_TO them_PRP subject_JJ to_TO the_DT appraisal_NN process_NN outlined_VBN in_IN Note_NN 27_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 120_CD ._.
For_IN every_DT $_$ 1_CD increase_NN decrease_NN in_IN the_DT merger_NN consideration_NN applicable_JJ to_TO those_DT TKT_NNP shareholders_NNS who_WP have_VBP asserted_VBN appraisal_NN rights_NNS ,_, the_DT total_JJ estimated_JJ purchase_NN price_NN would_MD increase_VB decrease_NN by_IN approximately_RB $_$ 11.3_CD million_CD ._.
52_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 53_CD As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN TKT_NNP ,_, cash_NN balances_NNS have_VBP been_VBN significantly_RB reduced_VBN ._.
Interest_NN receivable_NN has_VBZ increased_VBN as_IN increases_NNS in_IN US_NNP interest_NN rates_NNS have_VBP more_JJR than_IN offset_VB the_DT impact_NN of_IN the_DT reduced_JJ cash_NN balances_NNS ._.
The_DT average_JJ cash_NN balances_NNS pre-acquisition_JJ and_CC post-acquisition_NN of_IN TKT_NNP for_IN 2005_CD were_VBD $_$ 1.5_CD billion_CD and_CC $_$ 0.6_CD billion_CD respectively_RB ._.
Outstanding_JJ letters_NNS of_IN credit_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD irrevocable_JJ standby_JJ letters_NNS of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN in_IN the_DT amount_NN of_IN $_$ 15_CD million_CD providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS and_CC Bank_NNP of_IN America_NNP in_IN the_DT amount_NN of_IN $_$ 7.9_CD million_CD ,_, providing_VBG security_NN on_IN the_DT payment_NN of_IN lease_NN obligations_NNS ._.
Cash_NN requirements_NNS Aggregate_NNP contractual_JJ obligations_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Companys_NNPS contractual_JJ obligations_NNS were_VBD as_IN follows_VBZ :_: Payments_NNS due_JJ by_IN period_NN Less_RBR than_IN More_JJR than_IN Total_JJ 1_CD year_NN 13_CD years_NNS 35_CD years_NNS 5_CD years_NNS Contractual_JJ obligations_NNS $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Long-term_JJ debt_NN 116_CD 116_CD i_FW Operating_VBG leases_NNS 165,599_CD 26,110_CD 51,457_CD 38,016_CD 50,016_CD ii_FW Purchase_NN obligations_NNS 81,401_CD 69,733_CD 11,668_CD Other_JJ long-term_JJ liabilities_NNS iii_FW reflected_VBN on_IN the_DT balance_NN sheet_NN 491,244_CD 461,029_CD 30,187_CD 28_CD Total_JJ Notes_NNS i_FW The_DT Company_NN leases_VBZ certain_JJ properties_NNS ,_, motor_NN vehicles_NNS and_CC equipment_NN under_IN operating_VBG leases_NNS expiring_VBG through_IN 2025_CD ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN signed_VBD a_DT 20-year_JJ operating_NN lease_NN on_IN a_DT property_NN in_IN the_DT Republic_NNP of_IN Ireland_NNP and_CC acquired_VBD certain_JJ operating_VBG leases_NNS with_IN its_PRP$ acquisition_NN of_IN TKT_NNP ._.
ii_FW Purchase_NN obligations_NNS include_VBP agreements_NNS to_TO purchase_VB goods_NNS or_CC services_NNS that_WDT are_VBP enforceable_JJ and_CC legally_RB binding_JJ and_CC that_IN specify_VB all_DT significant_JJ terms_NNS ,_, including_VBG open_JJ purchase_NN orders_NNS ._.
Shire_NNP expects_VBZ to_TO fund_VB the_DT following_VBG commitments_NNS with_IN cash_NN flows_NNS from_IN operations_NNS :_: Clinical_JJ testing_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 16.3_CD million_CD to_TO contract_VB vendors_NNS for_IN administering_VBG and_CC executing_VBG clinical_JJ trials_NNS ._.
The_DT timing_NN of_IN payments_NNS is_VBZ not_RB reasonably_RB certain_JJ as_IN payments_NNS are_VBP dependent_JJ upon_IN actual_JJ services_NNS performed_VBN by_IN the_DT organizations_NNS as_IN determined_VBN by_IN patient_JJ enrolment_NN levels_NNS and_CC related_JJ activities_NNS ._.
However_RB ,_, the_DT Company_NN currently_RB expects_VBZ to_TO pay_VB $_$ 13.2_CD million_CD for_IN these_DT commitments_NNS throughout_IN 2006_CD as_IN ongoing_JJ trials_NNS are_VBP completed_VBN and_CC the_DT remainder_NN in_IN 2007_CD ._.
Contract_NN manufacturing_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 23.1_CD million_CD in_IN respect_NN of_IN contract_NN manufacturing_NN over_IN the_DT next_JJ 12_CD months_NNS ._.
Interests_NNS in_IN companies_NNS and_CC partnerships_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD outstanding_JJ commitments_NNS to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totalling_VBG $_$ 25.2_CD million_CD 2004_CD :_: $_$ 22_CD million_CD of_IN which_WDT $_$ 9.9_CD million_CD is_VBZ committed_VBN in_IN 2006_CD and_CC a_DT further_JJ $_$ 2.9_CD million_CD could_MD be_VB payable_JJ in_IN 2006_CD ,_, depending_VBG on_IN the_DT timing_NN of_IN capital_NN calls_NNS ._.
Manufacturing_NNP facilities_NNS At_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD committed_VBN a_DT total_NN of_IN $_$ 6.1_CD million_CD to_TO the_DT expansion_NN and_CC modification_NN of_IN its_PRP$ manufacturing_NN facilities_NNS at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP and_CC Cambridge_NNP ,_, Massachusetts_NNP ._.
Of_IN this_DT total_NN ,_, $_$ 3.2_CD million_CD is_VBZ to_TO facilitate_VB the_DT production_NN and_CC packaging_NN of_IN additional_JJ strategic_JJ products_NNS and_CC $_$ 2.9_CD million_CD is_VBZ for_IN the_DT design_NN and_CC construction_NN of_IN a_DT technology_NN center_NN at_IN Owings_NNP Mills_NNP ._.
All_DT costs_NNS are_VBP expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
Basingstoke_NNP ,_, UK_NNP expansion_NN The_DT Company_NN is_VBZ in_IN the_DT process_NN of_IN expanding_VBG its_PRP$ UK_NNP headquarters_NN at_IN Basingstoke_NNP ,_, UK_NNP ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD an_DT outstanding_JJ commitment_NN of_IN $_$ 4.5_CD million_CD ,_, which_WDT is_VBZ expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 53_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 54_CD Financial_NNP review_NN iii_FW Other_JJ liabilities_NNS reflected_VBN on_IN the_DT balance_NN sheet_NN include_VBP :_: Off-balance_JJ sheet_NN arrangements_NNS There_EX are_VBP no_DT off-balance_JJ sheet_NN arrangements_NNS that_WDT have_VBP ,_, or_CC are_VBP TKT_NNP shareholders_NNS asserting_VBG appraisal_NN rights_NNS reasonably_RB likely_JJ to_TO have_VB ,_, a_DT current_JJ or_CC future_JJ effect_NN on_IN the_DT Companys_NNPS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, appraisal_NN rights_NNS had_VBD been_VBN asserted_VBN in_IN financial_JJ condition_NN ,_, revenues_NNS or_CC expenses_NNS ,_, results_NNS of_IN operations_NNS ,_, respect_NN of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN ._.
liquidity_NN ,_, capital_NN expenditures_NNS or_CC capital_NN resources_NNS that_WDT are_VBP material_JJ As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN recorded_VBD a_DT liability_NN of_IN to_TO investors_NNS ._.
$_$ 419.9_CD million_CD based_VBN on_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN for_IN the_DT 11.3_CD million_CD shares_NNS outstanding_JJ at_IN that_DT time_NN plus_IN a_DT provision_NN Foreign_JJ currency_NN fluctuations_NNS for_IN interest_NN of_IN $_$ 7.7_CD million_CD that_WDT may_MD be_VB awarded_VBN by_IN the_DT court_NN see_VB Note_VB A_DT number_NN of_IN operating_VBG units_NNS in_IN the_DT Group_NNP have_VBP functional_JJ currencies_NNS 26_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS on_IN page_NN 120_CD ._.
Until_IN such_JJ other_JJ than_IN the_DT US_NNP Dollar_NNP ._.
As_IN such_JJ ,_, the_DT consolidated_JJ financial_JJ results_NNS time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ the_DT Company_NN is_VBZ unable_JJ are_VBP subject_JJ to_TO fluctuations_NNS in_IN exchange_NN rates_NNS ,_, particularly_RB those_DT between_IN to_TO determine_VB the_DT extent_NN of_IN its_PRP$ liability_NN ._.
For_IN every_DT $_$ 1_CD increase_NN decrease_NN the_DT US_NNP Dollar_NNP ,_, Canadian_NNP Dollar_NNP ,_, Pound_NNP Sterling_NNP ,_, Euro_NNP and_CC Swedish_NNP in_IN the_DT merger_NN consideration_NN applicable_JJ to_TO those_DT TKT_NNP shareholders_NNS Krona_NNP ._.
The_DT accumulated_VBN foreign_JJ currency_NN translation_NN differences_NNS who_WP have_VBP asserted_VBN appraisal_NN rights_NNS ,_, the_DT total_JJ estimated_JJ purchase_NN of_IN $_$ 62.2_CD million_CD are_VBP reported_VBN within_IN accumulated_VBN other_JJ comprehensive_JJ price_NN would_MD increase_VB decrease_NN by_IN approximately_RB $_$ 11.3_CD million_CD ._.
income_NN in_IN the_DT consolidated_JJ balance_NN sheet_NN and_CC $_$ 1.4_CD million_CD expense_NN is_VBZ reported_VBN in_IN other_JJ income_NN on_IN the_DT consolidated_JJ income_NN statement_NN ._.
The_DT contractual_JJ obligations_NNS table_NN above_IN does_VBZ not_RB include_VB payments_NNS yet_RB to_TO fall_VB due_JJ upon_IN the_DT occurrence_NN of_IN certain_JJ milestones_NNS and_CC other_JJ As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD five_CD outstanding_JJ forward_RB contractual_JJ commitments_NNS ._.
The_DT most_RBS significant_JJ payments_NNS are_VBP foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN equivalent_NN as_IN follows_VBZ :_: to_TO $_$ 206_CD million_CD to_TO manage_VB the_DT currency_NN risk_NN associated_VBN with_IN certain_JJ inter-company_JJ loans_NNS ._.
DAYTRANA_NNP In_IN connection_NN with_IN the_DT Companys_NNP acquisition_NN in_IN 2003_CD from_IN Noven_NNP Concentration_NNP of_IN credit_NN risk_NN of_IN the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO DAYTRANA_NNP ,_, Shire_NNP The_NNP Companys_NNP revenues_NNS from_IN product_NN sales_NNS are_VBP mainly_RB derived_VBN from_IN has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN the_DT agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS following_VBG milestones_NNS :_: $_$ 50_CD million_CD upon_IN FDA_NNP approval_NN of_IN the_DT product_NN ,_, with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
which_WDT will_MD be_VB capitalized_VBN and_CC amortized_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN :_: Such_JJ clients_NNS typically_RB have_VBP significant_JJ cash_NN resources_NNS and_CC as_IN such_JJ and_CC up_RB to_TO $_$ 75_CD million_CD ,_, linked_VBN to_TO future_JJ sales_NNS performance_NN ._.
An_DT approvable_JJ the_DT risk_NN is_VBZ considered_VBN minimal_JJ ._.
The_DT Company_NN has_VBZ taken_VBN positive_JJ steps_NNS letter_NN was_VBD received_VBN from_IN the_DT FDA_NNP on_IN December_NNP 23_CD ,_, 2005_CD ._.
Final_JJ to_TO manage_VB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS ._.
Shire_NNP regulatory_JJ approval_NN was_VBD received_VBN from_IN the_DT FDA_NNP on_IN April_NNP 6_CD ,_, 2006_CD ._.
operates_VBZ clearly_RB defined_VBN credit_NN evaluation_NN procedures_NNS ._.
For_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, there_EX were_VBD three_CD customers_NNS in_IN the_DT US_NNP who_WP NRP104_VBP accounted_VBN for_IN 69_CD %_NN of_IN the_DT Companys_NNPS total_VBP revenues_NNS ._.
In_IN connection_NN with_IN the_DT Companys_NNP collaboration_NN with_IN New_NNP River_NNP to_TO commercialize_VB NRP104_NNP ,_, the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ Financial_NNP instruments_NNS that_WDT potentially_RB expose_VB Shire_NNP to_TO concentrations_NNS payments_NNS on_IN the_DT achievement_NN of_IN the_DT following_VBG milestones_NNS :_: $_$ 50_CD million_CD of_IN credit_NN risk_NN consist_VBP primarily_RB of_IN short-term_JJ cash_NN investments_NNS and_CC upon_IN the_DT FDAs_NNS acceptance_NN of_IN filing_NN of_IN the_DT NDA_NNP :_: up_RP to_TO $_$ 300_CD million_CD trade_NN accounts_NNS receivable_JJ ._.
Excess_JJ cash_NN is_VBZ invested_VBN in_IN short-term_JJ following_VBG the_DT first_JJ commercial_JJ sale_NN of_IN the_DT product_NN ,_, depending_VBG on_IN the_DT money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN characteristics_NNS of_IN the_DT approved_VBN product_NN labeling_VBG :_: $_$ 100_CD million_CD on_IN deposits_NNS ,_, commercial_JJ paper_NN and_CC other_JJ debt_NN securities_NNS from_IN a_DT variety_NN achieving_VBG a_DT significant_JJ sales_NNS target_NN :_: and_CC $_$ 5_CD million_CD following_VBG the_DT first_JJ of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
These_DT investments_NNS typically_RB commercial_JJ sale_NN in_IN certain_JJ specified_VBN EU_NN markets_NNS ._.
An_DT upfront_JJ payment_NN bear_NN minimal_JJ risk_NN ._.
of_IN $_$ 50_CD million_CD was_VBD expensed_VBN as_IN an_DT R&D_NNP cost_NN during_IN the_DT first_JJ quarter_NN of_IN 2005_CD ._.
The_DT NDA_NNP for_IN NRP104_NNP was_VBD filed_VBN on_IN December_NNP 6_CD ,_, 2005_CD and_CC Inflation_NN accepted_VBN for_IN review_NN by_IN the_DT FDA_NNP on_IN January_NNP 26_CD ,_, 2006_CD ,_, triggering_VBG the_DT Although_IN at_IN reduced_JJ levels_NNS in_IN recent_JJ years_NNS ,_, inflation_NN continues_VBZ to_TO apply_VB $_$ 50_CD million_CD milestone_NN payment_NN ,_, which_WDT has_VBZ now_RB been_VBN paid_VBN ._.
upward_RB pressure_NN on_IN the_DT cost_NN of_IN goods_NNS and_CC services_NNS which_WDT are_VBP used_VBN in_IN the_DT business_NN ._.
However_RB ,_, the_DT Company_NN believes_VBZ that_IN the_DT net_JJ effect_NN of_IN FOSRENOL_NNP patent_NN rights_NNS inflation_NN on_IN its_PRP$ operations_NNS has_VBZ been_VBN minimal_JJ during_IN the_DT past_JJ three_CD years_NNS ._.
In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP from_IN AnorMED_NNP Inc._NNP in_IN 2004_CD ,_, the_DT Company_NN has_VBZ outstanding_JJ Treasury_NNP policies_NNS and_CC organization_NN commitments_NNS to_TO pay_VB AnorMED_NNP Inc._NNP $_$ 6_CD million_CD when_WRB FOSRENOL_NNP The_DT Companys_NNPS principal_JJ treasury_NN operations_NNS are_VBP co-ordinated_VBN by_IN is_VBZ approved_VBN in_IN certain_JJ European_JJ countries_NNS and_CC $_$ 6_CD million_CD upon_IN receipt_NN its_PRP$ corporate_JJ treasury_NN function_NN ,_, which_WDT is_VBZ based_VBN in_IN the_DT UK_NNP ._.
All_DT treasury_NN of_IN regulatory_JJ approval_NN in_IN Japan_NNP ._.
operations_NNS are_VBP conducted_VBN within_IN a_DT framework_NN of_IN policies_NNS and_CC procedures_NNS approved_VBN by_IN the_DT Board_NNP ._.
As_IN a_DT matter_NN of_IN policy_NN ,_, the_DT Other_JJ R&D_NNP commitments_NNS Company_NN does_VBZ not_RB undertake_VB speculative_JJ transactions_NNS that_WDT would_MD As_RB at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD commitments_NNS of_IN increase_NN its_PRP$ currency_NN or_CC interest_NN rate_NN exposure_NN ._.
$_$ 18_CD million_CD on_IN achievement_NN of_IN specified_VBN milestones_NNS from_IN products_NNS under_IN development_NN in_IN licensed_VBN from_IN third_JJ parties_NNS of_IN which_WDT $_$ 6.6_CD million_CD is_VBZ committed_VBN to_TO be_VB paid_VBN in_IN 2006_CD ._.
54_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Review_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:54_CD Page_NNP 55_CD As_IN a_DT matter_NN of_IN English_JJ law_NN ,_, Shire_NNP may_MD pay_VB dividends_NNS only_RB out_IN of_IN its_PRP$ The_NNP Board_NNP reviews_VBZ and_CC agrees_VBZ policies_NNS for_IN managing_VBG the_DT risks_NNS and_CC they_PRP are_VBP summarized_VBN below_IN :_: distributable_JJ profits_NNS ,_, which_WDT are_VBP the_DT accumulated_VBN realized_VBD profits_NNS under_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT United_NNP Kingdom_NNP Interest_NN rate_NN risk_NN including_VBG reserves_NNS arising_VBG from_IN a_DT reduction_NN of_IN share_NN capital_NN ,_, of_IN Shire_NNP plc_NN and_CC not_RB the_DT consolidated_JJ Group_NNP ,_, so_RB far_RB as_IN not_RB previously_RB As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN has_VBZ no_DT material_NN debt_NN outstanding_JJ ._.
Therefore_RB the_DT Companys_NNPS interest_NN charge_NN on_IN its_PRP$ debt_NN utilized_VBN by_IN distribution_NN or_CC capitalization_NN ,_, less_JJR accumulated_VBN realized_VBN losses_NNS ,_, so_RB far_RB as_IN not_RB previously_RB written_VBN off_RP in_IN a_DT reduction_NN or_CC obligations_NNS is_VBZ low_JJ and_CC consequently_RB the_DT Companys_NNPS interest_NN expense_NN charge_NN has_VBZ limited_VBN exposure_NN to_TO interest_NN rate_NN movements_NNS ._.
The_DT Company_NN reorganization_NN of_IN capital_NN duly_RB made_VBD ._.
is_VBZ exposed_VBN to_TO movements_NNS in_IN interest_NN rates_NNS affecting_VBG interest_NN income_NN ._.
This_DT exposure_NN is_VBZ primarily_RB to_TO US_NNP Dollar_NNP interest_NN rates_NNS ._.
As_IN the_DT Company_NN On_IN November_NNP 28_CD ,_, 2005_CD ,_, the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP approved_VBD a_DT reduction_NN of_IN Shires_NNP share_NN capital_NN to_TO take_VB effect_NN on_IN maintains_VBZ all_DT of_IN its_PRP$ investments_NNS on_IN a_DT short-term_JJ basis_NN for_IN liquidity_NN purposes_NNS this_DT risk_NN is_VBZ not_RB actively_RB managed_VBN ._.
November_NNP 29_CD ,_, 2005_CD ,_, when_WRB the_DT nominal_JJ value_NN of_IN each_DT Shire_NNP ordinary_JJ share_NN was_VBD reduced_VBN from_IN 3.50_CD to_TO 0.05_CD ._.
This_DT reduction_NN increased_VBD the_DT In_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, the_DT average_JJ interest_NN rate_NN received_VBD distributable_JJ reserves_NNS available_JJ to_TO Shire_VB to_TO approximately_RB $_$ 2.95_CD billion_CD ,_, which_WDT the_DT Directors_NNS of_IN Shire_NNP can_MD utilize_VB for_IN future_JJ dividend_NN payments_NNS on_IN cash_NN and_CC liquid_JJ investments_NNS was_VBD approximately_RB 2.90_CD %_NN per_IN annum_NN ._.
The_DT largest_JJS proportion_NN of_IN investments_NNS was_VBD in_IN US_NNP Dollar_NNP money_NN market_NN at_IN their_PRP$ discretion_NN ._.
As_IN a_DT result_NN of_IN this_DT capital_NN reduction_NN ,_, as_RB at_IN December_NNP 31_CD ,_, 2005_CD ,_, Shire_NNP had_VBD distributable_JJ profits_NNS of_IN $_$ 2,946_CD million_CD ._.
Future_JJ dividend_NN policy_NN will_MD Foreign_NNP exchange_NN risk_NN The_DT Company_NN is_VBZ exposed_VBN to_TO movements_NNS in_IN foreign_JJ exchange_NN rates_NNS be_VB dependent_JJ upon_IN distributable_JJ profits_NNS ,_, financial_JJ condition_NN ,_, the_DT terms_NNS of_IN any_DT then_RB existing_VBG debt_NN facilities_NNS and_CC other_JJ relevant_JJ factors_NNS existing_VBG against_IN the_DT US_NNP Dollar_NNP for_IN trading_VBG transactions_NNS and_CC the_DT translation_NN of_IN net_JJ assets_NNS ,_, liabilities_NNS and_CC earnings_NNS of_IN non-US_JJ subsidiaries_NNS ._.
trading_NN currencies_NNS of_IN the_DT Company_NN are_VBP the_DT US_NNP Dollar_NNP ,_, the_DT Canadian_JJ Dollar_NN ,_, Pounds_NNP Sterling_NNP ,_, the_DT Euro_NNP and_CC Swedish_NNP Krona_NNP ._.
The_DT consolidated_JJ financial_JJ statements_NNS of_IN foreign_JJ entities_NNS are_VBP translated_VBN using_VBG the_DT accounting_NN policies_NNS described_VBN in_IN Note_NN 3_CD to_TO the_DT Companys_NNP consolidated_JJ financial_JJ statements_NNS on_IN page_NN 86_CD ._.
Angus_NNP Russell_NNP The_NNP exposure_NN to_TO foreign_JJ exchange_NN risk_NN is_VBZ managed_VBN and_CC monitored_VBN by_IN the_DT treasury_NN function_NN ._.
Exposures_NNS are_VBP generally_RB managed_VBN through_IN natural_JJ hedging_NN via_IN the_DT currency_NN denomination_NN of_IN cash_NN balances_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD five_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 206_CD million_CD equivalent_JJ to_TO manage_VB the_DT currency_NN risk_NN associated_VBN with_IN certain_JJ inter-company_JJ loans_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD there_EX were_VBD net_JJ unrealized_JJ gains_NNS of_IN $_$ 2.6_CD million_CD on_IN these_DT contracts_NNS ._.
Market_NN risk_NN of_IN investments_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN has_VBZ $_$ 50.2_CD million_CD of_IN investments_NNS comprising_VBG equity_NN investment_NN funds_NNS ,_, private_JJ companies_NNS and_CC publicly-quoted_JJ equities_NNS ._.
The_DT public-quoted_JJ companies_NNS are_VBP exposed_VBN to_TO market_NN risk_NN ._.
No_DT financial_JJ instruments_NNS or_CC derivatives_NNS have_VBP been_VBN employed_VBN to_TO hedge_VB this_DT risk_NN ._.
Dividend_NN policy_NN An_DT interim_JJ dividend_NN for_IN the_DT first_JJ half_NN of_IN 2005_CD of_IN 1.8246_CD 1.0475_CD p_NN per_IN ordinary_JJ share_NN equivalent_NN to_TO 5.4738_CD per_IN ADS_NNPS and_CC 6.7629_CD Canadian_JJ per_IN exchangeable_JJ share_NN was_VBD paid_VBN in_IN October_NNP 2005_CD ._.
The_DT Board_NNP has_VBZ resolved_VBN to_TO pay_VB a_DT second_JJ interim_JJ dividend_NN of_IN 4.419_CD 2.5356_CD p_NN per_IN ordinary_JJ share_NN equivalent_NN to_TO 13.257_CD per_IN ADS_NNPS and_CC 15.2217_CD Canadian_JJ per_IN exchangeable_JJ share_NN for_IN the_DT six_CD months_NNS to_TO December_NNP 31_CD ,_, 2005_CD ._.
This_DT is_VBZ consistent_JJ with_IN Shires_NNP stated_VBD policy_NN of_IN paying_VBG a_DT dividend_NN semi-annually_RB ,_, set_VBN in_IN US_NNP cents_NNS per_IN share_NN ADS_NNPS ,_, with_IN the_DT first_JJ interim_JJ payment_NN in_IN each_DT year_NN being_VBG maintained_VBN at_IN a_DT consistent_JJ level_NN ._.
Any_DT growth_NN will_MD come_VB through_IN increasing_VBG the_DT second_JJ interim_JJ dividend_NN in_IN a_DT financial_JJ year_NN ._.
Shire_NNP intends_VBZ to_TO pursue_VB a_DT progressive_JJ dividend_NN policy_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 55_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 56_CD Nomination_NNP Committee_NNP report_NN Directors_NNS remuneration_JJ report_NN The_DT members_NNS of_IN the_DT Nomination_NNP Committee_NNP as_IN at_IN December_NNP 31_CD ,_, 2005_CD Introduction_NN were_VBD Dr_NNP James_NNP Cavanaugh_NNP Chairman_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP ,_, The_DT This_DT report_NN has_VBZ been_VBN prepared_VBN in_IN accordance_NN with_IN Schedule_NNP 7A_NN Hon_NNP James_NNP Grant_NNP and_CC Dr_NNP Barry_NNP Price_NNP ._.
A_DT majority_NN of_IN the_DT Committee_NNP has_VBZ to_TO the_DT Companies_NNS Act_NNP 1985_CD and_CC complies_VBZ with_IN the_DT Combined_NNP Code_NNP been_VBN determined_VBN by_IN Shires_NNP Board_NNP to_TO be_VB Independent_JJ Non-executive_JJ on_IN Corporate_JJ Governance_NN ._.
The_DT report_NN also_RB meets_VBZ the_DT relevant_JJ Directors_NNS for_IN the_DT purposes_NNS of_IN the_DT Combined_NNP Code_NNP ._.
Dr_NNP James_NNP requirements_NNS of_IN the_DT Listing_NNP Rules_NNP of_IN the_DT Financial_NNP Services_NNPS Authority_NNP Cavanaugh_NNP is_VBZ the_DT Chairman_NNP of_IN the_DT Company_NN and_CC in_IN this_DT capacity_NN and_CC describes_VBZ how_WRB the_DT Board_NNP has_VBZ applied_VBN the_DT principles_NNS relating_VBG to_TO is_VBZ not_RB considered_VBN to_TO be_VB independent_JJ under_IN the_DT Combined_NNP Code_NNP ._.
Directors_NNS remuneration_NN under_IN the_DT Directors_NNS Remuneration_NNP Report_NNP Regulations_NNPS 2002_CD ._.
As_IN required_VBN by_IN the_DT Act_NNP ,_, a_DT resolution_NN to_TO approve_VB the_DT The_DT Nomination_NNP Committee_NNP is_VBZ responsible_JJ for_IN identifying_VBG and_CC report_NN will_MD be_VB proposed_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG of_IN the_DT Company_NN nominating_NN ,_, for_IN the_DT approval_NN of_IN the_DT Board_NNP ,_, candidates_NNS for_IN the_DT Board_NNP ._.
at_IN which_WDT the_DT financial_JJ statements_NNS will_MD be_VB approved_VBN ._.
The_DT Act_NNP requires_VBZ The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Nomination_NNP Committee_NNP require_VBP it_PRP ,_, before_IN the_DT auditors_NNS to_TO report_VB to_TO the_DT Companys_NNPS members_NNS on_IN certain_JJ parts_NNS of_IN any_DT appointment_NN is_VBZ made_VBN ,_, to_TO evaluate_VB the_DT balance_NN of_IN skills_NNS ,_, knowledge_NN the_DT Directors_NNS remuneration_NN report_NN and_CC to_TO state_NN whether_IN in_IN their_PRP$ opinion_NN and_CC experience_NN on_IN the_DT Board_NNP and_CC ,_, in_IN light_NN of_IN this_DT evaluation_NN ,_, to_TO identify_VB these_DT parts_NNS of_IN the_DT report_NN have_VBP been_VBN properly_RB prepared_VBN in_IN accordance_NN the_DT capabilities_NNS required_VBN for_IN a_DT particular_JJ appointment_NN ._.
The_DT Committee_NNP with_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
The_DT report_NN has_VBZ therefore_RB been_VBN divided_VBN utilizes_VBZ the_DT services_NNS of_IN professional_JJ search_NN agencies_NNS specializing_VBG in_IN the_DT into_IN separate_JJ sections_NNS for_IN audited_JJ and_CC unaudited_JJ information_NN ._.
recruitment_NN of_IN high_JJ calibre_NN candidates_NNS ._.
The_DT Committee_NNP is_VBZ required_VBN to_TO consider_VB candidates_NNS from_IN a_DT wide_JJ range_NN of_IN backgrounds_NNS ,_, on_IN merit_NN and_CC Unaudited_JJ information_NN against_IN objective_JJ criteria_NNS ._.
It_PRP is_VBZ also_RB required_VBN to_TO ensure_VB that_IN candidates_NNS Dear_RB Shareholder_NN ,_, have_VBP sufficient_JJ time_NN to_TO devote_VB to_TO the_DT position_NN ._.
The_DT Committee_NNP also_RB Directors_NNS remuneration_NN monitors_VBZ succession_NN planning_NN to_TO the_DT Board_NNP and_CC oversees_VBZ succession_NN During_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD the_DT Remuneration_NNP Committee_NNP planning_VBG for_IN senior_JJ management_NN ._.
continued_VBD its_PRP$ work_NN ,_, on_IN behalf_NN of_IN the_DT Board_NNP ,_, on_IN Directors_NNS remuneration_NN ._.
During_IN 2005_CD ,_, the_DT Committee_NNP made_VBD recommendations_NNS to_TO the_DT Board_NNP on_IN the_DT appointment_NN of_IN Mr_NNP Patrick_NNP Langlois_NNP and_CC the_DT reappointment_NN During_IN the_DT past_JJ two_CD years_NNS ,_, the_DT Company_NN has_VBZ implemented_VBN a_DT business_NN of_IN Mr_NNP Nordmann_NNP ._.
strategy_NN and_CC model_NN focused_VBD on_IN identifying_VBG ,_, developing_VBG and_CC marketing_VBG pharmaceuticals_NNS in_IN targeted_JJ therapeutic_JJ areas_NNS for_IN diseases_NNS treated_VBN New_NNP Non-executive_JJ Directors_NNS receive_VBP a_DT customized_VBN induction_NN process_NN by_IN specialist_NN physicians_NNS ._.
Moving_VBG to_TO this_DT model_NN has_VBZ required_VBN the_DT sale_NN taking_VBG account_NN of_IN their_PRP$ particular_JJ experience_NN and_CC backgrounds_NNS ._.
of_IN non-core_JJ businesses_NNS and_CC site_NN consolidation_NN ,_, as_RB well_RB as_IN a_DT major_JJ internal_JJ This_DT process_NN includes_VBZ meetings_NNS with_IN senior_JJ management_NN ._.
reorganization_NN to_TO fully_RB integrate_VB and_CC align_VB key_JJ functions_NNS and_CC staff_NN on_IN a_DT global_JJ ,_, therapy_NN area_NN and_CC market_NN basis_NN ._.
As_IN part_NN of_IN the_DT reorganization_NN ,_, The_DT Committee_NNP met_VBD three_CD times_NNS during_IN 2005_CD ._.
All_DT members_NNS were_VBD present_JJ the_DT Company_NN has_VBZ established_VBN a_DT new_JJ US_NNP headquarters_NN office_NN in_IN Wayne_NNP ,_, at_IN the_DT meetings_NNS ._.
Pennsylvania_NNP where_WRB the_DT majority_NN of_IN our_PRP$ senior_JJ executives_NNS are_VBP based_VBN ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ recently_RB completed_VBN the_DT acquisition_NN of_IN TKT_NNP ,_, which_WDT is_VBZ based_VBN in_IN Cambridge_NNP ,_, Massachusetts_NNP ._.
The_DT Company_NN operates_VBZ in_IN a_DT competitive_JJ multinational_JJ environment_NN ._.
In_IN 2005_CD ,_, approximately_RB 90_CD %_NN of_IN the_DT Companys_NNP revenues_NNS were_VBD generated_VBN and_CC 80_CD %_NN of_IN its_PRP$ employees_NNS were_VBD based_VBN outside_IN the_DT UK_NNP ._.
Indeed_RB most_RBS Dr_JJ James_NNP Cavanaugh_NNP of_IN the_DT Companys_NNP revenues_NNS are_VBP generated_VBN in_IN the_DT US_NNP and_CC the_DT majority_NN Chairman_NN of_IN the_DT Nomination_NNP Committee_NNP of_IN its_PRP$ employees_NNS and_CC most_JJS of_IN its_PRP$ senior_JJ executives_NNS are_VBP based_VBN in_IN the_DT US_NNP ._.
The_DT importance_NN of_IN our_PRP$ US_NNP business_NN to_TO the_DT continuing_VBG growth_NN of_IN your_PRP$ Company_NN ,_, coupled_VBN with_IN the_DT fact_NN that_IN most_JJS of_IN our_PRP$ senior_JJ executives_NNS are_VBP based_VBN in_IN the_DT US_NNP ,_, presents_VBZ the_DT Committee_NNP with_IN particular_JJ challenges_NNS ._.
Key_NNP elements_NNS of_IN our_PRP$ remuneration_NN package_NN ,_, including_VBG long-term_JJ incentive_NN arrangements_NNS ,_, have_VBP been_VBN in_IN place_NN for_IN five_CD years_NNS or_CC more_JJR and_CC ,_, over_IN this_DT time_NN ,_, the_DT Company_NN has_VBZ grown_VBN and_CC changed_VBN significantly_RB ._.
As_IN a_DT result_NN of_IN both_DT the_DT growth_NN and_CC development_NN of_IN the_DT Company_NN and_CC the_DT competitive_JJ operating_NN environment_NN ,_, the_DT Committee_NNP reviewed_VBN senior_JJ executive_NN remuneration_NN during_IN 2005_CD and_CC conducted_VBD a_DT competitive_JJ benchmarking_NN study_NN ._.
On_IN the_DT basis_NN of_IN ,_, and_CC consistent_JJ with_IN ,_, data_NNS from_IN the_DT study_NN ,_, the_DT Committee_NNP modified_VBD the_DT remuneration_NN policy_NN and_CC proposed_VBD a_DT number_NN of_IN changes_NNS to_TO remuneration_VB including_VBG the_DT introduction_NN of_IN a_DT new_JJ share_NN plan_NN to_TO replace_VB Shires_NNP existing_VBG plans_NNS and_CC amendments_NNS to_TO the_DT annual_JJ incentive_NN plan_NN ._.
The_DT Committee_NNP conducted_VBD a_DT consultation_NN process_NN with_IN major_JJ shareholders_NNS regarding_VBG the_DT proposed_JJ programs_NNS and_CC made_VBN changes_NNS to_TO its_PRP$ proposals_NNS consistent_JJ with_IN shareholder_NN feedback_NN ._.
These_DT are_VBP described_VBN within_IN this_DT report_NN ._.
The_DT Remuneration_NNP Committee_NNP is_VBZ committed_VBN to_TO a_DT continuing_VBG dialogue_NN with_IN shareholders_NNS and_CC we_PRP take_VBP account_NN of_IN your_PRP$ views_NNS ._.
We_PRP hope_VBP that_IN this_DT report_NN provides_VBZ helpful_JJ context_NN and_CC explanation_NN about_IN the_DT policies_NNS and_CC practical_JJ considerations_NNS that_WDT influence_VBP our_PRP$ decisions_NNS ._.
Dr_NNP Barry_NNP Price_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP 56_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 57_CD Directors_NNS remuneration_JJ report_NN The_DT Remuneration_NNP Committee_NNP share-based_JJ compensation_NN is_VBZ a_DT key_JJ element_NN of_IN the_DT Companys_NNPS The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN all_DT elements_NNS of_IN the_DT remuneration_NN policy_NN as_IN it_PRP aligns_VBZ the_DT interests_NNS of_IN the_DT Companys_NNP executive_NN Directors_NNS remuneration_NN ,_, as_RB well_RB as_IN their_PRP$ performance_NN executives_NNS with_IN the_DT interests_NNS of_IN its_PRP$ shareholders_NNS ._.
of_IN compensation_NN also_RB utilizes_VBZ a_DT blended_JJ US_NNP UK_NNP market_NN comparison_NN to_TO determine_VB face_NN value_NN of_IN awards_NNS to_TO executive_JJ Directors_NNS :_: The_DT constitution_NN of_IN the_DT Committee_NNP was_VBD reviewed_VBN in_IN 2004_CD and_CC changes_NNS were_VBD made_VBN to_TO ensure_VB compliance_NN with_IN the_DT Combined_NNP Code_NNP ._.
The_DT benefits_NNS programs_NNS are_VBP locally_RB competitive_JJ and_CC provide_VB for_IN the_DT Company_NN considers_VBZ all_DT members_NNS of_IN the_DT Committee_NNP to_TO be_VB independent_JJ ._.
welfare_NN and_CC well-being_NN of_IN our_PRP$ employees_NNS and_CC their_PRP$ families_NNS :_: The_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP attend_VB the_DT Committee_NNP currently_RB aims_VBZ for_IN variable_JJ compensation_NN meetings_NNS of_IN the_DT Committee_NNP at_IN its_PRP$ invitation_NN ,_, but_CC neither_DT is_VBZ involved_VBN to_TO represent_VB over_IN two-thirds_NNS of_IN total_JJ remuneration_NN :_: and_CC in_IN any_DT decisions_NNS relating_VBG to_TO their_PRP$ own_JJ remuneration_NN ._.
the_DT Committee_NNP believes_VBZ that_IN executive_NN Directors_NNS should_MD be_VB The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP during_IN 2005_CD were_VBD :_: encouraged_VBD to_TO own_VB shares_NNS in_IN the_DT Company_NN in_IN order_NN to_TO ensure_VB the_DT alignment_NN of_IN their_PRP$ interests_NNS with_IN those_DT of_IN the_DT Companys_NNPS Dr_NNP Barry_NNP Price_NNP ,_, the_DT Senior_JJ Independent_NNP Director_NNP of_IN the_DT Company_NN shareholders_NNS ._.
Share_NN ownership_NN guidelines_NNS became_VBD effective_JJ and_CC Chairman_NNP of_IN the_DT Committee_NNP :_: in_IN 2006_CD ._.
Mr_NNP Robin_NNP Buchanan_NNP ,_, an_DT Independent_NNP Non-executive_JJ Director_NNP :_: and_CC The_DT remuneration_NN package_NN The_DT main_JJ elements_NNS of_IN the_DT remuneration_NN package_NN for_IN executive_NN Mr_NNP Ronald_NNP Nordmann_NNP ,_, an_DT Independent_NNP Non-executive_JJ Director_NNP ._.
Directors_NNS and_CC senior_JJ management_NN are_VBP :_: Details_NNS of_IN the_DT number_NN of_IN Committee_NNP meetings_NNS in_IN 2005_CD and_CC the_DT 1_CD Base_NNP salary_NN attendance_NN at_IN those_DT meetings_NNS is_VBZ set_VBN out_RP in_IN the_DT section_NN headed_VBD Corporate_JJ Governance_NNP Statements_NNP ._.
2_CD Annual_JJ Incentive_NNP Plan_NNP a_DT Cash_NN component_NN The_DT Remuneration_NNP Committee_NNP was_VBD materially_RB assisted_VBN in_IN 2005_CD by_IN Mrs_NNP b_NN Share_NN component_NN Anita_NNP Graham_NNP ,_, EVP_NNP Global_NNP Human_NNP Resources_NNPS ._.
The_DT following_VBG external_JJ advisers_NNS were_VBD appointed_VBN by_IN and_CC materially_RB assisted_VBD the_DT Committee_NNP :_: 3_CD Long-term_JJ Incentives_NNS c_NN Share_NN options_NNS Towers_NNP Perrin_NNP who_WP provided_VBD advice_NN in_IN relation_NN to_TO executive_JJ Directors_NNS d_SYM Long-term_JJ Incentive_NNP Plan_NNP remuneration_NN and_CC the_DT design_NN and_CC operation_NN of_IN the_DT Companys_NNP share_NN e_SYM Portfolio_NNP Share_NNP Plan_NNP incentive_NN schemes_NNS :_: 4_CD Pension_NN and_CC other_JJ benefits_NNS Deloitte_NNP &_CC Touche_NNP LLP_NNP who_WP also_RB provided_VBD audit_NN and_CC tax_NN services_NNS to_TO the_DT Company_NN who_WP provided_VBD data_NNS and_CC advice_NN on_IN the_DT design_NN and_CC The_DT share_NN component_NN under_IN the_DT Annual_JJ Incentive_NNP Plan_NNP ,_, and_CC the_DT operation_NN of_IN the_DT Companys_NNP incentive_NN schemes_NNS :_: and_CC Portfolio_NNP Share_NNP Plan_NNP ,_, were_VBD introduced_VBN as_IN a_DT result_NN of_IN the_DT remuneration_NN review_NN in_IN 2005_CD ._.
The_DT 2005_CD annual_JJ incentive_NN therefore_RB did_VBD not_RB contain_VB a_DT Slaughter_NN and_CC May_NNP ,_, who_WP provided_VBD general_JJ legal_JJ advice_NN to_TO the_DT share_NN component_NN ._.
Going_VBG forward_RB ,_, the_DT Portfolio_NNP Share_NNP Plan_NNP will_MD replace_VB Company_NN ._.
the_DT previous_JJ Share_NN Option_NN and_CC Long-term_JJ Incentive_NNP Plans_NNS ,_, and_CC no_DT further_JJ awards_NNS will_MD be_VB made_VBN under_IN these_DT plans_NNS ._.
Executive_NNP remuneration_NN policy_NN The_DT Remuneration_NNP Committee_NNP considers_VBZ that_IN an_DT effective_JJ remuneration_NN 1_CD Salary_JJ policy_NN ,_, aligned_VBN to_TO the_DT Companys_NNPS business_NN needs_NNS ,_, is_VBZ important_JJ to_TO the_DT The_DT Remuneration_NNP Committee_NNP reviews_VBZ salaries_NNS annually_RB ._.
It_PRP directly_RB impacts_VBZ the_DT Companys_NNP ability_NN to_TO recruit_VB ,_, and_CC early_RB 2005_CD the_DT Committee_NNP undertook_VBD a_DT competitive_JJ review_NN of_IN the_DT retain_VB and_CC motivate_VB high_JJ caliber_NN executives_NNS who_WP deliver_VBP sustained_VBN Companys_NNP executive_NN remuneration_NN programs_NNS and_CC practices_NNS ,_, including_VBG value_NN to_TO shareholders_NNS and_CC build_VB the_DT Company_NN for_IN long-term_JJ success_NN ._.
base_NN salary_NN benchmarks_NNS and_CC levels_NNS ._.
Based_VBN on_IN the_DT competitive_JJ analysis_NN the_DT Committee_NNP determined_VBD that_IN the_DT correct_JJ comparator_NN group_NN is_VBZ a_DT blend_VB The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN developing_VBG ,_, reviewing_VBG of_IN US_NNP and_CC UK_NNP companies_NNS with_IN sector_NN ,_, size_NN ,_, complexity_NN and_CC international_JJ and_CC overseeing_VBG the_DT implementation_NN of_IN the_DT Companys_NNP compensation_NN characteristics_NNS similar_JJ to_TO those_DT of_IN the_DT Company_NN ._.
Where_WRB appropriate_JJ ,_, and_CC benefits_NNS policy_NN ._.
The_DT Remuneration_NNP Committee_NNP regularly_RB monitors_VBZ the_DT competitive_JJ review_NN included_VBD a_DT detailed_JJ analysis_NN to_TO align_VB these_DT the_DT effectiveness_NN of_IN the_DT policy_NN and_CC reviews_VBZ this_DT policy_NN based_VBN on_IN characteristics_NNS to_TO best_JJS represent_VBP the_DT Companys_NNPS operating_VBG position_NN ._.
independent_JJ analysis_NN and_CC advice_NN ,_, an_DT understanding_NN of_IN the_DT business_NN drivers_NNS and_CC competitive_JJ environment_NN in_IN which_WDT the_DT Company_NN operates_VBZ As_IN part_NN of_IN its_PRP$ normal_JJ annual_JJ salary_NN review_NN process_NN ,_, the_DT Committee_NNP and_CC ongoing_JJ dialogue_NN with_IN shareholders_NNS ._.
conducts_VBZ a_DT review_NN of_IN a_DT range_NN of_IN factors_NNS such_JJ as_IN competitive_JJ market_NN data_NNS provided_VBN by_IN independent_JJ external_JJ consultants_NNS ,_, US_NNP and_CC UK_NNP The_DT Companys_NNP executive_NN compensation_NN and_CC benefits_NNS policy_NN market_NN conditions_NNS ,_, performance-related_JJ pay_NN increases_NNS across_IN the_DT is_VBZ based_VBN on_IN the_DT following_VBG principles_NNS :_: Company_NN and_CC individual_JJ skills_NNS ,_, performance_NN and_CC results_NNS achieved_VBN ._.
The_DT Remuneration_NNP Committees_NNS policy_NN is_VBZ for_IN salary_NN to_TO be_VB targeted_VBN base_NN pay_NN is_VBZ market_NN driven_VBN utilizing_VBG a_DT blended_JJ US_NNP UK_NNP market_NN at_IN or_CC around_IN the_DT median_NN of_IN the_DT blend_VB of_IN US_NNP UK_NNP comparators_NNS ,_, with_IN comparison_NN ,_, and_CC is_VBZ targeted_VBN at_IN or_CC around_IN the_DT median_NN relative_JJ appropriate_JJ differentiation_NN based_VBN upon_IN skills_NNS and_CC experience_NN as_RB well_RB to_TO the_DT comparison_NN :_: as_IN individual_JJ performance_NN ._.
Based_VBN on_IN this_DT review_NN ,_, salaries_NNS for_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP were_VBD increased_VBN the_DT Annual_JJ Incentive_NNP Plan_NNP is_VBZ performance-based_JJ and_CC is_VBZ linked_VBN to_TO 5_CD %_NN and_CC 4_CD %_NN effective_JJ January_NNP 1_CD ,_, 2006_CD ,_, respectively_RB ,_, to_TO $_$ 1,103,017_CD the_DT achievement_NN of_IN an_DT appropriate_JJ mix_NN of_IN corporate_JJ and_CC individual_JJ denominated_VBN in_IN $_$ and_CC 372,120_CD $_$ 677,630_CD equivalent_JJ based_VBN performance_NN targets_NNS ._.
The_DT Annual_JJ Incentive_NNP Plan_NNP allows_VBZ the_DT Company_NN on_IN the_DT average_JJ exchange_NN rates_NNS prevailing_VBG in_IN 2005_CD ._.
These_DT increases_NNS to_TO measure_VB and_CC reward_VB progress_NN against_IN its_PRP$ strategic_JJ goals_NNS and_CC are_VBP in_IN line_NN with_IN increases_NNS provided_VBN to_TO the_DT Companys_NNPS employees_NNS ._.
is_VBZ closely_RB tied_VBN to_TO delivery_NN of_IN sustained_JJ shareholder_NN value_NN :_: Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 57_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 58_CD Directors_NNS remuneration_JJ report_NN 2_CD Annual_JJ Incentive_NNP Plan_NNP Target_NNP Maximum_NNP Weighting_NN of_IN target_NN incentive_NN incentive_NN incentive_NN objectives_NNS Shire_NNP operates_VBZ an_DT Annual_JJ Incentive_NNP Plan_NNP which_WDT rewards_VBZ executive_NN as_IN a_DT %_NN as_IN a_DT %_NN Director_NNP performance_NN dependent_JJ on_IN achievement_NN of_IN pre-defined_JJ Board_NNP of_IN salary_NN of_IN salary_NN Corporate_JJ Individual_NN approved_VBD corporate_JJ objectives_NNS and_CC Committee_NNP approved_VBD individual_JJ Mr_NNP Matthew_NNP Emmens_NNP objectives_NNS ._.
The_DT Company_NN implemented_VBD the_DT Balanced_NNP Scorecard_NNP to_TO set_VB Chief_NNP Executive_NNP Officer_NNP 65_CD %_NN 115_CD %_NN 80_CD %_NN 20_CD %_NN corporate_JJ objectives_NNS in_IN 2005_CD ._.
The_DT Scorecard_NN organizes_VBZ corporate_JJ objectives_NNS into_IN all_DT areas_NNS that_WDT drive_VBP the_DT success_NN of_IN the_DT business_NN :_: financial_JJ ,_, Mr_NNP Angus_NNP Russell_NNP products_NNS and_CC markets_NNS ,_, people_NNS and_CC capabilities_NNS ,_, and_CC operational_JJ Chief_NNP Financial_NNP Officer_NNP 55_CD %_NN 100_CD %_NN 70_CD %_NN 30_CD %_NN effectiveness_NN ._.
The_DT incentive_NN payments_NNS awarded_VBD to_TO each_DT executive_NN Director_NNP for_IN 2005_CD At_IN the_DT start_NN of_IN the_DT year_NN corporate_JJ objectives_NNS are_VBP set_VBN by_IN the_DT Board_NNP for_IN reflect_VBP the_DT corporate_JJ and_CC individual_JJ achievements_NNS and_CC amounted_VBD to_TO each_DT area_NN of_IN the_DT Scorecard_NN ._.
These_DT objectives_NNS apply_VBP to_TO all_DT employees_NNS 115_CD %_NN of_IN salary_NN for_IN Mr_NNP Emmens_NNP and_CC 70_CD %_NN of_IN salary_NN for_IN Mr_NNP Russell_NNP ._.
participating_VBG in_IN the_DT Companys_NNP Annual_JJ Incentive_NNP Plan_NNP and_CC include_VBP a_DT description_NN of_IN the_DT objective_NN and_CC key_JJ performance_NN indicators_NNS KPI_NNP ,_, These_DT incentive_NN awards_NNS are_VBP consistent_JJ with_IN the_DT overall_JJ performance_NN including_VBG targets_NNS and_CC deadlines_NNS ._.
Awards_NNS under_IN the_DT Plan_NN are_VBP made_VBN only_RB of_IN the_DT Company_NN in_IN 2005_CD ,_, which_WDT included_VBD :_: when_WRB exacting_VBG levels_NNS of_IN performance_NN specified_VBN by_IN the_DT KPI_NNP have_VBP been_VBN achieved_VBN ._.
Objectives_NNS measured_VBN by_IN the_DT Companys_NNPS financial_JJ revenue_NN growth_NN of_IN 17_CD %_NN :_: performance_NN are_VBP assessed_VBN on_IN the_DT Companys_NNPS results_NNS ,_, as_IN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ._.
the_DT acquisition_NN of_IN TKT_NNP :_: The_DT detailed_JJ objectives_NNS and_CC performance_NN standards_NNS contain_VBP the_DT in-licensing_JJ acquisition_NN co-promotion_NN of_IN four_CD new_JJ products_NNS commercially_RB sensitive_JJ information_NN and_CC therefore_RB are_VBP not_RB detailed_VBN here_RB ._.
NRP104_CD ,_, ELAPRASE_NNP ,_, DYNEPO_NNP ,_, GA-GCB_NNP :_: However_RB ,_, some_DT of_IN the_DT objectives_NNS are_VBP summarized_VBN below_IN according_VBG to_TO the_DT four_CD Scorecard_NN areas_NNS for_IN 2005_CD :_: the_DT launch_NN of_IN four_CD new_JJ products_NNS FOSRENOL_NNP ,_, EQUETRO_NNP ,_, XAGRID_NNP ,_, PENTASA_NNP 500mg_CD :_: 1_CD Financial_NNP a_DT Growth_NN in_IN revenue_NN and_CC net_JJ income_NN :_: highly_RB successful_JJ achievement_NN of_IN R&D_NNP milestones_NNS including_VBG the_DT filing_NN b_NN Revenue_NN growth_NN tied_VBN to_TO the_DT acquisition_NN of_IN new_JJ products_NNS :_: of_IN MESAVANCE_NNP and_CC ELAPRASE_NNP in_IN the_DT US_NNP and_CC the_DT reinstatement_NN b_NN M&A_NNP and_CC divestiture_NN targets_NNS ._.
of_IN ADDERALL_NNP XR_NNP in_IN Canada_NNP :_: and_CC 2_CD Products_NNPS markets_VBZ the_DT highly_RB successful_JJ implementation_NN of_IN other_JJ Scorecard_NNP objectives_NNS a_DT Product_NNP launches_NNS :_: focused_VBN on_IN the_DT continuing_VBG growth_NN of_IN the_DT Company_NN ._.
b_NN Key_NNP R&D_NNP milestones_NNS such_JJ as_IN submissions_NNS and_CC approvals_NNS :_: b_NN Product_NNP pipeline_NN growth_NN progression_NN and_CC in-licensing_JJ acquisition_NN ._.
Changes_NNS to_TO the_DT Annual_JJ Incentive_NNP Plan_NNP for_IN 2006_CD following_VBG the_DT remuneration_NN review_NN and_CC subsequent_JJ consultation_NN with_IN shareholders_NNS 3_CD People_NNS and_CC capabilities_NNS As_IN part_NN of_IN the_DT remuneration_NN review_NN and_CC following_VBG consultation_NN with_IN a_DT Development_NNP of_IN capabilities_NNS in_IN areas_NNS of_IN core_NN competence_NN :_: the_DT Companys_NNPS major_JJ shareholders_NNS and_CC investor_NN bodies_NNS including_VBG b_NN The_DT staffing_NN and_CC development_NN of_IN our_PRP$ people_NNS :_: operationalizing_VBG the_DT ABI_NNP and_CC RREV_NNP ,_, the_DT Committee_NNP proposed_VBD some_DT changes_NNS to_TO the_DT new_JJ US_NNP headquarters_NN ._.
4_CD Operational_JJ effectiveness_NN As_IN described_VBN in_IN last_JJ years_NNS remuneration_JJ report_NN ,_, in_IN 2005_CD ,_, the_DT Company_NN a_DT Global_JJ product_NN development_NN targets_NNS :_: ceased_VBD the_DT matching_JJ share_NN portion_NN of_IN the_DT Plan_NN by_IN discontinuing_VBG the_DT b_NN Risk_NN management_NN ,_, compliance_NN initiatives_NNS and_CC operational_JJ Deferred_NNP Bonus_NNP Plan_NNP ._.
For_IN the_DT financial_JJ year_NN 2006_CD ,_, a_DT restricted_JJ share_NN excellence_NN targets_NNS ._.
element_NN has_VBZ been_VBN added_VBN to_TO the_DT Plan_NN ,_, so_IN the_DT Plan_NNP effectively_RB has_VBZ two_CD components_NNS :_: a_DT cash_NN component_NN and_CC a_DT share_NN component_NN ._.
Personal_JJ objectives_NNS are_VBP also_RB set_VBN at_IN the_DT beginning_NN of_IN the_DT year_NN and_CC are_VBP aligned_VBN with_IN individual_JJ accountabilities_NNS for_IN the_DT development_NN and_CC The_DT target_NN cash_NN incentive_NN for_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP execution_NN of_IN plans_NNS to_TO achieve_VB corporate_JJ objectives_NNS in_IN the_DT current_JJ year_NN Financial_NNP Officer_NNP remain_VBP respectively_RB at_IN the_DT 2005_CD levels_NNS of_IN 65_CD %_NN and_CC 55_CD %_NN and_CC build_VB for_IN the_DT future_JJ success_NN of_IN the_DT Company_NN ._.
of_IN salary_NN and_CC the_DT maximum_NN cash_NN incentive_NN amounts_NNS remain_VBP respectively_RB 115_CD %_NN and_CC 100_CD %_NN of_IN salary_NN ._.
The_DT Remuneration_NNP Committee_NNP assesses_VBZ performance_NN against_IN objectives_NNS in_IN the_DT first_JJ quarter_NN of_IN the_DT following_JJ year_NN ._.
Through_IN 2005_CD ,_, the_DT annual_JJ incentive_NN is_VBZ payable_JJ in_IN cash_NN and_CC is_VBZ not_RB pensionable_JJ ._.
The_DT target_NN incentive_NN is_VBZ paid_VBN where_WRB executive_JJ Directors_NNS have_VBP fully_RB achieved_VBN their_PRP$ individual_JJ objectives_NNS and_CC the_DT corporate_JJ objectives_NNS have_VBP been_VBN met_VBN in_IN full_JJ ._.
The_DT maximum_NN incentive_NN is_VBZ paid_VBN when_WRB the_DT Remuneration_NNP Committee_NNP determines_VBZ that_IN individual_JJ and_CC or_CC corporate_JJ performance_NN has_VBZ been_VBN exceptional_JJ ._.
Maximum_NNP incentive_NN payments_NNS for_IN 2005_CD were_VBD capped_VBN at_IN 115_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC 100_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP ._.
58_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 59_CD Directors_NNS remuneration_JJ report_NN The_DT new_JJ restricted_JJ share_NN element_NN will_MD be_VB set_VBN as_IN follows_VBZ :_: for_IN the_DT Chief_NNP The_NNP 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN ,_, which_WDT was_VBD approved_VBN by_IN Executive_NNP Officer_NNP ,_, the_DT target_NN restricted_VBN share_NN element_NN is_VBZ 20_CD %_NN and_CC the_DT shareholders_NNS in_IN 2000_CD ,_, contained_VBD an_DT unlimited_JJ retesting_NN feature_NN from_IN the_DT maximum_NN restricted_VBN share_NN element_NN is_VBZ 65_CD %_NN ._.
For_IN the_DT Chief_NNP Financial_NNP date_NN of_IN grant_NN ._.
The_DT Remuneration_NNP Committee_NNP decided_VBD ,_, after_IN consultation_NN Officer_NNP ,_, the_DT target_NN restricted_VBN share_NN element_NN is_VBZ 15_CD %_NN and_CC the_DT maximum_NN with_IN some_DT of_IN the_DT Companys_NNP major_JJ institutional_JJ shareholders_NNS in_IN 2003_CD ,_, restricted_VBN share_NN element_NN is_VBZ 55_CD %_NN ._.
Awards_NNS of_IN restricted_JJ shares_NNS will_MD be_VB that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT made_VBN in_IN the_DT same_JJ manner_NN as_IN awards_NNS of_IN cash_NN under_IN the_DT Plan_NN ,_, utilizing_VBG performance_NN condition_NN should_MD be_VB retested_VBN once_RB only_RB ,_, five_CD years_NNS after_IN the_DT the_DT same_JJ operational_JJ objectives_NNS and_CC measures_NNS per_IN Companys_NNP grant_NN and_CC then_RB only_RB where_WRB Shires_NNP EPS_NNP growth_NN has_VBZ not_RB met_VBN the_DT minimum_NN Balanced_JJ Scorecard_NN and_CC individual_JJ objectives_NNS ._.
The_DT levels_NNS of_IN target_NN and_CC level_NN of_IN performance_NN over_IN the_DT first_JJ three_CD years_NNS ._.
The_DT level_NN of_IN EPS_NNP growth_NN maximum_NN restricted_VBN shares_NNS have_VBP been_VBN set_VBN to_TO be_VB competitive_JJ in_IN both_DT over_IN the_DT five-year_JJ period_NN needs_VBZ to_TO be_VB commensurately_RB higher_JJR to_TO meet_VB the_DT UK_NNP and_CC US_NNP and_CC to_TO enable_VB Shire_NNP to_TO operate_VB a_DT common_JJ framework_NN for_IN the_DT retest_NN ._.
the_DT senior_JJ executive_NN team_NN irrespective_RB of_IN location_NN ._.
The_DT restricted_JJ share_NN element_NN is_VBZ earned_VBN at_IN the_DT same_JJ time_NN as_IN the_DT cash_NN portion_NN of_IN the_DT incentive_NN ,_, The_DT new_JJ Portfolio_NN Share_NN Plan_NN does_VBZ not_RB allow_VB re-testing_JJ ._.
but_CC is_VBZ deferred_VBN for_IN three_CD years_NNS ._.
As_IN discussed_VBN with_IN the_DT Companys_NNP major_JJ shareholders_NNS and_CC investor_NN bodies_NNS ,_, this_DT restricted_JJ share_NN element_NN is_VBZ taken_VBN The_DT table_NN below_IN sets_NNS out_IN the_DT share_NN options_NNS that_WDT were_VBD granted_VBN to_TO into_IN account_NN for_IN the_DT purposes_NNS of_IN determining_VBG competitive_JJ levels_NNS of_IN executive_NN Directors_NNS during_IN 2005_CD ._.
share-based_JJ and_CC total_JJ compensation_NN ._.
The_DT table_NN below_IN compares_VBZ the_DT Number_NN of_IN previous_JJ and_CC the_DT new_JJ Annual_JJ Incentive_NNP Plan_NNP structure_NN ._.
Executive_NNP Director_NNP and_CC ordinary_JJ Exercise_NN share_NN option_NN scheme_NN Date_NNP of_IN grant_NN Shares_NNP Price_NNP New_NNP Annual_JJ Incentive_NNP Plan_NNP Mr_NNP Matthew_NNP Emmens_NNP Previous_JJ Annual_JJ Incentive_NNP Plan_NNP cash_NN plus_CC 2000_CD Executive_NNP Scheme_NNP May_NNP 2005_CD 295,000_CD 5.585_CD cash_NN only_RB restricted_JJ shares_NNS Mr_NNP Angus_NNP Russell_NNP Target_NNP Maximum_NNP Target_NNP Maximum_NNP 2000_CD Executive_NNP Scheme_NNP May_NNP 2005_CD 195,000_CD 5.585_CD incentive_NN incentive_NN incentive_NN incentive_NN as_IN a_DT %_NN as_IN a_DT %_NN as_IN a_DT %_NN as_IN a_DT %_NN of_IN salary_NN of_IN salary_NN of_IN salary_NN of_IN salary_NN Details_NNS of_IN the_DT Companys_NNP share_NN option_NN schemes_NNS are_VBP set_VBN out_RP in_IN Note_NN 31_CD Mr_NNP Matthew_NNP Emmens_NNP 65_CD %_NN cash_NN 115_CD %_NN cash_NN to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
Performance_NNP conditions_NNS Chief_NNP Executive_NNP Officer_NNP 65_CD %_NN 115_CD %_NN 20_CD %_NN shares_NNS 65_CD %_NN shares_NNS attaching_VBG to_TO previous_JJ executive_NN option_NN grants_NNS are_VBP detailed_VBN in_IN the_DT audited_JJ section_NN of_IN this_DT Report_NNP ._.
Mr_NNP Angus_NNP Russell_NNP 55_CD %_NN cash_NN 100_CD %_NN cash_NN Chief_NNP Financial_NNP Officer_NNP 55_CD %_NN 100_CD %_NN 15_CD %_NN shares_NNS 55_CD %_NN shares_NNS b_NN Long-term_JJ Incentive_NNP Plan_NNP The_NNP Long-term_JJ Incentive_NNP Plan_NNP LTIP_NNP was_VBD adopted_VBN at_IN the_DT Companys_NNPS 3_CD Long-term_JJ Incentives_NNS 1998_CD Annual_JJ General_NNP Meeting_VBG and_CC amended_VBN in_IN 2000_CD ._.
Under_IN the_DT LTIP_NNP ,_, a_DT Share_NN options_NNS the_DT Remuneration_NNP Committee_NNP has_VBZ discretion_NN to_TO make_VB awards_NNS of_IN shares_NNS During_IN 2005_CD ,_, discretionary_JJ grants_NNS of_IN share_NN options_NNS under_IN the_DT subject_NN to_TO a_DT maximum_NN of_IN 100_CD %_NN of_IN salary_NN a_DT year_NN ._.
Companys_NNP 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN were_VBD made_VBN to_TO executive_JJ Directors_NNS to_TO align_VB their_PRP$ interests_NNS with_IN those_DT of_IN shareholders_NNS The_DT performance_NN condition_NN attached_VBN to_TO the_DT vesting_NN of_IN awards_NNS under_IN and_CC to_TO promote_VB sustained_VBN long-term_JJ Company_NN performance_NN ._.
The_DT face_NN the_DT LTIP_NNP is_VBZ Shires_NNP Total_NNP Shareholder_NN Return_NN TSR_NNP relative_JJ to_TO the_DT value_NN of_IN annual_JJ option_NN grants_NNS under_IN the_DT Scheme_NN was_VBD capped_VBN at_IN three_CD FTSE_NNP 100_CD Index_NNP over_IN a_DT three-year_JJ period_NN ._.
The_DT Committee_NNP considers_VBZ times_NNS salary_NN ._.
In_IN order_NN for_IN options_NNS to_TO vest_NN ,_, stretching_VBG performance_NN targets_NNS that_IN this_DT measure_NN is_VBZ a_DT reliable_JJ and_CC appropriate_JJ measure_NN of_IN the_DT must_MD be_VB met_VBN ._.
For_IN 2005_CD grants_NNS ,_, the_DT performance_NN target_NN is_VBZ based_VBN on_IN real_JJ Companys_NNPS performance_NN and_CC that_IN the_DT FTSE_NNP 100_CD is_VBZ an_DT appropriate_JJ growth_NN in_IN diluted_JJ Earnings_NNS Per_IN Share_NN EPS_NNP as_IN reported_VBN under_IN US_NNP GAAP_NNP benchmark_NN given_VBN that_IN the_DT Company_NN is_VBZ a_DT member_NN of_IN the_DT Index_NN ._.
adjusted_VBN to_TO ensure_VB a_DT consistent_JJ basis_NN of_IN measurement_NN ,_, as_IN approved_VBN by_IN the_DT Remuneration_NNP Committee_NNP ,_, including_VBG the_DT add_VB back_RB of_IN significant_JJ Under_IN the_DT LTIP_NNP :_: one_CD time_NN items_NNS ._.
all_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ in_IN the_DT top_JJ 10_CD %_NN of_IN the_DT FTSE_NNP 100_CD :_: The_DT earnings_NNS per_IN share_NN based_VBN measure_NN was_VBD introduced_VBN in_IN 2002_CD following_VBG consultation_NN with_IN major_JJ institutional_JJ shareholders_NNS and_CC ,_, during_IN the_DT course_NN 20_CD %_NN of_IN the_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ at_IN the_DT median_NN of_IN the_DT FTSE_NNP of_IN the_DT consultation_NN process_NN ,_, the_DT performance_NN test_NN for_IN executive_NN Directors_NNS 100_CD ,_, with_IN vesting_VBG between_IN these_DT points_NNS on_IN a_DT linear_JJ basis_NN :_: and_CC options_NNS was_VBD toughened_VBN compared_VBN to_TO that_DT for_IN other_JJ employees_NNS ._.
no_DT shares_NNS vest_NN if_IN Shires_NNP TSR_NNP is_VBZ below_IN the_DT median_NN of_IN the_DT FTSE_NNP 100_CD ._.
The_DT minimum_JJ performance_NN required_VBN in_IN order_NN for_IN executive_NN Directors_NNS options_NNS to_TO vest_NN is_VBZ that_IN Shires_NNP EPS_NNP grows_VBZ by_IN 15_CD %_NN in_IN excess_NN of_IN the_DT Retail_NNP The_NNP Remuneration_NNP Committee_NNP determines_VBZ whether_IN and_CC to_TO what_WP extent_NN Price_NNP Index_NNP RPI_NNP or_CC 5_CD %_NN on_IN average_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT performance_NN condition_NN has_VBZ been_VBN met_VBN on_IN the_DT basis_NN of_IN data_NNS provided_VBD the_DT date_NN of_IN grant_NN ._.
In_IN the_DT case_NN of_IN an_DT annual_JJ grant_NN of_IN options_NNS worth_JJ three_CD by_IN an_DT independent_JJ third_JJ party_NN ._.
To_TO date_NN ,_, all_DT awards_NNS made_VBN under_IN the_DT times_NNS salary_NN ,_, Shires_NNP EPS_NNP must_MD grow_VB by_IN 21_CD %_NN in_IN excess_NN of_IN RPI_NNP or_CC on_IN LTIP_NNP have_VBP been_VBN made_VBN as_IN a_DT conditional_JJ allocation_NN ,_, thereby_RB allowing_VBG ,_, average_JJ 7_CD %_NN a_DT year_NN in_IN the_DT three_CD years_NNS following_VBG the_DT date_NN of_IN grant_NN for_IN all_DT at_IN the_DT Remuneration_NNP Committees_NNS discretion_NN ,_, for_IN a_DT cash_NN equivalent_NN the_DT options_NNS to_TO vest_NN ._.
to_TO be_VB paid_VBN on_IN maturity_NN of_IN the_DT award_NN ._.
Whilst_IN the_DT performance_NN period_NN is_VBZ measured_VBN over_IN three_CD years_NNS ,_, an_DT award_NN is_VBZ normally_RB transferred_VBN after_IN Options_NNS with_IN a_DT value_NN the_DT fourth_JJ anniversary_NN of_IN grant_NN ,_, to_TO the_DT extent_NN the_DT performance_NN condition_NN on_IN grant_NN as_IN a_DT %_NN of_IN salary_NN Three-year_JJ EPS_NNP growth_NN has_VBZ been_VBN met_VBN ._.
Up_IN to_TO 100_CD %_NN RPI_NNP plus_CC 15_CD %_NN for_IN executive_NN Directors_NNS RPI_NNP plus_CC 9_CD %_NN for_IN all_DT other_JJ employees_NNS 101_CD %_NN to_TO 200_CD %_NN RPI_NNP plus_CC 15_CD %_NN 201_CD %_NN to_TO 300_CD %_NN RPI_NNP plus_CC 21_CD %_NN The_DT Portfolio_NN Share_NN Plan_NN has_VBZ replaced_VBN both_DT the_DT 2000_CD Executive_NNP Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 27_CD %_NN Share_NN Option_NN Scheme_NN and_CC the_DT Long-term_JJ Incentive_NNP Plan_NNP Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 59_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 60_CD Directors_NNS remuneration_JJ report_NN Directors_NNS were_VBD granted_VBN awards_NNS under_IN the_DT LTIP_NNP in_IN 2005_CD as_IN a_DT conditional_JJ for_IN the_DT Chief_NNP Executive_NNP Officer_NNP ,_, equivalent_JJ to_TO approximately_RB four_CD allocation_NN as_IN defined_VBN in_IN the_DT LTIP_NNP ,_, as_IN follows_VBZ :_: times_NNS base_NN salary_NN in_IN SARs_NNS and_CC three_CD times_NNS base_JJ salary_NN in_IN PSPs_NNS :_: and_CC Earliest_JJS date_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP ,_, equivalent_JJ to_TO approximately_RB on_IN which_WDT 2.2_CD times_NNS base_JJ salary_NN in_IN SARs_NNS and_CC 1.6_CD times_NNS base_JJ salary_NN in_IN PSPs_NNS ._.
Value_NN of_IN an_DT award_NN conditional_JJ Total_NNP can_MD be_VB award_NN at_IN number_NN of_IN transferred_VBN Performance_NNP criteria_NNS Date_NNP of_IN grant_NN date_NN ordinary_JJ to_TO a_DT Awards_NNP under_IN the_DT Plan_NN will_MD normally_RB vest_NN on_IN the_DT third_JJ anniversary_NN i_FW award_NN $_$ shares_NNS Director_NNP of_IN the_DT date_NN of_IN grant_NN ._.
In_IN the_DT case_NN of_IN executive_NN Directors_NNS ,_, awards_NNS will_MD only_RB vest_NN if_IN the_DT Committee_NNP determines_VBZ that_IN the_DT performance_NN Mr_NNP Matthew_NNP Emmens_NNP May_NNP 2005_CD 1,024,504_CD 97,468_CD May_NNP 2009_CD conditions_NNS have_VBP been_VBN satisfied_VBN and_CC that_IN ,_, in_IN the_DT opinion_NN of_IN the_DT Mr_NNP Angus_NNP Russell_NNP May_NNP 2005_CD 664,486_CD 63,217_CD May_NNP 2009_CD Committee_NNP ,_, the_DT underlying_VBG performance_NN of_IN the_DT Company_NN is_VBZ sufficient_JJ to_TO justify_VB the_DT vesting_NN of_IN the_DT award_NN ._.
i_FW Translated_VBN from_IN into_IN $_$ at_IN the_DT average_JJ exchange_NN rate_NN during_IN May_NNP 2005_CD ._.
Performance_NNP criteria_NNS will_MD be_VB based_VBN on_IN relative_JJ Total_JJ Shareholder_NN Return_NN TSR_NNP measured_VBN against_IN two_CD comparator_NN groups_NNS ._.
Vesting_VBG of_IN one-third_JJ c_NN The_DT New_NNP Portfolio_NNP Share_NNP Plan_NNP of_IN an_DT Award_NNP will_MD depend_VB upon_IN the_DT Companys_NNP performance_NN relative_JJ to_TO the_DT TSR_NNP performance_NN of_IN FTSE_NNP 100_CD constituents_NNS ,_, excluding_VBG financial_JJ As_IN part_NN of_IN the_DT remuneration_NN review_NN ,_, the_DT Committee_NNP proposed_VBD a_DT number_NN of_IN changes_NNS to_TO existing_VBG equity_NN plans_NNS ._.
Following_VBG consultation_NN with_IN the_DT institutions_NNS ._.
The_DT vesting_NN of_IN the_DT remaining_VBG two-thirds_NNS of_IN an_DT Award_NNP will_MD depend_VB upon_IN the_DT Companys_NNP performance_NN relative_JJ to_TO the_DT Companys_NNPS major_JJ shareholders_NNS and_CC investor_NN bodies_NNS including_VBG the_DT ABI_NNP and_CC RREV_NNP the_DT Committee_NNP made_VBD changes_NNS to_TO its_PRP$ initial_JJ proposals_NNS TSR_NNP performance_NN of_IN a_DT group_NN of_IN international_JJ companies_NNS from_IN the_DT pharmaceutical_JJ sector_NN see_VBP below_IN ._.
Vesting_VBG will_MD be_VB as_IN follows_VBZ :_: consistent_JJ with_IN shareholder_NN feedback_NN and_CC submitted_VBD the_DT new_JJ Plan_NN for_IN shareholder_NN vote_NN in_IN October_NNP 2005_CD ._.
The_DT Plan_NN was_VBD approved_VBN by_IN performance_NN below_IN the_DT median_NN versus_IN the_DT comparator_NN companies_NNS an_DT overwhelming_JJ majority_NN of_IN shareholders_NNS ._.
This_DT new_JJ Plan_NN ,_, The_DT Portfolio_NNP Share_NNP Plan_NNP the_DT Plan_NNP ,_, was_VBD adopted_VBN by_IN the_DT Companys_NNP shareholders_NNS and_CC the_DT FTSE_NNP 1000_CD %_NN vesting_NN :_: on_IN October_NNP 28_CD ,_, 2005_CD ._.
This_DT Plan_NN replaces_VBZ the_DT 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NN and_CC the_DT Long-term_JJ Incentive_NNP Plan_NNP ._.
The_DT Company_NN will_MD performance_NN at_IN median_JJ versus_IN the_DT comparator_NN companies_NNS and_CC the_DT 1_CD FTSE_NNP 10033_CD 3_CD %_NN vesting_NN :_: and_CC make_VB no_DT further_JJ awards_NNS to_TO executive_JJ Directors_NNS or_CC any_DT other_JJ employee_NN under_IN the_DT previous_JJ plans_NNS ._.
performance_NN between_IN median_NN and_CC upper_JJ quartile_NN versus_IN the_DT The_DT purpose_NN of_IN the_DT Plan_NN is_VBZ to_TO enable_VB the_DT Company_NN to_TO motivate_VB comparator_NN companies_NNS and_CC the_DT FTSE_NNP 100_CD straight-line_JJ vesting_NN 1_CD from_IN 33_CD 3_CD %_NN to_TO 100_CD %_NN for_IN at_IN or_CC above_IN upper_JJ quartile_JJ performance_NN ._.
and_CC reward_VB its_PRP$ workforce_NN by_IN reference_NN to_TO share_VB price_NN performance_NN ,_, and_CC to_TO link_VB the_DT interests_NNS of_IN participants_NNS with_IN those_DT of_IN our_PRP$ shareholders_NNS ._.
The_DT comparator_NN group_NN of_IN international_JJ companies_NNS from_IN the_DT The_DT Plan_NN is_VBZ designed_VBN to_TO align_VB the_DT interests_NNS of_IN selected_VBN employees_NNS of_IN the_DT Company_NN with_IN long-term_JJ value_NN creation_NN for_IN shareholders_NNS ._.
Participation_NN pharmaceutical_JJ sector_NN will_MD initially_RB include_VB the_DT following_JJ companies_NNS :_: in_IN the_DT Plan_NN is_VBZ discretionary_JJ ._.
Under_IN the_DT Plan_NN ,_, awards_NNS granted_VBN to_TO executive_JJ Directors_NNS will_MD be_VB subject_JJ to_TO a_DT performance_NN target_NN ,_, which_WDT must_MD ,_, in_IN normal_JJ Allergan_NNP ,_, Altana_NNP ,_, Biovail_NNP ,_, Cephalon_NNP ,_, Forest_NNP Labs_NNPS ,_, King_NNP ,_, Kos_NNP ,_, Lundbeck_NNP ,_, Medicis_NNP ,_, Novo_NNP Nordisk_NNP ,_, Schering_NNP AG_NNP ,_, Sepracor_NNP ,_, Serono_NNP ,_, UCB_NNP ,_, circumstances_NNS ,_, be_VB met_VBN before_IN the_DT award_NN vests_NNS ._.
Performance_NNP targets_NNS will_MD normally_RB be_VB measured_VBN over_IN a_DT period_NN of_IN not_RB less_JJR than_IN three_CD years_NNS ._.
Special_JJ rules_NNS apply_VBP in_IN the_DT event_NN of_IN the_DT participants_NNS employment_NN terminating_VBG early_JJ or_CC on_IN a_DT change_NN of_IN control_NN of_IN the_DT Company_NN ._.
The_DT Committee_NNP has_VBZ the_DT discretion_NN to_TO amend_VB this_DT group_NN of_IN companies_NNS to_TO ensure_VB that_IN the_DT group_NN stays_VBZ both_DT relevant_JJ and_CC representative_NN :_: The_DT Plan_NN is_VBZ split_VBN into_IN two_CD parts_NNS ,_, which_WDT can_MD be_VB operated_VBN separately_RB ._.
however_RB ,_, the_DT change_NN must_MD not_RB have_VB the_DT effect_NN of_IN making_VBG the_DT performance_NN criteria_NNS either_CC materially_RB easier_JJR or_CC materially_RB more_RBR difficult_JJ Under_IN Part_NNP A_NNP of_IN the_DT Plan_NN ,_, Stock_NNP Appreciation_NNP Right_NNP SAR_NNP Awards_NNPS to_TO achieve_VB ,_, in_IN the_DT opinion_NN of_IN the_DT Committee_NNP ,_, than_IN it_PRP was_VBD or_CC they_PRP were_VBD immediately_RB before_IN the_DT circumstance_NN in_IN question_NN ._.
A_DT SAR_NNP Award_NNP is_VBZ the_DT right_NN to_TO receive_VB shares_NNS or_CC ADSs_NNS in_IN the_DT Company_NN linked_VBN to_TO the_DT increase_NN in_IN value_NN of_IN a_DT specified_VBN number_NN TSR_NNP performance_NN will_MD be_VB measured_VBN using_VBG an_DT averaging_NN period_NN of_IN of_IN shares_NNS over_IN a_DT period_NN between_IN three_CD and_CC five_CD years_NNS from_IN the_DT date_NN of_IN grant_NN and_CC ,_, in_IN the_DT case_NN of_IN executive_NN Directors_NNS ,_, subject_JJ to_TO the_DT three_CD months_NNS ._.
In_IN addition_NN ,_, the_DT Committee_NNP will_MD have_VB regard_NN to_TO the_DT same_JJ calculation_NN using_VBG an_DT averaging_NN period_NN of_IN six_CD months_NNS as_IN part_NN of_IN a_DT fairness_NN satisfaction_NN of_IN performance_NN targets_NNS ._.
SAR_NNP Awards_NNPS will_MD normally_RB vest_NN three_CD years_NNS after_IN the_DT date_NN of_IN grant_NN ,_, subject_JJ to_TO the_DT satisfaction_NN of_IN review_NN to_TO ensure_VB that_IN vesting_VBG properly_RB reflects_VBZ underlying_VBG performance_NN ._.
performance_NN targets_NNS in_IN the_DT case_NN of_IN executive_NN Directors_NNS ,_, and_CC can_MD be_VB exercised_VBN up_RP until_IN the_DT fifth_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN ._.
If_IN the_DT performance_NN conditions_NNS are_VBP not_RB met_VBN ,_, awards_NNS will_MD lapse_NN ._.
Under_IN Part_NNP B_NNP of_IN the_DT Plan_NN ,_, Performance_NNP Share_NNP PSP_NNP Awards_NNPS can_MD d_SYM The_DT implementation_NN of_IN share_NN ownership_NN guidelines_NNS The_DT Remuneration_NNP Committee_NNP believes_VBZ that_IN executive_NN Directors_NNS and_CC be_VB granted_VBN ._.
A_DT PSP_NNP Award_NNP is_VBZ the_DT right_NN to_TO receive_VB a_DT specified_VBN number_NN of_IN shares_NNS or_CC ADSs_NNS three_CD years_NNS from_IN the_DT date_NN of_IN grant_NN ._.
In_IN the_DT case_NN certain_JJ other_JJ members_NNS of_IN senior_JJ management_NN should_MD be_VB encouraged_VBN to_TO own_VB shares_NNS in_IN the_DT Company_NN in_IN order_NN to_TO ensure_VB the_DT alignment_NN of_IN their_PRP$ of_IN executive_NN Directors_NNS ,_, performance_NN targets_NNS must_MD be_VB satisfied_VBN before_IN a_DT PSP_NNP Award_NNP vests_NNS ._.
Upon_IN vesting_VBG of_IN the_DT PSP_NNP Award_NNP ,_, shares_NNS interests_NNS with_IN those_DT of_IN the_DT Companys_NNP shareholders_NNS ._.
The_DT Committee_NNP discussed_VBD this_DT matter_NN with_IN shareholders_NNS during_IN its_PRP$ consultation_NN process_NN will_MD be_VB released_VBN to_TO the_DT participant_NN automatically_RB without_IN any_DT action_NN on_IN the_DT part_NN of_IN the_DT participant_NN ._.
in_IN 2005_CD ,_, and_CC has_VBZ developed_VBN share_NN ownership_NN guidelines_NNS which_WDT came_VBD into_IN effect_NN in_IN 2006_CD ._.
The_DT Plan_NNP contains_VBZ individual_JJ grant_NN limits_NNS set_VBN at_IN six_CD times_NNS base_JJ salary_NN for_IN SAR_NNP awards_NNS in_IN any_DT one_CD year_NN and_CC four_CD times_NNS base_JJ salary_NN for_IN PSP_NNP awards_NNS in_IN any_DT one_CD year_NN ._.
It_PRP is_VBZ the_DT Companys_NNP intention_NN for_IN awards_NNS granted_VBN under_IN the_DT Plan_NN to_TO executive_JJ Directors_NNS to_TO be_VB comprised_VBN of_IN either_DT or_CC both_DT a_DT SAR_NNP Award_NNP and_CC a_DT PSP_NNP Award_NNP ._.
For_IN 2006_CD ,_, it_PRP is_VBZ the_DT Companys_NNP intention_NN to_TO provide_VB grants_NNS to_TO the_DT Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP with_IN face_NN values_NNS calculated_VBN by_IN reference_NN to_TO the_DT average_JJ share_NN price_NN over_IN the_DT prior_JJ 12-month_JJ calendar_NN period_NN as_IN follows_VBZ :_: 60_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP 61_CD Directors_NNS remuneration_JJ report_NN The_DT Executive_NNP Share_NNP Ownership_NNP Guidelines_NNS are_VBP administered_VBN by_IN the_DT Service_NNP contracts_NNS Remuneration_NNP Committee_NNP and_CC are_VBP based_VBN on_IN the_DT following_VBG principles_NNS :_: The_DT Remuneration_NNP Committee_NNP continues_VBZ to_TO believe_VB that_IN executive_JJ Directors_NNS service_NN contracts_NNS should_MD be_VB for_IN a_DT rolling_JJ term_NN and_CC ,_, for_IN UK_NNP the_DT Committee_NNP believes_VBZ that_IN share_NN ownership_NN is_VBZ an_DT important_JJ contracts_NNS ,_, incorporate_VB notice_NN periods_NNS of_IN 12_CD months_NNS ._.
The_DT Committee_NNP element_NN of_IN an_DT executives_NNS role_NN in_IN running_VBG the_DT Company_NN and_CC also_RB believes_VBZ that_IN the_DT Company_NN should_MD retain_VB the_DT right_NN to_TO make_VB a_DT represents_VBZ both_DT a_DT commitment_NN by_IN the_DT executive_NN as_RB well_RB as_IN an_DT payment_NN in_IN lieu_NN of_IN notice_NN to_TO a_DT Director_NNP ._.
The_DT contracts_NNS contain_VBP obligations_NNS alignment_NN of_IN the_DT executives_NNS interests_NNS with_IN those_DT of_IN shareholders_NNS :_: on_IN the_DT executive_NN Directors_NNS in_IN respect_NN of_IN intellectual_JJ property_NN ,_, together_RB with_IN post-termination_JJ restrictions_NNS ._.
The_DT Committees_NNS view_VBP is_VBZ that_IN ,_, the_DT Committee_NNP believes_VBZ that_IN share_NN ownership_NN by_IN executives_NNS should_MD in_IN the_DT event_NN of_IN early_JJ termination_NN ,_, executive_NN Directors_NNS should_MD be_VB treated_VBN be_VB strongly_RB encouraged_VBN ,_, but_CC not_RB mandated_VBN :_: fairly_RB but_CC paid_VBD no_RB more_JJR than_IN is_VBZ necessary_JJ ._.
Moreover_RB ,_, there_EX should_MD be_VB no_DT element_NN of_IN reward_NN for_IN failure_NN ._.
the_DT Committee_NNP understands_VBZ that_IN ,_, depending_VBG on_IN personal_JJ and_CC other_JJ circumstances_NNS ,_, an_DT executive_NN may_MD not_RB be_VB able_JJ to_TO achieve_VB the_DT desired_VBN The_DT executive_NN Directors_NNS contracts_NNS of_IN employment_NN ,_, which_WDT were_VBD revised_VBN level_NN of_IN share_NN ownership_NN :_: following_VBG consultation_NN with_IN some_DT of_IN the_DT Companys_NNP major_JJ shareholders_NNS in_IN 2003_CD ,_, are_VBP dated_VBN March_NNP 10_CD ,_, 2004_CD in_IN the_DT case_NN of_IN Mr_NNP Russell_NNP and_CC the_DT Committee_NNP believes_VBZ that_IN executives_NNS should_MD understand_VB the_DT March_NNP 12_CD ,_, 2004_CD in_IN the_DT case_NN of_IN Mr_NNP Emmens_NNP ._.
Both_DT agreements_NNS were_VBD importance_NN of_IN share_NN ownership_NN in_IN the_DT stewardship_NN of_IN the_DT Company_NN ,_, revised_VBN on_IN November_NNP 21_CD ,_, 2005_CD to_TO provide_VB for_IN Shire_NNP plc_NN being_VBG and_CC both_DT appropriate_JJ time_NN and_CC latitude_NN will_MD be_VB provided_VBN to_TO executives_NNS established_VBN as_IN the_DT new_JJ holding_VBG company_NN for_IN the_DT Shire_NNP Group_NNP ._.
to_TO achieve_VB desired_VBN share_NN ownership_NN levels_NNS ,_, where_WRB possible_JJ :_: and_CC Mr_NNP Russells_NNPS contract_NN requires_VBZ him_PRP to_TO give_VB the_DT Company_NN 12_CD months_NNS notice_NN and_CC expires_VBZ on_IN him_PRP reaching_VBG 65_CD ._.
Mr_NNP Emmens_NNP contract_NN requires_VBZ share_NN ownership_NN levels_NNS will_MD be_VB reviewed_VBN annually_RB for_IN each_DT executive_NN ._.
him_PRP to_TO give_VB the_DT Company_NN six_CD months_NNS notice_NN and_CC no_DT age_NN is_VBZ specified_VBN for_IN retirement_NN ._.
The_DT Company_NN is_VBZ required_VBN to_TO give_VB Mr_NNP Russell_NNP 12_CD months_NNS Executives_NNS are_VBP encouraged_VBN ,_, within_IN a_DT five-year_JJ period_NN following_VBG the_DT notice_NN of_IN termination_NN ,_, other_JJ than_IN if_IN termination_NN is_VBZ for_IN cause_NN ,_, whereas_IN later_RB of_IN either_CC the_DT initiation_NN of_IN these_DT guidelines_NNS ,_, or_CC their_PRP$ appointment_NN it_PRP is_VBZ not_RB obliged_VBN to_TO give_VB Mr_NNP Emmens_NNP any_DT notice_NN ._.
If_IN Mr_NNP Emmens_NNP contract_NN or_CC election_NN ,_, to_TO attain_VB and_CC hold_VB an_DT investment_NN position_NN no_DT less_JJR than_IN the_DT is_VBZ terminated_VBN without_IN cause_NN the_DT Company_NN is_VBZ required_VBN to_TO pay_VB him_PRP one_CD multiples_NNS of_IN base_NN salary_NN set_VBN forth_RB below_IN ._.
years_NNS salary_NN and_CC the_DT cash_NN equivalent_NN of_IN one_CD years_NNS pension_NN ,_, car_NN and_CC other_JJ contractual_JJ benefits_NNS ._.
The_DT following_VBG are_VBP the_DT guideline_NN share_NN ownership_NN levels_NNS for_IN the_DT executive_NN Directors_NNS :_: In_IN the_DT event_NN of_IN termination_NN of_IN employment_NN within_IN twelve_CD months_NNS of_IN a_DT change_NN of_IN control_NN ,_, the_DT amount_NN payable_JJ in_IN respect_NN of_IN each_DT Chief_NNP Executive_NNP :_: 2_CD x_SYM Base_NNP Salary_NNP of_IN Mr_NNP Emmens_NNP and_CC Mr_NNP Russell_NNP is_VBZ one_CD years_NNS salary_NN and_CC the_DT cash_NN equivalent_NN of_IN one_CD years_NNS pension_NN ,_, car_NN and_CC other_JJ contractual_JJ benefits_NNS ._.
Chief_NNP Financial_NNP Officer_NNP :_: 1.5_CD x_SYM Base_NNP Salary_NNP Any_DT incentive_NN payable_JJ is_VBZ at_IN the_DT discretion_NN of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT contractual_JJ maximum_NN incentive_NN ._.
All_DT shares_NNS beneficially_RB owned_VBN by_IN an_DT executive_NN excluding_VBG unexercised_JJ vested_JJ Stock_NN Options_NNS or_CC SARs_NNS count_VBP towards_IN achieving_VBG these_DT guidelines_NNS ._.
The_DT amount_NN of_IN incentive_NN payable_JJ upon_IN termination_NN of_IN employment_NN in_IN any_DT other_JJ circumstances_NNS ,_, other_JJ than_IN for_IN cause_NN ,_, is_VBZ at_IN the_DT discretion_NN The_DT Remuneration_NNP Committee_NNP will_MD review_VB share_NN ownership_NN levels_NNS for_IN of_IN the_DT Remuneration_NNP Committee_NNP and_CC is_VBZ capped_VBN at_IN the_DT contractual_JJ each_DT executive_NN on_IN an_DT annual_JJ basis_NN ._.
The_DT Committee_NNP will_MD discuss_VB with_IN each_DT target_NN incentive_NN ._.
executive_JJ Director_NNP their_PRP$ plans_NNS for_IN share_NN ownership_NN on_IN a_DT regular_JJ basis_NN :_: the_DT Chief_NNP Executive_NNP Officer_NNP will_MD discuss_VB with_IN each_DT of_IN the_DT remaining_VBG executives_NNS Non-executive_JJ Directors_NNS and_CC the_DT Chairman_NNP their_PRP$ plans_NNS for_IN share_NN ownership_NN on_IN a_DT regular_JJ basis_NN ._.
Each_DT Non-executive_JJ Director_NNP is_VBZ paid_VBN a_DT fee_NN for_IN serving_VBG as_IN a_DT Director_NNP and_CC additional_JJ fees_NNS are_VBP paid_VBN for_IN membership_NN or_CC chairmanship_NN of_IN the_DT 4_CD Pension_NN and_CC other_JJ benefits_NNS Audit_NNP ,_, Remuneration_NNP and_CC Nomination_NNP Committees_NNS ._.
The_DT Chairman_NNP The_NNP Companys_NNPS policy_NN is_VBZ to_TO ensure_VB that_IN pension_NN benefits_NNS are_VBP competitive_JJ of_IN the_DT Company_NN receives_VBZ an_DT inclusive_JJ fee_NN ._.
Fees_NNS are_VBP determined_VBN by_IN the_DT in_IN the_DT markets_NNS in_IN which_WDT Shire_NNP operates_VBZ ._.
Shire_NNP contributes_VBZ 30_CD %_NN of_IN the_DT Chief_NNP Board_NNP ,_, with_IN the_DT exception_NN of_IN the_DT Chairmans_NNPS fee_NN which_WDT is_VBZ determined_VBN Executive_NNP Officers_NNPS annual_JJ salary_NN to_TO a_DT Supplemental_NNP Employee_NNP Retirement_NNP by_IN the_DT Remuneration_NNP Committee_NNP and_CC confirmed_VBN by_IN the_DT Board_NNP ._.
Plan_NNP SERP_NNP and_CC 401_CD k_NN Plan_NN in_IN the_DT US_NNP ._.
The_DT SERP_NNP is_VBZ an_DT unfunded_JJ defined_VBN Fees_NNS are_VBP benchmarked_VBN against_IN Non-executive_JJ Director_NNP fees_NNS of_IN benefit_NN scheme_NN :_: the_DT benefits_NNS are_VBP payable_JJ to_TO certain_JJ senior_JJ US_NNP employees_NNS comparable_JJ companies_NNS ._.
The_DT fees_NNS paid_VBN to_TO Non-executive_JJ Directors_NNS as_IN lump_NN sums_NNS on_IN leaving_VBG the_DT Groups_NNS employment_NN or_CC earlier_JJR due_JJ to_TO death_NN ,_, are_VBP not_RB performance-related_JJ ._.
Details_NNS of_IN fees_NNS paid_VBN to_TO the_DT Chairman_NNP and_CC disability_NN or_CC termination_NN ._.
The_DT amount_NN of_IN benefit_NN is_VBZ based_VBN on_IN the_DT value_NN of_IN Non-executive_JJ Directors_NNS in_IN 2005_CD are_VBP set_VBN out_RP in_IN the_DT table_NN on_IN page_NN 62_CD ._.
notional_JJ contributions_NNS adjusted_VBN for_IN earned_VBN investment_NN returns_NNS as_IN if_IN they_PRP were_VBD invested_VBN in_IN investments_NNS of_IN the_DT employees_NNS choice_NN ._.
The_DT Non-executive_JJ Directors_NNS are_VBP not_RB eligible_JJ to_TO join_VB the_DT Companys_NNPS pension_NN scheme_NN ._.
In_IN the_DT UK_NNP ,_, Shire_NNP operates_VBZ a_DT defined_VBN contribution_NN scheme_NN ._.
The_DT Company_NN contributes_VBZ 25_CD %_NN of_IN salary_NN for_IN the_DT Chief_NNP Financial_NNP Officer_NNP to_TO pension_NN Non-executive_JJ Directors_NNS do_VBP not_RB participate_VB in_IN any_DT of_IN the_DT Company_NN benefits_NNS ._.
The_DT implications_NNS of_IN the_DT forthcoming_JJ UK_NNP pension_NN tax_NN reforms_NNS ,_, share_NN schemes_NNS or_CC other_JJ employee_NN benefit_NN schemes_NNS and_CC no_DT options_NNS which_WDT become_VBP effective_JJ in_IN 2006_CD ,_, will_MD be_VB considered_VBN during_IN the_DT course_NN have_VBP been_VBN granted_VBN to_TO Non-executive_JJ Directors_NNS in_IN their_PRP$ capacity_NN as_IN of_IN the_DT year_NN and_CC the_DT Committee_NNP will_MD agree_VB any_DT policy_NN changes_NNS necessary_JJ Non-executive_JJ Directors_NNS of_IN Shire_NNP ._.
On_IN the_DT merger_NN of_IN Shire_NNP with_IN BioChem_NNP in_IN respect_NN of_IN the_DT pension_NN arrangements_NNS of_IN the_DT Chief_NNP Financial_NNP Officer_NNP Pharma_NNP Inc._NNP in_IN 2001_CD ,_, options_NNS were_VBD granted_VBN to_TO The_DT Hon_NNP James_NNP Grant_NNP and_CC other_JJ UK_NNP executives_NNS ._.
in_IN replacement_NN for_IN Mr_NNP Grants_NNPS BioChem_NNP Pharma_NNP options_NNS ._.
The_DT grant_NN of_IN these_DT replacement_NN options_NNS and_CC the_DT original_JJ BioChem_NNP Pharma_NNP option_NN In_IN addition_NN to_TO salary_NN ,_, the_DT executive_NN Directors_NNS receive_VBP certain_JJ benefits_NNS grant_NN were_VBD made_VBN on_IN the_DT same_JJ terms_NNS as_IN applied_VBN to_TO other_JJ employees_NNS in_IN kind_NN ,_, principally_RB a_DT car_NN or_CC car_NN allowance_NN ,_, life_NN insurance_NN ,_, private_JJ medical_JJ at_IN the_DT time_NN ,_, including_VBG that_IN these_DT options_NNS are_VBP not_RB subject_JJ to_TO any_DT insurance_NN and_CC dental_JJ cover_NN ._.
These_DT benefits_NNS are_VBP not_RB pensionable_JJ ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 61_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 62_CD Directors_NNS remuneration_JJ report_NN Non-executive_JJ Directors_NNS are_VBP appointed_VBN ordinarily_RB for_IN a_DT term_NN of_IN two_CD The_DT three-year_JJ graph_NN tracks_VBZ the_DT TSR_NNP performance_NN since_IN the_DT Company_NN years_NNS ,_, subject_JJ to_TO shareholder_NN approval_NN ._.
Non-executive_JJ Directors_NNS who_WP started_VBD to_TO implement_VB its_PRP$ new_JJ strategic_JJ plan_NN under_IN new_JJ management_NN ._.
have_VB served_VBN on_IN the_DT Board_NNP for_IN nine_CD years_NNS or_CC more_JJR are_VBP appointed_VBN for_IN one_CD year_NN terms_NNS and_CC ,_, in_IN accordance_NN with_IN the_DT Combined_NNP Code_NNP on_IN Corporate_NNP Three-year_JJ historical_JJ TSR_NNP performance_NN ._.
Change_NNP in_IN Governance_NNP ,_, are_VBP subject_JJ to_TO annual_JJ re-election_NN by_IN shareholders_NNS ._.
value_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN over_IN three_CD years_NNS ._.
Re-appointment_NN of_IN Non-executive_JJ Directors_NNS following_VBG the_DT expiry_NN 200_CD of_IN their_PRP$ term_NN of_IN appointment_NN is_VBZ subject_JJ to_TO Board_NNP approval_NN ._.
180_CD Details_NNS of_IN the_DT unexpired_JJ terms_NNS of_IN the_DT letters_NNS of_IN appointment_NN and_CC notice_NN 160_CD periods_NNS are_VBP as_IN follows_VBZ :_: 140_CD Date_NN of_IN Date_NNP of_IN Notice_NNP 120_CD Director_NNP appointment_NN term_NN expiry_JJ period_NN 100_CD Dr_NNP James_NNP Cavanaugh_NNP 24.03.05_CD 23.03.07_CD 3_CD months_NNS 80_CD Dr_NNP Barry_NNP Price_NNP 25.01.06_CD 24.01.07_CD 3_CD months_NNS 60_CD The_DT Hon_NNP James_NNP Grant_NNP 11.05.05_CD 10.05.07_CD 3_CD months_NNS 40_CD Mr_NNP Ronald_NNP Nordmann_NNP 23.12.05_CD 22.12.06_CD 3_CD months_NNS 20_CD Mr_NNP Robin_NNP Buchanan_NNP 30.07.05_CD 29.07.07_CD 3_CD months_NNS 0_CD Mr_NNP David_NNP Kappler_NNP 06.04.04_CD 05.04.06_CD 3_CD months_NNS 31.12.02_CD 31.12.03_CD 31.12.04_CD 31.12.05_CD Mr_NNP Patrick_NNP Langlois_NNP 11.11.05_CD 10.11.07_CD 3_CD months_NNS Shire_NNP TSR_NNP Ex-financials_NNPS FTSE_NNP 100_CD TSR_NNP The_DT fee_NN policy_NN structure_NN for_IN Non-executive_JJ Directors_NNS ,_, effective_JJ January_NNP 1_CD ,_, Comparator_NNP group_NN TSR_NNP 2006_CD ,_, is_VBZ presented_VBN in_IN the_DT table_NN below_IN ._.
Change_NNP in_IN i_FW 2006_CD Board_NNP membership_NN annual_JJ basic_JJ fees_NNS value_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN over_IN five_CD years_NNS ._.
Chairman_NNP of_IN the_DT Board_NNP inclusive_NN of_IN all_DT Committees_NNS 409,725_CD 160_CD Senior_JJ Non-executive_JJ Director_NNP inclusive_NN of_IN NED_NNP fee_NN 81,945_CD Non-executive_JJ Director_NNP 72,840_CD 140_CD Committee_NNP membership_NN fees_NNS 120_CD Audit_NNP Committee_NNP chair_NN 36,420_CD Remuneration_NNP Committee_NNP chair_NN 22,763_CD 100_CD Nomination_NNP Committee_NNP chair_NN 22,763_CD Audit_NNP Committee_NNP member_NN 18,210_CD 80_CD Remuneration_NNP Committee_NNP member_NN 13,658_CD Nomination_NNP Committee_NNP member_NN 9,105_CD 60_CD 40_CD i_FW Denominated_VBN in_IN sterling_NN and_CC translated_VBN into_IN $_$ at_IN the_DT average_JJ exchange_NN rate_NN prevailing_VBG in_IN 2005_CD ._.
20_CD Related_VBN party_NN transactions_NNS 0_CD Details_NNS of_IN transactions_NNS relating_VBG to_TO Dr_NNP James_NNP Cavanaugh_NNP ,_, The_DT Hon_NNP 31.12.00_CD 31.12.01_CD 31.12.02_CD 31.12.03_CD 31.12.04_CD 31.12.05_CD James_NNP Grant_NNP ,_, who_WP is_VBZ a_DT partner_NN of_IN a_DT Canadian_JJ law_NN firm_NN with_IN which_WDT the_DT Company_NN incurred_VBN professional_JJ fees_NNS during_IN the_DT year_NN and_CC with_IN Shire_NNP TSR_NNP Ex-financials_NNPS FTSE_NNP 100_CD TSR_NNP Dr_NNP Francesco_NNP Bellini_NNP ,_, a_DT former_JJ Non-executive_JJ Director_NNP ,_, are_VBP given_VBN Comparator_NNP group_NN TSR_NNP in_IN the_DT Directors_NNS report_VBP on_IN page_NN 114_CD ._.
Performance_NNP graph_NN Other_JJ remuneration_NN The_DT graphs_NNS below_IN set_VBN out_RP the_DT Total_JJ Shareholder_NN Return_NN TSR_NNP for_IN the_DT The_DT Company_NN believes_VBZ there_EX are_VBP benefits_NNS to_TO executive_JJ Directors_NNS three_CD and_CC five_CD years_NNS ending_VBG December_NNP 31_CD ,_, 2005_CD ._.
The_DT graphs_NNS compare_VBP participation_NN at_IN the_DT Board_NNP level_NN at_IN other_JJ companies_NNS ,_, including_VBG crossthe_NN performance_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN of_IN the_DT Companys_NNPS industry_NN and_CC cross-company_NN exposure_NN and_CC the_DT added_VBN perspective_NN shares_NNS with_IN that_DT of_IN a_DT holding_NN of_IN shares_NNS in_IN the_DT FTSE_NNP 100_CD index_NN excluding_VBG of_IN outside_JJ views_NNS ._.
It_PRP is_VBZ therefore_RB the_DT Companys_NNPS policy_NN to_TO allow_VB executive_JJ financial_JJ institutions_NNS and_CC with_IN a_DT holding_NN in_IN a_DT group_NN comprised_VBD of_IN the_DT Directors_NNS to_TO take_VB up_RP Non-executive_JJ positions_NNS at_IN other_JJ companies_NNS and_CC following_VBG pharma_JJ companies_NNS :_: Novo_NNP Nordisk_NNP ,_, Schering_NNP AG_NNP ,_, Serono_NNP ,_, retain_VBP associated_VBN earnings_NNS as_RB long_RB as_IN such_JJ appointments_NNS are_VBP expressly_RB Altana_NNP ,_, UCB_NNP ,_, Lundbeck_NNP ,_, Forest_NNP Labs_NNPS ,_, Allergan_NNP ,_, Sepracor_NNP ,_, Cephalon_NNP ,_, permitted_VBN by_IN the_DT Board_NNP of_IN Directors_NNS ._.
Mr_NNP Emmens_NNP was_VBD appointed_VBN Watson_NNP ,_, Biovail_NNP ,_, King_NNP ,_, Valeant_NNP ,_, Medicis_NNP and_CC Kos_NNP ._.
This_DT comparator_NN as_IN a_DT Non-executive_JJ Director_NNP of_IN Vertex_NNP Pharmaceuticals_NNP Inc_NNP during_IN 2004_CD ._.
group_NN is_VBZ a_DT blend_VB of_IN US_NNP and_CC UK_NNP companies_NNS with_IN sector_NN ,_, size_NN ,_, complexity_NN In_IN this_DT capacity_NN he_PRP was_VBD paid_VBN $_$ 37,917_CD in_IN 2005_CD ,_, which_WDT he_PRP will_MD retain_VB ._.
and_CC international_JJ characteristics_NNS similar_JJ to_TO those_DT of_IN the_DT Company_NN ._.
These_DT comparisons_NNS will_MD also_RB be_VB used_VBN to_TO determine_VB achievement_NN Mr_NNP Russell_NNP is_VBZ a_DT Non-executive_JJ Director_NNP of_IN The_NNP City_NNP of_IN London_NNP of_IN performance_NN conditions_NNS relating_VBG to_TO the_DT Annual_JJ Incentive_NNP Plan_NNP and_CC Investment_NNP Trust_NNP plc_NN and_CC its_PRP$ associated_VBN companies_NNS ,_, The_DT City_NNP of_IN London_NNP Portfolio_NNP Share_NNP Plan_NNP ._.
European_NNP Trust_NNP Limited_NNP ,_, The_NNP City_NNP of_IN London_NNP Investments_NNPS Limited_NNP and_CC The_NNP City_NNP of_IN London_NNP Finance_NNP Company_NNP Limited_NNP ._.
In_IN this_DT capacity_NN ,_, he_PRP was_VBD paid_VBN 17,500_CD $_$ 31,868_CD equivalent_NN in_IN 2005_CD ,_, which_WDT he_PRP will_MD retain_VB ._.
62_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN Value_NN of_IN hypothetical_JJ 100_CD holding_VBG Value_NN of_IN hypothetical_JJ 100_CD holding_VBG 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 63_CD Directors_NNS remuneration_JJ report_NN Audited_VBN information_NN Aggregate_NNP Directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Emoluments_NNP 4,289_CD 4,751_CD Money_NN purchase_NN pension_NN contributions_NNS 488_CD 450_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 194_CD 216_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 159_CD Compensation_NNP for_IN loss_NN of_IN office_NN 4,971_CD 5,576_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ benefits_NNS benefits_NNS Total_JJ Total_JJ Salary_NNP Incentive_NNP Fees_NNS in_IN kind_NN in_IN kind_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Executive_NNP i_FW v_FW Mr_NNP Matthew_NNP Emmens_NNP 1,049_CD 1,208_CD 29_CD 2,286_CD 2,601_CD ii_FW Mr_NNP Angus_NNP Russell_NNP 652_CD 415_CD 26_CD 10_CD 1,103_CD 1,126_CD ii_FW vi_FW Dr_FW Wilson_NNP Totten_NNP 469_CD Total_JJ executive_NN 1,701_CD 1,623_CD 55_CD 10_CD 3,389_CD 4,196_CD Non-executive_JJ i_FW Dr_FW James_NNP Cavanaugh_NNP 364 364 137_CD iii_FW Dr_FW Barry_NNP Price_NNP 132 132 110_CD i_FW The_DT Hon_NNP James_NNP Grant_NNP 82_CD 82_CD 73_CD i_FW Mr_NNP Ronald_NNP Nordmann_NNP 114_CD 114_CD 99_CD iii_NN Mr_NNP Robin_NNP Buchanan_NNP 87_CD 87_CD 73_CD iii_NN Mr_NNP David_NNP Kappler_NNP 109_CD 109_CD 63_CD iv_NN vii_FW Mr_NNP Patrick_NNP Langlois_NNP 12_CD 12_CD Total_JJ Non-executive_JJ 900 900 555_CD Total_JJ 1,701_CD 1,623_CD 900_CD 55_CD 10_CD 4,289_CD 4,751_CD Notes_NNP i_FW Paid_NNP in_IN $_$ ._.
ii_FW Salary_FW and_CC benefits_NNS in_IN kind_NN paid_VBN in_IN Sterling_NNP and_CC translated_VBN into_IN $_$ at_IN the_DT average_JJ exchange_NN rates_NNS for_IN the_DT year_NN ._.
Incentive_JJ payable_JJ in_IN Sterling_NNP and_CC translated_VBN at_IN the_DT exchange_NN rate_NN at_IN end_NN February_NNP 2006_CD ._.
iii_FW Fees_NNS paid_VBN in_IN Sterling_NNP and_CC translated_VBN into_IN $_$ at_IN the_DT average_JJ exchange_NN rates_NNS for_IN the_DT year_NN ._.
iv_NN Paid_VBN in_IN Euros_NNP and_CC translated_VBN into_IN $_$ at_IN the_DT average_JJ exchange_NN rate_NN for_IN the_DT service_NN period_NN ._.
v_FW The_DT Company_NN underwent_VBD a_DT major_JJ internal_JJ reorganization_NN in_IN 2004_CD ,_, which_WDT resulted_VBD in_IN the_DT Company_NN selecting_VBG Philadelphia_NNP as_IN its_PRP$ US_NNP corporate_JJ headquarters_NNS ._.
Mr_NNP Emmens_NNP was_VBD paid_VBN $_$ 770,000_CD in_IN connection_NN with_IN costs_NNS associated_VBN with_IN his_PRP$ relocation_NN to_TO the_DT Philadelphia_NNP area_NN ._.
vi_FW Dr_FW Totten_FW stepped_VBD down_RP as_IN a_DT Director_NNP of_IN the_DT Company_NN on_IN May_NNP 25_CD ,_, 2004_CD ._.
vii_FW Mr_NNP Langlois_NNP was_VBD appointed_VBN a_DT Non-executive_JJ Director_NNP on_IN November_NNP 11_CD ,_, 2005_CD ._.
Cash_NN benefits_NNS in_IN kind_NN represent_VBP expense_NN allowances_NNS including_VBG dental_JJ costs_NNS ._.
Non-cash_JJ benefits_NNS in_IN kind_NN consist_VBP of_IN private_JJ medical_JJ insurance_NN ._.
Details_NNS of_IN the_DT exercise_NN of_IN share_NN options_NNS are_VBP disclosed_VBN on_IN page_NN 64_CD ._.
Non-executive_JJ Director_NNP remuneration_NN is_VBZ to_TO from_IN the_DT date_NN of_IN resignation_NN appointment_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 63_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 64_CD Directors_NNS remuneration_JJ report_NN Directors_NNS pension_NN entitlements_NNS The_DT following_JJ Directors_NNS are_VBP members_NNS of_IN money_NN purchase_NN schemes_NNS ._.
Contributions_NNS made_VBN by_IN the_DT Company_NN not_RB included_VBD in_IN emoluments_NNS above_IN in_IN respect_NN of_IN 2005_CD were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD Name_NN of_IN Director_NNP $_$ 000_CD $_$ 000_CD Mr_NNP Matthew_NNP Emmens_NNP 323_CD 227_CD i_FW Mr_NNP Angus_NNP Russell_NNP 165_CD 157_CD Dr_NNP Wilson_NNP Totten_NNP stepped_VBD down_RP as_IN a_DT Director_NNP on_IN May_NNP 25_CD ,_, 2004 66 488 450_CD i_FW At_IN Mr_NNP Russells_NNP request_NN the_DT Company_NN deferred_VBN $_$ 59,000_CD of_IN pension_NN contributions_NNS earned_VBN in_IN 2005_CD ,_, to_TO be_VB paid_VBN in_IN 2006_CD ._.
Directors_NNS shareholdings_NNS Directors_NNS who_WP held_VBD office_NN at_IN the_DT end_NN of_IN the_DT year_NN had_VBD interests_NNS in_IN the_DT share_NN capital_NN of_IN the_DT Company_NN as_IN follows_VBZ all_DT interests_NNS are_VBP beneficial_JJ :_: 2005_CD 2004_CD Number_NN of_IN Number_NN of_IN Name_NN of_IN Director_NNP ordinary_JJ shares_NNS ordinary_JJ shares_NNS Dr_NNP James_NNP Cavanaugh_NNP 412,849_CD 412,849_CD Mr_NNP Matthew_NNP Emmens_NNP 18,938_CD Mr_NNP Angus_NNP Russell_NNP 1,882_CD Dr_NNP Barry_NNP Price_NNP 31,350_CD 31,350_CD The_DT Hon_NNP James_NNP Grant_NNP 68,269_CD 36,410_CD Mr_NNP Ronald_NNP Nordmann_NNP 46,966_CD 46,966_CD Mr_NNP Robin_NNP Buchanan_NNP 7,500_CD Mr_NNP David_NNP Kappler_NNP 5,000_CD 5,000_CD Mr_NNP Patrick_NNP Langlois_NNP Directors_NNS share_VBP options_NNS Aggregate_JJ emoluments_NNS disclosed_VBN above_IN do_VBP not_RB include_VB any_DT amounts_NNS for_IN the_DT value_NN of_IN options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN the_DT Company_NN granted_VBN to_TO or_CC held_VBN by_IN the_DT Directors_NNS ._.
Directors_NNS and_CC employees_NNS have_VBP been_VBN granted_VBN options_NNS over_IN ordinary_JJ shares_NNS under_IN the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP 2000_CD Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Holdings_NNP Limited_NNP Share_NNP Option_NN Scheme_NN SHL_NNP Scheme_NNP ,_, the_DT Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP ,_, the_DT Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP ,_, the_DT Roberts_NNP Stock_NNP Option_NN Plan_NNP Roberts_NNP Plan_NNP and_CC the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP ._.
Details_NNS of_IN options_NNS exercised_VBN during_IN the_DT year_NN with_IN prior-year_JJ comparatives_NNS are_VBP as_IN follows_VBZ :_: Gains_NNS on_IN Gains_NNS on_IN Exercise_NNP Market_NNP price_NN at_IN exercise_NN exercise_NN Number_NN of_IN price_NN exercise_NN date_NN 2005_CD 2004_CD Director_NNP Scheme_NNP options_NNS $_$ 000_CD $_$ 000_CD The_DT Hon_NNP James_NNP Grant_NNP BioChem_NNP Plan_NNP 31,859_CD 1.2400_CD 4.9950_CD 216_CD 31,859_CD 2.5000_CD 5.5850_CD 176 176 216_CD Mr_NNP Matthew_NNP Emmens_NNP Stock_NNP Purchase_NNP Plan_NNP 1,928_CD 4.0900_CD 7.2000_CD 11_CD Mr_NNP Angus_NNP Russell_NNP Sharesave_NNP Plan_NNP 1,882_CD 5.020_CD 7.0400_CD 7_CD 64_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 65_CD Directors_NNS remuneration_JJ report_NN Details_NNS of_IN options_NNS exercised_VBN after_IN ceasing_VBG to_TO be_VB a_DT Director_NNP are_VBP as_IN follows_VBZ :_: Gains_NNS on_IN Gains_NNS on_IN Exercise_NNP Market_NNP price_NN at_IN exercise_NN exercise_NN Number_NN of_IN price_NN exercise_NN date_NN 2005_CD 2004_CD Director_NNP Scheme_NNP options_NNS $_$ 000_CD $_$ 000_CD Dr_NNP Wilson_NNP Totten_NNP Executive_NNP Scheme_NNP B_NNP 141,138_CD 3.3850_CD 5.2000_CD 469_CD 301,775_CD 3.3800_CD 5.1592_CD 984_CD 8,862_CD 3.3850_CD 6.3500_CD 47_CD 25,000_CD 4.7050_CD 6.3500_CD 75_CD 2000_CD Executive_NNP Scheme_NNP B_NNP 122,368_CD 5.0650_CD 6.3500_CD 286_CD 203,612_CD 5.2600_CD 6.3500_CD 404_CD 812_CD 1,453_CD i_FW Mr_NNP Rolf_NNP Stahel_NNP Executive_NNP Scheme_NNP B_NNP 81,918_CD 3.3850_CD 6.4200_CD 476_CD i_FW On_IN November_NNP 23_CD ,_, 2005_CD a_DT gross_JJ payment_NN of_IN $_$ 482,103_CD paid_VBN in_IN Sterling_NNP and_CC translated_VBN into_IN $_$ at_IN the_DT average_JJ exchange_NN rate_NN in_IN November_NNP 2005_CD was_VBD made_VBN to_TO Mr_NNP Rolf_NNP Stahel_NNP in_IN connection_NN with_IN a_DT share_NN option_NN that_WDT was_VBD inadvertently_RB allowed_VBN to_TO lapse_NN ._.
The_DT option_NN was_VBD granted_VBN on_IN March_NNP 4_CD ,_, 2002_CD over_IN 209,211_CD shares_NNS with_IN an_DT exercise_NN price_NN of_IN 5.065_CD per_IN share_NN ._.
The_DT payment_NN ,_, which_WDT was_VBD subject_JJ to_TO tax_NN and_CC non-pensionable_JJ ,_, was_VBD intended_VBN to_TO put_VB Mr_NNP Stahel_NNP in_IN the_DT same_JJ position_NN as_IN if_IN he_PRP had_VBD exercised_VBN the_DT option_NN and_CC subsequently_RB sold_VBD the_DT shares_NNS on_IN the_DT day_NN on_IN which_WDT he_PRP notified_VBD the_DT Company_NN of_IN his_PRP$ desire_NN to_TO exercise_VB the_DT option_NN ._.
Following_VBG the_DT implementation_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN ,_, on_IN November_NNP 25_CD ,_, 2005_CD ,_, all_DT existing_VBG options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Old_NNP Options_NNPS were_VBD swapped_VBN for_IN new_JJ equivalent_JJ options_NNS to_TO acquire_VB ordinary_JJ shares_NNS in_IN Shire_NNP plc_NNP New_NNP Options_NNPS ._.
Any_DT performance_NN conditions_NNS attached_VBN to_TO the_DT Old_NNP Options_NNPS continue_VBP to_TO apply_VB to_TO the_DT New_NNP Options_NNPS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 65_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 66_CD Directors_NNS remuneration_JJ report_NN Notes_NNS i_FW Options_NNPS granted_VBN under_IN this_DT scheme_NN are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN Shires_NNP share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three_CD years_NNS ,_, they_PRP are_VBP thereafter_RB tested_VBN quarterly_JJ by_IN reference_NN to_TO share_VB price_NN growth_NN over_IN the_DT extended_JJ period_NN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS granted_VBN become_VBN exercisable_JJ ._.
On_IN February_NNP 28_CD ,_, 2000_CD ,_, the_DT Remuneration_NNP Committee_NNP of_IN the_DT Board_NNP exercised_VBD its_PRP$ powers_NNS to_TO amend_VB the_DT terms_NNS of_IN the_DT Executive_NNP Share_NNP Option_NN Scheme_NN so_RB as_IN to_TO include_VB a_DT cliff_NN vesting_VBG provision_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT Executive_NNP Scheme_NNP ._.
ii_FW Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
Employees_NNS may_MD enter_VB into_IN three_CD or_CC five-year_JJ savings_NNS contracts_NNS ._.
iii_FW Options_NNPS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT option_NN granted_VBN prior_RB to_TO August_NNP 2002_CD ,_, if_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, the_DT option_NN becomes_VBZ exercisable_JJ in_IN full_JJ ._.
If_IN it_PRP increases_VBZ by_IN at_IN least_JJS 14.5_CD %_NN per_IN annum_NN over_IN the_DT same_JJ three-year_JJ period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS granted_VBN become_VBN exercisable_JJ ._.
If_IN these_DT conditions_NNS are_VBP not_RB met_VBN after_IN the_DT initial_JJ three-year_JJ measurement_NN period_NN ,_, they_PRP will_MD thereafter_RB be_VB tested_VBN quarterly_JJ by_IN reference_NN to_TO compound_VB annual_JJ share_NN price_NN growth_NN over_IN an_DT extended_JJ period_NN ._.
The_DT performance_NN criteria_NNS were_VBD reviewed_VBN in_IN 2002_CD to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT Shire_NNP operates_VBZ ._.
Given_VBN Shires_NNPS development_NN ,_, it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT EPS-based_JJ measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
The_DT performance_NN criteria_NNS are_VBP based_VBN on_IN real_JJ growth_NN in_IN the_DT diluted_JJ earnings_NNS per_IN share_NN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ,_, adjusted_VBN to_TO ensure_VB a_DT consistent_JJ basis_NN of_IN measurement_NN ,_, as_IN approved_VBN by_IN the_DT Remuneration_NNP Committee_NNP ,_, including_VBG the_DT add_VB back_RB of_IN significant_JJ one-time_JJ items_NNS option_NN EPS_NNP ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS were_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP option_NN EPS_NNP growth_NN over_IN a_DT three-year_JJ period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP RPI_NNP for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN Directors_NNS ,_, RPI_NNP plus_CC 15_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 15_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 21_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 27_CD %_NN The_DT new_JJ EPS_NNP performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
After_IN consultation_NN with_IN certain_JJ of_IN its_PRP$ institutional_JJ shareholders_NNS ,_, the_DT Company_NN has_VBZ decided_VBN that_IN for_IN options_NNS granted_VBN under_IN the_DT scheme_NN from_IN 2004_CD onwards_NNS ,_, the_DT retest_NN of_IN the_DT performance_NN condition_NN if_IN Shires_NNP option_NN EPS_NNP growth_NN has_VBZ fallen_VBN short_JJ of_IN the_DT minimum_JJ annual_JJ average_JJ percentage_NN increase_NN over_IN the_DT three-year_JJ period_NN from_IN grant_NN ,_, has_VBZ been_VBN changed_VBN ._.
The_DT performance_NN condition_NN will_MD be_VB retested_VBN once_RB only_RB ,_, at_IN five_CD years_NNS after_IN the_DT grant_NN ._.
Hence_RB the_DT level_NN of_IN option_NN EPS_NNP growth_NN in_IN the_DT next_JJ two_CD years_NNS needs_VBZ to_TO be_VB consequentially_RB higher_JJR to_TO meet_VB the_DT test_NN ._.
Six_CD weeks_NNS prior_RB to_TO the_DT expiration_NN date_NN ,_, any_DT options_NNS that_WDT have_VBP not_RB become_VB exercisable_JJ at_IN an_DT earlier_JJR date_NN ,_, automatically_RB vest_NN without_IN reference_NN to_TO the_DT performance_NN criteria_NNS ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
iv_NN Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP on_IN May_NNP 11_CD ,_, 2001_CD ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChem_NNP Pharma_NNP Inc._NNP s_VBZ common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
All_DT BioChem_NNP Pharma_NNP Inc._NNP options_NNS ,_, which_WDT were_VBD not_RB already_RB exercisable_JJ ,_, vested_JJ and_CC became_VBD exercisable_JJ as_IN a_DT result_NN of_IN the_DT acquisition_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN ._.
v_FW Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
The_DT offering_NN period_NN is_VBZ for_IN 27_CD months_NNS ._.
The_DT market_NN price_NN of_IN the_DT ordinary_JJ shares_NNS at_IN December_NNP 31_CD ,_, 2005_CD was_VBD 7.44_CD and_CC the_DT range_NN during_IN the_DT year_NN was_VBD 5.39_CD to_TO 7.53_CD ._.
Long-term_JJ Incentive_NNP Plan_NNP LTIP_NNP The_NNP following_VBG award_NN ,_, granted_VBN under_IN the_DT Long-term_JJ Incentive_NNP Plan_NNP lapsed_VBD during_IN the_DT year_NN 2005_CD and_CC no_DT payment_NN was_VBD made_VBN under_IN it_PRP as_IN the_DT performance_NN criteria_NNS was_VBD not_RB met_VBN at_IN the_DT maturity_NN date_NN :_: Actual_NNP Initial_JJ award_NN performanceDate_NNP of_IN Director_NNP Date_NNP of_IN award_NN made_VBN related_JJ award_NN maturity_NN i_FW Mr_NNP Angus_NNP Russell_NNP 05.06.01_CD 11,535_CD 06.06.05_CD i_FW The_DT performance_NN criteria_NNS attaching_VBG to_TO awards_NNS made_VBN under_IN the_DT Long-term_JJ Incentive_NNP Plan_NNP are_VBP detailed_VBN on_IN page_NN 59_CD ._.
Performance_NNP conditions_NNS attaching_VBG to_TO awards_NNS made_VBN under_IN the_DT Long-term_JJ Incentive_NNP Plan_NNP are_VBP detailed_VBN on_IN page_NN 59_CD ._.
Following_VBG the_DT implementation_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN ,_, on_IN November_NNP 25_CD ,_, 2005_CD ,_, all_DT awards_NNS over_IN ordinary_JJ shares_NNS in_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NNP Old_NNP Awards_NNPS were_VBD swapped_VBN for_IN new_JJ equivalent_JJ awards_NNS over_IN ordinary_JJ shares_NNS in_IN Shire_NNP plc_NNP New_NNP Awards_NNP ._.
Any_DT performance_NN conditions_NNS attached_VBN to_TO the_DT Old_NNP Awards_NNPS continue_VBP to_TO apply_VB to_TO the_DT New_NNP Awards_NNP ._.
Portfolio_NNP Share_NNP Plan_NNP PSP_NNP The_NNP Shire_NNP plc_NN PSP_NNP was_VBD adopted_VBN at_IN the_DT Companys_NNP Extraordinary_JJ General_NNP Meeting_VBG held_VBN on_IN October_NNP 28_CD ,_, 2005_CD ._.
No_DT awards_NNS ,_, under_IN the_DT PSP_NNP ,_, were_VBD made_VBN to_TO executive_JJ Directors_NNS in_IN 2005_CD ._.
Approval_NN This_DT report_NN was_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS on_IN February_NNP 22_CD ,_, 2006_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: Dr_NNP Barry_NNP Price_NNP Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 67_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 68_CD Audit_NNP Committee_NNP report_NN Membership_NN review_NN at_IN least_JJS annually_RB the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ The_DT members_NNS of_IN the_DT Committee_NNP as_IN at_IN December_NNP 31_CD ,_, 2005_CD were_VBD control_NN system_NN in_IN the_DT overall_JJ context_NN of_IN the_DT Companys_NNPS risk_NN David_NNP Kappler_NNP Chairman_NNP ,_, Barry_NNP Price_NNP ,_, Ronald_NNP Nordmann_NNP and_CC Patrick_NNP management_NN system_NN :_: Langlois_NNP ._.
Mr_NNP Kappler_NNP ,_, Dr_NNP Price_NNP and_CC Mr_NNP Nordmann_NNP served_VBD as_IN members_NNS of_IN the_DT Committee_NNP throughout_IN 2005_CD and_CC Mr_NNP Langlois_NNP became_VBD a_DT member_NN oversee_VBP the_DT Companys_NNPS anti-fraud_JJ programs_NNS and_CC controls_NNS of_IN the_DT Committee_NNP upon_IN his_PRP$ appointment_NN to_TO the_DT Board_NNP in_IN November_NNP and_CC to_TO oversee_VB the_DT investigation_NN and_CC remediation_NN of_IN any_DT alleged_JJ 2005_CD ._.
Each_DT of_IN the_DT members_NNS of_IN the_DT Committee_NNP has_VBZ been_VBN determined_VBN or_CC suspected_VBN fraud_NN :_: by_IN Shires_NNP Board_NNP to_TO be_VB an_DT Independent_JJ Non-executive_JJ Director_NNP for_IN the_DT purposes_NNS of_IN The_DT UK_NNP Combined_NNP Code_NNP on_IN Corporate_NNP Governance_NNP monitor_NN and_CC review_VB the_DT internal_JJ operational_JJ audit_NN program_NN ,_, the_DT Combined_NNP Code_NNP ._.
Each_DT member_NN also_RB satisfies_VBZ the_DT NASDAQ_NNP consider_VB the_DT findings_NNS of_IN internal_JJ operational_JJ audit_NN reviews_NNS and_CC rules_NNS regarding_VBG the_DT independence_NN of_IN members_NNS of_IN the_DT Audit_NNP Committee_NNP ._.
managements_NNS response_NN to_TO them_PRP :_: and_CC Mr_NNP David_NNP Kappler_NNP chairs_VBZ the_DT Committee_NNP ._.
The_DT Board_NNP is_VBZ satisfied_VBN that_IN review_NN compliance_NN with_IN treasury_NN policy_NN ._.
Mr_NNP Kappler_NNP ,_, in_IN his_PRP$ capacity_NN as_IN Chairman_NNP of_IN the_DT Committee_NNP ,_, has_VBZ recent_JJ and_CC relevant_JJ financial_JJ experience_NN ._.
The_DT Board_NNP has_VBZ determined_VBN that_IN The_DT Committee_NNP reports_NNS to_TO the_DT Board_NNP on_IN any_DT matter_NN on_IN which_WDT Mr_NNP Kappler_NNP is_VBZ the_DT Committees_NNS financial_JJ expert_NN for_IN the_DT purposes_NNS of_IN the_DT it_PRP considers_VBZ that_IN action_NN is_VBZ required_VBN and_CC makes_VBZ recommendations_NNS Sarbanes-Oxley_NNP Act_NNP 2002_CD ._.
Mr_NNP Kappler_NNP was_VBD a_DT Director_NNP of_IN Camelot_NNP for_IN steps_NNS to_TO be_VB taken_VBN ._.
The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Committee_NNP Group_NNP plc_NN from_IN 1996_CD to_TO 2002_CD and_CC he_PRP serves_VBZ as_IN a_DT Non-executive_JJ Director_NNP give_VBP it_PRP authority_NN to_TO investigate_VB any_DT activity_NN within_IN its_PRP$ Terms_NNS of_IN Reference_NNP at_IN HMV_NNP Group_NNP plc_NN and_CC Intercontinental_NNP Hotels_NNPS Group_NNP plc._NN ._.
Additionally_RB ,_, and_CC to_TO be_VB responsible_JJ for_IN the_DT resolution_NN of_IN disagreements_NNS between_IN he_PRP is_VBZ Non-executive_JJ Chairman_NNP at_IN Premier_NNP Foods_NNP plc._NN ._.
Mr_NNP Kappler_NNP management_NN and_CC the_DT auditor_NN regarding_VBG the_DT Companys_NNPS financial_JJ is_VBZ a_DT fellow_NN of_IN the_DT Chartered_NNP Institute_NNP of_IN Management_NNP Accountants_NNPS ._.
The_DT Committee_NNP is_VBZ also_RB authorized_VBN to_TO seek_VB any_DT information_NN it_PRP requires_VBZ from_IN any_DT employee_NN of_IN the_DT Company_NN in_IN order_NN to_TO perform_VB The_DT members_NNS of_IN the_DT Committee_NNP are_VBP chosen_VBN from_IN amongst_IN the_DT its_PRP$ duties_NNS and_CC to_TO call_VB any_DT employee_NN to_TO be_VB questioned_VBN at_IN a_DT meeting_NN Non-executive_JJ Directors_NNS of_IN the_DT Company_NN who_WP are_VBP independent_JJ for_IN the_DT of_IN the_DT Committee_NNP ._.
purposes_NNS of_IN the_DT Combined_NNP Code_NNP and_CC the_DT NASDAQ_NNP rules_NNS and_CC are_VBP selected_VBN on_IN the_DT basis_NN of_IN their_PRP$ knowledge_NN and_CC experience_NN of_IN financial_JJ matters_NNS and_CC The_DT Committee_NNP met_VBD on_IN six_CD occasions_NNS in_IN 2005_CD ._.
Each_DT meeting_NN was_VBD financial_JJ reporting_NN ._.
Committee_NNP members_NNS hold_VBP office_NN for_IN an_DT initial_JJ period_NN attended_VBN by_IN all_DT members_NNS of_IN the_DT Committee_NNP ._.
At_IN the_DT invitation_NN of_IN the_DT of_IN two_CD years_NNS ,_, subject_JJ to_TO continuing_VBG as_IN a_DT Director_NNP of_IN the_DT Company_NN ._.
Chairman_NNP ,_, the_DT Chief_NNP Executive_NNP Officer_NNP ,_, the_DT Chief_NNP Financial_NNP Officer_NNP Thereafter_RB ,_, they_PRP may_MD hold_VB office_NN for_IN such_JJ duration_NN as_IN determined_VBN by_IN the_DT and_CC the_DT Group_NNP Financial_NNP Controller_NNP attended_VBD all_DT of_IN the_DT Committees_NNS Board_NNP ._.
Details_NNS of_IN the_DT fees_NNS paid_VBN to_TO members_NNS of_IN the_DT Committee_NNP are_VBP set_VBN meetings_NNS in_IN 2005_CD ._.
In_IN addition_NN ,_, at_IN the_DT invitation_NN of_IN the_DT Chairman_NNP ,_, the_DT out_RP in_IN the_DT Directors_NNS remuneration_NN report_NN on_IN page_NN 62_CD ._.
Chief_NNP Risk_NNP Officer_NNP and_CC Head_NNP of_IN Internal_NNP Audit_NNP attended_VBD each_DT of_IN the_DT four_CD quarterly_JJ meetings_NNS at_IN which_WDT risk_NN management_NN systems_NNS and_CC internal_JJ Role_NN of_IN Committee_NNP audit_NN programs_NNS were_VBD reviewed_VBN ._.
The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Committee_NNP have_VBP been_VBN approved_VBN by_IN the_DT Board_NNP and_CC are_VBP available_JJ for_IN review_NN on_IN Shires_NNP website_NN ._.
The_DT key_JJ In_IN accordance_NN with_IN its_PRP$ Terms_NNS of_IN Reference_NNP ,_, the_DT Committee_NNP held_VBD a_DT functions_NNS of_IN the_DT Committee_NNP under_IN its_PRP$ Terms_NNS of_IN Reference_NNP are_VBP to_TO :_: number_NN of_IN private_JJ meetings_NNS with_IN the_DT lead_NN partner_NN from_IN the_DT Companys_NNP external_JJ auditors_NNS and_CC the_DT Companys_NNP Chief_NNP Internal_NNP Auditor_NNP during_IN monitor_NN the_DT integrity_NN of_IN the_DT financial_JJ statements_NNS of_IN the_DT Company_NN ,_, the_DT course_NN of_IN the_DT year_NN without_IN any_DT Executive_NNP member_NN of_IN the_DT Board_NNP including_VBG its_PRP$ annual_JJ and_CC quarterly_JJ reports_NNS ,_, preliminary_JJ results_NNS in_IN attendance_NN ._.
The_DT purpose_NN of_IN these_DT meetings_NNS was_VBD to_TO facilitate_VB free_JJ announcements_NNS and_CC any_DT other_JJ corporate_JJ announcement_NN relating_VBG and_CC open_JJ discussions_NNS between_IN the_DT Audit_NNP Committee_NNP members_NNS and_CC to_TO the_DT Companys_NNPS financial_JJ performance_NN :_: the_DT Chief_NNP Internal_NNP Auditor_NNP and_CC the_DT external_JJ lead_NN audit_NN partner_NN separately_RB from_IN the_DT main_JJ sessions_NNS of_IN the_DT Audit_NNP Committee_NNP which_WDT were_VBD attended_VBN ensure_VB clarity_NN of_IN disclosure_NN in_IN financial_JJ reporting_NN and_CC the_DT presentation_NN by_IN the_DT Chief_NNP Financial_NNP Officer_NNP and_CC the_DT Group_NNP Financial_NNP Controller_NNP ._.
of_IN a_DT balanced_JJ and_CC understandable_JJ assessment_NN of_IN the_DT Companys_NNPS financial_JJ position_NN :_: Approval_NN of_IN audit_NN and_CC non-audit_JJ services_NNS provided_VBN by_IN auditor_NN The_DT Committee_NNP has_VBZ adopted_VBN formal_JJ policies_NNS and_CC procedures_NNS in_IN relation_NN have_VBP the_DT primary_JJ responsibility_NN for_IN making_VBG a_DT recommendation_NN to_TO the_DT provision_NN of_IN audit_NN and_CC non-audit_JJ services_NNS by_IN the_DT external_JJ auditor_NN ,_, to_TO be_VB put_VBN to_TO shareholders_NNS for_IN approval_NN at_IN the_DT Annual_JJ General_NNP which_WDT were_VBD most_RBS recently_RB revised_VBN in_IN February_NNP 2006_CD ._.
The_DT principal_JJ Meeting_VBG in_IN relation_NN to_TO the_DT appointment_NN ,_, re-appointment_NN ,_, removal_NN purpose_NN of_IN these_DT policies_NNS and_CC procedures_NNS is_VBZ to_TO ensure_VB that_IN the_DT and_CC remuneration_NN of_IN the_DT external_JJ auditor_NN and_CC to_TO assess_VB ,_, at_IN least_JJS independence_NN of_IN the_DT external_JJ auditor_NN is_VBZ not_RB impaired_VBN ._.
annually_RB ,_, the_DT objectivity_NN and_CC independence_NN of_IN the_DT external_JJ auditor_NN :_: The_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD and_CC accordingly_RB the_DT Committees_NNS policy_NN review_NN and_CC discuss_VB issues_NNS and_CC recommendations_NNS arising_VBG from_IN prohibits_VBZ the_DT provision_NN of_IN certain_JJ non-audit_JJ services_NNS to_TO the_DT Company_NN the_DT external_JJ audit_NN ,_, and_CC any_DT matters_NNS the_DT external_JJ auditor_NN may_MD wish_VB by_IN the_DT external_JJ auditor_NN ,_, including_VBG :_: to_TO discuss_VB :_: bookkeeping_NN or_CC other_JJ services_NNS related_VBN to_TO the_DT accounting_NN records_NNS set_VBN and_CC apply_VB a_DT formal_JJ policy_NN in_IN relation_NN to_TO the_DT provision_NN of_IN non-audit_JJ or_CC financial_JJ statements_NNS of_IN the_DT Company_NN :_: services_NNS by_IN the_DT external_JJ auditor_NN with_IN a_DT view_NN to_TO preserving_VBG the_DT external_JJ auditors_NNS independence_NN and_CC objectivity_NN :_: design_NN and_CC implementation_NN of_IN financial_JJ information_NN systems_NNS :_: establish_VB procedures_NNS for_IN the_DT receipt_NN ,_, retention_NN and_CC treatment_NN appraisal_NN or_CC valuation_NN services_NNS ,_, fairness_NN opinions_NNS or_CC contributionof_NN complaints_NNS received_VBN by_IN the_DT Company_NN regarding_VBG accounting_NN ,_, in-kind_JJ reports_NNS :_: and_CC internal_JJ accounting_NN controls_NNS or_CC auditing_NN matters_NNS :_: actuarial_JJ or_CC internal_JJ audit_NN outsourcing_VBG services_NNS ._.
68_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 69_CD Audit_NNP Committee_NNP report_NN Other_JJ types_NNS of_IN audit_NN and_CC non-audit_JJ services_NNS may_MD be_VB performed_VBN 2_CD Internal_NNP financial_JJ control_NN and_CC risk_NN management_NN systems_NNS by_IN the_DT external_JJ auditor_NN if_IN the_DT work_NN is_VBZ either_DT specifically_RB pre-approved_JJ the_DT Companys_NNPS risk_NN management_NN strategy_NN ,_, its_PRP$ internal_JJ audit_NN strategy_NN ,_, by_IN the_DT Committee_NNP or_CC the_DT work_NN falls_VBZ within_IN the_DT Committees_NNS schedule_VBP its_PRP$ plan_NN and_CC progress_NN in_IN complying_VBG with_IN Section_NN 404_CD of_IN the_DT of_IN pre-approved_JJ services_NNS ._.
The_DT Committees_NNS pre-approval_JJ policy_NN covers_VBZ Sarbanes-Oxley_NNP Act_NNP 2002_CD and_CC the_DT effectiveness_NN of_IN the_DT Companys_NNP three_CD categories_NNS of_IN work_NN audit_NN services_NNS ,_, audit-related_JJ services_NNS and_CC tax_NN system_NN of_IN internal_JJ control_NN during_IN the_DT year_NN :_: services_NNS ._.
If_IN the_DT proposed_VBN services_NNS to_TO be_VB provided_VBN by_IN the_DT external_JJ auditor_NN fall_NN within_IN a_DT category_NN of_IN pre-approved_JJ services_NNS ,_, they_PRP may_MD be_VB provided_VBN revisions_NNS to_TO the_DT policy_NN for_IN the_DT management_NN of_IN treasury_NN were_VBD by_IN the_DT auditor_NN without_IN being_VBG specifically_RB approved_VBN by_IN the_DT Committee_NNP ,_, reviewed_VBN and_CC recommended_VBN for_IN approval_NN to_TO the_DT Board_NNP :_: provided_VBD that_DT management_NN does_VBZ not_RB need_VB to_TO exercise_VB any_DT discretion_NN in_IN determining_VBG whether_IN a_DT proposed_JJ service_NN falls_VBZ within_IN one_CD of_IN the_DT quarterly_JJ reports_NNS on_IN treasury_NN investments_NNS and_CC compliance_NN pre-approved_JJ categories_NNS ._.
In_IN all_DT cases_NNS ,_, the_DT Committee_NNP is_VBZ notified_VBN with_IN treasury_NN policy_NN were_VBD discussed_VBN :_: of_IN any_DT pre-approved_JJ service_NN that_WDT is_VBZ provided_VBN by_IN the_DT auditor_NN ._.
approval_NN of_IN the_DT insurance_NN renewal_NN program_NN for_IN 2005_CD 6_CD :_: Any_DT service_NN proposed_VBN to_TO be_VB provided_VBN by_IN the_DT auditor_NN which_WDT is_VBZ not_RB a_DT pre-approved_JJ service_NN must_MD be_VB approved_VBN in_IN advance_NN by_IN the_DT Committee_NNP ,_, monitoring_NN of_IN the_DT Groups_NNS whistle-blowing_JJ and_CC fraud_NN policies_NNS :_: and_CC which_WDT will_MD consider_VB whether_IN the_DT independence_NN ,_, skills_NNS and_CC experience_NN of_IN the_DT auditor_NN make_VB it_PRP a_DT suitable_JJ supplier_NN of_IN the_DT proposed_JJ service_NN ._.
the_DT Companys_NNPS internal_JJ controls_NNS over_IN financial_JJ reporting_NN ._.
Committee_NNP activities_NNS 3_CD External_NNP auditor_NN During_IN 2005_CD ,_, the_DT business_NN discussed_VBN by_IN the_DT Committee_NNP included_VBD The_DT Committee_NNP reviewed_VBD the_DT performance_NN of_IN the_DT external_JJ auditor_NN the_DT following_NN :_: following_VBG the_DT completion_NN of_IN the_DT 2004_CD audit_NN process_NN ,_, which_WDT resulted_VBD in_IN the_DT Committee_NNP resolving_VBG to_TO recommend_VB that_IN the_DT Company_NN submit_VB 1_CD Financial_NNP statements_NNS a_DT resolution_NN to_TO the_DT 2005_CD Annual_JJ General_NNP Meeting_VBG to_TO re-appoint_VB Deloitte_NNP the_DT financial_JJ disclosures_NNS contained_VBN in_IN the_DT Companys_NNP quarterly_JJ &_CC Touche_NNP LLP_NNP as_IN the_DT Companys_NNP external_JJ auditor_NN ._.
At_IN forthcoming_JJ results_NNS announcements_NNS :_: meetings_NNS in_IN 2006_CD ,_, the_DT Committee_NNP will_MD conduct_VB a_DT formal_JJ review_NN of_IN the_DT performance_NN of_IN the_DT external_JJ auditor_NN and_CC the_DT effectiveness_NN of_IN the_DT audit_NN various_JJ accounting_NN matters_NNS ,_, including_VBG the_DT application_NN of_IN the_DT process_NN in_IN connection_NN with_IN the_DT 2005_CD financial_JJ year_NN audit_NN ._.
Companys_NNS critical_JJ accounting_NN policies_NNS and_CC new_JJ accounting_NN standards_NNS in_IN the_DT context_NN of_IN the_DT financial_JJ disclosures_NNS ,_, including_VBG the_DT Throughout_IN the_DT year_NN ,_, the_DT Committee_NNP has_VBZ kept_VBN the_DT objectivity_NN and_CC acquisition_NN of_IN TKT_NNP ,_, the_DT impact_NN of_IN the_DT Health_NNP Canada_NNP suspension_NN independence_NN of_IN the_DT external_JJ auditor_NN under_IN review_NN and_CC has_VBZ obtained_VBN of_IN ADDERALL_NNP XR_NNP ,_, the_DT impact_NN of_IN fair_JJ value_NN accounting_NN for_IN sharereports_NNS from_IN the_DT Companys_NNP external_JJ auditor_NN describing_VBG all_DT relationships_NNS based_VBN compensation_NN and_CC new_JJ Inventory_NNP Management_NNP Agreements_NNP between_IN the_DT auditor_NN and_CC the_DT Company_NN ._.
The_DT Committee_NNP has_VBZ remained_VBN with_IN key_JJ US_NNP wholesalers_NNS :_: satisfied_JJ that_IN neither_CC the_DT level_NN of_IN non-audit_JJ services_NNS nor_CC the_DT nature_NN of_IN the_DT work_NN performed_VBN by_IN the_DT external_JJ auditors_NNS has_VBZ in_IN any_DT way_NN impaired_VBN their_PRP$ a_DT review_NN of_IN the_DT Companys_NNP preparations_NNS for_IN the_DT adoption_NN in_IN 2005_CD objectivity_NN and_CC independence_NN ._.
Details_NNS of_IN the_DT fees_NNS paid_VBN to_TO the_DT external_JJ of_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP ,_, including_VBG the_DT auditors_NNS are_VBP disclosed_VBN in_IN Note_NN 7_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
approval_NN of_IN the_DT Companys_NNP accounting_NN policies_NNS under_IN IFRS_NNP ._.
The_DT Audit_NNP Committee_NNP reviewed_VBD and_CC approved_VBD the_DT Companys_NNP publication_NN in_IN September_NNP 2005_CD of_IN its_PRP$ half-yearly_JJ financial_JJ statements_NNS and_CC full-year_JJ comparative_JJ financial_JJ statements_NNS for_IN 2004_CD ,_, as_IN prepared_VBN in_IN accordance_NN with_IN IFRS_NNP :_: and_CC quarterly_JJ reports_NNS from_IN the_DT external_JJ auditors_NNS were_VBD received_VBN by_IN the_DT David_NNP Kappler_NNP Committee_NNP and_CC discussed_VBN ._.
The_DT reports_NNS addressed_VBD the_DT following_VBG Chairman_NN of_IN the_DT Audit_NNP Committee_NNP key_JJ areas_NNS :_: auditor_NN responsibility_NN and_CC independence_NN :_: significant_JJ accounting_NN estimates_NNS and_CC judgements_NNS made_VBN by_IN management_NN :_: audit_NN adjustments_NNS proposed_VBN and_CC whether_IN they_PRP were_VBD corrected_VBN by_IN management_NN :_: and_CC significant_JJ accounting_NN policies_NNS and_CC unusual_JJ transactions_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 69_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 70_CD Corporate_JJ governance_NN statements_NNS The_DT Company_NN is_VBZ committed_VBN to_TO high_JJ standards_NNS Independence_NNP of_IN Directors_NNS of_IN corporate_JJ governance_NN The_DT Board_NNP considers_VBZ Dr_NNP Barry_NNP Price_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP ,_, The_DT Hon_NNP The_NNP Board_NNP is_VBZ committed_VBN to_TO high_JJ standards_NNS of_IN corporate_JJ governance_NN James_NNP Grant_NNP ,_, Mr_NNP Robin_NNP Buchanan_NNP ,_, Mr_NNP David_NNP Kappler_NNP and_CC Mr_NNP Patrick_NNP and_CC supports_VBZ the_DT provisions_NNS and_CC principles_NNS set_VBN out_RP in_IN The_DT Combined_VBN Langlois_NNP to_TO be_VB Independent_JJ Non-executive_JJ Directors_NNS ._.
The_DT Board_NNP Code_NNP on_IN Corporate_NNP Governance_NNP issued_VBN by_IN the_DT UK_NNP Financial_NNP Reporting_NNP views_VBZ each_DT of_IN these_DT Non-executive_JJ Directors_NNS to_TO be_VB independent_JJ Council_NNP in_IN July_NNP 2003_CD the_DT Combined_NNP Code_NNP ._.
of_IN management_NN ,_, independent_JJ in_IN judgement_NN and_CC character_NN and_CC free_JJ from_IN any_DT business_NN or_CC other_JJ relationship_NN which_WDT could_MD materially_RB interfere_VB Statement_NN of_IN compliance_NN with_IN the_DT Combined_NNP Code_NNP with_IN the_DT exercise_NN of_IN their_PRP$ independent_JJ judgement_NN ._.
Throughout_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD the_DT Company_NN has_VBZ ,_, in_IN the_DT Directors_NNS opinion_NN ,_, complied_VBN with_IN the_DT provisions_NNS set_VBN out_RP The_DT Board_NNP has_VBZ taken_VBN into_IN consideration_NN that_IN The_DT Hon_NNP James_NNP Grant_NNP in_IN Section_NNP 1_CD of_IN the_DT Combined_NNP Code_NNP ._.
is_VBZ a_DT partner_NN of_IN Stikeman_NNP Elliot_NNP ,_, a_DT Canadian_JJ law_NN firm_NN which_WDT ,_, from_IN time_NN to_TO time_NN ,_, provides_VBZ legal_JJ advice_NN to_TO the_DT Shire_NNP Group_NNP ._.
The_DT Board_NNP considers_VBZ The_NNP Board_NNP Mr_NNP Grant_NNP to_TO be_VB independent_JJ notwithstanding_IN his_PRP$ position_NN as_IN he_PRP is_VBZ The_DT Board_NNP comprises_VBZ the_DT Chairman_NNP ,_, two_CD Executive_NNP and_CC six_CD not_RB involved_VBN in_IN the_DT provision_NN of_IN legal_JJ advice_NN to_TO the_DT Shire_NNP Group_NNP and_CC Non-executive_JJ Directors_NNS and_CC meets_VBZ at_IN least_JJS six_CD times_NNS a_DT year_NN ._.
is_VBZ not_RB engaged_VBN in_IN marketing_VBG the_DT services_NNS of_IN Stikeman_NNP Elliott_NNP to_TO the_DT The_DT Non-executive_JJ Directors_NNS bring_VBP judgement_NN which_WDT is_VBZ independent_JJ Shire_NNP Group_NNP ._.
Stikeman_NNP Elliott_NNP is_VBZ one_CD of_IN a_DT range_NN of_IN legal_JJ and_CC other_JJ of_IN management_NN to_TO Board_NNP deliberations_NNS ._.
The_DT executive_NN Directors_NNS professional_JJ advisors_NNS engaged_VBN by_IN the_DT Shire_NNP Group_NNP from_IN time_NN to_TO time_NN ._.
have_VB responsibility_NN for_IN day-to-day_JJ business_NN operations_NNS ._.
Accordingly_RB ,_, the_DT Board_NNP does_VBZ not_RB consider_VB the_DT relationship_NN between_IN the_DT Shire_NNP Group_NNP and_CC Stikeman_NNP Elliott_NNP to_TO be_VB material_JJ and_CC the_DT fact_NN that_IN The_NNP Board_NNP has_VBZ overall_JJ responsibility_NN for_IN managing_VBG the_DT Company_NN and_CC Mr_NNP Grant_NNP is_VBZ a_DT partner_NN at_IN that_DT firm_NN does_VBZ not_RB ,_, in_IN the_DT Boards_NNPS assessment_NN ,_, its_PRP$ strategic_JJ direction_NN and_CC seeks_VBZ to_TO provide_VB effective_JJ leadership_NN and_CC affect_VB his_PRP$ independence_NN ._.
Mr_NNP Grant_NNP was_VBD a_DT Board_NNP member_NN of_IN BioChem_NNP the_DT control_NN required_VBN for_IN a_DT listed_VBN company_NN ._.
The_DT Board_NNP discharges_VBZ those_DT Pharma_NNP Inc._NNP prior_RB to_TO its_PRP$ merger_NN with_IN Shire_NNP in_IN 2001_CD ._.
Mr_NNP Grant_NNP has_VBZ responsibilities_NNS through_IN regularly_RB scheduled_VBN meetings_NNS ._.
The_DT Board_NNP an_DT extensive_JJ knowledge_NN of_IN Shires_NNP business_NN and_CC he_PRP brings_VBZ valued_VBN has_VBZ formally_RB reserved_VBN specific_JJ matters_NNS to_TO itself_PRP for_IN determination_NN which_WDT expertize_VBP to_TO the_DT Board_NNP ._.
include_VBP strategic_JJ issues_NNS ,_, budgeting_NN ,_, changes_NNS in_IN share_NN capital_NN ,_, approval_NN of_IN the_DT Companys_NNPS financial_JJ statements_NNS and_CC entry_NN into_IN material_NN contracts_NNS ._.
The_DT Board_NNP ,_, when_WRB making_VBG its_PRP$ determination_NN on_IN the_DT independence_NN Matters_NNS not_RB formally_RB reserved_VBN to_TO the_DT Board_NNP are_VBP delegated_VBN to_TO the_DT of_IN Dr_NNP Price_NNP ,_, gave_VBD particular_JJ consideration_NN to_TO the_DT fact_NN that_IN Dr_NNP Price_NNP has_VBZ Executive_NNP Committee_NNP and_CC to_TO various_JJ other_JJ Board_NNP committees_NNS whose_WP$ been_VBN a_DT serving_VBG member_NN of_IN the_DT Board_NNP for_IN ten_CD years_NNS ,_, that_IN the_DT Combined_VBN functions_NNS are_VBP described_VBN below_IN ._.
Code_NNP suggests_VBZ that_IN length_NN of_IN service_NN of_IN nine_CD years_NNS or_CC more_JJR is_VBZ relevant_JJ to_TO a_DT determination_NN of_IN independence_NN and_CC that_IN re-appointment_JJ should_MD The_DT Board_NNP reviews_VBZ the_DT Companys_NNP internal_JJ controls_NNS and_CC risk_NN be_VB subject_JJ to_TO rigorous_JJ review_NN ._.
The_DT Board_NNP was_VBD also_RB mindful_JJ of_IN the_DT need_NN management_NN policies_NNS and_CC approves_VBZ its_PRP$ Code_NNP of_IN Ethics_NNPS ._.
The_DT Board_NNP to_TO ensure_VB progressive_JJ refreshening_NN of_IN the_DT Board_NNP ._.
In_IN this_DT regard_NN the_DT approves_VBZ major_JJ investment_NN and_CC contractual_JJ decisions_NNS which_WDT exceed_VBP Board_NNP took_VBD into_IN account_NN that_IN there_EX have_VBP been_VBN substantial_JJ changes_NNS defined_VBN thresholds_NNS ._.
It_PRP also_RB monitors_VBZ and_CC evaluates_VBZ the_DT performance_NN to_TO the_DT Board_NNP membership_NN in_IN recent_JJ years_NNS ,_, including_VBG the_DT appointments_NNS of_IN the_DT Shire_NNP Group_NNP as_IN a_DT whole_NN ,_, through_IN engaging_VBG with_IN the_DT of_IN Mr_NNP Buchanan_NNP and_CC Mr_NNP Emmens_NNP in_IN 2003_CD ,_, Mr_NNP Kappler_NNP in_IN 2004_CD and_CC Chief_NNP Executive_NNP Officer_NNP ,_, Chief_NNP Financial_NNP Officer_NNP and_CC members_NNS Mr_NNP Langlois_NNP in_IN 2005_CD ._.
Having_VBG considered_VBN the_DT issue_NN ,_, the_DT Board_NNP has_VBZ of_IN the_DT Executive_NNP Committee_NNP ,_, as_IN appropriate_JJ ._.
no_DT hesitation_NN in_IN asking_VBG Dr_NNP Price_NNP to_TO remain_VB on_IN the_DT Board_NNP ._.
Dr_NNP Prices_NNS commitment_NN to_TO the_DT Company_NN is_VBZ undiminished_JJ and_CC his_PRP$ performance_NN The_DT Board_NNP members_NNS receive_VBP detailed_VBN information_NN from_IN executive_NN continues_VBZ to_TO be_VB effective_JJ ._.
In_IN accordance_NN with_IN the_DT Combined_NNP Code_NNP ,_, Directors_NNS ,_, the_DT Company_NNP Secretary_NNP ,_, members_NNS of_IN the_DT Executive_NNP Dr_NNP Prices_NNS re-appointment_JJ to_TO the_DT Board_NNP is_VBZ for_IN a_DT one-year_JJ term_NN ._.
Committee_NNP and_CC other_JJ senior_JJ managers_NNS to_TO enable_VB them_PRP to_TO discharge_VB His_PRP$ re-appointment_NN will_MD be_VB subject_JJ to_TO shareholder_NN approval_NN at_IN the_DT their_PRP$ responsibilities_NNS efficiently_RB and_CC effectively_RB ._.
All_DT Directors_NNS have_VBP 2006_CD Annual_JJ General_NNP Meeting_VBG ._.
access_NN to_TO the_DT advice_NN and_CC guidance_NN of_IN the_DT Company_NNP Secretary_NNP and_CC are_VBP encouraged_VBN to_TO seek_VB independent_JJ advice_NN at_IN the_DT Companys_NNP Throughout_IN 2005_CD and_CC up_RB to_TO the_DT date_NN of_IN publication_NN of_IN this_DT report_NN ,_, expense_NN ,_, where_WRB they_PRP feel_VBP it_PRP is_VBZ appropriate_JJ ._.
The_DT Board_NNP is_VBZ of_IN the_DT opinion_NN at_IN least_JJS half_PDT the_DT Board_NNP ,_, excluding_VBG the_DT Chairman_NNP ,_, comprised_VBD that_IN each_DT of_IN its_PRP$ members_NNS has_VBZ the_DT knowledge_NN ,_, aptitude_NN and_CC experience_NN Non-executive_JJ Directors_NNS determined_VBN by_IN the_DT Board_NNP to_TO be_VB independent_JJ ._.
to_TO perform_VB the_DT functions_NNS required_VBN of_IN a_DT director_NN of_IN a_DT listed_VBN company_NN ._.
Board_NNP and_CC Committee_NNP changes_NNS Biographical_NNP details_NNS of_IN the_DT members_NNS of_IN the_DT Board_NNP are_VBP shown_VBN on_IN pages_NNS Mr_NNP Patrick_NNP Langlois_NNP joined_VBD the_DT Board_NNP as_IN a_DT Non-executive_JJ Director_NNP 4041_CD ._.
and_CC a_DT member_NN of_IN the_DT Audit_NNP Committee_NNP on_IN November_NNP 11_CD ,_, 2005_CD ._.
70_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 71_CD Corporate_JJ governance_NN statements_NNS Board_NNP meetings_NNS Senior_JJ Non-executive_JJ Director_NNP During_IN 2005_CD ,_, there_EX were_VBD 13_CD Board_NNP meetings_NNS of_IN which_WDT seven_CD were_VBD faceDr_NNP Barry_NNP Price_NNP is_VBZ the_DT Senior_JJ Independent_NNP Non-executive_JJ Director_NNP ._.
to-face_JJ meetings_NNS and_CC six_CD held_VBN by_IN telephone_NN ._.
Board_NNP meetings_NNS are_VBP well_RB Dr_NNP Price_NNP is_VBZ the_DT Companys_NNP longest-serving_JJ Director_NNP and_CC as_IN such_JJ he_PRP attended_VBD ._.
The_DT record_NN of_IN attendance_NN by_IN Directors_NNS at_IN Board_NNP meetings_NNS has_VBZ significant_JJ knowledge_NN of_IN Shire_NNP and_CC its_PRP$ business_NN ._.
Dr_NNP Prices_NNS in-depth_JJ is_VBZ set_VBN out_RP below_IN :_: knowledge_NN of_IN Shire_NNP and_CC the_DT pharmaceutical_JJ industry_NN generally_RB is_VBZ acknowledged_JJ and_CC utilized_VBN by_IN the_DT Board_NNP ._.
Dr_NNP Price_NNP chairs_VBZ meetings_NNS held_VBD Number_NNP of_IN by_IN the_DT Non-executive_JJ Directors_NNS during_IN the_DT year_NN in_IN the_DT absence_NN of_IN the_DT meetings_NNS Out_IN of_IN Attendance_NN executive_NN Directors_NNS and_CC the_DT Chairman_NNP ._.
Dr_NNP Price_NNP is_VBZ available_JJ ,_, as_IN required_VBN ,_, Directors_NNS attended_VBD possible_JJ %_NN for_IN consultation_NN with_IN major_JJ shareholders_NNS on_IN any_DT matter_NN of_IN concern_NN ._.
James_NNP Cavanaugh_NNP Chairman_NNP 13_CD 13_CD 100_CD Supply_NN of_IN information_NN The_DT executive_NN Directors_NNS and_CC the_DT Company_NNP Secretary_NNP are_VBP responsible_JJ Matthew_NNP Emmens_NNP for_IN ensuring_VBG that_IN detailed_VBN information_NN is_VBZ provided_VBN to_TO Board_NNP members_NNS Chief_NNP Executive_NNP Officer_NNP 13_CD 13_CD 100_CD in_IN advance_NN of_IN any_DT scheduled_VBN Board_NNP meeting_NN ._.
Before_IN decisions_NNS are_VBP Angus_NNP Russell_NNP made_VBD ,_, consideration_NN is_VBZ given_VBN to_TO the_DT adequacy_NN of_IN information_NN available_JJ Chief_NNP Financial_NNP Officer_NNP 13_CD 13_CD 100_CD to_TO the_DT Board_NNP and_CC ,_, if_IN necessary_JJ ,_, decisions_NNS are_VBP deferred_VBN if_IN further_JJ information_NN is_VBZ required_VBN ._.
The_DT Company_NNP Secretary_NNP ,_, Ms_NNP Tatjana_NNP May_NNP ,_, Barry_NNP Price_NNP is_VBZ also_RB secretary_NN to_TO all_DT of_IN the_DT Board_NNP committees_NNS ._.
Senior_JJ Non-executive_JJ Director_NNP 12_CD 13_CD 92_CD The_DT Hon_NNP James_NNP Grant_NNP Appointment_NNP and_CC re-election_NN of_IN Directors_NNS Non-executive_JJ Director_NNP 12_CD 13_CD 92_CD The_DT Board_NNP has_VBZ authority_NN to_TO appoint_VB any_DT person_NN to_TO be_VB a_DT Director_NNP ._.
Any_DT Director_NNP so_RB appointed_JJ must_MD retire_VB and_CC submit_VB himself_PRP for_IN election_NN Ronald_NNP Nordmann_NNP at_IN the_DT next_JJ Annual_JJ General_NNP Meeting_VBG ._.
Non-executive_JJ Director_NNP 13_CD 13_CD 100_CD Robin_NNP Buchanan_NNP Non-executive_JJ Directors_NNS are_VBP appointed_VBN ordinarily_RB for_IN a_DT term_NN of_IN two_CD Non-executive_JJ Director_NNP 13_CD 13_CD 100_CD years_NNS ,_, subject_JJ to_TO shareholder_NN approval_NN ._.
Non-executive_JJ Directors_NNS who_WP have_VBP served_VBN on_IN the_DT Board_NNP for_IN nine_CD years_NNS or_CC more_JJR are_VBP appointed_VBN David_NNP Kappler_NNP for_IN one_CD year_NN terms_NNS and_CC ,_, in_IN accordance_NN with_IN the_DT Combined_NNP Code_NNP Non-executive_JJ Director_NNP 13_CD 13_CD 100_CD on_IN Corporate_JJ Governance_NN ,_, are_VBP subject_JJ to_TO annual_JJ re-election_NN by_IN Patrick_NNP Langlois_NNP shareholders_NNS ._.
Re-appointment_NN of_IN Non-executive_JJ Directors_NNS following_VBG Non-executive_JJ Director_NNP the_DT expiry_NN of_IN their_PRP$ term_NN of_IN appointment_NN is_VBZ subject_JJ to_TO Board_NNP approval_NN ._.
appointed_VBN November_NNP 11_CD ,_, 2005_CD 1_CD 1_CD 100_CD At_IN every_DT Annual_JJ General_NNP Meeting_VBG a_DT minimum_NN of_IN one-third_NN of_IN the_DT Directors_NNS must_MD retire_VB from_IN office_NN and_CC may_MD offer_VB themselves_PRP for_IN reThe_NNP Chairman_NNP and_CC the_DT Non-executive_JJ Directors_NNS met_VBD during_IN the_DT year_NN election_NN by_IN shareholders_NNS ._.
Accordingly_RB ,_, no_DT Director_NNP should_MD serve_VB without_IN the_DT executive_NN Directors_NNS being_VBG present_JJ ._.
for_IN more_JJR than_IN three_CD years_NNS without_IN being_VBG subject_JJ to_TO re-election_NN ._.
Chairman_NNP and_CC Chief_NNP Executive_NNP Officer_NNP All_NNP of_IN the_DT current_JJ Directors_NNS of_IN Shire_NNP plc_NN were_VBD appointed_VBN by_IN the_DT Board_NNP as_IN The_DT offices_NNS of_IN Chairman_NNP and_CC Chief_NNP Executive_NNP Officer_NNP are_VBP held_VBN separately_RB ._.
a_DT result_NN of_IN the_DT scheme_NN of_IN arrangement_NN implemented_VBN on_IN November_NNP 25_CD ,_, The_DT Chairman_NNP ,_, Dr_NNP James_NNP Cavanaugh_NNP ,_, is_VBZ responsible_JJ for_IN the_DT conduct_NN 2005_CD ,_, whereby_WRB Shire_NNP plc_NN was_VBD established_VBN as_IN the_DT new_JJ UK_NNP listed_VBN holding_NN of_IN the_DT Board_NNP and_CC ensures_VBZ that_IN Board_NNP discussions_NNS are_VBP conducted_VBN in_IN Company_NN for_IN the_DT Shire_NNP Group_NNP in_IN place_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP such_PDT a_DT way_NN that_IN all_DT views_NNS are_VBP taken_VBN into_IN account_NN ,_, so_RB that_IN no_DT individual_JJ plc_NN Scheme_NN ._.
As_IN a_DT result_NN of_IN the_DT implementation_NN of_IN the_DT Scheme_NNP ,_, all_DT Director_NNP or_CC small_JJ group_NN of_IN Directors_NNS dominates_VBZ proceedings_NNS ._.
The_DT Chief_NNP of_IN the_DT Directors_NNS of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN became_VBD Directors_NNS Executive_NNP Officer_NNP has_VBZ the_DT overall_JJ responsibility_NN for_IN running_VBG the_DT business_NN of_IN Shire_NNP plc_NN but_CC were_VBD appointed_VBN by_IN the_DT Board_NNP rather_RB than_IN shareholders_NNS ._.
on_IN a_DT day-to-day_JJ basis_NN and_CC chairs_VBZ the_DT Executive_NNP Committee_NNP ._.
Accordingly_RB ,_, at_IN the_DT Annual_JJ General_NNP Meeting_VBG to_TO be_VB held_VBN in_IN 2006_CD ,_, all_DT of_IN the_DT Directors_NNS will_MD retire_VB and_CC offer_VB themselves_PRP for_IN re-election_NN ._.
The_DT roles_NNS and_CC responsibilities_NNS of_IN the_DT Chairman_NNP and_CC the_DT Chief_NNP Executive_NNP Officer_NNP are_VBP clearly_RB defined_VBN ,_, separate_JJ and_CC have_VBP been_VBN approved_VBN by_IN Further_JJ information_NN concerning_VBG all_PDT the_DT Directors_NNS standing_VBG for_IN re-election_NN the_DT Board_NNP ._.
at_IN the_DT Annual_JJ General_NNP Meeting_VBG ,_, including_VBG their_PRP$ biographies_NNS ,_, will_MD be_VB included_VBN in_IN the_DT Notice_NNP of_IN Meeting_VBG to_TO Shareholders_NNS ._.
The_DT terms_NNS of_IN appointment_NN of_IN each_DT of_IN the_DT Non-executive_JJ Directors_NNS and_CC the_DT service_NN contracts_NNS of_IN the_DT executive_NN Directors_NNS will_MD be_VB made_VBN available_JJ for_IN inspection_NN at_IN the_DT Companys_NNP Annual_JJ General_NNP Meeting_VBG in_IN 2006_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 71_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 72_CD Corporate_JJ governance_NN statements_NNS Board_NNP performance_NN evaluation_NN 3_CD Nomination_NNP Committee_NNP The_NNP Company_NNP conducted_VBD evaluations_NNS of_IN the_DT performance_NN of_IN the_DT Board_NNP ,_, The_DT Nomination_NNP Committee_NNP is_VBZ responsible_JJ for_IN identifying_VBG and_CC its_PRP$ committees_NNS and_CC its_PRP$ Directors_NNS in_IN 2005_CD ._.
The_DT 2005_CD evaluations_NNS were_VBD nominating_JJ ,_, for_IN the_DT approval_NN of_IN the_DT Board_NNP ,_, candidates_NNS for_IN the_DT Board_NNP ._.
The_DT undertaken_VBN by_IN way_NN of_IN questionnaires_NNS prepared_VBN by_IN the_DT Chairman_NNP and_CC Committee_NNP also_RB ensures_VBZ adequate_JJ succession_NN planning_NN for_IN the_DT Board_NNP the_DT Company_NNP Secretary_NNP ._.
The_DT reviews_NNS covered_VBD a_DT wide_JJ range_NN of_IN matters_NNS and_CC senior_JJ management_NN ._.
This_DT Committee_NNP meets_VBZ as_IN required_VBN and_CC in_IN 2005_CD including_VBG adequacy_NN of_IN the_DT composition_NN of_IN the_DT Board_NNP and_CC its_PRP$ Committees_NNS ,_, was_VBD chaired_VBN by_IN Dr_NNP James_NNP Cavanaugh_NNP ._.
Mr_NNP Ronald_NNP Nordmann_NNP ,_, The_DT Hon_NNP performance_NN of_IN Directors_NNS and_CC the_DT adequacy_NN of_IN information_NN provided_VBN ._.
James_NNP Grant_NNP and_CC Dr_NNP Barry_NNP Price_NNP also_RB served_VBD on_IN this_DT Committee_NNP in_IN 2005_CD ._.
Responses_NNS were_VBD aggregated_VBN on_IN a_DT non-attributed_JJ basis_NN and_CC circulated_VBN All_DT members_NNS participated_VBD in_IN all_DT discussions_NNS of_IN this_DT Committee_NNP in_IN 2005_CD ._.
to_TO each_DT Board_NNP and_CC Committee_NNP member_NN ._.
The_DT responses_NNS then_RB formed_VBD the_DT basis_NN of_IN a_DT discussion_NN between_IN the_DT relevant_JJ members_NNS of_IN the_DT Board_NNP The_DT Nomination_NNP Committee_NNP retains_VBZ the_DT services_NNS of_IN executive_JJ search_NN or_CC Committee_NN with_IN ,_, respectively_RB ,_, the_DT Chairman_NNP and_CC the_DT Committee_NNP consultants_NNS to_TO assist_VB it_PRP in_IN the_DT identification_NN and_CC nomination_NN of_IN new_JJ Chairman_NNP ._.
A_DT number_NN of_IN minor_JJ improvements_NNS to_TO operating_VBG procedures_NNS Board_NNP candidates_NNS ._.
For_IN further_JJ information_NN about_IN the_DT Nomination_NNP Committee_NNP ,_, its_PRP$ Committees_NNS of_IN the_DT Board_NNP membership_NN and_CC activities_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD The_DT Board_NNP has_VBZ established_VBN the_DT Audit_NNP Committee_NNP ,_, the_DT Remuneration_NNP please_VB refer_VBP to_TO the_DT Nomination_NNP Committee_NNP report_NN on_IN page_NN 56_CD ._.
Committee_NNP ,_, the_DT Nomination_NNP Committee_NNP and_CC the_DT Executive_NNP Committee_NNP ._.
Each_DT committee_NN has_VBZ its_PRP$ own_JJ written_VBN terms_NNS of_IN reference_NN which_WDT have_VBP 4_CD Executive_NNP Committee_NNP been_VBN approved_VBN by_IN the_DT Board_NNP ._.
The_DT Terms_NNS of_IN Reference_NNP of_IN the_DT Audit_NNP ,_, The_NNP Board_NNP has_VBZ delegated_VBN the_DT day-to-day_JJ management_NN of_IN the_DT Company_NN Nomination_NN and_CC Remuneration_NNP Committees_NNS are_VBP available_JJ on_IN the_DT to_TO the_DT Executive_NNP Committee_NNP ,_, which_WDT operates_VBZ within_IN clear_JJ and_CC formal_JJ Companys_NNP website_NN ._.
Details_NNS of_IN each_DT committee_NN are_VBP as_IN follows_VBZ :_: parameters_NNS ._.
The_DT Executive_NNP Committee_NNP meets_VBZ at_IN least_JJS 11_CD times_NNS per_IN year_NN ._.
The_DT Chief_NNP Executive_NNP is_VBZ the_DT Chairman_NNP 1_CD Audit_NNP Committee_NNP of_IN the_DT Executive_NNP Committee_NNP ,_, which_WDT on_IN December_NNP 31_CD ,_, 2005_CD consisted_VBD The_DT Audit_NNP Committee_NNP has_VBZ been_VBN established_VBN for_IN the_DT purpose_NN of_IN of_IN 11_CD Executive_NNP Vice_NNP Presidents_NNP including_VBG the_DT two_CD executive_NN Directors_NNS ._.
overseeing_VBG the_DT accounting_NN and_CC financial_JJ reporting_NN processes_NNS of_IN the_DT The_NNP Executive_NNP Committee_NNP reports_VBZ to_TO and_CC seeks_VBZ guidance_NN from_IN the_DT Company_NN ,_, the_DT audit_NN of_IN its_PRP$ financial_JJ statements_NNS and_CC the_DT Companys_NNP Board_NNP on_IN a_DT regular_JJ basis_NN ._.
It_PRP meets_VBZ at_IN least_JJS four_CD times_NNS a_DT year_NN ._.
The_DT members_NNS of_IN the_DT Audit_NNP Committee_NNP are_VBP all_DT Independent_NNP Non-executive_JJ The_DT Members_NNS of_IN the_DT Executive_NNP Committee_NNP as_IN at_IN December_NNP 31_CD ,_, 2005_CD Directors_NNS ._.
For_IN further_JJ information_NN about_IN the_DT Audit_NNP Committee_NNP ,_, its_PRP$ were_VBD Matthew_NNP Emmens_NNP Chief_NNP Executive_NNP Officer_NNP ,_, Angus_NNP Russell_NNP membership_NN and_CC activities_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD ,_, Chief_NNP Financial_NNP Officer_NNP and_CC Executive_NNP Vice_NNP President_NNP of_IN Global_NNP Finance_NNP ,_, please_VB refer_VBP to_TO the_DT Audit_NNP Committee_NNP report_NN on_IN pages_NNS 6869_CD ._.
Tatjana_NNP May_NNP General_NNP Counsel_NNP ,_, Executive_NNP Vice_NNP President_NNP of_IN Global_NNP Legal_NNP Affairs_NNP and_CC Company_NNP Secretary_NNP ,_, Anita_NNP Graham_NNP Executive_NNP Vice_NNP 2_CD Remuneration_NNP Committee_NNP President_NNP Global_NNP Human_NNP Resources_NNPS ,_, Eliseo_NNP Salinas_NNP Executive_NNP Vice_NNP The_NNP Remuneration_NNP Committee_NNP determines_VBZ on_IN behalf_NN of_IN the_DT Board_NNP President_NNP of_IN Global_NNP R&D_NNP ,_, Greg_NNP Flexter_NNP Executive_NNP Vice_NNP President_NNP the_DT remuneration_NN policy_NN for_IN the_DT executive_NN Directors_NNS and_CC other_JJ senior_JJ and_CC General_NNP Manager_NNP ,_, North_NNP America_NNP ,_, Joseph_NNP Rus_NNP Executive_NNP Vice_NNP executives_NNS and_CC the_DT fixing_VBG of_IN the_DT terms_NNS of_IN employment_NN of_IN the_DT executive_NN President_NNP and_CC General_NNP Manager_NNP ,_, International_NNP ,_, Barbara_NNP Deptula_NNP Directors_NNS ._.
The_DT remuneration_NN of_IN the_DT Non-executive_JJ Directors_NNS is_VBZ Executive_NNP Vice_NNP President_NNP of_IN Business_NNP Development_NNP ,_, John_NNP Lee_NNP determined_VBN by_IN the_DT Board_NNP ._.
The_DT remuneration_NN of_IN the_DT executive_NN Directors_NNS Executive_NNP Vice_NNP President_NNP of_IN Supply_NNP Chain_NNP and_CC Quality_NNP ,_, Mike_NNP Cola_NNP and_CC the_DT Chairman_NNP is_VBZ determined_VBN by_IN the_DT Remuneration_NNP Committee_NNP ._.
Executive_NNP Vice_NNP President_NNP of_IN Global_NNP Business_NNP Units_NNP and_CC David_NNP The_NNP remuneration_NN of_IN the_DT members_NNS of_IN the_DT Executive_NNP Committee_NNP ,_, other_JJ Pendergast_NNP Executive_NNP Vice_NNP President_NNP of_IN Human_NNP Genetic_NNP Therapies_NNPS ._.
than_IN the_DT executive_NN Directors_NNS ,_, is_VBZ determined_VBN by_IN the_DT Chief_NNP Executive_NNP Officer_NNP following_VBG discussion_NN with_IN the_DT Remuneration_NNP Committee_NNP ._.
The_DT Executive_NNP Committee_NNP normally_RB meets_VBZ once_RB a_DT month_NN to_TO deliberate_VB The_DT members_NNS of_IN the_DT Remuneration_NNP Committee_NNP are_VBP all_DT Independent_NNP on_IN major_JJ business_NN issues_NNS ._.
It_PRP also_RB considers_VBZ those_DT matters_NNS that_WDT are_VBP of_IN Non-executive_JJ Directors_NNS ._.
a_DT size_NN and_CC significance_NN as_IN to_TO require_VB referral_NN to_TO the_DT Board_NNP before_IN such_JJ matters_NNS are_VBP referred_VBN to_TO the_DT Board_NNP for_IN final_JJ consideration_NN and_CC decision_NN ._.
The_DT Remuneration_NNP Committee_NNP engages_VBZ external_JJ consultants_NNS to_TO advise_VB on_IN aspects_NNS of_IN remuneration_NN ,_, as_IN it_PRP considers_VBZ necessary_JJ ._.
Directors_NNS remuneration_VBP The_DT Companys_NNP remuneration_NN policy_NN is_VBZ described_VBN in_IN the_DT Directors_NNS The_DT Remuneration_NNP Committee_NNP met_VBD on_IN seven_CD occasions_NNS in_IN 2005_CD ._.
remuneration_NN report_NN on_IN pages_NNS 5667_CD ._.
The_DT report_NN details_NNS the_DT level_NN Dr_NNP Barry_NNP Price_NNP chaired_VBD the_DT Remuneration_NNP Committee_NNP throughout_IN the_DT of_IN remuneration_NN for_IN Directors_NNS and_CC the_DT basis_NN upon_IN which_WDT executive_JJ year_NN and_CC Mr_NNP Robin_NNP Buchanan_NNP and_CC Mr_NNP Ronald_NNP Nordmann_NNP were_VBD members_NNS remuneration_NN is_VBZ determined_VBN ._.
All_DT members_NNS attended_VBD all_DT meetings_NNS ._.
For_IN further_JJ information_NN about_IN the_DT Remuneration_NNP Committee_NNP ,_, its_PRP$ membership_NN and_CC activities_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2005_CD ,_, please_VB refer_VBP to_TO the_DT Directors_NNS remuneration_NN report_NN on_IN pages_NNS 5667_CD ._.
72_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 73_CD Corporate_JJ governance_NN statements_NNS Relations_NNS with_IN shareholders_NNS The_DT Board_NNP receives_VBZ advice_NN and_CC information_NN from_IN the_DT Corporate_JJ The_DT Company_NN is_VBZ committed_VBN to_TO maintaining_VBG constructive_JJ relationships_NNS Responsibility_NNP Committee_NNP CR_NNP Committee_NNP to_TO make_VB this_DT assessment_NN ._.
The_DT CR_NNP Committee_NNP ,_, which_WDT is_VBZ chaired_VBN by_IN the_DT Chief_NNP Financial_NNP Officer_NNP ,_, meets_VBZ three_CD times_NNS a_DT year_NN and_CC is_VBZ responsible_JJ for_IN setting_VBG the_DT policies_NNS The_DT Company_NN announces_VBZ its_PRP$ financial_JJ results_NNS quarterly_RB ._.
The_DT Chief_NNP and_CC procedures_NNS that_WDT manage_VBP SEE_VB issues_NNS ,_, risks_NNS and_CC opportunities_NNS ._.
Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP give_VBP presentations_NNS SEE_VB risks_NNS are_VBP managed_VBN within_IN the_DT overall_JJ framework_NN of_IN risk_NN on_IN the_DT results_NNS each_DT quarter_NN by_IN teleconference_NN for_IN institutional_JJ investors_NNS ,_, management_NN ,_, explained_VBD below_IN under_IN the_DT heading_VBG internal_JJ control_NN ._.
The_DT full-year_JJ results_NNS under_IN US_NNP GAAP_NNP are_VBP included_VBN in_IN the_DT Companys_NNP Annual_JJ Review_NNP ,_, along_IN with_IN a_DT summary_NN This_DT year_NN the_DT Company_NN has_VBZ again_RB decided_VBN to_TO produce_VB a_DT stand-alone_JJ financial_JJ statement_NN of_IN the_DT Companys_NNPS results_NNS under_IN International_NNP report_NN on_IN Corporate_JJ Responsibility_NN ._.
This_DT is_VBZ available_JJ on_IN request_NN or_CC Financial_JJ Reporting_NNP Standards_NNPS IFRS_NNP ._.
Full_NNP IFRS_NNP results_NNS are_VBP included_VBN from_IN the_DT Shire_NNP website_NN ._.
in_IN the_DT Companys_NNP Annual_JJ Report_NNP ._.
As_IN the_DT Company_NN has_VBZ securities_NNS listed_VBN on_IN NASDAQ_NNP in_IN the_DT US_NNP ,_, the_DT Company_NN also_RB files_VBZ quarterly_JJ reports_NNS on_IN Code_NNP of_IN Ethics_NNPS Form_NN 10-Q_NN and_CC an_DT annual_JJ report_NN on_IN Form_NN 10-K_NN with_IN the_DT US_NNP Securities_NNPS The_DT Company_NN is_VBZ committed_VBN to_TO the_DT maintenance_NN of_IN high_JJ ethical_JJ and_CC Exchange_NNP Commission_NNP SEC_NNP ._.
standards_NNS in_IN its_PRP$ dealings_NNS with_IN all_DT persons_NNS with_IN whom_WP it_PRP is_VBZ involved_VBN ._.
The_DT Companys_NNP Code_NNP of_IN Ethics_NNPS applies_VBZ to_TO all_DT Directors_NNS and_CC The_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP ,_, supported_VBD employees_NNS and_CC is_VBZ available_JJ for_IN review_NN on_IN the_DT Companys_NNP website_NN ._.
by_IN other_JJ senior_JJ executives_NNS ,_, also_RB arrange_VBP individual_JJ and_CC group_NN meetings_NNS with_IN major_JJ shareholders_NNS throughout_IN the_DT year_NN to_TO discuss_VB the_DT Companys_NNPS Dividends_NNPS strategy_NN and_CC performance_NN and_CC to_TO understand_VB the_DT views_NNS of_IN major_JJ The_DT Company_NN commenced_VBD the_DT payment_NN of_IN a_DT semi-annual_JJ dividend_NN shareholders_NNS ,_, which_WDT are_VBP then_RB communicated_VBN to_TO the_DT Board_NNP as_IN a_DT whole_NN ._.
in_IN 2004_CD with_IN the_DT aim_NN to_TO grow_VB the_DT total_JJ dividend_NN paid_VBN for_IN each_DT year_NN The_DT Chairman_NNP and_CC the_DT Senior_JJ Independent_NNP Non-executive_JJ Director_NNP progressively_RB ._.
As_IN a_DT result_NN of_IN the_DT adoption_NN of_IN this_DT dividend_NN policy_NN ,_, are_VBP available_JJ also_RB to_TO meet_VB with_IN major_JJ shareholders_NNS ._.
the_DT Company_NN intends_VBZ to_TO declare_VB interim_JJ dividends_NNS twice_RB per_IN year_NN ,_, with_IN the_DT first_JJ payment_NN made_VBN around_IN September_NNP October_NNP ,_, following_VBG The_DT Companys_NNP website_NN at_IN www_NN ._.
com_NN provides_VBZ information_NN determination_NN of_IN first-half_JJ results_NNS ,_, and_CC the_DT second_JJ payment_NN around_IN about_IN the_DT Company_NN and_CC its_PRP$ business_NN and_CC is_VBZ regularly_RB updated_VBN ._.
April_NNP May_NNP of_IN each_DT year_NN ,_, following_VBG finalization_NN of_IN the_DT full-year_JJ results_NNS ._.
The_DT Companys_NNP Investor_NNP Relations_NNP department_NN acts_VBZ as_IN a_DT contact_NN The_DT Company_NN does_VBZ not_RB intend_VB to_TO put_VB a_DT resolution_NN to_TO shareholders_NNS to_TO point_VB for_IN investors_NNS throughout_IN the_DT year_NN ._.
approve_VB a_DT final_JJ dividend_NN at_IN the_DT Annual_JJ General_NNP Meeting_VBG which_WDT is_VBZ held_VBN in_IN June_NNP each_DT year_NN because_IN if_IN the_DT Company_NN was_VBD to_TO delay_VB payment_NN The_DT Company_NN holds_VBZ its_PRP$ Annual_JJ General_NNP Meeting_VBG in_IN London_NNP ._.
At_IN the_DT of_IN the_DT second-half_JJ final_JJ dividend_NN ,_, by_IN seeking_VBG shareholder_NN approval_NN for_IN annual_JJ meeting_NN ,_, a_DT business_NN presentation_NN is_VBZ made_VBN to_TO shareholders_NNS the_DT payment_NN at_IN the_DT Annual_JJ General_NNP Meeting_VBG ,_, the_DT Company_NN would_MD not_RB and_CC shareholders_NNS are_VBP given_VBN the_DT opportunity_NN to_TO ask_VB questions_NNS of_IN the_DT be_VB able_JJ to_TO maintain_VB an_DT even_JJ payment_NN cycle_NN at_IN approximately_RB six-month_JJ Directors_NNS ._.
The_DT Directors_NNS also_RB make_VBP themselves_PRP available_JJ informally_RB intervals_NNS unless_IN first-half_JJ dividend_NN payments_NNS were_VBD also_RB delayed_VBN ._.
This_DT is_VBZ after_IN the_DT meeting_NN to_TO answer_VB questions_NNS from_IN shareholders_NNS ._.
beneficial_JJ for_IN the_DT Company_NN ,_, both_DT from_IN a_DT cash_NN flow_NN planning_NN and_CC from_IN an_DT accounting_NN perspective_NN and_CC is_VBZ beneficial_JJ for_IN shareholders_NNS as_IN dividends_NNS Balanced_JJ and_CC timely_JJ assessment_NN of_IN positions_NNS and_CC prospects_NNS are_VBP paid_VBN promptly_RB and_CC a_DT smooth_JJ payment_NN cycle_NN is_VBZ maintained_VBN ._.
The_DT Company_NN strives_VBZ to_TO give_VB timely_JJ assessments_NNS of_IN matters_NNS that_WDT impact_VBP on_IN its_PRP$ business_NN and_CC financial_JJ position_NN and_CC to_TO present_VB scientific_JJ Donations_NNS to_TO Political_NNP Organizations_NNPS and_CC EU_NNP Political_NNP Expenditure_NNP and_CC other_JJ information_NN in_IN a_DT balanced_JJ way_NN ._.
At_IN the_DT Annual_JJ General_NNP Meeting_VBG in_IN June_NNP 2005_CD ,_, shareholders_NNS authorized_VBD the_DT Company_NN to_TO make_VB donations_NNS to_TO EU_NNP Political_NNP Organizations_NNPS and_CC Corporate_NNP Responsibility_NNP CR_NNP to_TO incur_VB EU_NNP Political_NNP Expenditure_NNP ,_, under_IN the_DT provisions_NNS of_IN the_DT Political_NNP The_NNP Company_NNP recognizes_VBZ the_DT impact_NN that_IN its_PRP$ business_NN may_MD have_VB on_IN Parties_NNS ,_, Elections_NNS and_CC Referendums_NNP Act_NNP 2000_CD ,_, of_IN up_RB to_TO 25,000_CD ,_, people_NNS and_CC the_DT environment_NN as_RB well_RB as_IN the_DT wider_JJR implications_NNS of_IN its_PRP$ equivalent_JJ to_TO $_$ 45,525_CD at_IN average_JJ 2005_CD exchange_NN rates_NNS respectively_RB ,_, operations_NNS on_IN the_DT general_JJ community_NN ._.
The_DT Company_NN therefore_RB attaches_VBZ each_DT year_NN ._.
Although_IN the_DT Company_NN does_VBZ not_RB make_VB and_CC does_VBZ not_RB intend_VB great_JJ importance_NN to_TO social_JJ and_CC environmental_JJ issues_NNS and_CC to_TO ethical_JJ to_TO make_VB payments_NNS or_CC donations_NNS to_TO EU_NNP political_JJ parties_NNS ,_, within_IN the_DT business_NN practices_NNS ._.
Accordingly_RB ,_, ultimate_JJ responsibility_NN for_IN them_PRP is_VBZ normal_JJ meaning_NN of_IN that_DT expression_NN ,_, the_DT definition_NN in_IN the_DT legislation_NN taken_VBN at_IN the_DT highest_JJS levels_NNS ._.
The_DT Board_NNP reviews_VBZ the_DT Companys_NNP general_NN of_IN EU_NNP Political_NNP Organization_NNP is_VBZ wide_JJ ._.
It_PRP can_MD extend_VB to_TO bodies_NNS which_WDT approach_VBP to_TO corporate_JJ responsibility_NN ._.
The_DT Board_NNP also_RB reviews_VBZ the_DT the_DT Company_NN might_MD wish_VB to_TO support_VB including_VBG those_DT concerned_JJ specific_JJ business_NN risks_NNS related_VBN to_TO Social_NNP ,_, Environmental_NNP and_CC Ethical_NNP with_IN policy_NN review_NN and_CC law_NN reform_NN ._.
The_DT Company_NN made_VBD no_DT donations_NNS SEE_VBP matters_NNS annually_RB ._.
to_TO either_DT EU_NNP or_CC non-EU_NNP Political_NNP Organizations_NNPS during_IN 2005_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 73_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 74_CD Corporate_JJ governance_NN statements_NNS Annual_JJ General_NNP Meeting_VBG 2006_CD On_IN behalf_NN of_IN the_DT Board_NNP ,_, the_DT Audit_NNP Committee_NNP has_VBZ the_DT responsibility_NN for_IN The_DT 2006_CD Annual_JJ General_NNP Meeting_VBG will_MD be_VB held_VBN on_IN Wednesday_NNP ,_, June_NNP 21_CD ,_, reviewing_VBG the_DT effectiveness_NN of_IN the_DT system_NN of_IN internal_JJ financial_JJ controls_NNS 2006_CD ._.
The_DT business_NN to_TO be_VB transacted_VBN at_IN the_DT meeting_NN will_MD include_VB :_: and_CC the_DT audit_NN process_NN ._.
The_DT Audit_NNP Committee_NNP has_VBZ independent_JJ access_NN to_TO the_DT auditor_NN throughout_IN the_DT year_NN in_IN addition_NN to_TO presentations_NNS from_IN the_DT receiving_VBG the_DT Companys_NNPS accounts_NNS for_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, auditor_NN on_IN a_DT quarterly_JJ basis_NN ._.
Any_DT significant_JJ findings_NNS or_CC identified_VBN risks_NNS 2005_CD ,_, together_RB with_IN the_DT Directors_NNS Report_NNP ,_, Remuneration_NNP Report_NNP are_VBP closely_RB examined_VBN and_CC are_VBP reported_VBN to_TO the_DT Board_NNP with_IN and_CC the_DT Auditors_NNS Report_VBP on_IN those_DT accounts_NNS and_CC the_DT auditable_JJ part_NN recommendations_NNS for_IN action_NN ._.
of_IN the_DT Remuneration_NNP Report_NNP :_: The_DT Company_NN has_VBZ established_VBN a_DT Disclosure_NNP Committee_NNP ,_, which_WDT approving_VBG the_DT 2005_CD Directors_NNS remuneration_JJ report_NN :_: is_VBZ chaired_VBN by_IN the_DT Chief_NNP Financial_NNP Officer_NNP ._.
Its_PRP$ membership_NN includes_VBZ senior_JJ managers_NNS from_IN the_DT legal_JJ ,_, finance_NN and_CC risk_NN departments_NNS ._.
electing_VBG each_DT of_IN Dr_NNP James_NNP Cavanaugh_NNP ,_, Mr_NNP Matthew_NNP Emmens_NNP ,_, Its_PRP$ responsibilities_NNS include_VBP ensuring_VBG that_IN information_NN disclosed_VBD Mr_NNP Angus_NNP Russell_NNP ,_, Mr_NNP Robin_NNP Buchanan_NNP ,_, The_DT Hon_NNP James_NNP Grant_NNP ,_, to_TO investors_NNS in_IN the_DT Companys_NNP periodic_JJ financial_JJ reports_NNS is_VBZ recorded_VBN ,_, Mr_NNP David_NNP Kappler_NNP ,_, Mr_NNP Ronald_NNP Nordmann_NNP ,_, Dr_NNP Barry_NNP Price_NNP and_CC summarized_VBN and_CC reported_VBN accurately_RB ._.
Mr_NNP Patrick_NNP Langlois_NNP to_TO the_DT Board_NNP :_: Following_VBG the_DT enactment_NN of_IN the_DT Sarbanes-Oxley_NNP Act_NNP 2002_CD in_IN the_DT re-appointing_JJ Deloitte_NNP &_CC Touche_NNP LLP_NNP as_IN auditors_NNS and_CC authorizing_VBG United_NNP States_NNPS ,_, the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP the_DT Audit_NNP Committee_NNP to_TO approve_VB their_PRP$ remuneration_NN :_: Officer_NNP are_VBP required_VBN to_TO complete_VB formal_JJ certifications_NNS ,_, which_WDT confirm_VBP ,_, inter_VBP alia_NN ,_, that_WDT :_: giving_VBG the_DT Directors_NNS the_DT authority_NN to_TO disapply_VB pre-emption_JJ rights_NNS when_WRB allotting_VBG new_JJ shares_NNS in_IN certain_JJ circumstances_NNS :_: the_DT annual_JJ report_NN on_IN Form_NN 10-K_NN in_IN the_DT United_NNP States_NNPS does_VBZ not_RB contain_VB any_DT material_NN misstatements_NNS or_CC omissions_NNS :_: giving_VBG authority_NN to_TO the_DT Company_NN to_TO make_VB limited_JJ donations_NNS to_TO EU_NNP political_JJ organizations_NNS and_CC to_TO incur_VB limited_JJ EU_NNP political_JJ financial_JJ information_NN reported_VBN in_IN Form_NN 10-K_JJ fairly_RB presents_VBZ the_DT financial_JJ expenditure_NN :_: and_CC condition_NN ,_, results_NNS of_IN operations_NNS and_CC cash_NN flows_NNS of_IN the_DT Company_NN :_: authorizing_VBG the_DT Company_NN to_TO make_VB market_NN purchases_NNS of_IN up_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP are_VBP to_TO 10_CD %_NN of_IN the_DT Companys_NNPS issued_VBD share_NN capital_NN ._.
responsible_JJ for_IN determining_VBG and_CC maintaining_VBG disclosure_NN controls_NNS and_CC procedures_NNS for_IN the_DT purposes_NNS of_IN financial_JJ reporting_NN in_IN the_DT United_NNP States_NNPS :_: Financial_NNP disclosure_NN ,_, internal_JJ control_NN and_CC the_DT role_NN of_IN the_DT auditors_NNS The_DT Board_NNP has_VBZ ,_, through_IN the_DT Audit_NNP Committee_NNP ,_, established_VBD formal_JJ the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP and_CC transparent_JJ arrangements_NNS for_IN financial_JJ reporting_NN ,_, internal_JJ control_NN have_VBP evaluated_VBN the_DT effectiveness_NN of_IN those_DT disclosure_NN controls_NNS and_CC external_JJ auditing_NN ._.
The_DT Audit_NNP Committees_NNS terms_NNS of_IN reference_NN extend_VBP and_CC procedures_NNS :_: to_TO the_DT Companys_NNPS risk_NN management_NN activities_NNS as_IN a_DT whole_JJ and_CC not_RB just_RB the_DT financial_JJ aspects_NNS of_IN internal_JJ control_NN ._.
the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP have_VBP indicated_VBN in_IN Form_NN 10-K_JJ whether_IN there_EX were_VBD any_DT significant_JJ changes_NNS All_DT employees_NNS can_MD raise_VB any_DT concerns_NNS in_IN any_DT of_IN these_DT areas_NNS with_IN in_IN the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN :_: and_CC the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP in_IN the_DT strictest_JJS confidence_NN ._.
The_DT Company_NN operates_VBZ a_DT Global_JJ Compliance_NNP Helpline_NNP ,_, which_WDT provides_VBZ based_VBN on_IN the_DT evaluation_NN of_IN the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT a_DT confidential_JJ means_NNS through_IN which_WDT all_DT employees_NNS are_VBP able_JJ to_TO report_VB Chief_NNP Financial_NNP Officer_NNP ,_, all_DT significant_JJ deficiencies_NNS and_CC material_NN concerns_NNS relating_VBG to_TO financial_JJ disclosure_NN ,_, internal_JJ control_NN and_CC other_JJ weaknesses_NNS in_IN the_DT design_NN or_CC operation_NN of_IN internal_JJ control_NN over_IN compliance_NN issues_NNS in_IN good_JJ faith_NN without_IN fear_NN of_IN discrimination_NN or_CC reprisal_NN ._.
financial_JJ reporting_NN which_WDT are_VBP reasonably_RB likely_JJ to_TO affect_VB adversely_RB the_DT Companys_NNPS ability_NN to_TO record_NN ,_, process_NN ,_, summarize_VB and_CC report_VB 1_CD Financial_NNP reporting_VBG financial_JJ information_NN included_VBD in_IN Form_NN 10-K_NN have_VBP been_VBN disclosed_VBN The_DT Board_NNP has_VBZ ultimate_JJ responsibility_NN for_IN the_DT preparation_NN of_IN accounts_NNS to_TO the_DT Companys_NNPS auditors_NNS ._.
and_CC for_IN the_DT monitoring_NN of_IN systems_NNS of_IN internal_JJ financial_JJ control_NN ._.
The_DT Board_NNP strives_VBZ to_TO present_VB a_DT balanced_JJ and_CC understandable_JJ assessment_NN The_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT Chief_NNP Financial_NNP Officer_NNP have_VBP of_IN the_DT Companys_NNP position_NN and_CC its_PRP$ prospects_NNS and_CC endeavors_NNS to_TO present_VB completed_VBN these_DT certifications_NNS and_CC they_PRP have_VBP been_VBN filed_VBN with_IN the_DT SEC_NNP scientific_JJ and_CC other_JJ information_NN in_IN a_DT balanced_JJ way_NN ._.
The_DT Company_NN in_IN the_DT United_NNP States_NNPS as_IN part_NN of_IN the_DT Companys_NNP annual_JJ report_NN in_IN the_DT publishes_VBZ quarterly_JJ financial_JJ reports_NNS so_IN that_IN its_PRP$ shareholders_NNS can_MD United_NNP States_NNPS on_IN Form_NN 10-K_NN ._.
monitor_NN the_DT Companys_NNPS financial_JJ position_NN regularly_RB ._.
74_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 75_CD Corporate_JJ governance_NN statements_NNS 2_CD Risk_NN management_NN ,_, compliance_NN and_CC internal_JJ control_NN iv_VBD a_DT range_NN of_IN corporate_JJ policies_NNS and_CC procedures_NNS have_VBP been_VBN The_DT Board_NNP ,_, in_IN accordance_NN with_IN the_DT Turnbull_NNP Guidance_NNP on_IN internal_JJ implemented_VBN :_: control_NN ,_, recognizes_VBZ its_PRP$ overall_JJ responsibility_NN to_TO maintain_VB a_DT sound_JJ system_NN of_IN internal_JJ control_NN to_TO safeguard_VB shareholders_NNS investments_NNS and_CC the_DT v_NN the_DT internal_JJ audit_NN department_NN ,_, overseen_VBN by_IN the_DT Vice_NNP President_NNP Companys_NNP assets_NNS and_CC to_TO regularly_RB review_VB its_PRP$ effectiveness_NN ._.
Whilst_IN the_DT Internal_NNP Audit_NNP ,_, carries_VBZ out_RP regular_JJ reviews_NNS of_IN control_NN activities_NNS and_CC Board_NNP acknowledges_VBZ its_PRP$ responsibility_NN for_IN the_DT system_NN of_IN internal_JJ control_NN ,_, reports_NNS findings_NNS to_TO management_NN :_: and_CC there_EX are_VBP limitations_NNS in_IN any_DT system_NN of_IN internal_JJ control_NN and_CC accordingly_RB even_RB the_DT most_RBS effective_JJ system_NN can_MD provide_VB only_JJ reasonable_JJ and_CC not_RB vi_VB the_DT Audit_NNP Committee_NNP considers_VBZ the_DT major_JJ findings_NNS of_IN any_DT internal_JJ absolute_JJ assurance_NN ._.
Such_JJ a_DT system_NN is_VBZ designed_VBN to_TO manage_VB rather_RB than_IN investigations_NNS and_CC managements_NNS response_NN to_TO them_PRP ._.
The_DT Audit_NNP eliminate_VB the_DT risk_NN of_IN failure_NN to_TO achieve_VB business_NN objectives_NNS and_CC can_MD Committee_NNP reports_NNS annually_RB to_TO the_DT Board_NNP on_IN the_DT effectiveness_NN of_IN the_DT provide_VBP only_JJ reasonable_JJ and_CC not_RB absolute_JJ assurance_NN against_IN material_NN Companys_NNS control_VBP environment_NN ._.
Effective_JJ identification_NN ,_, assessment_NN and_CC management_NN of_IN risks_NNS The_DT Board_NNP has_VBZ reviewed_VBN both_DT the_DT key_JJ risks_NNS faced_VBN by_IN the_DT Company_NN and_CC The_DT management_NN of_IN business_NN risk_NN is_VBZ essential_JJ for_IN ensuring_VBG that_IN the_DT the_DT effectiveness_NN of_IN the_DT Companys_NNP internal_JJ control_NN systems_NNS in_IN 2005_CD ._.
Company_NN creates_VBZ and_CC preserves_VBZ shareholder_NN value_NN ._.
Accordingly_RB ,_, Outside_JJ of_IN its_PRP$ review_NN ,_, the_DT Board_NNP delegates_NNS responsibility_NN to_TO the_DT Audit_NNP the_DT Company_NN has_VBZ an_DT ongoing_JJ process_NN for_IN identifying_VBG ,_, evaluating_VBG and_CC Committee_NNP for_IN more_RBR regular_JJ review_NN of_IN both_DT key_JJ risks_NNS and_CC internal_JJ managing_VBG the_DT significant_JJ risks_NNS that_IN it_PRP faces_VBZ ._.
This_DT process_NN has_VBZ been_VBN controls_NNS and_CC for_IN monitoring_VBG the_DT activities_NNS of_IN the_DT internal_JJ audit_NN function_NN ._.
in_IN operation_NN throughout_IN the_DT period_NN under_IN review_NN and_CC up_RB to_TO the_DT date_NN The_DT Audit_NNP Committee_NNP has_VBZ kept_VBN these_DT areas_NNS under_IN review_NN in_IN 2005_CD ._.
of_IN the_DT signing_NN of_IN the_DT accounts_NNS ._.
All_DT risks_NNS are_VBP recorded_VBN on_IN a_DT corporate_JJ risk_NN schedule_NN which_WDT allocates_VBZ specific_JJ responsibility_NN to_TO members_NNS The_DT Company_NN has_VBZ risk_NN management_NN ,_, compliance_NN and_CC internal_JJ audit_NN of_IN the_DT Executive_NNP Committee_NNP ._.
This_DT schedule_NN has_VBZ been_VBN reviewed_VBN functions_NNS ._.
A_DT Chief_NNP Compliance_NNP Officer_NNP was_VBD appointed_VBN in_IN 2005_CD and_CC the_DT by_IN the_DT Audit_NNP Committee_NNP during_IN 2005_CD ._.
role_NN of_IN Chief_NNP Risk_NNP Officer_NNP combined_VBN with_IN it_PRP ._.
The_DT role_NN of_IN Chief_NNP Compliance_NNP and_CC Risk_NNP Officer_NNP and_CC the_DT role_NN of_IN Director_NNP of_IN Internal_NNP Audit_NNP ,_, which_WDT Effective_NNP internal_JJ control_NN procedures_NNS are_VBP separate_JJ ,_, report_NN to_TO the_DT Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP The_NNP Company_NNP has_VBZ a_DT system_NN of_IN control_NN procedures_NNS ._.
Compliance_NN with_IN Officer_NNP ,_, respectively_RB ,_, but_CC each_DT have_VBP direct_JJ access_NN to_TO the_DT Chairman_NNP ,_, these_DT procedures_NNS is_VBZ monitored_VBN through_IN a_DT system_NN of_IN internal_JJ review_NN and_CC the_DT Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP and_CC the_DT other_JJ members_NNS of_IN the_DT regular_JJ reports_NNS on_IN financial_JJ performance_NN ._.
Any_DT significant_JJ issues_NNS arising_VBG Audit_NNP Committee_NNP ._.
They_PRP also_RB both_DT attend_VB and_CC present_VB regularly_RB at_IN Audit_NNP are_VBP reported_VBN to_TO the_DT Audit_NNP Committee_NNP ._.
During_IN 2005_CD ,_, the_DT Company_NN has_VBZ Committee_NNP meetings_NNS ._.
made_VBD a_DT significant_JJ investment_NN in_IN its_PRP$ internal_JJ financial_JJ control_NN procedures_NNS as_IN part_NN of_IN its_PRP$ compliance_NN with_IN s404_CD Sarbanes-Oxley_NNP Act_NNP requirements_NNS ._.
The_DT Companys_NNPS risk_NN management_NN ,_, compliance_NN and_CC internal_JJ audit_NN This_DT has_VBZ included_VBN the_DT review_NN ,_, documentation_NN and_CC testing_NN of_IN all_DT key_JJ strategy_NN is_VBZ based_VBN on_IN a_DT risk_NN and_CC control_NN framework_NN containing_VBG the_DT internal_JJ financial_JJ controls_NNS ._.
The_DT conclusion_NN of_IN this_DT exercise_NN is_VBZ that_IN following_VBG key_JJ elements_NNS :_: the_DT Company_NN had_VBD an_DT effective_JJ system_NN of_IN internal_JJ controls_NNS over_IN its_PRP$ US_NNP GAAP_NNP Form_NN 10-K_JJ financial_JJ reporting_NN at_IN December_NNP 31_CD ,_, 2005_CD ._.
an_DT effective_JJ control_NN environment_NN :_: Effective_JJ internal_JJ audit_NN an_DT effective_JJ process_NN to_TO identify_VB ,_, assess_VB and_CC manage_VB risks_NNS :_: The_DT internal_JJ review_NN of_IN the_DT Companys_NNPS control_VBP procedures_NNS and_CC compliance_NN with_IN them_PRP is_VBZ mostly_RB undertaken_VBN through_IN internal_JJ audit_NN ._.
The_DT effective_JJ internal_JJ control_NN procedures_NNS :_: and_CC Audit_NNP Committee_NNP monitors_VBZ and_CC reviews_VBZ the_DT internal_JJ audit_NN program_NN ,_, considers_VBZ the_DT findings_NNS of_IN internal_JJ audit_NN reviews_NNS and_CC managements_NNS effective_JJ internal_JJ audit_NN ._.
response_NN to_TO them_PRP ,_, and_CC ensures_VBZ efficient_JJ co-ordination_NN between_IN the_DT Companys_NNP internal_JJ and_CC external_JJ auditors_NNS ._.
The_DT Companys_NNP internal_JJ audit_NN Effective_JJ control_NN environment_NN function_NN ,_, comprizing_VBG a_DT mixture_NN of_IN internal_JJ and_CC out-sourced_JJ resource_NN ,_, The_DT key_JJ elements_NNS of_IN the_DT Companys_NNPS control_VBP environment_NN are_VBP as_IN follows_VBZ :_: was_VBD operational_JJ throughout_IN 2005_CD ._.
The_DT Audit_NNP Committee_NNP ,_, which_WDT is_VBZ responsible_JJ for_IN monitoring_VBG the_DT activity_NN of_IN the_DT internal_JJ audit_NN function_NN ,_, i_FW the_DT Board_NNP has_VBZ overall_JJ responsibility_NN to_TO maintain_VB the_DT internal_JJ control_NN has_VBZ reviewed_VBN the_DT effectiveness_NN of_IN the_DT internal_JJ audit_NN during_IN 2005_CD ._.
system_NN and_CC has_VBZ delegated_VBN certain_JJ responsibilities_NNS to_TO the_DT Executive_NNP Committee_NNP and_CC or_CC the_DT Audit_NNP Committee_NNP :_: 3_CD External_NNP auditing_NN The_DT Audit_NNP Committee_NNP has_VBZ the_DT primary_JJ responsibility_NN for_IN determining_VBG ii_FW a_DT framework_NN of_IN Corporate_JJ Values_NNS and_CC a_DT Code_NNP of_IN Ethics_NNPS which_WDT sets_VBZ the_DT remuneration_NN of_IN ,_, and_CC overseeing_VBG the_DT work_NN of_IN ,_, any_DT accounting_NN firm_NN appropriate_JJ standards_NNS of_IN ethical_JJ behavior_NN are_VBP operational_JJ throughout_IN engaged_VBN to_TO conduct_VB the_DT external_JJ audit_NN ._.
The_DT Audit_NNP Committee_NNP assesses_VBZ the_DT Group_NNP :_: at_IN least_JJS annually_RB the_DT objectivity_NN and_CC independence_NN of_IN the_DT external_JJ auditor_NN taking_VBG into_IN account_NN relevant_JJ regulatory_JJ requirements_NNS ._.
iii_FW the_DT internal_JJ structure_NN of_IN the_DT organization_NN is_VBZ well_RB documented_VBN with_IN The_DT Audit_NNP Committee_NNP reviews_VBZ and_CC approves_VBZ the_DT annual_JJ external_JJ audit_NN clear_JJ reporting_NN lines_NNS and_CC clear_JJ limits_NNS of_IN authority_NN for_IN different_JJ matters_NNS :_: plan_NN each_DT year_NN and_CC ensures_VBZ it_PRP is_VBZ consistent_JJ with_IN the_DT scope_NN of_IN the_DT auditors_NNS engagement_NN ._.
The_DT Audit_NNP Committee_NNP also_RB considers_VBZ whether_IN the_DT skills_NNS and_CC experience_NN of_IN the_DT external_JJ audit_NN firm_NN make_VBP it_PRP a_DT suitable_JJ supplier_NN of_IN non-audit_JJ services_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 75_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 76_CD Corporate_JJ governance_NN statements_NNS The_DT Audit_NNP Committee_NNP has_VBZ set_VBN and_CC applies_VBZ a_DT formal_JJ policy_NN in_IN relation_NN The_DT Companys_NNPS management_NN assessed_VBD the_DT effectiveness_NN of_IN the_DT to_TO the_DT provision_NN of_IN non-audit_JJ services_NNS by_IN the_DT external_JJ auditor_NN specifying_VBG Companys_NNP internal_JJ control_NN over_IN financial_JJ reporting_NN for_IN the_DT purposes_NNS of_IN the_DT types_NNS of_IN non-audit_JJ work_NN :_: the_DT Companys_NNP Annual_JJ Report_NNP on_IN Form_NN 10-K_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, which_WDT was_VBD filed_VBN with_IN the_DT US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP i_FW for_IN which_WDT the_DT external_JJ auditors_NNS are_VBP excluded_VBN :_: on_IN March_NNP 1_CD ,_, 2006_CD ._.
In_IN making_VBG this_DT assessment_NN ,_, the_DT Companys_NNP management_NN used_VBD the_DT criteria_NNS set_VBN forth_RB by_IN the_DT Committee_NNP ii_NN for_IN which_WDT the_DT external_JJ auditors_NNS can_MD be_VB engaged_VBN without_IN referral_NN of_IN Sponsoring_VBG Organizations_NNP of_IN the_DT Treadway_NNP Commission_NNP COSO_NNP to_TO the_DT Committee_NNP :_: and_CC in_IN Internal_NNP Control-Integrated_NNP Framework_NNP ._.
iii_NN for_IN which_WDT a_DT case-by-case_JJ decision_NN is_VBZ necessary_JJ ,_, with_IN a_DT view_NN Based_VBN on_IN its_PRP$ assessment_NN ,_, management_NN believes_VBZ that_IN ,_, as_IN of_IN to_TO preserving_VBG the_DT auditors_NNS independence_NN and_CC objectivity_NN ._.
The_DT Audit_NNP December_NNP 31_CD ,_, 2005_CD ,_, the_DT Companys_NNP internal_JJ control_NN over_IN financial_JJ Committee_NNP also_RB considers_VBZ the_DT fees_NNS paid_VBN to_TO the_DT external_JJ auditors_NNS reporting_VBG is_VBZ effective_JJ based_VBN on_IN those_DT criteria_NNS ._.
and_CC whether_IN the_DT fee_NN levels_NNS for_IN non-audit_JJ services_NNS ,_, individually_RB and_CC in_IN aggregate_JJ ,_, relative_JJ to_TO the_DT audit_NN fee_NN are_VBP appropriate_JJ to_TO enable_VB Deloitte_NNP &_CC Touche_NNP LLP_NNP ,_, an_DT independent_JJ registered_JJ public_JJ accounting_NN a_DT proper_JJ audit_NN to_TO be_VB conducted_VBN ._.
firm_NN ,_, has_VBZ issued_VBN an_DT audit_NN report_NN on_IN managements_NNS assessment_NN of_IN the_DT Companys_NNP internal_JJ control_NN over_IN its_PRP$ Form_NN 10-K_NN US_NNP GAAP_NNP financial_JJ Going_VBG concern_NN basis_NN reporting_NN ._.
The_DT Auditors_NNS Report_NNP appears_VBZ on_IN pages_NNS F-2_NN and_CC F-3_NN After_IN making_VBG enquiries_NNS ,_, the_DT Directors_NNS have_VBP formed_VBN a_DT judgement_NN ,_, at_IN the_DT of_IN the_DT Companys_NNP Annual_JJ Report_NNP in_IN the_DT United_NNP States_NNPS on_IN Form_NN 10-K_NN ._.
time_NN of_IN approving_VBG the_DT financial_JJ statements_NNS ,_, that_IN there_EX is_VBZ a_DT reasonable_JJ expectation_NN that_IN the_DT Group_NNP has_VBZ adequate_JJ resources_NNS to_TO continue_VB in_IN Changes_NNS in_IN internal_JJ control_NN over_IN financial_JJ reporting_NN operational_JJ existence_NN for_IN the_DT foreseeable_JJ future_NN ._.
For_IN this_DT reason_NN the_DT In_NNP 2004_CD ,_, the_DT Company_NN commenced_VBD the_DT implementation_NN of_IN a_DT new_JJ Directors_NNS continue_VBP to_TO adopt_VB the_DT going_VBG concern_NN basis_NN in_IN preparing_VBG the_DT integrated_VBN information_NN system_NN covering_VBG financial_JJ processes_NNS ,_, production_NN ,_, financial_JJ statements_NNS ._.
Further_JJ implementations_NNS were_VBD made_VBN in_IN the_DT fourth_JJ quarter_NN of_IN 2005_CD and_CC more_JJR are_VBP planned_VBN for_IN 2006_CD and_CC 2007_CD ._.
Disclosure_NN controls_NNS and_CC procedures_NNS The_DT implementations_NNS have_VBP involved_VBN changes_NNS in_IN the_DT Companys_NNP The_NNP Company_NNP ,_, under_IN the_DT supervision_NN and_CC with_IN the_DT participation_NN of_IN the_DT information_NN systems_NNS that_WDT included_VBD aspects_NNS of_IN the_DT Companys_NNP internal_JJ Companys_NNP management_NN ,_, including_VBG the_DT Chief_NNP Executive_NNP Officer_NNP and_CC the_DT control_NN over_IN financial_JJ reporting_NN and_CC therefore_RB changes_NNS to_TO the_DT Companys_NNP Chief_NNP Financial_NNP Officer_NNP ,_, has_VBZ performed_VBN an_DT evaluation_NN of_IN the_DT effectiveness_NN internal_JJ control_NN over_IN financial_JJ reporting_NN ._.
The_DT Company_NN has_VBZ reviewed_VBN of_IN the_DT Companys_NNP disclosure_NN controls_NNS and_CC procedures_NNS ,_, in_IN relation_NN each_DT system_NN as_IN it_PRP is_VBZ being_VBG implemented_VBN and_CC the_DT controls_NNS affected_VBN by_IN to_TO its_PRP$ Form_NN 10-K_NN US_NNP GAAP_NNP reporting_NN ,_, as_RB at_IN December_NNP 31_CD ,_, 2005_CD ._.
the_DT implementation_NN of_IN the_DT new_JJ systems_NNS and_CC made_VBN appropriate_JJ changes_NNS The_DT Companys_NNPS management_NN necessarily_RB applied_VBD its_PRP$ judgement_NN to_TO affected_JJ internal_JJ controls_NNS as_IN it_PRP implemented_VBD the_DT new_JJ systems_NNS ._.
in_IN assessing_VBG the_DT costs_NNS and_CC benefits_NNS of_IN such_JJ controls_NNS and_CC procedures_NNS ,_, Management_NNP believes_VBZ that_IN the_DT controls_NNS as_IN modified_VBN are_VBP appropriate_JJ which_WDT by_IN their_PRP$ nature_NN can_MD provide_VB only_JJ reasonable_JJ assurance_NN regarding_VBG and_CC functioning_VBG effectively_RB ._.
Based_VBN on_IN this_DT evaluation_NN ,_, the_DT Companys_NNP Chief_NNP Executive_NNP Officer_NNP and_CC Chief_NNP Financial_NNP Officer_NNP During_IN the_DT period_NN covered_VBN by_IN this_DT Annual_JJ Review_NNP ,_, the_DT Company_NN concluded_VBD that_IN the_DT Companys_NNP disclosure_NN controls_NNS and_CC procedures_NNS are_VBP concluded_VBN the_DT acquisition_NN of_IN TKT_NNP ._.
Significant_JJ material_NN weaknesses_NNS effective_JJ at_IN a_DT reasonable_JJ level_NN of_IN assurance_NN for_IN gathering_NN ,_, analyzing_VBG in_IN TKTs_NNS internal_JJ control_NN over_IN financial_JJ reporting_NN were_VBD identified_VBN with_IN and_CC disclosing_VBG the_DT information_NN that_IN the_DT Company_NN is_VBZ required_VBN to_TO respect_VB to_TO its_PRP$ sales_NNS and_CC marketing_NN subsidiary_NN ,_, TKT_NNP Europe_NNP A._NN B._NNP disclose_VB in_IN the_DT reports_NNS it_PRP files_VBZ under_IN the_DT US_NNP Securities_NNP Exchange_NNP Act_NNP formerly_RB TKT_NNP Europe-5S_NNP A._NNP B._NNP ,_, or_CC TKT_NNP Europe_NNP ,_, as_RB at_IN December_NNP 31_CD ,_, of_IN 1934_CD ,_, within_IN the_DT time_NN periods_NNS specified_VBN in_IN the_DT rules_NNS and_CC forms_NNS of_IN the_DT 2004_CD ,_, as_IN described_VBN in_IN TKTs_NNP Annual_JJ Report_NNP on_IN Form_NN 10-K_NN for_IN 2004_CD ._.
US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP ._.
The_DT Company_NN undertook_VBD a_DT review_NN of_IN these_DT material_NN weaknesses_NNS following_VBG completion_NN of_IN the_DT Companys_NNP acquisition_NN of_IN TKT_NNP and_CC has_VBZ Managements_NNP report_NN on_IN internal_JJ control_NN over_IN financial_JJ reporting_NN undertaken_VBN appropriate_JJ remediation_NN activities_NNS ._.
Management_NNP believes_VBZ The_DT Companys_NNP management_NN is_VBZ responsible_JJ for_IN establishing_VBG and_CC that_IN the_DT controls_NNS as_IN modified_VBN are_VBP appropriate_JJ and_CC functioning_VBG effectively_RB ._.
maintaining_VBG adequate_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN defined_VBN in_IN Rule_NNP 13_CD a_DT to_TO 15_CD f_SYM or_CC 15_CD d_SYM -15_CD f_SYM promulgated_VBN under_IN the_DT US_NNP Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD ._.
Because_IN of_IN its_PRP$ inherent_JJ limitations_NNS ,_, internal_JJ control_NN over_IN financial_JJ reporting_NN may_MD not_RB prevent_VB or_CC detect_VB misstatements_NNS ._.
Projections_NNS of_IN any_DT evaluation_NN of_IN effectiveness_NN to_TO future_JJ periods_NNS are_VBP subject_JJ to_TO the_DT risk_NN that_IN controls_NNS may_MD become_VB inadequate_JJ because_IN of_IN changes_NNS in_IN conditions_NNS ,_, or_CC that_IN the_DT degree_NN of_IN compliance_NN with_IN the_DT policies_NNS or_CC procedures_NNS may_MD deteriorate_VB ._.
76_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 77_CD Report_NNP of_IN independent_JJ registered_JJ public_JJ accounting_NN rm_NN To_TO the_DT Board_NNP of_IN Directors_NNS and_CC Stockholders_NNP of_IN Shire_NNP plc_NN ,_, Because_IN of_IN the_DT inherent_JJ limitations_NNS of_IN internal_JJ control_NN over_IN financial_JJ Basingstoke_NNP ,_, England_NNP reporting_NN ,_, including_VBG the_DT possibility_NN of_IN collusion_NN or_CC improper_JJ management_NN We_PRP have_VBP audited_VBN the_DT accompanying_VBG consolidated_JJ balance_NN sheets_NNS override_NN of_IN controls_NNS ,_, material_NN misstatements_NNS due_JJ to_TO error_NN or_CC fraud_NN may_MD of_IN Shire_NNP plc_NN and_CC subsidiaries_NNS the_DT Company_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD not_RB be_VB prevented_VBN or_CC detected_VBN on_IN a_DT timely_JJ basis_NN ._.
Also_RB ,_, projections_NNS of_IN any_DT and_CC 2004_CD ,_, and_CC the_DT related_JJ consolidated_JJ statements_NNS of_IN operations_NNS ,_, evaluation_NN of_IN the_DT effectiveness_NN of_IN the_DT internal_JJ control_NN over_IN financial_JJ stockholders_NNS equity_NN ,_, comprehensive_JJ income_NN ,_, and_CC cash_NN flows_NNS reporting_VBG to_TO future_JJ periods_NNS are_VBP subject_JJ to_TO the_DT risk_NN that_IN the_DT controls_NNS may_MD for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2005_CD ._.
become_VBN inadequate_JJ because_IN of_IN changes_NNS in_IN conditions_NNS ,_, or_CC that_IN the_DT We_PRP also_RB have_VBP audited_VBN managements_NNS assessment_NN ,_, included_VBD in_IN the_DT degree_NN of_IN compliance_NN with_IN the_DT policies_NNS or_CC procedures_NNS may_MD deteriorate_VB ._.
accompanying_VBG Management_NNP Report_NNP on_IN Internal_NNP Controls_NNP Over_NNP Financial_NNP Reporting_NNP ,_, that_IN the_DT Company_NN maintained_VBD effective_JJ internal_JJ control_NN In_IN our_PRP$ opinion_NN ,_, the_DT consolidated_JJ financial_JJ statements_NNS referred_VBD to_TO above_IN over_IN financial_JJ reporting_NN as_IN of_IN December_NNP 31_CD ,_, 2005_CD ,_, based_VBN on_IN criteria_NNS present_JJ fairly_RB ,_, in_IN all_DT material_NN respects_VBZ ,_, the_DT financial_JJ position_NN of_IN the_DT established_VBN in_IN Internal_NNP Control_NNP Integrated_NNP Framework_NNP issued_VBN by_IN the_DT Company_NN as_IN of_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD ,_, and_CC the_DT results_NNS of_IN its_PRP$ Committee_NNP of_IN Sponsoring_NNP Organizations_NNP of_IN the_DT Treadway_NNP Commission_NNP ._.
operations_NNS and_CC its_PRP$ cash_NN flows_VBZ for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN The_DT Companys_NNPS management_NN is_VBZ responsible_JJ for_IN these_DT financial_JJ ended_VBN December_NNP 31_CD ,_, 2005_CD ,_, in_IN conformity_NN with_IN accounting_NN principles_NNS statements_NNS and_CC the_DT financial_JJ statement_NN schedule_NN ,_, for_IN maintaining_VBG generally_RB accepted_VBN in_IN the_DT United_NNP States_NNPS of_IN America_NNP ._.
Also_RB ,_, in_IN our_PRP$ opinion_NN ,_, effective_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN ,_, and_CC for_IN its_PRP$ assessment_NN such_JJ financial_JJ statement_NN schedule_NN ,_, when_WRB considered_VBN in_IN relation_NN to_TO the_DT of_IN the_DT effectiveness_NN of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN ._.
Our_PRP$ basic_JJ consolidated_JJ financial_JJ statements_NNS taken_VBN as_IN a_DT whole_NN ,_, presents_VBZ responsibility_NN is_VBZ to_TO express_VB an_DT opinion_NN on_IN these_DT financial_JJ statements_NNS fairly_RB ,_, in_IN all_DT material_NN respects_VBZ ,_, the_DT information_NN set_VBN forth_RB therein_RB ._.
Also_RB ,_, in_IN and_CC the_DT financial_JJ statement_NN schedule_NN ,_, an_DT opinion_NN on_IN managements_NNS our_PRP$ opinion_NN ,_, managements_NNS assessment_NN that_IN the_DT Company_NN maintained_VBD assessment_NN ,_, and_CC an_DT opinion_NN on_IN the_DT effectiveness_NN of_IN the_DT Companys_NNP effective_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN of_IN December_NNP 31_CD ,_, internal_JJ control_NN over_IN financial_JJ reporting_NN based_VBN on_IN our_PRP$ audits_NN ._.
2005_CD ,_, is_VBZ fairly_RB stated_VBN ,_, in_IN all_DT material_NN respects_VBZ ,_, based_VBN on_IN the_DT criteria_NNS established_VBN in_IN Internal_NNP Control_NNP Integrated_NNP Framework_NNP issued_VBN by_IN the_DT We_PRP conducted_VBD our_PRP$ audits_NN in_IN accordance_NN with_IN the_DT standards_NNS Committee_NNP of_IN Sponsoring_NNP Organizations_NNP of_IN the_DT Treadway_NNP Commission_NNP ._.
of_IN the_DT Public_NNP Company_NNP Accounting_NNP Oversight_NNP Board_NNP United_NNP States_NNPS ._.
Furthermore_RB ,_, in_IN our_PRP$ opinion_NN ,_, the_DT Company_NN maintained_VBD ,_, in_IN all_DT material_NN Those_DT standards_NNS require_VBP that_IN we_PRP plan_VBP and_CC perform_VBP the_DT audit_NN to_TO obtain_VB respects_NNS ,_, effective_JJ internal_JJ control_NN over_IN financial_JJ reporting_NN as_IN of_IN reasonable_JJ assurance_NN about_IN whether_IN the_DT financial_JJ statements_NNS are_VBP free_JJ December_NNP 31_CD ,_, 2005_CD ,_, based_VBN on_IN the_DT criteria_NNS established_VBN in_IN Internal_NNP Control_NNP of_IN material_NN misstatement_NN and_CC whether_IN effective_JJ internal_JJ control_NN over_IN Integrated_NNP Framework_NNP issued_VBN by_IN the_DT Committee_NNP of_IN Sponsoring_VBG financial_JJ reporting_NN was_VBD maintained_VBN in_IN all_DT material_NN respects_VBZ ._.
Our_PRP$ audit_NN Organizations_NNP of_IN the_DT Treadway_NNP Commission_NNP ._.
of_IN financial_JJ statements_NNS included_VBD examining_VBG ,_, on_IN a_DT test_NN basis_NN ,_, evidence_NN supporting_VBG the_DT amounts_NNS and_CC disclosures_NNS in_IN the_DT financial_JJ statements_NNS ,_, Deloitte_NNP &_CC Touche_NNP LLP_NNP assessing_VBG the_DT accounting_NN principles_NNS used_VBN and_CC significant_JJ estimates_NNS Reading_VBG ,_, England_NNP made_VBN by_IN management_NN ,_, and_CC evaluating_VBG the_DT overall_JJ financial_JJ statement_NN March_NNP 1_CD ,_, 2006_CD presentation_NN ._.
Our_PRP$ audit_NN of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN included_VBD obtaining_VBG an_DT understanding_NN of_IN internal_JJ control_NN over_IN financial_JJ reporting_NN ,_, evaluating_VBG managements_NNS assessment_NN ,_, testing_NN and_CC evaluating_VBG the_DT design_NN and_CC operating_VBG effectiveness_NN of_IN internal_JJ control_NN ,_, and_CC performing_VBG such_JJ other_JJ procedures_NNS as_IN we_PRP considered_VBD necessary_JJ in_IN the_DT circumstances_NNS ._.
We_PRP believe_VBP that_IN our_PRP$ audits_NN provide_VB a_DT reasonable_JJ basis_NN for_IN our_PRP$ opinions_NNS ._.
A_DT companys_NNS internal_JJ control_NN over_IN financial_JJ reporting_NN is_VBZ a_DT process_NN designed_VBN by_IN ,_, or_CC under_IN the_DT supervision_NN of_IN ,_, the_DT companys_NNS principal_JJ executive_NN and_CC principal_JJ financial_JJ officers_NNS ,_, or_CC persons_NNS performing_VBG similar_JJ functions_NNS ,_, and_CC effected_VBN by_IN the_DT companys_NNS board_NN of_IN directors_NNS ,_, management_NN ,_, and_CC other_JJ personnel_NNS to_TO provide_VB reasonable_JJ assurance_NN regarding_VBG the_DT reliability_NN of_IN financial_JJ reporting_NN and_CC the_DT preparation_NN of_IN financial_JJ statements_NNS for_IN external_JJ purposes_NNS in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS ._.
A_DT companys_NNS internal_JJ control_NN over_IN financial_JJ reporting_NN includes_VBZ those_DT policies_NNS and_CC procedures_NNS that_WDT 1_CD pertain_NN to_TO the_DT maintenance_NN of_IN records_NNS that_IN ,_, in_IN reasonable_JJ detail_NN ,_, accurately_RB and_CC fairly_RB reflect_VBP the_DT transactions_NNS and_CC dispositions_NNS of_IN the_DT assets_NNS of_IN the_DT company_NN :_: 2_CD provide_VBP reasonable_JJ assurance_NN that_WDT transactions_NNS are_VBP recorded_VBN as_RB necessary_JJ to_TO permit_VB preparation_NN of_IN financial_JJ statements_NNS in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS and_CC that_IN receipts_NNS and_CC expenditures_NNS of_IN the_DT company_NN are_VBP being_VBG made_VBN only_RB in_IN accordance_NN with_IN authorizations_NNS of_IN management_NN and_CC directors_NNS of_IN the_DT company_NN :_: and_CC 3_CD provide_VBP reasonable_JJ assurance_NN regarding_VBG prevention_NN or_CC timely_JJ detection_NN of_IN unauthorized_JJ acquisition_NN ,_, use_NN ,_, or_CC disposition_NN of_IN the_DT companys_NNS assets_NNS that_WDT could_MD have_VB a_DT material_NN effect_NN on_IN the_DT financial_JJ statements_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 77_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 78_CD Consolidated_NNP balance_NN sheets_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN share_NN data_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 656,456_CD 1,111,477_CD Restricted_VBN cash_NN 30,568_CD 21,627_CD Short-term_JJ investments_NNS 10_CD 6,947_CD 324,411_CD Accounts_NNPS receivable_NN ,_, net_JJ 7_CD 329,924_CD 222,546_CD Inventories_NNS 8_CD 136,057_CD 41,230_CD Deferred_JJ tax_NN asset_NN 29_CD 54,186_CD 70,387_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 9_CD 98,084_CD 137,271_CD Total_JJ current_JJ assets_NNS 1,312,222_CD 1,928,949_CD Investments_NNP 11_CD 50,162_CD 63,267_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 12_CD 233,999_CD 131,351_CD Goodwill_NNP 13_CD 367,652_CD 235,396_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ 14_CD 729,304_CD 309,297_CD Deferred_JJ tax_NN asset_NN 29_CD 61,994_CD 7,724_CD Other_JJ non-current_JJ assets_NNS 15_CD 42,907_CD 38,895_CD Total_JJ assets_NNS 2,798,240_CD 2,714,879_CD Liabilities_NNS and_CC shareholders_NNS equity_NN Current_JJ liabilities_NNS :_: Loan_NN facility_NN to_TO ID_NNP Biomedical_NNP ,_, Inc._NNP 43,162_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS 16_CD 431,819_CD 311,231_CD Liability_NN to_TO dissenting_VBG shareholders_NNS 4_CD 427,609_CD Other_JJ current_JJ liabilities_NNS 17_CD 105,993_CD 77,558_CD Total_JJ current_JJ liabilities_NNS 965,421_CD 431,951_CD Long-term_JJ debt_NN ,_, excluding_VBG current_JJ installments_NNS 116_CD 116_CD Other_JJ non-current_JJ liabilities_NNS 19_CD 43,437_CD 32,159_CD Total_JJ liabilities_NNS 1,008,974_CD 464,226_CD Commitments_NNS and_CC contingencies_NNS 21_CD Shareholders_NNS equity_NN :_: Common_JJ stock_NN of_IN 5p_JJ par_JJ value_NN :_: 18,333,006,420_CD shares_NNS authorized_VBN :_: and_CC 495,733,782_CD shares_NNS issued_VBN and_CC outstanding_JJ 2004_CD :_: 800,000,000_CD shares_NNS authorized_VBN :_: and_CC 484,916,034_CD shares_NNS issued_VBN and_CC outstanding_JJ 2_CD 42,728_CD 41,796_CD Exchangeable_JJ shares_NNS :_: 2,187,793_CD shares_NNS issued_VBN and_CC outstanding_JJ 2004_CD :_: 4,226,476_CD 101,248_CD 195,830_CD Treasury_NNP stock_NN 22_CD 2,813_CD 264_CD Additional_JJ paid-in_JJ capital_NN 1,205,257_CD 1,070,675_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 71,472_CD 131,939_CD Retained_VBN earnings_NNS 371,374_CD 810,677_CD Total_JJ shareholders_NNS equity_NN 1,789,266_CD 2,250,653_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 2,798,240_CD 2,714,879_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
78_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 79_CD Consolidated_NNP statements_NNS of_IN operations_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN share_NN data_NNS 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Revenues_NNS :_: Product_NN sales_NNS 1,327,660_CD 1,112,457_CD 1,004,307_CD Royalties_NNS 242,910_CD 230,364_CD 203,573_CD Licensing_NN and_CC development_NN 15,002_CD 13,479_CD 3,677_CD Other_JJ revenues_NNS 13,744_CD 6,907_CD 13_CD Total_JJ revenues_NNS 1,599,316_CD 1,363,207_CD 1,211,570_CD Costs_NNS and_CC expenses_NNS :_: Cost_NN of_IN product_NN sales_NNS 213,964_CD 141,909_CD 143,160_CD Research_NNP and_CC development_NN 336,217_CD 196,265_CD 187,677_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 705,559_CD 516,645_CD 409,717_CD Intangible_JJ asset_NN impairment_NN 14_CD 5,632_CD 13,477_CD 27,489_CD Reorganization_NN costs_NNS 6_CD 9,335_CD 48,469_CD 23,940_CD Integration_NN costs_NNS 5_CD 9,716_CD In-process_JJ R&D_NNP write-off_NN 4_CD 673,000_CD Total_JJ operating_NN expenses_NNS 1,953,423_CD 916,765_CD 791,983_CD Operating_NN loss_NN income_NN 354,107_CD 446,442_CD 419,587_CD Interest_NN income_NN 35,300_CD 21,901_CD 16,856_CD Interest_NN expense_NN 27_CD 12,023_CD 12,294_CD 9,451_CD Other_JJ income_NN expense_NN ,_, net_JJ 26_CD 9,945_CD 3,845_CD 20,645_CD Total_JJ other_JJ income_NN expense_NN ,_, net_JJ 33,222_CD 13,452_CD 13,240_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS ,_, equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_NNS and_CC discontinued_VBN operations_NNS 320,885_CD 459,894_CD 406,347_CD Income_NN taxes_NNS 29_CD 92,083_CD 129,103_CD 107,353_CD Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_VBZ 30_CD 1,000_CD 2,508_CD 1,057_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS 413,968_CD 333,299_CD 297,937_CD Loss_NN from_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, $_$ nil_JJ and_CC $_$ nil_JJ respectively_RB 6_CD 20,135_CD 21,886_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS net_NN of_IN income_NN tax_NN expense_NN of_IN $_$ nil_CD ,_, $_$ nil_JJ and_CC $_$ nil_JJ respectively_RB 6_CD 3,125_CD 44,157_CD Net_JJ loss_NN income_NN 410,843_CD 269,007_CD 276,051_CD Earnings_NNS per_IN share_NN basic_JJ 24_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS 82.7_CD 67.2_CD 59.8_CD Loss_NN from_IN discontinued_VBN operations_NNS 4.1_CD 4.4_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS 0.6_CD 8.9_CD 82.1_CD 54.2_CD 55.4_CD Earnings_NNS per_IN share_NN diluted_VBN 24_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS 82.7_CD 65.9_CD 58.4_CD Loss_NN from_IN discontinued_VBN operations_NNS 4.0_CD 4.2_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS 0.6_CD 8.6_CD 82.1_CD 53.3_CD 54.2_CD Weighted_VBN average_JJ number_NN of_IN shares_NNS :_: Basic_JJ 500,243,137_CD 496,306,604_CD 498,212,826_CD Diluted_NNP 500,243,137_CD 511,267,432_CD 518,967,395_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 79_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 80_CD Consolidated_NNP statements_NNS of_IN changes_NNS in_IN shareholders_NNS equity_NN In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN share_NN data_NNS Accumulated_VBN other_JJ Common_JJ Exchangeable_JJ comprestock_NN shares_NNS Additionalhensive_NNP Total_NNP Common_NNP number_NN Exchangeable_JJ number_NN Treasury_NNP paid-in_JJ income_NN Retained_VBN shareholders_NNS stock_NN shares_NNS shares_NNS shares_NNS stock_NN capital_NN losses_NNS earnings_NNS equity_NN $_$ 000_CD 000s_CD $_$ 000_CD 000s_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN at_IN December_NNP 31_CD ,_, 2002_CD 40,051_CD 484,344_CD 272,523_CD 5,874_CD 1,027,499_CD 41,431_CD 274,524_CD 1,573,166_CD Effect_NN of_IN Scheme_NNP i_FW of_IN Arrangement_NNP 2,882,142_CD 2,882,142_CD i_FW Effect_NN of_IN capital_NN reduction_NN 2,880,447_CD 2,880,447_CD Net_JJ income_NN 276,051276,051_CD Foreign_JJ currency_NN translation_NN 114,116_CD 114,116_CD Redemption_NN of_IN common_JJ stock_NN 654_CD 7,593_CD 51,738_CD 52,392_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 9_CD 104_CD 1,856_CD 34_CD 1,847_CD Options_NNS exercised_VBN 90_CD 1,040_CD 5,105_CD 5,195_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 24_CD 24_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 692_CD 692_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ investments_NNS 6,322_CD 6,322_CD As_IN at_IN December_NNP 31_CD ,_, 2003_CD 41,191_CD 477,895_CD 270,667_CD 5,840_CD 981,686_CD 79,007_CD 550,575_CD 1,923,126_CD Net_JJ income_NN 269,007269,007_CD Foreign_JJ currency_NN translation_NN 46,801_CD 46,801_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 417_CD 4,839_CD 74,837_CD 1,614_CD 74,420_CD Options_NNS exercised_VBN 181_CD 2,09813,23513,416_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 216_CD 216_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 354_CD 354_CD New_NNP shares_NNS issued_VBD 7_CD 84 764 771_CD Treasury_NNP stock_NN 51,286_CD shares_NNS 264_CD 264_CD Unrealized_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 27,011_CD 27,011_CD Realized_VBN gain_NN on_IN available-for-sale_JJ securities_NNS 20,880_CD 20,880_CD Dividends_NNPS 8,905_CD 8,905_CD As_IN at_IN December_NNP 31_CD ,_, 2004_CD 41,796_CD 484,916_CD 195,830_CD 4,226_CD 264_CD 1,070,675_CD 131,939_CD 810,677_CD 2,250,653_CD Net_JJ loss_NN 410,843_CD 410,843_CD Foreign_JJ currency_NN translation_NN 55,976_CD 55,976_CD Exchange_NNP of_IN exchangeable_JJ shares_NNS 527_CD 6,116_CD 94,582_CD 2,038_CD 94,055_CD Options_NNS exercised_VBN 405_CD 4,70236,70837,113_CD Stock_NN option_NN compensation_NN and_CC warrants_NNS 392_CD 392_CD Tax_NNP benefit_NN associated_VBN with_IN exercise_NN of_IN stock_NN options_NNS 3,427_CD 3,427_CD Treasury_NNP stock_NN 242,302_CD shares_NNS 2,549_CD 2,549_CD Unrealized_JJ holding_VBG loss_NN on_IN available-for-sale_JJ securities_NNS 1,018_CD 1,018_CD Realized_VBN gain_NN on_IN available-for-sale_JJ securities_NNS 3,473_CD 3,473_CD Dividends_NNPS 28,460_CD 28,460_CD As_IN at_IN December_NNP 31_CD ,_, 2005_CD 42,728_CD 495,734_CD 101,248_CD 2,188_CD 2,813_CD 1,205,257_CD 71,472_CD 371,374_CD 1,789,266_CD i_FW Net_JJ increase_NN to_TO common_JJ stock_NN is_VBZ $_$ 1.7_CD million_CD ._.
The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Dividends_NNS per_IN share_NN During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN declared_VBD dividends_NNS totaling_VBG 5.6746_CD per_IN ordinary_JJ share_NN ,_, equivalent_JJ to_TO 17.02_CD per_IN American_JJ Depositary_NNP Share_NN ,_, and_CC 21.09_CD Canadian_JJ per_IN exchangeable_JJ share_NN ._.
Treasury_NNP stock_NN 191,016_CD shares_NNS were_VBD purchased_VBN during_IN 2005_CD at_IN a_DT cost_NN to_TO the_DT Company_NN of_IN $_$ 2.5_CD million_CD ._.
80_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 81_CD Consolidated_NNP statements_NNS of_IN comprehensive_JJ income_NN In_IN thousands_NNS of_IN US_NNP Dollars_NNPS 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ loss_NN income_NN 410,843_CD 269,007_CD 276,051_CD Other_JJ comprehensive_JJ income_NN :_: Foreign_JJ currency_NN translation_NN 55,976_CD 46,801_CD 114,116_CD Unrealized_JJ holding_VBG loss_NN gain_NN on_IN available-for-sale_JJ securities_NNS 1,018_CD 27,011_CD 6,322_CD Realized_VBN gain_NN on_IN available-for-sale_JJ securities_NNS 3,473_CD 20,880_CD Comprehensive_JJ loss_NN income_NN 471,310_CD 321,939_CD 396,489_CD The_DT components_NNS of_IN accumulated_VBN other_JJ comprehensive_JJ income_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Foreign_JJ currency_NN translation_NN 62,246_CD 118,222_CD Unrealized_JJ holding_NN gains_NNS on_IN available-for-sale_JJ securities_NNS 9,226_CD 13,717_CD Accumulated_VBN other_JJ comprehensive_JJ income_NN 71,472_CD 131,939_CD There_EX are_VBP no_DT material_NN tax_NN effects_NNS related_VBN to_TO the_DT items_NNS included_VBD above_RB ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 81_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 82_CD Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN Revised_VBN Revised_VBN 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN flows_VBZ from_IN activities_NNS :_: Net_JJ loss_NN income_NN from_IN continuing_VBG operations_NNS 413,968_CD 333,299_CD 297,937_CD Adjustments_NNS to_TO reconcile_VB net_JJ income_NN to_TO net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS :_: Depreciation_NN and_CC amortization_NN :_: Cost_NN of_IN product_NN sales_NNS 3,483_CD 2,740_CD 2,550_CD SG&A_NNP 67,977_CD 58,513_CD 35,642_CD Stock_NN option_NN compensation_NN 392_CD 216_CD 24_CD In-process_NN R&D_NNP write-off_NN 673,000_CD Write_VBP down_IN of_IN long-term_JJ assets_NNS 14,064_CD 29,317_CD 59,820_CD Gain_NN on_IN sale_NN of_IN long-term_JJ assets_NNS 3,854_CD 15,268_CD 169_CD Gain_NN on_IN sale_NN of_IN drug_NN formulation_NN business_NN 6_CD 3,561_CD Movement_NNP in_IN deferred_JJ taxes_NNS 22,295_CD 14,979_CD 22,193_CD Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_VBZ 1,000_CD 2,508_CD 1,057_CD Other_JJ 1,468_CD Changes_NNS in_IN operating_VBG assets_NNS and_CC liabilities_NNS ,_, net_NN of_IN acquisitions_NNS :_: Increase_VB in_IN accounts_NNS receivable_JJ 79,885_CD 28,066_CD 45,408_CD Increase_VBP in_IN sales_NNS deduction_NN accrual_NN 18,616_CD 50,746_CD 20,357_CD Decrease_NN in_IN inventory_NN 8,582_CD 2,185_CD 6,261_CD Increase_VBP decrease_NN in_IN prepayments_NNS and_CC other_JJ current_JJ assets_NNS 40,111_CD 2,509_CD 11,765_CD Increase_VBP in_IN property_NN ,_, plant_NN and_CC equipment_NN held_VBN for_IN sale_NN 12,470_CD Increase_VBP decrease_NN in_IN other_JJ assets_NNS 731_CD 13,520_CD 291_CD Increase_VBP decrease_NN in_IN accounts_NNS and_CC notes_NNS payable_JJ and_CC other_JJ liabilities_NNS 122,949_CD 76,793_CD 890_CD Decrease_NN increase_NN in_IN deferred_JJ revenue_NN 13,520_CD 6,151_CD 19,372_CD Returns_NNS on_IN investments_NNS 4,710_CD 4,043_CD 2,289_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 362_CD 30,525_CD 24,131_CD A_DT Net_JJ cash_NN provided_VBN by_IN operating_VBG activities_NNS 381,076_CD 488,686_CD 354,934_CD Cash_NN flows_VBZ from_IN investing_VBG activities_NNS :_: Movement_NNP in_IN short-term_JJ investments_NNS 366,731_CD 20,282_CD 11,997_CD Movements_NNS in_IN restricted_JJ cash_NN 768_CD 24,847_CD 5,531_CD Purchase_NN of_IN subsidiary_NN undertaking_NN 1,114,048_CD Expenses_NNS of_IN acquisition_NN 37,491_CD Purchase_NN of_IN long-term_JJ investments_NNS 7,700_CD 6,124_CD 5,643_CD Purchase_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 86,239_CD 57,603_CD 44,681_CD Purchase_NN of_IN intangible_JJ assets_NNS 20,491_CD 30,209_CD 47,049_CD Proceeds_NNS from_IN sale_NN of_IN long-term_JJ investments_NNS 10,135_CD 26,733_CD 1,000_CD Proceeds_NNS from_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 116_CD 3,527_CD 1,262_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 3,701_CD Proceeds_NNS from_IN sale_NN of_IN assets_NNS held_VBN for_IN sale_NN 11,289_CD Proceeds_NNS from_IN sale_NN of_IN drug_NN formulation_NN business_NN 557_CD Returns_NNS of_IN investments_NNS 3,774_CD 1,450_CD Loans_NNS made_VBN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP 43,162_CD 56,838_CD Deferred_JJ proceeds_NNS from_IN sale_NN of_IN the_DT vaccines_NNS business_NN 92,236_CD 34,912_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 12,715_CD 7,484_CD B_NNP Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 836,350_CD 77,312_CD 85,067_CD 82_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 83_CD Consolidated_NNP statements_NNS of_IN cash_NN flows_NNS continued_VBD In_IN thousands_NNS of_IN US_NNP Dollars_NNP Revised_VBD Revised_VBN 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS :_: Redemption_NN of_IN 2_CD %_NN convertible_JJ loan_NN notes_NNS 370,109_CD 29,775_CD Repayment_NN of_IN long-term_JJ debt_NN ,_, capital_NN leases_NNS and_CC notes_NNS 6,079_CD 231_CD Proceeds_NNS from_IN exercise_NN of_IN options_NNS 37,113_CD 13,416_CD 5,195_CD Proceeds_NNS from_IN issue_NN of_IN common_JJ stock_NN ,_, net_JJ 771_CD Tax_NNP benefit_NN of_IN stock_NN option_NN compensation_NN ,_, charged_VBN directly_RB to_TO reserves_NNS 3,427_CD 354_CD 692_CD Payments_NNS for_IN redemption_NN of_IN common_JJ stock_NN 52,392_CD Payments_NNS to_TO acquire_VB treasury_NN stock_NN 2,480_CD 264_CD Payment_NN of_IN dividend_NN 28,460_CD 8,905_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 706_CD C_NNP Net_JJ cash_NN provided_VBN by_IN used_VBN in_IN financing_NN activities_NNS 9,600_CD 370,816_CD 77,217_CD Effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS on_IN cash_NN and_CC cash_NN equivalents_NNS 9,347_CD 7,567_CD 25,133_CD Effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS on_IN discontinued_VBN operations_NNS 10_CD 111_CD D_NNP Net_JJ effect_NN of_IN foreign_JJ exchange_NN rate_NN changes_NNS 9,347_CD 7,557_CD 25,244_CD A_DT B_NNP C_NNP D_NNP Net_JJ decrease_NN increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 455,021_CD 48,115_CD 217,894_CD Cash_NN flows_NNS used_VBN in_IN discontinued_VBN operations_NNS 327_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN period_NN 1,111,477_CD 1,063,362_CD 845,141_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN period_NN 656,456_CD 1,111,477_CD 1,063,362_CD Supplemental_NNP information_NN associated_VBN with_IN continuing_VBG operations_NNS :_: Revised_VBN Revised_VBN 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Interest_NN paid_VBN 4,334_CD 4,849_CD 7,716_CD Income_NN taxes_NNS paid_VBD 54,096_CD 123,510_CD 118,527_CD Non_NNP cash_NN activities_NNS :_: Proceeds_NNS from_IN sale_NN of_IN drug_NN formulation_NN business_NN :_: Equity_NN in_IN Supernus_NNP Pharmaceuticals_NNP Inc._NNP 3,900_CD Proceeds_NNS from_IN sale_NN of_IN a_DT business_NN :_: 4,931,864_CD shares_NNS of_IN IDB_NNP 60,000_CD Escrow_NNP funds_NNS 30,000_CD The_DT accompanying_JJ notes_NNS are_VBP an_DT integral_JJ part_NN of_IN these_DT consolidated_JJ financial_JJ statements_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 83_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 84_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 1_CD Description_NN of_IN operations_NNS Shire_NNP plcs_VBZ Shire_NNP and_CC its_PRP$ subsidiaries_NNS ,_, collectively_RB referred_VBD to_TO as_IN the_DT Company_NN or_CC the_DT Group_NNP ,_, strategic_JJ goal_NN is_VBZ to_TO become_VB the_DT leading_VBG specialty_NN pharmaceutical_JJ company_NN that_WDT focuses_VBZ on_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN ._.
Shires_NNP therapeutic_JJ focus_NN is_VBZ on_IN Central_NNP Nervous_NNP System_NNP CNS_NNP ,_, Gastro-Intestinal_NNP GI_NNP ,_, Human_NNP Genetic_NNP Therapies_NNPS Shire_NNP HGT_NNP and_CC General_NNP Products_NNPS GP_NNP ._.
The_DT structure_NN is_VBZ sufficiently_RB flexible_JJ to_TO allow_VB Shire_NNP to_TO target_VB new_JJ therapeutic_JJ areas_NNS to_TO the_DT extent_NN opportunities_NNS arise_VBP through_IN acquisitions_NNS ._.
Shire_NNP believes_VBZ that_IN a_DT carefully_RB selected_VBN portfolio_NN of_IN products_NNS with_IN strategically_RB aligned_VBN and_CC relatively_RB small-scale_JJ sales_NNS forces_NNS will_MD deliver_VB strong_JJ results_NNS ._.
Shires_NNP focused_VBD strategy_NN is_VBZ to_TO develop_VB and_CC market_NN products_NNS for_IN specialty_NN physicians_NNS ._.
Shires_NNP in-licensing_NN ,_, merger_NN and_CC acquisition_NN efforts_NNS are_VBP focused_VBN on_IN products_NNS in_IN niche_NN markets_NNS with_IN strong_JJ intellectual_JJ property_NN protection_NN either_RB in_IN the_DT US_NNP or_CC Europe_NNP ._.
Consistent_JJ with_IN this_DT strategy_NN the_DT Company_NN completed_VBD the_DT acquisition_NN of_IN Transkaryotic_NNP Therapies_NNPS Inc._NNP ._.
TKT_NNP on_IN July_NNP 27_CD ,_, 2005_CD ._.
This_DT acquisition_NN added_VBD Shire_NNP HGT_NNP to_TO the_DT Groups_NNS existing_VBG business_NN ,_, which_WDT is_VBZ complementary_JJ to_TO ,_, and_CC consistent_JJ with_IN ,_, the_DT Companys_NNP stated_VBD strategy_NN of_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN using_VBG small-scale_JJ sales_NNS forces_NNS ._.
TKT_NNP was_VBD renamed_VBN Shire_NNP Human_NNP Genetic_NNP Therapies_NNPS with_IN effect_NN from_IN January_NNP 17_CD ,_, 2006_CD ._.
2_CD Change_NNP in_IN reporting_VBG entity_NN On_IN November_NNP 25_CD ,_, 2005_CD ,_, Shire_NNP plc_NN ,_, a_DT public_JJ limited_JJ Company_NN incorporated_VBN in_IN England_NNP and_CC Wales_NNP ,_, became_VBD the_DT holding_VBG company_NN of_IN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN SPG_NNP pursuant_JJ to_TO a_DT Scheme_NN of_IN Arrangement_NN under_IN Section_NN 425_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD that_WDT was_VBD approved_VBN by_IN the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP and_CC the_DT shareholders_NNS of_IN SPG_NNP the_DT Scheme_NNP of_IN Arrangement_NNP ._.
Pursuant_JJ to_TO the_DT Scheme_NN of_IN Arrangement_NN ,_, ordinary_JJ shares_NNS ,_, each_DT having_VBG a_DT nominal_JJ value_NN of_IN 3.50_CD ,_, of_IN Shire_NNP Shire_NNP Ordinary_NNP Shares_NNP were_VBD exchanged_VBN for_IN ordinary_JJ shares_NNS ,_, each_DT having_VBG a_DT nominal_JJ value_NN of_IN 0.05_CD of_IN SPG_NNP SPG_NNP Ordinary_NNP Shares_NNP ,_, on_IN a_DT one-for-one_JJ basis_NN ._.
As_IN a_DT result_NN of_IN the_DT Scheme_NNP of_IN Arrangement_NNP ,_, SPG_NNP is_VBZ now_RB a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP and_CC has_VBZ been_VBN re-registered_VBN as_IN a_DT private_JJ Company_NN under_IN the_DT name_NN Shire_NNP Pharmaceuticals_NNP Group_NNP Limited_NNP ._.
The_DT Shire_NNP Ordinary_NNP Shares_NNP carry_VBP substantially_RB the_DT same_JJ rights_NNS as_IN did_VBD the_DT SPG_NNP Ordinary_NNP Shares_NNP ._.
The_DT Scheme_NN of_IN Arrangement_NN did_VBD not_RB involve_VB any_DT payment_NN for_IN the_DT new_JJ Shire_NNP Ordinary_NNP Shares_NNP ._.
Shires_NNP Board_NNP of_IN Directors_NNS ,_, management_NN and_CC corporate_JJ governance_NN arrangements_NNS immediately_RB following_VBG the_DT Scheme_NN of_IN Arrangement_NN were_VBD the_DT same_JJ as_IN SPG_NNP immediately_RB before_IN the_DT Scheme_NN of_IN Arrangement_NN became_VBD effective_JJ ._.
The_DT consolidated_JJ assets_NNS and_CC liabilities_NNS of_IN Shire_NNP immediately_RB after_IN the_DT Scheme_NN of_IN Arrangement_NN were_VBD the_DT same_JJ as_IN the_DT consolidated_JJ assets_NNS and_CC liabilities_NNS of_IN SPG_NNP immediately_RB prior_RB thereto_RB ._.
The_DT SPG_NNP Ordinary_NNP Shares_NNP underlying_VBG the_DT SPG_NNP American_NNP Depositary_NNP Shares_NNP the_DT SPG_NNP ADSs_NNPS ,_, each_DT representing_VBG three_CD SPG_NNP Ordinary_NNP Shares_NNP ,_, participated_VBD in_IN the_DT Scheme_NNP of_IN Arrangement_NNP like_IN all_DT other_JJ SPG_NNP Ordinary_NNP Shares_NNP ._.
The_DT Scheme_NN of_IN Arrangement_NN did_VBD not_RB involve_VB any_DT payment_NN for_IN the_DT new_JJ Shire_NNP ADSs_NNP ,_, which_WDT represent_VBP three_CD ordinary_JJ shares_NNS of_IN Shire_NNP ._.
Shire_NNP was_VBD incorporated_VBN on_IN June_NNP 27_CD ,_, 2005_CD ._.
Prior_RB to_TO November_NNP 25_CD ,_, 2005_CD Shire_NNP had_VBD not_RB commenced_VBN trading_NN or_CC made_VBN any_DT profits_NNS or_CC trading_NN losses_NNS ._.
On_IN November_NNP 28_CD ,_, 2005_CD ,_, the_DT High_NNP Court_NNP of_IN Justice_NNP in_IN England_NNP and_CC Wales_NNP approved_VBD a_DT reduction_NN of_IN Shires_NNP share_NN capital_NN to_TO take_VB effect_NN on_IN November_NNP 29_CD ,_, 2005_CD ,_, when_WRB the_DT nominal_JJ value_NN of_IN each_DT Shire_NNP ordinary_JJ share_NN was_VBD reduced_VBN from_IN 3.50_CD to_TO 0.05_CD ._.
This_DT reduction_NN increased_VBD the_DT distributable_JJ reserves_NNS potentially_RB available_JJ to_TO Shire_VB to_TO approximately_RB $_$ 2.95_CD billion_CD ,_, which_WDT the_DT Directors_NNS of_IN Shire_NNP can_MD utilize_VB for_IN future_JJ dividend_NN payments_NNS at_IN their_PRP$ discretion_NN ._.
In_IN accordance_NN with_IN Statement_NN of_IN Financial_NNP Accounting_NNP Standards_NNPS SFAS_NNP No._NN ._.
141_CD Accounting_NN for_IN Business_NNP Combinations_NNPS ,_, the_DT corporate_JJ restructuring_NN is_VBZ accounted_VBN for_IN as_IN a_DT reorganization_NN of_IN entities_NNS under_IN common_JJ control_NN ._.
Accordingly_RB ,_, the_DT historical_JJ financial_JJ statements_NNS prior_RB to_TO the_DT reorganization_NN are_VBP labeled_VBN as_IN those_DT of_IN Shire_NNP ,_, but_CC continue_VBP to_TO represent_VB the_DT operations_NNS of_IN SPG_NNP ._.
For_IN periods_NNS prior_RB to_TO the_DT corporate_JJ restructuring_NN ,_, the_DT equity_NN of_IN Shire_NNP represents_VBZ the_DT historical_JJ equity_NN of_IN SPG_NNP ,_, restated_VBN to_TO reflect_VB the_DT nominal_JJ value_NN of_IN shares_NNS received_VBN in_IN the_DT Scheme_NN of_IN Arrangement_NN as_IN adjusted_VBN by_IN the_DT reduction_NN of_IN capital_NN ._.
The_DT difference_NN in_IN the_DT nominal_JJ value_NN of_IN shares_NNS before_IN and_CC after_IN the_DT restatement_NN relates_VBZ to_TO the_DT effect_NN of_IN foreign_JJ exchange_NN movements_NNS and_CC the_DT offset_VBN is_VBZ recorded_VBN in_IN additional_JJ paid-in_JJ capital_NN ._.
Earnings_NNS per_IN share_NN are_VBP unaffected_JJ by_IN the_DT reorganization_NN ._.
All_DT SPG_NNP stock_NN options_NNS granted_VBN to_TO Directors_NNS and_CC employees_NNS under_IN stock_NN option_NN plans_NNS that_WDT were_VBD in_IN existence_NN immediately_RB prior_RB to_TO the_DT Scheme_NN of_IN Arrangement_NN were_VBD exchangeable_JJ for_IN stock_NN options_NNS in_IN Shire_NNP on_IN a_DT one-for-one_JJ basis_NN with_IN no_DT change_NN in_IN any_DT of_IN the_DT terms_NNS or_CC conditions_NNS ._.
The_DT number_NN of_IN stock_NN options_NNS for_IN which_WDT this_DT exchange_NN did_VBD not_RB take_VB place_NN was_VBD not_RB material_NN ._.
For_IN presented_VBN periods_NNS prior_RB to_TO the_DT 2005_CD corporate_JJ restructuring_NN ,_, the_DT equity_NN of_IN Shire_NNP represents_VBZ the_DT historical_JJ equity_NN of_IN SPG_NNP ,_, restated_VBN to_TO reflect_VB the_DT change_NN in_IN nominal_JJ value_NN of_IN shares_NNS resulting_VBG from_IN the_DT corporate_JJ restructuring_NN ._.
The_DT increase_NN in_IN the_DT value_NN of_IN common_JJ stock_NN at_IN December_NNP 31_CD ,_, 2002_CD of_IN $_$ 1.7_CD million_CD to_TO $_$ 41.7_CD million_CD on_IN restatement_NN is_VBZ due_JJ to_TO differences_NNS between_IN the_DT historic_JJ exchange_NN rates_NNS used_VBN to_TO convert_VB SPGs_NNP Sterling_NNP denominated_VBD nominal_JJ share_NN capital_NN into_IN US_NNP Dollars_NNPS ,_, and_CC the_DT exchange_NN rate_NN at_IN the_DT time_NN of_IN the_DT corporate_JJ restructuring_NN ._.
The_DT offset_VBN is_VBZ recorded_VBN in_IN additional_JJ paid-in_JJ capital_NN ._.
84_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 85_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS a_DT Basis_NN of_IN preparation_NN The_DT accompanying_VBG consolidated_JJ financial_JJ statements_NNS include_VBP the_DT accounts_NNS of_IN Shire_NNP and_CC all_DT of_IN its_PRP$ subsidiary_NN undertakings_NNS after_IN elimination_NN of_IN intercompany_NN accounts_NNS and_CC transactions_NNS ._.
b_NN Use_NN of_IN estimates_NNS in_IN consolidated_JJ financial_JJ statements_NNS The_DT preparation_NN of_IN consolidated_JJ financial_JJ statements_NNS ,_, in_IN conformity_NN with_IN US_NNP generally_RB accepted_VBD accounting_NN principles_NNS GAAP_NNP and_CC Securities_NNP Exchange_NNP Commission_NNP SEC_NNP regulations_NNS ,_, requires_VBZ management_NN to_TO make_VB estimates_NNS and_CC assumptions_NNS that_WDT affect_VBP the_DT reported_VBN amounts_NNS of_IN assets_NNS and_CC liabilities_NNS ,_, disclosure_NN of_IN contingent_JJ assets_NNS and_CC liabilities_NNS at_IN the_DT date_NN of_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC reported_VBD amounts_NNS of_IN revenues_NNS and_CC expenses_NNS during_IN the_DT reporting_NN period_NN ._.
Actual_JJ results_NNS could_MD differ_VB from_IN those_DT estimates_NNS ._.
Estimates_NNS and_CC assumptions_NNS are_VBP primarily_RB made_VBN in_IN relation_NN to_TO provisions_NNS for_IN sales_NNS deductions_NNS ,_, valuation_NN of_IN intangible_JJ assets_NNS and_CC fixed_VBN asset_NN investments_NNS ,_, contingent_JJ liabilities_NNS ,_, the_DT valuation_NN of_IN tax_NN assets_NNS and_CC liabilities_NNS ,_, the_DT valuation_NN of_IN in-process_JJ research_NN and_CC development_NN and_CC inventory_NN acquired_VBN with_IN TKT_NNP and_CC the_DT amount_NN payable_JJ to_TO former_JJ holders_NNS of_IN TKT_NNP common_JJ stock_NN of_IN approximately_RB 11.3_CD million_CD shares_NNS who_WP have_VBP submitted_VBN written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS in_IN relation_NN to_TO the_DT Companys_NNPS acquisition_NN of_IN TKT_NNP on_IN July_NNP 27_CD ,_, 2005_CD ._.
c_NN Revenue_NN recognition_NN The_DT Company_NN recognizes_VBZ revenue_NN when_WRB :_: there_EX is_VBZ persuasive_JJ evidence_NN of_IN an_DT agreement_NN or_CC arrangement_NN :_: delivery_NN of_IN products_NNS has_VBZ occurred_VBN or_CC services_NNS have_VBP been_VBN rendered_VBN :_: the_DT sellers_NNS price_NN to_TO the_DT buyer_NN is_VBZ fixed_VBN or_CC determinable_JJ :_: and_CC collectability_NN is_VBZ reasonably_RB assured_VBN ._.
The_DT Companys_NNPS principal_JJ revenue_NN streams_NNS and_CC their_PRP$ respective_JJ accounting_NN treatments_NNS are_VBP discussed_VBN below_IN :_: i_FW Product_NNP sales_NNS Revenue_NN for_IN the_DT sales_NNS of_IN products_NNS is_VBZ recognized_VBN upon_IN shipment_NN to_TO customers_NNS or_CC at_IN the_DT time_NN of_IN delivery_NN depending_VBG on_IN the_DT terms_NNS of_IN sale_NN ._.
Provisions_NNS for_IN rebates_NNS ,_, product_NN returns_NNS and_CC discounts_NNS to_TO customers_NNS are_VBP provided_VBN for_IN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
The_DT Company_NN monitors_NNS and_CC tracks_VBZ the_DT amount_NN of_IN sales_NNS deductions_NNS based_VBN on_IN historical_JJ experience_NN to_TO estimate_VB the_DT amount_NN of_IN reduction_NN to_TO revenue_NN ._.
ii_FW Licensing_NN and_CC development_NN fees_NNS Licensing_VBG and_CC development_NN fees_NNS represent_VBP revenues_NNS derived_VBN from_IN product_NN out-licensing_JJ agreements_NNS and_CC from_IN contract_NN research_NN and_CC development_NN agreements_NNS ._.
Initial_JJ license_NN fees_NNS received_VBN in_IN connection_NN with_IN product_NN out-licensing_JJ agreements_NNS ,_, even_RB where_WRB such_JJ fees_NNS are_VBP non-refundable_JJ and_CC not_RB creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN of_IN the_DT license_NN term_NN ,_, or_CC the_DT period_NN of_IN the_DT associated_VBN collaborative_JJ assistance_NN ._.
In_IN circumstances_NNS where_WRB initial_JJ license_NN fees_NNS are_VBP not_RB for_IN a_DT defined_VBN period_NN ,_, revenues_NNS are_VBP deferred_VBN and_CC recognized_VBN over_IN the_DT period_NN to_TO the_DT expiration_NN of_IN the_DT relevant_JJ patent_NN to_TO which_WDT the_DT license_NN relates_VBZ ._.
Revenue_NN from_IN contract_NN research_NN and_CC development_NN agreements_NNS is_VBZ recognized_VBN as_IN the_DT services_NNS are_VBP performed_VBN ._.
iii_FW Royalty_NN income_NN Royalty_NN income_NN relating_VBG to_TO licensed_JJ technology_NN is_VBZ recognized_VBN when_WRB the_DT licensee_NN sells_VBZ the_DT underlying_JJ product_NN ._.
The_DT Company_NN receives_VBZ sales_NNS information_NN from_IN the_DT licensee_NN on_IN a_DT monthly_JJ basis_NN ._.
For_IN any_DT period_NN that_IN the_DT information_NN is_VBZ not_RB available_JJ ,_, the_DT Company_NN estimates_VBZ sales_NNS amounts_NNS based_VBN on_IN the_DT historical_JJ product_NN information_NN ._.
Where_WRB applicable_JJ ,_, all_DT revenues_NNS are_VBP stated_VBN net_NN of_IN value_NN added_VBD tax_NN and_CC similar_JJ taxes_NNS ,_, and_CC trade_NN discounts_NNS ._.
No_DT revenue_NN is_VBZ recognized_VBN for_IN consideration_NN ,_, the_DT value_NN or_CC receipt_NN of_IN which_WDT is_VBZ dependent_JJ on_IN future_JJ events_NNS ,_, future_JJ performance_NN ,_, or_CC refund_NN obligations_NNS ._.
iv_NN Milestones_NNS During_IN the_DT term_NN of_IN certain_JJ research_NN and_CC development_NN agreements_NNS and_CC licensing_NN agreements_NNS ,_, the_DT Company_NN receives_VBZ non-refundable_JJ milestones_NNS as_IN certain_JJ technical_JJ targets_NNS are_VBP achieved_VBN ._.
Revenues_NNS are_VBP recognized_VBN on_IN achievement_NN of_IN such_JJ milestones_NNS ._.
The_DT Company_NN also_RB receives_VBZ non-refundable_JJ clinical_JJ milestones_NNS when_WRB certain_JJ targets_NNS are_VBP achieved_VBN during_IN the_DT clinical_JJ phases_NNS of_IN development_NN ,_, such_JJ as_IN the_DT submission_NN of_IN clinical_JJ data_NNS to_TO a_DT regulatory_JJ authority_NN ._.
These_DT clinical_JJ milestones_NNS are_VBP recognized_VBN when_WRB receivable_JJ i._NN e._NN on_IN completion_NN of_IN the_DT relevant_JJ phase_NN ._.
If_IN milestone_NN payments_NNS are_VBP creditable_JJ against_IN future_JJ royalty_NN payments_NNS ,_, the_DT milestones_NNS are_VBP deferred_VBN and_CC released_VBN over_IN the_DT period_NN in_IN which_WDT the_DT royalties_NNS are_VBP anticipated_VBN to_TO be_VB paid_VBN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 85_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 86_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD d_SYM Sales_NNS deductions_NNS i_FW Rebates_NNPS Rebates_NNPS primarily_RB consist_VBP of_IN statutory_JJ rebates_NNS to_TO state_NN Medicaid_NNP agencies_NNS and_CC contractual_JJ rebates_NNS with_IN health-maintenance_NN organizations_NNS ._.
These_DT rebates_NNS are_VBP based_VBN on_IN price_NN differentials_NNS between_IN a_DT base_NN price_NN and_CC the_DT selling_NN price_NN ._.
As_IN a_DT result_NN ,_, rebates_NNS generally_RB increase_VB as_IN a_DT percentage_NN of_IN the_DT selling_NN price_NN over_IN the_DT life_NN of_IN the_DT product_NN as_IN prices_NNS increase_NN ._.
Provisions_NNS for_IN rebates_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS ,_, with_IN estimates_NNS of_IN future_JJ utilization_NN derived_VBN from_IN historical_JJ trends_NNS ._.
ii_FW Returns_NNPS The_DT Company_NN estimates_VBZ the_DT proportion_NN of_IN recorded_JJ revenue_NN that_WDT will_MD result_VB in_IN a_DT return_NN ,_, based_VBN on_IN historical_JJ trends_NNS and_CC when_WRB applicable_JJ ,_, specific_JJ factors_NNS affecting_VBG certain_JJ products_NNS at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT accrual_NN is_VBZ recorded_VBN as_IN a_DT reduction_NN to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
iii_FW Coupons_NNPS The_DT Company_NN uses_VBZ coupons_NNS as_IN a_DT form_NN of_IN sales_NNS incentive_NN ._.
An_DT accrual_NN is_VBZ established_VBN based_VBN on_IN the_DT Companys_NNP expectation_NN of_IN the_DT level_NN of_IN coupon_NN redemption_NN ,_, using_VBG historical_JJ trends_NNS ._.
iv_FW Discounts_NNPS The_DT Company_NN offers_VBZ cash_NN discounts_NNS to_TO customers_NNS for_IN the_DT early_JJ payment_NN of_IN receivables_NN ._.
Those_DT discounts_NNS are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN and_CC accounts_NNS receivable_NN in_IN the_DT same_JJ period_NN that_IN the_DT related_JJ sale_NN is_VBZ recorded_VBN ._.
v_FW Wholesaler_NNP chargebacks_VBZ The_DT Company_NN has_VBZ contractual_JJ agreements_NNS whereby_WRB it_PRP supplies_VBZ certain_JJ products_NNS to_TO third_JJ parties_NNS at_IN predetermined_VBN prices_NNS ._.
Wholesalers_NNS acting_VBG as_IN intermediaries_NNS in_IN these_DT transactions_NNS are_VBP reimbursed_VBN by_IN the_DT Company_NN if_IN the_DT predetermined_VBN prices_NNS are_VBP less_JJR than_IN the_DT prices_NNS paid_VBN by_IN the_DT wholesaler_NN to_TO the_DT Company_NN ._.
Accruals_NNS for_IN wholesaler_NN chargebacks_NNS ,_, which_WDT are_VBP based_VBN on_IN historical_JJ trends_NNS ,_, are_VBP recorded_VBN as_IN reductions_NNS to_TO revenue_NN in_IN the_DT same_JJ period_NN as_IN the_DT related_JJ sales_NNS are_VBP recorded_VBN ._.
e_LS Cost_NN of_IN product_NN sales_NNS Cost_NN of_IN sales_NNS includes_VBZ both_DT the_DT cost_NN of_IN purchasing_VBG finished_JJ product_NN for_IN sale_NN ,_, together_RB with_IN the_DT cost_NN of_IN raw_JJ materials_NNS and_CC manufacturing_VBG for_IN those_DT products_NNS that_WDT are_VBP manufactured_VBN by_IN the_DT Company_NN ._.
Royalties_NNS that_WDT are_VBP payable_JJ on_IN those_DT products_NNS that_IN the_DT Company_NN does_VBZ not_RB own_VB the_DT rights_NNS to_TO are_VB also_RB included_VBN in_IN cost_NN of_IN sales_NNS ._.
f_LS Leased_VBN assets_NNS The_DT costs_NNS of_IN operating_VBG leases_NNS are_VBP charged_VBN to_TO operations_NNS on_IN a_DT straight-line_JJ basis_NN over_IN the_DT lease_NN term_NN ,_, even_RB if_IN rental_JJ payments_NNS are_VBP not_RB made_VBN on_IN such_PDT a_DT basis_NN ._.
Assets_NNS acquired_VBN under_IN capital_NN leases_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN as_IN tangible_JJ fixed_JJ assets_NNS and_CC are_VBP depreciated_VBN over_IN the_DT shorter_JJR of_IN the_DT period_NN of_IN the_DT lease_NN or_CC their_PRP$ useful_JJ lives_NNS ._.
The_DT capital_NN elements_NNS of_IN future_JJ lease_NN payments_NNS are_VBP recorded_VBN as_IN liabilities_NNS ,_, while_IN the_DT interest_NN element_NN is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT period_NN of_IN the_DT lease_NN to_TO produce_VB a_DT level_NN yield_NN on_IN the_DT balance_NN of_IN the_DT capital_NN lease_NN obligation_NN ._.
g_NN Advertising_NN expense_NN The_DT Company_NN expenses_NNS the_DT cost_NN of_IN advertising_NN as_IN incurred_VBN ._.
Advertising_NN costs_NNS amounted_VBD to_TO $_$ 62.3_CD million_CD ,_, $_$ 47.6_CD million_CD ,_, and_CC $_$ 40.7_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD respectively_RB ._.
h_NN Valuation_NN and_CC impairment_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS The_DT Company_NN evaluates_VBZ the_DT carrying_VBG value_NN of_IN long-lived_JJ assets_NNS other_JJ than_IN goodwill_NN and_CC investments_NNS for_IN impairment_NN whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG amounts_NNS of_IN the_DT assets_NNS may_MD not_RB be_VB recoverable_JJ ._.
When_WRB such_PDT a_DT determination_NN is_VBZ made_VBN ,_, managements_NNS estimate_NN of_IN undiscounted_JJ cash_NN flows_VBZ to_TO be_VB generated_VBN by_IN the_DT assets_NNS is_VBZ compared_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT assets_NNS to_TO determine_VB whether_IN an_DT impairment_NN has_VBZ occurred_VBN ._.
If_IN an_DT impairment_NN is_VBZ indicated_VBN ,_, the_DT amount_NN of_IN the_DT impairment_NN recognized_VBN in_IN the_DT consolidated_JJ financial_JJ statements_NNS is_VBZ determined_VBN by_IN estimating_VBG the_DT fair_JJ value_NN of_IN the_DT assets_NNS and_CC recording_VBG a_DT loss_NN for_IN the_DT amount_NN that_IN the_DT carrying_VBG value_NN exceeds_VBZ the_DT estimated_VBN fair_JJ value_NN ._.
This_DT fair_JJ value_NN is_VBZ usually_RB determined_VBN based_VBN on_IN estimated_VBN discounted_JJ cash_NN flows_NNS ._.
i_FW Finance_NNP costs_NNS of_IN debt_NN Finance_NNP costs_NNS of_IN debt_NN are_VBP recorded_VBN as_IN a_DT deferred_JJ asset_NN and_CC amortized_VBN to_TO the_DT statement_NN of_IN operations_NNS over_IN the_DT term_NN of_IN the_DT debt_NN ,_, using_VBG the_DT effective_JJ interest_NN rate_NN method_NN ._.
Deferred_JJ financing_NN costs_NNS relating_VBG to_TO debt_NN extinguishments_NNS are_VBP written_VBN off_RP and_CC reflected_VBN in_IN interest_NN expense_NN in_IN the_DT consolidated_JJ statements_NNS of_IN operations_NNS ._.
j_NNP Foreign_NNP currency_NN Monetary_NNP assets_NNS and_CC liabilities_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT balance_NN sheet_NN date_NN ._.
Transactions_NNS in_IN foreign_JJ currencies_NNS are_VBP translated_VBN into_IN the_DT relevant_JJ functional_JJ currency_NN at_IN the_DT rate_NN of_IN exchange_NN ruling_NN at_IN the_DT date_NN of_IN the_DT transaction_NN ._.
Transaction_NN gains_NNS and_CC losses_NNS are_VBP recognized_VBN in_IN arriving_VBG at_IN operating_VBG net_JJ loss_NN income_NN ._.
The_DT results_NNS of_IN overseas_JJ operations_NNS ,_, whose_WP$ functional_JJ currency_NN is_VBZ not_RB US_NNP Dollars_NNPS ,_, are_VBP translated_VBN at_IN the_DT average_JJ monthly_JJ rates_NNS of_IN exchange_NN during_IN the_DT period_NN and_CC their_PRP$ balance_NN sheets_NNS at_IN the_DT rates_NNS ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
The_DT cumulative_JJ effect_NN of_IN exchange_NN rate_NN movements_NNS is_VBZ included_VBN in_IN a_DT separate_JJ component_NN of_IN other_JJ comprehensive_JJ income_NN ._.
86_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 87_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD Foreign_JJ currency_NN exchange_NN transaction_NN gains_NNS and_CC losses_NNS on_IN an_DT after-tax_JJ basis_NN included_VBD in_IN consolidated_JJ net_JJ income_NN in_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD ,_, and_CC 2003_CD ,_, amounted_VBD to_TO a_DT $_$ 1.4_CD million_CD loss_NN ,_, $_$ 2.5_CD million_CD loss_NN and_CC $_$ 6.7_CD million_CD loss_NN ,_, respectively_RB ._.
k_NN Income_NN taxes_NNS The_DT Company_NN provides_VBZ for_IN income_NN taxes_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP provided_VBN for_IN differences_NNS between_IN the_DT carrying_VBG amounts_NNS of_IN assets_NNS and_CC liabilities_NNS in_IN the_DT consolidated_JJ financial_JJ statements_NNS and_CC the_DT tax_NN bases_NNS of_IN assets_NNS and_CC liabilities_NNS that_WDT will_MD result_VB in_IN future_JJ taxable_JJ or_CC deductible_JJ amounts_NNS ._.
The_DT deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP measured_VBN using_VBG the_DT enacted_VBN tax_NN laws_NNS and_CC rates_NNS applicable_JJ to_TO the_DT periods_NNS in_IN which_WDT the_DT differences_NNS are_VBP expected_VBN to_TO affect_VB taxable_JJ income_NN ._.
Income_NNP tax_NN expense_NN is_VBZ computed_VBN as_IN the_DT tax_NN payable_JJ or_CC refundable_JJ for_IN the_DT period_NN ,_, plus_CC or_CC minus_CC the_DT change_NN during_IN the_DT period_NN in_IN deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS ._.
Deferred_JJ tax_NN assets_NNS are_VBP reduced_VBN by_IN a_DT valuation_NN allowance_NN when_WRB ,_, in_IN the_DT opinion_NN of_IN management_NN ,_, it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN some_DT portion_NN or_CC all_DT of_IN the_DT deferred_JJ tax_NN assets_NNS will_MD not_RB be_VB realized_VBN ._.
l_NN Earnings_NNS per_IN share_NN Earnings_NNS per_IN share_NN is_VBZ computed_VBN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
Basic_JJ earnings_NNS per_IN share_NN is_VBZ based_VBN upon_IN net_JJ income_NN loss_NN available_JJ to_TO ordinary_JJ shareholders_NNS divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT period_NN ._.
Diluted_JJ earnings_NNS per_IN share_NN is_VBZ based_VBN upon_IN net_JJ income_NN loss_NN available_JJ to_TO ordinary_JJ shareholders_NNS adjusted_VBN for_IN the_DT impact_NN on_IN interest_NN expense_NN of_IN including_VBG convertible_JJ debt_NN in_IN ordinary_JJ share_NN equivalents_NNS on_IN an_DT if_IN converted_VBN basis_NN divided_VBN by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ share_NN equivalents_NNS outstanding_JJ during_IN the_DT period_NN ,_, adjusted_VBN for_IN the_DT effect_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS that_WDT were_VBD outstanding_JJ during_IN the_DT year_NN ._.
Such_JJ potentially_RB dilutive_JJ shares_NNS are_VBP excluded_VBN when_WRB the_DT effect_NN would_MD be_VB to_TO increase_VB earnings_NNS per_IN share_NN or_CC reduce_VB a_DT loss_NN per_IN share_NN ._.
m_VB Employee_NNP stock_NN plans_VBZ The_DT Company_NN accounts_NNS for_IN its_PRP$ stock_NN options_NNS using_VBG the_DT intrinsic-value_JJ method_NN prescribed_VBN in_IN Accounting_NNP Principles_NNP Board_NNP Opinion_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS APB_NNP No._NN ._.
Accordingly_RB ,_, compensation_NN cost_NN of_IN stock_NN options_NNS is_VBZ measured_VBN as_IN the_DT excess_NN ,_, if_IN any_DT ,_, of_IN the_DT quoted_VBN market_NN price_NN of_IN Shires_NNP ordinary_JJ shares_NNS at_IN the_DT measurement_NN date_NN over_IN the_DT option_NN exercise_NN price_NN and_CC is_VBZ charged_VBN to_TO operations_NNS over_IN the_DT vesting_JJ period_NN ._.
For_IN plans_NNS where_WRB the_DT measurement_NN date_NN occurs_VBZ after_IN the_DT grant_NN date_NN ,_, referred_VBD to_TO as_IN variable_JJ plans_NNS ,_, compensation_NN cost_NN is_VBZ re-measured_JJ on_IN the_DT basis_NN of_IN the_DT current_JJ market_NN value_NN of_IN Shires_NNP ordinary_JJ shares_NNS at_IN the_DT end_NN of_IN each_DT reporting_NN period_NN ._.
The_DT Company_NN recognizes_VBZ compensation_NN expense_NN for_IN variable_JJ plans_NNS with_IN performance_NN conditions_NNS if_IN achievement_NN of_IN those_DT conditions_NNS becomes_VBZ probable_JJ ._.
123_CD ,_, Accounting_NNP for_IN Stock_NNP Based_VBD Compensation_NNP SFAS_NNP No._NN ._.
123_CD ,_, the_DT Company_NN has_VBZ included_VBN in_IN these_DT financial_JJ statements_NNS the_DT required_JJ pro-forma_FW disclosures_NNS as_IN if_IN the_DT fair_JJ value_NN method_NN of_IN accounting_NN had_VBD been_VBN applied_VBN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD seven_CD stock-based_JJ employee_NN compensation_NN plans_NNS ,_, which_WDT are_VBP described_VBN more_RBR fully_RB in_IN Note_NN 31_CD ._.
The_DT following_VBG table_NN illustrates_VBZ the_DT effect_NN on_IN net_JJ income_NN and_CC earnings_NNS per_IN share_NN if_IN the_DT Company_NN had_VBD applied_VBN the_DT fair_JJ value_NN recognition_NN provisions_NNS of_IN SFAS_NNP No._NN ._.
2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Net_JJ loss_NN income_NN ,_, as_IN reported_VBN 410,843_CD 269,007_CD 276,051_CD Add_VB :_: Stock-based_JJ employee_NN compensation_NN charge_NN credit_NN included_VBN in_IN reported_JJ net_JJ income_NN ,_, net_NN of_IN related_JJ tax_NN effects_NNS 392_CD 216_CD 24_CD Deduct_NN :_: Total_JJ stock-based_JJ employee_NN compensation_NN expense_NN determined_VBN under_IN a_DT fair_JJ value_NN based_VBN method_NN for_IN all_DT awards_NNS ,_, net_NN of_IN related_JJ tax_NN effects_NNS 25,982_CD 32,966_CD 31,956_CD Pro_FW forma_FW net_JJ loss_NN income_NN 436,433_CD 236,257_CD 244,071_CD 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, Earnings_NNS per_IN share_NN As_IN reported_VBN basic_JJ 82.1_CD 54.2_CD 55.4_CD As_IN reported_VBN diluted_VBN 82.1_CD 53.3_CD 54.2_CD Pro-forma_JJ basic_JJ 87.2_CD 47.6_CD 49.0_CD Pro-forma_JJ diluted_VBN 87.2_CD 46.9_CD 48.0_CD The_DT fair_JJ value_NN of_IN the_DT share-based_JJ payment_NN used_VBN to_TO compute_VB pro-forma_FW net_JJ loss_NN income_NN and_CC per_IN share_NN disclosures_NNS represents_VBZ the_DT estimated_VBN present_JJ value_NN at_IN grant_NN date_NN using_VBG the_DT Black-Scholes_NNP option-pricing_NN model_NN with_IN the_DT following_VBG weighted_JJ average_JJ assumptions_NNS :_: Year_NN to_TO December_NNP 31_CD ,_, 2005 2004 2003_CD Risk-free_JJ interest_NN rate_NN 3.93_CD 4.59_CD %_NN 2.46_CD 4.19_CD %_NN 1.89_CD 3.40_CD %_NN Expected_VBN dividend_NN yield_NN 0.6_CD %_NN 0_CD %_NN :_: 0.6_CD %_NN 0_CD %_NN Weighted_JJ average_NN expected_VBN life_NN 6.5_CD years_NNS 6.8_CD years_NNS 4.9_CD years_NNS Weighted_JJ average_NN expected_VBN volatility_NN 47.7_CD %_NN 48.5_CD %_NN 60.0_CD %_NN From_IN January_NNP 1_CD ,_, 2006_CD the_DT Company_NN will_MD apply_VB SFAS_NNP No._NN ._.
123_CD revised_VBN 2004_CD ,_, Share-Based_NNP Payment_NN SFAS_NNP No._NN ._.
123R_CD issued_VBN by_IN the_DT Financial_NNP Accounting_NNP Standards_NNP Board_NNP FASB_NNP in_IN December_NNP 2004_CD ._.
See_VB Note_NN 3_CD x_SYM iii_FW for_IN details_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 87_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 88_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD n_JJ Cash_NN and_CC cash_NN equivalents_NNS Cash_NN and_CC cash_NN equivalents_NNS are_VBP defined_VBN as_IN short-term_JJ highly_RB liquid_JJ investments_NNS with_IN original_JJ maturities_NNS of_IN 90_CD days_NNS or_CC less_JJR ._.
o_NN Short-term_JJ investments_NNS Short-term_JJ investments_NNS consist_VBP of_IN commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS ._.
In_IN accordance_NN with_IN SFAS_NNP No._NN ._.
115_CD ,_, Accounting_NNP for_IN Certain_NNP Investments_NNP in_IN Debt_NNP and_CC Equity_NNP Securities_NNPS SFAS_NNP No._NN ._.
115_CD ,_, and_CC based_VBN on_IN the_DT Companys_NNP intentions_NNS regarding_VBG these_DT instruments_NNS ,_, the_DT Company_NN has_VBZ classified_VBN all_DT short-term_JJ investments_NNS held_VBN at_IN December_NNP 31_CD ,_, 2005_CD as_IN available-for-sale_JJ ._.
Accordingly_RB ,_, the_DT Company_NN records_NNS these_DT investments_NNS at_IN their_PRP$ fair_JJ values_NNS with_IN unrealized_JJ gains_NNS and_CC losses_NNS included_VBD in_IN the_DT consolidated_JJ statements_NNS of_IN comprehensive_JJ income_NN ,_, net_NN of_IN any_DT related_JJ tax_NN effect_NN ._.
Realized_VBN gains_NNS and_CC losses_NNS and_CC declines_NNS in_IN value_NN judged_VBN to_TO be_VB other-than-temporary_JJ on_IN available-for-sale_JJ securities_NNS are_VBP included_VBN in_IN other_JJ income_NN expense_NN ,_, net_JJ see_VBP Note_NN 26_CD ._.
Institutional_JJ and_CC managed_VBD cash_NN funds_NNS are_VBP short-term_JJ money_NN market_NN instruments_NNS ,_, including_VBG bank_NN and_CC building_NN society_NN term_NN deposits_NNS and_CC other_JJ debt_NN securities_NNS from_IN a_DT variety_NN of_IN companies_NNS with_IN strong_JJ credit_NN ratings_NNS ._.
p_NNP Financial_NNP instruments_NNS derivatives_NNS The_DT Company_NN uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO manage_VB its_PRP$ exposure_NN to_TO foreign_JJ exchange_NN risk_NN associated_VBN with_IN intercompany_NN loan_NN arrangements_NNS ._.
These_DT instruments_NNS consist_VBP of_IN forward_RB foreign_JJ exchange_NN contracts_NNS and_CC foreign_JJ exchange_NN swaps_NNS ._.
The_DT Company_NN does_VBZ not_RB adopt_VB hedge_JJ accounting_NN treatment_NN for_IN these_DT instruments_NNS and_CC movements_NNS in_IN their_PRP$ fair_JJ values_NNS are_VBP recognized_VBN in_IN the_DT statement_NN of_IN operations_NNS ._.
The_DT fair_JJ values_NNS of_IN these_DT instruments_NNS are_VBP included_VBN on_IN the_DT balance_NN sheet_NN in_IN current_JJ assets_NNS liabilities_NNS ._.
q_NN Inventories_NNS Inventories_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN including_VBG manufacturing_NN overheads_NNS ,_, where_WRB appropriate_JJ or_CC net_JJ realizable_JJ value_NN ._.
Cost_NN incurred_VBN in_IN bringing_VBG each_DT product_NN to_TO its_PRP$ present_JJ location_NN and_CC condition_NN is_VBZ based_VBN on_IN purchase_NN costs_NNS calculated_VBN on_IN a_DT first-in_NN ,_, first-out_JJ basis_NN ,_, including_VBG transport_NN ._.
Net_JJ realizable_JJ value_NN is_VBZ based_VBN on_IN estimated_VBN normal_JJ selling_NN price_NN less_RBR further_JJ costs_NNS expected_VBN to_TO be_VB incurred_VBN to_TO completion_NN and_CC disposal_NN ._.
r_NN Assets_NNS held_VBN for_IN sale_NN An_DT asset_NN is_VBZ classified_VBN as_IN held_VBN for_IN sale_NN when_WRB ,_, amongst_IN other_JJ things_NNS ,_, the_DT Company_NN has_VBZ committed_VBN to_TO a_DT plan_NN of_IN disposition_NN ,_, the_DT asset_NN is_VBZ available_JJ for_IN immediate_JJ sale_NN ,_, and_CC the_DT plan_NN is_VBZ not_RB expected_VBN to_TO change_VB significantly_RB ._.
s_PRP Investments_NNPS The_DT Company_NN has_VBZ certain_JJ investments_NNS in_IN pharmaceutical_JJ and_CC biotechnology_NN companies_NNS ._.
Investments_NNP are_VBP accounted_VBN for_IN using_VBG the_DT equity_NN method_NN of_IN accounting_NN if_IN the_DT investment_NN gives_VBZ the_DT Company_NN the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, but_CC not_RB control_VB over_RP ,_, the_DT investee_NN ._.
Significant_JJ influence_NN is_VBZ generally_RB deemed_VBN to_TO exist_VB if_IN the_DT Company_NN has_VBZ an_DT ownership_NN interest_NN in_IN the_DT voting_NN stock_NN of_IN the_DT investee_NN between_IN 20_CD %_NN and_CC 50_CD %_NN ,_, although_IN other_JJ factors_NNS ,_, such_JJ as_IN representation_NN on_IN the_DT investees_NNS Board_NNP of_IN Directors_NNS and_CC the_DT impact_NN of_IN commercial_JJ arrangements_NNS ,_, are_VBP considered_VBN in_IN determining_VBG whether_IN the_DT equity_NN method_NN of_IN accounting_NN is_VBZ appropriate_JJ ._.
Under_IN the_DT equity_NN method_NN of_IN accounting_NN ,_, the_DT Company_NN records_NNS its_PRP$ investments_NNS in_IN equity-method_JJ investees_NNS in_IN the_DT consolidated_JJ balance_NN sheet_NN as_IN investments_NNS and_CC its_PRP$ share_NN of_IN the_DT investees_NNS earnings_NNS or_CC losses_NNS together_RB with_IN other-than-temporary_JJ impairments_NNS in_IN value_NN as_IN equity_NN in_IN earnings_NNS losses_NNS of_IN equity_NN method_NN investees_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
All_DT other_JJ equity_NN investments_NNS ,_, which_WDT consist_VBP of_IN investments_NNS for_IN which_WDT the_DT Company_NN does_VBZ not_RB have_VB the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN ,_, are_VBP accounted_VBN for_IN under_IN the_DT cost_NN method_NN or_CC at_IN fair_JJ value_NN ._.
Investments_NNP in_IN private_JJ companies_NNS are_VBP carried_VBN at_IN cost_NN ,_, less_JJR provisions_NNS for_IN other-than-temporary_JJ impairment_NN in_IN value_NN ._.
For_IN public_JJ companies_NNS that_WDT have_VBP readily_RB determinable_JJ fair_JJ values_NNS ,_, the_DT Company_NN classifies_VBZ its_PRP$ equity_NN investments_NNS as_IN availablefor-sale_JJ and_CC ,_, accordingly_RB ,_, records_NNS these_DT investments_NNS at_IN their_PRP$ fair_JJ values_NNS with_IN unrealized_JJ gains_NNS and_CC losses_NNS included_VBD in_IN the_DT consolidated_JJ statements_NNS of_IN comprehensive_JJ income_NN ,_, net_NN of_IN any_DT related_JJ tax_NN effect_NN ._.
The_DT cost_NN of_IN securities_NNS sold_VBN is_VBZ based_VBN on_IN the_DT specific_JJ identification_NN method_NN ._.
Interest_NN and_CC dividends_NNS on_IN securities_NNS classified_VBN as_IN available-for-sale_NN are_VBP included_VBN as_IN interest_NN income_NN ._.
t_NN Property_NN ,_, plant_NN and_CC equipment_NN Property_NN ,_, plant_NN and_CC equipment_NN is_VBZ shown_VBN at_IN cost_NN ,_, less_JJR accumulated_VBN depreciation_NN and_CC any_DT impairment_NN ._.
The_DT cost_NN of_IN significant_JJ assets_NNS includes_VBZ capitalized_JJ interest_NN incurred_VBN during_IN the_DT construction_NN period_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN a_DT straight-line_JJ basis_NN at_IN rates_NNS calculated_VBN to_TO write-off_NN the_DT cost_NN less_JJR estimated_VBN residual_JJ value_NN of_IN each_DT asset_NN over_IN its_PRP$ estimated_VBN useful_JJ life_NN as_IN follows_VBZ :_: Buildings_NNS 2050_CD years_NNS Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 310_CD years_NNS Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 310_CD years_NNS The_DT cost_NN of_IN land_NN is_VBZ not_RB depreciated_VBN ._.
Expenditures_NNS for_IN maintenance_NN and_CC repairs_NNS are_VBP charged_VBN to_TO operations_NNS as_IN incurred_VBN ._.
The_DT costs_NNS of_IN major_JJ renewals_NNS and_CC improvements_NNS are_VBP capitalized_VBN ._.
At_IN the_DT time_NN property_NN ,_, plant_NN and_CC equipment_NN is_VBZ retired_VBN or_CC otherwise_RB disposed_JJ of_IN ,_, the_DT cost_NN and_CC accumulated_VBN depreciation_NN are_VBP eliminated_VBN from_IN the_DT asset_NN and_CC accumulated_VBN depreciation_NN accounts_NNS ._.
The_DT profit_NN or_CC loss_NN on_IN such_JJ disposition_NN is_VBZ reflected_VBN in_IN operating_VBG loss_NN income_NN ._.
88_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 89_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD u_JJ Goodwill_NNP and_CC other_JJ intangible_JJ assets_NNS i_FW Goodwill_NNP In_IN a_DT business_NN combination_NN ,_, goodwill_NN represents_VBZ the_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT consideration_NN given_VBN over_IN the_DT fair_JJ value_NN of_IN the_DT identifiable_JJ assets_NNS and_CC liabilities_NNS acquired_VBN ._.
Goodwill_NN is_VBZ not_RB amortized_VBN to_TO operations_NNS ,_, but_CC instead_RB is_VBZ reviewed_VBN for_IN impairment_NN ,_, at_IN least_JJS annually_RB or_CC whenever_WRB events_NNS or_CC changes_NNS in_IN circumstances_NNS indicate_VBP that_IN the_DT carrying_VBG value_NN may_MD not_RB be_VB recoverable_JJ ._.
Some_DT factors_NNS the_DT Company_NN considers_VBZ important_JJ which_WDT could_MD trigger_VB an_DT impairment_NN review_NN include_VBP the_DT following_NN :_: i_FW significant_JJ underperformance_NN of_IN a_DT reporting_VBG unit_NN relative_JJ to_TO expected_VBN historical_JJ or_CC projected_VBN future_JJ operating_NN results_NNS :_: ii_FW significant_JJ changes_NNS in_IN the_DT manner_NN of_IN the_DT Companys_NNPS use_NN of_IN acquired_VBN assets_NNS or_CC the_DT strategy_NN for_IN the_DT overall_JJ business_NN :_: and_CC iii_FW significant_JJ negative_JJ industry_NN or_CC economic_JJ trends_NNS ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS ,_, goodwill_NN is_VBZ reviewed_VBN for_IN impairment_NN by_IN comparing_VBG the_DT carrying_VBG value_NN of_IN each_DT reporting_VBG units_NNS net_JJ assets_NNS including_VBG allocated_VBN goodwill_NN to_TO the_DT fair_JJ value_NN of_IN those_DT net_JJ assets_NNS ._.
If_IN the_DT reporting_VBG units_NNS carrying_VBG amount_NN is_VBZ greater_JJR than_IN its_PRP$ fair_JJ value_NN ,_, then_RB a_DT second_JJ step_NN is_VBZ performed_VBN whereby_WRB the_DT portion_NN of_IN the_DT fair_JJ value_NN that_WDT relates_VBZ to_TO the_DT reporting_VBG units_NNS goodwill_NN is_VBZ compared_VBN to_TO the_DT carrying_VBG value_NN of_IN that_DT goodwill_NN ._.
The_DT Company_NN recognizes_VBZ a_DT goodwill_NN impairment_NN charge_NN for_IN the_DT amount_NN the_DT carrying_VBG value_NN of_IN goodwill_NN exceeds_VBZ the_DT fair_JJ value_NN ._.
The_DT Company_NN has_VBZ determined_VBN that_IN there_EX are_VBP no_DT impairment_NN losses_NNS for_IN any_DT of_IN the_DT reporting_NN periods_NNS covered_VBN by_IN these_DT financial_JJ statements_NNS ._.
ii_FW Other_JJ intangible_JJ assets_NNS Other_JJ intangible_JJ assets_NNS ,_, which_WDT comprise_VBP intellectual_JJ property_NN including_VBG trademarks_NNS for_IN products_NNS with_IN a_DT defined_VBN revenue_NN stream_NN namely_RB commercial_JJ products_NNS or_CC rights_NNS to_TO products_NNS awaiting_VBG final_JJ regulatory_JJ approval_NN ,_, are_VBP recorded_VBN at_IN cost_NN and_CC amortized_VBN over_IN the_DT estimated_VBN useful_JJ life_NN of_IN the_DT related_JJ product_NN ,_, which_WDT ranges_VBZ from_IN 535_CD years_NNS weighted_VBN average_JJ 16_CD years_NNS ._.
Intellectual_NNP property_NN with_IN no_DT defined_VBN revenue_NN stream_NN ,_, where_WRB the_DT related_JJ product_NN has_VBZ not_RB yet_RB completed_VBN the_DT necessary_JJ approval_NN process_NN ,_, is_VBZ written_VBN off_RP to_TO operations_NNS on_IN acquisition_NN ._.
The_DT following_VBG factors_NNS are_VBP considered_VBN in_IN estimating_VBG useful_JJ lives_NNS ._.
Where_WRB an_DT intangible_JJ asset_NN is_VBZ a_DT composite_NN of_IN a_DT number_NN of_IN factors_NNS ,_, the_DT period_NN of_IN amortization_NN is_VBZ determined_VBN from_IN considering_VBG these_DT factors_NNS together_RB :_: expected_VBN use_NN of_IN the_DT asset_NN :_: regulatory_JJ ,_, legal_JJ or_CC contractual_JJ provisions_NNS ,_, including_VBG the_DT regulatory_JJ approval_NN and_CC review_NN process_NN ,_, patent_NN issues_NNS and_CC actions_NNS by_IN government_NN agencies_NNS :_: the_DT effects_NNS of_IN obsolescence_NN ,_, changes_NNS in_IN demand_NN ,_, competing_VBG products_NNS and_CC other_JJ economic_JJ factors_NNS ,_, including_VBG the_DT stability_NN of_IN the_DT market_NN ,_, known_VBN technological_JJ advances_NNS ,_, development_NN of_IN competing_VBG drugs_NNS that_WDT are_VBP more_RBR effective_JJ clinically_RB or_CC economically_RB :_: and_CC actions_NNS of_IN competitors_NNS ,_, suppliers_NNS ,_, regulatory_JJ agencies_NNS or_CC others_NNS that_WDT may_MD eliminate_VB current_JJ competitive_JJ advantages_NNS ._.
v_FW Non-monetary_JJ transactions_NNS The_DT Company_NN enters_VBZ into_IN certain_JJ non-monetary_JJ transactions_NNS that_WDT involve_VBP either_CC the_DT granting_VBG of_IN a_DT license_NN over_IN the_DT Companys_NNP patents_NNS or_CC the_DT disposal_NN of_IN an_DT asset_NN or_CC group_NN of_IN assets_NNS in_IN exchange_NN for_IN a_DT nonmonetary_JJ asset_NN ,_, usually_RB equity_NN ._.
The_DT Company_NN accounts_NNS for_IN these_DT transactions_NNS at_IN fair_JJ value_NN where_WRB the_DT Company_NN is_VBZ able_JJ to_TO determine_VB the_DT fair_JJ value_NN within_IN reasonable_JJ limits_NNS ._.
To_TO the_DT extent_NN that_IN the_DT Company_NN concludes_VBZ that_IN it_PRP is_VBZ unable_JJ to_TO determine_VB the_DT fair_JJ value_NN of_IN a_DT transaction_NN ,_, that_IN transaction_NN is_VBZ accounted_VBN for_IN at_IN the_DT recorded_JJ amounts_NNS of_IN the_DT assets_NNS exchanged_VBD ._.
Management_NN is_VBZ required_VBN to_TO exercise_VB its_PRP$ judgment_NN in_IN determining_VBG whether_IN or_CC not_RB the_DT fair_JJ value_NN of_IN the_DT asset_NN received_VBD or_CC that_DT given_VBN up_RP can_MD be_VB determined_VBN ._.
w_VB Reclassifications_NNP Certain_NNP amounts_VBZ reported_VBN in_IN previous_JJ years_NNS have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT 2005_CD presentation_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 89_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 90_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD x_SYM New_NNP accounting_NN pronouncements_NNS i_FW Adopted_VBN in_IN the_DT current_JJ year_NN :_: EITF_NNP 03-13_CD In_IN November_NNP 2004_CD ,_, the_DT Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP reached_VBD a_DT consensus_NN on_IN EITF_NNP 03-13_CD ,_, Applying_VBG the_DT Conditions_NNS in_IN Paragraph_NNP 42_CD of_IN SFAS_NNP 144_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS ,_, in_IN Determining_VBG Whether_NNP to_TO Report_NNP Discontinued_NNP Operations_NNP EITF_NNP 03-13_CD ._.
The_DT purpose_NN of_IN the_DT EITF_NNP is_VBZ to_TO clarify_VB when_WRB a_DT disposition_NN should_MD be_VB classified_VBN as_IN a_DT discontinued_VBN operation_NN caused_VBN by_IN the_DT contravening_VBG wording_NN of_IN paragraph_NN 42_CD of_IN SFAS_NNP No._NN ._.
144_CD ,_, Accounting_NNP for_IN the_DT Impairment_NN or_CC Disposal_NN of_IN Long-Lived_NNP Assets_NNPS SFAS_NNP No._NN ._.
The_DT EITF_NNP reached_VBD a_DT consensus_NN that_WDT classification_NN of_IN a_DT disposed_JJ component_NN as_IN a_DT discontinued_VBN operation_NN is_VBZ appropriate_JJ only_RB if_IN the_DT ongoing_JJ entity_NN :_: has_VBZ no_DT continuing_VBG direct_JJ cash_NN flows_VBZ a_DT term_NN EITF_NNP 03-13_CD introduces_VBZ to_TO interpret_VB paragraph_NN 42_CD a_DT :_: and_CC does_VBZ not_RB retain_VB an_DT interest_NN ,_, contract_NN ,_, or_CC other_JJ arrangement_NN sufficient_JJ to_TO enable_VB it_PRP to_TO exert_VB significant_JJ influence_NN over_IN the_DT disposed_JJ components_NNS operating_VBG and_CC financial_JJ policies_NNS after_IN the_DT disposal_NN transaction_NN an_DT interpretation_NN of_IN paragraph_NN 42_CD b._NN EITF_NNP 03-13_CD should_MD be_VB applied_VBN to_TO components_NNS that_WDT are_VBP disposed_VBN of_IN or_CC classified_VBN as_IN held_VBN for_IN sale_NN in_IN periods_NNS beginning_VBG after_IN December_NNP 15_CD ,_, 2004_CD ._.
Previously_RB reported_VBN operating_NN results_NNS within_IN an_DT enterprises_NNS fiscal_JJ year_NN that_WDT includes_VBZ the_DT ratification_NN date_NN may_MD be_VB reclassified_VBN to_TO reflect_VB the_DT consensus_NN ._.
The_DT adoption_NN of_IN EITF_NNP 03-13_CD has_VBZ had_VBN no_DT impact_NN on_IN the_DT Companys_NNP reporting_NN of_IN discontinued_VBN operations_NNS as_IN the_DT Company_NN has_VBZ not_RB disposed_VBN of_IN any_DT operations_NNS in_IN the_DT period_NN to_TO which_WDT this_DT guidance_NN has_VBZ been_VBN relevant_JJ ._.
EITF_NNP 05-06_CD In_IN June_NNP 2005_CD the_DT EITF_NNP reached_VBD consensus_NN on_IN Issue_NNP 05-6_CD ,_, Determining_VBG the_DT Amortization_NNP Period_NNP for_IN Leasehold_NNP Improvements_NNP Purchased_NNP after_IN Lease_NNP Inception_NNP or_CC Acquired_VBN in_IN a_DT Business_NN Combination_NN EITF_NNP 05-6_CD ._.
EITF_NNP 05-6_CD requires_VBZ leasehold_NN improvements_NNS acquired_VBN in_IN a_DT business_NN combination_NN to_TO be_VB amortized_VBN over_IN the_DT shorter_JJR of_IN the_DT useful_JJ life_NN of_IN the_DT assets_NNS or_CC a_DT term_NN that_WDT includes_VBZ required_VBN lease_NN periods_NNS and_CC renewals_NNS deemed_VBD to_TO be_VB reasonably_RB assured_VBN at_IN the_DT date_NN of_IN acquisition_NN ._.
Additionally_RB ,_, the_DT Issue_NNP requires_VBZ improvements_NNS placed_VBN in_IN service_NN significantly_RB after_IN and_CC not_RB contemplated_VBN at_IN or_CC near_IN the_DT beginning_NN of_IN the_DT lease_NN term_NN to_TO be_VB amortized_VBN over_IN the_DT shorter_JJR of_IN the_DT useful_JJ life_NN of_IN the_DT assets_NNS or_CC a_DT term_NN that_WDT includes_VBZ required_VBN lease_NN periods_NNS and_CC renewals_NNS deemed_VBD to_TO be_VB reasonably_RB assured_VBN at_IN the_DT date_NN the_DT leasehold_NN improvements_NNS are_VBP purchased_VBN ._.
The_DT adoption_NN of_IN EITF_NNP 05-6_CD has_VBZ had_VBN no_DT material_NN impact_NN on_IN the_DT Companys_NNP consolidated_JJ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
SFAS_NNP 153_CD In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
153_CD ,_, Exchanges_NNS of_IN Non-monetary_JJ Assets_NNS an_DT amendment_NN of_IN APB_NNP Opinion_NNP No._NN ._.
153_CD ,_, which_WDT amends_VBZ APB_NNP Opinion_NNP No._NN ._.
29_CD ,_, Accounting_NN for_IN Non-monetary_JJ Transactions_NNS to_TO eliminate_VB the_DT exception_NN for_IN non-monetary_JJ exchanges_NNS of_IN similar_JJ productive_JJ assets_NNS and_CC replaces_VBZ it_PRP with_IN a_DT general_JJ exception_NN for_IN exchanges_NNS of_IN non-monetary_JJ assets_NNS that_WDT do_VBP not_RB have_VB commercial_JJ substance_NN ._.
153_CD is_VBZ effective_JJ for_IN non-monetary_JJ asset_NN exchanges_NNS occurring_VBG in_IN fiscal_JJ periods_NNS beginning_VBG after_IN June_NNP 15_CD ,_, 2005_CD ._.
153_CD has_VBZ had_VBN no_DT material_NN impact_NN on_IN the_DT Companys_NNP consolidated_JJ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
ii_FW To_TO be_VB adopted_VBN in_IN future_NN periods_NNS EITF_NNP 03-01_CD In_IN March_NNP 2004_CD ,_, the_DT EITF_NNP reached_VBD a_DT consensus_NN on_IN Issue_NNP 03-01_CD ,_, The_DT Meaning_NNP of_IN Other-Than-Temporary_NNP Impairment_NNP and_CC Its_PRP$ Application_NN to_TO Certain_NNP Investments_NNP EITF_NNP 03-01_CD ._.
EITF_NNP 03-01_CD is_VBZ applicable_JJ to_TO a_DT debt_NN and_CC equity_NN securities_NNS within_IN the_DT scope_NN of_IN SFAS_NNP No._NN ._.
115_CD ,_, b_NN debt_NN and_CC equity_NN securities_NNS within_IN the_DT scope_NN of_IN SFAS_NNP No._NN ._.
124_CD and_CC those_DT held_VBN by_IN an_DT investor_NN that_WDT reports_VBZ a_DT performance_NN indicator_NN ,_, and_CC c_NN equity_NN securities_NNS not_RB within_IN the_DT scope_NN of_IN SFAS_NNP No._NN ._.
115_CD and_CC not_RB accounted_VBD for_IN under_IN the_DT Accounting_NNP Principles_NNP Board_NNP Opinion_NNP 18s_NNS equity_NN method_NN e._FW g._FW cost_NN method_NN investments_NNS ._.
EITF_NNP 03-01_CD provides_VBZ a_DT step_NN model_NN to_TO determine_VB whether_IN an_DT investment_NN is_VBZ impaired_VBN and_CC if_IN an_DT impairment_NN is_VBZ other-than-temporary_JJ ._.
In_IN addition_NN ,_, it_PRP requires_VBZ that_IN investors_NNS provide_VBP certain_JJ disclosures_NNS for_IN cost_NN method_NN investments_NNS and_CC ,_, if_IN applicable_JJ ,_, other_JJ information_NN related_VBN specifically_RB to_TO cost_VB method_NN investments_NNS ,_, such_JJ as_IN the_DT aggregate_JJ carrying_NN amount_NN of_IN cost_NN method_NN investments_NNS ,_, the_DT aggregate_JJ amount_NN of_IN cost_NN method_NN investments_NNS that_IN the_DT investor_NN did_VBD not_RB evaluate_VB for_IN impairment_NN because_IN an_DT impairment_NN indicator_NN was_VBD not_RB present_JJ ,_, and_CC the_DT situations_NNS under_IN which_WDT the_DT fair_JJ value_NN of_IN a_DT cost_NN method_NN investment_NN is_VBZ not_RB estimated_VBN ._.
The_DT disclosures_NNS relating_VBG to_TO cost_VB method_NN investments_NNS should_MD not_RB be_VB aggregated_VBN with_IN other_JJ types_NNS of_IN investments_NNS ._.
The_DT effective_JJ date_NN for_IN the_DT prospective_JJ application_NN of_IN the_DT EITF_NNP 03-01_CD impairment_NN model_NN to_TO all_DT current_JJ and_CC future_JJ investments_NNS has_VBZ been_VBN delayed_VBN by_IN the_DT FASB_NNP Issues_NNP FASB_NNP Staff_NNP Position_NNP FSP_NNP EITF_NNP 03-01-1_CD ._.
The_DT disclosure_NN requirements_NNS are_VBP effective_JJ for_IN annual_JJ periods_NNS for_IN fiscal_JJ years_NNS ending_VBG after_IN June_NNP 15_CD ,_, 2004_CD ._.
The_DT Company_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN EITF_NNP 03-01_CD to_TO have_VB a_DT material_NN impact_NN on_IN its_PRP$ consolidated_JJ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
90_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 91_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 3_CD Summary_NNP of_IN significant_JJ accounting_NN policies_NNS continued_VBD SFAS_NNP No._NN ._.
123R_CD In_IN December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
123R_CD requires_VBZ that_IN the_DT cost_NN resulting_VBG from_IN all_DT share-based_JJ payment_NN transactions_NNS be_VB recognized_VBN in_IN the_DT financial_JJ statements_NNS at_IN fair_JJ value_NN and_CC that_IN excess_JJ tax_NN benefits_NNS be_VB reported_VBN as_IN a_DT financing_NN cash_NN inflow_NN rather_RB than_IN as_IN a_DT reduction_NN of_IN taxes_NNS paid_VBN ._.
123R_CD is_VBZ effective_JJ for_IN the_DT Company_NN from_IN January_NNP 1_CD ,_, 2006_CD ._.
123R_CD requires_VBZ public_JJ companies_NNS to_TO account_VB for_IN share-based_JJ payments_NNS using_VBG the_DT modified-prospective_JJ method_NN and_CC permits_VBZ public_JJ companies_NNS also_RB to_TO account_VB for_IN share-based_JJ payments_NNS using_VBG the_DT method_NN ._.
Under_IN the_DT modified-prospective_JJ method_NN ,_, from_IN the_DT effective_JJ date_NN ,_, compensation_NN cost_NN is_VBZ recognized_VBN based_VBN on_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
123R_CD for_IN all_DT new_JJ share-based_JJ awards_NNS and_CC based_VBN on_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
123_CD for_IN all_DT awards_NNS granted_VBN prior_RB to_TO the_DT effective_JJ date_NN of_IN SFAS_NNP No._NN ._.
123R_CD that_WDT remain_VBP unvested_JJ on_IN the_DT effective_JJ date_NN ._.
The_DT method_NN permits_VBZ companies_NNS to_TO restate_VB ,_, based_VBN on_IN the_DT amounts_NNS previously_RB recognized_VBN under_IN SFAS_NNP No._NN ._.
123_CD for_IN pro-forma_FW disclosure_NN purposes_NNS ,_, either_CC all_DT prior_RB periods_NNS presented_VBN or_CC prior_RB interim_JJ periods_NNS in_IN the_DT year_NN of_IN adoption_NN ._.
123_CD pro-forma_FW disclosures_NNS given_VBN in_IN Note_NN 3_CD m_NN above_IN show_NN the_DT impact_NN of_IN the_DT Company_NN adopting_VBG the_DT method_NN in_IN prior_JJ periods_NNS ._.
123R_CD ,_, the_DT Company_NN will_MD adopt_VB the_DT method_NN ._.
151_CD In_IN November_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD SFAS_NNP No._NN ._.
151_CD ,_, Inventory_NNP Costs_NNS an_DT amendment_NN of_IN ARB_NNP No._NN ._.
151_CD clarifies_VBZ that_IN abnormal_JJ amounts_NNS of_IN idle_JJ facility_NN expense_NN ,_, freight_NN ,_, handling_VBG costs_NNS ,_, and_CC wasted_VBD materials_NNS spoilage_NN should_MD be_VB recognized_VBN as_IN currentperiod_NN charges_NNS and_CC requires_VBZ the_DT allocation_NN of_IN fixed_JJ production_NN overheads_NNS to_TO inventory_NN based_VBN on_IN the_DT normal_JJ capacity_NN of_IN the_DT production_NN facilities_NNS ._.
151_CD is_VBZ effective_JJ for_IN fiscal_JJ years_NNS beginning_VBG after_IN June_NNP 15_CD ,_, 2005_CD ._.
The_DT Company_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
151_CD to_TO have_VB a_DT material_NN impact_NN on_IN its_PRP$ consolidated_JJ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
154_CD ,_, Accounting_NNP Changes_NNS and_CC Error_NNP Corrections_NNPS replacement_NN of_IN APB_NNP Opinion_NNP No._NN ._.
154_CD changes_NNS the_DT accounting_NN for_IN and_CC reporting_VBG of_IN a_DT change_NN in_IN accounting_NN principle_NN by_IN requiring_VBG retrospective_JJ application_NN to_TO prior_RB periods_NNS financial_JJ statements_NNS of_IN changes_NNS in_IN accounting_NN principle_NN unless_IN impracticable_JJ ._.
154_CD is_VBZ effective_JJ for_IN accounting_VBG changes_NNS made_VBN in_IN fiscal_JJ years_NNS beginning_VBG after_IN December_NNP 15_CD ,_, 2005_CD ._.
154_CD will_MD have_VB no_DT impact_NN on_IN historical_JJ results_NNS :_: rather_RB the_DT impact_NN depends_VBZ upon_IN future_JJ changes_NNS to_TO accounting_VBG principles_NNS ._.
124-1_CD In_IN November_NNP 2005_CD ,_, the_DT FASB_NNP issued_VBD FASB_NNP Staff_NNP Position_NNP FSP_NNP FAS_NNP 115-1_CD and_CC 124-1_CD ,_, The_DT Meaning_NNP of_IN Other-Than-Temporary_NNP Impairment_NNP and_CC Its_PRP$ Application_NN to_TO Certain_NNP Investments_NNP ._.
The_DT guidance_NN in_IN this_DT FSP_NNP addresses_VBZ the_DT determination_NN of_IN when_WRB an_DT investment_NN is_VBZ considered_VBN impaired_VBN ,_, whether_IN that_DT impairment_NN is_VBZ other_JJ than_IN temporary_JJ ,_, and_CC the_DT measurement_NN of_IN an_DT impairment_NN loss_NN ._.
The_DT FSP_NNP also_RB includes_VBZ accounting_NN considerations_NNS subsequent_JJ to_TO the_DT recognition_NN of_IN an_DT other-than-temporary_JJ impairment_NN and_CC requires_VBZ certain_JJ disclosures_NNS about_IN unrealized_JJ losses_NNS that_WDT have_VBP not_RB been_VBN recognized_VBN as_IN other-than-temporary_JJ impairments_NNS ._.
115-1_CD and_CC SFAS_NNP 124-1_CD is_VBZ effective_JJ for_IN the_DT Company_NN in_IN the_DT first_JJ quarter_NN of_IN fiscal_JJ year_NN 2006_CD ._.
The_DT Company_NN does_VBZ not_RB expect_VB the_DT adoption_NN of_IN FSP_NNP SFAS_NNP No._NN ._.
115-1_CD and_CC SFAS_NNP 124-1_CD to_TO have_VB a_DT material_NN impact_NN on_IN its_PRP$ consolidated_JJ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
EITF_NNP 04-5_CD In_IN June_NNP 2005_CD ,_, the_DT EITF_NNP reached_VBD a_DT consensus_NN regarding_VBG the_DT issue_NN ,_, Investors_NNP Accounting_NNP for_IN an_DT Investment_NN in_IN a_DT Limited_NNP Partnership_NNP When_WRB the_DT Investor_NN Is_VBZ the_DT Sole_NNP General_NNP Partner_NNP and_CC the_DT Limited_NNP Partners_NNPS Have_VBP Certain_NNP Rights_NNP Issue_NNP ,_, on_IN how_WRB to_TO evaluate_VB whether_IN a_DT partnership_NN should_MD be_VB consolidated_VBN by_IN one_CD of_IN its_PRP$ partners_NNS ._.
The_DT scope_NN of_IN this_DT Issue_NN is_VBZ limited_VBN to_TO limited_JJ partnerships_NNS or_CC similar_JJ entities_NNS such_JJ as_IN limited_JJ liability_NN companies_NNS that_WDT have_VBP governing_VBG provisions_NNS that_WDT are_VBP the_DT functional_JJ equivalent_NN of_IN a_DT limited_JJ partnership_NN that_WDT are_VBP not_RB variable_JJ interest_NN entities_NNS under_IN FASB_NNP Interpretation_NNP 46_CD R._NNP The_NNP EITF_NNP concluded_VBD that_IN a_DT general_JJ partner_NN or_CC a_DT group_NN of_IN general_JJ partners_NNS of_IN a_DT limited_JJ partnership_NN is_VBZ presumed_VBN to_TO control_VB the_DT limited_JJ partnership_NN ,_, unless_IN either_CC the_DT limited_JJ partners_NNS have_VBP the_DT substantive_JJ ability_NN to_TO dissolve_VB the_DT limited_JJ partnership_NN or_CC otherwise_RB remove_VB the_DT general_JJ partner_NN without_IN cause_NN or_CC the_DT limited_JJ partners_NNS have_VBP substantive_JJ participating_VBG rights_NNS ._.
The_DT guidance_NN in_IN this_DT Issue_NN is_VBZ effective_JJ after_IN June_NNP 29_CD ,_, 2005_CD for_IN general_JJ partners_NNS of_IN all_DT new_JJ limited_JJ partnerships_NNS formed_VBN and_CC for_IN existing_VBG limited_JJ partnerships_NNS for_IN which_WDT the_DT partnership_NN agreements_NNS are_VBP modified_VBN ._.
For_IN general_JJ partners_NNS in_IN all_DT other_JJ pre-existing_JJ limited_JJ partnerships_NNS ,_, the_DT guidance_NN in_IN this_DT Issue_NN is_VBZ effective_JJ no_RB later_RB than_IN the_DT beginning_NN of_IN the_DT first_JJ reporting_NN period_NN in_IN fiscal_JJ years_NNS beginning_VBG after_IN December_NNP 15_CD ,_, 2005_CD ._.
The_DT Company_NN will_MD adopt_VB EITF_NNP 04-5_CD at_IN the_DT beginning_NN of_IN the_DT second_JJ quarter_NN of_IN fiscal_JJ year_NN 2006_CD and_CC is_VBZ currently_RB reviewing_VBG the_DT impact_NN this_DT issue_NN will_MD have_VB on_IN its_PRP$ financial_JJ statements_NNS ._.
y_RB Statutory_JJ accounts_NNS The_DT consolidated_JJ financial_JJ statements_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD ,_, and_CC for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, do_VBP not_RB comprise_VB statutory_JJ accounts_NNS within_IN the_DT meaning_NN of_IN Section_NN 240_CD of_IN the_DT UK_NNP Companies_NNP Act_NNP 1985_CD ._.
Statutory_JJ accounts_NNS prepared_VBN in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT UK_NNP for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2004_CD and_CC 2003_CD ,_, have_VBP been_VBN delivered_VBN to_TO the_DT Registrar_NNP of_IN Companies_NNS for_IN England_NNP and_CC Wales_NNP ._.
The_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS was_VBD unqualified_JJ ._.
z_SYM Revisions_NNPS During_IN 2005_CD ,_, the_DT Company_NN changed_VBD the_DT presentation_NN of_IN its_PRP$ Statements_NNS of_IN cash_NN flows_VBZ to_TO separately_RB present_VB the_DT cash_NN flows_VBZ from_IN discontinued_VBN operations_NNS within_IN the_DT categories_NNS operating_VBG ,_, investing_VBG and_CC financing_VBG activities_NNS ,_, which_WDT in_IN prior_JJ periods_NNS were_VBD reported_VBN on_IN a_DT combined_VBN basis_NN as_IN a_DT single_JJ amount_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 91_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 92_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combinations_NNS :_: TKT_NNP acquisition_NN On_IN July_NNP 27_CD ,_, 2005_CD ,_, Shire_NNP completed_VBD its_PRP$ acquisition_NN of_IN TKT_NNP in_IN an_DT all-cash_JJ transaction_NN ._.
The_DT acquisition_NN was_VBD effected_VBN by_IN merging_VBG a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP with_IN and_CC into_IN TKT_NNP ,_, with_IN TKT_NNP continuing_VBG as_IN the_DT surviving_VBG corporation_NN ._.
As_IN consideration_NN ,_, Shire_NNP paid_VBD to_TO TKTs_NNS stockholders_NNS $_$ 37_CD in_IN cash_NN for_IN each_DT share_NN of_IN TKT_NNP common_JJ stock_NN outstanding_JJ at_IN the_DT time_NN of_IN the_DT acquisition_NN ,_, less_JJR any_DT applicable_JJ withholding_NN taxes_NNS ._.
The_DT total_JJ cash_NN consideration_NN for_IN the_DT acquisition_NN of_IN TKT_NNP is_VBZ expected_VBN to_TO be_VB approximately_RB $_$ 1.6_CD billion_CD ,_, subject_JJ to_TO change_VB as_RB may_MD be_VB required_VBN by_IN the_DT appraisal_NN rights_NNS process_NN see_VBP below_IN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, shareholders_NNS owning_VBG approximately_RB 24.8_CD million_CD TKT_NNP shares_NNS being_VBG 69_CD %_NN of_IN the_DT 36.2_CD million_CD TKT_NNP shares_NNS outstanding_JJ at_IN the_DT acquisition_NN date_NN had_VBD accepted_VBN the_DT offer_NN and_CC $_$ 917.9_CD million_CD has_VBZ been_VBN paid_VBN to_TO them_PRP :_: $_$ 83.9_CD million_CD was_VBD paid_VBN in_IN connection_NN with_IN TKT_NNP stock_NN options_NNS :_: and_CC $_$ 170.1_CD million_CD in_IN connection_NN with_IN convertible_JJ notes_NNS outstanding_JJ at_IN the_DT date_NN of_IN acquisition_NN ._.
In_IN connection_NN with_IN the_DT acquisition_NN ,_, as_RB at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN submitted_VBN written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS and_CC elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD per_IN share_NN merger_NN consideration_NN ._.
To_TO the_DT extent_NN that_IN these_DT demands_NNS were_VBD validly_RB asserted_VBN in_IN accordance_NN with_IN the_DT applicable_JJ requirements_NNS of_IN Delaware_NNP law_NN and_CC these_DT holders_NNS perfect_JJ their_PRP$ rights_NNS thereunder_NN ,_, such_JJ holders_NNS will_MD be_VB entitled_VBN to_TO receive_VB the_DT fair_JJ value_NN of_IN their_PRP$ shares_NNS as_IN determined_VBN by_IN the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP ._.
The_DT determination_NN of_IN fair_JJ value_NN of_IN the_DT TKT_NNP shares_NNS will_MD be_VB made_VBN excluding_VBG any_DT element_NN of_IN value_NN arising_VBG from_IN the_DT transaction_NN ,_, such_JJ as_IN cost_NN savings_NNS or_CC business_NN synergies_NNS ._.
The_DT Delaware_NNP Court_NNP of_IN Chancery_NNP may_MD ascribe_VB a_DT valuation_NN to_TO the_DT shares_NNS that_WDT is_VBZ greater_JJR than_IN ,_, less_JJR than_IN or_CC equal_JJ to_TO $_$ 37_CD per_IN share_NN and_CC may_MD award_NN interest_NN on_IN the_DT amount_NN determined_VBN in_IN the_DT appraisal_NN process_NN ._.
Shire_NNP has_VBZ recognized_VBN a_DT liability_NN in_IN respect_NN of_IN the_DT fair_JJ value_NN of_IN those_DT TKT_NNP shareholders_NNS who_WP have_VBP asserted_VBN appraisal_NN rights_NNS based_VBN on_IN $_$ 37_CD per_IN share_NN ._.
If_IN the_DT court_NN ascribes_VBZ a_DT different_JJ valuation_NN to_TO $_$ 37_CD this_DT will_MD result_VB in_IN an_DT adjustment_NN to_TO goodwill_NN ._.
In_IN addition_NN ,_, the_DT Company_NN has_VBZ recorded_VBN a_DT provision_NN for_IN interest_NN ,_, based_VBN on_IN the_DT $_$ 37_CD per_IN share_NN amount_NN ,_, of_IN $_$ 7.7_CD million_CD for_IN the_DT period_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, which_WDT has_VBZ been_VBN charged_VBN to_TO the_DT statement_NN of_IN operations_NNS ._.
For_IN accounting_VBG purposes_NNS ,_, the_DT acquisition_NN of_IN TKT_NNP has_VBZ been_VBN accounted_VBN for_IN as_IN a_DT purchase_NN business_NN combination_NN in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
Under_IN the_DT purchase_NN method_NN of_IN accounting_NN ,_, the_DT assets_NNS acquired_VBN and_CC the_DT liabilities_NNS assumed_VBD from_IN TKT_NNP are_VBP recorded_VBN at_IN the_DT date_NN of_IN acquisition_NN at_IN their_PRP$ respective_JJ fair_JJ values_NNS ._.
Financial_NNP statements_NNS and_CC reported_VBD results_NNS of_IN operations_NNS of_IN Shire_NNP will_MD reflect_VB these_DT values_NNS ,_, with_IN the_DT results_NNS of_IN TKT_NNP included_VBD from_IN July_NNP 27_CD ,_, 2005_CD ,_, in_IN the_DT statement_NN of_IN operations_NNS ._.
The_DT following_NN is_VBZ an_DT estimate_NN of_IN the_DT purchase_NN price_NN for_IN TKT_NNP :_: $_$ 000_CD Common_JJ stock_NN Number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN non-dissenting_JJ 24,809,126_CD Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD 917,937_CD Number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN dissenting_VBG 11,349,150_CD i_FW Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD 419,919_CD Total_JJ number_NN of_IN shares_NNS of_IN TKT_NNP common_JJ stock_NN outstanding_JJ as_IN at_IN July_NNP 27_CD ,_, 2005_CD 36,158,276_CD 1,337,856_CD Stock_NNP options_NNS Cash_NN cost_NN of_IN settling_VBG TKT_NNP stock_NN options_NNS 83,877_CD Convertible_JJ notes_NNS Nominal_JJ value_NN of_IN convertible_JJ loan_NN notes_NNS as_IN at_IN July_NNP 27_CD ,_, 2005_CD in_IN $_$ 000s_CD 85,000_CD Conversion_NNP ratio_NN into_IN TKT_NNP common_JJ stock_NN 18.49_CD Total_JJ shares_NNS payable_JJ upon_IN conversion_NN 4,597,080_CD Price_NN per_IN TKT_NNP share_NN $_$ 37.00_CD Cost_NN of_IN settling_VBG convertible_JJ notes_NNS 170,092_CD Direct_JJ costs_NNS of_IN acquisition_NN 37,491_CD Total_JJ estimated_VBN purchase_NN price_NN 1,629,316_CD The_DT estimated_VBN purchase_NN price_NN stated_VBN above_IN has_VBZ been_VBN allocated_VBN on_IN a_DT preliminary_JJ basis_NN according_VBG to_TO Shires_NNP estimate_NN of_IN the_DT fair_JJ value_NN of_IN assets_NNS acquired_VBN and_CC liabilities_NNS assumed_VBD ._.
The_DT fair_JJ values_NNS of_IN certain_JJ pre-acquisition_JJ contingencies_NNS ,_, in_IN particular_JJ those_DT relating_VBG to_TO the_DT Purported_NNP Class_NNP Action_NNP Shareholder_NN Suit_NN see_VBP Note_NN 21_CD d_SYM for_IN further_JJ details_NNS are_VBP yet_RB to_TO be_VB determined_VBN ._.
Shire_NNP currently_RB does_VBZ not_RB have_VB sufficient_JJ information_NN to_TO reliably_RB measure_VB the_DT contingencies_NNS ._.
i_FW In_IN addition_NN to_TO the_DT $_$ 37_CD per_IN TKT_NNP share_NN ,_, interest_NN of_IN $_$ 7.7_CD million_CD has_VBZ been_VBN accrued_VBN ._.
Total_JJ liability_NN to_TO dissenting_VBG shareholders_NNS included_VBN in_IN the_DT balance_NN sheet_NN is_VBZ $_$ 427.6_CD million_CD ._.
92_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 93_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combinations_NNS :_: TKT_NNP acquisition_NN continued_VBD The_DT purchase_NN price_NN was_VBD allocated_VBN as_IN follows_VBZ :_: Book_NNP value_NN Adjustments_NNP Fair_NNP value_NN Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD Assets_NNPS Current_JJ assets_NNS :_: Cash_NN and_CC cash_NN equivalents_NNS 56,814_CD 56,814_CD Restricted_VBN cash_NN 8,173_CD 8,173_CD Short-term_JJ investments_NNS 46,896_CD 46,896_CD Accounts_NNPS receivable_NN ,_, net_JJ 28,361_CD 28,361_CD Inventories_NNS a_DT 12,890_CD 88,879_CD 101,769_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS 7,997_CD 7,997_CD Total_JJ current_JJ assets_NNS 161,131_CD 88,879_CD 250,010_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ 57,297_CD 57,297_CD Goodwill_NNP 39,038_CD 39,038_CD on_IN TKT_NNP acquisition_NN c_NN 166,414_CD 166,414_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ d_SYM 20,210_CD 460,790_CD 481,000_CD In-process_JJ research_NN and_CC development_NN e_SYM 673,000_CD 673,000_CD Deferred_JJ tax_NN asset_NN b_NN 96,833_CD 96,833_CD Other_JJ non-current_JJ assets_NNS 3,281_CD 3,281_CD Total_JJ assets_NNS 280,957_CD 1,446,878_CD 1,727,835_CD Liabilities_NNP Current_NNP liabilities_NNS :_: Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS f_LS 35,365_CD 437_CD 35,802_CD Deferred_JJ tax_NN liability_NN b_NN 36,440_CD 36,440_CD Other_JJ current_JJ liabilities_NNS 24,471_CD 24,471_CD Total_JJ current_JJ liabilities_NNS 59,836_CD 36,877_CD 96,713_CD Other_JJ long-term_JJ liabilities_NNS 1,806_CD 1,806_CD Total_JJ liabilities_NNS 61,642_CD 36,877_CD 98,519_CD Estimated_VBN fair_JJ value_NN of_IN identifiable_JJ assets_NNS acquired_VBN and_CC liabilities_NNS assumed_VBD 219,315_CD 1_CD ,_, 410,001_CD 1,629,316_CD The_DT fair_JJ values_NNS of_IN assets_NNS acquired_VBN and_CC liabilities_NNS assumed_VBD will_MD be_VB determined_VBN as_RB soon_RB as_IN possible_JJ and_CC ,_, in_IN any_DT event_NN ,_, no_RB later_RB than_IN one_CD year_NN from_IN the_DT acquisition_NN date_NN if_IN such_JJ fair_JJ values_NNS can_MD be_VB measured_VBN in_IN this_DT time_NN frame_NN ._.
To_TO the_DT extent_NN that_WDT estimates_VBZ need_NN to_TO be_VB adjusted_VBN ,_, Shire_NNP will_MD do_VB so_RB in_IN future_NN periods_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
In_IN the_DT fourth_JJ quarter_NN of_IN 2005_CD ,_, the_DT following_VBG estimates_NNS were_VBD adjusted_VBN :_: Fair_NNP value_NN net_JJ assets_NNS adjustment_NN Nature_NN of_IN adjustment_NN $_$ 000_CD Change_NNP in_IN deferred_JJ tax_NN rate_NN 21,987_CD Change_NNP in_IN deferred_JJ tax_NN asset_NN on_IN TKT_NNP losses_NNS carried_VBD forward_JJ net_NN of_IN valuation_NN allowances_NNS 40,504_CD Determination_NN of_IN the_DT fair_JJ value_NN of_IN certain_JJ contingent_JJ liabilities_NNS outstanding_JJ at_IN the_DT acquisition_NN date_NN 18,020_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 93_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 94_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combinations_NNS :_: TKT_NNP acquisition_NN continued_VBD a_DT Inventory_NNP Components_NNP of_IN the_DT increase_NN in_IN fair_JJ value_NN for_IN acquired_VBN inventory_NN are_VBP as_IN follows_VBZ :_: Book_NNP Fair_NNP value_NN Fair_NN value_NN adjustment_NN value_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD Finished_VBN goods_NNS 3,377_CD 66,814_CD 70,191_CD Work-in-process_JJ 7,027_CD 22,065_CD 29,092_CD Raw_NNP materials_NNS 2,486_CD 2,486_CD 12,890_CD 88,879_CD 101,769_CD Finished_VBN goods_NNS were_VBD fair_JJ valued_VBN at_IN estimated_VBN selling_NN price_NN less_CC the_DT sum_NN of_IN costs_NNS of_IN disposal_NN and_CC a_DT reasonable_JJ profit_NN allowance_NN for_IN the_DT selling_NN effort_NN of_IN the_DT Company_NN ._.
Work_NN in-process_NN was_VBD fair_JJ valued_VBN on_IN the_DT same_JJ basis_NN less_RBR costs_NNS to_TO complete_VB ._.
All_DT cost_NN of_IN product_NN sales_NNS of_IN REPLAGAL_NNP ,_, since_IN the_DT acquisition_NN ,_, are_VBP at_IN the_DT fair_JJ value_NN of_IN the_DT inventory_NN acquired_VBN ._.
b_NN Deferred_JJ taxes_NNS The_DT estimated_VBN tax_NN effects_NNS of_IN the_DT acquisition_NN ,_, including_VBG TKT_NNP trading_NN losses_NNS and_CC the_DT effect_NN of_IN the_DT fair_JJ value_NN adjustments_NNS for_IN inventory_NN and_CC other_JJ intangible_JJ assets_NNS are_VBP as_IN follows_VBZ :_: $_$ 000_CD i_FW Deferred_JJ tax_NN asset_NN on_IN TKT_NNP losses_NNS carried_VBD forward_JJ net_NN of_IN valuation_NN allowance_NN of_IN $_$ 60.3_CD million_CD long_JJ term_NN 285,757_CD Deferred_JJ tax_NN liability_NN on_IN other_JJ intangible_JJ assets_NNS long_JJ term_NN 188,924_CD Deferred_JJ tax_NN asset_NN ,_, net_JJ 96,833_CD Deferred_JJ tax_NN liability_NN on_IN inventory_NN current_JJ 36,440_CD Deferred_JJ tax_NN ,_, net_JJ 60,393_CD i_FW Any_DT future_JJ changes_NNS in_IN the_DT valuation_NN allowance_NN will_MD be_VB reflected_VBN in_IN the_DT carrying_VBG value_NN of_IN goodwill_NN ._.
As_IN noted_VBN above_IN ,_, in_IN the_DT final_JJ quarter_NN of_IN 2005_CD the_DT following_VBG estimates_NNS relating_VBG to_TO deferred_VBN tax_NN were_VBD adjusted_VBN for_IN :_: the_DT deferred_JJ tax_NN rate_NN has_VBZ been_VBN adjusted_VBN to_TO reflect_VB the_DT US_NNP federal_JJ rate_NN and_CC state_NN tax_NN combined_VBN 41_CD %_NN rate_NN that_WDT should_MD apply_VB to_TO measure_VB the_DT deferred_JJ tax_NN liability_NN :_: and_CC the_DT deferred_JJ tax_NN asset_NN on_IN TKT_NNP losses_NNS ,_, which_WDT increased_VBD as_IN a_DT result_NN of_IN the_DT identification_NN of_IN further_JJ tax_NN deductible_JJ expenses_NNS in_IN prior_JJ years_NNS ._.
c_NN Goodwill_NNP In_IN accordance_NN with_IN the_DT requirements_NNS of_IN SFAS_NNP No._NN ._.
142_CD ,_, Goodwill_NNP and_CC Other_JJ Intangible_NNP Assets_NNPS SFAS_NNP No._NN ._.
142_CD ,_, the_DT goodwill_NN associated_VBN with_IN the_DT TKT_NNP acquisition_NN will_MD not_RB be_VB amortized_VBN but_CC will_MD be_VB subject_JJ to_TO the_DT Companys_NNPS impairment_NN review_NN ._.
Goodwill_NN resulting_VBG from_IN this_DT acquisition_NN has_VBZ been_VBN allocated_VBN to_TO the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
d_LS Other_JJ intangible_JJ assets_NNS The_DT acquired_VBN identifiable_JJ intangible_JJ assets_NNS are_VBP attributable_JJ to_TO the_DT following_VBG categories_NNS :_: Book_NNP Fair_NNP value_NN Fair_NN value_NN adjustment_NN value_NN Asset_NNP life_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD years_NNS i_FW Intellectual_NNP property_NN 335,000_CD 335,000_CD 1420_CD ii_FW Customer_NN relationships_NNS 14,909_CD 104,091_CD 119,000_CD 15_CD ii_FW Other_JJ survey_NN data_NNS 5,301_CD 21,699_CD 27,000_CD 7_CD 20,210_CD 460,790_CD 481,000_CD Notes_NNS i_FW Relates_VBZ to_TO REPLAGAL_NNP excluding_VBG US_NNP and_CC Japan_NNP and_CC DYNEPO_NNP for_IN the_DT treatment_NN of_IN anemia_NN associated_VBN with_IN kidney_NN disease_NN ._.
ii_FW Relates_VBZ to_TO REPLAGAL_NNP excluding_VBG US_NNP and_CC Japan_NNP ._.
Acquired_VBN identifiable_JJ intangible_JJ assets_NNS have_VBP been_VBN allocated_VBN to_TO the_DT Pharmaceutical_NNP Products_NNPS reporting_VBG segment_NN ._.
Acquired_VBN identifiable_JJ intangible_JJ assets_NNS represent_VBP the_DT value_NN associated_VBN with_IN developed_JJ technology_NN to_TO which_WDT the_DT Company_NN has_VBZ all_DT associated_VBN rights_NNS ._.
These_DT rights_NNS can_MD include_VB the_DT right_NN to_TO develop_VB ,_, use_VB ,_, market_NN ,_, sell_VB and_CC or_CC offer_NN for_IN sale_NN the_DT technical_JJ processes_NNS ,_, intellectual_JJ property_NN and_CC institutional_JJ understanding_NN including_VBG the_DT way_NN in_IN which_WDT compounds_VBZ react_VB in_IN the_DT body_NN ,_, an_DT understanding_NN of_IN the_DT mechanisms_NNS of_IN action_NN which_WDT allow_VBP the_DT compound_NN to_TO work_VB and_CC the_DT knowledge_NN related_VBN to_TO the_DT associated_VBN clinical_JJ and_CC marketing_NN studies_NNS performed_VBN for_IN these_DT compounds_NNS that_WDT were_VBD acquired_VBN as_IN part_NN of_IN the_DT transaction_NN with_IN respect_NN to_TO products_NNS and_CC or_CC processes_VBZ that_DT have_VBP been_VBN developed_VBN ._.
94_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 95_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combinations_NNS :_: TKT_NNP acquisition_NN continued_VBD The_DT fair_JJ value_NN of_IN all_DT of_IN the_DT identifiable_JJ intangible_JJ assets_NNS has_VBZ been_VBN determined_VBN using_VBG an_DT income_NN approach_NN on_IN a_DT project-by-project_JJ basis_NN ._.
This_DT method_NN starts_VBZ with_IN a_DT forecast_NN of_IN all_DT of_IN the_DT expected_JJ future_JJ net_JJ cash_NN flows_VBZ either_CC generated_VBD or_CC saved_VBD as_IN a_DT result_NN of_IN ownership_NN of_IN the_DT intellectual_JJ property_NN ,_, the_DT customer_NN relationships_NNS and_CC the_DT other_JJ intangible_JJ assets_NNS ._.
These_DT cash_NN flows_NNS are_VBP then_RB adjusted_VBN to_TO present_JJ value_NN by_IN applying_VBG an_DT appropriate_JJ discount_NN rate_NN that_WDT reflects_VBZ the_DT risk_NN factors_NNS associated_VBN with_IN the_DT cash_NN flow_NN streams_NNS ._.
The_DT forecast_NN of_IN future_JJ cash_NN flows_VBZ requires_VBZ various_JJ assumptions_NNS to_TO be_VB made_VBN ,_, including_VBG :_: revenue_NN that_WDT is_VBZ reasonably_RB likely_JJ to_TO result_VB from_IN the_DT sale_NN of_IN products_NNS including_VBG the_DT estimated_VBN number_NN of_IN units_NNS to_TO be_VB sold_VBN ,_, estimated_VBN selling_NN prices_NNS ,_, estimated_VBN market_NN penetration_NN and_CC estimated_VBN market_NN share_NN and_CC year-over-year_JJ growth_NN rates_NNS over_IN the_DT product_NN life_NN cycles_NNS :_: royalty_NN or_CC license_NN fees_NNS saved_VBN by_IN owning_VBG the_DT intellectual_JJ property_NN associated_VBN with_IN the_DT products_NNS :_: cost_NN of_IN sales_NNS for_IN the_DT products_NNS using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ sources_NNS of_IN market_NN data_NNS :_: sales_NNS and_CC marketing_NN expense_NN using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ sources_NNS of_IN market_NN data_NNS :_: general_JJ and_CC administrative_JJ expenses_NNS :_: research_NN and_CC development_NN expenses_NNS :_: and_CC the_DT estimated_VBN life_NN of_IN the_DT products_NNS ._.
The_DT valuations_NNS are_VBP based_VBN on_IN information_NN at_IN the_DT time_NN of_IN the_DT acquisition_NN and_CC the_DT expectations_NNS and_CC assumptions_NNS that_WDT have_VBP been_VBN deemed_VBN reasonable_JJ by_IN the_DT Companys_NNP management_NN ._.
No_DT assurance_NN can_MD be_VB given_VBN ,_, however_RB ,_, that_IN the_DT underlying_VBG assumptions_NNS or_CC events_NNS associated_VBN with_IN such_JJ assets_NNS will_MD occur_VB as_IN projected_VBN ._.
For_IN these_DT reasons_NNS ,_, among_IN others_NNS ,_, the_DT actual_JJ cash_NN flows_NNS may_MD vary_VB from_IN the_DT forecast_NN future_JJ cash_NN flows_NNS ._.
e_LS In-process_JJ research_NN and_CC development_NN As_IN required_VBN by_IN FASB_NNP Interpretation_NNP No._NN ._.
2_CD to_TO Business_NNP Combinations_NNPS Accounted_NNP for_IN by_IN the_DT Purchase_NNP Method_NNP FIN_NNP 4_CD ,_, the_DT portion_NN of_IN the_DT purchase_NN price_NN allocated_VBN to_TO in-process_JJ research_NN and_CC development_NN of_IN $_$ 673_CD million_CD was_VBD immediately_RB expensed_VBN ._.
A_DT project-by-project_JJ valuation_NN using_VBG the_DT guidance_NN in_IN SFAS_NNP No._NN ._.
141_CD and_CC the_DT American_NNP Institute_NNP of_IN Certified_NNP Public_NNP Accountants_NNPS AICPA_NNP Practice_NNP Aid_NNP Assets_NNPS Acquired_VBN in_IN a_DT Business_NN Combination_NN to_TO Be_VB Used_VBN In_IN Research_NNP and_CC Development_NNP Activities_NNPS :_: A_DT Focus_NN on_IN Software_NNP ,_, Electronic_NNP Devices_NNPS and_CC Pharmaceutical_NNP Industries_NNPS has_VBZ been_VBN performed_VBN by_IN independent_JJ valuation_NN specialists_NNS to_TO determine_VB the_DT fair_JJ value_NN of_IN research_NN and_CC development_NN projects_NNS of_IN TKT_NNP which_WDT were_VBD in-process_JJ ,_, but_CC not_RB yet_RB completed_VBN ._.
The_DT fair_JJ value_NN was_VBD determined_VBN using_VBG the_DT income_NN approach_NN on_IN a_DT project-by-project_JJ basis_NN ._.
This_DT method_NN starts_VBZ with_IN a_DT forecast_NN of_IN the_DT expected_JJ future_JJ net_JJ cash_NN flows_NNS ._.
These_DT cash_NN flows_NNS are_VBP then_RB adjusted_VBN to_TO present_JJ value_NN by_IN applying_VBG an_DT appropriate_JJ discount_NN rate_NN that_WDT reflects_VBZ the_DT projects_NNS stage_NN of_IN completion_NN and_CC other_JJ risk_NN factors_NNS ._.
These_DT other_JJ risk_NN factors_NNS can_MD include_VB the_DT nature_NN of_IN the_DT product_NN ,_, the_DT scientific_JJ data_NN associated_VBN with_IN the_DT technology_NN ,_, the_DT current_JJ patent_NN situation_NN and_CC market_NN competition_NN ._.
The_DT forecast_NN of_IN future_JJ cash_NN flows_VBZ required_VBN various_JJ assumptions_NNS to_TO be_VB made_VBN including_VBG :_: revenue_NN that_WDT is_VBZ likely_JJ to_TO result_VB from_IN specific_JJ in-process_JJ research_NN and_CC development_NN projects_NNS ,_, including_VBG estimated_VBN number_NN of_IN units_NNS to_TO be_VB sold_VBN ,_, estimated_VBN selling_NN prices_NNS ,_, estimated_VBN market_NN penetration_NN and_CC estimated_VBN market_NN share_NN and_CC year-over-year_JJ growth_NN rates_NNS over_IN the_DT product_NN life_NN cycles_NNS :_: cost_NN of_IN sales_NNS related_VBN to_TO the_DT potential_JJ products_NNS using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ sources_NNS of_IN market_NN data_NNS :_: sales_NNS and_CC marketing_NN expense_NN using_VBG historical_JJ data_NNS ,_, industry_NN data_NNS or_CC other_JJ market_NN data_NNS :_: general_JJ and_CC administrative_JJ expenses_NNS :_: and_CC research_NN and_CC development_NN expenses_NNS ._.
In_IN addition_NN the_DT Company_NN considered_VBN :_: the_DT projects_NNS stage_NN of_IN completion_NN :_: the_DT costs_NNS incurred_VBN to_TO date_NN :_: the_DT projected_VBN costs_NNS to_TO complete_VB :_: the_DT contribution_NN ,_, if_IN any_DT ,_, of_IN the_DT acquired_VBN identifiable_JJ intangible_JJ assets_NNS :_: the_DT projected_VBN launch_NN date_NN of_IN the_DT potential_JJ product_NN :_: and_CC the_DT estimated_VBN life_NN of_IN the_DT potential_JJ product_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 95_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 96_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 4_CD Business_NN combinations_NNS :_: TKT_NNP acquisition_NN continued_VBD To_TO the_DT extent_NN that_IN the_DT in-process_JJ research_NN and_CC development_NN project_NN is_VBZ expected_VBN to_TO utilize_VB the_DT acquired_VBN identified_VBN intangible_JJ assets_NNS ,_, the_DT value_NN of_IN the_DT in-process_JJ research_NN and_CC development_NN project_NN has_VBZ been_VBN reduced_VBN to_TO reflect_VB this_DT utilization_NN ._.
The_DT acquired_VBN identified_VBN intangible_JJ assets_NNS include_VBP the_DT technical_JJ processes_NNS ,_, intellectual_JJ property_NN ,_, and_CC institutional_JJ understanding_NN with_IN respect_NN to_TO products_NNS and_CC processes_NNS that_WDT have_VBP been_VBN completed_VBN and_CC that_WDT may_MD aid_VB in_IN the_DT development_NN of_IN future_JJ products_NNS or_CC processes_NNS ._.
f_LS Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS Included_VBD in_IN Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS are_VBP the_DT following_VBG fair_JJ value_NN adjustments_NNS :_: i_FW Restructuring_NN costs_NNS An_DT estimate_NN of_IN restructuring_NN costs_NNS that_WDT impact_VBP goodwill_NN ,_, pursuant_JJ to_TO EITF_NNP Issue_NNP No._NN ._.
95-3_CD ,_, Recognition_NN of_IN Liabilities_NNS in_IN Connection_NN with_IN Purchase_NNP Business_NNP Combinations_NNPS EITF_NNP 95-3_CD ._.
Such_JJ costs_NNS total_JJ $_$ 2_CD million_CD and_CC are_VBP associated_VBN with_IN the_DT involuntary_JJ termination_NN of_IN 15_CD TKT_NNP employees_NNS all_DT of_IN whom_WP had_VBD left_VBN the_DT Company_NN by_IN December_NNP 31_CD ,_, 2005_CD ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, $_$ 1.5_CD million_CD had_VBD been_VBN paid_VBN and_CC $_$ 0.5_CD million_CD was_VBD outstanding_JJ :_: and_CC ii_FW Deferred_JJ revenue_NN A_DT fair_JJ value_NN adjustment_NN of_IN $_$ 1.6_CD million_CD in_IN respect_NN of_IN a_DT deferred_JJ revenue_NN stream_NN relating_VBG to_TO pre-acquisition_JJ activities_NNS of_IN TKT_NNP ._.
Pro-forma_JJ financial_JJ information_NN The_DT following_VBG unaudited_JJ pro-forma_FW financial_JJ information_NN presents_VBZ the_DT combined_VBN results_NNS of_IN the_DT operations_NNS of_IN Shire_NNP and_CC TKT_NNP as_IN if_IN the_DT acquisition_NN had_VBD occurred_VBN at_IN the_DT beginning_NN of_IN the_DT periods_NNS presented_VBN ._.
The_DT unaudited_JJ pro-forma_FW financial_JJ information_NN is_VBZ not_RB necessarily_RB indicative_JJ of_IN what_WP the_DT consolidated_JJ results_NNS of_IN operations_NNS actually_RB would_MD have_VB been_VBN had_VBD the_DT acquisition_NN been_VBN completed_VBN at_IN the_DT dates_NNS indicated_VBD ._.
In_IN addition_NN ,_, the_DT unaudited_JJ pro-forma_FW financial_JJ information_NN does_VBZ not_RB purport_VB to_TO project_VB the_DT future_JJ results_NNS of_IN operations_NNS of_IN the_DT combined_VBN Company_NN ._.
2005_CD 2004_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Revenues_NNS 1,652,875_CD 1,441,333_CD Income_NN before_IN extraordinary_JJ items_NNS and_CC cumulative_JJ effect_NN of_IN change_NN in_IN accounting_NN principles_NNS 220,034_CD 187,968_CD Net_JJ income_NN 220,034_CD 187,968_CD Per_IN share_NN amounts_NNS :_: Net_JJ income_NN per_IN common_JJ share_NN basic_JJ 44.0_CD 37.9_CD Net_JJ income_NN per_IN common_JJ share_NN diluted_VBN 43.5_CD 37.4_CD The_DT unaudited_JJ pro-forma_FW financial_JJ information_NN above_IN reflects_VBZ the_DT following_VBG pro-forma_FW adjustments_NNS applied_VBD using_VBG the_DT principles_NNS of_IN Article_NNP 11_CD of_IN Regulation_NN S-X_NN under_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD :_: i_FW elimination_NN of_IN historical_JJ amortization_NN expense_NN recorded_VBN by_IN legacy_NN TKT_NNP for_IN definite-lived_JJ intangible_JJ assets_NNS :_: ii_FW elimination_NN of_IN interest_NN expense_NN recorded_VBN by_IN legacy_NN TKT_NNP on_IN convertible_JJ loan_NN notes_NNS :_: iii_FW an_DT adjustment_NN to_TO increase_VB interest_NN expense_NN by_IN $_$ 6_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, and_CC $_$ 8.1_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, to_TO reflect_VB the_DT interest_NN payable_JJ to_TO dissenting_VBG shareholders_NNS :_: iv_VB an_DT adjustment_NN to_TO decrease_VB interest_NN income_NN by_IN $_$ 15_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, and_CC $_$ 17.4_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, to_TO reflect_VB the_DT cash_NN consideration_NN paid_VBN to_TO TKT_NNP shareholders_NNS ,_, option_NN holders_NNS and_CC convertible_JJ note_NN holders_NNS :_: and_CC v_VB an_DT adjustment_NN to_TO increase_VB amortization_NN expense_NN based_VBN on_IN the_DT estimated_VBN fair_JJ value_NN of_IN identifiable_JJ intangible_JJ assets_NNS from_IN the_DT purchase_NN price_NN allocation_NN ,_, which_WDT are_VBP being_VBG amortized_VBN over_IN their_PRP$ estimated_VBN useful_JJ lives_NNS over_IN a_DT range_NN of_IN 720_CD years_NNS ,_, of_IN approximately_RB $_$ 13.7_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, and_CC $_$ 23.4_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ._.
In_IN addition_NN ,_, the_DT unaudited_JJ pro-forma_FW financial_JJ information_NN above_IN excludes_VBZ the_DT following_VBG material_NN ,_, non-recurring_JJ purchase_NN accounting_NN adjustments_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, as_IN follows_VBZ :_: an_DT in-process_JJ research_NN and_CC development_NN charge_NN of_IN $_$ 673_CD million_CD :_: a_DT $_$ 41.9_CD million_CD charge_NN relating_VBG to_TO the_DT use_NN or_CC sale_NN of_IN purchased_VBN inventory_NN that_WDT was_VBD written_VBN up_RP to_TO fair_JJ value_NN reported_VBN in_IN cost_NN of_IN product_NN sales_NNS :_: and_CC a_DT $_$ 17.2_CD million_CD credit_NN relating_VBG to_TO the_DT current_JJ deferred_JJ tax_NN liability_NN with_IN regard_NN to_TO the_DT purchased_VBN inventory_NN charge_NN in_IN cost_NN of_IN product_NN sales_NNS above_IN ._.
96_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 97_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 5_CD Integration_NN costs_NNS In_IN connection_NN with_IN the_DT acquisition_NN of_IN TKT_NNP the_DT Companys_NNP management_NN approved_VBD and_CC initiated_VBD plans_NNS to_TO restructure_VB the_DT operations_NNS of_IN the_DT enlarged_JJ Company_NN to_TO eliminate_VB duplicate_VB facilities_NNS and_CC reduce_VB costs_NNS ._.
Integration_NN costs_NNS represent_VBP incremental_JJ costs_NNS incurred_VBN by_IN the_DT Company_NN directly_RB related_VBN to_TO the_DT absorption_NN of_IN the_DT TKT_NNP business_NN into_IN the_DT Company_NN ,_, including_VBG expenditures_NNS for_IN consulting_NN and_CC systems_NNS integration_NN ._.
The_DT charges_NNS have_VBP been_VBN presented_VBN as_IN integration_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS and_CC are_VBP accounted_VBN for_IN solely_RB within_IN the_DT Pharmaceutical_NNP Products_NNPS reporting_VBG segment_NN ._.
Integration_NN costs_NNS expensed_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD :_: Costs_NNS recorded_VBD Paid_VBN in_IN in_IN year_NN to_TO year_NN to_TO December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN 2005_CD 2005_CD liability_NN Notes_NNS $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN and_CC retention_NN payments_NNS for_IN key_JJ TKT_NNP employees_NNS 7,031_CD 1,097_CD 5,934_CD Information_NN technology_NN costs_VBZ 1,049_CD 1,049_CD Other_JJ 1,636_CD 1,436_CD 200_CD 9,716_CD 3,582_CD 6,134_CD Current_JJ liabilities_NNS 17_CD 8,916_CD 3,582_CD 5,293_CD Other_JJ long-term_JJ liabilities_NNS 19 800 841_CD 9,716_CD 3,582_CD 6,134_CD 6_CD Reorganizations_NNPS Actions_NNPS commenced_VBD in_IN 2005_CD Sale_NNP of_IN the_DT drug_NN formulation_NN business_NN On_IN December_NNP 22_CD ,_, 2005_CD ,_, Shire_NNP sold_VBD its_PRP$ drug_NN formulation_NN business_NN to_TO Supernus_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Supernus_NNP ,_, a_DT newly-formed_JJ specialty_NN pharmaceutical_JJ company_NN funded_VBN by_IN two_CD venture_NN capital_NN companies_NNS ._.
The_DT sale_NN resulted_VBD in_IN :_: a_DT profit_NN on_IN sale_NN of_IN $_$ 3.6_CD million_CD ._.
Proceeds_NNS from_IN the_DT sale_NN included_VBD an_DT equity_NN interest_NN of_IN less_JJR than_IN 10_CD %_NN in_IN Supernus_NNP ,_, which_WDT has_VBZ been_VBN included_VBN in_IN investments_NNS in_IN private_JJ companies_NNS see_VBP Note_VB 11_CD at_IN its_PRP$ fair_JJ value_NN of_IN $_$ 3.9_CD million_CD ._.
The_DT fair_JJ value_NN was_VBD determined_VBN by_IN reference_NN to_TO the_DT cash_NN invested_VBN in_IN Supernus_NNP by_IN the_DT venture_NN capital_NN companies_NNS :_: the_DT transfer_NN of_IN the_DT lease_NN on_IN the_DT East_NNP Gude_NNP Drive_NNP ,_, Rockville_NNP premises_NNS to_TO Supernus_NNP ,_, with_IN Shire_NNP being_VBG released_VBN from_IN all_DT obligations_NNS under_IN the_DT lease_NN by_IN the_DT landlord_NN :_: an_DT ongoing_JJ projects_NNS agreement_NN relating_VBG to_TO services_NNS that_WDT Supernus_NNP will_MD continue_VB to_TO provide_VB to_TO Shire_VB for_IN a_DT transitional_JJ period_NN ending_VBG on_IN or_CC about_IN March_NNP 31_CD ,_, 2006_CD ,_, on_IN certain_JJ Shire_NNP projects_NNS until_IN the_DT projects_NNS are_VBP moved_VBN to_TO third-party_JJ suppliers_NNS :_: and_CC the_DT severance_NN of_IN 28_CD employees_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, 16_CD had_VBD left_VBN the_DT Company_NN ,_, and_CC the_DT remaining_VBG employees_NNS are_VBP expected_VBN to_TO leave_VB by_IN March_NNP 31_CD ,_, 2006_CD ._.
Severance_NN payments_NNS are_VBP being_VBG made_VBN to_TO the_DT former_JJ employees_NNS over_IN a_DT 42-week_JJ period_NN ,_, as_IN required_VBN by_IN local_JJ regulations_NNS ._.
The_DT sale_NN has_VBZ been_VBN reflected_VBN in_IN the_DT statement_NN of_IN operations_NNS as_IN follows_VBZ :_: Research_NNP and_CC Other_JJ income_NN development_NN expense_NN ,_, net_JJ expense_NN $_$ 000_CD $_$ 000_CD Gain_NN on_IN disposition_NN 3,561_CD Employee_NNP severance_NN 1,216_CD Other_JJ costs_NNS 192_CD 3,561_CD 1,408_CD All_DT items_NNS are_VBP recorded_VBN in_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 97_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 98_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 6_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2004_CD North_JJ American_JJ site_NN consolidation_NN As_IN previously_RB disclosed_VBN ,_, the_DT Company_NN began_VBD a_DT consolidation_NN of_IN its_PRP$ North_JJ American_JJ sites_NNS in_IN 2004_CD ,_, with_IN the_DT aim_NN of_IN decreasing_VBG the_DT number_NN of_IN sites_NNS from_IN 16_CD to_TO four_CD ,_, including_VBG the_DT opening_NN of_IN a_DT new_JJ US_NNP headquarters_NN office_NN in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
The_DT Company_NN recorded_VBN reorganization_NN costs_NNS of_IN $_$ 48.5_CD million_CD in_IN 2004_CD ,_, and_CC $_$ 9.3_CD million_CD in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
The_DT primary_JJ costs_NNS associated_VBN with_IN the_DT site_NN consolidation_NN included_VBD :_: severance_NN costs_NNS relating_VBG to_TO 137_CD employees_NNS :_: retention_NN payments_NNS to_TO key_JJ employees_NNS :_: relocation_NN costs_NNS relating_VBG to_TO 85_CD employees_NNS who_WP were_VBD moved_VBN to_TO Wayne_NNP ,_, Pennsylvania_NNP :_: costs_NNS of_IN duplicate_VBP facilities_NNS including_VBG lease_NN exit_NN costs_NNS :_: and_CC other_JJ incremental_JJ costs_NNS associated_VBN with_IN the_DT site_NN closures_NNS ,_, such_JJ as_IN legal_JJ ,_, consultancy_NN ,_, the_DT write-down_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN and_CC information_NN technology_NN costs_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, all_DT 137_CD employees_NNS had_VBD left_VBN the_DT Company_NN ._.
The_DT cost_NN of_IN the_DT employee_NN severance_NN was_VBD ratably_RB recognized_VBN over_IN the_DT period_NN from_IN the_DT communication_NN date_NN to_TO the_DT termination_NN date_NN ._.
In_IN addition_NN ,_, all_DT 85_CD of_IN those_DT employees_NNS who_WP had_VBD agreed_VBN to_TO relocate_VB have_VB relocated_VBN ._.
The_DT cost_NN of_IN relocation_NN was_VBD recorded_VBN as_IN it_PRP was_VBD incurred_VBN ._.
The_DT following_JJ table_NN presents_VBZ the_DT cost_NN of_IN the_DT reorganization_NN recorded_VBN to_TO date_NN and_CC the_DT total_JJ costs_NNS of_IN the_DT reorganization_NN ._.
Total_JJ costs_NNS Total_JJ costs_NNS recorded_VBN in_IN recorded_VBN in_IN year_NN to_TO year_NN to_TO December_NNP 31_CD ,_, December_NNP 31_CD ,_, Total_JJ costs_NNS of_IN 2005_CD 2004_CD reorganization_NN $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 1.6_CD 33.8_CD 35.4_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_NNS 0.5_CD 2.9_CD 3.4_CD Duplicate_NNP facilities_NNS 7.2_CD 5.1_CD 12.3_CD Information_NN technology_NN costs_VBZ 2.1_CD 2.1_CD Other_JJ costs_NNS 3.4_CD 3.4_CD 9.3_CD 48.5_CD 57.8_CD These_DT charges_NNS have_VBP been_VBN reflected_VBN within_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS and_CC are_VBP accounted_VBN for_IN solely_RB within_IN the_DT Pharmaceutical_NNP Products_NNPS reporting_VBG segment_NN ._.
As_IN noted_VBN above_IN ,_, certain_JJ of_IN the_DT costs_NNS associated_VBN with_IN the_DT reorganization_NN will_MD be_VB paid_VBN in_IN subsequent_JJ periods_NNS ._.
The_DT following_VBG provides_VBZ a_DT reconciliation_NN of_IN the_DT liability_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2005_CD 2005_CD liability_NN Notes_NNS $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 1.7_CD 1.6_CD 2.7_CD 0.6_CD Consultancy_NN costs_NNS 0.5_CD 0.5_CD Duplicate_NNP facilities_NNS 2.5_CD 7.2_CD 2.5_CD 7.2_CD 4.2_CD 9.3_CD 5.7_CD 7.8_CD Current_JJ liabilities_NNS 17_CD 1.7_CD 7.4_CD 5.7_CD 3.4_CD Other_JJ long-term_JJ liabilities_NNS 19_CD 2.5_CD 1.9_CD 4.4_CD 4.2_CD 9.3_CD 5.7_CD 7.8_CD The_DT remaining_VBG relocation_NN costs_NNS are_VBP expected_VBN to_TO be_VB paid_VBN in_IN 2006_CD ._.
The_DT duplicate_VBP facilities_NNS costs_NNS will_MD be_VB paid_VBN over_IN the_DT remaining_VBG life_NN of_IN the_DT relevant_JJ leases_NNS ,_, which_WDT all_DT expire_VBP before_IN October_NNP 31_CD ,_, 2012_CD ._.
98_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 99_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 6_CD Reorganizations_NNS continued_VBD The_DT following_JJ provides_VBZ a_DT reconciliation_NN of_IN the_DT liability_NN as_IN at_IN December_NNP 31_CD ,_, 2004_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2004_CD 2004_CD liability_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Employee_NN severance_NN and_CC relocation_NN costs_NNS 33.8_CD 32.1_CD 1.7_CD Write-off_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 1.2_CD 1.2_CD Consultancy_NN costs_VBZ 2.9_CD 2.9_CD Duplicate_NNP facilities_NNS 5.1_CD 2.6_CD 2.5_CD Information_NN technology_NN costs_VBZ 2.1_CD 2.1_CD Other_JJ costs_NNS 3.4_CD 3.4_CD 48.5_CD 44.3_CD 4.2_CD iii_FW Disposition_NNP of_IN the_DT vaccines_NNS business_NN On_IN September_NNP 9_CD ,_, 2004_CD the_DT Company_NN completed_VBD the_DT disposition_NN of_IN its_PRP$ vaccines_NNS business_NN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP ._.
The_DT total_JJ consideration_NN for_IN the_DT sale_NN was_VBD $_$ 120_CD million_CD comprizing_VBG $_$ 30_CD million_CD of_IN cash_NN received_VBN at_IN completion_NN ,_, $_$ 30_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN and_CC due_JJ on_IN the_DT first_JJ anniversary_NN of_IN completion_NN and_CC $_$ 60_CD million_CD received_VBN at_IN completion_NN in_IN the_DT form_NN of_IN 4,931,864_CD subscription_NN receipts_NNS of_IN IDB_NNP ._.
If_IN ,_, prior_RB to_TO January_NNP 10_CD ,_, 2005_CD ,_, IDB_NNP were_VBD to_TO raise_VB up_RP to_TO $_$ 60_CD million_CD from_IN equity_NN related_VBN issuances_NNS ,_, then_RB it_PRP was_VBD required_VBN under_IN the_DT terms_NNS of_IN the_DT sale_NN agreement_NN to_TO redeem_VB the_DT subscription_NN receipts_NNS from_IN Shire_NNP for_IN $_$ 60_CD million_CD ._.
Accordingly_RB ,_, following_VBG the_DT completion_NN of_IN such_PDT a_DT fund_NN raising_VBG on_IN January_NNP 7_CD ,_, 2005_CD ,_, IDB_NNP redeemed_VBD the_DT subscription_NN receipts_NNS from_IN Shire_NNP for_IN $_$ 60_CD million_CD in_IN cash_NN ._.
On_IN the_DT first_JJ anniversary_NN of_IN completion_NN ,_, Shire_NNP received_VBD the_DT $_$ 30_CD million_CD of_IN cash_NN held_VBN in_IN escrow_NN ._.
As_IN part_NN of_IN the_DT transaction_NN ,_, Shire_NNP entered_VBD into_IN an_DT agreement_NN to_TO provide_VB IDB_NNP with_IN a_DT loan_NN facility_NN of_IN up_RB to_TO $_$ 100_CD million_CD ,_, which_WDT could_MD be_VB drawn_VBN down_RB over_IN the_DT four_CD years_NNS following_VBG completion_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, IDB_NNP had_VBD drawn_VBN down_IN the_DT entire_JJ $_$ 100_CD million_CD loan_NN ._.
It_PRP was_VBD required_VBN that_IN this_DT facility_NN be_VB used_VBN by_IN IDB_NNP to_TO fund_VB the_DT development_NN of_IN injectable_JJ flu_NN and_CC pipeline_NN products_NNS within_IN the_DT vaccines_NNS business_NN acquired_VBD from_IN Shire_NNP ._.
Drawings_NNS under_IN the_DT loan_NN facility_NN are_VBP segregated_VBN into_IN two_CD components_NNS :_: i_FW Drawings_NNPS for_IN injectable_JJ flu_NN development_NN of_IN $_$ 70.6_CD million_CD which_WDT are_VBP repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ non-Canadian_JJ injectable_JJ flu_NN products_NNS ,_, subject_JJ to_TO minimum_JJ annual_JJ repayments_NNS in_IN respect_NN of_IN the_DT first_JJ $_$ 30_CD million_CD of_IN the_DT drawing_NN ,_, to_TO be_VB made_VBN between_IN 2007_CD and_CC 2017_CD :_: and_CC ii_FW Drawings_NNPS for_IN pipeline_NN development_NN of_IN $_$ 29.4_CD million_CD which_WDT are_VBP repayable_JJ out_IN of_IN income_NN generated_VBN by_IN IDB_NNP on_IN future_JJ pipeline_NN products_NNS and_CC have_VBP no_DT fixed_VBN repayment_NN schedule_NN ._.
The_DT transaction_NN gave_VBD rise_NN to_TO an_DT overall_JJ loss_NN on_IN disposition_NN of_IN the_DT vaccines_NNS business_NN of_IN $_$ 41.1_CD million_CD ,_, recorded_VBN as_IN a_DT loss_NN on_IN disposition_NN at_IN completion_NN in_IN 2004_CD of_IN $_$ 44.2_CD million_CD and_CC a_DT subsequent_JJ provision_NN release_NN of_IN $_$ 3.1_CD million_CD being_VBG recognized_VBN during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
This_DT net_JJ loss_NN on_IN disposition_NN of_IN $_$ 41.1_CD million_CD comprises_VBZ a_DT gain_NN on_IN disposition_NN of_IN net_JJ assets_NNS of_IN $_$ 28.9_CD million_CD together_RB with_IN a_DT provision_NN for_IN a_DT loss_NN of_IN $_$ 70_CD million_CD out_IN of_IN the_DT $_$ 100_CD million_CD loan_NN facility_NN available_JJ to_TO IDB_NNP ._.
This_DT provision_NN was_VBD made_VBN on_IN the_DT basis_NN that_IN those_DT loan_NN repayments_NNS based_VBN solely_RB on_IN future_JJ sales_NNS of_IN flu_NN and_CC pipeline_NN products_NNS in_IN development_NN provided_VBN no_DT certainty_NN of_IN recovery_NN ._.
The_DT historical_JJ consolidated_JJ financial_JJ statements_NNS reflect_VBP the_DT vaccines_NNS business_NN as_IN a_DT discontinued_VBN operation_NN for_IN all_DT periods_NNS presented_VBN ._.
The_DT results_NNS of_IN the_DT discontinued_VBN operation_NN have_VBP been_VBN removed_VBN from_IN all_DT periods_NNS on_IN a_DT line-by-line_JJ basis_NN from_IN product_NN sales_NNS revenue_NN to_TO income_NN from_IN continuing_VBG operations_NNS ._.
The_DT net_JJ loss_NN from_IN the_DT discontinued_VBN operation_NN ,_, together_RB with_IN the_DT loss_NN on_IN disposition_NN ,_, are_VBP shown_VBN as_IN separate_JJ line_NN items_NNS ._.
Operating_VBG results_NNS of_IN the_DT discontinued_VBN operations_NNS are_VBP summarized_VBN below_IN ._.
2004_CD 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Revenues_NNS :_: Product_NN sales_NNS 3,626_CD 25,531_CD Total_JJ revenues_NNS 3,626_CD 25,531_CD Costs_NNS and_CC expenses_NNS :_: Cost_NN of_IN product_NN sales_NNS 8,304_CD 19,954_CD Research_NNP and_CC development_NN 9,222_CD 20,879_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 5,614_CD 9,671_CD Total_JJ operating_NN expenses_NNS 23,140_CD 50,504_CD Operating_NN loss_NN 19,514_CD 24,973_CD Other_JJ expense_NN income_NN ,_, net_JJ 621_CD 3,087_CD Loss_NN from_IN discontinued_VBN operations_NNS 20,135_CD 21,886_CD Loss_NN on_IN disposition_NN 44,157_CD 64,292_CD 21,886_CD At_IN December_NNP 31_CD ,_, 2004_CD ,_, the_DT assets_NNS and_CC liabilities_NNS of_IN the_DT discontinued_VBN vaccines_NNS operation_NN were_VBD $_$ nil_JJ ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 99_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 100_CD Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 6_CD Reorganizations_NNS continued_VBD Actions_NNS commenced_VBN in_IN 2003_CD i_FW Closure_NN of_IN Lead_JJ Optimization_NNP The_DT closure_NN of_IN Lead_JJ Optimization_NN resulted_VBD in_IN :_: the_DT severance_NN of_IN 134_CD employees_NNS ._.
As_IN at_IN December_NNP 2004_CD ,_, all_DT employees_NNS had_VBD left_VBN the_DT Company_NN :_: a_DT $_$ 6_CD million_CD write-off_NN of_IN tangible_JJ fixed_JJ assets_NNS ._.
These_DT assets_NNS ,_, primarily_RB laboratory_NN equipment_NN ,_, were_VBD used_VBN by_IN Lead_JJ Optimization_NN for_IN research_NN and_CC development_NN and_CC had_VBD no_DT alternative_JJ use_NN :_: and_CC the_DT cancellation_NN ,_, to_TO the_DT extent_NN possible_JJ ,_, of_IN contracts_NNS directly_RB relating_VBG to_TO Lead_JJ Optimization_NN ._.
The_DT costs_NNS associated_VBN with_IN these_DT actions_NNS have_VBP been_VBN reflected_VBN in_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD and_CC 2004_CD ._.
There_EX are_VBP no_DT outstanding_JJ liabilities_NNS related_VBN to_TO the_DT closure_NN of_IN Lead_JJ Optimization_NN at_IN December_NNP 31_CD ,_, 2005_CD ._.
The_DT following_VBG provides_VBZ a_DT roll-forward_NN of_IN the_DT liability_NN to_TO December_NNP 31_CD ,_, 2004_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2004_CD 2004_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 3,452_CD 118_CD 3,570_CD Other_JJ costs_NNS 325_CD 9_CD 98_CD 236_CD 3,777_CD 127_CD 3,668_CD 236_CD The_DT following_VBG provides_VBZ a_DT roll-forward_NN of_IN the_DT liability_NN as_IN at_IN December_NNP 31_CD ,_, 2003_CD :_: Costs_NNS recorded_VBN Utilization_NN in_IN year_NN to_TO in_IN year_NN to_TO Opening_NNP December_NNP 31_CD ,_, December_NNP 31_CD ,_, Closing_NN liability_NN 2003_CD 2003_CD liability_NN $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Employee_NN severance_NN 6,425_CD 2,973_CD 3,452_CD Write_VB down_IN of_IN tangible_JJ fixed_JJ assets_NNS 6,026_CD 6,026_CD Other_JJ costs_NNS 800 475 325_CD 13,251_CD 9,474_CD 3,777_CD ii_FW Disposition_NNP of_IN North_NNP American_NNP facilities_NNS Subsequent_JJ to_TO the_DT closure_NN of_IN Lead_JJ Optimization_NN and_CC the_DT decision_NN to_TO dispose_VB of_IN the_DT vaccines_NNS business_NN ,_, the_DT Company_NN began_VBD an_DT assessment_NN of_IN its_PRP$ property_NN needs_VBZ in_IN Canada_NNP and_CC the_DT US_NNP ._.
As_IN a_DT result_NN of_IN this_DT initial_JJ process_NN the_DT Company_NN decided_VBD to_TO dispose_VB of_IN its_PRP$ building_NN in_IN Laval_NNP ,_, Canada_NNP and_CC to_TO relocate_VB the_DT employees_NNS ._.
The_DT Company_NN also_RB decided_VBD to_TO sell_VB its_PRP$ building_NN in_IN Buffalo_NNP Grove_NNP ,_, US_NNP ._.
As_IN at_IN December_NNP 31_CD ,_, 2003_CD ,_, the_DT Company_NN had_VBD obtained_VBN valuations_NNS of_IN the_DT properties_NNS and_CC entered_VBD into_IN sale_NN negotiations_NNS with_IN third_JJ parties_NNS on_IN the_DT Laval_NNP property_NN and_CC was_VBD actively_RB seeking_VBG buyers_NNS for_IN its_PRP$ Buffalo_NNP Grove_NNP facility_NN ._.
Based_VBN on_IN these_DT negotiations_NNS ,_, the_DT valuations_NNS obtained_VBN ,_, the_DT limitations_NNS on_IN use_NN of_IN the_DT building_NN in_IN its_PRP$ current_JJ state_NN and_CC the_DT overall_JJ real_JJ estate_NN market_NN ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN charge_NN of_IN $_$ 10.7_CD million_CD in_IN the_DT year_NN ended_VBD December_NNP 31_CD ,_, 2003_CD ,_, which_WDT is_VBZ included_VBN in_IN reorganization_NN costs_NNS in_IN the_DT consolidated_JJ statement_NN of_IN operations_NNS ._.
The_DT Company_NN reclassified_VBD to_TO prepaid_JJ expenses_NNS and_CC other_JJ current_JJ assets_NNS the_DT assets_NNS held_VBN for_IN sale_NN ._.
The_DT properties_NNS were_VBD disposed_VBN of_IN in_IN 2004_CD ._.
100_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 101_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 7_CD Accounts_NNPS receivable_NN ,_, net_JJ Trade_NNP receivables_NN at_IN December_NNP 31_CD ,_, 2005_CD ,_, of_IN $_$ 329.9_CD million_CD December_NNP 31_CD ,_, 2004_CD :_: $_$ 222.5_CD million_CD ,_, are_VBP stated_VBN net_NN of_IN a_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC sales_NNS discounts_NNS of_IN $_$ 9.7_CD million_CD December_NNP 31_CD ,_, 2004_CD :_: $_$ 4.3_CD million_CD ._.
The_DT movement_NN in_IN the_DT provision_NN for_IN doubtful_JJ accounts_NNS and_CC sales_NNS discounts_NNS is_VBZ as_IN follows_VBZ :_: 2005 2004 2003_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD As_IN at_IN January_NNP 1_CD ,_, 4,264_CD 7,853_CD 4,585_CD Charged_VBN to_TO operations_NNS 51,060_CD 38,218_CD 42,841_CD Released_VBN to_TO income_NN 3,395_CD Utilization_NN 45,577_CD 38,412_CD 39,573_CD As_IN at_IN December_NNP 31_CD ,_, 9,747_CD 4,264_CD 7,853_CD Revenues_NNS are_VBP mainly_RB derived_VBN in_IN the_DT US_NNP 69_CD %_NN of_IN total_JJ revenues_NNS from_IN agreements_NNS with_IN major_JJ pharmaceutical_JJ companies_NNS and_CC relationships_NNS with_IN pharmaceutical_JJ wholesale_JJ distributors_NNS and_CC retail_JJ pharmacy_NN chains_NNS ._.
Significant_JJ customers_NNS are_VBP disclosed_VBN in_IN Note_NN 25_CD ._.
Such_JJ clients_NNS have_VBP significant_JJ cash_NN resources_NNS and_CC therefore_RB any_DT credit_NN risk_NN associated_VBN with_IN these_DT transactions_NNS is_VBZ considered_VBN minimal_JJ ._.
8_CD Inventories_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Finished_VBN goods_NNS 63,315_CD 22,349_CD Work-in-process_JJ 53,963_CD 11,831_CD Raw_NNP materials_NNS 18,779_CD 7,050_CD 136,057_CD 41,230_CD The_DT increase_NN in_IN inventory_NN is_VBZ due_JJ to_TO the_DT acquisition_NN of_IN TKT_NNP see_VBP Note_NN 4_CD ._.
9_CD Prepaid_NN expenses_NNS and_CC other_JJ current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Prepaid_NN expenses_NNS 30,245_CD 31,401_CD Income_NNP tax_NN receivable_NN 40,802_CD Value_NNP added_VBD taxes_NNS receivable_JJ 10,185_CD 2,124_CD Supplemental_NNP Executive_NNP Retirement_NNP Plan_NNP SERP_NNP investment_NN 28_CD 1,276_CD 1,784_CD Subscription_NN receipts_NNS 6_CD 60,000_CD Cash_NN held_VBN in_IN escrow_NN 6_CD 30,000_CD Other_JJ current_JJ assets_NNS 15,576_CD 11,962_CD 98,084_CD 137,271_CD 10_CD Short-term_JJ investments_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Institutional_JJ and_CC managed_VBD cash_NN funds_NNS 6,947_CD 174,752_CD Commercial_JJ paper_NN 149,659_CD 6,947_CD 324,411_CD In_IN July_NNP 2005_CD ,_, the_DT Company_NN liquidated_VBN all_DT short-term_JJ investments_NNS to_TO provide_VB funds_NNS for_IN the_DT acquisition_NN of_IN TKT_NNP ._.
The_DT investments_NNS balance_NN at_IN December_NNP 31_CD ,_, 2005_CD ,_, was_VBD inherited_VBN through_IN that_DT acquisition_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 101_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 102_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_JJ 11_CD Investments_NNPS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Investments_NNPS in_IN private_JJ companies_NNS 9,008_CD 2,451_CD Available-for-sale_JJ securities_NNS 18,131_CD 29,970_CD Equity-method_JJ investments_NNS 23,023_CD 30,846_CD 50,162_CD 63,267_CD The_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 2_CD million_CD on_IN its_PRP$ investments_NNS during_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 15.4_CD million_CD :_: 2003_CD $_$ 15.5_CD million_CD ._.
All_DT impairments_NNS in_IN the_DT three_CD years_NNS presented_VBN were_VBD recorded_VBN in_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
a_DT Investments_NNP in_IN private_JJ companies_NNS Additions_NNS to_TO investments_NNS in_IN private_JJ companies_NNS included_VBD a_DT $_$ 3.9_CD million_CD investment_NN in_IN Supernus_NNP less_JJR than_IN 10_CD %_NN of_IN total_JJ equity_NN ,_, as_IN part_NN consideration_NN for_IN the_DT sale_NN of_IN the_DT drug_NN formulation_NN business_NN ._.
The_DT fair_JJ value_NN of_IN the_DT investment_NN was_VBD determined_VBN by_IN reference_NN to_TO cash_VB invested_VBN in_IN Supernus_NNP by_IN the_DT other_JJ investors_NNS ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 1.6_CD million_CD against_IN its_PRP$ investments_NNS in_IN private_JJ companies_NNS based_VBN on_IN a_DT decline_NN in_IN the_DT estimates_NNS of_IN their_PRP$ fair_JJ value_NN that_IN the_DT Company_NN believes_VBZ are_VBP other-than-temporary_JJ ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 9.8_CD million_CD against_IN these_DT investments_NNS based_VBN on_IN changes_NNS in_IN the_DT estimates_NNS of_IN their_PRP$ fair_JJ value_NN ._.
This_DT amount_NN includes_VBZ $_$ 4.2_CD million_CD to_TO reduce_VB the_DT value_NN of_IN an_DT investment_NN in_IN a_DT private_JJ company_NN that_WDT gained_VBD a_DT listing_NN on_IN March_NNP 24_CD ,_, 2004_CD :_: the_DT initial_JJ listing_NN price_NN was_VBD below_IN the_DT anticipated_JJ flotation_NN price_NN used_VBN to_TO value_VB the_DT investment_NN at_IN December_NNP 31_CD ,_, 2003_CD and_CC the_DT Company_NN believed_VBD the_DT decline_NN in_IN value_NN was_VBD other-than-temporary_JJ ._.
After_IN the_DT date_NN of_IN the_DT listing_VBG the_DT investment_NN was_VBD reclassified_VBN to_TO available-for-sale_JJ securities_NNS and_CC so_RB any_DT changes_NNS since_IN the_DT initial_JJ listing_NN date_NN have_VBP been_VBN recorded_VBN in_IN other_JJ comprehensive_JJ income_NN ._.
The_DT changes_NNS in_IN fair_JJ market_NN value_NN ,_, which_WDT resulted_VBD in_IN the_DT write-downs_NNS referred_VBD to_TO above_IN were_VBD based_VBN on_IN the_DT Companys_NNP estimates_NNS of_IN fair_JJ value_NN ._.
These_DT estimates_NNS were_VBD derived_VBN from_IN financial_JJ and_CC other_JJ publicly_RB available_JJ information_NN such_JJ as_IN press_NN releases_NNS and_CC recent_JJ capital_NN raising_VBG activities_NNS ._.
b_NN Available-for-sale_JJ securities_NNS Gain_NN on_IN sale_NN During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD the_DT Company_NN sold_VBD an_DT investment_NN in_IN an_DT available-for-sale_JJ security_NN ,_, valued_VBN at_IN $_$ 6_CD million_CD ,_, realizing_VBG a_DT gain_NN on_IN the_DT sale_NN of_IN $_$ 3.9_CD million_CD ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN sold_VBD an_DT investment_NN in_IN an_DT available-for-sale_JJ security_NN ,_, valued_VBN at_IN $_$ 11.9_CD million_CD ,_, realizing_VBG a_DT gain_NN on_IN the_DT sale_NN of_IN $_$ 14.8_CD million_CD 2003_CD :_: $_$ nil_JJ ._.
Other-than-temporary_JJ impairment_NN The_DT Company_NN recorded_VBN other-than-temporary_JJ impairments_NNS of_IN $_$ 0.4_CD million_CD ,_, $_$ 1.6_CD million_CD and_CC $_$ nil_CD against_IN its_PRP$ available-for-sale_JJ securities_NNS in_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD respectively_RB ._.
At_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD no_DT available-for-sale_JJ investments_NNS in_IN a_DT significant_JJ unrealized_JJ loss_NN position_NN for_IN which_WDT other-than-temporary_JJ impairments_NNS have_VBP not_RB been_VBN recognized_VBN ._.
102_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 103_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_JJ 11_CD Investments_NNPS continued_VBD c_NN Equity_NN method_NN investments_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD GSK_NNP 5,954_CD 6,179_CD GeneChem_NNP Funds_NNPS 12,659_CD 18,343_CD Other_JJ 4,410_CD 6,324_CD 23,023_CD 30,846_CD i_FW GSK_NNP The_NNP Company_NNP has_VBZ accounted_VBN for_IN its_PRP$ commercialization_NN partnership_NN with_IN GSK_NNP through_IN which_WDT the_DT products_NNS 3TC_NNP and_CC ZEFFIX_NNP are_VBP marketed_VBN in_IN Canada_NNP ,_, using_VBG the_DT equity_NN method_NN of_IN accounting_NN ._.
The_DT Companys_NNP 50_CD %_NN share_NN of_IN the_DT partnership_NN is_VBZ included_VBN within_IN Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_NNS ._.
ii_FW GeneChem_NNP Funds_NNPS The_DT GeneChem_NNP Technologies_NNPS Venture_NNP Fund_NNP and_CC the_DT GeneChem_NNP Therapeutics_NNPS Venture_NNP Fund_NNP The_NNP Funds_NNPS are_VBP Canadian_JJ limited_JJ partnerships_NNS investing_VBG in_IN healthcare_NN research_NN and_CC development_NN companies_NNS ,_, in_IN which_WDT the_DT Company_NN owns_VBZ 30_CD %_NN and_CC 11_CD %_NN of_IN the_DT issued_VBN shares_NNS respectively_RB ._.
At_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Funds_NNS net_JJ assets_NNS totaled_VBD approximately_RB $_$ 71_CD million_CD 2004_CD :_: $_$ 107_CD million_CD ._.
The_DT Company_NN is_VBZ involved_VBN as_IN a_DT limited_JJ partner_NN and_CC the_DT general_JJ partner_NN of_IN the_DT Funds_NNPS :_: involvement_NN in_IN the_DT Funds_NNS dates_NNS from_IN between_IN 1997_CD and_CC 2000_CD ._.
The_DT Companys_NNP exposure_NN to_TO loss_NN as_IN a_DT result_NN of_IN its_PRP$ involvement_NN with_IN the_DT Funds_NNPS is_VBZ limited_VBN to_TO the_DT carrying_VBG value_NN of_IN the_DT investment_NN ,_, $_$ 12.7_CD million_CD at_IN December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 18.3_CD million_CD ,_, 2003_CD :_: $_$ 19.8_CD million_CD and_CC its_PRP$ commitment_NN to_TO further_JJ investment_NN of_IN $_$ 1.7_CD million_CD 2004_CD :_: $_$ 2.9_CD million_CD ,_, 2003_CD :_: $_$ 4.1_CD million_CD ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, the_DT Company_NN recorded_VBD an_DT impairment_NN of_IN $_$ 4_CD million_CD against_IN the_DT investment_NN in_IN the_DT Funds_NNPS following_VBG reviews_NNS of_IN the_DT Funds_NNPS investment_NN portfolios_NNS that_WDT identified_VBD other-than-temporary_JJ declines_NNS in_IN the_DT value_NN of_IN certain_JJ private_JJ and_CC publicly_RB quoted_VBN securities_NNS held_VBN by_IN the_DT Funds_NNS ._.
12_CD Property_NN ,_, plant_NN and_CC equipment_NN ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Land_NNP and_CC buildings_NNS 157,242_CD 80,631_CD Office_NNP furniture_NN ,_, fittings_NNS and_CC equipment_NN 91,142_CD 67,301_CD Warehouse_NNP ,_, laboratory_NN and_CC manufacturing_NN equipment_NN 44,080_CD 31,657_CD Assets_NNS under_IN construction_NN 18,360_CD 3,166_CD 310,824_CD 182,755_CD Less_RBR :_: accumulated_VBN depreciation_NN 76,825_CD 51,404_CD 233,999_CD 131,351_CD The_DT increase_NN in_IN property_NN ,_, plant_NN and_CC equipment_NN net_NN ,_, is_VBZ principally_RB due_JJ to_TO the_DT acquisition_NN of_IN TKT_NNP see_VBP Note_NN 4_CD ._.
Depreciation_NN expense_NN for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD was_VBD $_$ 32.7_CD million_CD ,_, $_$ 22.5_CD million_CD and_CC $_$ 14.1_CD million_CD respectively_RB ._.
The_DT expense_NN in_IN 2005_CD included_VBD a_DT $_$ 6.5_CD million_CD impairment_NN loss_NN related_VBN to_TO the_DT plant_NN and_CC equipment_NN of_IN the_DT drug_NN formulation_NN business_NN ._.
At_IN the_DT time_NN of_IN the_DT impairment_NN loss_NN ,_, the_DT Company_NN was_VBD expecting_VBG to_TO close_VB the_DT business_NN and_CC ,_, because_IN the_DT carrying_VBG value_NN of_IN the_DT assets_NNS exceeded_VBD the_DT expected_JJ future_JJ cash_NN flows_VBZ resulting_VBG from_IN the_DT closure_NN ,_, the_DT assets_NNS were_VBD considered_VBN impaired_VBN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 103_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 104_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 13_CD Goodwill_NNP ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Goodwill_NNP arising_VBG on_IN businesses_NNS acquired_VBN 367,652_CD 235,396_CD The_DT increase_NN in_IN the_DT net_JJ book_NN value_NN of_IN goodwill_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ,_, is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: $_$ 000_CD As_IN at_IN January_NNP 1_CD ,_, 2005_CD 235,396_CD Acquisitions_NNPS 166,414_CD Asset_NNP impairments_NNS Disposals_NNP Foreign_NNP currency_NN translation_NN 34,158_CD As_IN at_IN December_NNP 31_CD ,_, 2005_CD 367,652_CD The_DT Company_NN recognized_VBD $_$ 166_CD million_CD as_IN goodwill_NN on_IN acquisition_NN of_IN TKT_NNP see_VBP Note_NN 4_CD ,_, in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
This_DT goodwill_NN is_VBZ recorded_VBN in_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
Goodwill_NN by_IN operating_VBG segment_NN In_IN prior_RB reporting_VBG periods_NNS ,_, the_DT Companys_NNP internal_JJ management_NN reporting_VBG structure_NN was_VBD based_VBN on_IN a_DT combination_NN of_IN geography_NN and_CC function_NN ._.
As_IN a_DT result_NN the_DT Company_NN had_VBD operating_VBG segments_NNS for_IN the_DT US_NNP and_CC International_NNP sales_NNS and_CC marketing_NN businesses_NNS ,_, research_NN and_CC development_NN costs_NNS and_CC a_DT Corporate_JJ segment_NN which_WDT included_VBD corporate_JJ costs_NNS and_CC royalty_NN income_NN ._.
Following_VBG an_DT internal_JJ restructuring_NN of_IN the_DT business_NN ,_, management_NN has_VBZ re-evaluated_VBN and_CC amended_VBN its_PRP$ internal_JJ reporting_NN structures_NNS and_CC as_IN a_DT result_NN ,_, changed_VBD its_PRP$ reporting_NN segments_NNS ._.
Effective_JJ January_NNP 1_CD ,_, 2005_CD ,_, Shires_NNP internal_JJ management_NN reporting_VBG structures_NNS have_VBP been_VBN changed_VBN to_TO show_VB two_CD operating_VBG segments_NNS ,_, Pharmaceutical_NNP Products_NNPS and_CC Royalties_NNPS ._.
The_DT Pharmaceutical_NNP Products_NNPS segment_NN comprises_VBZ four_CD therapeutic_JJ areas_NNS :_: CNS_NNP ,_, GI_NNP ,_, Shire_NNP HGT_NNP and_CC GP_NNP ._.
The_DT net_JJ book_NN value_NN of_IN goodwill_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD is_VBZ all_DT held_VBN in_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
14_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Other_JJ intangible_JJ assets_NNS :_: Intellectual_NNP property_NN rights_NNS acquired_VBD 978,869_CD 543,969_CD Less_RBR :_: accumulated_VBN amortization_NN 249_CD ,_, 565_CD 234,672_CD 729,304_CD 309,297_CD The_DT increase_NN in_IN the_DT net_JJ book_NN value_NN of_IN other_JJ intangible_JJ assets_NNS for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: Other_JJ intangible_JJ assets_NNS $_$ 000_CD As_IN at_IN January_NNP 1_CD ,_, 2005_CD 309,297_CD Acquisitions_NNPS 1,155,511_CD In-process_JJ research_NN and_CC development_NN write-off_NN 673,000_CD Amortization_NN charged_VBN 45,266_CD Asset_NNP impairments_NNS 5,632_CD Disposals_NNP Foreign_NNP currency_NN translation_NN 11,606_CD As_IN at_IN December_NNP 31_CD ,_, 2005_CD 729,304_CD The_DT Company_NN acquired_VBD $_$ 481_CD million_CD of_IN other_JJ identifiable_JJ intangible_JJ assets_NNS ,_, net_NN of_IN $_$ 673_CD million_CD of_IN in-process_JJ research_NN and_CC development_NN expensed_VBD to_TO the_DT income_NN statement_NN ,_, at_IN fair_JJ value_NN ,_, as_IN part_NN of_IN the_DT acquisition_NN of_IN TKT_NNP ._.
The_DT weighted_JJ average_JJ amortization_NN period_NN of_IN these_DT assets_NNS is_VBZ 16.8_CD years_NNS ._.
These_DT assets_NNS relate_VBP to_TO intellectual_JJ property_NN $_$ 335_CD million_CD ,_, customer_NN relationships_NNS $_$ 119_CD million_CD and_CC other_JJ finite-lived_JJ assets_NNS $_$ 27_CD million_CD see_VBP Note_NN 4_CD ._.
104_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 105_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 14_CD Other_JJ intangible_JJ assets_NNS ,_, net_JJ continued_VBD Amortization_NNP charged_VBD for_IN the_DT three_CD years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD was_VBD $_$ 45.3_CD million_CD ,_, $_$ 38.7_CD million_CD and_CC $_$ 26.4_CD million_CD ,_, respectively_RB ._.
The_DT useful_JJ economic_JJ lives_NNS of_IN all_DT intangible_JJ assets_NNS that_WDT continue_VBP to_TO be_VB amortized_VBN under_IN SFAS_NNP No._NN ._.
142_CD are_VBP reviewed_VBN periodically_RB by_IN management_NN ._.
During_IN 2005_CD ,_, management_NN became_VBD aware_JJ of_IN competitor_NN intelligence_NN ,_, which_WDT it_PRP believed_VBD would_MD reduce_VB the_DT useful_JJ economic_JJ life_NN of_IN one_CD of_IN the_DT Companys_NNPS products_NNS ._.
Consequently_RB ,_, the_DT Company_NN has_VBZ decreased_VBN the_DT useful_JJ economic_JJ life_NN of_IN the_DT product_NN ,_, which_WDT has_VBZ resulted_VBN in_IN an_DT additional_JJ amortization_NN charge_NN in_IN 2005_CD of_IN $_$ 1.7_CD million_CD and_CC will_MD increase_VB the_DT expected_VBN annual_JJ amortization_NN charge_NN from_IN 2006_CD by_IN $_$ 6.8_CD million_CD ._.
The_DT effect_NN of_IN this_DT additional_JJ charge_NN is_VBZ to_TO reduce_VB net_JJ income_NN in_IN 2005_CD by_IN $_$ 1.2_CD million_CD and_CC increase_VB losses_NNS per_IN share_NN by_IN 0.2_CD ._.
Management_NNP estimates_VBZ that_IN the_DT annual_JJ amortization_NN charges_NNS in_IN respect_NN of_IN intangible_JJ fixed_VBN assets_NNS held_VBD as_RB at_IN December_NNP 31_CD ,_, 2005_CD will_MD average_VB approximately_RB $_$ 90_CD million_CD for_IN each_DT of_IN the_DT five_CD years_NNS to_TO December_NNP 31_CD ,_, 2010_CD ._.
Estimated_VBN amortization_NN expense_NN can_MD be_VB affected_VBN by_IN various_JJ factors_NNS including_VBG future_JJ acquisitions_NNS ,_, disposals_NNS of_IN product_NN rights_NNS and_CC the_DT technological_JJ advancement_NN and_CC regulatory_JJ approval_NN of_IN competitor_NN products_NNS ._.
During_IN 2005_CD ,_, the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 5.6_CD million_CD ._.
These_DT impairments_NNS resulted_VBD from_IN the_DT approval_NN of_IN generic_JJ versions_NNS of_IN AGRYLIN_NNP and_CC the_DT decision_NN not_RB to_TO support_VB and_CC promote_VB certain_JJ non-core_JJ products_NNS going_VBG forward_RB ._.
During_IN 2004_CD ,_, the_DT Company_NN recorded_VBN impairments_NNS of_IN $_$ 13.5_CD million_CD ._.
These_DT impairments_NNS resulted_VBD from_IN a_DT change_NN of_IN operational_JJ management_NN and_CC their_PRP$ views_NNS of_IN the_DT economic_JJ value_NN and_CC strategic_JJ worth_NN of_IN the_DT products_NNS concerned_VBN ,_, which_WDT decreased_VBD estimated_VBN future_JJ cash_NN flows_NNS ._.
During_IN 2003_CD the_DT Company_NN recorded_VBN asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD and_CC an_DT asset_NN write-down_NN of_IN $_$ 15.4_CD million_CD ._.
The_DT asset_NN impairments_NNS of_IN $_$ 12.1_CD million_CD resulted_VBD from_IN a_DT decline_NN in_IN product_NN prices_NNS ,_, which_WDT decreased_VBD estimated_VBN future_JJ cash_NN flows_NNS ._.
The_DT asset_NN write-down_NN of_IN $_$ 15.4_CD million_CD resulted_VBD from_IN a_DT decision_NN not_RB to_TO renew_VB product_NN licenses_NNS that_WDT were_VBD not_RB core_NN to_TO the_DT business_NN ._.
15_CD Other_JJ non-current_JJ assets_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD SERP_NNP investment_NN 28_CD 7,576_CD 7,698_CD IDB_NNP loan_NN 6_CD 31,491_CD 30,000_CD Other_JJ assets_NNS 3,840_CD 1,197_CD 42,907_CD 38,895_CD Further_JJ details_NNS of_IN the_DT SERP_NNP investment_NN are_VBP provided_VBN in_IN Note_NN 28_CD ._.
The_DT amount_NN shown_VBN above_IN is_VBZ the_DT cash_NN surrender_NN value_NN of_IN life_NN insurance_NN policies_NNS ,_, which_WDT is_VBZ backed_VBN by_IN short-term_JJ investments_NNS ._.
A_DT liability_NN of_IN $_$ 4.6_CD million_CD is_VBZ included_VBN within_IN Notes_NNP 17_CD and_CC 19_CD 2004_CD :_: $_$ 5.5_CD million_CD ._.
16_CD Accounts_NNPS payable_JJ and_CC accrued_VBN expenses_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Trade_NNP accounts_NNS payable_JJ 70,958_CD 35,008_CD Accrued_VBN rebates_NNS Medicaid_NNP 83,624_CD 84,758_CD Accrued_VBN rebates_NNS managed_VBD care_NN 21,825_CD 14,667_CD Sales_NNS return_VBP reserve_NN 31,788_CD 22,530_CD Accrued_VBN bonuses_NNS 39,372_CD 23,171_CD Accrued_VBN coupons_NNS 5,177_CD 15,869_CD Research_NNP and_CC development_NN accruals_NNS 22,108_CD 10,924_CD Marketing_NNP accrual_NN 17,415_CD 26,095_CD Accrued_VBN royalties_NNS 4,703_CD 8,250_CD Accrued_VBN rent_NN 7,284_CD Deferred_JJ revenue_NN 11,835_CD 14,472_CD Reorganization_NN accrual_NN 6_CD 3,404_CD 1,936_CD Accrued_VBN settlement_NN costs_NNS 13,000_CD Other_JJ accrued_VBN expenses_NNS 99,326_CD 53,551_CD 431,819_CD 311,231_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 105_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 106_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 17_CD Other_JJ current_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Income_NN taxes_NNS payable_JJ 93,563_CD 42,521_CD Deferred_JJ payments_NNS 18,980_CD Value_NNP added_VBD taxes_NNS 3,811_CD SERP_NNP 28_CD 1,277_CD 1,904_CD Other_JJ accrued_VBN liabilities_NNS 7,342_CD 14,153_CD 105,993_CD 77,558_CD 18_CD Long-term_JJ debt_NN i_FW Multicurrency_NNP Revolving_NNP Facilities_NNP Agreement_NNP In_IN connection_NN with_IN the_DT acquisition_NN of_IN TKT_NNP ,_, Shire_NNP and_CC certain_JJ members_NNS of_IN the_DT Shire_NNP Group_NNP entered_VBD into_IN a_DT Multicurrency_NNP Revolving_NNP Facilities_NNP Agreement_NNP the_DT Facilities_NNP Agreement_NN with_IN ABN_NNP AMRO_NNP Bank_NNP N._NNP V._NNP Barclays_NNP Capital_NNP ,_, Citigroup_NNP Global_NNP Markets_NNP Limited_NNP ,_, HSBC_NNP Bank_NNP plc_NN and_CC The_DT Royal_NNP Bank_NNP of_IN Scotland_NNP plc_VBP the_DT Lenders_NNP on_IN June_NNP 15_CD ,_, 2005_CD ._.
The_DT Facilities_NNP Agreement_NNP comprises_VBZ two_CD credit_NN facilities_NNS :_: i_FW a_DT committed_JJ multicurrency_NN three-year_JJ revolving_JJ loan_NN facility_NN in_IN an_DT aggregate_JJ amount_NN of_IN $_$ 500_CD million_CD Facility_NN A_DT and_CC ii_FW a_DT committed_JJ 364_CD day_NN revolving_JJ loan_NN facility_NN in_IN an_DT aggregate_JJ amount_NN of_IN $_$ 300_CD million_CD Facility_NN B_NN and_CC ,_, together_RB with_IN Facility_NN A_DT ,_, the_DT Facilities_NNPS ._.
Shire_NNP has_VBZ agreed_VBN to_TO act_VB as_IN guarantor_NN for_IN any_DT of_IN its_PRP$ subsidiaries_NNS that_WDT borrow_VBP under_IN the_DT Facilities_NNP Agreement_NNP ._.
Facility_NN A_DT may_MD be_VB used_VBN for_IN general_JJ corporate_JJ purposes_NNS ,_, including_VBG financing_VBG the_DT purchase_NN price_NN and_CC other_JJ costs_NNS with_IN respect_NN to_TO the_DT acquisition_NN of_IN TKT_NNP including_VBG refinancing_NN TKTs_NNS existing_VBG indebtedness_NN ._.
Facility_NN B_NN may_MD be_VB used_VBN only_RB for_IN financing_VBG certain_JJ milestone_NN payments_NNS due_JJ under_IN the_DT agreement_NN between_IN Shire_NNP and_CC ,_, inter_VB alia_NN ,_, New_NNP River_NNP Pharmaceuticals_NNP Inc._NNP ._.
New_NNP River_NNP ,_, dated_VBN January_NNP 31_CD ,_, 2005_CD ._.
Facility_NN A_DT terminates_NNS on_IN June_NNP 15_CD ,_, 2008_CD and_CC Facility_NNP B_NNP terminates_VBZ on_IN June_NNP 14_CD ,_, 2006_CD ._.
At_IN Shires_NNP request_NN ,_, the_DT Lenders_NNP may_MD agree_VB to_TO successive_JJ annual_JJ extensions_NNS of_IN Facility_NN B_NNP ,_, but_CC not_RB beyond_IN the_DT maturity_NN date_NN of_IN Facility_NNP A._NNP Alternatively_RB ,_, Shire_NNP has_VBZ the_DT right_NN to_TO draw_VB Facility_NN B_NN or_CC convert_VB existing_VBG loans_NNS under_IN Facility_NN B_NNP into_IN a_DT term_NN loan_NN with_IN the_DT same_JJ maturity_NN date_NN as_IN Facility_NNP A._NNP The_NNP availability_NN of_IN loans_NNS under_IN each_DT of_IN the_DT Facilities_NNPS is_VBZ subject_JJ to_TO customary_JJ conditions_NNS ,_, including_VBG the_DT absence_NN of_IN any_DT defaults_NNS thereunder_RB and_CC the_DT accuracy_NN in_IN all_DT material_NN respects_VBZ of_IN Shires_NNP representations_NNS and_CC warranties_NNS contained_VBD therein_RB ._.
The_DT Facilities_NNP include_VBP representations_NNS and_CC warranties_NNS ,_, covenants_NNS and_CC events_NNS of_IN default_NN ,_, including_VBG requirements_NNS that_WDT Shires_VBZ ratio_NN of_IN Net_JJ Debt_NN to_TO EBITDA_NNP as_IN defined_VBN in_IN the_DT Facilities_NNP Agreement_NNP not_RB exceed_VB 3.0_CD to_TO 1_CD and_CC that_IN the_DT ratio_NN of_IN EBITDA_NNP to_TO Net_JJ Interest_NN be_VB not_RB less_JJR than_IN 4.0_CD to_TO 1_CD ,_, both_DT in_IN respect_NN of_IN the_DT most_RBS recently_RB ended_VBN fiscal_JJ year_NN ,_, and_CC limitations_NNS on_IN the_DT creation_NN of_IN liens_NNS ,_, disposal_NN of_IN assets_NNS ,_, incurrence_NN of_IN indebtedness_NN ,_, making_VBG of_IN loans_NNS and_CC giving_VBG of_IN guarantees_NNS ._.
Interest_NN on_IN loans_NNS under_IN the_DT Facilities_NNPS will_MD be_VB payable_JJ on_IN the_DT last_JJ day_NN of_IN each_DT interest_NN period_NN ,_, which_WDT period_NN may_MD be_VB one_CD ,_, two_CD ,_, three_CD or_CC six_CD months_NNS at_IN the_DT election_NN of_IN Shire_NNP or_CC as_IN otherwise_RB agreed_VBN with_IN the_DT Lenders_NNP ._.
The_DT interest_NN rate_NN on_IN each_DT loan_NN for_IN each_DT interest_NN period_NN is_VBZ the_DT percentage_NN rate_NN per_IN annum_NN ,_, which_WDT is_VBZ the_DT aggregate_NN of_IN the_DT applicable_JJ margin_NN ranging_VBG from_IN 0.35_CD to_TO 0.65_CD %_NN per_IN annum_NN ,_, depending_VBG on_IN the_DT ratio_NN of_IN Net_JJ Debt_NN to_TO EBITDA_NNP ,_, LIBOR_NNP ,_, and_CC mandatory_JJ cost_NN ,_, if_IN any_DT as_IN calculated_VBN in_IN accordance_NN with_IN Schedule_NN 5_CD of_IN the_DT Facilities_NNP Agreement_NNP ._.
Shire_NN shall_MD also_RB pay_VB fees_NNS equal_JJ to_TO 35_CD %_NN per_IN annum_NN of_IN the_DT applicable_JJ margin_NN on_IN available_JJ commitments_NNS under_IN Facility_NN A_DT for_IN the_DT availability_NN period_NN applicable_JJ to_TO Facility_NN A_DT and_CC 20_CD %_NN per_IN annum_NN of_IN the_DT applicable_JJ margin_NN on_IN available_JJ commitments_NNS under_IN Facility_NN B_NN for_IN the_DT availability_NN period_NN applicable_JJ to_TO Facility_NN B_NN in_IN respect_NN of_IN the_DT period_NN prior_RB to_TO January_NNP 1_CD ,_, 2007_CD ,_, and_CC 30_CD %_NN per_IN annum_NN of_IN the_DT applicable_JJ margin_NN thereafter_RB ._.
Interest_NN on_IN overdue_JJ amounts_NNS under_IN the_DT Facilities_NNPS will_MD accrue_VB at_IN a_DT rate_NN ,_, which_WDT is_VBZ one_CD percent_NN higher_JJR than_IN the_DT rates_NNS otherwise_RB applicable_JJ to_TO the_DT loans_NNS under_IN the_DT Facilities_NNPS ._.
Upon_IN a_DT change_NN of_IN control_NN of_IN Shire_NNP or_CC upon_IN the_DT occurrence_NN of_IN an_DT event_NN of_IN default_NN and_CC the_DT expiration_NN of_IN any_DT applicable_JJ cure_NN period_NN ,_, the_DT total_JJ commitments_NNS under_IN the_DT Facilities_NNPS may_MD be_VB canceled_VBN ,_, all_DT or_CC part_NN of_IN the_DT loans_NNS ,_, together_RB with_IN accrued_VBN interest_NN and_CC all_DT other_JJ amounts_NNS accrued_VBN or_CC outstanding_JJ may_MD be_VB immediately_RB due_JJ and_CC payable_JJ and_CC all_DT or_CC part_NN of_IN the_DT loans_NNS may_MD become_VB payable_JJ on_IN demand_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD not_RB drawn_VBN down_RP on_IN these_DT facilities_NNS ._.
ii_FW TKT_FW convertible_JJ loan_NN notes_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD all_DT of_IN TKTs_NNS 1.25_CD %_NN 2011_CD Convertible_JJ Notes_NNS had_VBD been_VBN converted_VBN and_CC redeemed_VBN ._.
iii_FW Capital_NNP leases_VBZ During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN served_VBD notice_NN to_TO buy_VB out_RP its_PRP$ remaining_VBG capital_NN leases_NNS ,_, totaling_VBG $_$ 5.7_CD million_CD ,_, relating_VBG to_TO its_PRP$ manufacturing_NN facility_NN in_IN Maryland_NNP ._.
Repayment_NN of_IN the_DT leases_NNS occurred_VBD in_IN October_NNP 2004_CD ._.
106_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 107_NNP Notes_NNP to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 19_CD Other_JJ long-term_JJ liabilities_NNS December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD SERP_NNP 28_CD 3,314_CD 3,591_CD Long-term_JJ bonuses_NNS 4,796_CD 4,425_CD Deferred_JJ revenue_NN 5,939_CD 9,074_CD Insurance_NN provisions_NNS 11,315_CD 9,274_CD Deferred_VBN rent_NN 7,283_CD Onerous_JJ lease_NN provisions_NNS 7,705_CD 3,988_CD Other_JJ accrued_VBN liabilities_NNS 3,085_CD 1,807_CD 43,437_CD 32,159_CD Deferred_JJ revenue_NN relates_VBZ to_TO amounts_NNS received_VBN from_IN the_DT out-licensing_NN of_IN AGRYLIN_NNP ,_, FOSRENOL_NNP ,_, ELAPRASE_NNP and_CC REPLAGAL_NNP in_IN Japan_NNP and_CC the_DT global_JJ out-licensing_NN of_IN TROXATYL_NNP ._.
The_DT onerous_JJ lease_NN provisions_NNS at_IN December_NNP 31_CD ,_, 2005_CD include_VBP $_$ 4.4_CD million_CD in_IN respect_NN of_IN the_DT North_JJ American_JJ site_NN consolidation_NN 2004_CD :_: $_$ 2.5_CD million_CD ._.
20_CD Financial_NNP instruments_NNS The_DT estimated_VBN fair_JJ value_NN of_IN the_DT Companys_NNPS financial_JJ instruments_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD is_VBZ summarized_VBN below_IN ._.
Certain_JJ estimates_NNS and_CC judgments_NNS were_VBD required_VBN to_TO develop_VB the_DT fair_JJ value_NN amounts_NNS ._.
The_DT fair_JJ value_NN amounts_NNS shown_VBN below_IN are_VBP not_RB necessarily_RB indicative_JJ of_IN the_DT amounts_NNS that_IN the_DT Company_NN would_MD realize_VB upon_IN disposition_NN ,_, nor_CC do_VBP they_PRP indicate_VBP the_DT Companys_NNPS intent_NN or_CC ability_NN to_TO dispose_VB of_IN the_DT financial_JJ instrument_NN ._.
The_DT following_VBG methods_NNS and_CC assumptions_NNS were_VBD used_VBN to_TO estimate_VB the_DT fair_JJ value_NN of_IN each_DT material_NN class_NN of_IN financial_JJ instrument_NN :_: short-term_JJ investments_NNS commercial_JJ paper_NN and_CC institutional_JJ and_CC managed_VBD cash_NN funds_NNS the_DT carrying_NN value_NN approximates_VBZ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ nature_NN of_IN these_DT instruments_NNS :_: restricted_JJ cash_NN the_DT carrying_VBG value_NN either_CC approximates_VBZ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ nature_NN of_IN the_DT instruments_NNS or_CC equals_VBZ the_DT fair_JJ value_NN as_IN such_JJ instruments_NNS are_VBP marked_VBN to_TO market_NN :_: investments_NNS available-for-sale_JJ securities_NNS the_DT carrying_NN value_NN of_IN non-current_JJ investments_NNS with_IN readily_RB determinable_JJ market_NN values_NNS equals_VBZ the_DT fair_JJ value_NN as_IN such_JJ instruments_NNS are_VBP marked_VBN to_TO market_NN :_: long-term_JJ debt_NN the_DT fair_JJ value_NN of_IN long-term_JJ debt_NN is_VBZ estimated_VBN based_VBN on_IN the_DT discounted_JJ future_JJ cash_NN flows_VBZ using_VBG currently_RB available_JJ interest_NN rates_NNS or_CC ,_, where_WRB the_DT debt_NN instrument_NN is_VBZ traded_VBN ,_, by_IN reference_NN to_TO the_DT market_NN price_NN :_: IDB_NNP subscription_NN receipts_NNS the_DT carrying_NN value_NN in_IN 2004_CD equals_VBZ the_DT fair_JJ value_NN as_IN the_DT subscription_NN receipts_NNS were_VBD repurchased_VBN on_IN January_NNP 7_CD ,_, 2005_CD for_IN $_$ 60_CD million_CD :_: and_CC derivatives_NNS derivative_JJ instruments_NNS comprise_VBP forward_RB foreign_JJ exchange_NN contracts_NNS and_CC foreign_JJ exchange_NN swaps_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD five_CD outstanding_JJ forward_RB foreign_JJ exchange_NN contracts_NNS with_IN a_DT total_JJ principal_JJ amount_NN of_IN $_$ 206_CD million_CD equivalent_JJ to_TO manage_VB the_DT currency_NN risk_NN associated_VBN with_IN certain_JJ intercompany_NN loans_NNS ._.
The_DT Company_NN does_VBZ not_RB seek_VB hedge_JJ accounting_NN treatment_NN for_IN these_DT hedges_NNS and_CC therefore_RB changes_NNS in_IN the_DT fair_JJ value_NN of_IN these_DT derivatives_NNS are_VBP accounted_VBN for_IN in_IN the_DT statement_NN of_IN operations_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD there_EX were_VBD net_JJ unrealized_JJ gains_NNS of_IN $_$ 2.6_CD m_NN on_IN these_DT contracts_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 107_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 108_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 20_CD Financial_NNP instruments_NNS continued_VBD The_DT carrying_VBG amounts_NNS and_CC corresponding_JJ fair_JJ values_NNS of_IN financial_JJ instruments_NNS are_VBP as_IN follows_VBZ :_: Carrying_VBG amount_NN Fair_NN value_NN December_NNP 31_CD ,_, 2005_CD Notes_NNS $_$ 000_CD $_$ 000_CD Financial_JJ assets_NNS :_: Short-term_JJ investments_NNS institutional_JJ and_CC managed_VBD cash_NN funds_NNS 6,947_CD 6,947_CD Restricted_VBN cash_NN 30,568_CD 30,568_CD Investments_NNP available-for-sale_JJ securities_NNS 11_CD 18,131_CD 18,131_CD Other_JJ current_JJ assets_NNS derivatives_NNS 2,554_CD 2,554_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 116_CD 116_CD Carrying_VBG amount_NN Fair_NN value_NN December_NNP 31_CD ,_, 2004_CD Notes_NNS $_$ 000_CD $_$ 000_CD Financial_JJ assets_NNS :_: Short-term_JJ investments_NNS commercial_JJ paper_NN 149,659_CD 149,659_CD Short-term_JJ investments_NNS institutional_JJ and_CC managed_VBD cash_NN funds_NNS 174,752_CD 175,185_CD Restricted_VBN cash_NN 21,627_CD 21,627_CD Investments_NNP available-for-sale_JJ securities_NNS 11_CD 29,970_CD 29,970_CD IDB_NNP subscription_NN receipts_NNS 9_CD 60,000_CD 60,000_CD Financial_NNP liabilities_NNS :_: Long-term_JJ debt_NN 116_CD 117_CD The_DT carrying_VBG amounts_NNS of_IN cash_NN and_CC cash_NN equivalents_NNS ,_, accounts_NNS receivable_JJ ,_, accounts_NNS payable_JJ and_CC accrued_VBN liabilities_NNS approximate_JJ fair_JJ value_NN because_IN of_IN the_DT short-term_JJ maturity_NN of_IN these_DT instruments_NNS ._.
21_CD Commitments_NNS and_CC contingencies_NNS a_DT Leases_NNP Future_NNP minimum_NN lease_NN payments_NNS presented_VBD below_IN include_VBP principal_JJ lease_NN payments_NNS and_CC other_JJ fixed_VBN executory_NN fees_NNS under_IN lease_NN arrangements_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD :_: Operating_NN leases_VBZ $_$ 000_CD 2006_CD 26,110_CD 2007_CD 26,610_CD 2008_CD 24,847_CD 2009_CD 21,279_CD 2010_CD 16,737_CD Thereafter_RB 50,016_CD 165,599_CD i_FW Operating_NN leases_VBZ The_DT Company_NN leases_VBZ facilities_NNS ,_, motor_NN vehicles_NNS and_CC certain_JJ equipment_NN under_IN operating_VBG leases_NNS expiring_VBG through_IN 2025_CD ._.
Lease_NNP and_CC rental_JJ expense_NN included_VBD in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS in_IN the_DT accompanying_VBG statements_NNS of_IN operations_NNS amounted_VBD to_TO $_$ 20.6_CD million_CD ,_, $_$ 15.3_CD million_CD and_CC $_$ 12.2_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD ,_, respectively_RB ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD ,_, Shire_NNP Inc._NNP a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, signed_VBD two_CD 11-year_JJ operating_NN leases_NNS on_IN properties_NNS in_IN Wayne_NNP ,_, Pennsylvania_NNP ._.
Shire_NNP US_NNP ,_, Inc._NNP another_DT wholly-owned_JJ subsidiary_NN ,_, acts_VBZ as_IN guarantor_NN in_IN respect_NN of_IN these_DT leases_NNS ._.
The_DT future_JJ minimum_NN lease_NN payments_NNS under_IN the_DT lease_NN agreements_NNS are_VBP $_$ 57.6_CD million_CD in_IN aggregate_NN ._.
viii_FW Restricted_VBN cash_NN in_IN respect_NN of_IN leases_NNS At_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD $_$ 5.5_CD million_CD of_IN restricted_VBN cash_NN held_VBN as_IN collateral_NN for_IN certain_JJ equipment_NN leases_VBZ 2004_CD :_: $_$ 5.3_CD million_CD ._.
108_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 109_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 21_CD Commitments_NNS and_CC contingencies_NNS continued_VBD b_NN Letters_NNS of_IN credit_NN and_CC guarantees_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD the_DT following_VBG letters_NNS of_IN credit_NN :_: i_FW an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Barclays_NNP Bank_NNP plc_NN ,_, in_IN the_DT amount_NN of_IN $_$ 15_CD million_CD ,_, providing_VBG security_NN on_IN the_DT recoverability_NN of_IN insurance_NN claims_NNS ._.
The_DT Company_NN has_VBZ restricted_VBN cash_NN of_IN $_$ 15_CD million_CD ,_, as_IN required_VBN by_IN this_DT letter_NN of_IN credit_NN :_: and_CC ix_VB an_DT irrevocable_JJ standby_JJ letter_NN of_IN credit_NN with_IN Bank_NNP of_IN America_NNP in_IN the_DT amount_NN of_IN $_$ 7.9_CD million_CD ,_, providing_VBG security_NN on_IN the_DT payment_NN of_IN lease_NN obligations_NNS ._.
The_DT Company_NN has_VBZ restricted_VBN cash_NN of_IN $_$ 7.9_CD million_CD ,_, as_IN required_VBN by_IN this_DT letter_NN of_IN credit_NN ._.
c_NN Commitments_NNS i_FW DAYTRANA_NNP In_IN connection_NN with_IN the_DT Companys_NNP acquisition_NN in_IN 2003_CD from_IN Noven_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Noven_NNP of_IN the_DT worldwide_JJ sales_NNS and_CC marketing_NN rights_NNS to_TO DAYTRANA_NNP ,_, Shire_NNP has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN the_DT following_VBG milestones_NNS :_: $_$ 50_CD million_CD upon_IN FDA_NNP approval_NN of_IN the_DT product_NN ,_, which_WDT will_MD be_VB capitalized_VBN and_CC amortized_VBN over_IN its_PRP$ useful_JJ economic_JJ life_NN :_: and_CC up_RB to_TO $_$ 75_CD million_CD ,_, linked_VBN to_TO future_JJ sales_NNS performance_NN ._.
An_DT approvable_JJ letter_NN was_VBD received_VBN from_IN the_DT FDA_NNP on_IN December_NNP 23_CD ,_, 2005_CD ._.
x_LS NRP104_CD In_IN connection_NN with_IN the_DT Companys_NNP collaboration_NN with_IN New_NNP River_NNP to_TO commercialize_VB NRP104_NNP ,_, the_DT Company_NN has_VBZ an_DT obligation_NN to_TO make_VB certain_JJ payments_NNS on_IN the_DT achievement_NN of_IN the_DT following_VBG milestones_NNS :_: $_$ 50_CD million_CD upon_IN the_DT FDAs_NNS acceptance_NN of_IN filing_NN of_IN the_DT NDA_NNP :_: up_RP to_TO $_$ 300_CD million_CD following_VBG the_DT first_JJ commercial_JJ sale_NN of_IN the_DT product_NN ,_, depending_VBG on_IN the_DT characteristics_NNS of_IN the_DT approved_VBN product_NN labeling_VBG :_: $_$ 100_CD million_CD on_IN achieving_VBG a_DT significant_JJ sales_NNS target_NN :_: and_CC $_$ 5_CD million_CD following_VBG the_DT first_JJ commercial_JJ sale_NN in_IN certain_JJ specified_VBN EU_NN markets_NNS ._.
An_DT upfront_JJ payment_NN of_IN $_$ 50_CD million_CD was_VBD expensed_VBN as_IN an_DT R&D_NNP cost_NN during_IN the_DT first_JJ quarter_NN of_IN 2005_CD ._.
The_DT NDA_NNP for_IN NRP104_NNP was_VBD filed_VBN on_IN December_NNP 6_CD ,_, 2005_CD and_CC accepted_VBD for_IN review_NN by_IN the_DT FDA_NNP on_IN January_NNP 26_CD ,_, 2006_CD ,_, triggering_VBG the_DT $_$ 50_CD million_CD milestone_NN payment_NN ,_, which_WDT has_VBZ now_RB been_VBN paid_VBN ._.
xi_FW FOSRENOL_NNP patent_NN rights_NNS In_IN connection_NN with_IN the_DT Companys_NNP purchase_NN of_IN the_DT global_JJ patents_NNS for_IN FOSRENOL_NNP from_IN AnorMed_NNP Inc._NNP in_IN 2004_CD ,_, the_DT Company_NN has_VBZ outstanding_JJ commitments_NNS to_TO pay_VB AnorMED_NNP Inc._NNP $_$ 6_CD million_CD when_WRB FOSRENOL_NNP is_VBZ approved_VBN in_IN certain_JJ European_JJ countries_NNS and_CC $_$ 6_CD million_CD upon_IN receipt_NN of_IN regulatory_JJ approval_NN in_IN Japan_NNP ._.
xii_FW Other_JJ research_NN and_CC development_NN commitments_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD commitments_NNS of_IN $_$ 18_CD million_CD payable_JJ on_IN achievement_NN of_IN specified_VBN milestones_NNS for_IN products_NNS under_IN development_NN in-licensed_JJ from_IN third_JJ parties_NNS ,_, of_IN which_WDT $_$ 6.6_CD million_CD is_VBZ committed_VBN to_TO be_VB paid_VBN in_IN 2006_CD ._.
xiii_FW TKT_FW shareholders_NNS seeking_VBG appraisal_NN rights_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, appraisal_NN rights_NNS had_VBD been_VBN asserted_VBN in_IN respect_NN of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN ._.
For_IN further_JJ information_NN see_VBP section_NN d_SYM below_IN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN recorded_VBD a_DT liability_NN of_IN $_$ 419.9_CD million_CD based_VBN on_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN for_IN the_DT 11.3_CD million_CD shares_NNS outstanding_JJ at_IN that_DT time_NN plus_IN a_DT provision_NN for_IN interest_NN of_IN $_$ 7.7_CD million_CD that_WDT may_MD be_VB awarded_VBN by_IN the_DT Court_NNP see_VB Note_VB 27_CD ._.
Until_IN such_JJ time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ the_DT Company_NN is_VBZ unable_JJ to_TO determine_VB the_DT extent_NN of_IN its_PRP$ liability_NN ._.
xiv_NN Clinical_JJ testing_NN As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 16.3_CD million_CD to_TO contract_VB vendors_NNS for_IN administering_VBG and_CC executing_VBG clinical_JJ trials_NNS ._.
The_DT timing_NN of_IN payments_NNS is_VBZ not_RB reasonably_RB certain_JJ as_IN payments_NNS are_VBP dependent_JJ upon_IN actual_JJ services_NNS performed_VBN by_IN the_DT organizations_NNS as_IN determined_VBN by_IN patient_JJ enrollment_NN levels_NNS and_CC related_JJ activities_NNS ._.
However_RB ,_, the_DT Company_NN expects_VBZ to_TO pay_VB $_$ 13.2_CD million_CD for_IN these_DT commitments_NNS throughout_IN 2006_CD as_IN ongoing_JJ trials_NNS are_VBP completed_VBN and_CC the_DT remainder_NN in_IN 2007_CD ._.
xv_NN Contract_NN manufacturing_VBG As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD committed_VBN to_TO pay_VB approximately_RB $_$ 23.1_CD million_CD in_IN respect_NN of_IN contract_NN manufacturing_NN over_IN the_DT next_JJ 12_CD months_NNS ._.
xvi_FW Investment_NN commitments_NNS As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD outstanding_JJ commitments_NNS to_TO subscribe_VB for_IN interests_NNS in_IN companies_NNS and_CC partnerships_NNS for_IN amounts_NNS totaling_VBG $_$ 25.2_CD million_CD 2004_CD :_: $_$ 22_CD million_CD of_IN which_WDT $_$ 9.9_CD million_CD is_VBZ committed_VBN in_IN 2006_CD and_CC a_DT further_JJ $_$ 2.9_CD million_CD could_MD be_VB payable_JJ in_IN 2006_CD ,_, depending_VBG on_IN the_DT timing_NN of_IN capital_NN calls_NNS ._.
xvii_JJ Manufacturing_NNP facilities_NNS At_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD committed_VBN a_DT total_NN of_IN $_$ 6.1_CD million_CD to_TO the_DT expansion_NN and_CC modification_NN of_IN its_PRP$ manufacturing_NN facilities_NNS at_IN Owings_NNP Mills_NNP ,_, Maryland_NNP and_CC Cambridge_NNP ,_, Massachusetts_NNP ._.
Of_IN this_DT total_NN ,_, $_$ 3.2_CD million_CD is_VBZ to_TO facilitate_VB the_DT production_NN and_CC packaging_NN of_IN additional_JJ strategic_JJ products_NNS and_CC $_$ 2.9_CD million_CD is_VBZ for_IN the_DT design_NN and_CC construction_NN of_IN a_DT technology_NN center_NN at_IN Owings_NNP Mills_NNP ._.
All_DT costs_NNS are_VBP expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
xviii_NNS Basingstoke_NNP ,_, UK_NNP expansion_NN The_DT Company_NN is_VBZ in_IN the_DT process_NN of_IN expanding_VBG its_PRP$ UK_NNP headquarters_NN at_IN Basingstoke_NNP ,_, UK_NNP ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD the_DT Company_NN had_VBD an_DT outstanding_JJ commitment_NN of_IN $_$ 4.5_CD million_CD ,_, which_WDT is_VBZ expected_VBN to_TO be_VB incurred_VBN in_IN 2006_CD ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 109_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 110_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 21_CD Commitments_NNS and_CC contingencies_NNS continued_VBD d_SYM Legal_NNP proceedings_NNS General_NNP The_NNP Company_NNP accounts_VBZ for_IN litigation_NN losses_NNS and_CC insurance_NN claims_NNS and_CC provisions_NNS in_IN accordance_NN with_IN SFAS_NNP No._NN ._.
5_CD ,_, Accounting_NNP for_IN Contingencies_NNPS SFAS_NNP No._NN ._.
5_CD ,_, loss_NN contingency_NN provisions_NNS are_VBP recorded_VBN for_IN probable_JJ losses_NNS when_WRB management_NN is_VBZ able_JJ to_TO reasonably_RB estimate_VB the_DT loss_NN ._.
Where_WRB the_DT estimated_JJ loss_NN lies_VBZ within_IN a_DT range_NN and_CC no_DT particular_JJ amount_NN within_IN that_DT range_NN is_VBZ a_DT better_JJR estimate_NN than_IN any_DT other_JJ amount_NN ,_, the_DT minimum_NN amount_NN is_VBZ recorded_VBN ._.
In_IN other_JJ cases_NNS managements_NNS best_JJS estimate_NN of_IN the_DT loss_NN is_VBZ recorded_VBN ._.
These_DT estimates_NNS are_VBP developed_VBN substantially_RB before_IN the_DT ultimate_JJ loss_NN is_VBZ known_VBN and_CC the_DT estimates_NNS are_VBP refined_VBN in_IN each_DT accounting_NN period_NN in_IN light_NN of_IN additional_JJ information_NN becoming_VBG known_VBN ._.
In_IN instances_NNS where_WRB the_DT Company_NN is_VBZ unable_JJ to_TO develop_VB a_DT reasonable_JJ estimate_NN of_IN loss_NN ,_, no_DT litigation_NN loss_NN is_VBZ recorded_VBN at_IN that_DT time_NN ._.
As_IN information_NN becomes_VBZ known_VBN a_DT loss_NN provision_NN is_VBZ set_VBN up_RP when_WRB a_DT reasonable_JJ estimate_NN can_MD be_VB made_VBN ._.
The_DT estimates_NNS are_VBP reviewed_VBN quarterly_JJ and_CC the_DT estimates_NNS are_VBP changed_VBN when_WRB expectations_NNS are_VBP revised_VBN ._.
Any_DT outcome_NN upon_IN settlement_NN that_IN deviates_VBZ from_IN the_DT Companys_NNPS estimate_NN may_MD result_VB in_IN an_DT additional_JJ expense_NN in_IN a_DT future_JJ accounting_NN period_NN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD provisions_NNS for_IN litigation_NN losses_NNS ,_, insurance_NN claims_NNS and_CC other_JJ disputes_NNS totaled_VBD $_$ 27.8_CD million_CD 2004_CD :_: $_$ 9.3_CD million_CD ._.
Phentermine_NNP Shire_NNP US_NNP Inc._NNP ._.
SUS_NNP ,_, a_DT wholly-owned_JJ subsidiary_NN of_IN Shire_NNP ,_, is_VBZ a_DT defendant_NN in_IN ten_NN lawsuits_NNS still_RB pending_VBG in_IN both_DT US_NNP federal_JJ and_CC state_NN courts_NNS which_WDT seek_VBP damages_NNS for_IN ,_, among_IN other_JJ things_NNS ,_, personal_JJ injury_NN arising_VBG from_IN phentermine_NN products_NNS supplied_VBD for_IN the_DT treatment_NN of_IN obesity_NN by_IN SUS_NNP and_CC several_JJ other_JJ pharmaceutical_JJ companies_NNS ._.
SUS_NNP ,_, formerly_RB known_VBN as_IN Shire_NNP Richwood_NNP Inc._NNP has_VBZ been_VBN sued_VBN as_IN a_DT manufacturer_NN and_CC distributor_NN of_IN phentermine_NN ,_, an_DT anorectic_NN used_VBN in_IN the_DT short-term_JJ treatment_NN of_IN obesity_NN and_CC one_CD of_IN the_DT products_NNS addressed_VBN by_IN the_DT lawsuits_NNS ._.
The_DT suits_NNS relate_VBP to_TO phentermine_VB either_CC alone_RB or_CC together_RB with_IN fenfluramine_NN or_CC dexenfluramine_NN ._.
The_DT lawsuits_NNS generally_RB allege_VBP the_DT following_VBG claims_NNS :_: the_DT defendants_NNS marketed_VBN phentermine_NN and_CC other_JJ products_NNS for_IN the_DT treatment_NN of_IN obesity_NN and_CC misled_VBD users_NNS about_IN the_DT products_NNS and_CC dangers_NNS associated_VBN with_IN them_PRP :_: the_DT defendants_NNS failed_VBD adequately_RB to_TO test_NN phentermine_NN individually_RB and_CC when_WRB taken_VBN in_IN combination_NN with_IN the_DT other_JJ drugs_NNS :_: and_CC the_DT defendants_NNS knew_VBD or_CC should_MD have_VB known_VBN about_IN the_DT negative_JJ effects_NNS of_IN the_DT drugs_NNS and_CC should_MD have_VB informed_VBN the_DT public_JJ about_IN such_JJ risks_NNS and_CC or_CC failed_VBD to_TO provide_VB appropriate_JJ warning_NN labels_NNS ._.
SUS_NNP has_VBZ been_VBN named_VBN as_IN a_DT defendant_NN in_IN a_DT total_NN of_IN 4,199_CD such_JJ phentermine_NN lawsuits_NNS ,_, in_IN respect_NN of_IN which_WDT SUS_NNP has_VBZ been_VBN dismissed_VBN as_IN a_DT defendant_NN in_IN 4,189_CD cases_NNS ._.
Five_CD of_IN the_DT ten_NN remaining_VBG cases_NNS name_NN Shire_NNP as_IN a_DT defendant_NN ,_, but_CC have_VBP not_RB been_VBN served_VBN as_IN required_VBN by_IN state_NN and_CC federal_JJ rules_NNS of_IN civil_JJ procedure_NN ._.
It_PRP is_VBZ expected_VBN that_IN Shire_NNP will_MD be_VB dismissed_VBN from_IN the_DT remaining_VBG cases_NNS based_VBN upon_IN lack_NN of_IN product_NN identification_NN or_CC agreement_NN of_IN the_DT parties_NNS ._.
SUS_NNP became_VBD involved_VBN with_IN phentermine_NN through_IN its_PRP$ acquisition_NN of_IN certain_JJ assets_NNS of_IN Rexar_NNP Pharmacal_NNP Corporation_NNP Rexar_NNP in_IN January_NNP 1994_CD ._.
In_IN addition_NN to_TO SUS_NNP potentially_RB incurring_VBG liability_NN as_IN a_DT result_NN of_IN its_PRP$ own_JJ production_NN of_IN Oby-Cap_NNP ,_, a_DT phentermine_JJ product_NN ,_, the_DT plaintiffs_NNS may_MD additionally_RB seek_VB to_TO impose_VB liability_NN on_IN SUS_NNP as_IN successor_NN to_TO Rexar_NNP ._.
SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB all_PDT the_DT lawsuits_NNS ._.
SUS_NNP denies_VBZ liability_NN on_IN a_DT number_NN of_IN grounds_NNS including_VBG lack_NN of_IN scientific_JJ evidence_NN that_IN phentermine_NN ,_, properly_RB prescribed_VBN ,_, causes_VBZ the_DT alleged_JJ side_NN effects_NNS and_CC that_IN SUS_NNP did_VBD not_RB promote_VB phentermine_NN for_IN long-term_JJ combined_VBN use_NN as_IN part_NN of_IN the_DT fen_NN phen_NN diet_NN ._.
Accordingly_RB ,_, SUS_NNP intends_VBZ to_TO defend_VB vigorously_RB any_DT and_CC all_DT claims_NNS made_VBN against_IN the_DT Company_NN in_IN respect_NN of_IN phentermine_NN ._.
Legal_JJ expenses_NNS to_TO date_NN have_VBP been_VBN paid_VBN by_IN Eon_NNP Labs_NNPS ,_, Inc._NNP ._.
Eon_NNP ,_, the_DT supplier_NN to_TO SUS_NNP ,_, or_CC Eons_NNS insurance_NN carriers_NNS but_CC such_JJ insurance_NN is_VBZ now_RB exhausted_VBN ._.
Eon_NNP has_VBZ agreed_VBN to_TO defend_VB and_CC indemnify_VB SUS_NNP in_IN this_DT litigation_NN pursuant_JJ to_TO an_DT agreement_NN dated_VBN November_NNP 30_CD ,_, 2000_CD between_IN Eon_NNP and_CC SUS_NNP ._.
ADDERALL_NNP XR_NNP a_DT Barr_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Shires_NNP extended_VBD release_NN once_RB daily_JJ version_NN of_IN ADDERALL_NNP ,_, ADDERALL_NNP XR_NNP is_VBZ covered_VBN by_IN US_NNP patent_NN No._NN ._.
6,322,819_CD the_DT 819_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
In_IN January_NNP 2003_CD the_DT Company_NN was_VBD notified_VBN that_IN Barr_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP Barrs_NNP ANDA_NNP products_NNS prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD Patent_NN ,_, and_CC alleging_VBG that_IN the_DT 819_CD Patent_NN is_VBZ not_RB infringed_VBN by_IN Barrs_NNP ANDA_NNP products_NNS ._.
In_IN August_NNP 2003_CD Shire_NNP was_VBD notified_VBN that_IN Barr_NNP also_RB was_VBD seeking_VBG permission_NN to_TO market_VB its_PRP$ ANDA_NNP products_NNS prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 300_CD Patent_NN and_CC alleging_VBG that_IN the_DT 300_CD Patent_NN is_VBZ invalid_JJ ._.
Shire_NNP Laboratories_NNPS ,_, Inc_NNP ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Barr_NNP for_IN infringement_NN of_IN the_DT 819_CD Patent_NN in_IN February_NNP 2003_CD and_CC for_IN infringement_NN of_IN the_DT 300_CD Patent_NN in_IN September_NNP 2003_CD ._.
The_DT schedules_NNS for_IN the_DT lawsuits_NNS against_IN Barr_NNP with_IN respect_NN to_TO the_DT 819_CD and_CC 300_CD Patents_NNP were_VBD consolidated_VBN in_IN December_NNP 2003_CD ._.
The_DT Company_NN is_VBZ seeking_VBG a_DT ruling_NN that_WDT Barrs_VBZ ANDA_NNP and_CC ANDA_NNP products_NNS infringe_VBP the_DT 819_CD and_CC 300_CD Patents_NNP and_CC that_IN its_PRP$ ANDA_NNP should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT patents_NNS ._.
The_DT Company_NN is_VBZ also_RB seeking_VBG injunctions_NNS to_TO prevent_VB Barr_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP products_NNS before_IN the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, and_CC its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN September_NNP 27_CD ,_, 2004_CD Barr_NNP filed_VBD an_DT amended_VBN Answer_NNP ,_, Affirmative_NNP Defense_NNP and_CC Counterclaim_NNP in_IN which_WDT Barr_NNP added_VBD the_DT following_VBG counterclaims_NNS :_: invalidity_NN of_IN the_DT 819_CD patent_NN ,_, non-infringement_NN of_IN the_DT 300_CD Patent_NN and_CC unenforceability_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP due_JJ to_TO inequitable_JJ conduct_NN ._.
Shire_NNP has_VBZ asserted_VBN affirmative_JJ defenses_NNS ,_, alleging_VBG ,_, among_IN other_JJ things_NNS ,_, that_IN Barr_NNP has_VBZ waived_VBN its_PRP$ right_NN to_TO assert_VB the_DT counterclaims_NNS set_VBN forth_RB in_IN its_PRP$ September_NNP 27_CD ,_, 2004_CD amended_VBN Answer_NNP ._.
Under_IN the_DT Courts_NNPS schedule_NN summary_NN judgment_NN motions_NNS were_VBD to_TO be_VB filed_VBN and_CC fully_RB briefed_VBN by_IN October_NNP 14_CD ,_, 2005_CD ._.
Neither_DT Shire_NNP nor_CC Barr_NNP filed_VBD summary_NN judgment_NN motions_NNS ._.
On_IN December_NNP 9_CD ,_, 2005_CD ,_, the_DT Court_NNP continued_VBD the_DT final_JJ pre-trial_JJ conference_NN to_TO March_NNP 10_CD ,_, 2006_CD ._.
Shires_NNP lawsuits_NNS triggered_VBD stays_NNS of_IN final_JJ FDA_NNP approval_NN of_IN Barrs_NNP ANDA_NNP of_IN up_RB to_TO 30_CD months_NNS from_IN the_DT date_NN of_IN the_DT Companys_NNP receipt_NN of_IN Barrs_NNP notice_NN letters_NNS ._.
The_DT second_JJ and_CC final_JJ 30-month_JJ stay_NN related_VBN to_TO the_DT lawsuit_NN regarding_VBG the_DT 300_CD Patent_NN expired_VBD on_IN February_NNP 18_CD ,_, 2006_CD ._.
As_IN the_DT stay_NN has_VBZ expired_VBN ,_, the_DT FDA_NNP may_MD approve_VB Barrs_NNP ANDA_NNP ,_, subject_JJ to_TO satisfaction_NN by_IN Barr_NNP of_IN the_DT FDAs_NNS requirements_NNS ._.
Barr_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ ANDA_NNP products_NNS upon_IN receipt_NN of_IN final_JJ FDA_NNP approval_NN ._.
On_IN October_NNP 19_CD ,_, 2005_CD Shire_NNP brought_VBD another_DT lawsuit_NN against_IN Barr_NNP in_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP alleging_VBG infringement_NN of_IN US_NNP Patent_NNP No._NN ._.
The_DT Company_NN is_VBZ seeking_VBG an_DT injunction_NN to_TO prevent_VB Barr_NNP from_IN infringing_VBG the_DT 768_CD Patent_NN ,_, damages_NNS in_IN the_DT event_NN that_IN Barr_NNP should_MD commercialize_VB its_PRP$ ANDA_NNP Products_NNPS ,_, attorneys_NNS fees_NNS and_CC costs_NNS ._.
Barr_NNP has_VBZ moved_VBN to_TO dismiss_VB this_DT action_NN asserting_VBG that_IN there_EX is_VBZ no_DT subject_JJ matter_NN jurisdiction_NN ._.
A_DT hearing_NN on_IN this_DT motion_NN was_VBD held_VBN on_IN February_NNP 17_CD ,_, 2006_CD ._.
No_DT decision_NN on_IN this_DT motion_NN has_VBZ yet_RB been_VBN made_VBN ._.
110_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 111_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 21_CD Commitments_NNS and_CC contingencies_NNS continued_VBD ADDERALL_NNP XR_NNP continued_VBD b_NN Impax_NNP Laboratories_NNP Inc._NNP ._.
In_IN November_NNP 2003_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Impax_NNP Laboratories_NNPS ,_, Inc._NNP ._.
Impax_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 30mg_JJ strength_NN of_IN ADDERALL_NNP XR_NNP Impaxs_NNP ANDA_NNP product_NN prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN December_NNP 2003_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP received_VBD an_DT additional_JJ notification_NN from_IN Impax_NNP advising_VBG of_IN the_DT filing_NN of_IN an_DT amendment_NN to_TO its_PRP$ ANDA_NNP for_IN a_DT generic_JJ version_NN of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ and_CC 25mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP in_IN addition_NN to_TO the_DT 30mg_JJ strength_NN ,_, the_DT subject_NN of_IN Impaxs_NNP initial_JJ ANDA_NNP submission_NN ._.
In_IN January_NNP 2005_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Impax_NNP for_IN infringement_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
As_IN part_NN of_IN the_DT October_NNP 19_CD ,_, 2005_CD lawsuit_NN against_IN Barr_NNP ,_, Shire_NNP also_RB brought_VBD suit_NN in_IN the_DT Southern_NNP District_NNP of_IN New_NNP York_NNP against_IN Impax_NNP for_IN infringing_VBG the_DT 768_CD Patent_NN ._.
Impax_NNP filed_VBD a_DT declaratory_JJ judgment_NN action_NN in_IN Delaware_NNP alleging_VBG that_IN the_DT 768_CD Patent_NN was_VBD invalid_JJ and_CC that_IN its_PRP$ ANDA_NNP did_VBD not_RB infringe_VB the_DT 768_CD Patent_NN ._.
On_IN January_NNP 19_CD ,_, 2006_CD ,_, Shire_NNP and_CC Impax_NNP announced_VBD that_IN all_DT pending_VBG litigation_NN in_IN connection_NN with_IN Impaxs_NNP ANDA_NNP had_VBD been_VBN settled_VBN ._.
As_IN part_NN of_IN the_DT settlement_NN ,_, Impax_NNP confirmed_VBD that_IN its_PRP$ proposed_VBN generic_JJ products_NNS infringe_VBP Shires_NNP 819_CD ,_, 300_CD and_CC 768_CD Patents_NNP and_CC that_IN the_DT three_CD patents_NNS are_VBP valid_JJ and_CC enforceable_JJ ._.
Under_IN the_DT terms_NNS of_IN the_DT settlement_NN agreement_NN ,_, Impax_NNP will_MD be_VB permitted_VBN to_TO market_NN generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP in_IN the_DT United_NNP States_NNPS no_RB later_RB than_IN January_NNP 1_CD ,_, 2010_CD and_CC will_MD pay_VB Shire_NNP a_DT royalty_NN from_IN those_DT sales_NNS ._.
In_IN certain_JJ situations_NNS ,_, such_JJ as_IN the_DT launch_NN of_IN another_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ,_, Impax_NNP may_MD be_VB permitted_VBN to_TO enter_VB the_DT market_NN as_IN Shires_NNP authorized_VBD generic_JJ ._.
No_DT payments_NNS to_TO Impax_NNP are_VBP involved_VBN in_IN the_DT settlement_NN agreement_NN ._.
The_DT settlement_NN agreement_NN ,_, which_WDT was_VBD effective_JJ immediately_RB ,_, has_VBZ been_VBN submitted_VBN to_TO the_DT United_NNP States_NNPS Federal_NNP Trade_NNP Commission_NNP for_IN its_PRP$ review_NN ,_, as_IN required_VBN by_IN law_NN ._.
In_IN December_NNP 2004_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Colony_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Colony_NN had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 5mg_JJ ,_, 10mg_JJ ,_, 15mg_JJ ,_, 20mg_JJ ,_, 25mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
Shire_NNP has_VBZ chosen_VBN not_RB to_TO sue_VB Colony_NNP ._.
In_IN February_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Teva_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ versions_NNS of_IN the_DT 10mg_JJ and_CC 30mg_JJ strengths_NNS of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS 819_CD and_CC 300_CD Patents_NNP ._.
In_IN June_NNP 2005_CD ,_, Shire_NNP was_VBD notified_VBN that_IN Teva_NNP had_VBD amended_VBN its_PRP$ ANDA_NNP to_TO seek_VB permission_NN to_TO market_NN additional_JJ strengths_NNS of_IN 5mg_CD ,_, 15mg_CD and_CC 20mg_CD of_IN its_PRP$ generic_JJ ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
In_IN January_NNP 2006_CD ,_, Shire_NNP received_VBD a_DT third_JJ notice_NN letter_NN that_WDT Teva_NNP had_VBD further_JJ amended_VBN its_PRP$ ANDA_NNP to_TO seek_VB permission_NN to_TO market_VB the_DT 25mg_JJ strength_NN generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP prior_RB to_TO the_DT expiration_NN of_IN the_DT 819_CD and_CC 300_CD Patents_NNP ._.
On_IN March_NNP 2_CD ,_, 2006_CD Shire_NNP filed_VBD a_DT lawsuit_NN in_IN the_DT Eastern_NNP District_NNP of_IN Pennsylvania_NNP alleging_VBG that_IN Tevas_NNP ANDA_NNP products_NNS infringe_VBP both_DT the_DT 819_CD and_CC 300_CD Patents_NNP ._.
The_DT lawsuit_NN will_MD trigger_VB a_DT stay_NN of_IN FDA_NNP approval_NN of_IN Tevas_NNP 25mg_JJ strength_NN product_NN for_IN up_RB to_TO 30_CD months_NNS from_IN the_DT date_NN of_IN the_DT Companys_NNP receipt_NN of_IN Tevas_NNP notice_NN ._.
There_EX is_VBZ no_DT such_JJ stay_NN with_IN respect_NN to_TO Tevas_NNP 5mg_CD ,_, 10mg_CD ,_, 15mg_CD ,_, 20mg_JJ and_CC 30mg_JJ strength_NN versions_NNS of_IN ADDERALL_NNP XR_NNP ._.
None_NN of_IN Barr_NNP ,_, Colony_NNP or_CC Teva_NNP may_MD launch_VB their_PRP$ generic_JJ versions_NNS of_IN ADDERALL_NNP XR_NNP before_IN they_PRP receive_VBP final_JJ FDA_NNP approval_NN of_IN their_PRP$ respective_JJ ANDAs_NNS ._.
The_DT FDA_NNP may_MD grant_VB 180_CD days_NNS of_IN generic_JJ market_NN exclusivity_NN to_TO Barr_NNP as_IN the_DT first_JJ to_TO file_VB an_DT ANDA_NNP for_IN a_DT generic_JJ version_NN of_IN ADDERALL_NNP XR_NNP ._.
Neither_DT Colony_NNP nor_CC Teva_NNP may_MD market_VB their_PRP$ ANDA_NNP products_NNS until_IN FDA_NNP final_JJ approval_NN of_IN their_PRP$ ANDAs_NNS and_CC upon_IN the_DT expiration_NN of_IN the_DT first_JJ to_TO files_NNS exclusivity_NN rights_NNS ._.
In_IN August_NNP 2003_CD ,_, the_DT Company_NN was_VBD notified_VBN that_IN Nostrum_NNP Pharmaceuticals_NNP ,_, Inc._NNP ._.
Nostrum_NNP had_VBD submitted_VBN an_DT ANDA_NNP under_IN the_DT Hatch-Waxman_NNP Act_NNP seeking_VBG permission_NN to_TO market_VB its_PRP$ generic_JJ version_NN of_IN the_DT 300mg_JJ strength_NN of_IN CARBATROL_NNP Nostrums_NNPS ANDA_NNP product_NN prior_RB to_TO the_DT expiration_NN date_NN of_IN the_DT Companys_NNPS US_NNP patents_NNS for_IN CARBATROL_NNP ,_, US_NNP patent_NN No._NN ._.
5,912,013_CD the_DT 013_CD Patent_NN and_CC US_NNP patent_NN No._NN ._.
The_DT notification_NN alleges_VBZ that_IN the_DT 013_CD and_CC 570_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN ._.
On_IN September_NNP 18_CD ,_, 2003_CD ,_, Shire_NNP Laboratories_NNPS filed_VBD suit_NN against_IN Nostrum_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN New_NNP Jersey_NNP alleging_VBG infringement_NN of_IN these_DT two_CD patents_NNS by_IN Nostrums_NNP ANDA_NNP and_CC ANDA_NNP product_NN ._.
The_DT Company_NN was_VBD seeking_VBG a_DT ruling_NN that_WDT Nostrums_VBZ ANDA_NNP infringes_VBZ the_DT 013_CD and_CC 570_CD Patents_NNP and_CC should_MD not_RB be_VB approved_VBN before_IN the_DT expiration_NN date_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ._.
The_DT Company_NN was_VBD also_RB seeking_VBG an_DT injunction_NN to_TO prevent_VB Nostrum_NNP from_IN commercializing_VBG its_PRP$ ANDA_NNP product_NN before_IN the_DT expiration_NN of_IN the_DT 013_CD and_CC 570_CD Patents_NNP ,_, damages_NNS in_IN the_DT event_NN that_WDT Nostrum_NNP should_MD engage_VB in_IN such_JJ commercialization_NN ,_, as_RB well_RB as_IN its_PRP$ attorneys_NNS fees_NNS and_CC costs_NNS ._.
On_IN January_NNP 23_CD ,_, 2004_CD ,_, the_DT Company_NN amended_VBD the_DT complaint_NN to_TO drop_VB the_DT allegations_NNS with_IN respect_NN to_TO the_DT 013_CD Patent_NN while_IN maintaining_VBG the_DT suit_NN with_IN respect_NN to_TO the_DT 570_CD Patent_NN ._.
By_IN way_NN of_IN counterclaims_NNS Nostrum_NNP is_VBZ seeking_VBG a_DT declaration_NN that_IN the_DT 570_CD and_CC 013_CD Patents_NNP are_VBP not_RB infringed_VBN by_IN Nostrums_NNP ANDA_NNP product_NN ._.
Nostrum_NNP also_RB was_VBD seeking_VBG actual_JJ and_CC punitive_JJ damages_NNS for_IN alleged_JJ abuse_NN of_IN process_NN by_IN Shire_NNP ._.
On_IN July_NNP 12_CD ,_, 2004_CD ,_, the_DT Court_NNP dismissed_VBD Nostrums_NNP abuse_NN of_IN process_NN counterclaim_NN for_IN failure_NN to_TO state_VB a_DT claim_NN upon_IN which_WDT relief_NN can_MD be_VB granted_VBN ._.
On_IN December_NNP 10_CD ,_, 2004_CD ,_, Nostrum_NNP filed_VBD a_DT summary_NN judgment_NN motion_NN seeking_VBG a_DT declaration_NN of_IN non-infringement_NN of_IN the_DT 570_CD Patent_NN ._.
Shires_NNP opposition_NN to_TO this_DT motion_NN was_VBD filed_VBN on_IN January_NNP 14_CD ,_, 2005_CD ._.
The_DT Court_NNP heard_VBD arguments_NNS with_IN respect_NN to_TO Nostrums_NNP motion_NN on_IN July_NNP 15_CD ,_, 2005_CD ._.
At_IN the_DT conclusion_NN of_IN the_DT hearing_VBG the_DT Court_NNP denied_VBD Nostrums_NNP motion_NN for_IN summary_NN judgment_NN of_IN non-infringement_NN ._.
The_DT parties_NNS have_VBP been_VBN directed_VBN by_IN the_DT Court_NNP to_TO propose_VB a_DT schedule_NN for_IN expert_NN depositions_NNS and_CC claim_NN construction_NN briefing_NN ._.
No_DT trial_NN date_NN has_VBZ been_VBN set_VBN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 111_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 112_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 21_CD Commitments_NNS and_CC contingencies_NNS continued_VBD Nostrum_NNP may_MD not_RB launch_VB a_DT generic_JJ version_NN of_IN CARBATROL_NNP before_IN it_PRP receives_VBZ final_JJ approval_NN of_IN its_PRP$ ANDA_NNP from_IN the_DT FDA_NNP ._.
The_DT lawsuit_NN triggered_VBD a_DT stay_NN of_IN FDA_NNP approval_NN of_IN up_RB to_TO 30_CD months_NNS from_IN Shires_NNP receipt_NN of_IN Nostrums_NNP notice_NN letter_NN ._.
The_DT 30-month_JJ stay_NN expired_VBD on_IN February_NNP 6_CD ,_, 2006_CD ._.
Following_VBG expiry_NN of_IN the_DT stay_NN ,_, Nostrum_NNP could_MD be_VB in_IN a_DT position_NN to_TO market_VB its_PRP$ 300mg_JJ extended-release_NN carbamazepine_NN product_NN upon_IN FDA_NNP final_JJ approval_NN of_IN its_PRP$ ANDA_NNP ._.
GA-GCB_NNP In_IN January_NNP 2005_CD ,_, Genzyme_NNP Corporation_NNP Genzyme_NNP filed_VBD suit_NN against_IN TKT_NNP in_IN the_DT District_NNP Court_NNP of_IN Tel_NNP Aviv-Jaffa_NNP ,_, Israel_NNP ,_, claiming_VBG that_IN TKTs_NNP Phase_NN 1_CD 2_CD clinical_JJ trial_NN in_IN Israel_NNP evaluating_VBG GA-GCB_NNP for_IN the_DT treatment_NN of_IN Gaucher_NNP Disease_NNP infringes_VBZ one_CD or_CC more_JJR claims_NNS of_IN Genzymes_NNP Israeli_NNP Patent_NNP No._NN ._.
In_IN addition_NN ,_, Genzyme_NNP filed_VBD a_DT motion_NN for_IN preliminary_JJ injunction_NN ,_, including_VBG a_DT request_NN for_IN an_DT ex_FW parte_FW hearing_NN and_CC relief_NN on_IN the_DT merits_NNS ,_, to_TO immediately_RB seize_VB and_CC destroy_VB all_DT GA-GCB_NNP being_VBG used_VBN to_TO treat_VB patients_NNS and_CC to_TO prevent_VB TKT_NNP from_IN submitting_VBG data_NNS generated_VBD from_IN the_DT clinical_JJ trial_NN to_TO regulatory_JJ agencies_NNS ._.
In_IN March_NNP 2005_CD the_DT District_NNP Court_NNP refused_VBD to_TO grant_VB Genzymes_NNP motion_NN for_IN a_DT preliminary_JJ injunction_NN ._.
The_DT lawsuit_NN was_VBD dismissed_VBN in_IN January_NNP 2006_CD ._.
DYNEPO_NNP In_IN April_NNP 1997_CD ,_, Amgen_NNP Inc._NNP ._.
Amgen_NNP commenced_VBD a_DT patent_NN infringement_NN action_NN against_IN TKT_NNP and_CC Sanofi-Aventis_NNP in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP ._.
In_IN January_NNP 2001_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP concluded_VBD that_IN DYNEPO_NNP infringed_VBD eight_CD of_IN the_DT 18_CD claims_NNS of_IN five_CD patents_NNS that_WDT Amgen_NNP had_VBD asserted_VBN ._.
Amgen_NNP did_VBD not_RB seek_VB and_CC was_VBD not_RB awarded_VBN monetary_JJ damages_NNS ._.
This_DT decision_NN was_VBD subsequently_RB appealed_VBN to_TO the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
In_IN January_NNP 2003_CD ,_, the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP issued_VBD a_DT decision_NN affirming_VBG in_IN part_NN and_CC reversing_VBG in_IN part_NN the_DT decision_NN of_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP ,_, remanded_VBD the_DT action_NN to_TO the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP for_IN further_JJ proceedings_NNS and_CC instructed_VBD the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP to_TO reconsider_VB the_DT validity_NN of_IN Amgens_NNP patents_NNS in_IN the_DT light_NN of_IN potentially_RB invalidating_VBG prior_RB art_NN ._.
In_IN October_NNP 2004_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP issued_VBD a_DT decision_NN on_IN the_DT remanded_VBN issues_NNS ,_, finding_VBG that_IN certain_JJ claims_NNS related_VBN to_TO four_CD patents_NNS held_VBN by_IN Amgen_NNP are_VBP infringed_VBN by_IN TKT_NNP and_CC Sanofi-Aventis_NNP ._.
In_IN December_NNP 2004_CD ,_, TKT_NNP and_CC Sanofi-Aventis_NNP filed_VBD a_DT notice_NN of_IN appeal_NN of_IN the_DT decision_NN of_IN the_DT United_NNP States_NNPS District_NNP Court_NNP of_IN Massachusetts_NNP to_TO the_DT United_NNP States_NNP Court_NNP of_IN Appeals_NNPS for_IN the_DT Federal_NNP Circuit_NNP ._.
An_DT oral_JJ hearing_NN was_VBD held_VBN at_IN the_DT Federal_NNP Circuit_NNP in_IN December_NNP 2005_CD ._.
No_DT decision_NN has_VBZ been_VBN rendered_VBN at_IN this_DT time_NN ._.
If_IN TKT_NNP and_CC Sanofi-Aventis_NNP are_VBP not_RB successful_JJ in_IN the_DT DYNEPO_NNP litigation_NN at_IN the_DT appellate_JJ level_NN ,_, TKT_NNP and_CC Sanofi-Aventis_NNP would_MD be_VB precluded_VBN from_IN making_VBG ,_, using_VBG and_CC selling_VBG DYNEPO_NNP in_IN the_DT United_NNP States_NNPS until_IN the_DT expiration_NN of_IN the_DT relevant_JJ patents_NNS ._.
TKT_NNP is_VBZ required_VBN to_TO reimburse_VB Sanofi-Aventis_NNP ,_, which_WDT controls_VBZ the_DT litigation_NN and_CC is_VBZ paying_VBG the_DT litigation_NN expenses_NNS ,_, for_IN 50_CD %_NN of_IN the_DT expenses_NNS incurred_VBN in_IN connection_NN with_IN the_DT litigation_NN from_IN and_CC after_IN March_NNP 26_CD ,_, 2004_CD ._.
In_IN the_DT event_NN that_WDT Sanofi-Aventis_NNP launches_VBZ DYNEPO_NNP in_IN the_DT US_NNP ,_, Sanofi-Aventis_NNP is_VBZ entitled_VBN to_TO deduct_VB up_RP to_TO 50_CD %_NN of_IN any_DT royalties_NNS that_WDT Sanofi-Aventis_NNP may_MD otherwise_RB owe_VB to_TO TKT_NNP with_IN respect_NN to_TO the_DT sale_NN of_IN DYNEPO_NNP until_IN then_RB Sanofi-Aventis_NNP has_VBZ recouped_VBN the_DT full_JJ amount_NN of_IN TKTs_NNS share_NN of_IN the_DT litigation_NN expenses_NNS ._.
TKT_NNP has_VBZ the_DT right_NN to_TO control_VB any_DT other_JJ litigation_NN that_WDT might_MD arise_VB outside_IN of_IN the_DT United_NNP States_NNPS and_CC is_VBZ responsible_JJ for_IN all_DT litigation_NN expenses_NNS incurred_VBN in_IN connection_NN with_IN such_JJ litigation_NN from_IN and_CC after_IN March_NNP 26_CD ,_, 2004_CD ._.
Gene_NNP activation_NN In_IN 1996_CD ,_, Applied_NNP Research_NNP Systems_NNP Holding_NNP N._NNP V._NNP a_DT wholly-owned_JJ subsidiary_NN of_IN Serono_NNP S._NNP A._NNP Serono_NNP and_CC Cell_NNP Genesys_NNP ,_, became_VBD involved_VBN in_IN a_DT patent_NN interference_NN involving_VBG Seronos_NNP US_NNP Patent_NNP No._NN ._.
5,272,071_CD the_DT 071_CD Patent_NN ,_, which_WDT purportedly_RB covers_VBZ certain_JJ methods_NNS of_IN gene_NN activation_NN ._.
In_IN June_NNP 2004_CD ,_, the_DT Board_NNP of_IN Patent_NNP Appeals_NNPS and_CC Interferences_NNPS of_IN the_DT US_NNP Patent_NNP and_CC Trademark_NNP Office_NNP PTO_NNP held_VBD that_IN both_DT Serono_NNP and_CC Cell_NNP Genesys_NNPS were_VBD entitled_VBN to_TO certain_JJ claims_NNS in_IN their_PRP$ respective_JJ patent_NN and_CC patent_NN application_NN ,_, and_CC Serono_NNP and_CC Cell_NNP Genesys_NNP each_DT appealed_VBD the_DT decision_NN of_IN the_DT interference_NN to_TO the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP and_CC the_DT US_NNP District_NNP Court_NNP of_IN the_DT District_NNP of_IN Columbia_NNP ,_, respectively_RB ._.
TKT_NNP was_VBD not_RB a_DT party_NN to_TO this_DT interference_NN ._.
In_IN August_NNP 2004_CD ,_, Serono_NNP served_VBD TKT_NNP with_IN an_DT amended_VBN complaint_NN in_IN the_DT appeal_NN of_IN the_DT PTO_NNP decision_NN that_WDT was_VBD filed_VBN in_IN the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP ._.
The_DT amended_VBN complaint_NN alleges_VBZ that_IN TKT_NNP infringes_VBZ Seronos_NNP 071_CD Patent_NN ._.
In_IN August_NNP 2005_CD ,_, the_DT US_NNP District_NNP Court_NNP of_IN Massachusetts_NNP severed_VBD and_CC stayed_VBD the_DT infringement_NN action_NN pending_VBG resolution_NN of_IN the_DT interference_NN claim_NN at_IN the_DT District_NNP Court_NNP level_NN ._.
Appraisal_NN rights_NNS In_IN connection_NN with_IN Shires_NNP merger_NN with_IN TKT_NNP ,_, former_JJ holders_NNS of_IN approximately_RB 11.7_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN submitted_VBN written_VBN demands_NNS to_TO the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP for_IN appraisal_NN of_IN these_DT shares_NNS and_CC ,_, as_IN a_DT result_NN ,_, elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD per_IN share_NN merger_NN consideration_NN ._.
On_IN October_NNP 10_CD ,_, 2005_CD ,_, at_IN the_DT request_NN of_IN one_CD of_IN the_DT holders_NNS to_TO tender_VB 365,000_CD shares_NNS at_IN the_DT merger_NN price_NN of_IN $_$ 37_CD per_IN share_NN ,_, TKT_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT holders_NNS demand_NN ._.
On_IN October_NNP 12_CD ,_, 2005_CD ,_, the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP granted_VBD this_DT motion_NN ,_, and_CC the_DT holder_NN tendered_VBD the_DT shares_NNS at_IN the_DT merger_NN consideration_NN of_IN $_$ 37_CD per_IN share_NN ._.
Therefore_RB ,_, as_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN maintained_VBD written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS and_CC have_VBP elected_VBN not_RB to_TO accept_VB the_DT $_$ 37_CD merger_NN consideration_NN ._.
In_IN November_NNP 2005_CD ,_, the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP approved_VBD a_DT consolidation_NN order_NN filed_VBN by_IN TKT_NNP whereby_WRB actions_NNS brought_VBN by_IN all_DT petitioners_NNS have_VBP been_VBN consolidated_VBN as_IN one_CD case_NN ._.
To_TO the_DT extent_NN that_IN the_DT remaining_VBG demands_NNS were_VBD validly_RB asserted_VBN in_IN accordance_NN with_IN the_DT applicable_JJ requirements_NNS of_IN Delaware_NNP law_NN and_CC the_DT former_JJ holders_NNS perfect_JJ their_PRP$ rights_NNS thereunder_NN ,_, such_JJ former_JJ holders_NNS will_MD be_VB entitled_VBN to_TO receive_VB the_DT fair_JJ value_NN of_IN these_DT shares_NNS as_IN determined_VBN by_IN the_DT Delaware_NNP Court_NNP of_IN Chancery_NNP ._.
The_DT determination_NN of_IN fair_JJ value_NN will_MD be_VB made_VBN excluding_VBG any_DT element_NN of_IN value_NN arising_VBG from_IN the_DT transaction_NN ,_, such_JJ as_IN cost_NN savings_NNS or_CC business_NN synergies_NNS ._.
112_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 113_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 21_CD Commitments_NNS and_CC contingencies_NNS continued_VBD The_DT total_JJ consideration_NN for_IN the_DT acquisition_NN of_IN TKT_NNP ,_, including_VBG amounts_NNS payable_JJ in_IN respect_NN of_IN stock_NN options_NNS and_CC convertible_JJ securities_NNS ,_, is_VBZ approximately_RB $_$ 1.6_CD billion_CD at_IN the_DT merger_NN price_NN of_IN $_$ 37_CD per_IN share_NN ._.
This_DT could_MD change_VB if_IN Shire_NNP is_VBZ required_VBN to_TO pay_VB a_DT different_JJ amount_NN of_IN consideration_NN in_IN respect_NN of_IN the_DT approximately_RB 11.3_CD million_CD shares_NNS for_IN which_WDT holders_NNS have_VBP asserted_VBN appraisal_NN rights_NNS ._.
Until_IN such_JJ time_NN as_IN the_DT appraisal_NN process_NN is_VBZ complete_JJ ,_, the_DT Company_NN is_VBZ unable_JJ to_TO determine_VB the_DT extent_NN of_IN its_PRP$ liability_NN ._.
Class_NN action_NN shareholder_NN suit_NN In_IN January_NNP and_CC February_NNP 2003_CD ,_, various_JJ parties_NNS filed_VBD purported_JJ class_NN action_NN lawsuits_NNS against_IN TKT_NNP and_CC Richard_NNP Selden_NNP ,_, TKTs_NNP former_JJ Chief_NNP Executive_NNP Officer_NNP ,_, in_IN the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP ._.
The_DT complaints_NNS generally_RB allege_VBP securities_NNS fraud_NN during_IN the_DT period_NN from_IN January_NNP 2001_CD through_IN January_NNP 2003_CD ._.
Each_DT of_IN the_DT complaints_NNS asserts_VBZ claims_NNS under_IN Section_NN 10_CD b_NN of_IN the_DT Securities_NNP Exchange_NNP Act_NNP of_IN 1934_CD ,_, Rule_NNP 10b-5_JJ promulgated_VBN thereunder_NN ,_, and_CC Section_NNP 20_CD a_DT of_IN the_DT Exchange_NNP Act_NNP ,_, and_CC alleges_VBZ that_IN TKT_NNP and_CC its_PRP$ officers_NNS made_VBD false_JJ and_CC misleading_JJ statements_NNS and_CC failed_VBD to_TO disclose_VB material_NN information_NN concerning_VBG the_DT status_NN and_CC progress_NN for_IN obtaining_VBG United_NNP States_NNPS marketing_NN approval_NN of_IN TKTs_NNS REPLAGAL_NNP product_NN to_TO treat_VB Fabry_NNP Disease_NNP during_IN that_DT period_NN ._.
In_IN March_NNP 2003_CD ,_, various_JJ plaintiffs_NNS filed_VBD motions_NNS to_TO consolidate_VB ,_, to_TO appoint_VB lead_JJ plaintiff_NN ,_, and_CC to_TO approve_VB plaintiffs_NNS selections_NNS of_IN lead_NN plaintiffs_NNS counsel_NN ._.
In_IN April_NNP 2003_CD ,_, various_JJ plaintiffs_NNS filed_VBD a_DT Joint_NNP Stipulation_NNP and_CC Proposed_NNP Order_NNP of_IN Lead_JJ Plaintiff_NNP Applicants_NNPS to_TO Consolidate_VB Actions_NNS ,_, to_TO Appoint_VB Lead_JJ Plaintiffs_NNS and_CC to_TO Approve_VB Lead_JJ Plaintiffs_NNS Selection_NN of_IN Lead_JJ Counsel_NNP ,_, Executive_NNP Committee_NNP and_CC Liaison_NNP Counsel_NNP ._.
In_IN April_NNP 2003_CD ,_, the_DT Court_NNP endorsed_VBD the_DT Proposed_NNP Order_NNP ,_, thereby_RB consolidating_VBG the_DT various_JJ matters_NNS under_IN one_CD matter_NN :_: In_IN re_NN Transkaryotic_NNP Therapies_NNPS ,_, Inc._NNP ._.
Securities_NNP Litigation_NNP ,_, C._NNP A._NNP In_NNP July_NNP 2003_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT Consolidated_NNP and_CC Amended_NNP Class_NNP Action_NNP Complaint_NNP the_DT Amended_NNP Complaint_NNP against_IN TKT_NNP :_: Dr_NNP Selden_NNP :_: Daniel_NNP Geffken_NNP ,_, TKTs_NNP former_JJ Chief_NNP Financial_NNP Officer_NNP :_: Walter_NNP Gilbert_NNP ,_, Jonathan_NNP S._NNP Leff_NNP ,_, Rodman_NNP W._NNP Moorhead_NNP ,_, III_NNP ,_, and_CC Wayne_NNP P._NNP Yetter_NNP ,_, then_RB members_NNS of_IN TKTs_NNP Board_NNP of_IN Directors_NNS :_: William_NNP R._NNP Miller_NNP and_CC James_NNP E._NNP Thomas_NNP ,_, former_JJ members_NNS of_IN TKTs_NNP Board_NNP of_IN Directors_NNS :_: and_CC SG_NNP Cowen_NNP Securities_NNP Corporation_NNP ,_, Deutsche_NNP Bank_NNP Securities_NNP Inc._NNP ._.
Pacific_NNP Growth_NNP Equities_NNPS ,_, Inc._NNP and_CC Leerink_NNP Swann_NNP &_CC Company_NNP ,_, underwriters_NNS of_IN TKTs_NNS common_JJ stock_NN in_IN prior_JJ public_JJ offerings_NNS ._.
The_DT Amended_NNP Complaint_NNP alleges_VBZ securities_NNS fraud_NN during_IN the_DT period_NN from_IN January_NNP 4_CD ,_, 2001_CD ,_, through_IN January_NNP 10_CD ,_, 2003_CD ._.
The_DT Amended_NNP Complaint_NNP alleges_VBZ that_IN the_DT defendants_NNS made_VBD false_JJ and_CC misleading_JJ statements_NNS and_CC failed_VBD to_TO disclose_VB material_NN information_NN concerning_VBG the_DT status_NN and_CC progress_NN for_IN obtaining_VBG United_NNP States_NNPS marketing_NN approval_NN of_IN REPLAGAL_NNP during_IN that_DT period_NN ._.
The_DT Amended_NNP Complaint_NNP asserts_VBZ claims_NNS against_IN Dr_NNP Selden_NNP and_CC TKT_NNP under_IN Section_NNP 10_CD b_NN of_IN the_DT Exchange_NNP Act_NNP and_CC Rule_NNP 10b-5_JJ promulgated_VBN thereunder_NN :_: and_CC against_IN Dr_NNP Selden_NNP under_IN Section_NNP 20_CD a_DT of_IN the_DT Exchange_NNP Act_NNP ._.
The_DT Amended_NNP Complaint_NNP also_RB asserts_VBZ claims_NNS based_VBN on_IN TKTs_NNS public_JJ offerings_NNS of_IN June_NNP 29_CD ,_, 2001_CD ,_, December_NNP 18_CD ,_, 2001_CD and_CC December_NNP 26_CD ,_, 2001_CD ,_, against_IN each_DT of_IN the_DT defendants_NNS under_IN Section_NN 11_CD of_IN the_DT Securities_NNP Act_NNP of_IN 1933_CD and_CC against_IN Dr_NNP Selden_NNP under_IN Section_NNP 15_CD of_IN the_DT Securities_NNP Act_NNP :_: and_CC against_IN SG_NNP Cowen_NNP Securities_NNP Corporation_NNP ,_, Deutsche_NNP Bank_NNP Securities_NNP Inc._NNP ._.
Pacific_NNP Growth_NNP Equities_NNPS ,_, Inc._NNP and_CC Leerink_NNP Swann_NNP &_CC Company_NNP under_IN Section_NNP 12_CD a_DT 2_CD of_IN the_DT Securities_NNP Act_NNP ._.
The_DT plaintiffs_NNS seek_VBP equitable_JJ and_CC monetary_JJ relief_NN ,_, an_DT unspecified_JJ amount_NN of_IN damages_NNS ,_, with_IN interest_NN ,_, and_CC attorneys_NNS fees_NNS and_CC costs_NNS ._.
In_IN September_NNP 2003_CD ,_, TKT_NNP filed_VBD a_DT motion_NN to_TO dismiss_VB the_DT Amended_NNP Complaint_NNP ._.
A_DT hearing_NN of_IN the_DT motion_NN occurred_VBD in_IN December_NNP 2003_CD ._.
In_IN May_NNP 2004_CD ,_, the_DT United_NNP States_NNPS District_NNP Court_NNP for_IN the_DT District_NNP of_IN Massachusetts_NNP issued_VBD a_DT Memorandum_NNP of_IN Decision_NNP and_CC Order_NNP denying_VBG in_IN part_NN and_CC granting_VBG in_IN part_NN TKTs_NNS motion_NN to_TO dismiss_VB the_DT purported_JJ class_NN action_NN lawsuit_NN ._.
In_IN the_DT Memorandum_NNP ,_, the_DT Court_NNP found_VBD several_JJ allegations_NNS against_IN TKT_NNP arose_VBD out_IN of_IN forward-looking_JJ statements_NNS protected_VBN by_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT Private_JJ Securities_NNPS Litigation_NNP Reform_NNP Act_NNP of_IN 1995_CD PSLRA_NNP ._.
The_DT Court_NNP dismissed_VBD those_DT statements_NNS as_IN falling_VBG within_IN the_DT PSLRAs_NNP safe_JJ harbor_NN provisions_NNS ._.
The_DT Court_NNP also_RB dismissed_VBD claims_NNS based_VBN on_IN the_DT public_JJ offerings_NNS of_IN June_NNP 29_CD ,_, 2001_CD ,_, and_CC December_NNP 18_CD ,_, 2001_CD ,_, because_IN no_DT plaintiff_NN had_VBD standing_VBG to_TO bring_VB such_JJ claims_NNS ._.
The_DT Court_NNP allowed_VBD all_DT other_JJ allegations_NNS to_TO remain_VB ._.
In_IN June_NNP 2004_CD ,_, TKT_NNP submitted_VBD an_DT unopposed_JJ motion_NN seeking_VBG clarification_NN from_IN the_DT Court_NNP that_IN the_DT Memorandum_NNP dismissed_VBD claims_NNS based_VBN on_IN the_DT first_JJ two_CD offerings_NNS as_IN to_TO all_DT defendants_NNS ._.
The_DT Court_NNP granted_VBD the_DT motion_NN ._.
In_IN July_NNP 2004_CD ,_, the_DT plaintiffs_NNS voluntarily_RB dismissed_VBD all_DT claims_NNS based_VBN on_IN the_DT third_JJ offering_NN because_IN no_DT plaintiff_NN had_VBD standing_VBG to_TO bring_VB such_JJ claims_NNS ._.
The_DT plaintiffs_NNS subsequently_RB filed_VBD a_DT motion_NN seeking_VBG permission_NN to_TO notify_VB certain_JJ TKT_NNP investors_NNS of_IN the_DT dismissal_NN of_IN the_DT claims_NNS based_VBN on_IN the_DT offerings_NNS ,_, and_CC to_TO inform_VB those_DT investors_NNS of_IN their_PRP$ opportunity_NN to_TO intervene_VB in_IN the_DT lawsuit_NN ._.
TKT_NNP filed_VBD an_DT opposition_NN to_TO this_DT motion_NN in_IN July_NNP 2004_CD ._.
A_DT hearing_NN on_IN this_DT motion_NN was_VBD held_VBN in_IN September_NNP 2004_CD ._.
The_DT Court_NNP denied_VBD this_DT motion_NN ._.
TKT_NNP filed_VBD an_DT answer_NN to_TO the_DT Amended_NNP Complaint_NNP in_IN July_NNP 2004_CD ._.
The_DT plaintiffs_NNS then_RB filed_VBD a_DT motion_NN for_IN class_NN certification_NN in_IN July_NNP 2004_CD ._.
TKT_NNP filed_VBD an_DT opposition_NN to_TO this_DT motion_NN in_IN March_NNP 2005_CD ,_, and_CC the_DT plaintiffs_NNS filed_VBD a_DT reply_NN in_IN April_NNP 2005_CD ._.
A_DT hearing_NN on_IN class_NN certification_NN was_VBD held_VBN in_IN April_NNP 2005_CD ._.
Following_VBG that_DT hearing_NN ,_, TKT_NNP filed_VBD a_DT supplemental_JJ brief_NN in_IN opposition_NN to_TO the_DT motion_NN for_IN class_NN certification_NN and_CC the_DT plaintiffs_NNS filed_VBD a_DT supplemental_JJ brief_NN in_IN support_NN of_IN the_DT motion_NN ._.
In_IN November_NNP 2005_CD ,_, the_DT court_NN granted_VBD the_DT plaintiffs_NNS motion_NN for_IN class_NN certification_NN ._.
On_IN September_NNP 14_CD ,_, 2005_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT Notice_NNP of_IN Related_NNP Case_NNP Pursuant_NNP to_TO Local_JJ Rule_NNP 40.1_CD G_NNP ,_, in_IN which_WDT they_PRP appeared_VBD to_TO seek_VB reassignment_NN of_IN a_DT matter_NN filed_VBN on_IN September_NNP 1_CD ,_, 2005_CD ,_, entitled_VBN Securities_NNP and_CC Exchange_NNP Commission_NNP v._CC Richard_NNP B._NNP Selden_NNP ,_, Civil_NNP Action_NNP No._NN ._.
the_DT SEC_NNP Action_NNP ,_, to_TO the_DT court_NN considering_VBG this_DT matter_NN ._.
On_IN September_NNP 15_CD ,_, 2005_CD ,_, the_DT defendants_NNS filed_VBD a_DT response_NN to_TO the_DT notice_NN ,_, opposing_VBG reassignment_NN of_IN the_DT SEC_NNP Action_NNP ._.
On_IN October_NNP 7_CD ,_, 2005_CD ,_, the_DT plaintiffs_NNS filed_VBD a_DT memorandum_NN in_IN response_NN to_TO the_DT defendants_NNS response_NN ._.
On_IN October_NNP 21_CD ,_, 2005_CD ,_, the_DT Court_NNP entered_VBD an_DT Order_NN ,_, which_WDT stated_VBD that_IN it_PRP did_VBD not_RB deem_VB the_DT cases_NNS related_VBN under_IN Local_JJ Rule_NNP 40.1_CD ._.
The_DT Company_NN is_VBZ obligated_VBN to_TO indemnify_VB Dr_NNP Selden_NNP for_IN his_PRP$ costs_NNS incurred_VBN in_IN connection_NN with_IN the_DT SEC_NNP Action_NNP ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 113_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 114_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 22_CD Shareholders_NNS equity_NN i_FW Authorized_VBN common_JJ stock_NN The_DT authorized_VBN stock_NN of_IN Shire_NNP plc_NN as_IN at_IN December_NNP 31_CD ,_, 2005_CD was_VBD 18,333,006,420_CD ordinary_JJ shares_NNS ,_, 10,000,000_CD special_JJ voting_NN shares_NNS ,_, 50,000_CD non-voting_JJ preference_NN shares_NNS and_CC two_CD deferred_JJ ordinary_JJ shares_NNS ._.
The_DT special_JJ voting_NN shares_NNS are_VBP held_VBN by_IN a_DT Voting_NNP Trustee_NNP ,_, providing_VBG the_DT holders_NNS of_IN exchangeable_JJ shares_NNS in_IN Shire_NNP Acquisition_NNP ,_, Inc._NNP with_IN as_RB nearly_RB as_IN practicable_JJ voting_NN rights_NNS equivalent_NN to_TO those_DT attached_VBN to_TO Shires_NNP ordinary_JJ shares_NNS ._.
The_DT non-voting_JJ preference_NN shares_NNS and_CC deferred_VBN ordinary_JJ shares_NNS were_VBD authorized_VBN and_CC issued_VBN for_IN the_DT purpose_NN of_IN the_DT Scheme_NN of_IN Arrangement_NN only_RB and_CC will_MD be_VB redeemed_VBN in_IN 2006_CD ._.
ii_FW Dividends_NNPS Under_IN English_NNP law_NN ,_, Shire_NNP can_MD pay_VB dividends_NNS only_RB out_IN of_IN its_PRP$ distributable_JJ reserves_NNS ,_, defined_VBN as_IN the_DT accumulated_VBN realized_VBD profits_NNS under_IN UK_NNP generally_RB accepted_VBD accounting_NN principles_NNS including_VBG reserves_NNS arising_VBG from_IN a_DT reduction_NN of_IN share_NN capital_NN ,_, of_IN the_DT parent_NN Company_NN ,_, Shire_NNP plc_NN and_CC not_RB the_DT consolidated_JJ Group_NNP ,_, so_RB far_RB as_IN not_RB previously_RB utilized_VBN by_IN distribution_NN or_CC capitalization_NN ,_, less_JJR accumulated_VBN realized_VBN losses_NNS ,_, so_RB far_RB as_IN not_RB previously_RB written_VBN off_RP in_IN a_DT reduction_NN or_CC reorganization_NN of_IN capital_NN duly_RB made_VBD ._.
Shire_NNP can_MD make_VB a_DT distribution_NN only_RB if_IN the_DT distribution_NN does_VBZ not_RB reduce_VB its_PRP$ net_JJ assets_NNS below_IN the_DT aggregate_NN of_IN the_DT called-up_JJ share_NN capital_NN and_CC undistributable_JJ reserves_NNS ._.
Any_DT dividends_NNS will_MD be_VB at_IN the_DT discretion_NN of_IN the_DT Board_NNP of_IN Directors_NNS ,_, will_MD be_VB declared_VBN in_IN US_NNP Dollars_NNPS and_CC will_MD be_VB paid_VBN in_IN Pounds_NNP Sterling_NNP to_TO Ordinary_NNP Shareholders_NNP ,_, US_NNP Dollars_NNPS to_TO ADS_NNPS holders_NNS and_CC Canadian_JJ Dollars_NNS to_TO Exchangeable_JJ Shareholders_NNS ._.
At_IN December_NNP 31_CD ,_, 2005_CD ,_, Shires_NNP distributable_JJ reserves_NNS were_VBD $_$ 2,946_CD million_CD ._.
iii_FW Treasury_NNP stock_NN The_DT Company_NN records_NNS the_DT purchase_NN of_IN its_PRP$ own_JJ shares_NNS as_IN a_DT reduction_NN of_IN shareholders_NNS equity_NN based_VBN on_IN the_DT price_NN paid_VBN for_IN the_DT shares_NNS ._.
On_IN December_NNP 22_CD ,_, 2005_CD the_DT Company_NN requested_VBD its_PRP$ Employee_NNP Share_NN Ownership_NNP Trust_NNP to_TO place_VB an_DT irrevocable_JJ instruction_NN with_IN the_DT Companys_NNP brokers_NNS to_TO make_VB purchases_NNS in_IN the_DT open_JJ market_NN of_IN a_DT fixed_VBN number_NN of_IN shares_NNS during_IN the_DT period_NN between_IN December_NNP 23_CD ,_, 2005_CD and_CC February_NNP 23_CD ,_, 2006_CD ,_, the_DT date_NN the_DT Company_NN announced_VBD its_PRP$ full-year_JJ results_NNS for_IN 2005_CD ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD a_DT total_NN of_IN 191,016_CD shares_NNS had_VBD been_VBN purchased_VBN under_IN this_DT purchase_NN instruction_NN for_IN total_JJ consideration_NN of_IN $_$ 2.5_CD million_CD ,_, including_VBG stamp_NN duty_NN and_CC broker_NN commission_NN ._.
23_CD Related_VBN parties_NNS i_FW Professional_NNP fees_NNS The_DT Company_NN incurred_VBN professional_JJ fees_NNS with_IN Stikeman_NNP Elliott_NNP ,_, a_DT law_NN firm_NN in_IN which_WDT the_DT Hon_NNP James_NNP Grant_NNP ,_, a_DT Non-executive_JJ Director_NNP of_IN Shire_NNP ,_, is_VBZ a_DT partner_NN ,_, totaling_VBG $_$ 0.5_CD million_CD for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD 2004_CD :_: $_$ 2.1_CD million_CD :_: 2003_CD :_: $_$ 0.8_CD million_CD ._.
In_IN April_NNP 2004_CD Shire_NNP BioChem_NNP Inc._NNP ._.
BioChem_NNP ,_, a_DT subsidiary_NN of_IN Shire_NNP ,_, sold_VBD a_DT Canadian_JJ property_NN to_TO NeuroChem_NNP Inc._NNP for_IN $_$ 7.8_CD million_CD CAN$_NNP 10.5_CD million_CD ._.
Dr_NNP Bellini_NNP ,_, a_DT Non-executive_JJ Director_NNP of_IN Biochem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT Non-executive_JJ Director_NNP of_IN Shire_NNP and_CC Mr_NNP Nordmann_NNP ,_, a_DT Non-executive_JJ Director_NNP of_IN Shire_NNP are_VBP both_DT Directors_NNS of_IN NeuroChem_NNP Inc._NNP ._.
Dr_NNP Bellini_NNP had_VBD an_DT indirect_JJ substantial_JJ interest_NN in_IN the_DT issued_VBN share_NN capital_NN of_IN Neurochem_NNP Inc._NNP at_IN the_DT time_NN of_IN the_DT transaction_NN ._.
In_IN April_NNP 2004_CD ,_, the_DT Company_NN contributed_VBD cash_NN of_IN $_$ 3.7_CD million_CD CAN$_NNP 5_CD million_CD and_CC equipment_NN and_CC intellectual_JJ property_NN to_TO the_DT start-up_NN of_IN a_DT new_JJ Canadian-based_JJ pharmaceutical_JJ research_NN and_CC development_NN organization_NN ,_, ViroChem_NNP Pharma_NNP Inc._NNP ._.
ViroChem_NNP ,_, in_IN return_NN for_IN an_DT equity_NN interest_NN and_CC royalties_NNS on_IN the_DT sale_NN of_IN certain_JJ products_NNS subsequently_RB launched_VBN by_IN ViroChem_NNP ._.
In_IN April_NNP 2005_CD ,_, the_DT Company_NN contributed_VBD cash_NN of_IN $_$ 4.1_CD million_CD CAN$_NNP 5_CD million_CD to_TO ViroChem_NNP in_IN return_NN for_IN an_DT additional_JJ equity_NN interest_NN ._.
Dr_NNP Bellini_NNP ,_, a_DT Non-executive_JJ Director_NNP of_IN BioChem_NNP and_CC ,_, until_IN May_NNP 10_CD ,_, 2003_CD ,_, a_DT Non-executive_JJ Director_NNP of_IN Shire_NNP ,_, had_VBD ,_, at_IN the_DT time_NN of_IN the_DT transaction_NN ,_, an_DT indirect_JJ substantial_JJ interest_NN in_IN a_DT company_NN ,_, which_WDT is_VBZ a_DT co-investor_NN of_IN ViroChem_NNP ._.
The_DT Company_NN has_VBZ undertaken_VBN to_TO invest_VB an_DT additional_JJ $_$ 4.3_CD million_CD CAN$_NNP 5_CD million_CD in_IN ViroChem_NNP ._.
In_IN October_NNP 2005_CD ,_, the_DT Company_NN sub-leased_VBD its_PRP$ office_NN premises_NNS in_IN Newport_NNP to_TO Xanodyne_NNP Pharmaceuticals_NNP Inc._NNP ._.
Dr_NNP James_NNP Cavanaugh_NNP ,_, the_DT Non-executive_JJ Chairman_NN of_IN the_DT Company_NN ,_, is_VBZ the_DT Chairman_NNP of_IN Xanodyne_NNP Pharmaceuticals_NNP Inc._NNP ._.
As_IN a_DT result_NN of_IN the_DT transaction_NN the_DT Company_NN will_MD receive_VB $_$ 7.8_CD million_CD net_NN of_IN inducements_NNS in_IN lease_NN income_NN over_IN the_DT sub-lease_JJ period_NN from_IN Xanodyne_NNP ._.
114_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 115_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 24_CD Earnings_NNS per_IN share_NN The_DT following_VBG table_NN reconciles_NNS loss_NN income_NN from_IN continuing_VBG operations_NNS and_CC the_DT weighted_JJ average_JJ ordinary_JJ shares_NNS outstanding_JJ for_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN share_NN for_IN the_DT periods_NNS presented_VBN :_: 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS 413,968_CD 333,299_CD 297,937_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 20,135_CD 21,886_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS 3,125_CD 44,157_CD Numerator_NN for_IN basic_JJ loss_NN earnings_NNS per_IN share_NN 410,843_CD 269,007_CD 276,051_CD Interest_NN charged_VBN on_IN convertible_JJ debt_NN ,_, net_NN of_IN tax_NN 3,421_CD 5,218_CD Numerator_NN for_IN diluted_JJ loss_NN earnings_NNS per_IN share_NN 410,843_CD 272,428_CD 281,269_CD Year_NN to_TO December_NNP 31_CD ,_, 2005 2004 2003_CD Weighted_JJ average_JJ number_NN of_IN shares_NNS outstanding_JJ Number_NN of_IN shares_NNS Number_NNP of_IN shares_NNS Number_NNP of_IN Shares_NNP Basic_NNP 500,243,137_CD 496,306,604_CD 498,212,826_CD Effect_NN of_IN dilutive_JJ shares_NNS :_: Share_NN options_NNS 3,035,620_CD 1,859,076_CD Convertible_JJ debt_NN 11,858,416_CD 18,895,493_CD Warrants_NNS 66,792_CD 14,960,828_CD 20,754,569_CD Diluted_NNP 500,243,137_CD 511,267,432_CD 518,967,395_CD Basic_JJ earnings_NNS per_IN share_NN :_: Loss_NN income_NN from_IN continuing_VBG operations_NNS 82.7_CD 67.2_CD 59.8_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 4.1_CD 4.4_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS 0.6_CD 8.9_CD 82.1_CD 54.2_CD 55.4_CD Diluted_VBN earnings_NNS per_IN share_NN :_: Loss_NN income_NN from_IN continuing_VBG operations_NNS 82.7_CD 65.9_CD 58.4_CD Loss_NN from_IN discontinued_VBN operations_NNS ,_, net_NN of_IN tax_NN 4.0_CD 4.2_CD Gain_NNP loss_NN on_IN disposition_NN of_IN discontinued_VBN operations_NNS 0.6_CD 8.6_CD 82.1_CD 53.3_CD 54.2_CD The_DT share_NN options_NNS ,_, warrants_NNS and_CC convertible_JJ debt_NN not_RB included_VBD in_IN the_DT calculation_NN of_IN the_DT diluted_VBN weighted_JJ average_JJ number_NN of_IN shares_NNS are_VBP shown_VBN below_IN :_: 2005 2004 2003_CD i_FW ii_FW ii_FW Year_NN to_TO December_NNP 31_CD ,_, Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS Share_NN options_NNS 20,680,407_CD 16,640,724_CD 17,006,093_CD Warrants_NNS 1,346,407_CD 1,346,407_CD Convertible_JJ debt_NN 5,756_CD 22,032,570_CD 16,640,724_CD 18,352,500_CD Notes_NNS i_FW Not_RB included_VBN as_IN the_DT Company_NN made_VBD a_DT loss_NN during_IN the_DT calculation_NN period_NN ._.
ii_FW Not_RB included_VBN as_IN the_DT exercise_NN price_NN exceeded_VBD the_DT Companys_NNPS average_JJ share_NN price_NN during_IN the_DT calculation_NN period_NN ._.
During_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2004_CD the_DT Company_NN recorded_VBD a_DT loss_NN on_IN redemption_NN of_IN the_DT convertible_JJ loan_NN notes_NNS of_IN $_$ 7.4_CD million_CD ,_, which_WDT resulted_VBD from_IN the_DT write-off_NN of_IN unamortized_JJ debt_NN issuance_NN costs_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 115_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 116_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 25_CD Segment_NN reporting_VBG SFAS_NNP No._NN ._.
131_CD establishes_VBZ standards_NNS for_IN reporting_VBG information_NN about_IN operating_VBG segments_NNS and_CC related_VBN disclosures_NNS ,_, products_NNS and_CC services_NNS ,_, geographic_JJ areas_NNS and_CC major_JJ customers_NNS ._.
Operating_VBG segments_NNS are_VBP components_NNS of_IN an_DT enterprise_NN about_IN which_WDT separate_JJ financial_JJ information_NN is_VBZ available_JJ that_IN is_VBZ evaluated_VBN regularly_RB by_IN the_DT chief_NN operating_VBG decision-maker_NN in_IN deciding_VBG how_WRB to_TO allocate_VB resources_NNS and_CC in_IN assessing_VBG performance_NN ._.
Shire_NNP sells_VBZ a_DT number_NN of_IN pharmaceutical_JJ products_NNS in_IN multiple_JJ geographic_JJ markets_NNS across_IN the_DT world_NN ._.
The_DT Company_NN is_VBZ continuously_RB looking_VBG to_TO develop_VB and_CC replenish_VB the_DT pharmaceutical_JJ product_NN pipeline_NN and_CC has_VBZ continued_VBN to_TO focus_VB on_IN meeting_VBG the_DT needs_NNS of_IN the_DT specialist_NN physician_NN in_IN targeting_VBG therapeutic_JJ areas_NNS within_IN its_PRP$ pool_NN of_IN expertize_NN ._.
In_IN prior_RB reporting_VBG periods_NNS ,_, the_DT Companys_NNP internal_JJ management_NN reporting_VBG structure_NN was_VBD based_VBN on_IN a_DT combination_NN of_IN geography_NN and_CC function_NN ._.
As_IN a_DT result_NN the_DT Company_NN provided_VBD segment_NN information_NN ,_, which_WDT showed_VBD geographic_JJ sales_NNS and_CC costs_NNS for_IN the_DT US_NNP and_CC International_NNP sales_NNS and_CC marketing_NN businesses_NNS ,_, research_NN and_CC development_NN costs_NNS and_CC a_DT Corporate_JJ segment_NN which_WDT included_VBD corporate_JJ costs_NNS and_CC royalty_NN income_NN ._.
Effective_JJ January_NNP 1_CD ,_, 2005_CD ,_, Shires_NNP internal_JJ management_NN reporting_VBG structures_NNS have_VBP been_VBN changed_VBN to_TO show_VB two_CD segments_NNS ,_, Pharmaceutical_NNP Products_NNPS and_CC Royalties_NNPS ._.
The_DT Pharmaceutical_NNP Products_NNPS segment_NN comprises_VBZ four_CD therapeutic_JJ areas_NNS ,_, CNS_NNP ,_, GI_NNP ,_, Shire_NNP HGT_NNP and_CC GP_NNP and_CC all_DT products_NNS have_VBP been_VBN aggregated_VBN for_IN reporting_VBG purposes_NNS within_IN this_DT segment_NN ._.
The_DT Company_NN evaluates_VBZ performance_NN based_VBN on_IN revenue_NN and_CC operating_NN income_NN ._.
The_DT Company_NN does_VBZ not_RB have_VB inter-segment_JJ transactions_NNS ._.
Prior_RB period_NN amounts_NNS have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT new_JJ current_JJ period_NN presentation_NN ._.
The_DT Pharmaceutical_NNP Products_NNPS segment_NN represents_VBZ the_DT Companys_NNP commercial_JJ operations_NNS and_CC costs_NNS in_IN respect_NN of_IN products_NNS currently_RB promoted_VBN and_CC sold_VBN together_RB with_IN costs_NNS of_IN developing_VBG projects_NNS for_IN future_JJ commercialization_NN ._.
The_DT Royalties_NNS segment_NN represents_VBZ royalties_NNS earned_VBN from_IN the_DT out-licensing_NN of_IN projects_NNS to_TO third_JJ parties_NNS ._.
These_DT projects_NNS have_VBP been_VBN developed_VBN and_CC commercialized_VBN by_IN the_DT third_JJ party_NN and_CC royalties_NNS are_VBP being_VBG received_VBN on_IN the_DT sale_NN of_IN the_DT commercialized_JJ product_NN ._.
All_DT Other_JJ has_VBZ been_VBN included_VBN in_IN the_DT table_NN below_IN in_IN order_NN to_TO reconcile_VB the_DT segments_NNS to_TO the_DT total_JJ consolidated_JJ figures_NNS ._.
Costs_NNS have_VBP not_RB been_VBN allocated_VBN to_TO Royalties_NNS below_IN as_IN the_DT magnitude_NN of_IN the_DT costs_NNS incurred_VBN in_IN respect_NN of_IN managing_VBG this_DT segment_NN is_VBZ small_JJ and_CC the_DT internal_JJ reporting_NN consequently_RB does_VBZ not_RB allocate_VB costs_NNS to_TO this_DT segment_NN ._.
Assets_NNS that_WDT are_VBP directly_RB attributable_JJ to_TO the_DT Royalty_NN segment_NN have_VBP been_VBN separately_RB disclosed_VBN from_IN the_DT Pharmaceutical_NNP Products_NNPS segment_NN ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 3.5_CD million_CD is_VBZ included_VBN in_IN cost_NN of_IN product_NN sales_NNS ._.
116_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 117_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 25_CD Segment_NN reporting_NN continued_VBD Pharmaceutical_NNP Segment_NNP products_NNS Royalties_NNP sub-total_JJ All_DT other_JJ Total_JJ Year_NN to_TO December_NNP 31_CD ,_, 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Product_NN sales_NNS 1,112,457_CD 1,112,457_CD 1,112,457_CD Royalties_NNS 230,364_CD 230,364_CD 230,364_CD Licensing_NN and_CC development_NN 13,479_CD 13,479_CD Other_JJ revenues_NNS 6,907_CD 6,907_CD Total_JJ revenues_NNS 1,112,457_CD 230,364_CD 1,342,821_CD 20,386_CD 1,363,207_CD Cost_NN of_IN product_NN sales_NNS 141,909_CD 141,909_CD 141,909_CD Research_NNP and_CC development_NN 192,958_CD 192,958_CD 3,307_CD 196,265_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 458,132_CD 458,132_CD 458,132_CD i_FW Depreciation_NN and_CC amortization_NN 58,513_CD 58,513_CD 58,513_CD Intangible_JJ asset_NN impairment_NN 13,477_CD 13,477_CD 13,477_CD Reorganization_NN costs_NNS 48,469_CD 48,469_CD 48,469_CD Total_JJ operating_NN expenses_NNS 913,458_CD 913,458_CD 3,307_CD 916,765_CD Operating_NN income_NN 198,999_CD 230,364_CD 429,363_CD 17,079_CD 446,442_CD Total_JJ assets_NNS from_IN continuing_VBG operations_NNS 2,653,984_CD 60,895_CD 2,714,879_CD 2,714,879_CD Long-lived_JJ assets_NNS 785,930_CD 785,930_CD 785,930_CD Capital_NN expenditure_NN on_IN long-lived_JJ assets_NNS 93,936_CD 93,936_CD 93,936_CD i_FW Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 2.7_CD million_CD is_VBZ included_VBN in_IN cost_NN of_IN product_NN sales_NNS ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 2.6_CD million_CD is_VBZ included_VBN in_IN cost_NN of_IN product_NN sales_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 117_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 118_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 25_CD Segment_NN reporting_NN continued_VBD Supplemental_NNP information_NN To_TO improve_VB comparability_NN between_IN periods_NNS for_IN investors_NNS ,_, the_DT previous_JJ reporting_NN format_NN has_VBZ also_RB been_VBN used_VBN to_TO report_VB the_DT current_JJ period_NN to_TO December_NNP 31_CD ,_, 2005_CD together_RB with_IN the_DT previously_RB reported_VBN segmental_JJ analysis_NN for_IN the_DT periods_NNS to_TO December_NNP 31_CD ,_, 2004_CD and_CC December_NNP 31_CD ,_, 2003_CD ._.
Whilst_NNP there_EX is_VBZ no_DT requirement_NN to_TO include_VB this_DT disclosure_NN under_IN SFAS_NNP No._NN ._.
131_CD as_IN the_DT new_JJ internal_JJ reporting_NN format_NN has_VBZ been_VBN used_VBN for_IN the_DT current_JJ and_CC historic_JJ period_NN ,_, management_NN believes_VBZ that_IN during_IN 2005_CD ,_, it_PRP may_MD be_VB useful_JJ to_TO include_VB the_DT previously_RB reported_VBN segmental_JJ analysis_NN for_IN comparative_JJ purposes_NNS ._.
This_DT internal_JJ management-reporting_JJ format_NN is_VBZ no_RB longer_RB used_VBN as_IN the_DT basis_NN for_IN making_VBG decisions_NNS within_IN the_DT business_NN ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 3.5_CD million_CD is_VBZ included_VBN within_IN cost_NN of_IN product_NN sales_NNS ._.
Depreciation_NN and_CC amortization_NN relating_VBG to_TO research_NN and_CC development_NN assets_NNS are_VBP included_VBN within_IN US_NNP and_CC International_NNP segments_NNS ._.
Depreciation_NN and_CC amortization_NN relating_VBG to_TO research_NN and_CC development_NN assets_NNS are_VBP included_VBN in_IN US_NNP and_CC International_NNP segments_NNS ._.
118_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 119_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 25_CD Segment_NN reporting_NN continued_VBD US_NNP International_NNP Corporate_NNP R&D_NNP Total_NNP Year_NN to_TO December_NNP 31_CD ,_, 2003_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD External_NNP revenues_NNS :_: Product_NN sales_NNS 846,438_CD 157,869_CD 1,004,307_CD Royalties_NNS 14_CD 10,314_CD 193,245_CD 203,573_CD Licensing_NN and_CC development_NN 3,376_CD 301_CD 3,677_CD Other_JJ revenues_NNS 13_CD 13_CD Total_JJ revenues_NNS 849,841_CD 168,484_CD 193,245_CD 1,211,570_CD Cost_NN of_IN product_NN sales_NNS 94,597_CD 48,563_CD 143,160_CD ii_NNP Research_NNP and_CC development_NN 194,902_CD 194,902_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ 234,091_CD 80,968_CD 56,755_CD 371,814_CD i_FW ii_FW Depreciation_NN and_CC amortization_NN 19,278_CD 8,536_CD 26,804_CD 54,618_CD Intangible_JJ asset_NN impairment_NN 11,687_CD 15,802_CD 27,489_CD Total_JJ operating_NN expenses_NNS 359,653_CD 153,869_CD 83,559_CD 194,902_CD 791,983_CD Operating_NN income_NN loss_NN 490,188_CD 14,615_CD 109,686_CD 194,902_CD 419,587_CD Total_JJ assets_NNS from_IN continuing_VBG operations_NNS 697,460_CD 413,134_CD 1,269,300_CD 109,131_CD 2,489,025_CD Long-lived_JJ assets_NNS 238,774_CD 233,313_CD 200,225_CD 46,691_CD 719,003_CD Capital_NN expenditure_NN on_IN long-lived_JJ assets_NNS 18,324_CD 46,368_CD 15,827_CD 16,854_CD 97,373_CD Notes_NNS i_FW Included_VBN in_IN depreciation_NN and_CC amortization_NN are_VBP the_DT write-downs_NNS of_IN property_NN ,_, plant_NN and_CC equipment_NN of_IN $_$ 6_CD million_CD Corporate_JJ segment_NN and_CC assets_NNS held_VBN for_IN resale_NN of_IN $_$ 10.7_CD million_CD Corporate_JJ segment_NN ._.
Depreciation_NN from_IN manufacturing_VBG plants_NNS $_$ 2.6_CD million_CD is_VBZ included_VBN within_IN cost_NN of_IN product_NN sales_NNS ._.
ii_FW Costs_NNS associated_VBN with_IN the_DT closure_NN of_IN the_DT Lead_JJ Optimization_NN division_NN and_CC other_JJ related_JJ activities_NNS in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2003_CD are_VBP :_: Research_NNP and_CC development_NN $_$ 7.2_CD million_CD and_CC Depreciation_NNP and_CC amortization_NN $_$ 16.7_CD million_CD ._.
These_DT amounts_NNS are_VBP reflected_VBN in_IN reorganization_NN costs_NNS in_IN the_DT statement_NN of_IN operations_NNS ._.
Material_NNP customers_NNS In_IN the_DT periods_NNS set_VBN out_RP below_IN ,_, certain_JJ customers_NNS ,_, all_DT within_IN the_DT Pharmaceutical_NNP Products_NNPS operating_VBG segment_NN ,_, accounted_VBD for_IN greater_JJR than_IN 10_CD %_NN of_IN the_DT Companys_NNPS total_VBP revenues_NNS :_: 2005 2005 2004 2004_CD 2003_CD 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN $_$ 000_CD %_NN revenue_NN Cardinal_NNP Health_NNP Inc._NNP 599,504_CD 37_CD %_NN 339,136_CD 25_CD %_NN 274,771_CD 23_CD %_NN McKesson_NNP Corp._NNP 345,659_CD 22_CD %_NN 303,965_CD 22_CD %_NN 269,364_CD 22_CD %_NN Amerisource_NNP Bergen_NNP Corp._NNP 154,724_CD 10_CD %_NN 167,998_CD 12_CD %_NN 175,856_CD 15_CD %_NN Walgreen_NNP Co._NNP 156,578_CD 11_CD %_NN 158,689_CD 13_CD %_NN Amounts_NNS outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, in_IN respect_NN of_IN these_DT material_NN customers_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD Cardinal_NNP Health_NNP Inc._NNP 94,100_CD 28,178_CD McKesson_NNP Corp._NNP 47,230_CD 23,535_CD Amerisource_NNP Bergen_NNP Corp._NNP 20,365_CD 8,515_CD Walgreen_NNP Co._NNP 16,975_CD 161,695_CD 77,203_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 119_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 120_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 26_CD Other_JJ income_NN expense_NN ,_, net_JJ 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD SERP_NNP valuation_NN adjustment_NN 489 264 175_CD Impairment_NN of_IN long-term_JJ investments_NNS 11_CD 1,973_CD 15,364_CD 15,540_CD GeneChem_NNP Funds_NNPS management_NN fee_NN 4,332_CD 4,036_CD 3,755_CD Gain_NN on_IN sale_NN of_IN available-for-sale_JJ security_NN 11_CD 3,934_CD 14,805_CD Gain_NN on_IN sale_NN of_IN drug_NN formulation_NN business_NN 3,561_CD Foreign_NNP exchange_NN 1,396_CD 2,467_CD 6,716_CD Other_JJ 998_CD 2,571_CD 2,319_CD 9,945_CD 3,845_CD 20,645_CD 27_CD Interest_NN expense_NN Interest_NN expense_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD was_VBD $_$ 12_CD million_CD ._.
Included_VBN in_IN this_DT amount_NN was_VBD a_DT $_$ 7.7_CD million_CD provision_NN for_IN interest_NN ,_, which_WDT may_MD be_VB awarded_VBN by_IN the_DT court_NN in_IN respect_NN of_IN amounts_NNS due_JJ to_TO former_JJ holders_NNS of_IN approximately_RB 11.3_CD million_CD shares_NNS of_IN TKT_NNP common_JJ stock_NN who_WP have_VBP submitted_VBN written_VBN demands_NNS for_IN appraisal_NN of_IN these_DT shares_NNS ._.
The_DT provision_NN was_VBD based_VBN on_IN an_DT estimate_NN of_IN Shires_NNP average_JJ marginal_JJ cost_NN of_IN borrowing_NN from_IN the_DT acquisition_NN date_NN ._.
In_IN addition_NN ,_, Shire_NNP incurred_VBD interest_NN expense_NN of_IN $_$ 1.2_CD million_CD relating_VBG to_TO the_DT costs_NNS of_IN a_DT bridging_VBG loan_NN to_TO finance_VB the_DT TKT_NNP acquisition_NN ._.
In_IN 2004_CD interest_NN expense_NN of_IN $_$ 12.3_CD million_CD 2003_CD :_: $_$ 9.5_CD million_CD included_VBD the_DT write-off_NN of_IN $_$ 7.4_CD million_CD of_IN deferred_VBN financing_NN costs_NNS following_VBG the_DT redemption_NN of_IN $_$ 370.1_CD million_CD of_IN convertible_JJ loan_NN notes_NNS during_IN 2004_CD and_CC the_DT interest_NN expense_NN prior_RB to_TO the_DT redemption_NN of_IN $_$ 4.2_CD million_CD ._.
28_CD Retirement_NNP benefits_NNS a_DT Personal_JJ defined_VBN contribution_NN pension_NN plans_VBZ The_DT Company_NN makes_VBZ contributions_NNS to_TO defined_VBN contribution_NN retirement_NN plans_NNS that_WDT together_RB cover_VBP substantially_RB all_DT employees_NNS ._.
For_IN the_DT defined_VBN contribution_NN retirement_NN plans_NNS ,_, the_DT level_NN of_IN the_DT Companys_NNP contribution_NN is_VBZ fixed_VBN at_IN a_DT set_VBN percentage_NN of_IN employees_NNS pay_VBP ._.
Company_NN contributions_NNS to_TO personal_JJ defined_VBN contribution_NN pension_NN plans_NNS totaled_VBD $_$ 14.1_CD million_CD ,_, $_$ 9_CD million_CD and_CC $_$ 16.1_CD million_CD for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD ,_, respectively_RB ,_, and_CC were_VBD charged_VBN to_TO operations_NNS as_IN they_PRP became_VBD payable_JJ ._.
b_NN Defined_VBN benefit_NN pension_NN plans_NNS i_FW The_DT Roberts_NNP SERP_NNP The_NNP Roberts_NNP SERP_NNP is_VBZ for_IN some_DT US_NNP employees_NNS of_IN Roberts_NNP Pharmaceutical_NNP Corporation_NNP Roberts_NNP who_WP met_VBD certain_JJ age_NN and_CC service_NN requirements_NNS ._.
Shire_NNP acquired_VBD Roberts_NNP in_IN 1999_CD ,_, and_CC the_DT plan_NN was_VBD discontinued_VBN in_IN 2000_CD ._.
There_EX were_VBD no_DT contributions_NNS payable_JJ by_IN the_DT Company_NN in_IN respect_NN of_IN 2005_CD ._.
The_DT Company_NN paid_VBD a_DT lump_NN sum_NN of_IN $_$ 18_CD million_CD into_IN the_DT Roberts_NNP SERP_NNP ,_, which_WDT was_VBD accounted_VBN for_IN as_IN a_DT fair_JJ value_NN adjustment_NN on_IN the_DT acquisition_NN of_IN Roberts_NNP to_TO make_VB good_JJ the_DT deficit_NN on_IN this_DT scheme_NN at_IN the_DT time_NN of_IN acquisition_NN ._.
This_DT lump_NN sum_NN payment_NN has_VBZ led_VBN to_TO the_DT Company_NN having_VBG no_DT future_JJ liability_NN under_IN the_DT SERP_NNP ,_, which_WDT has_VBZ been_VBN closed_VBN to_TO new_JJ members_NNS with_IN contributions_NNS no_RB longer_RB payable_JJ by_IN existing_VBG members_NNS ._.
Assets_NNS are_VBP set_VBN aside_RB to_TO fund_VB these_DT benefits_NNS in_IN a_DT Rabbi_NNP Trust_NNP ._.
The_DT legal_JJ form_NN of_IN the_DT trust_NN is_VBZ such_JJ that_IN the_DT assets_NNS held_VBD to_TO cover_VB the_DT pension_NN liabilities_NNS are_VBP available_JJ to_TO the_DT general_JJ creditors_NNS of_IN the_DT Company_NN on_IN winding_VBG up_RP ._.
Accordingly_RB ,_, the_DT assets_NNS held_VBN by_IN the_DT trust_NN are_VBP not_RB plan_VB assets_NNS and_CC are_VBP recorded_VBN on_IN the_DT balance_NN sheet_NN ._.
In_IN accordance_NN with_IN EITF_NNP 97-14_CD ,_, Accounting_NNP for_IN Deferred_NNP Compensation_NNP Arrangements_NNP Where_WRB Amounts_VBZ Earned_VBN Are_VBP Held_VBN in_IN a_DT Rabbi_NNP Trust_NNP and_CC Invested_VBN the_DT assets_NNS and_CC liabilities_NNS of_IN $_$ 7.6_CD million_CD and_CC $_$ 4.6_CD million_CD ,_, respectively_RB ,_, are_VBP shown_VBN on_IN the_DT balance_NN sheet_NN within_IN the_DT categories_NNS Other_JJ non-current_JJ assets_NNS ,_, Other_JJ current_JJ liabilities_NNS and_CC Other_JJ non-current_JJ liabilities_NNS ._.
ii_FW The_DT Shire_NNP SERP_NNP The_NNP Shire_NNP SERP_NNP defined_VBD benefit_NN scheme_NN is_VBZ an_DT unfunded_JJ arrangement_NN :_: the_DT benefits_NNS are_VBP payable_JJ to_TO certain_JJ senior_JJ US_NNP employees_NNS as_IN lump_NN sums_NNS on_IN leaving_VBG the_DT Companys_NNPS employment_NN or_CC earlier_JJR due_JJ to_TO death_NN ,_, disability_NN or_CC termination_NN ._.
The_DT amount_NN of_IN benefit_NN is_VBZ based_VBN on_IN the_DT value_NN of_IN notional_JJ contributions_NNS increased_VBN with_IN earned_VBN investment_NN returns_NNS as_IN if_IN they_PRP were_VBD invested_VBN in_IN investments_NNS of_IN the_DT employees_NNS choice_NN ._.
The_DT entire_JJ benefit_NN liability_NN has_VBZ been_VBN recognized_VBN on_IN the_DT balance_NN sheet_NN ._.
120_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 121_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 29_CD Income_NN taxes_NNS The_DT components_NNS of_IN pre_NN tax_NN income_NN from_IN continuing_VBG operations_NNS are_VBP as_IN follows_VBZ :_: 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD UK_NNP 70,318_CD 67,363_CD 76,267_CD US_NNP 61,162_CD 265,770_CD 285,221_CD In-process_JJ research_NN and_CC development_NN 673,000_CD Other_JJ jurisdictions_NNS 220,635_CD 261,487_CD 197,393_CD Sub-total_JJ 320,885_CD 459,894_CD 406,347_CD Equity_NNP Investees_NNP 1,000_CD 2,508_CD 1,057_CD The_DT provision_NN for_IN income_NN taxes_NNS by_IN location_NN of_IN the_DT taxing_VBG jurisdiction_NN for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, consisted_VBN of_IN the_DT following_NN :_: 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Current_JJ income_NN taxes_NNS :_: UK_NNP corporation_NN tax_NN 7,417_CD 746_CD US_NNP federal_JJ tax_NN 16,740_CD 98,668_CD 101,174_CD US_NNP state_NN and_CC local_JJ taxes_NNS 7,325_CD 5,107_CD 4,313_CD Other_JJ jurisdictions_NNS 39,123_CD 36,417_CD 18,792_CD Total_JJ current_JJ taxes_NNS 70,605_CD 140,938_CD 124,279_CD Deferred_JJ taxes_NNS :_: UK_NNP corporation_NN tax_NN 5,418_CD 482_CD 9,696_CD US_NNP federal_JJ tax_NN 8,167_CD 12,171_CD 3,647_CD US_NNP state_NN and_CC local_JJ taxes_NNS 3,293_CD 104_CD 180_CD Other_JJ jurisdictions_NNS 27,520_CD 922_CD 30,449_CD Total_JJ deferred_JJ taxes_NNS 21,478_CD 11,835_CD 16,926_CD Total_JJ income_NN taxes_NNS attributable_JJ to_TO continuing_VBG operations_NNS 92,083_CD 129,103_CD 107,353_CD Total_JJ income_NN taxes_NNS attributable_JJ to_TO discontinued_VBN operations_NNS Total_JJ income_NN taxes_NNS 92,083_CD 129,103_CD 107,353_CD The_DT reconciliation_NN of_IN income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS and_CC discontinued_VBN operations_NNS to_TO the_DT provision_NN for_IN income_NN taxes_NNS is_VBZ shown_VBN in_IN the_DT table_NN below_IN :_: 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD $_$ 000_CD Loss_NN income_NN from_IN continuing_VBG operations_NNS before_IN income_NN taxes_NNS and_CC equity_NN in_IN net_JJ losses_NNS income_NN of_IN associates_NNS and_CC discontinued_VBN operations_NNS 320,885_CD 459,894_CD 406,347_CD UK_NNP Corporation_NNP tax_NN rate_NN 30_CD %_NN 30_CD %_NN 30_CD %_NN Adjustments_NNS to_TO derive_VB effective_JJ rate_NN :_: Non-deductible_JJ items_NNS :_: Permanent_JJ differences_NNS 9.4_CD %_NN 2.0_CD %_NN 1.1_CD %_NN In-process_JJ research_NN and_CC development_NN 62.9_CD %_NN Other_JJ items_NNS :_: Change_NNP in_IN valuation_NN allowance_NN 6.7_CD %_NN 3.3_CD %_NN 7.1_CD %_NN Difference_NN in_IN taxation_NN rates_NNS 0.4_CD %_NN 0.6_CD %_NN 11.2_CD %_NN Prior_RB year_NN adjustment_NN 1.0_CD %_NN 4.5_CD %_NN 2.1_CD %_NN Change_NNP in_IN prior_JJ year_NN tax_NN rates_NNS 0.7_CD %_NN Other_JJ 0.2_CD %_NN 0.5_CD %_NN 2.7_CD %_NN Provision_NNP for_IN income_NN taxes_NNS on_IN continuing_VBG operations_NNS 28.7_CD %_NN 28.1_CD %_NN 26.4_CD %_NN Differences_NNS between_IN Shires_NNP fiscal_JJ 2005_CD effective_JJ tax_NN rate_NN and_CC its_PRP$ statutory_JJ rate_NN of_IN 30_CD %_NN principally_RB result_VB from_IN the_DT effect_NN of_IN the_DT acquisition_NN of_IN TKT_NNP and_CC the_DT impact_NN of_IN the_DT accounting_NN for_IN costs_NNS associated_VBN with_IN the_DT write-off_NN of_IN in-process_JJ research_NN and_CC development_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 121_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 122_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 29_CD Income_NN taxes_NNS continued_VBD The_DT significant_JJ components_NNS of_IN deferred_JJ income_NN tax_NN assets_NNS and_CC liabilities_NNS and_CC their_PRP$ balance_NN sheet_NN classifications_NNS ,_, as_RB at_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Deferred_VBN tax_NN assets_NNS :_: Deferred_JJ revenue_NN 6,375_CD 5,866_CD Inventory_NNP and_CC warranty_NN provisions_NNS 12,197_CD 5,928_CD Losses_NNS carried_VBD forward_RB 417,877_CD 194,523_CD Provisions_NNS for_IN product_NN returns_NNS and_CC doubtful_JJ accounts_NNS 28,268_CD 7,586_CD Restructuring_NNP 50,318_CD 25,200_CD Intangibles_NNPS 19,389_CD Other_JJ 44,845_CD 29,234_CD Gross_NNP deferred_VBN tax_NN assets_NNS 579,269_CD 268,337_CD Less_RBR :_: valuation_NN allowance_NN 235,121_CD 152,915_CD 344,148_CD 115,422_CD Deferred_JJ tax_NN liabilities_NNS :_: Excess_NN of_IN tax_NN value_NN over_IN book_NN value_NN of_IN assets_NNS 227,968_CD 37,311_CD Net_JJ deferred_JJ tax_NN assets_NNS 116,180_CD 78,111_CD Balance_NN sheet_NN classifications_NNS :_: Deferred_JJ tax_NN assets_NNS current_JJ 54,186_CD 70,387_CD Deferred_JJ tax_NN assets_NNS non-current_JJ 61,994_CD 7,724_CD 116,180_CD 78,111_CD The_DT approximate_JJ net_JJ operating_NN loss_NN carry-forwards_NNS as_IN at_IN December_NNP 31_CD ,_, are_VBP as_IN follows_VBZ :_: December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD US_NNP federal_JJ tax_NN NOLs_NNS 270,277_CD 25,416_CD US_NNP state_NN tax_NN NOLs_NNS 99,386_CD 93,542_CD UK_NNP NOLs_NNP 227,755_CD 246,966_CD Canadian_JJ NOLs_NNS 153,235_CD 438,523_CD Foreign_JJ tax_NN jurisdictions_NNS 82,885_CD 100,808_CD The_DT tax_NN losses_NNS shown_VBN above_IN have_VBP the_DT following_VBG expiration_NN dates_NNS :_: December_NNP 31_CD ,_, 2005_CD $_$ 000_CD Within_IN 1_CD year_NN 27,133_CD Within_IN 12_CD years_NNS 13,925_CD Within_IN 23_CD years_NNS 14,941_CD Within_IN 34_CD years_NNS 18,784_CD Within_IN 45_CD years_NNS 22,534_CD Within_IN 56_CD years_NNS 10,219_CD Within_IN 67_CD years_NNS 3,943_CD After_IN 7_CD years_NNS 288,813_CD Available_JJ indefinitely_RB 433,245_CD As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, the_DT Company_NN had_VBD a_DT valuation_NN allowance_NN of_IN $_$ 235_CD million_CD to_TO reduce_VB its_PRP$ deferred_JJ tax_NN assets_NNS to_TO estimated_VBN realizable_JJ value_NN ._.
The_DT valuation_NN allowance_NN relates_VBZ to_TO the_DT deferred_VBN tax_NN assets_NNS arising_VBG from_IN operating_VBG loss_NN carry-forwards_NNS and_CC capital_NN loss_NN carry-forwards_NNS ._.
The_DT utilization_NN of_IN operating_VBG loss_NN carry-forwards_NNS is_VBZ restricted_VBN to_TO the_DT taxable_JJ income_NN of_IN the_DT subsidiary_NN generating_VBG the_DT losses_NNS ._.
In_IN addition_NN ,_, capital_NN loss_NN carry-forwards_NNS can_MD only_RB be_VB offset_VBN against_IN capital_NN gains_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, based_VBN upon_IN the_DT level_NN of_IN historical_JJ taxable_JJ income_NN and_CC projections_NNS for_IN future_JJ taxable_JJ income_NN over_IN the_DT periods_NNS in_IN which_WDT the_DT temporary_JJ differences_NNS are_VBP anticipated_VBN to_TO reverse_VB ,_, and_CC reasonable_JJ and_CC feasible_JJ tax-planning_JJ strategies_NNS ,_, management_NN believes_VBZ it_PRP is_VBZ more_RBR likely_JJ than_IN not_RB that_IN the_DT Company_NN will_MD realize_VB the_DT benefits_NNS of_IN these_DT deductible_JJ differences_NNS ,_, net_NN of_IN the_DT valuation_NN allowances_NNS ._.
However_RB ,_, the_DT amount_NN of_IN the_DT deferred_JJ tax_NN asset_NN considered_VBN realizable_JJ could_MD be_VB adjusted_VBN in_IN the_DT future_NN if_IN estimates_NNS of_IN taxable_JJ income_NN are_VBP revised_VBN ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, we_PRP have_VBP not_RB made_VBN a_DT tax_NN provision_NN on_IN approximately_RB $_$ 1.7_CD billion_CD of_IN unremitted_JJ earnings_NNS of_IN our_PRP$ international_JJ subsidiaries_NNS ._.
As_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, these_DT earnings_NNS are_VBP expected_VBN to_TO be_VB reinvested_VBN overseas_RB ._.
Because_IN of_IN complexity_NN ,_, it_PRP is_VBZ not_RB practical_JJ to_TO compute_VB the_DT estimated_VBN deferred_VBN tax_NN liability_NN on_IN these_DT earnings_NNS ._.
122_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 123_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_JJ 30_CD Equity_NN in_IN losses_NNS earnings_NNS of_IN equity_NN method_NN investees_VBZ 2005 2004 2003_CD Year_NN to_TO December_NNP 31_CD ,_, Notes_NNP $_$ 000_CD $_$ 000_CD $_$ 000_CD GSK_NNP 11_CD 5,325_CD 4,433_CD 3,495_CD GeneChem_NNP Funds_NNPS 11_CD 3,962_CD 75_CD Other_JJ 2,363_CD 2,000_CD 4,552_CD 1,000_CD 2,508_CD 1,057_CD 31_CD Share-based_JJ compensation_NN plans_NNS Historically_NNP the_DT Company_NN has_VBZ granted_VBN options_NNS to_TO Directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS under_IN six_CD stock_NN option_NN plans_NNS ._.
On_IN November_NNP 28_CD ,_, 2005_CD the_DT ordinary_JJ shareholders_NNS of_IN Shire_NNP approved_VBD the_DT adoption_NN of_IN the_DT Shire_NNP plc_NN Portfolio_NNP Share_NNP Plan_NNP Parts_NNP A_NNP and_CC B_NNP ,_, a_DT new_JJ share_NN based_VBN compensation_NN plan_NN ,_, which_WDT provides_VBZ for_IN stock-settled_JJ share_NN appreciation_NN rights_NNS and_CC performance_NN share_NN awards_NNS to_TO be_VB made_VBN to_TO Directors_NNS and_CC employees_NNS over_IN ordinary_JJ shares_NNS and_CC American_JJ depositary_JJ shares_NNS ._.
No_DT further_JJ awards_NNS will_MD be_VB made_VBN under_IN the_DT previous_JJ stock_NN option_NN plans_NNS ._.
The_DT following_VBG awards_NNS were_VBD outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD :_: Expiration_NNP Compensation_NNP Number_NNP of_IN period_NN from_IN Scheme_NNP type_NN awards_NNS date_NN of_IN issue_NN Vesting_JJ period_NN Executive_NNP Scheme_NNP Stock_NNP options_NNS 1,176,784_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS 2000_CD Executive_NNP Scheme_NNP Stock_NNP options_NNS 22,787,658_CD 10_CD years_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS Sharesave_NNP Scheme_NNP Stock_NNP options_NNS 337,371_CD 6_CD months_NNS after_IN vesting_VBG 3_CD or_CC 5_CD years_NNS Stock_NNP Purchase_NNP Plan_NNP Stock_NNP options_NNS 640,777_CD On_IN vesting_VBG date_NN 27_CD months_NNS SLI_NNP Plan_NNP Stock_NNP options_NNS 2,567_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP BioChem_NNP Plan_NNP Stock_NNP options_NNS 3,525,582_CD 10_CD years_NNS Immediate_NNP on_IN acquisition_NN by_IN Shire_NNP Total_NNP stock_NN option_NN awards_NNS 28,470,739_CD Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN appreciation_NN 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS rights_NNS ordinary_JJ shares_NNS 449,490_CD 5_CD years_NNS for_IN executive_NN Directors_NNS only_RB Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN appreciation_NN 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS i_FW rights_NNS ADSs_NNS 2,812,176_CD 5_CD years_NNS for_IN executive_NN Directors_NNS only_RB Total_JJ Portfolio_NN Share_NN Plan_NNP Part_NNP A_NNP 3,261,666_CD Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP Performance_NNP shares_NNS 3_CD years_NNS ,_, subject_JJ to_TO performance_NN criteria_NNS for_IN executive_NN Directors_NNS only_RB i_FW For_IN the_DT purposes_NNS of_IN this_DT table_NN ADSs_NNS have_VBP been_VBN converted_VBN into_IN ordinary_JJ shares_NNS ._.
One_CD ADS_NNPS is_VBZ equivalent_JJ to_TO three_CD ordinary_JJ shares_NNS ._.
a_DT Stock_NN option_NN plans_VBZ i_FW Shire_FW Pharmaceuticals_NNP Executive_NNP Share_NNP Option_NN Scheme_NNP Parts_NNP A_NNP and_CC B_NNP Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Executive_NNP Scheme_NNP are_VBP subject_JJ to_TO performance_NN criteria_NNS and_CC can_MD not_RB be_VB exercised_VBN in_IN full_JJ ,_, unless_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN at_IN least_JJS 20.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ._.
If_IN Shires_NNP ordinary_JJ share_NN price_NN increases_NNS at_IN a_DT compound_NN rate_NN of_IN 14.5_CD %_NN per_IN annum_NN over_IN a_DT minimum_JJ three-year_JJ measurement_NN period_NN ,_, 60_CD %_NN of_IN the_DT options_NNS may_MD be_VB exercised_VBN ._.
If_IN the_DT share_NN price_NN does_VBZ not_RB meet_VB these_DT conditions_NNS at_IN any_DT time_NN ,_, none_NN of_IN the_DT options_NNS will_MD become_VB exercisable_JJ ._.
ii_FW Shire_FW plc_FW 2000_CD Executive_NNP Share_NNP Option_NN Scheme_NNP 2000_CD Executive_NNP Scheme_NNP Options_NNPS granted_VBN under_IN this_DT scheme_NN are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 123_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 124_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 31_CD Share-based_JJ compensation_NN plans_NNS continued_VBD The_DT performance_NN criteria_NNS were_VBD reviewed_VBN in_IN 2002_CD to_TO ensure_VB the_DT criteria_NNS reflected_VBD the_DT market_NN in_IN which_WDT Shire_NNP operates_VBZ ._.
Given_VBN Shires_NNPS development_NN ,_, it_PRP was_VBD considered_VBN appropriate_JJ that_IN an_DT earnings_NNS per_IN share-based_JJ measure_NN should_MD be_VB adopted_VBN in_IN place_NN of_IN share_NN price_NN growth_NN targets_NNS ._.
The_DT performance_NN criteria_NNS are_VBP based_VBN on_IN real_JJ growth_NN in_IN the_DT diluted_JJ earnings_NNS per_IN share_NN reported_VBN in_IN the_DT Companys_NNP Form_NN 10-K_NN under_IN US_NNP GAAP_NNP ,_, adjusted_VBN to_TO ensure_VB a_DT consistent_JJ basis_NN of_IN measurement_NN ,_, as_IN approved_VBN by_IN the_DT Remuneration_NNP Committee_NNP ,_, including_VBG the_DT add_VB back_RB of_IN significant_JJ one_CD time_NN items_NNS option_NN EPS_NNP ._.
Therefore_RB ,_, the_DT performance_NN criteria_NNS were_VBD amended_VBN so_RB that_IN an_DT option_NN would_MD become_VB exercisable_JJ in_IN full_JJ if_IN Shires_NNP option_NN EPS_NNP growth_NN over_IN a_DT three-year_JJ period_NN from_IN the_DT date_NN of_IN award_NN exceeds_VBZ the_DT UK_NNP Retail_NNP Prices_NNS Index_NNP RPI_NNP for_IN the_DT following_VBG tranches_NNS of_IN grants_NNS :_: Options_NNS with_IN a_DT grant_NN value_NN of_IN up_RB to_TO 100_CD %_NN of_IN salary_NN RPI_NNP plus_CC 9_CD %_NN directors_NNS ,_, RPI_NNP plus_CC 15_CD %_NN Between_IN 101_CD %_NN and_CC 200_CD %_NN of_IN salary_NN RPI_NNP plus_CC 15_CD %_NN Between_IN 201_CD %_NN and_CC 300_CD %_NN of_IN salary_NN RPI_NNP plus_CC 21_CD %_NN Over_IN 301_CD %_NN of_IN salary_NN RPI_NNP plus_CC 27_CD %_NN The_DT new_JJ earnings_NNS per_IN share_NN performance_NN criteria_NNS apply_VBP to_TO options_NNS granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP from_IN August_NNP 2002_CD ._.
iii_FW Shire_FW Pharmaceuticals_NNPS Sharesave_NNP Scheme_NNP Sharesave_NNP Scheme_NNP Options_NNPS granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS are_VBP issued_VBN to_TO employees_NNS ._.
iv_FW Shire_FW plc_FW Employee_NNP Stock_NNP Purchase_NNP Plan_NNP Stock_NNP Purchase_NNP Plan_NNP Under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP ,_, options_NNS are_VBP granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT fair_JJ market_NN value_NN of_IN a_DT share_NN on_IN the_DT enrolment_NN date_NN the_DT first_JJ day_NN of_IN the_DT offering_NN period_NN or_CC the_DT exercise_NN date_NN the_DT last_JJ day_NN of_IN the_DT offering_NN period_NN ,_, whichever_WDT is_VBZ the_DT lower_JJR ._.
v_NN Pharmavene_NNP 1991_CD Stock_NNP Option_NN Plan_NN SLI_NNP Plan_NNP Options_NNPS issued_VBN under_IN the_DT SLI_NNP Plan_NNP were_VBD originally_RB granted_VBN over_IN shares_NNS in_IN SLI_NNP ,_, formerly_RB Pharmavene_NNP Inc._NNP a_DT company_NN acquired_VBN by_IN the_DT Company_NN on_IN March_NNP 23_CD ,_, 1997_CD ._.
Exercise_NN of_IN these_DT options_NNS results_NNS in_IN the_DT option_NN holder_NN receiving_VBG ordinary_JJ shares_NNS in_IN Shire_NNP ._.
As_IN a_DT result_NN of_IN the_DT acquisition_NN of_IN SLI_NNP ,_, and_CC in_IN accordance_NN with_IN the_DT terms_NNS of_IN the_DT original_JJ share_NN option_NN plan_NN ,_, all_DT options_NNS granted_VBN under_IN that_DT plan_NN became_VBD immediately_RB capable_JJ of_IN exercise_NN ._.
It_PRP is_VBZ intended_VBN that_IN no_DT further_JJ options_NNS will_MD be_VB granted_VBN under_IN the_DT SLI_NNP Plan_NNP ._.
vi_FW BioChem_NNP Stock_NNP Option_NN Plan_NN BioChem_NNP Plan_NNP Following_VBG the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP on_IN May_NNP 11_CD ,_, 2001_CD ,_, the_DT BioChem_NNP Stock_NNP Option_NN Plan_NN was_VBD amended_VBN such_JJ that_IN options_NNS over_IN BioChem_NNP Pharma_NNP Inc._NNP s_VBZ common_JJ stock_NN became_VBD options_NNS over_IN ordinary_JJ shares_NNS of_IN Shire_NNP ._.
A_DT summary_NN of_IN the_DT status_NN of_IN the_DT Companys_NNP stock_NN option_NN plans_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD ,_, 2004_CD and_CC 2003_CD and_CC of_IN the_DT related_JJ transactions_NNS during_IN the_DT periods_NNS then_RB ended_VBD is_VBZ presented_VBN below_IN :_: Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN Year_NN to_TO December_NNP 31_CD ,_, 2005_CD shares_NNS Outstanding_JJ as_IN at_IN beginning_NN of_IN period_NN 5.85_CD 27,343,625_CD Granted_VBN 5.88_CD 8,733,811_CD Exercised_VBN 4.53_CD 4,701,699_CD Forfeited_NNP 8.17_CD 2,904,998_CD Outstanding_JJ as_IN at_IN end_NN of_IN period_NN 5.85_CD 28,470,739_CD Exercisable_JJ as_IN at_IN end_NN of_IN period_NN 7.97_CD 7,987,369_CD 8,156,000_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
These_DT options_NNS were_VBD granted_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT market_NN value_NN on_IN the_DT date_NN of_IN grant_NN ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 3.08_CD ._.
124_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 125_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 31_CD Share-based_JJ compensation_NN plans_NNS continued_VBD 110,647_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 5.13_CD ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 80_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 3.24_CD ._.
36,690_CD and_CC 430,474_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 5.86_CD and_CC 5.85_CD ,_, respectively_RB ._.
These_DT options_NNS were_VBD granted_VBN with_IN an_DT exercise_NN price_NN equal_JJ to_TO 85_CD %_NN of_IN the_DT mid-market_JJ price_NN on_IN the_DT day_NN before_IN invitations_NNS were_VBD issued_VBN to_TO employees_NNS ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 2.00_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN Year_NN to_TO December_NNP 31_CD ,_, 2004_CD shares_NNS Outstanding_JJ as_IN at_IN beginning_NN of_IN period_NN 6.10_CD 25,995,543_CD Granted_VBN 5.14_CD 6,966,411_CD Exercised_VBN 3.71_CD 2,097,716_CD Forfeited_NNP 7.58_CD 3,520,613_CD Outstanding_JJ as_IN at_IN end_NN of_IN period_NN 5.85_CD 27,343,625_CD Exercisable_JJ as_IN at_IN end_NN of_IN period_NN 8.65_CD 8,728,709_CD 6,665,144_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 2.78_CD ._.
94,861_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 3.74_CD ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 2.31_CD ._.
173,613_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 3.92_CD ._.
In_IN relation_NN to_TO a_DT grant_NN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 8.06_CD in_IN 2001_CD ,_, an_DT additional_JJ 32,793_CD options_NNS were_VBD granted_VBN at_IN a_DT price_NN of_IN 4.58_CD on_IN the_DT 2004_CD maturity_NN date_NN ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 1.28_CD ._.
Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN Year_NN to_TO December_NNP 31_CD ,_, 2003_CD shares_NNS Outstanding_JJ as_IN at_IN beginning_NN of_IN period_NN 7.17_CD 20,051,297_CD Granted_VBN 3.52_CD 9,407,852_CD Exercised_VBN 2.86_CD 1,039,439_CD Forfeited_NNP 6.31_CD 2,424,167_CD Outstanding_JJ as_IN at_IN end_NN of_IN period_NN 6.10_CD 25,995,543_CD Exercisable_JJ as_IN at_IN end_NN of_IN period_NN 7.15_CD 8,989,450_CD 8,819,199_CD options_NNS were_VBD granted_VBN under_IN the_DT 2000_CD Executive_NNP Scheme_NNP ._.
These_DT options_NNS were_VBD issued_VBN with_IN exercise_NN prices_NNS equivalent_JJ to_TO the_DT market_NN value_NN on_IN the_DT date_NN of_IN grant_NN ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 1.93_CD ._.
182,639_CD options_NNS were_VBD granted_VBN under_IN the_DT Sharesave_NNP Scheme_NNP at_IN a_DT price_NN of_IN 3.86_CD ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 2.56_CD ._.
406,014_CD options_NNS were_VBD granted_VBN under_IN the_DT Stock_NNP Purchase_NNP Plan_NNP at_IN a_DT price_NN of_IN 4.09_CD ._.
The_DT weighted_JJ average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN was_VBD 2.55_CD ._.
Options_NNS outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_NN exercise_NN average_JJ exercise_NN price_NN of_IN options_NNS Number_NN of_IN price_NN of_IN options_NNS Exercise_NN prices_NNS Weighted_VBN average_JJ outstanding_JJ options_NNS exercisable_JJ Number_NN of_IN options_NNS outstanding_JJ remaining_VBG life_NN exercisable_JJ 5,651,719_CD 0.01_CD 4.00_CD 6.8_CD 3.46_CD 26,547_CD 3.19_CD 14,772,839_CD 4.01_CD 6.00_CD 8.1_CD 5.36_CD 2,070,405_CD 5.19_CD 5,739,709_CD 6.01_CD 10.00_CD 4.3_CD 7.05_CD 3,669,918_CD 7.20_CD 2,306,472_CD 10.01_CD 13.00_CD 4.0_CD 11.84_CD 2,220,499_CD 11.89_CD 28,470,739_CD 7,987,369_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 125_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 126_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 31_CD Share-based_JJ compensation_NN plans_NNS continued_VBD b_NN Stock-settled_JJ share_NN appreciation_NN rights_NNS Portfolio_NN Share_NN Plan_NNP Part_NNP A_NNP Stock-settled_JJ share_NN appreciation_NN rights_NNS granted_VBN under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP A_NNP are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
In_IN respect_NN of_IN any_DT award_NN made_VBD to_TO executive_JJ Directors_NNS performance_NN conditions_NNS will_MD be_VB based_VBN on_IN relative_JJ total_JJ shareholder_NN return_NN ._.
Vesting_VBG will_MD depend_VB on_IN relative_JJ total_JJ shareholder_NN return_NN performance_NN against_IN two_CD comparator_NN groups_NNS ._.
For_IN one-third_NN of_IN the_DT award_NN ,_, the_DT comparator_NN group_NN will_MD be_VB the_DT Financial_NNP Times_NNP Stock_NNP Exchange_NNP 100_CD constituents_NNS excluding_VBG financial_JJ institutions_NNS and_CC for_IN two-thirds_NNS of_IN the_DT award_NN the_DT comparator_NN group_NN will_MD be_VB a_DT group_NN of_IN international_JJ companies_NNS from_IN the_DT pharmaceutical_JJ sector_NN ._.
In_IN addition_NN ,_, before_IN awards_NNS granted_VBN to_TO executive_JJ Directors_NNS will_MD vest_NN ,_, the_DT Committee_NNP must_MD be_VB satisfied_VBN that_IN the_DT underlying_VBG performance_NN of_IN the_DT Company_NN is_VBZ sufficient_JJ to_TO justify_VB this_DT ._.
Where_WRB median_JJ performance_NN is_VBZ achieved_VBN ,_, 1_CD 33_CD 3_CD %_NN of_IN stock-settled_JJ share_NN appreciation_NN rights_NNS will_MD vest_NN ,_, rising_VBG on_IN a_DT straight-line_JJ basis_NN to_TO full_JJ vesting_NN at_IN upper_JJ quartile_JJ performance_NN ._.
Awards_RB granted_VBN to_TO employees_NNS below_IN executive_JJ Director_NNP level_NN will_MD not_RB be_VB subject_JJ to_TO performance_NN conditions_NNS ._.
Once_RB awards_NNS have_VBP vested_VBN ,_, participants_NNS will_MD have_VB until_IN the_DT fifth_JJ anniversary_NN of_IN the_DT date_NN of_IN grant_NN to_TO exercise_VB their_PRP$ awards_NNS ._.
A_DT summary_NN of_IN the_DT status_NN of_IN the_DT Companys_NNPS stock-settled_VBD share_NN appreciation_NN rights_NNS as_IN at_IN December_NNP 31_CD ,_, 2005_CD and_CC of_IN the_DT related_JJ transactions_NNS during_IN the_DT periods_NNS then_RB ended_VBD is_VBZ presented_VBN below_IN :_: Year_NN to_TO December_NNP 31_CD ,_, 2005_CD Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN Ordinary_NNP shares_NNS shares_NNS Outstanding_JJ as_IN at_IN beginning_NN of_IN period_NN Granted_VBN 7.17_CD 449,490_CD Exercised_VBN Forfeited_NNP Outstanding_JJ as_IN at_IN end_NN of_IN period_NN 7.17_CD 449,490_CD Exercisable_JJ as_IN at_IN end_NN of_IN period_NN 449,490_CD stock-settled_JJ share_NN appreciation_NN rights_NNS were_VBD granted_VBN over_IN ordinary_JJ shares_NNS under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP A._NNP The_NNP weighted_JJ average_NN fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD is_VBZ 2.85_CD ._.
Stock-settled_JJ share_NN appreciation_NN rights_NNS over_IN ordinary_JJ shares_NNS outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_NN exercise_NN average_JJ exercise_NN price_NN of_IN options_NNS Number_NN of_IN price_NN of_IN options_NNS Exercise_NN prices_NNS Weighted_VBN average_JJ outstanding_JJ options_NNS exercisable_JJ Number_NN of_IN options_NNS outstanding_JJ remaining_VBG life_NN exercisable_JJ 449,490_CD 6.01_CD 10.00_CD 4.9_CD 7.17_CD Year_NN to_TO December_NNP 31_CD ,_, 2005_CD Weighted_JJ average_JJ exercise_NN price_NN Number_NN of_IN American_JJ Depositary_NNP Shares_NNP $_$ ADSs_JJ Outstanding_JJ as_IN at_IN beginning_NN of_IN period_NN Granted_VBN 37.80_CD 940,392_CD Exercised_VBN Forfeited_NNP 37.70_CD 3,000_CD Outstanding_JJ as_IN at_IN end_NN of_IN period_NN 37.80_CD 937,392_CD Exercisable_JJ as_IN at_IN end_NN of_IN period_NN 940,392_CD stock-settled_JJ share_NN appreciation_NN rights_NNS were_VBD granted_VBN over_IN American_JJ Depositary_NNP Shares_NNP equivalent_JJ to_TO 2,821,176_CD ordinary_JJ shares_NNS under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP A._NNP The_NNP 937,392_CD stock-settled_JJ share_NN appreciation_NN rights_NNS over_IN ADSs_NNS outstanding_JJ at_IN December_NNP 31_CD ,_, 2005_CD are_VBP equivalent_JJ to_TO 2,812,176_CD ordinary_JJ shares_NNS ._.
The_DT average_JJ fair_JJ value_NN of_IN options_NNS granted_VBN in_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD is_VBZ $_$ 14.92_CD ._.
126_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 127_CD Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN 31_CD Share-based_JJ compensation_NN plans_NNS continued_VBD Stock-settled_JJ share_NN appreciation_NN rights_NNS over_IN American_JJ Depositary_NNP Shares_NNP outstanding_JJ as_IN at_IN December_NNP 31_CD ,_, 2005_CD have_VBP the_DT following_VBG characteristics_NNS :_: Weighted_JJ Weighted_JJ average_NN exercise_NN average_JJ exercise_NN price_NN of_IN options_NNS Number_NN of_IN price_NN of_IN options_NNS Exercise_NN prices_NNS Weighted_VBN average_JJ outstanding_JJ options_NNS exercisable_JJ Number_NN of_IN options_NNS outstanding_JJ $_$ remaining_JJ life_NN $_$ exercisable_JJ $_$ 2,812,176_CD 35.01_CD 40.00_CD 4.9_CD 37.80_CD c_NN Performance_NNP share_NN plan_NN Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP Performance_NNP share_NN awards_NNS granted_VBN under_IN the_DT Portfolio_NNP Share_NNP Plan_NNP Part_NNP B_NNP are_VBP exercisable_JJ subject_NN to_TO certain_JJ performance_NN criteria_NNS ._.
For_IN one-third_NN of_IN an_DT award_NN ,_, the_DT comparator_NN group_NN will_MD be_VB the_DT Financial_NNP Times_NNP Stock_NNP Exchange_NNP 100_CD constituents_NNS excluding_VBG financial_JJ institutions_NNS and_CC for_IN two-thirds_NNS of_IN the_DT award_NN the_DT comparator_NN group_NN will_MD be_VB a_DT group_NN of_IN international_JJ companies_NNS from_IN the_DT pharmaceutical_JJ sector_NN ._.
In_IN addition_NN ,_, before_IN awards_NNS granted_VBN to_TO executive_JJ Directors_NNS will_MD vest_NN ,_, the_DT Committee_NNP must_MD be_VB satisfied_VBN 1_CD that_IN the_DT underlying_VBG performance_NN of_IN the_DT Company_NN is_VBZ sufficient_JJ to_TO justify_VB this_DT ._.
Where_WRB median_JJ performance_NN is_VBZ achieved_VBN ,_, 33_CD 3_CD %_NN of_IN stock-settled_JJ share_NN appreciation_NN rights_NNS will_MD vest_NN ,_, rising_VBG on_IN a_DT straight-line_JJ basis_NN to_TO full_JJ vesting_NN at_IN upper_JJ quartile_JJ performance_NN ._.
At_IN December_NNP 31_CD ,_, 2005_CD no_DT awards_NNS had_VBD been_VBN made_VBN ._.
32_CD Subsequent_JJ event_NN IDB_NNP loan_NN repayment_NN On_IN February_NNP 10_CD ,_, 2006_CD the_DT Company_NN received_VBD notice_NN from_IN IDB_NNP that_IN it_PRP intended_VBD to_TO repay_VB in_IN full_JJ all_DT drawings_NNS for_IN injectable_JJ flu_NN development_NN of_IN $_$ 70.6_CD million_CD ,_, together_RB with_IN accrued_VBN and_CC capitalized_VBN interest_NN of_IN $_$ 8.1_CD million_CD see_VBP Note_NN 6_CD ._.
The_DT Company_NN received_VBD the_DT $_$ 78.7_CD million_CD outstanding_JJ on_IN February_NNP 14_CD ,_, 2006_CD ._.
The_DT amounts_NNS outstanding_JJ in_IN respect_NN of_IN drawings_NNS for_IN pipeline_NN development_NN principal_JJ drawings_NNS of_IN $_$ 29.4_CD million_CD ,_, are_VBP unaffected_JJ by_IN this_DT repayment_NN ._.
Quarterly_JJ results_NNS of_IN operations_NNS unaudited_JJ The_DT following_VBG table_NN presents_NNS summarized_VBN unaudited_JJ quarterly_JJ results_NNS for_IN the_DT years_NNS to_TO December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD ._.
ii_FW During_IN Q3_NNP 2004_CD the_DT Company_NN recorded_VBD a_DT loss_NN on_IN redemption_NN of_IN the_DT convertible_JJ loan_NN notes_NNS of_IN $_$ 7.4_CD million_CD ,_, which_WDT resulted_VBD from_IN the_DT write-off_NN of_IN unamortized_JJ debt_NN issuance_NN costs_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 127_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 128_CD Five-year_JJ review_NN In_IN thousands_NNS of_IN US_NNP Dollars_NNPS ,_, except_IN where_WRB indicated_VBN Selected_VBN financial_JJ data_NNS The_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN below_IN as_RB at_IN December_NNP 31_CD ,_, 2005_CD and_CC 2004_CD and_CC for_IN each_DT of_IN the_DT three_CD years_NNS in_IN the_DT period_NN ended_VBD December_NNP 31_CD ,_, 2005_CD were_VBD derived_VBN from_IN the_DT audited_JJ consolidated_JJ financial_JJ statements_NNS of_IN the_DT Company_NN ,_, included_VBD herein_NN ._.
The_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN below_IN as_RB at_IN December_NNP 31_CD ,_, 2003_CD ,_, 2002_CD and_CC 2001_CD and_CC for_IN the_DT two_CD years_NNS to_TO December_NNP 31_CD ,_, 2002_CD were_VBD derived_VBN from_IN the_DT audited_JJ consolidated_JJ financial_JJ statements_NNS of_IN the_DT Company_NN ,_, which_WDT are_VBP not_RB included_VBN herein_NN ._.
Certain_JJ amounts_NNS reported_VBN in_IN previous_JJ years_NNS have_VBP been_VBN reclassified_VBN to_TO conform_VB to_TO the_DT 2005_CD presentation_NN ._.
These_DT were_VBD in_IN respect_NN of_IN the_DT implementation_NN of_IN the_DT new_JJ business_NN model_NN in_IN 2004_CD and_CC the_DT closure_NN of_IN Lead_JJ Optimization_NN together_RB with_IN the_DT exit_NN of_IN certain_JJ properties_NNS in_IN 2003_CD ._.
Included_VBN in_IN 2001_CD were_VBD $_$ 29.7_CD million_CD of_IN asset_NN impairment_NN charges_NNS ,_, $_$ 83.5_CD million_CD of_IN merger_NN transaction_NN expenses_NNS and_CC $_$ 10.2_CD million_CD of_IN costs_NNS in_IN relation_NN to_TO the_DT disposition_NN of_IN certain_JJ assets_NNS ._.
All_DT of_IN these_DT costs_NNS were_VBD in_IN relation_NN to_TO the_DT merger_NN with_IN BioChem_NNP in_IN 2001_CD ._.
ii_FW Total_JJ other_JJ income_NN expense_NN ,_, net_JJ includes_VBZ interest_NN receivable_NN and_CC payable_JJ ,_, the_DT gain_NN or_CC loss_NN on_IN the_DT sale_NN of_IN assets_NNS ,_, impairment_NN of_IN long-term_JJ investments_NNS and_CC transactional_JJ foreign_JJ exchange_NN ._.
In_IN 2005_CD it_PRP includes_VBZ $_$ 3.9_CD million_CD on_IN the_DT sale_NN of_IN a_DT portfolio_NN investment_NN and_CC $_$ 3.6_CD million_CD on_IN the_DT sale_NN of_IN the_DT drug_NN formulation_NN business_NN ._.
In_IN 2004_CD it_PRP includes_VBZ $_$ 14.9_CD million_CD on_IN the_DT sale_NN of_IN a_DT portfolio_NN investment_NN ._.
See_VB Note_VB 26_CD to_TO the_DT consolidated_JJ financial_JJ statements_NNS in_IN this_DT Form_NN 10-K_NN ._.
In_IN 2001_CD there_EX was_VBD a_DT $_$ 55.7_CD million_CD write-down_NN of_IN investments_NNS related_VBN to_TO the_DT BioChem_NNP merger_NN ._.
iii_FW As_IN a_DT consequence_NN of_IN the_DT adoption_NN of_IN SFAS_NNP No._NN ._.
142_CD with_IN effect_NN from_IN January_NNP 1_CD ,_, 2002_CD ,_, the_DT amortization_NN expense_NN included_VBD in_IN 2001_CD in_IN the_DT selected_VBN consolidated_JJ financial_JJ data_NNS presented_VBN is_VBZ not_RB on_IN a_DT consistent_JJ basis_NN of_IN accounting_NN with_IN subsequent_JJ periods_NNS ._.
Net_JJ income_NN for_IN 2001_CD would_MD have_VB been_VBN $_$ 49.5_CD million_CD if_IN goodwill_NN had_VBD not_RB been_VBN amortized_VBN ._.
128_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 129_CD Statement_NN of_IN Directors_NNS responsibilities_NNS Directors_NNS responsibilities_NNS The_DT Directors_NNS are_VBP responsible_JJ for_IN keeping_VBG proper_JJ accounting_NN records_NNS The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT Annual_JJ Report_NNP and_CC the_DT which_WDT disclose_VBP with_IN reasonable_JJ accuracy_NN at_IN any_DT time_NN the_DT financial_JJ financial_JJ statements_NNS ._.
The_DT Directors_NNS have_VBP chosen_VBN to_TO prepare_VB accounts_NNS position_NN of_IN the_DT Company_NN ,_, for_IN safeguarding_VBG the_DT assets_NNS ,_, for_IN taking_VBG for_IN the_DT Group_NNP in_IN accordance_NN with_IN International_NNP Financial_NNP Reporting_NNP reasonable_JJ steps_NNS for_IN the_DT prevention_NN and_CC detection_NN of_IN fraud_NN and_CC other_JJ Standards_NNPS IFRS_NNP and_CC for_IN the_DT Company_NN in_IN accordance_NN with_IN United_NNP irregularities_NNS and_CC for_IN the_DT preparation_NN of_IN a_DT Directors_NNS Report_NNP and_CC Kingdom_NNP Generally_RB Accepted_JJ Accounting_NN Practice_NN UK_NNP GAAP_NNP ._.
Directors_NNS Remuneration_NNP Report_NNP which_WDT comply_VBP with_IN the_DT requirements_NNS of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
In_IN the_DT case_NN of_IN UK_NNP GAAP_NNP accounts_NNS ,_, the_DT Directors_NNS are_VBP required_VBN to_TO prepare_VB financial_JJ statements_NNS for_IN each_DT financial_JJ year_NN which_WDT give_VBP a_DT true_JJ and_CC fair_JJ The_DT Directors_NNS are_VBP responsible_JJ for_IN the_DT maintenance_NN and_CC integrity_NN of_IN the_DT view_NN of_IN the_DT state_NN of_IN affairs_NNS of_IN the_DT Company_NN and_CC of_IN the_DT profit_NN or_CC loss_NN Company_NN website_NN ._.
Legislation_NN in_IN the_DT United_NNP Kingdom_NNP governing_VBG the_DT of_IN the_DT Company_NN for_IN that_DT period_NN ._.
In_IN preparing_VBG these_DT financial_JJ statements_NNS ,_, preparation_NN and_CC dissemination_NN of_IN financial_JJ statements_NNS differs_VBZ from_IN the_DT Directors_NNS are_VBP required_VBN to_TO :_: legislation_NN in_IN other_JJ jurisdictions_NNS ._.
select_JJ suitable_JJ accounting_NN policies_NNS and_CC then_RB apply_VB them_PRP consistently_RB :_: make_VB judgments_NNS and_CC estimates_NNS that_WDT are_VBP reasonable_JJ and_CC prudent_JJ :_: and_CC state_NN whether_IN applicable_JJ accounting_NN standards_NNS have_VBP been_VBN followed_VBN ._.
In_IN the_DT case_NN of_IN IFRS_NNP accounts_NNS ,_, International_NNP Accounting_NNP Standard_NNP 1_CD requires_VBZ that_IN financial_JJ statements_NNS present_JJ fairly_RB for_IN each_DT financial_JJ year_NN the_DT Companys_NNPS financial_JJ position_NN ,_, financial_JJ performance_NN and_CC cash_NN flows_NNS ._.
This_DT requires_VBZ the_DT faithful_JJ representation_NN of_IN the_DT effects_NNS of_IN transactions_NNS ,_, other_JJ events_NNS and_CC conditions_NNS in_IN accordance_NN with_IN the_DT definitions_NNS and_CC recognition_NN criteria_NNS for_IN assets_NNS ,_, liabilities_NNS ,_, income_NN and_CC expenses_NNS set_VBN out_RP in_IN the_DT International_NNP Accounting_NNP Standards_NNP Boards_NNP Framework_NNP for_IN the_DT preparation_NN and_CC Presentation_NN of_IN Financial_NNP Statements_NNP ._.
In_IN virtually_RB all_DT circumstances_NNS ,_, a_DT fair_JJ presentation_NN will_MD be_VB achieved_VBN by_IN compliance_NN with_IN all_DT applicable_JJ International_NNP Financial_NNP Reporting_NNP Standards_NNPS ._.
Directors_NNS are_VBP also_RB required_VBN to_TO :_: properly_RB select_JJ and_CC apply_VB accounting_NN policies_NNS :_: present_JJ information_NN ,_, including_VBG accounting_NN policies_NNS ,_, in_IN a_DT manner_NN that_WDT provides_VBZ relevant_JJ ,_, reliable_JJ ,_, comparable_JJ and_CC understandable_JJ information_NN :_: and_CC provide_VB additional_JJ disclosures_NNS when_WRB compliance_NN with_IN the_DT specific_JJ requirements_NNS in_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS is_VBZ insufficient_JJ to_TO enable_VB users_NNS to_TO understand_VB the_DT impact_NN of_IN particular_JJ transactions_NNS ,_, other_JJ events_NNS and_CC conditions_NNS on_IN the_DT entitys_NNS financial_JJ position_NN and_CC financial_JJ performance_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 129_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 130_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD General_NNP Business_NNP review_NN The_DT summary_NN financial_JJ statement_NN does_VBZ not_RB contain_VB sufficient_JJ A_DT review_NN of_IN the_DT Groups_NNS business_NN and_CC important_JJ events_NNS during_IN the_DT information_NN to_TO allow_VB for_IN as_RB full_JJ an_DT understanding_NN of_IN the_DT results_NNS year_NN and_CC likely_JJ future_NN developments_NNS is_VBZ set_VBN out_RP in_IN the_DT Chairmans_NNPS and_CC state_NN of_IN affairs_NNS of_IN the_DT Company_NN or_CC Group_NNP and_CC of_IN the_DT policies_NNS statement_NN ,_, the_DT Chief_NNP Executive_NNP Officers_NNPS review_NN ,_, the_DT financial_JJ review_NN and_CC arrangements_NNS concerning_VBG Directors_NNS remuneration_NN ,_, as_RB would_MD and_CC the_DT Directors_NNS remuneration_NN report_NN in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ be_VB provided_VBN by_IN the_DT full_JJ annual_JJ financial_JJ statements_NNS and_CC reports_NNS ._.
accounts_NNS ,_, which_WDT are_VBP similar_JJ to_TO the_DT statements_NNS contained_VBN in_IN the_DT annual_JJ The_DT summary_NN financial_JJ statement_NN is_VBZ prepared_VBN in_IN accordance_NN with_IN review_NN at_IN the_DT front_NN of_IN this_DT document_NN which_WDT form_VBP part_NN of_IN this_DT summary_NN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP ._.
information_NN ,_, the_DT full_JJ UK_NNP statutory_JJ accounts_NNS ,_, the_DT auditors_NNS report_VBP on_IN those_DT accounts_NNS and_CC the_DT Directors_NNS report_NN should_MD be_VB consulted_VBN ._.
Details_NNS of_IN post_NN balance_NN sheet_NN events_NNS are_VBP contained_VBN within_IN the_DT Notes_NNS to_TO the_DT consolidated_JJ financial_JJ statements_NNS ._.
In_IN accordance_NN with_IN Section_NN 239_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD shareholders_NNS have_VBP a_DT right_NN and_CC can_MD elect_VB to_TO obtain_VB the_DT full_JJ report_NN Directors_NNS and_CC accounts_NNS free_JJ of_IN charge_NN by_IN writing_VBG to_TO :_: The_DT Directors_NNS who_WP served_VBD during_IN the_DT year_NN were_VBD as_IN follows_VBZ :_: The_DT Company_NNP Secretary_NNP Dr_NNP James_NNP Cavanaugh_NNP Shire_NNP plc_NNP Chairman_NNP ,_, Non-executive_JJ Director_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP and_CC Chairman_NNP of_IN the_DT Nomination_NNP Committee_NNP Chineham_NNP Basingstoke_NNP Mr_NNP Matthew_NNP Emmens_NNP Hampshire_NNP Chief_NNP Executive_NNP Officer_NNP RG24_NNP 8EP_NNP Mr_NNP Angus_NNP Russell_NNP The_NNP full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS are_VBP signed_VBN on_IN behalf_NN Chief_NNP Financial_NNP Officer_NNP of_IN the_DT Board_NNP by_IN AC_NNP Russell_NNP ,_, Chief_NNP Financial_NNP Officer_NNP ._.
Dr_NNP Barry_NNP Price_NNP The_NNP Companys_NNP auditors_NNS have_VBP given_VBN an_DT unqualified_JJ report_NN on_IN the_DT Senior_JJ Non-executive_JJ Director_NNP statutory_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ._.
and_CC Chairman_NNP of_IN the_DT Remuneration_NNP Committee_NNP The_NNP report_NN did_VBD not_RB contain_VB any_DT statement_NN under_IN Section_NN 237_CD 2_CD or_CC 3_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
The_DT Hon_NNP James_NNP Grant_NNP Non-executive_JJ Director_NNP Summary_NNP Directors_NNS report_VBP Results_NNS and_CC dividends_NNS Mr_NNP Ronald_NNP Nordmann_NNP For_IN the_DT year_NN to_TO 31_CD December_NNP 2005_CD ,_, the_DT Companys_NNP total_NN revenues_NNS Non-executive_JJ Director_NNP increased_VBN by_IN 17_CD %_NN to_TO $_$ 1,599.3_CD million_CD ,_, compared_VBN to_TO $_$ 1,363.2_CD million_CD in_IN 2004_CD ._.
Net_JJ loss_NN for_IN the_DT year_NN to_TO 31_CD December_NNP 2005_CD was_VBD $_$ 177.4_CD million_CD Mr_NNP Robin_NNP Buchanan_NNP compared_VBD to_TO net_JJ income_NN of_IN $_$ 96.5_CD million_CD in_IN 2004_CD ._.
The_DT results_NNS for_IN Non-executive_JJ Director_NNP 2005_CD include_VBP a_DT $_$ 527_CD million_CD impairment_NN of_IN the_DT goodwill_NN that_WDT arose_VBD on_IN the_DT acquisition_NN of_IN BioChem_NNP Pharma_NNP Inc._NNP 2004_CD :_: $_$ 132.6_CD million_CD Mr_NNP David_NNP Kappler_NNP impairment_NN recorded_VBN ._.
Non-executive_JJ Director_NNP and_CC Chairman_NNP of_IN the_DT Audit_NNP Committee_NNP The_DT net_JJ assets_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2005_CD were_VBD $_$ 4,083.1_CD million_CD 2004_CD :_: $_$ 4,244.9_CD million_CD ._.
Mr_NNP Patrick_NNP Langlois_NNP Non-executive_JJ Director_NNP In_IN respect_NN of_IN the_DT six_CD months_NNS to_TO 31_CD December_NNP 2005_CD the_DT Board_NNP appointed_VBN 11_CD November_NNP 2005_CD resolved_VBN to_TO pay_VB a_DT second_JJ interim_JJ dividend_NN of_IN 4.419_CD per_IN ordinary_JJ share_NN 2004_CD :_: 3.85_CD US_NNP per_IN share_NN ._.
Together_RB with_IN the_DT first_JJ interim_JJ payment_NN of_IN 1.8246_CD US_NNP per_IN ordinary_JJ share_NN ,_, 2004_CD :_: 1.82_CD per_IN share_NN ,_, this_DT represents_VBZ total_JJ dividends_NNS for_IN 2005_CD of_IN 6.2436_CD per_IN ordinary_JJ share_NN 2004_CD :_: 5.67_CD per_IN share_NN ._.
This_DT is_VBZ consistent_JJ with_IN Shires_NNP stated_VBD policy_NN of_IN paying_VBG a_DT dividend_NN Tatjana_NNP May_NNP semi-annually_RB ,_, set_VBN in_IN US_NNP per_IN share_NN ADS_NNPS ,_, with_IN the_DT first_JJ interim_JJ Company_NN Secretary_NNP payment_NN in_IN each_DT year_NN being_VBG maintained_VBN at_IN a_DT consistent_JJ level_NN ._.
Any_DT 22_CD March_NNP 2006_CD growth_NN will_MD come_VB through_IN increasing_VBG the_DT second_JJ interim_JJ dividend_NN in_IN a_DT financial_JJ year_NN ._.
130_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 131_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Independent_NNP Auditors_NNS Statement_NN to_TO the_DT Members_NNS of_IN Shire_NNP plc_NN :_: Basis_NN of_IN opinion_NN We_PRP have_VBP examined_VBN the_DT summary_NN financial_JJ statement_NN which_WDT comprises_VBZ We_PRP conducted_VBD our_PRP$ work_NN in_IN accordance_NN with_IN bulletin_NN 1999_CD 6_CD the_DT summary_NN Directors_NNS report_NN ,_, consolidated_JJ income_NN statement_NN ,_, The_DT Auditors_NNS Statement_NN on_IN the_DT Summary_NNP Financial_NNP Statement_NNP issued_VBD consolidated_JJ statement_NN of_IN recognized_VBN income_NN and_CC expense_NN ,_, by_IN the_DT Auditing_NNP Practices_NNPS Board_NNP for_IN use_NN in_IN the_DT United_NNP Kingdom_NNP ._.
consolidated_JJ balance_NN sheet_NN ,_, consolidated_JJ cash_NN flow_NN statement_NN and_CC Notes_NNS 14_CD of_IN the_DT summary_NN financial_JJ statement_NN ._.
Opinion_NN In_IN our_PRP$ opinion_NN ,_, the_DT summary_NN financial_JJ statement_NN is_VBZ consistent_JJ with_IN This_DT report_NN is_VBZ made_VBN solely_RB to_TO the_DT Companys_NNPS members_NNS ,_, as_IN a_DT body_NN ,_, in_IN the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS accordance_NN with_IN section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ._.
Our_PRP$ work_NN has_VBZ remuneration_VBN report_NN of_IN Shire_NNP plc_NN for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD been_VBN undertaken_VBN so_RB that_IN we_PRP might_MD state_VB to_TO the_DT Companys_NNPS members_NNS and_CC complies_NNS with_IN the_DT applicable_JJ requirements_NNS of_IN Section_NN 251_CD those_DT matters_NNS we_PRP are_VBP required_VBN to_TO state_NN to_TO them_PRP in_IN an_DT auditors_NNS report_NN and_CC of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
To_TO the_DT fullest_JJS extent_NN permitted_VBN by_IN law_NN ,_, we_PRP do_VBP not_RB The_DT auditors_NNS report_VBP on_IN the_DT Groups_NNS annual_JJ accounts_NNS was_VBD unqualified_JJ ._.
accept_VB or_CC assume_VB responsibility_NN to_TO anyone_NN other_JJ than_IN the_DT Company_NN and_CC the_DT Companys_NNPS members_NNS as_IN a_DT body_NN ,_, for_IN our_PRP$ audit_NN work_NN ,_, for_IN this_DT report_NN ,_, Deloitte_NNP &_CC Touche_NNP LLP_NNP or_CC for_IN the_DT opinions_NNS we_PRP have_VBP formed_VBN ._.
Chartered_NNP Accountants_NNPS and_CC Registered_NNP Auditors_NNS Reading_VBG ,_, UK_NNP Respective_NNP responsibilities_NNS of_IN Directors_NNS and_CC auditors_NNS 22_CD March_NNP 2006_CD The_DT Directors_NNS are_VBP responsible_JJ for_IN preparing_VBG the_DT annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN in_IN accordance_NN with_IN applicable_JJ law_NN ._.
Our_PRP$ responsibility_NN is_VBZ to_TO report_VB to_TO you_PRP our_PRP$ opinion_NN on_IN the_DT consistency_NN of_IN the_DT summary_NN financial_JJ statement_NN with_IN the_DT full_JJ annual_JJ accounts_NNS ,_, the_DT Directors_NNS report_NN and_CC the_DT Directors_NNS remuneration_NN report_NN ,_, and_CC its_PRP$ compliance_NN with_IN the_DT relevant_JJ requirements_NNS of_IN Section_NN 251_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD and_CC the_DT regulations_NNS made_VBD thereunder_RB ._.
We_PRP report_VBP whether_IN the_DT auditors_NNS opinion_NN on_IN the_DT full_JJ annual_JJ accounts_NNS was_VBD unqualified_JJ or_CC qualified_VBN ._.
We_PRP also_RB read_VBD the_DT other_JJ information_NN contained_VBN in_IN the_DT annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN as_IN described_VBN in_IN the_DT contents_NNS section_NN ,_, and_CC consider_VB the_DT implications_NNS for_IN our_PRP$ report_NN if_IN we_PRP become_VBP aware_JJ of_IN any_DT apparent_JJ misstatements_NNS or_CC material_NN inconsistencies_NNS with_IN the_DT summary_NN financial_JJ statement_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 131_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 132_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Consolidated_NNP income_NN statement_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Continuing_VBG operations_NNS :_: Revenue_NN 1,599,316_CD 1,363,207_CD Cost_NN of_IN sales_NNS 215,336_CD 142,557_CD Gross_NNP profit_NN 1,383,980_CD 1,220,650_CD Research_NNP and_CC development_NN 287,146_CD 210,974_CD Selling_NNP ,_, general_JJ and_CC administrative_JJ including_VBG $_$ 526,956,000_CD 2004_CD :_: $_$ 132,576,000_CD goodwill_NN impairment_NN 1,255,707_CD 718,890_CD Operating_NN loss_NN profit_NN 158,873_CD 290,786_CD Investment_NN revenues_NNS 35,300_CD 21,901_CD Finance_NNP costs_NNS 17,420_CD 14,771_CD Share_NN of_IN post_NN tax_NN loss_NN profit_NN from_IN associates_NNS and_CC joint_JJ ventures_NNS 1,000_CD 4,508_CD Loss_NN profit_NN before_IN tax_NN 141,993_CD 302,424_CD Taxation_NNP 38,510_CD 141,623_CD Loss_NN profit_NN for_IN the_DT year_NN from_IN continuing_VBG operations_NNS 180,503_CD 160,801_CD Discontinued_VBN operations_NNS :_: Profit_NN loss_NN for_IN the_DT year_NN from_IN discontinued_VBN operations_NNS 3,125_CD 64,292_CD Loss_NN profit_NN for_IN the_DT year_NN 177,378_CD 96,509_CD Loss_NN earnings_NNS per_IN share_NN expressed_VBN in_IN per_IN share_NN basic_JJ 35.5_CD 19.4_CD diluted_VBN 35.5_CD 19.3_CD Loss_NN earnings_NNS per_IN share_NN from_IN continuing_VBG operations_NNS expressed_VBN in_IN per_IN share_NN basic_JJ 36.1_CD 32.4_CD diluted_VBN 36.1_CD 32.2_CD Consolidated_NNP statement_NN of_IN recognized_VBN income_NN and_CC expense_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Loss_NN profit_NN for_IN the_DT year_NN 177,378_CD 96,509_CD Exchange_NNP differences_NNS on_IN translation_NN of_IN foreign_JJ operations_NNS 28,855_CD 34,066_CD Unrealised_JJ holding_VBG gain_NN on_IN available-for-sale_JJ securities_NNS 9,226_CD Net_JJ loss_NN gain_NN recognized_VBD directly_RB to_TO equity_NN 19,629_CD 34,066_CD Total_JJ recognized_VBN expense_NN income_NN for_IN the_DT year_NN 197,007_CD 130,575_CD 132_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 133_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Consolidated_NNP balance_NN sheet_NN December_NNP 31_CD ,_, December_NNP 31_CD ,_, 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Assets_NNPS Non-current_JJ assets_NNS Goodwill_NNP 2,209,460_CD 2,246,220_CD Other_JJ intangible_JJ assets_NNS 1,394,677_CD 322,258_CD Property_NN ,_, plant_NN and_CC equipment_NN 218,199_CD 128,202_CD Deferred_JJ tax_NN assets_NNS 67,283_CD 85,041_CD Investments_NNP accounted_VBD for_IN using_VBG equity_NN method_NN 23,023_CD 30,848_CD Available-for-sale_JJ investments_NNS 27,139_CD 76,550_CD Other_JJ receivables_NN 42,907_CD 38,895_CD 3,982,688_CD 2,928,014_CD Current_JJ assets_NNS Inventories_NNS 136,057_CD 41,230_CD Trade_NNP and_CC other_JJ receivables_NN 387,206_CD 299,817_CD Current_JJ tax_NN assets_NNS 27,983_CD Trading_NN investments_NNS 6,947_CD 324,845_CD Cash_NN and_CC cash_NN equivalents_NNS 656,456_CD 1,111,477_CD Restricted_VBN cash_NN 30,568_CD 21,627_CD 1,245,217_CD 1,798,996_CD Total_JJ assets_NNS 5,227,905_CD 4,727,010_CD Liabilities_NNS and_CC shareholders_NNS equity_NN Non-current_JJ liabilities_NNS Borrowings_NNS 4,704_CD 4,242_CD Trade_NNP and_CC other_JJ payables_NNS 18,036_CD 12,963_CD Deferred_JJ tax_NN liabilities_NNS 127,691_CD Long-term_JJ provisions_NNS 25,401_CD 26,232_CD 175,832_CD 43,437_CD Current_JJ liabilities_NNS Borrowings_NNS 2,667_CD 2,420_CD Trade_NNP and_CC other_JJ payables_NNS 435,725_CD 344,367_CD Liability_NN to_TO dissenting_VBG shareholders_NNS 427,609_CD Current_JJ tax_NN liabilities_NNS 94,416_CD 46,757_CD Provisions_NNS 8,523_CD 45,097_CD 968,940_CD 438,641_CD Total_JJ liabilities_NNS 1,144,772_CD 482,078_CD Shareholders_NNS equity_NN Share_NN capital_NN 42,728_CD 36,083_CD Share_NN premium_NN 2,977_CD 4,883,219_CD Treasury_NNP shares_NNS 2,813_CD 264_CD Exchangeable_JJ shares_NNS 101,248_CD 195,830_CD Capital_NN reduction_NN reserve_NN 2,946,490_CD Capital_NNP reserve_NN 4,729_CD Other_JJ reserve_NN 2,099,652_CD 36,121_CD Retained_VBN earnings_NNS 1,107,149_CD 910,786_CD Total_JJ shareholders_NNS equity_NN 4,083,133_CD 4,244,932_CD Total_JJ liabilities_NNS and_CC shareholders_NNS equity_NN 5,227,905_CD 4,727,010_CD The_DT summary_NN financial_JJ statement_NN was_VBD approved_VBN by_IN the_DT Board_NNP of_IN Directors_NNS and_CC authorised_VBN for_IN issue_NN on_IN 22_CD March_NNP 2006_CD and_CC signed_VBN on_IN its_PRP$ behalf_NN by_IN :_: A_DT Russell_NNP Director_NNP Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 133_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 134_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Consolidated_NNP cash_NN flow_NN statement_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Net_JJ cash_NN flows_VBZ from_IN operating_VBG activities_NNS 401,187_CD 465,762_CD Cash_NN flow_NN from_IN investing_VBG activities_NNS Movement_NNP in_IN restricted_JJ cash_NN 768_CD 24,847_CD Purchase_NN of_IN subsidiary_NN undertaking_NN ,_, net_NN of_IN cash_NN and_CC cash_NN equivalents_NNS 1,114,048_CD Expense_NN of_IN acquisitions_NNS 37,491_CD Loan_NN made_VBN to_TO ID_NNP Biomedical_NNP Corporation_NNP IDB_NNP 43,162_CD 56,838_CD Purchase_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 71,946_CD 49,746_CD Purchase_NN of_IN intangible_JJ assets_NNS 92,139_CD 42,293_CD Purchases_NNS of_IN financial_JJ assets_NNS 7,700_CD 6,124_CD Net_JJ decrease_NN increase_NN in_IN current_JJ financial_JJ assets_NNS 366,731_CD 20,282_CD Proceeds_NNS from_IN sale_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN PP&E_NNP 1,169_CD 4,360_CD Proceeds_NNS from_IN sale_NN of_IN intangible_JJ assets_NNS 3,701_CD Proceeds_NNS from_IN sale_NN of_IN financial_JJ assets_NNS 10,135_CD 26,733_CD Proceeds_NNS from_IN PP&E_NNP held_VBD for_IN sale_NN 11,289_CD Proceeds_NNS from_IN sale_NN of_IN drug_NN formulation_NN business_NN 557_CD Proceeds_NNS from_IN sale_NN of_IN discontinued_VBN business_NN 92,236_CD 34,912_CD Interest_NN received_VBD 34,203_CD 21,901_CD Dividend_NN received_VBN from_IN associates_NNS 3,774_CD 1,450_CD Dividend_NN from_IN joint_JJ venture_NN 4,710_CD 4,043_CD Investing_VBG activities_NNS of_IN discontinued_VBN business_NN 12,715_CD Net_JJ cash_NN used_VBN in_IN investing_VBG activities_NNS 853,739_CD 54,762_CD Cash_NN flows_VBZ from_IN financing_VBG activities_NNS Proceeds_NNS from_IN issuance_NN of_IN ordinary_JJ shares_NNS ,_, net_JJ 771_CD Proceeds_NNS from_IN exercise_NN of_IN share_NN options_NNS 37,113_CD 13,416_CD Purchase_NN of_IN treasury_NN shares_NNS 2,480_CD 264_CD Redemption_NN of_IN 2_CD %_NN guaranteed_VBN convertible_JJ loan_NN notes_NNS 2011_CD 370,109_CD Movement_NNP in_IN finance_NN lease_NN obligations_NNS 708_CD 5,351_CD Dividends_NNPS paid_VBD 28,460_CD 8,905_CD Net_JJ cash_NN from_IN used_VBN in_IN financing_NN activities_NNS 6,881_CD 370,442_CD Net_JJ decrease_NN increase_NN in_IN cash_NN and_CC cash_NN equivalents_NNS 445,671_CD 40,558_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN beginning_NN of_IN year_NN 1,111,477_CD 1,063,362_CD Effect_NN of_IN foreign_JJ currency_NN translation_NN 9,350_CD 7,557_CD Cash_NN and_CC cash_NN equivalents_NNS at_IN end_NN of_IN year_NN 656,456_CD 1,111,477_CD 134_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 135_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD 1_CD Basis_NN of_IN preparation_NN The_DT summary_NN financial_JJ statement_NN has_VBZ been_VBN prepared_VBN under_IN IFRS_NNP in_IN accordance_NN with_IN the_DT accounting_NN policies_NNS set_VBN out_RP in_IN the_DT full_JJ UK_NNP statutory_JJ annual_JJ accounts_NNS for_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD ._.
2_CD Directors_NNS remuneration_JJ Executive_NNP remuneration_NN policy_NN The_DT Remuneration_NNP Committee_NNP considers_VBZ that_IN an_DT effective_JJ remuneration_NN policy_NN ,_, aligned_VBN to_TO the_DT Companys_NNPS business_NN needs_NNS ,_, is_VBZ important_JJ to_TO the_DT Companys_NNPS success_NN ._.
It_PRP directly_RB impacts_VBZ the_DT Companys_NNP ability_NN to_TO recruit_VB ,_, retain_VB and_CC motivate_VB high_JJ calibre_NN executives_NNS who_WP deliver_VBP sustained_VBN value_NN to_TO shareholders_NNS and_CC build_VB the_DT Company_NN for_IN long-term_JJ success_NN ._.
The_DT Remuneration_NNP Committee_NNP is_VBZ responsible_JJ for_IN developing_VBG ,_, reviewing_VBG and_CC overseeing_VBG the_DT implementation_NN of_IN the_DT Companys_NNP compensation_NN and_CC benefits_NNS policy_NN ._.
The_DT Remuneration_NNP Committee_NNP regularly_RB monitors_VBZ the_DT effectiveness_NN of_IN the_DT policy_NN and_CC reviews_VBZ this_DT policy_NN based_VBN on_IN independent_JJ analysis_NN and_CC advice_NN ,_, an_DT understanding_NN of_IN the_DT business_NN drivers_NNS and_CC competitive_JJ environment_NN in_IN which_WDT the_DT Company_NN operates_VBZ and_CC ongoing_JJ dialogue_NN with_IN shareholders_NNS ._.
The_DT Companys_NNP executive_NN compensation_NN and_CC benefits_NNS policy_NN is_VBZ based_VBN on_IN the_DT following_VBG principles_NNS :_: base_NN pay_NN is_VBZ market_NN driven_VBN utilising_VBG a_DT blended_JJ US_NNP UK_NNP market_NN comparison_NN ,_, and_CC is_VBZ targeted_VBN at_IN or_CC around_IN the_DT median_NN relative_JJ to_TO the_DT comparison_NN :_: the_DT Annual_JJ Incentive_NNP Plan_NNP is_VBZ performance-based_JJ and_CC is_VBZ linked_VBN to_TO the_DT achievement_NN of_IN an_DT appropriate_JJ mix_NN of_IN corporate_JJ and_CC individual_JJ performance_NN targets_NNS ._.
The_DT Annual_JJ Incentive_NNP Plan_NNP allows_VBZ the_DT Company_NN to_TO measure_VB and_CC reward_VB progress_NN against_IN its_PRP$ strategic_JJ goals_NNS and_CC is_VBZ closely_RB tied_VBN to_TO delivery_NN of_IN sustained_JJ shareholder_NN value_NN :_: share-based_JJ compensation_NN is_VBZ a_DT key_JJ element_NN of_IN the_DT Companys_NNP remuneration_NN policy_NN as_IN it_PRP aligns_VBZ the_DT interests_NNS of_IN the_DT Companys_NNPS executives_NNS with_IN the_DT interests_NNS of_IN its_PRP$ shareholders_NNS ._.
This_DT element_NN of_IN compensation_NN also_RB utilises_VBZ a_DT blended_JJ US_NNP UK_NNP market_NN comparison_NN to_TO determine_VB face_NN value_NN of_IN awards_NNS to_TO executive_JJ Directors_NNS :_: benefits_NNS programs_NNS are_VBP locally_RB competitive_JJ and_CC provide_VB for_IN the_DT welfare_NN and_CC well-being_NN of_IN our_PRP$ employees_NNS and_CC their_PRP$ families_NNS :_: the_DT Committee_NNP currently_RB aims_VBZ for_IN variable_JJ compensation_NN to_TO represent_VB over_IN two-thirds_NNS of_IN total_JJ remuneration_NN :_: and_CC the_DT Committee_NNP believes_VBZ that_IN executive_NN Directors_NNS should_MD be_VB encouraged_VBN to_TO own_VB shares_NNS in_IN the_DT Company_NN in_IN order_NN to_TO ensure_VB the_DT alignment_NN of_IN their_PRP$ interests_NNS with_IN those_DT of_IN the_DT Companys_NNP shareholders_NNS ._.
Share_NN ownership_NN guidelines_NNS became_VBD effective_JJ in_IN 2006_CD ._.
Aggregate_NNP Directors_NNS remuneration_VBP The_DT total_JJ amounts_NNS for_IN Directors_NNS remuneration_NN and_CC other_JJ benefits_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Emoluments_NNP 4,289_CD 4,751_CD Post-employment_NN benefits_NNS 488_CD 450_CD Amounts_NNS receivable_JJ under_IN long-term_JJ incentive_NN schemes_NNS 159_CD Termination_NN benefits_NNS 1,172_CD Gains_NNS on_IN exercise_NN of_IN share_NN options_NNS 194_CD 216_CD 4,971_CD 6,748_CD The_DT numbers_NNS of_IN Directors_NNS who_WP were_VBD members_NNS of_IN Group_NNP retirement_NN schemes_NNS were_VBD as_IN follows_VBZ :_: 2005_CD 2004_CD Number_NNP Number_NNP Defined_NNP contribution_NN schemes_NNS 2_CD 3_CD Defined_VBN benefit_NN scheme_NN SERP_NNP 1_CD 1_CD The_DT above_JJ amounts_NNS for_IN remuneration_NN include_VBP the_DT following_VBG in_IN respect_NN of_IN the_DT highest-paid_JJ Director_NNP :_: 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD Aggregate_JJ emoluments_NNS 2,286_CD 2,601_CD Pension_NN contributions_NNS 323_CD 227_CD 2,609_CD 2,828_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 135_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 136_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Directors_NNS emoluments_VBZ Cash_NNP Non-cash_JJ benefits_NNS benefits_NNS Total_JJ Total_JJ Salary_NNP Incentive_NNP Fees_NNS in_IN kind_NN in_IN kind_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD $_$ 000_CD Executive_NNP i_FW v_FW Mr_NNP Matthew_NNP Emmens_NNP 1,049_CD 1,208_CD 29_CD 2,286_CD 2,601_CD ii_FW Mr_NNP Angus_NNP Russell_NNP 652_CD 415_CD 26_CD 10_CD 1,103_CD 1,126_CD ii_FW vi_FW Dr_FW Wilson_NNP Totten_NNP 469_CD Total_NNP Executive_NNP 1,701_CD 1,623_CD 55_CD 10_CD 3,389_CD 4,196_CD Non-executive_JJ i_FW Dr_FW James_NNP Cavanaugh_NNP 364 364 137_CD iii_FW Dr_FW Barry_NNP Price_NNP 132 132 110_CD i_FW The_DT Hon_NNP James_NNP Grant_NNP 82_CD 82_CD 73_CD i_FW Mr_NNP Ronald_NNP Nordmann_NNP 114_CD 114_CD 99_CD iii_NN Mr_NNP Robin_NNP Buchanan_NNP 87_CD 87_CD 73_CD iii_NN Mr_NNP David_NNP Kappler_NNP 109_CD 109_CD 63_CD iv_NN vii_FW Mr_NNP Patrick_NNP Langlois_NNP 12_CD 12_CD Total_JJ Non-executive_JJ 900 900 555_CD Total_JJ 1,701_CD 1,623_CD 900_CD 55_CD 10_CD 4,289_CD 4,751_CD Notes_NNP i_FW Paid_NNP in_IN $_$ ._.
v_FW The_DT Company_NN underwent_VBD a_DT major_JJ internal_JJ reorganisation_NN in_IN 2004_CD ,_, which_WDT resulted_VBD in_IN the_DT Company_NN selecting_VBG Philadelphia_NNP as_IN its_PRP$ US_NNP corporate_JJ headquarters_NNS ._.
vi_FW Dr_FW Totten_FW stepped_VBD down_RP as_IN a_DT Director_NNP of_IN the_DT Company_NN on_IN 25_CD May_NNP 2004_CD ._.
vii_FW Mr_NNP Langlois_NNP was_VBD appointed_VBN a_DT Non-executive_JJ Director_NNP on_IN 11_CD November_NNP 2005_CD ._.
136_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 137_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Performance_NNP graph_NN The_DT graphs_NNS shown_VBN set_VBN out_RP the_DT Total_JJ Shareholder_NN Return_NN TSR_NNP for_IN the_DT three_CD and_CC five_CD years_NNS ending_VBG 31_CD December_NNP 2005_CD ._.
The_DT graphs_NNS compare_VBP the_DT performance_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN of_IN the_DT Companys_NNP shares_NNS with_IN that_DT of_IN a_DT holding_NN of_IN shares_NNS in_IN the_DT FTSE_NNP 100_CD index_NN excluding_VBG financial_JJ institutions_NNS and_CC with_IN a_DT holding_NN in_IN a_DT group_NN comprised_VBD of_IN the_DT following_VBG pharma_NN companies_NNS :_: Novo_NNP Nordisk_NNP ,_, Schering_NNP AG_NNP ,_, Serono_NNP ,_, Altana_NNP ,_, UCB_NNP ,_, Lundbeck_NNP ,_, Forest_NNP Labs_NNPS ,_, Allergan_NNP ,_, Sepracor_NNP ,_, Cephalon_NNP ,_, Watson_NNP ,_, Biovail_NNP ,_, King_NNP ,_, Valeant_NNP ,_, Medicis_NNP and_CC Kos_NNP ._.
This_DT comparator_NN group_NN is_VBZ a_DT blend_VB of_IN US_NNP and_CC UK_NNP companies_NNS with_IN sector_NN ,_, size_NN ,_, complexity_NN and_CC international_JJ characteristics_NNS similar_JJ to_TO those_DT of_IN the_DT Company_NN ._.
These_DT comparisons_NNS will_MD also_RB be_VB used_VBN to_TO determine_VB achievement_NN of_IN performance_NN conditions_NNS relating_VBG to_TO the_DT Annual_JJ Incentive_NNP Plan_NNP and_CC Portfolio_NNP Share_NNP Plan_NNP ._.
The_DT three-year_JJ graph_NN tracks_VBZ the_DT TSR_NNP performance_NN since_IN the_DT Company_NN started_VBD to_TO implement_VB its_PRP$ new_JJ strategic_JJ plan_NN under_IN new_JJ management_NN ._.
Change_NNP in_IN Three-year_JJ historical_JJ TSR_NNP performance_NN ._.
Change_NNP in_IN value_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN over_IN three_CD years_NNS ._.
value_NN of_IN a_DT hypothetical_JJ 100_CD holding_NN over_IN five_CD years_NNS ._.
160 200 180 140_CD 160 120 140 100_CD 120_CD 80_CD 100_CD 80_CD 60_CD 60_CD 40_CD 40_CD 20_CD 20_CD 0_CD 0_CD 31.12.00_CD 31.12.01_CD 31.12.02_CD 31.12.03_CD 31.12.04_CD 31.12.05_CD 31.12.02_CD 31.12.03_CD 31.12.04_CD 31.12.05_CD Shire_NNP TSR_NNP Shire_NNP TSR_NNP Ex-financials_NNPS FTSE_NNP 100_CD TSR_NNP Ex-financials_NNS FTSE_NNP 100_CD TSR_NNP Comparator_NNP group_NN TSR_NNP Comparator_NNP group_NN TSR_NNP 3_CD Loss_NN earnings_NNS per_IN ordinary_JJ share_NN EPS_NNP Basic_JJ EPS_NNP is_VBZ calculated_VBN by_IN dividing_VBG the_DT loss_NN earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS by_IN the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS outstanding_JJ during_IN the_DT year_NN ,_, excluding_VBG those_DT held_VBN in_IN the_DT employee_NN share_NN trust_NN ,_, which_WDT are_VBP treated_VBN as_IN canceled_VBN ._.
For_IN diluted_VBN EPS_NNP ,_, the_DT weighted_JJ average_JJ number_NN of_IN ordinary_JJ shares_NNS in_IN issue_NN is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT dilutive_JJ potential_JJ ordinary_JJ shares_NNS ._.
For_IN the_DT year_NN to_TO 31_CD December_NNP 2005_CD share_NN options_NNS to_TO purchase_VB approximately_RB 20.7_CD million_CD ordinary_JJ shares_NNS and_CC warrants_NNS to_TO purchase_VB 1.3_CD million_CD ordinary_JJ shares_NNS were_VBD not_RB dilutive_JJ and_CC were_VBD therefore_RB excluded_VBN from_IN the_DT computation_NN of_IN diluted_VBN EPS_NNP ._.
The_DT $_$ 370_CD million_CD loan_NN note_NN convertible_JJ debt_NN was_VBD excluded_VBN from_IN the_DT calculation_NN of_IN weighted_JJ average_JJ number_NN of_IN shares_NNS for_IN diluted_VBN EPS_NNP in_IN 2004_CD as_IN it_PRP was_VBD not_RB dilutive_JJ ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 137_CD Shire_NNP plc_NN Value_NN of_IN hypothetical_JJ 100_CD holding_VBG Value_NN of_IN hypothetical_JJ 100_CD holding_VBG 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 138_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD Reconciliations_NNS of_IN the_DT earnings_NNS and_CC weighted_JJ average_JJ number_NN of_IN shares_NNS used_VBN in_IN the_DT calculations_NNS are_VBP set_VBN out_RP below_IN ._.
Weighted_JJ average_JJ Loss_NN number_NN of_IN Per-share_JJ 2005_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ and_CC diluted_JJ EPS_NNP Loss_NN attributable_JJ to_TO ordinary_JJ shareholders_NNS 177,378_CD 500,243,137_CD 35.5_CD Weighted_VBN average_JJ Earnings_NNS number_NN of_IN Per-share_JJ 2004_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ EPS_NNP Earnings_NNS attributable_JJ to_TO ordinary_JJ shareholders_NNS 96,509_CD 496,306,604_CD 19.4_CD Effect_NN of_IN dilutive_JJ securities_NNS Share_NN options_NNS 3,035,620_CD 0.1_CD Warrants_NNS 66,792_CD Diluted_NNP EPS_NNP 96,509_CD 499,409,016_CD 19.3_CD Loss_NN earnings_NNS per_IN share_NN from_IN continuing_VBG and_CC discontinued_VBN operations_NNS :_: Weighted_JJ average_JJ Loss_NN number_NN of_IN Per-share_JJ 2005_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ and_CC diluted_JJ EPS_NNP Loss_NN from_IN continuing_VBG operations_NNS 180,503_CD 500,243,137_CD 36.1_CD Gain_NN from_IN discontinued_VBN operations_NNS 3,125_CD 500,243,137_CD 0.6_CD Weighted_VBN average_JJ Earnings_NNS number_NN of_IN Per-share_JJ 2004_CD $_$ 000_CD shares_NNS amount_NN Basic_JJ EPS_NNP Profit_NN from_IN continuing_VBG operations_NNS 160,801_CD 496,306,604_CD 32.4_CD Loss_NN from_IN discontinued_VBN operations_NNS 64,292_CD 496,306,604_CD 13.0_CD Diluted_NNP EPS_NNP Profit_NN from_IN continuing_VBG operations_NNS 160,801_CD 499,409,016_CD 32.2_CD Loss_NN from_IN discontinued_VBN operations_NNS 64,292_CD 499,409,016_CD 12.9_CD 138_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 139_CD Summary_NNP financial_JJ statement_NN IFRS_NNP For_IN the_DT year_NN ended_VBD 31_CD December_NNP 2005_CD 4_CD Loss_NN profit_NN for_IN the_DT year_NN 2005_CD 2004_CD $_$ 000_CD $_$ 000_CD The_DT following_JJ items_NNS have_VBP been_VBN included_VBN in_IN arriving_VBG at_IN the_DT loss_NN profit_NN from_IN continuing_VBG operations_NNS :_: Staff_NN costs_NNS :_: wages_NNS and_CC salaries_NNS 234,425_CD 179,174_CD social_JJ security_NN costs_NNS 20,674_CD 15,333_CD pensions_NNS costs_NNS defined_VBN contribution_NN plans_NNS 13,461_CD 8,722_CD pensions_NNS costs_NNS defined_VBN benefit_NN plans_NNS 607_CD 284_CD share-based_JJ payments_NNS to_TO Directors_NNS and_CC employees_NNS 27,383_CD 15,815_CD 296,550_CD 219,328_CD Inventories_NNS :_: cost_NN of_IN inventories_NNS recognized_VBN as_IN expense_NN included_VBN in_IN cost_NN of_IN sales_NNS 184,353_CD 119,943_CD inventory_NN write-down_NN included_VBD in_IN cost_NN of_IN sales_NNS 9,432_CD 3,788_CD Depreciation_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN :_: owned_VBN assets_NNS 20,099_CD 20,140_CD under_IN finance_NN leases_NNS 2,904_CD 2,528_CD Impairment_NN of_IN goodwill_NN 526,956_CD 132,576_CD Impairment_NN of_IN intangible_JJ assets_NNS 4,410_CD 19,626_CD Impairment_NN of_IN property_NN ,_, plant_NN and_CC equipment_NN 6,458_CD 1,587_CD Amortisation_NNP of_IN intangible_JJ assets_NNS included_VBN in_IN selling_NN ,_, general_JJ and_CC administrative_JJ expenses_NNS all_DT acquired_VBN 49,516_CD 42,138_CD Operating_NN lease_NN rentals_NNS :_: property_NN ,_, plant_NN and_CC machinery_NN 14,445_CD 6,563_CD other_JJ 2,673_CD 3,495_CD Profit_NN on_IN disposal_NN of_IN financial_JJ assets_NNS 4,100_CD 14,805_CD Impairment_NN of_IN financial_JJ assets_NNS 1,974_CD 17,455_CD Net_JJ foreign_JJ exchange_NN losses_NNS 10,212_CD 2,466_CD Reorganisation_NN costs_NNS 2,301_CD 55,505_CD Integration_NN costs_NNS 11,727_CD Government_NN grants_NNS towards_IN research_NN 26_CD Auditors_NNS remuneration_NN for_IN audit_NN services_NNS 5,121_CD 5,401_CD Accounts_NNPS payable_JJ to_TO Deloitte_NNP &_CC Touche_NNP LLP_NNP and_CC their_PRP$ associates_NNS by_IN the_DT Group_NNP in_IN respect_NN of_IN non-audit_JJ services_NNS were_VBD $_$ 2.8_CD million_CD 2004_CD :_: $_$ 4.9_CD million_CD ._.
A_DT more_JJR detailed_JJ analysis_NN of_IN auditors_NNS remuneration_NN on_IN a_DT worldwide_JJ basis_NN is_VBZ provided_VBN below_RB ._.
2005_CD 2004_CD Year_NN to_TO December_NNP 31_CD ,_, $_$ 000_CD $_$ 000_CD i_FW Audit_NNP fees_NNS 2,731_CD 3,253_CD ii_FW Audit-related_JJ fees_NNS 2,390_CD 2,148_CD iii_FW Tax_NNP fees_NNS 2,066_CD 4,734_CD iv_NN All_DT other_JJ fees_NNS 708_CD 183_CD Total_JJ fees_NNS 7,895_CD 10,318_CD Notes_NNS i_FW Audit_NNP fees_NNS consisted_VBD of_IN audit_NN work_NN only_RB the_DT Independent_NNP Registered_NNP Public_NNP Accountant_NNP can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN statutory_JJ audits_NN and_CC included_VBD the_DT audit_NN of_IN managements_NNS assessment_NN that_IN the_DT Group_NNP maintained_VBD effective_JJ internal_JJ control_NN over_IN 10-K_JJ financial_JJ reporting_NN and_CC the_DT audit_NN of_IN the_DT effectiveness_NN of_IN the_DT Groups_NNS internal_JJ control_NN over_IN 10-K_JJ financial_JJ reporting_NN ._.
ii_FW Audit_NNP related_JJ fees_NNS consist_VBP of_IN work_NN generally_RB only_RB the_DT Independent_NNP Registered_NNP Public_NNP Accountant_NNP can_MD reasonably_RB be_VB expected_VBN to_TO perform_VB ,_, such_JJ as_IN procedures_NNS relating_VBG to_TO regulatory_JJ filings_NNS ._.
iii_FW Tax_NNP fees_NNS consisted_VBD principally_RB of_IN assistance_NN with_IN matters_NNS related_VBN to_TO compliance_NN ,_, planning_NN and_CC advice_NN in_IN various_JJ tax_NN jurisdictions_NNS ._.
iv_NN All_DT other_JJ fees_NNS relate_VBP to_TO assisting_VBG the_DT remuneration_NN committee_NN and_CC corporate_JJ responsibility_NN ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 139_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 140_CD Shire_NNP head_NN ofce_NN and_CC main_JJ operating_NN locations_NNS Shire_NNP plc_NN Shire_NNP Italia_NNP S._NNP p._NNP A._NN Chief_NNP Executive_NNP Officer_NNP :_: Matthew_NNP Emmens_NNP Managing_VBG Director_NNP :_: Gian_NNP Piero_NNP Reverberi_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP Via_NNP Provinciale_NNP Lucchese_NNP ,_, 70_CD Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP 50019_CD Sesto_NNP F._NNP No_NNP FI_NNP United_NNP Kingdom_NNP Italy_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Tel_NNP 39_CD 0_CD 55 3025050_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Fax_NNP 39_CD 0_CD 55 3025051_CD Shire_NNP Pharmaceuticals_NNPS Ltd_NNP Shire_NNP Pharmaceuticals_NNP Iberica_NNP SL_NNP Managing_VBG Director_NNP :_: John_NNP Freeman_NNP Managing_VBG Director_NNP :_: Jos_NNP Antonio_NNP Senz_NNP fide_NNP Broto_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP P_NNP Pintor_NNP Rosales_NNP ,_, n_NN 40_CD ,_, Bajo_NNP Izda_NNP ._.
Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP 28008_CD Madrid_NNP United_NNP Kingdom_NNP Spain_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Tel_NNP 34 915 500 691_CD Fax_NNP 44_CD 0_CD 1256 894708_CD Fax_NNP 34 915 493 695_CD Shire_NNP Pharmaceuticals_NNP Ireland_NNP Ltd_NNP Shire_NNP US_NNP Manufacturing_NNP Inc._NNP ._.
General_NNP Manager_NNP :_: Brian_NNP Martin_NNP Executive_NNP Vice_NNP President_NNP Building_NNP 1A_NNP ,_, Citylink_NNP Business_NNP Park_NNP Global_NNP Supply_NNP Chain_NNP &_CC Quality_NNP :_: John_NNP Lee_NNP Old_NNP Naas_NNP Road_NNP ,_, Dublin_NNP 12_CD 11200_CD Gundry_NNP Lane_NNP Ireland_NNP Owings_NNP Mills_NNP ,_, Maryland_NNP 21117_CD Tel_NNP 353_CD 1_CD 429_CD 7700_CD USA_NNP Fax_NNP 353_CD 1_CD 429_CD 7701_CD Tel_NNP 1_CD 410 413 1000_CD Fax_NN 1_CD 410 413 2000_CD Shire_NNP Pharmaceutical_NNP Contracts_NNPS Ltd_NNP Singapore_NNP representative_JJ office_NN Shire_NNP BioChem_NNP Inc._NNP ._.
Managing_VBG Director_NNP :_: Tony_NNP Ooi_NNP Vice_NNP President_NNP and_CC LiFung_NNP Centre_NNP General_NNP Manager_NNP :_: Claude_NNP Perron_NNP 5_CD B_NNP ,_, Toh_NNP Guan_NNP Road_NNP East_NNP ,_, #_# 03-09A_CD 2250_CD Alfred-Nobel_NNP Blvd._NNP ._.
Suite_NN 500_CD Singapore_NNP 608829_CD Ville_NNP Saint-Laurent_NNP ,_, Qubec_NNP H4S_NNP 2C9_NNP Tel_NNP 65 6665 2795_CD Canada_NNP Fax_NNP 65 6665 2797_CD Tel_NNP 1_CD 514 787 2300_CD Fax_NN 1_CD 514 787 2427_CD Shire_NNP Deutschland_NNP GmbH_NNP &_CC Co_NNP KG_NNP Managing_VBG Director_NNP :_: Leonhard_NNP Terp_NNP Shire_NNP Human_NNP Generic_NNP Therapies_NNPS Siegburger_NNP Strae_NNP 126_CD Executive_NNP Vice_NNP President_NNP D-50679_NNP Kln_NNP and_CC General_NNP Manager_NNP :_: David_NNP Pendergast_NNP Germany_NNP 700_CD Main_NNP Street_NNP Tel_NNP 49_CD 221_CD 8_CD 80_CD 47_CD 30_CD Cambridge_NNP ,_, Massachusetts_NNP 02139_CD Fax_NNP 49_CD 221_CD 8_CD 80_CD 47_CD 41_CD USA_NNP Tel_NNP 1_CD 617 349 0200_CD Shire_NNP France_NNP S._NNP A._NNP Fax_NNP 1_CD 617 613 4004_CD Managing_VBG Director_NNP :_: Vincent_NNP Lucet_NNP 88_CD ,_, rue_NN du_NNP Dme_NNP 92514_CD Boulogne-Billancourt_NNP Cedex_NNP France_NNP Tel_NNP 33_CD 0_CD 146_CD 10_CD 90_CD 00_CD Fax_NNP 33_CD 0_CD 146_CD 08_CD 21_CD 49_CD 140_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 141_CD Shareholder_NN information_NN Registered_NNP office_NN address_NN US_NNP Shareholders_NNP Hampshire_NNP International_NNP Business_NNP Park_NNP i_FW ADSs_NNP Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP The_NNP Companys_NNP American_NNP Depository_NNP Shares_NNP ADSs_NNP ,_, each_DT representing_VBG United_NNP Kingdom_NNP three_CD ordinary_JJ shares_NNS ,_, are_VBP listed_VBN on_IN the_DT NASDAQ_NNP national_JJ market_NN under_IN Registered_NNP in_IN England_NNP the_DT symbol_NN SHPGY_NNP ._.
The_DT Company_NN files_VBZ reports_NNS and_CC other_JJ documents_NNS No._NN ._.
05492592_CD with_IN the_DT Securities_NNPS and_CC Exchange_NNP Commission_NNP SEC_NNP which_WDT are_VBP available_JJ for_IN inspection_NN and_CC copying_NN at_IN the_DT SECs_NNS public_JJ reference_NN Investor_NN relations_NNS facilities_NNS or_CC can_MD be_VB obtained_VBN by_IN writing_VBG to_TO the_DT Company_NNP Secretary_NNP ._.
Europe_NNP and_CC Rest_VB of_IN the_DT World_NNP :_: Cla_NNP Rosenfeld_NNP Tel_NNP 44_CD 0_CD 1256 894160_CD ii_FW ADS_NNPS Depositary_NNP Fax_NNP 44_CD 0_CD 1256 894708_CD Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP is_VBZ the_DT depositary_NN for_IN Email_NNP investorrelations@uk_NNP ._.
com_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plc_NN ADSs_NNS ._.
All_DT enquiries_NNS concerning_VBG ADS_NNPS records_NNS ,_, certificates_NNS or_CC transfer_NN of_IN ordinary_JJ shares_NNS into_IN ADSs_NNS should_MD North_NNP America_NNP :_: Brian_NNP Piper_NNP be_VB addressed_VBN to_TO :_: Tel_NNP 1_CD 484 595 8800_CD Fax_NN 1_CD 484 595 8151_CD Morgan_NNP Guaranty_NNP Trust_NNP Company_NN of_IN New_NNP York_NNP Email_NNP bpiper@us_VBZ ._.
com_NN PO_NNP Box_NNP 8205_CD Boston_NNP ,_, Massachusetts_NNP 02266-8205_CD www_NN ._.
com_NN USA_NNP Tel_NNP 1_CD 781 575 4328_CD Registrars_NNPS and_CC transfer_VB office_NN Fax_NN 1_CD 781 575 4088_CD All_DT administrative_JJ enquiries_NNS relating_VBG to_TO shareholdings_NNS should_MD be_VB addressed_VBN to_TO Lloyds_NNP TSB_NNP Registrars_NNPS ,_, clearly_RB stating_VBG the_DT registered_VBN Canadian_JJ Shareholders_NNS shareholders_NNS name_NN and_CC address_NN ._.
i_FW Exchangeable_JJ Shares_NNS of_IN Shire_NNP Acquisition_NNP Inc._NNP ._.
Exchangeable_JJ shares_NNS in_IN Shire_NNP Acquisition_NNP Inc._NNP are_VBP convertible_JJ into_IN three_CD Lloyds_NNP TSB_NNP Registrars_NNPS ordinary_JJ shares_NNS of_IN Shire_NNP or_CC one_CD ADS_NNPS representing_VBG three_CD ordinary_JJ shares_NNS Customer_NN Services_NNPS ,_, The_DT Causeway_NNP of_IN Shire_NNP ._.
Exchangeable_JJ shares_NNS trade_NN on_IN the_DT Toronto_NNP Stock_NNP Exchange_NNP Worthing_NNP ,_, West_NNP Sussex_NNP BN99_NNP 6DA_NNP under_IN the_DT symbol_NN SHQ_NNP ._.
Shires_NNP ordinary_JJ shares_NNS are_VBP listed_VBN on_IN the_DT United_NNP Kingdom_NNP London_NNP Stock_NNP Exchange_NNP and_CC Shires_NNP ADSs_NNS are_VBP listed_VBN on_IN the_DT NASDAQ_NNP Tel_NNP 44 870 600 3970_CD national_JJ market_NN ._.
ii_FW Trustee_NN for_IN Exchangeable_JJ Shareholders_NNS Natcan_NNP Trust_NNP Company_NNP ,_, a_DT wholly_RB owned_VBN subsidiary_NN of_IN the_DT National_NNP Bank_NNP of_IN Canada_NNP ,_, acts_VBZ as_IN Trustee_NN for_IN Exchangeable_JJ Shareholders_NNS ._.
All_DT enquiries_NNS concerning_VBG Exchangeable_JJ Share_NN records_NNS or_CC conversions_NNS of_IN Exchangeable_JJ Shares_NNS into_IN ordinary_JJ shares_NNS of_IN Shire_NNP or_CC ADSs_NNS should_MD be_VB addressed_VBN to_TO :_: Natcan_NNP Trust_NNP Company_NNP 1100_CD University_NNP Street_NNP Suite_NNP 900_CD Montreal_NNP ,_, Qubec_NNP H3B_NNP 2G7_NNP Canada_NNP Tel_NNP 1_CD 514 871 7171_CD 1_CD 800 341 1419_CD Fax_NN 1_CD 514 871 7442_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 141_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 142_CD Shire_NNP Trade_NNP Marks_NNP Cautionary_NNP statements_NNS Shire_NNP Trade_NNP Marks_NNP Cautionary_NNP statements_NNS ADDERALL_NNP XR_NNP mixed_JJ salt_NN of_IN a_DT single_JJ entity_NN amphetamine_NN Statements_NNS included_VBD herein_NN that_WDT are_VBP not_RB historical_JJ facts_NNS are_VBP forwardADDERALL_NNP mixed_JJ salt_NN of_IN a_DT single_JJ entity_NN amphetamine_NN looking_VBG statements_NNS ._.
Such_JJ forward-looking_JJ statements_NNS involve_VBP a_DT AGRYLIN_NNP anagrelide_NN hydrochloride_NN number_NN of_IN risks_NNS and_CC uncertainties_NNS and_CC are_VBP subject_JJ to_TO change_VB at_IN any_DT AMATINE_NNP midodrine_NN hydrochloride_NN time_NN ._.
In_IN the_DT event_NN such_JJ risks_NNS or_CC uncertainties_NNS materialize_VBP ,_, Shires_NNP CALCICHEW_NNP calcium_NN carbonate_NN results_NNS could_MD be_VB materially_RB affected_VBN ._.
The_DT risks_NNS and_CC uncertainties_NNS CARBATROL_NNP carbamazepine_NN include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, risks_NNS associated_VBN with_IN :_: the_DT inherent_JJ COLAZIDE_NNP balsalazide_NN uncertainty_NN of_IN pharmaceutical_JJ research_NN ,_, product_NN development_NN ,_, DAYTRANA_NNP methylphenidate_NN transdermal_NN system_NN manufacturing_NN and_CC commercialization_NN :_: the_DT impact_NN of_IN competitive_JJ ELAPRASE_NNP idursulfase_NN products_NNS ,_, including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, the_DT impact_NN of_IN those_DT on_IN Shires_NNP EQUETRO_NNP carbamazepine_NN Attention_NN Deficit_NN and_CC Hyperactivity_NNP Disorder_NNP ADHD_NNP franchise_NN :_: patents_NNS ,_, FOSRENOL_NNP lanthanum_NN carbonate_NN including_VBG ,_, but_CC not_RB limited_VBN to_TO ,_, legal_JJ challenges_NNS relating_VBG to_TO Shires_NNP ADHD_NNP GENE-ACTIVATED_NNP GA-GCB_NNP glucocerebrosidase_NN franchise_NN :_: government_NN regulation_NN and_CC approval_NN ,_, including_VBG ,_, but_CC not_RB MESAVANCE_NNP mesalamine_NN limited_VBN to_TO ,_, the_DT expected_VBN product_NN approval_NN dates_NNS of_IN SPD503_CD ADHD_NNP ,_, PROAMATINE_NNP midodrine_NN hydrochloride_NN SPD465_CD ADHD_NNP ,_, MESAVANCE_NNP SPD476_NNP ulcerative_JJ colitis_NNS ,_, REMINYL_NNP galantamine_NN hydrobromide_NN ELAPRASE_NNP idursulfase_NN Hunter_NNP Syndrome_NNP ,_, and_CC NRP104_NNP ADHD_NNP ,_, UK_NNP and_CC Republic_NNP of_IN Ireland_NNP including_VBG its_PRP$ scheduling_NN classification_NN by_IN the_DT Drug_NNP Enforcement_NNP REMINYL_NNP XL_NNP galantamine_NN hydrobromide_NN Administration_NN in_IN the_DT United_NNP States_NNPS :_: Shires_NNS ability_NN to_TO benefit_VB from_IN its_PRP$ UK_NNP and_CC Republic_NNP of_IN Ireland_NNP acquisition_NN of_IN Transkaryotic_NNP Therapies_NNPS ,_, Inc._NNP :_: Shires_NNS ability_NN to_TO secure_VB REPLAGAL_NNP agalsidase_JJ alfa_IN new_JJ products_NNS for_IN commercialization_NN and_CC or_CC development_NN :_: and_CC other_JJ SOLARAZE_NNP diclofenac_NN sodium_NN 3_CD %_NN risks_NNS and_CC uncertainties_NNS detailed_VBN from_IN time_NN to_TO time_NN in_IN Shires_NNP filings_NNS and_CC TROXATYL_NNP troxacitabine_VBD its_PRP$ predecessor_NN registrant_NN Shire_NNP Pharmaceuticals_NNP Group_NNP plcs_VBZ filings_NNS VANIQA_NNP eflornithine_NN hydrochloride_NN with_IN the_DT US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP ,_, including_VBG Shires_NNP XAGRID_NNP anagrelide_NN hydrochloride_NN Annual_JJ Report_NNP on_IN Form_NN 10-K_NN for_IN the_DT year_NN to_TO December_NNP 31_CD ,_, 2005_CD ._.
Third-party_JJ Trade_NNP Marks_NNP The_NNP statements_NNS of_IN the_DT individuals_NNS and_CC medical_JJ practitioners_NNS appearing_VBG 3TC_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP in_IN the_DT operating_NN review_NN on_IN pages_NNS 1635_CD of_IN this_DT document_NN have_VBP been_VBN COMBIVIR_JJ trade_NN mark_NN of_IN GSK_NNP made_VBN by_IN and_CC represent_VB the_DT views_NNS of_IN the_DT named_VBN individuals_NNS ._.
The_DT views_NNS DYNEPO_NNP trade_NN mark_NN of_IN Aventis_NNP Pharma_NNP Holdings_NNP GmbH_NNP represented_VBD are_VBP those_DT of_IN the_DT named_VBN medical_JJ practitioners_NNS and_CC should_MD EPIVIR_NNP trade_NN mark_NN of_IN GSK_NNP not_RB necessarily_RB be_VB taken_VBN to_TO represent_VB the_DT views_NNS of_IN Shire_NNP ._.
EPIVIR-HBV_JJ trade_NN mark_NN of_IN GSK_NNP HEPTOVIR_NNP trade_NN mark_NN of_IN GSK_NNP PENTASA_NNP mesalamine_NN trade_NN mark_NN of_IN Ferring_NNP AS_NNP RAZADYNE_NNP trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP RAZADYNE_NNP ER_NNP trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP REMINYL_NNP trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP ,_, excluding_VBG UK_NNP and_CC Republic_NNP of_IN Ireland_NNP REMINYL_NNP XL_NNP galantamine_NN hydrobromide_NN trade_NN mark_NN of_IN Johnson_NNP &_CC Johnson_NNP ,_, excluding_VBG UK_NNP and_CC Republic_NNP of_IN Ireland_NNP TRIZIVIR_NNP trade_NN mark_NN of_IN GSK_NNP ZEFFIX_NNP lamivudine_NN trade_NN mark_NN of_IN GSK_NNP 142_CD Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 143_CD Glossary_NNP of_IN terms_NNS Animo_NNP acid_NN MPS_NNP Society_NNP An_DT organic_JJ compound_NN containing_VBG an_DT amino_JJ group_NN NH_NNP ,_, a_DT carboxylic_JJ Society_NNP ._.
2_CD acid_NN group_NN COOH_NNP ,_, and_CC any_DT of_IN various_JJ side_NN groups_NNS ,_, especially_RB any_DT of_IN the_DT 20_CD compounds_NNS that_WDT have_VBP the_DT basic_JJ formula_NN NH_NNP CHRCOOH_NNP ,_, 2_CD and_CC that_DT link_NN together_RB by_IN peptide_NN bonds_NNS to_TO form_VB proteins_NNS or_CC that_DT function_NN One_CD of_IN a_DT series_NN of_IN inherited_VBN metabolic_JJ disorders_NNS affecting_VBG a_DT type_NN of_IN as_IN chemical_NN messengers_NNS and_CC as_IN intermediates_NNS in_IN metabolism_NN ._.
complex_JJ carbohydrate_NN called_VBD a_DT mucopolysaccharide_NN that_WDT is_VBZ deposited_VBN in_IN body_NN tissues_NNS because_IN the_DT person_NN lacks_VBZ the_DT specific_JJ enzyme_NN needed_VBN Animo_NNP acid_NN sequence_NN to_TO metabolize_VB it_PRP ._.
Peptide_NNP sequence_NN or_CC amino_JJ acid_NN sequence_NN is_VBZ the_DT order_NN in_IN which_WDT amino_JJ acid_NN residues_NNS ,_, connected_VBN by_IN peptide_NN bonds_NNS ,_, lie_VBP in_IN the_DT chain_NN ._.
NICE_NNP The_NNP sequence_NN is_VBZ generally_RB reported_VBN from_IN the_DT N-terminal_JJ end_NN containing_VBG UK_NNP National_NNP Institute_NNP of_IN Clinical_NNP Excellence_NNP ._.
free_JJ amino_JJ group_NN to_TO the_DT C-terminal_JJ end_NN containing_VBG free_JJ carboxyl_NN group_NN ._.
Peptide_NNP sequence_NN is_VBZ often_RB called_VBN protein_NN sequence_NN if_IN it_PRP represents_VBZ the_DT Pharmacovigilance_NNP primary_JJ structure_NN of_IN a_DT protein_NN ._.
The_DT pharmacological_JJ science_NN relating_VBG to_TO the_DT detection_NN ,_, assessment_NN ,_, understanding_NN and_CC prevention_NN of_IN adverse_JJ effects_NNS ,_, particularly_RB long-term_JJ Carbohydrate_NNP structure_NN and_CC short-term_JJ side_NN effects_NNS ,_, of_IN medicines_NNS Source_NN :_: The_DT Importance_NN In_IN glycoproteins_NNS ,_, in_IN addition_NN to_TO the_DT amino_JJ acid_NN backbone_NN or_CC otherwise_RB of_IN Pharmacovigilance_NNP ,_, WHO_WP 2002_CD ._.
referred_VBD to_TO as_IN a_DT protein_NN ,_, other_JJ molecules_NNS are_VBP conjugated_VBN to_TO the_DT protein_NN in_IN particular_JJ places_NNS ,_, such_JJ as_IN carbohydrates_NNS ._.
Carbohydrates_NNS means_VBZ sugars_NNS Phase_NN 1_CD or_CC chains_NNS of_IN sugars_NNS ._.
A_DT single_JJ sugar_NN is_VBZ a_DT monosaccharide_NN ,_, a_DT long_JJ chain_NN Clinical_JJ trials_NNS usually_RB conducted_VBN in_IN healthy_JJ human_JJ volunteers_NNS would_MD be_VB a_DT polysaccharide_NN ,_, etc._FW ._.
These_DT sugars_NNS are_VBP important_JJ for_IN activity_NN to_TO determine_VB if_IN a_DT drug_NN candidate_NN is_VBZ safe_JJ for_IN more_JJR extensive_JJ testing_NN ._.
and_CC are_VBP also_RB part_NN of_IN the_DT uptake_NN mechanism_NN for_IN the_DT protein_NN within_IN cells_NNS and_CC tissues_NNS ._.
Phase_NN 2_CD Clinical_JJ trials_NNS conducted_VBN in_IN patients_NNS with_IN relevant_JJ disease_NN to_TO assess_VB CHADD_NNP the_DT safety_NN and_CC efficacy_NN of_IN the_DT drug_NN candidate_NN ._.
Children_NNS and_CC adults_NNS with_IN attention_NN deficit_NN hyperactivity_NN disorder_NN ._.
Phase_NN 3_CD Glycoproteins_NNP Clinical_NNP trials_NNS conducted_VBN in_IN the_DT target_NN patient_NN population_NN to_TO Any_DT of_IN a_DT group_NN of_IN conjugated_JJ proteins_NNS that_WDT contain_VBP a_DT carbohydrate_NN comprehensively_RB assess_VB the_DT safety_NN and_CC efficacy_NN of_IN the_DT drug_NN candidate_NN ._.
Pivotal_JJ study_NN Immunogenic_NNP A_NNP major_JJ clinical_JJ trial_NN that_WDT has_VBZ a_DT significant_JJ impact_NN on_IN the_DT labeling_VBG Producing_NNP an_DT immune_JJ response_NN ._.
Lysosomal_NNP Platelet_NNP Membrane-enclosed_JJ compartment_NN in_IN cells_NNS ,_, containing_VBG many_JJ A_DT constituent_NN of_IN blood_NN that_WDT help_VBP form_VB clots_NNS to_TO control_VB bleeding_NN ._.
hydrolytic_JJ enzymes_NNS :_: where_WRB large_JJ molecules_NNS and_CC cellular_JJ components_NNS are_VBP broken_VBN down_RP ._.
Pre-clinical_JJ study_NN Studies_NNS of_IN compounds_NNS conducted_VBN in_IN the_DT laboratory_NN ,_, in_IN isolated_JJ tissues_NNS ,_, Lysosomal_NNP Storage_NNP Diseases_NNPS LSDs_NNPS or_CC in_IN living_VBG animals_NNS ._.
Are_VBP a_DT group_NN of_IN which_WDT over_IN forty_NN disorders_NNS are_VBP currently_RB known_VBN that_IN result_NN from_IN defects_NNS in_IN lysosomal_JJ function_NN ._.
Proof_NNP of_IN Concept_NNP study_NN A_DT study_NN intended_VBN to_TO show_VB that_IN a_DT hypothesis_NN or_CC concept_NN is_VBZ valid_JJ ._.
MHRA_NNP Medicine_NNP and_CC Healthcare_NNP products_NNS Regulatory_NNP agency_NN ._.
Molecule_NNP The_NNP smallest_JJS particle_NN of_IN a_DT substance_NN that_WDT retains_VBZ the_DT chemical_NN and_CC physical_JJ properties_NNS of_IN the_DT substance_NN and_CC is_VBZ composed_VBN of_IN two_CD or_CC more_JJR atoms_NNS :_: a_DT group_NN of_IN like_IN or_CC different_JJ atoms_NNS held_VBN together_RB by_IN chemical_NN forces_NNS ._.
Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 143_CD Shire_NNP plc_NN 6361_CD Accounts_NNPS 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:57_CD Page_NNP 144_CD Designed_VBN and_CC produced_VBN by_IN Bostock_NNP and_CC Pollitt_NNP Limited_NNP ,_, London_NNP The_DT paper_NN used_VBN in_IN this_DT publication_NN is_VBZ made_VBN from_IN 100_CD %_NN recycled_JJ fibers_NNS sourced_VBD entirely_RB from_IN post_NN consumer_NN waste_NN ,_, is_VBZ Elemental_JJ Chlorine_NNP Free_NNP ECF_NNP and_CC is_VBZ accredited_VBN to_TO ISO_NNP 14001_CD ._.
6361_CD Cover_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP fc2_CD Shire_NNP plc_NN Annual_JJ review_NN and_CC summary_NN financial_JJ statement_NN 2005_CD 6361_CD Cover_NNP 2005_CD ._.
qxd_NN 24_CD 4_CD 06_CD 12:56_CD Page_NNP fc1_CD Shire_NNP plc_NN Annual_JJ review_NN and_CC summary_NN finan_NN Hampshire_NNP International_NNP Business_NNP Park_NNP Shire_NNP plc_NN Basingstoke_NNP ,_, Hampshire_NNP RG24_NNP 8EP_NNP United_NNP Kingdom_NNP Tel_NNP 44_CD 0_CD 1256 894000_CD Fax_NNP 44_CD 0_CD 1256 894708_CD www_NN ._.
